<SEC-DOCUMENT>0001753926-23-000344.txt : 20230331
<SEC-HEADER>0001753926-23-000344.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331134024
ACCESSION NUMBER:		0001753926-23-000344
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vivani Medical, Inc.
		CENTRAL INDEX KEY:			0001266806
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36747
		FILM NUMBER:		23786289

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET, SUITE 280
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		818-833-5000

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET, SUITE 280
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SECOND SIGHT MEDICAL PRODUCTS INC
		DATE OF NAME CHANGE:	20031010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>g083419_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:eyes="http://secondsight.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_eyes_secondsight.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001266806 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_071_XDX_g083419__10k.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001266806</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0019" name="dei:EntityIncorporationStateCountryCode">CA</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationReserveNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnRepurchaseOfDebtInstrument" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:GainFromBargainPurchase" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:PppLoanForgiveness" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:CashAcquiredInMergerForStockConsideration" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:CancellationOfSafeBorrowing" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EstimateOfCancellations" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MinimumMember" id="xdx2ixbrl0503" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MaximumMember" id="xdx2ixbrl0505" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P7Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember" id="xdx2ixbrl0507" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember" id="xdx2ixbrl0509" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P7Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" id="xdx2ixbrl0511" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P2Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" id="xdx2ixbrl0512" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" id="xdx2ixbrl0514" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" id="xdx2ixbrl0515" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P10Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31" id="xdx2ixbrl0614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0660" name="eyes:GrantReceivedFundingPeriod">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0664" decimals="-3" scale="3" unitRef="USD">14169</ix:nonFraction>
  <ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0666" decimals="-3" scale="3" unitRef="USD">7072</ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-12-282022-12-31_custom_RightOfferingMember" id="xdx2ixbrl0684" name="eyes:ClassOfWarrantsOrRightsTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="eyes:ClassOfWarrantOrRightExercised" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0699" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:ClassOfWarrantOrRightForfeitedOrExpired" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0701" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:ClassOfWarrantOrRightIssued" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0705" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:ClassOfWarrantOrRightExerciseIssued" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0707" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="eyes:ClassOfWarrantOrRightForfeitedOrExpired" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0713" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0719" name="eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne">P1Y5M16D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0725" name="eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2">P2Y3M22D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0731" name="eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise">P2Y3M22D</ix:nonNumeric>
  <ix:nonFraction name="eyes:ShareBasedCompensation1" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0742" decimals="0" unitRef="USD">1470000</ix:nonFraction>
  <ix:nonFraction name="eyes:ShareBasedCompensation1" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0743" decimals="0" unitRef="USD">1668000</ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" id="xdx2ixbrl0762" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y0M29D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MinimumMember" id="xdx2ixbrl0764" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MaximumMember" id="xdx2ixbrl0766" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y0M29D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0811" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P7Y1M24D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0817" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">P6Y6M18D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0823" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P1Y2M12D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" id="xdx2ixbrl0875" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" contextRef="AsOf2021-12-31_custom_NPMMember" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2022-12-31_custom_NPMMember" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" id="xdx2ixbrl0895" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2022-12-31" id="xdx2ixbrl0896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2021-12-31_custom_NPMMember" id="xdx2ixbrl0897" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" contextRef="From2022-01-012022-12-31_custom_NPMMember" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1037" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="eyes-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyes:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-27_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SecondSightSwitzerlandSarlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">eyes:SecondSightSwitzerlandSarlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-282022-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-28</xbrli:startDate>
        <xbrli:endDate>2022-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-282022-08-30_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-28</xbrli:startDate>
        <xbrli:endDate>2022-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_ProFormaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_ProFormaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eyes:CountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BiopharmDivisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eyes:BiopharmDivisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_BiopharmDivisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eyes:BiopharmDivisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NeuromodulationDivisionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eyes:NeuromodulationDivisionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyes:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyes:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_RightOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RightOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RightOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-282022-12-31_custom_RightOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-28</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RightOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NPMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LegacySSMPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:LegacySSMPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NPMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NPMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LegacySSMPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:LegacySSMPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NPMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-072022-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-07</xbrli:startDate>
        <xbrli:endDate>2022-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-262023-03-03_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-26</xbrli:startDate>
        <xbrli:endDate>2023-03-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_us-gaap_SubsequentEventMember_custom_MrAdamsMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyes:MrAdamsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001266806</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000906" toRefs="Footnote000979"></ix:relationship>
  <ix:relationship fromRefs="Fact000908" toRefs="Footnote000979"></ix:relationship>
  <ix:relationship fromRefs="Fact000910" toRefs="Footnote000979"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="text-align: left"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>UNITED
STATES&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_90E_edei--DocumentType_c20220101__20221231_z7OgRVKuQXQj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--DocumentAnnualReport_c20220101__20221231_zLCdpxUGjKX5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">ANNUAL REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Fiscal Year Ended <span id="xdx_900_edei--DocumentPeriodEndDate_c20220101__20221231_ztxNPtniHvjl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--DocumentTransitionReport_c20220101__20221231_zIFYaYMLkPDi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ________
to ________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number <span id="xdx_902_edei--EntityFileNumber_c20220101__20221231_zuoXc6aogVPj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-36747</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b><span id="xdx_90C_edei--EntityRegistrantName_c20220101__20221231_zKgMaStorzMh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">Vivani
Medical, Inc.</ix:nonNumeric></span></b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<i>Exact name of registrant as specified
in its charter</i>)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_dxL_c20220101__20221231_zo3kYFg5bsJ2" title="::XDX::CA"><span style="-sec-ix-hidden: xdx2ixbrl0019">California&#160;</span></span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(State or other jurisdiction
of incorporation or organization)</i></p></td>
    <td style="width: 50%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20220101__20221231_zfOlujcHoith"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">02-0692322</ix:nonNumeric></span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(I.R.S. Employer Identification
No.)</i></p></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220101__20221231_z0Nv5mZV4PD5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">5858 Horton Street</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20220101__20221231_zL1Z5EZdoa53"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite
    280</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressCityOrTown_c20220101__20221231_zQz4M3jMvJed"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Emeryville</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20220101__20221231_zMhMxAXWY1Vl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20220101__20221231_zTnoOOK9OsP3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">94608</ix:nonNumeric></span></b></span></td>
    </tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(<i>Address
    of principal executive offices, including zip code</i>)</b></span></td>
    </tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: (<b><span id="xdx_90D_edei--CityAreaCode_c20220101__20221231_z4zo7L4x00V8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">818</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20220101__20221231_zDau2Rl1sDNa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">833-5000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section
12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 34%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered</b></span></td></tr>
<tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockMember_zoO12hoqYDQd"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockMember_zzb5833d8aY4"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" name="dei:TradingSymbol">VANI</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--CommonStockMember_zLKnEFEnpVBl"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span></td></tr>
<tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_zFZtvRtECQsk"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_WarrantsMember" name="dei:Security12bTitle">Warrants</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_zQjBM8pM0QIf"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_WarrantsMember" name="dei:TradingSymbol">VANIW</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;<b><span id="xdx_906_edei--SecurityExchangeName_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_z4SpbWUdFhof" style="display: none; visibility: hidden"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_WarrantsMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></b></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section
12(g) of the Act: None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zJUBkT2pbPYh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_902_edei--EntityVoluntaryFilers_c20220101__20221231_zfRGA4e2ztel"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90E_edei--EntityCurrentReportingStatus_c20220101__20221231_zf1TT4fWFvTi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically on its corporate website, if any, every Interactive Data File required to be submitted and pursuant
to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit). <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20220101__20221231_zNfv6lhOd1za"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of
&#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;, and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td>
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20220101__20221231_zanPT5d02bY2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> &#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_900_edei--EntitySmallBusiness_c20220101__20221231_zIyna9gBJg8f"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20220101__20221231_zBenRaL5Lqs3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared
or issued its audit report. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the
registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#9744;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_900_edei--EntityShellCompany_c20220101__20221231_zI99aW7S3Dt2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the shares
of the registrant&#8217;s Common Stock held by non-affiliates of the registrant as of June 30, 2022, computed by reference to the
closing sales price on the Nasdaq Capital Market on June 30, 2022, was approximately $<span id="xdx_901_edei--EntityPublicFloat_iI_dm_c20220630_zZiSF8VCVJw2"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">57.1</ix:nonFraction> million</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 27, 2023, the registrant had
<span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20230327_z95SAnNtagRh"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-27" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,735,770</ix:nonFraction></span> shares of common stock, no par value per share and <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20230327__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hgSvmG9CD9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-27_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,680,938</ix:nonFraction></span> warrants outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_900_edei--DocumentsIncorporatedByReferenceTextBlock_c20220101__20221231_zXBF6AOVFLle" title="Documents Incorporated by Reference"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions
of the registrant&#8217;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) are
incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Registrant
intends to file a definitive proxy statement pursuant to Regulation 14A with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within
120 days after the end of registrant&#8217;s fiscal year end of December 31, 2022.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="text-align: left"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 10%; padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="width: 85%; padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><a href="#a001_v1"><span style="font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a002_v1"><span style="font-size: 10pt">Item 1.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a002_v1"><span style="font-size: 10pt">Business</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right">5</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a003_v1"><span style="font-size: 10pt">Item 1A.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a003_v1"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a004_v1"><span style="font-size: 10pt">Item 1B.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a004_v1"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a005_v1"><span style="font-size: 10pt">Item 2.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a005_v1"><span style="font-size: 10pt">Properties</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a006_v1"><span style="font-size: 10pt">Item 3.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a006_v1"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a007_v1"><span style="font-size: 10pt">Item 4.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a007_v1"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><a href="#a008_v1"><span style="font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a009_v1"><span style="font-size: 10pt">Item 5.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a009_v1"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a010_v1"><span style="font-size: 10pt">Item 6.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a010_v1"><span style="font-size: 10pt">Reserved</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a011_v1"><span style="font-size: 10pt">Item 7.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a011_v1"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a012_v1"><span style="font-size: 10pt">Item 7A.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a012_v1"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a013_v1"><span style="font-size: 10pt">Item 8.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a013_v1"><span style="font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a014_v1"><span style="font-size: 10pt">Item 9.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a014_v1"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a015_v1"><span style="font-size: 10pt">Item 9A.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a015_v1"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a016_v1"><span style="font-size: 10pt">Item 9B.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a016_v1"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a017_v1"><span style="font-size: 10pt">Item 9C.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a017_v1"><span style="font-size: 10pt">Disclosure regarding foreign jurisdictions that prevent inspections</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><a href="#a018_v1"><span style="font-size: 10pt"><b>PART III</b></span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a019_v1"><span style="font-size: 10pt">Item 10.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a019_v1"><span style="font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a020_v1"><span style="font-size: 10pt">Item 11.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a020_v1"><span style="font-size: 10pt">Executive Compensation</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a021_v1"><span style="font-size: 10pt">Item 12.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a021_v1"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a022_v1"><span style="font-size: 10pt">Item 13.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a022_v1"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a023_v1"><span style="font-size: 10pt">Item 14.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a023_v1"><span style="font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><a href="#a024_v1"><span style="font-size: 10pt"><b>PART IV</b></span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a025_v1"><span style="font-size: 10pt">Item 15.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a025_v1"><span style="font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a026_v1"><span style="font-size: 10pt">Item 16.</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a026_v1"><span style="font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt">&#160;</td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td colspan="2" style="padding-right: 0.5pt; padding-left: 0.5pt"><a href="#a027_v1"><span style="font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td style="padding-right: 0.5pt; padding-left: 0.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: 0.2pt"><i>Below is a summary of
the principal risk factors related to the Annual Report on Form 10-K (&#8220;10-K&#8221;) for the fiscal year ended December 31,
2022. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8203;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Summary of Risk Factors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business is subject to a number of risks of which you should
be aware before making an investment decision. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of
this Form 10-K. These risks include, but are not limited to, the following:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">We are a preclinical-stage company with a limited operating history, and have no products
approved for commercial sale. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">We are dependent on the successful development, regulatory approval and commercialization
of one or more product candidates, and may achieve any of these objectives.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>We intend to utilize the 505(b)(2) pathway for the regulatory approval of NPM-119. Final marketing approval of NPM-119 or any
of our other product candidates by the FDA, or other regulatory authorities may be delayed, limited, or denied, any of which would
adversely affect our ability to generate operating revenues.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable
terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our
product development, commercialization efforts or other operations.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience
delays in developing our product candidates, and our clinical development efforts may not yield favorable results.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>From time to time, we expect to release results from preclinical studies and clinical trials. Positive results from preclinical
studies and early-stage clinical trials may not be predictive of future results, and initial positive results in any of our clinical
trials may not be indicative of results obtained when the trial is completed or in later stage trials.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">We are subject to a multitude of manufacturing risks, including reliance on third parties,
any of which could substantially increase our costs and limit supply of our product candidates. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">We may not be able to protect our proprietary or licensed technology. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">Claims or lawsuits relating to infringement of intellectual property rights brought by
or against us may adversely affect our business, financial condition, and results of operations. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">We may be unable to adequately prevent disclosure of trade secrets and other proprietary
information. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8203;</p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND FACTORS THAT MAY AFFECT FUTURE RESULTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">This Annual Report
on Form 10-K, or Annual Report, includes forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, or the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.
All statements other than statements of historical fact contained in this Annual Report are forward-looking statements. In some
cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221;
&#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221;
&#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology,
although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are
not limited to, statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated operating and financial performance, business plans, and prospects;</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expectations for our products, including anticipated regulatory submissions, study completion, approvals, clinical trial results and other developing data that become available, potential market size, and potential reimbursement pathways;</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the initiation, timing, design, progress and results of our clinical trials, and our research and development program; and</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the success of the business combination on including future
    capital expenditures, expenses, synergies, economic performance, indebtedness, financial condition, losses, future prospects,
    business and management strategies for the management, expansion and growth of the combined company&#8217;s operations and
    other conditions to the successful synergies of the business combination.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Any forward-looking
statements in this Annual Report reflect our current views with respect to future events or to our future financial performance
and involve known and unknown risks, uncertainties, assumptions and other factors described under the &#8220;Risk Factors&#8221;
section and elsewhere in this Annual Report, that may cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these uncertainties,
you should not place undue reliance on these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">In addition, statements
that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that
we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and investors are cautioned not to unduly rely upon these statements as predictions of future events. Except
as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information
becomes available in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">This Annual Report
also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases,
including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties
and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise
expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar
data prepared by market research firms and other third parties, industry, medical and general publications, government data and
similar sources<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a001_v1"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a002_v1"></span>Item 1. Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Our Company</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b>Company Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani
Medical, Inc. (&#8220;Vivani,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar
terms) is a preclinical &#160;&#160;stage biopharmaceutical company which develops miniaturized, subdermal implants utilizing
its proprietary NanoPortal&#8482; technology to enable long-term, near constant-rate delivery of a broad range of medicines to
treat chronic diseases. Vivani uses this platform technology to develop and potentially commercialize drug implant candidates,
alone or in collaboration with pharmaceutical company partners to address a leading cause of poor clinical outcomes in the treatment
of chronic disease, medication non-adherence. According to the US Centers for Disease Control and Prevention (CDC), adherence
is defined as the extent to which an individual&#8217;s behavior, including taking medications, corresponds to recommendations
from a health care provider. For example, approximately 50% of patients treated for type 2 diabetes are medication non-adherent,
which can lead to poor clinical outcomes. We are developing a portfolio of miniature, sub-dermal drug implant candidates that,
unlike most oral and injectable medicines, are designed with the goal of guaranteeing medication adherence by delivering therapeutic
drug levels for up to 6 months or the life of the implant. In addition, our aim is to minimize fluctuations in patients&#8217;
drug levels through the use of our NanoPortal technology, which may improve the tolerability profiles for medicines that produce
side effects associated with fluctuating drug levels in the blood.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani resulted from the August
2022 business combination of Second Sight Medical Products, Inc. (Second Sight) and Nano Precision Medical, Inc. (NPM). Since
inception, Vivani&#8217;s main priority has been the further development of the Company&#8217;s lead program, NPM-119, a
miniature, 6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes under the Company&#8217;s
Biopharm Division (formerly NPM). In parallel, Vivani&#8217;s new management team remained committed to identifying and
exploring strategic options for the Neuromodulation Division (formerly Second Sight) that will enable further development of
its pioneering neurostimulation systems to help patients recover critical body functions.&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, Vivani announced the filing of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission
(&#8220;SEC&#8221;) for the proposed initial public offering of Cortigent, Inc. (&#8220;Cortigent&#8221;). Cortigent, currently
a wholly-owned subsidiary of Vivani,  was formed for the purpose of advancing the business of Vivani&#8217;s neuromodulation
division and is expected to continue to be majority-owned by Vivani immediately following the initial public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, Vivani&#8217;s focus will be on the further development of NPM-119 and its emerging pipeline of innovative miniature,
long-term drug implants to treat patients with chronic diseases and high unmet medical need. The origins of this business started
while its current Vivani CEO and NPM co-founder Adam Mendelsohn and two of his graduate school colleagues at the University of
California, San Francisco (UCSF) and the University of California, Berkeley (UCB), entered business school competitions leveraging
their growing knowledge of chemistry, drug delivery, and nanoscale technology to propose the development of new miniature, biocompatible,
drug implant prototypes capable of releasing therapeutic drug levels over an extended period of time. Based on their success and
encouragement from professors and others, including medical device/pharmaceutical icon Al Mann, Dr. Mendelsohn and colleagues
started Nano Precision Medical in 2009 and operations began in 2011 in an incubator on the UCB campus. Today, the company has
grown to nearly 40 full-time employees and its current headquarters and operations are located at 5858 Horton Street, Emeryville,
California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Proprietary NanoPortal&#8482; Implant Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani&#8217;s
implant technology, which we refer to as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide
many months of therapeutic delivery of potent molecules. The technology has no moving parts, which is intended to minimize fluctuating
drug delivery over the duration of the implant and is also tunable. Vivani has primarily been developing implant candidates around
peptide therapeutics, but the technology has potential application across a wide range of molecular types. The key innovative
component of the technology is a biocompatible titanium-oxide nano-porous membrane which consists of millions of precisely
sized nanotubes whose inner diameters represent the only path for drug molecules to exit the reservoir once the implant is fully
assembled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="img001_v15.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the key to the technology&#8217;s ability to achieve near constant release without moving parts is the ability to precisely
tune the inner diameter of the nanotubes to the same size range as individual drug molecules. If the inner diameter of the nanotubes
is smaller than the size of a given drug molecule, there would be no release at all. If the inner diameter of the nanotubes is
much larger than the size of a given drug molecule, the rate at which the drug leaves the reservoir would follow traditional physics
and would decrease over time as the drug concentration decreases. However, when the opening is close enough in size to the drug
molecules, the drug release is constrained and can result in a variety of desirable delivery profiles, including near constant
release. Vivani&#8217;s NanoPortal technology has demonstrated near constant release in an animal model for six months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
drug molecules with adequate potency and stability, NanoPortal can allow minimization of the implant size while extending implant
duration. A custom delivery profile can also be achieved by adjusting the number of accessible nanotubes, engineering changes
to the implant, and/or changes in formulation parameters. With the design flexibility afforded by the NanoPortal technology, Vivani
plans to develop a portfolio of drug implant candidates aimed at addressing chronic diseases with high unmet medical needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani&#8217;s
NanoPortal technology has demonstrated near constant <i>in vitro </i>release &#160;&#160;for two dose configurations (see left
portion of the chart below). <i>In vitro</i> testing was performed at 37&#176;C on implant devices stored in a buffer solution
adjusted to a physiological pH of 7.4. For a high-dose configuration, the observed near-constant release was demonstrated over
the 12-week measurement period, after which the drug began to be depleted. For a low-dose configuration, the observed near-constant
release lasted for 24 weeks. In addition, the near-constant <i>in vitro </i>release observed has been shown to translate into
sustained exposure levels <i>in vivo </i>over a 6-month duration in an animal model (depicted in a separate chart below). Finally, NanoPortal has demonstrated minimal <i>in vitro</i>&#160;fluctuations during 2.5-hour interval sampling periods which demonstrates
a very smooth release profile (see right portion of the chart below for individual device release rates).</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="img002_v15.jpg" alt="" style="height: 331px; width: 600px" /></p>





<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Emerging Portfolio</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Although
Vivani&#8217;s proprietary NanoPortal implant technology may potentially be broadly applied across a wide range of therapeutic
molecules and disease areas, our initial focus is on peptide therapeutics for the treatment of patients with metabolic disease.
The pipeline table below-depicts our current portfolio of
four distinct pre-clinical stage programs targeting type 2 diabetes (in humans and companion cats), obesity, and NASH (non-alcoholic
steatohepatitis).</span></p>





<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="img003_v15.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary description of each pipeline program:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPM-119</b>:
This exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes with an
anticipated duration of six months. Exenatide is a GLP-1 receptor agonist (GLP-1 RA or GLP-1) and was originally approved as the
twice-daily subdermal injection, Byetta&#174; (exenatide) injection, approved in 2005 by the U.S. Food and Drug Administration
(FDA) as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a
sulfonylurea, or a combination of metformin and a sulfonylurea but have not achieved adequate glycemic control. Byetta was the
first GLP-1 to reach the U.S. marketplace.&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the CDC, more than 37 million Americans have diabetes and 90-95% have type 2 diabetes. The total number of people living worldwide
with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. According to the American Diabetes Association
(ADA), the total cost of diagnosed diabetes in the U.S. was $327 billion in 2017, including $237 billion for direct medical costs
and $90 billion for reduced productivity. In 2022, the global sales of GLP-1 receptor agonists products was nearly $20 billion.
Because the current drug adherence rate for type 2 diabetes is only 40-60% for oral and injectable GLP-1 products, Vivani
believes there is significant unmet need for a GLP-1 implant that could address non-adherence. Vivani holds all commercial rights
to NPM-119. </span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe NPM-119, our lead drug implant candidate, has the potential to address two important limitations of the GLP-1category,
namely, poor real-world medication adherence, and a potentially undesirable gastrointestinal tolerability profile.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address real-world medication adherence, NPM-119 is designed to provide 6 months of steady dosing from a single miniature, subdermal
implant. Current GLP-1 products are associated with only 50-60% real-world medication adherence. Non-adherent patients do not
receive the full potential benefits of existing treatments. In addition, medication non-adherence for patients with type 2 diabetes
is associated with approximately $5,500 per non-adherent patient in avoidable healthcare costs associated with unnecessary acute
care and hospitalization visits.&#160;&#160; NPM-119 has the potential to offer a highly differentiated 6-month dosage form to
address the medication adherence challenge. Results from a small, third-party market research study funded by Vivani indicate
that the majority of physicians will be highly likely to recommend a product with the NPM-119 target product profile to their
type 2 diabetes patients. In the market research study, primary care physicians (n=10) provided an average rating of 8.3 out of
10 in terms of likelihood of recommending a product with NPM-119&#8217;s target product profile. These preliminary results are
encouraging since 90% of type 2 diabetes patients are treated in a primary care setting.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
well-documented side effect of the GLP-1 class is poor gastrointestinal (GI) tolerability. GI intolerance can present as nausea
and vomiting which can lead to volume loss (hypovolemia), acute kidney injury (AKI) and potentially major cardiovascular adverse
events. GI-related issues are the most commonly reported side effect for all drugs in the GLP-1class. In responding to a marketing
application filed for Intarcia Therapeutics&#8217; ITCA 650 &#160;&#160;exenatide implant candidate, with a proposed indication
for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM), the FDA
stated in a July 29, 2022 letter that they believe that marked increases in the dose of a GLP-1 are responsible for increased
risk of GI intolerance. The establishment of marked GLP-1 dose increases being responsible for GI intolerance combined with the
daily <i>in vitro </i>variability exhibited by ITCA 650 resulted in the FDA summarizing their findings as &#8220;The clinical
data in the three pivotal clinical trials for ITCA 650&#8211;including the high rates of nausea, vomiting, and diarrhea, the high
rates of discontinuations due to these adverse gastrointestinal reactions, and most notably, the increased risk of acute kidney
injury (AKI) comprise safety signals whose root cause can reasonably be concluded to be irregular and uncontrolled exenatide release&#8221;
and &#8220;The data provided to validate the limits of the in vitro dose delivery specifications did not support the safe and
effective use of the device constituent of ITCA 650.&#8221; We believe Vivani&#8217;s NanoPortal technology, which is specifically
designed and tested to deliver regular and controlled exenatide release, may overcome these challenges. Our NanoPortal implant
technology has no moving parts that could otherwise contribute to variations in drug release rates. NanoPortal has demonstrated
the ability to release exenatide with minimal fluctuations <i>in vitro </i>on time scales that are even shorter than a day as
exhibited by the 2.5-hour <i>in vitro </i>release rates that are shown in the Technology section above. Since the half-life of
exenatide in humans is 2.4-4 hours, steady release from one 2.5-hour interval to the next is expected to be associated with minimal
device-related exposure fluctuations, potentially minimizing the opportunity for gastrointestinal events.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investigational new drug application (IND) to support the initiation of clinical studies with NPM-119 is planned for submission
in 2023. Vivani&#8217;s initial clinical study, called LIBERATE-1, is designed as a 12-week, randomized, Phase 2 clinical study
to investigate the safety, tolerability and full pharmacokinetic profile of NPM-119 in patients with type 2 diabetes. The study
will include a Bydureon BCise&#174; (exenatide extended-release injectable suspension) comparator, will investigate glycemic control
as a secondary endpoint, and will also evaluate changes in weight. &#160;The study will recruit patients on a non-exenatide GLP-1
therapy which will be discontinued prior to randomization. Conditional &#160;&#160;institutional review board (IRB) approval has
been obtained &#160;pending IND clearance. The LIBERATE-1 study design was discussed in multiple FDA interactions and is planned
to initiate in mid-2023, subject to IND clearance. The pharmacokinetic profile obtained in a preclinical study with the NPM-119
configuration (n=8) intended for use in LIBERATE-1 is provided in the graphic below. The left axis shows experimentally measured
exenatide plasma concentrations from rats implanted with NPM-119. The right axis shows expected exenatide plasma concentrations
in humans, assuming there are no NPM-119 specific translation effects, based on previously established clearance rate differences
between rats and humans when exposed to steady state delivery of exenatide. Since the EC<sub>50</sub> (concentration of exenatide
which provides half maximal response) is 0.0835 ng/mL, this pharmacokinetic profile is expected to provide therapeutic exposure
levels of exenatide in humans unless, for example, there are any device-specific pharmacokinetic translation effects from rats
to humans which the results of LIBERATE-1 will determine. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="img004_v15.jpg" alt="" style="height: 300px; width: 700px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani
has also made progress towards preparing for future clinical development of NPM-119. In the second half of 2023, Vivani is planning
to relocate into a new facility designed to provide suitable capacity for manufacturing of clinical materials for registration
studies as well as commercial-scale supply. Based on preliminary discussions with the FDA, Vivani intends to pursue the 505(b)(2)
pathway and believes that a single pivotal trial evaluating a 6-month NPM-119 configuration that is representative of the proposed
commercial configuration may be sufficient to support registration in the U.S. That said, throughout the NPM-119 development process,
we also intend to further engage with regulatory authorities on the timing, duration, endpoints, number of enrolled patients and
other aspects of trial design for future clinical trials of NPM-119.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br />
</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have conducted a pre-clinical study to evaluate proof-of-concept activity of NPM-119. In that study, a six-month implantation of
NPM-119 into rats was associated with steady exenatide concentration over the duration of the implant, as depicted in the figure
below. </span>&#160;&#160;&#160;</p>





<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="img005_v15.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the NPM-119 program targeting the treatment of patients with type 2 diabetes, Vivani believes that the results of
LIBERATE-1, if favorable, could support the further exploration of NPM-119 for obesity with a higher dose&#160; configuration.
This would be similar to the strategy Novo Nordisk has taken with its semaglutide injection franchise, Ozempic&#174; and Wegovy&#174;
for type 2 diabetes and obesity, respectively.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OKV-119</b>:
This exenatide implant is under development for the treatment of obese and diabetic companion cats. In 2017, there were over 90
million cats in the U.S. 20-30 million cats have obesity, and 2-4 million cats have diabetes. Over $100 billion is spent on pets
in the U.S. each year, this spending is expected to triple over the next 10 years, and pet health is the fastest-growing sub-segment
of this market. Since cats are difficult to medicate, we believe that a small subdermal implant administered by a veterinarian
can be a welcome option for many pet owners, if approved.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
program is partnered with Okava Pharmaceuticals, Inc. (&#8220;Okava&#8221;) who is responsible for management and funding of the
development and regulatory activities of OKV-119&#160; and, if approved, ultimate commercialization of this product. In 2022,
OKV-119 advanced out of the feasibility stage after having produced in vivo data demonstrating a configuration that provided adequate
exenatide exposure to companion felines over a 12-week duration.&#160;&#160; Vivani does not anticipate any significant Vivani
focus beyond the support of product development and manufacturing activities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPM-139</b>&#160;:
This implant candidate is in feasibility testing for the treatment of patients with obesity. The undisclosed compound, is the
proprietary molecule of a large pharmaceutical company &#160;with whom we have entered into a material transfer agreement to conduct
feasibility studies. The undisclosed compound is the drug substance in an approved product which is marketed in the U.S. for the
treatment of obesity. Although the initial target product profile is under development as a six-month implant, we believe this
product candidate has the potential for once-yearly administration based on preliminary results of feasibility testing to date.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for GLP-1 therapy in the treatment of patients with obesity is also attractive and growing rapidly. As an example, Novo
Nordisk&#8217;s Wegovy&#174; (semaglutide injection) sold $336M in the fourth quarter of 2022, which represents a 111% increase
quarter-over-quarter from the third quarter of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPM-159</b>&#160;:
This potential &#160;six-month implant candidate is in feasibility testing for the treatment of patients with non-alcoholic steatohepatitis
(NASH). The undisclosed compound is the proprietary molecule of a large pharmaceutical company&#160; with whom we have entered
into a material transfer agreement to conduct feasibility studies. The undisclosed compound is in a drug class that has already
demonstrated, in clinical trials by a third party, signals of clinical activity for the treatment of NASH, and multiple product
candidates based on that drug class are currently under development in the U.S.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our current pipeline, Vivani intends to apply its extensive experience and proprietary implant technology to develop a pipeline
of drug implant candidates that have the potential to address chronic diseases with high unmet medical needs across multiple therapeutic
categories and disease areas. For example, Vivani is also following the evaluation of the GLP-1 agonist semaglutide in the treatment
of NASH and Alzheimer&#8217;s disease &#160;. If one or more of these trials shows encouraging results, Vivani believes that a
miniature long-term drug implant could have the potential to be an attractive alternative treatment option in these underserved
patient populations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani&#8217;s
mission is to provide people with the freedom to live healthier. Vivani develops miniaturized drug implants using its proprietary
NanoPortal implant technology to enable delivery of a broad range of medicines to treat chronic diseases. These products, designed
to address poor medication adherence, are anticipated to significantly improve the health of otherwise non-adherent patients and
to provide assurance to their family members and to the health care professionals who treat them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani
plans to initially test its technology and business model through the clinical and regulatory development of its lead program,
NPM-119 (exenatide implant). The active drug, exenatide, is a member of the GLP-1 receptor agonist class of drugs. Drug products,
including drug substances within this relatively new drug class, have already been successfully developed and marketed for the
treatment of both type 2 diabetes and obesity and GLP-1 products are the category leader in revenue for both the type 2 diabetes
and obesity drug treatment categories. In addition, GLP-1 receptor agonists have shown promising early clinical results in NASH
and they are being evaluated in other therapeutic areas including Alzheimer&#8217;s disease. Vivani intends to complete IND-enabling
studies and submit an IND to permit a first-in-human (FIH) study of NPM-119 in type 2 diabetes in 2023. In addition, Vivani intends
to advance its early-stage programs in obesity and NASH with two undisclosed collaborations with global pharmaceutical companies.
Its business strategy includes:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcing
                                         top-line results from LIBERATE-1 in the first half of 2024;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilizing the 505(b)(2) abbreviated approval
                                                                                                                                                     pathway for NPM-119 and, where applicable, for other programs whenever feasible;</span></td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing
                                         the feasibility assessments for NPM-139 and NPM-159 in 2023;</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
                                         manufacturing capabilities and systems to produce materials for a future clinical development
                                         of our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining,
                                         expanding, and protecting its intellectual property portfolio;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seeking
                                         regulatory approvals for any product candidates that successfully complete clinical trials;
                                         and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adding
                                         operational, financial, and management information systems and personnel, including personnel
                                         to support its planned product development and commercialization efforts, as well as
                                         to support its regulatory responsibilities as a public reporting company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.
We face competition and potential competition from a number of sources, including pharmaceutical and biotechnology companies,
generic drug companies, drug delivery companies and academic and research institutions. Some of these companies are developing
therapies that are directly competitive to our approach. We believe the key competitive factors that will affect the development
and commercial success of our product candidates include ease of administration and convenience of dosing, therapeutic efficacy,
safety and tolerability profiles and cost. Many of our potential competitors have substantially greater financial, technical and
human resources than we do, as well as more experience in the development of product candidates, obtaining FDA and other foreign
regulatory approvals of products, and the commercialization of those products. Consequently, our competitors may develop similar
products to address the indications targeted by our current product candidates or for other indications we may pursue in the future,
and such competitors&#8217; products may be more effective, better tolerated and less costly than our product candidates. Our
competitors may also be more successful in manufacturing and marketing their products than we are. We will also face competition
in recruiting and retaining qualified personnel and establishing clinical trial sites and patient enrollment in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competition for Vivani will be dependent upon the individual product candidate in development. For Vivani&#8217;s lead asset,
NPM-119, the competition could be defined as any drug product/manufacturer approved for use in the treatment of patients with
type 2 diabetes. However, we believe that our more direct competitors comprise other GLP-1 receptor agonist and combination products
with a GLP-1 receptor agonist component approved or in development for type 2 diabetes only. In May 2022, Lilly&#8217;s Mounjaro&#8482;
(tirzepatide) was approved as the first and only combination GIP and GLP-1 receptor agonist for the treatment of adults with type
2 diabetes. Manufacturers with approved GLP-1 receptor agonists include Lilly, Novo Nordisk, AstraZeneca, and Sanofi.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the marketed GLP-1 products, Intarcia Therapeutics has continued to seek approval of ITCA 650 (six-month exenatide
implant) for the treatment of patients with type 2 diabetes since 2016. In public correspondence, FDA asserted that the ITCA 650
NDA did not meet criteria for approval because (i) data submitted in the application do not show that the product would be safe
under the proposed conditions of use and (ii) the methods used in, and the facilities and controls used for, the manufacture,
processing, or packing of the product are not shown to be adequate to preserve its identity, strength, quality, and purity. Further
correspondence disclosed additional deficiencies which included, but were not limited to, data that did not demonstrate adequate
device reliability in regard to dose delivery. While the ultimate fate of ITCA 650 remains unclear from a regulatory approval
perspective, the information provided by FDA and Intarcia, informs our development path and regulatory strategy. In addition,
the support for a six-month exenatide implant provided by patients, physicians, key opinion leaders and the American Diabetes
Association provides confidence for the NPM-119 opportunity.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the challenges experienced by ITCA 650 may have been related to Intarcia&#8217;s proprietary implant technology. The potential
differentiation between Intarcia&#8217;s DUROS (osmotic pump) implant technology and Vivani&#8217;s NanoPortal (no moving parts)
implant technology could be a key differentiator based on recent FDA correspondence. In addition, Vivani&#8217;s NanoPortal technology
should also allow for a much smaller size implant and corresponding needle gauge, which may facilitate easier insertion and removal
of NPM-119 compared to ITCA 650. Although no head-to-head clinical studies of NPM-119 and ITCA 650 have been conducted, there
are differences in the underlying delivery technology between these two drug/device combination candidates, which may result in
different release profiles, as depicted below:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="img006_v15.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NPM-119</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM-119
(exenatide implant) candidate is a GLP-1 receptor agonist in development for the treatment of type 2 diabetes. Competition in
the GLP-1 class for this indication includes the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lilly
                                         (Trulicity&#174;/dulaglutide) and (Mounjaro&#8482;/ GIP and dulaglutide dual agonist)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novo
                                         Nordisk (Victoza&#174;/liraglutide); (Ozempic&#174;/semaglutide); and (Rybelsus&#174;/semaglutide)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AstraZeneca
                                         (Bydureon BCise&#174;/exenatide); and (Byetta&#174;/exenatide)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanofi
                                         (Adlyxin&#174;/lixisenatide)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe NPM-119, our lead drug implant candidate, has the potential to address two important aspects of the GLP-1category which
are associated with the above-mentioned products, namely, poor real-world medication adherence and potential undesirable gastrointestinal
tolerability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NPM-139</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM-139
(undisclosed active pharmaceutical ingredient) is in feasibility testing for the treatment of patients with obesity. According
to the World Obesity Atlas 2022, one billion adults globally will have obesity (BMI &#8805;30 kg/m2), or about 18% of the adult population,
by 2030. In addition, it is expected that there will be 103 million children and 150 million adolescents living with obesity by
2030 as well.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
in the treatment of obesity includes the following:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Teva&#8217;s
                                         Adipex&#174; (phentermine) and generics</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roche&#8217;s
                                         Xenical&#174; (orlistat) generics</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivus&#8217;s
                                         Qsymia&#174; (phentermine/topiramate extended release)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orexigen&#8217;s
                                         Contrave&#174; (bupropion/naltrexone)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novo
                                         Nordisk&#8217;s Saxenda&#174; (liraglutide) and Wegovy&#174; (semaglutide)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NPM-159</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM-159
(undisclosed active pharmaceutical ingredient)&#160; is in feasibility testing for the treatment of non-alcoholic steatohepatitis
(NASH). According to the American Liver Foundation, approximately 5% of the U.S. adult population have NASH. About 20% of the
U.S. adult population have non-alcoholic fatty liver disease (NAFLD). NASH is the more severe form of NAFLD in which patients
have hepatitis or swelling or inflammation of the liver and liver cell damage.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no currently approved drugs for the treatment of NASH. Although the active drug in NPM-159 is undisclosed, there is encouraging
preliminary clinical data from another member in this class of drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani
currently does not have a commercial infrastructure in any geography. As we progress our programs through development, we may
build a commercial infrastructure in the United States and selected other territories to support the commercialization of each
of our product candidates when we believe a regulatory approval in a particular territory is likely. We intend to conduct market
research in connection with designing our commercialization strategy for each of our product candidates. We may seek licensing
or other strategic collaborations with, for example, global pharmaceutical company partners, to support our commercialization
efforts. We will consider a range of options including building a commercial capability internally, leveraging third-party biopharmaceutical
commercialization organizations, other strategic partners, distributors and/or contract sales forces to expand the commercial
availability of our product candidates when appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 27.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani
was incorporated under the laws of California on December 17, 2009. Its operations began in 2010. Vivani&#8217;s corporate office
is located at 5858 Horton St. #280, Emeryville, California, 94608; its telephone number is (415) 506-8462; and its website is
located at www.vivani.com. In November 2022, Vivani signed a long-term lease for a new facility at 1350 South Loop Road, Alameda,
CA 94502 to accommodate office space, R&amp;D, analytical labs and a GMP manufacturing suite to support our research and development
activities. We plan to initiate our move into the new facility in September 2023 and have it completed by the end of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chemistry,
Manufacturing, and Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani
has developed production processes and quality systems to support the manufacture of NPM-119 clinical materials for use in the
currently planned first-in-human (LIBERATE-1) clinical study. A small number of processes are continuing to be refined prior to
the production of the materials to be used in the study. In addition, efforts have also been initiated to support potential subsequent
clinical investigations&#160;.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vivani
has established in-house research, development, and manufacturing capabilities in its corporate headquarters in Emeryville, California,
U.S. Vivani has also engaged with contract manufacturers and/or analytical laboratories for selected processes when appropriate.
In general, Vivani purchases the drug substance from a third-party manufacturer and all assembly processes in which the drug substance
is present, including the associated in-process testing, are intended to be performed by contract manufacturers&#160;. Several
device components and all raw materials are purchased from outside vendors according to established specifications. The device
assembly processes, including the associated in-process testing, and final product testing are anticipated to be performed by
Vivani in Emeryville. The custom applicator&#160;, which is intended to facilitate subdermal placement of the implant in patients,
has been designed and will be manufactured by a contract manufacturer. Several device components and the drug substance are purchased
from outside vendors according to established specifications.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the NPM-119 program advances, Vivani may also engage with additional contract analytical and manufacturing organizations as needed.
Currently, Vivani is not a party to any long-term, commercial manufacturing agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b>&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 27, 2023, Vivani held or controlled
14 issued U.S. patents, 8 pending U.S. patent applications, and 12 patents in various jurisdictions outside the United States.
Additionally, Vivani is pursuing 22 corresponding patent applications that are pending in various foreign jurisdictions. Further
advancement of Vivani&#8217;s intellectual property portfolio will require the filing of patent applications related to its proprietary
manufacturing process and product candidates. Vivani has patents extending into Australia, China, Germany, India, Japan, Netherlands,
New Zealand, Republic of Korea, Russia and the United States of America, as well as trade secrets protecting Vivani&#8217;s intellectual
property. Vivani&#8217;s patent prosecution strategy includes exploration of opportunities to expand its patent life and use cases
in order to broaden its existing patent portfolio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Below is a further description of certain
of Vivani&#8217;s key issued patents, including the category of protection, expiration date, number of related patents issued in
foreign jurisdictions and the product candidates to which each patent relates. Vivani currently holds or controls:</p>



<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>14 patents issued in the United States (U.S. Patent Nos. 7,687,431, 9,814,867, 9,770,412, 10,479,868, 11,021,576, 10,045,943,
10,688,056, 9,511,212, 10,105,523, 10,792,481, 10,525,248, 11,129,791, 11,191,935 and 11,191,935) and 12 patents issued in foreign
jurisdictions. The patents are directed to the manufacture and use of a drug delivery system and more specifically, to a titania
nanotube membrane and capsule utilizing the proprietary NanoPortal technology platform. The methods include methods of drug delivery
and treatment with a composition such as exenatide, methods to implant a drug delivery system, and methods of manufacturing a nanoporous
membrane, as well as an implantable drug delivery system, a titania nanotube membrane, and titania nanotubes. These U.S. patents
relate to an apparatus to implant a drug delivery system, an implantable drug delivery system comprising exenatide, a titania nanotube
membrane, a method of making a titania nanotube membrane, and a method of making titania nanotubes, which are expected to expire
in 2025-2038, while patents issued in foreign jurisdictions are expected to expire in 2024-2035;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>4 patents issued in the United States (U.S. Patent Nos. 9,511,212, 10,792,481, 11,129,791 and 11,478,430), which are also directed
to implantable drug delivery devices. These U.S. patents relate to exenatide and are expected to expire in 2035 and 2037;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>3 patents issued in the United States (U.S. Patent Nos. 10,525,248, 10,105,523 and 11,191,935), which are also directed to
apparatuses and methods for promoting fluid uptake. These U.S. patents relate to an apparatus to implant a drug delivery system
and are expected to expire in 2036 and 2038;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>5 patents issued in the United States (U.S. Patent Nos. 10,479,868, 11,021,576, 10,045,943, 10,688,056 and 11,478,430) and
3 patent issued in a foreign jurisdiction which are also directed to formulations. These U.S. patents relate to an exenatide composition
and an implantable drug delivery system comprising exenatide and are expected to expire in 2035;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>1 patent issued in the United States (U.S. Patent No. 9,770,412), which is also directed to coated nanoporous membranes. This
U.S. patent relates to a method of manufacturing a nanoporous membrane and a nanopore membrane, which is expected to expire in
2035;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>1 patent issued in the United States (U.S. Patent No. 9,814,867) and 4 patents issued in foreign jurisdictions, which are also
directed to titania nanotube membranes. This U.S. patent relates to a method of making a titania nanotube membrane and is expected
to expire in 2034;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>1 patent issued in the United States (U.S. Patent No. 7,687,431) and 5 patents issued in foreign jurisdictions, which are also
directed to nanotube fabrication. This U.S. patent relates to a method of making titania nanotubes and is expected to expire in
2025; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>8 pending U.S. applications and 22 applications pending in foreign jurisdictions, which are directed to implantable drug delivery
devices, methods to control release, and formulations.</td></tr></table>



<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
possible, Vivani seeks to protect its inventions by filing U.S. patents as well as foreign counterpart applications in select
other countries. Because patent applications in the U.S. are maintained in secrecy for at least eighteen months after the applications
are filed, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, Vivani
cannot be certain that it was the first to make the inventions covered by each of its issued or pending patent applications, or
that Vivani was the first to file for protection of inventions set forth in such patent applications. Vivani&#8217;s planned,
or potential products may be covered by third-party patents or other intellectual property rights, in which case continued development
and marketing of its products would require a license. Required licenses may not be available to Vivani on commercially acceptable
terms, if at all. If Vivani does not obtain these licenses, it could encounter delays in product introductions while it attempts
to design around the patents, or Vivani could find that the development, manufacture, or sale of products requiring such licenses
are not possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, Vivani also relies on know-how, trade secrets, and the careful monitoring of proprietary information,
all of which can be difficult to protect. Vivani seeks to protect some of its proprietary technology and processes by entering
into confidentiality agreements with its employees, consultants, and contractors. These agreements may be breached, Vivani may
not have adequate remedies for any breach and its trade secrets may otherwise become known or be independently discovered by competitors.
To the extent that Vivani&#8217;s employees or its consultants or contractors use intellectual property owned by others in their
work for Vivani, disputes may also arise as to the rights in related or resulting know-how and inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in the U.S. at the federal, state, and local level and in other countries extensively regulate, among other things,
the research and clinical development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping,
promotion, advertising, distribution, post-approval monitoring and reporting, marketing, pricing, and export and import of drugs,
medical devices and combinations of drugs and devices (combination products) such as those we are developing. Generally, before
a new drug or drug-device combination product can be marketed, considerable data demonstrating its quality, safety, and efficacy
must be obtained, organized into a format specific to each regulatory authority, submitted for review, and approved by the relevant
regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., the FDA regulates drugs, devices and combination products under the Federal Food, Drug, and Cosmetic Act (FDCA), and
its implementing regulations. These products are also subject to other federal, state and local statutes and regulations. The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.
requirements at any time during the product development process, approval process or after approval, may subject an applicant
to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s, or another regulatory
authority&#8217;s, refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters,
product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions,
fines, debarment, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial
enforcement action could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Drug Development </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are subject to regulation as combination products, which means that they are composed of both a drug product
and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by
different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction
over its regulation based on a determination of the combination product&#8217;s primary mode of action, which is the single mode
of action that provides the most important therapeutic action. In the case of our product candidates, the primary mode of action
is attributable to the drug component of the product, which means that the FDA&#8217;s Center for Drug Evaluation and Research
has primary jurisdiction over the premarket development, review and approval of our product candidates. Accordingly, we plan to
investigate our products through the IND framework and seek approval through the NDA pathway. The process required by the FDA
before a drug may be marketed in the U.S. generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                         of extensive preclinical laboratory tests, animal studies and formulation studies in
                                         accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice
                                         regulations; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                         to the FDA of an IND, which must become effective before human clinical trials may begin;
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                         by an independent institutional review board (IRB) representing each clinical site before
                                         each clinical trial may be initiated;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                         of adequate and well-controlled human clinical trials in accordance with an applicable
                                         IND and other clinical study related regulations, sometimes referred to as good clinical
                                         practices (GCP) regulations, to establish the safety and efficacy of the proposed drug
                                         for its proposed indication; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                         to the FDA of an NDA which, for a combination product like our product candidates, is
                                         expected to include information and data regarding the drug delivery device technology;
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                         completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                         at which the product, or components thereof, are produced to assess compliance with the
                                         FDA&#8217;s current good manufacturing practice requirements (cGMP); </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                         FDA inspection of Vivani ,the clinical trial sites or other vendors that generated the
                                         data in support of the NDA; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                         of associated user fees;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
                                         by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                         review and approval of the NDA prior to any commercial marketing or sale; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                         with any post-approval requirements, including the potential requirement to implement
                                         a Risk Evaluation and Mitigation Strategy (REMS), and the potential requirements to conduct
                                         post-approval studies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a pharmaceutical product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include
laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. A sponsor must submit
the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data
or literature, to the FDA as part of the IND. An IND is an exemption from the FDCA that allows an unapproved product to be shipped
in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational
product to humans. The sponsor must also include a protocol detailing, among other things, the objectives of the initial clinical
trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical trial
lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical
trial and places the trial on a clinical hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve
any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before
or during clinical trials due to safety concerns or non-compliance, and may be imposed on all drug products within a certain class
of drugs. The FDA also can impose partial clinical holds, for example, prohibiting the initiation of clinical trials of a certain
duration or for a certain dose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations.
These regulations include the requirement that all research subjects provide informed consent in writing before their participation
in any clinical trial. Further, an IRB must review and approve the plan for any clinical trial before it commences at any institution,
and the IRB must conduct continuing review and reapprove the study at least annually. An IRB considers, among other things, whether
the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits.
The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical
trial subject or his or her legal representative and must monitor the clinical trial until completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
new clinical protocol and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols
detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria,
and the parameters to be used to monitor subject safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         1. The product is initially introduced into a small number of healthy human subjects
                                         or patients and tested for safety, dosage tolerance, absorption, metabolism, distribution
                                         and excretion and, if possible, to gain early evidence on effectiveness. In the case
                                         of some products for severe or life-threatening diseases, especially when the product
                                         is suspected or known to be unavoidably toxic, the initial human testing may be conducted
                                         in patients. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         2. Involves clinical trials in a limited patient population to identify possible adverse
                                         effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
                                         targeted diseases and to determine dosage tolerance and optimal dosage and schedule.
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                         3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety
                                         in an expanded patient population at geographically dispersed clinical trial sites. These
                                         clinical trials are intended to establish the overall risk/benefit relationship of the
                                         product and provide an adequate basis for product labeling. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are
used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances,
the FDA may mandate the performance of Phase 4 trials. Companies that conduct certain clinical trials also are required to register
them and post the results of completed clinical trials on a government-sponsored database, such as ClinicalTrials.gov in the United
States, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA,
and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings
from other studies that suggest a significant risk to humans exposed to the product, findings from animal or in vitro testing
that suggest a significant risk to human subjects, and any clinically important increase in the rate of a serious suspected adverse
reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical
trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial
is not being conducted in accordance with the IRB&#8217;s requirements or if the product has been associated with unexpected serious
harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the
clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a
trial may move forward at designated check points based on access to certain data from the study. The clinical trial sponsor may
also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about
the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and
purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. In addition, for certain
combination products it may be necessary to conduct human factors studies prior to NDA submission to ascertain the usability of
the product by patients in real-world settings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NDA
and FDA Review Process </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process,
analytical tests conducted on the drug, proposed labeling and other relevant information, are submitted to the FDA as part of
an NDA for a new drug, requesting approval to market the product. An NDA for a new drug must contain proof of the drug&#8217;s
safety and efficacy. The submission of an NDA is subject to the payment of a substantial application user fee, and the sponsor
of an approved NDA is also subject to an annual program user fee; although a waiver of some such fees may be obtained under certain
limited circumstances. For example, the agency will waive the application fee for the first human drug application that a small
business or its affiliate submits for review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting
an NDA for filing. The FDA typically makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to
accept the NDA for filing means that the FDA has made a threshold determination that the application is sufficiently complete
to permit a substantive review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (PDUFA),
the FDA&#8217;s goal to complete its substantive review of a standard NDA and respond to the applicant is ten months from the
receipt of the NDA. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended
by FDA requests for additional information or clarification and may go through multiple review cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product
is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and
preserve the product&#8217;s identity, strength, quality and purity. During its review, the FDA will likely re-analyze the clinical
trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation
of an NDA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive
a timely approval, if at all. The FDA may refer applications for novel drug products or drug products which present difficult
questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review,
evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound
by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine
whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and
facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with
GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an
approval letter or a complete response letter (CRL). An approval letter authorizes commercial marketing of the drug with specific
prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the
application will not be approved in its present form. A CRL usually describes all the specific deficiencies in the NDA identified
by the FDA. The CRL may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other
significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued,
the applicant may either resubmit the NDA, addressing all the deficiencies identified in the letter, or withdraw the application.
Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for
approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret
the same data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant
difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited
to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value
of the product. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the product
labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls
and specifications, or a commitment to conduct postmarket testing or clinical trials and surveillance to monitor the effects of
approved products. For example, the FDA may require Phase 4 clinical trials to further assess drug safety and effectiveness and
may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA
may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the drug. If the FDA
concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS&#894; the FDA will not approve the NDA without
an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe
use, such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations
on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product
approvals may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>505(b)(2)
Approval Process </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NDAs
for most new drug products are based on at least two adequate and well-controlled clinical studies and must contain substantial
evidence of the safety and effectiveness of the proposed new product for the proposed use. These applications are submitted under
Section 505(b)(1) of the FDCA. The FDA is authorized, however, to approve an alternative type of NDA under Section 505(b)(2) of
the FDCA. An application under 505(b)(2) provides an alternate regulatory pathway for the FDA to approve a new product and permits
reliance for such approval on published literature or an FDA finding of safety and effectiveness for a previously approved similar
drug product, or published literature. Specifically, Section 505(b)(2) permits the filing of an NDA where one or more of the investigations
relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained
a right of reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,
Section 505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant.
NDAs filed under Section 505(b)(2) may provide an alternative and potentially more expeditious pathway to FDA approval for new
or improved formulations or new uses of previously approved products. If the 505(b)(2) applicant can establish that reliance on
the FDA&#8217;s previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical
or clinical studies of the new product. Typically, 505(b)(2) applicants must perform additional trials to support the change from
the previously approved drug and to further demonstrate the new product&#8217;s safety and effectiveness. The FDA may then approve
the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well
as for any new indication sought by the 505(b)(2) applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Trials </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act (PREA), an NDA or supplement to an NDA must contain data to assess the safety and efficacy of
the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for
each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor who is planning to
submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage
form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (PSP) within sixty days of an end-of-Phase
2 meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies
that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach,
or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full
or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the
sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes
to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or
other clinical development programs. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for
submission of data or full or partial waivers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Marketing
Requirements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, monitoring
and recordkeeping activities, reporting to the applicable regulatory authorities of adverse events with the product, providing
the regulatory authorities with updated safety and efficacy information, and product sampling and distribution requirements in
accordance with the Prescription Drug Marketing Act, a part of the FDCA. Moreover, each component of a combination product retains
its regulatory status (as a drug or device, for example) and is subject to the requirements established by the FDA for that type
of component. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are
placed on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription
drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug
promotion and advertising, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted
to the FDA in conjunction with their first use. In addition, a pharmaceutical company must comply with restrictions on promoting
drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling (known as &#8220;off-label
use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities
involving the internet. Although physicians may prescribe legally available drugs for off-label uses, manufacturers and their
agents may not market or promote such off-label uses or provide off-label information in the promotion of drug products that is
not consistent with the approved labeling for those products. The FDA and other regulatory and enforcement authorities actively
enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval
has not been obtained. A company that is found to have improperly promoted off-label uses may be subject to corrective advertising
in addition to significant liability, which may include civil and administrative remedies as well as criminal sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA
regulations require that combination products be manufactured in specific approved facilities and in accordance with cGMPs applicable
to drugs and devices, including certain QSR requirements. We rely, and expect to continue to rely, on third parties for the production
of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require among other
things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation
to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution
of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic
unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws. Accordingly, manufacturers
must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These
regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality
assurance activities. NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and
monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable,
their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure
to conform to cGMPs, could result in enforcement actions that interrupt the operation of any such facilities or the ability to
distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result
in restrictions on a product, manufacturer, or holder of an approved NDA, including, among other things, recall or withdrawal
of the product from the market. Additionally, manufacturers and other parties involved in the drug supply chain for prescription
drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted,
stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require post-marketing testing, known as Phase 4 testing, a risk evaluation and mitigation strategy (REMS) to assure
the safe use of the drug, and surveillance to monitor the effects of an approved product or place conditions on an approval that
could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure
to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative
enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil
or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s
approved labeling, including the addition of new warnings and contraindications, and may require the implementation of other risk
management measures. Also, new government requirements, including those resulting from new legislation, may be established, or
the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development and impact
approved products already on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Designation and Exclusivity </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals
in the United States. Alternatively, orphan drug designation may be available if the disease or the condition affects 200,000
or more individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug
for this type of disease or condition will be recovered from sales in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs,
tax advantages, and user-fee waivers. In addition, if a product is the first to receive FDA approval of the indication for which
it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application
to market the same drug for the same orphan indication for a period of seven years, except in limited circumstances, such as a
showing of clinical superiority over the product with orphan exclusivity. Competitors, however, may receive approval of different
products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different
indication for which the orphan product has exclusivity, which may permit off-label use for the orphan indication. Orphan product
exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same
drug or biological product as defined by the FDA for the same orphan indication or if our product candidate is determined to be
contained within the competitor&#8217;s product for the same indication or disease. If a drug or biological product designated
as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to
orphan product exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Marketing Exclusivity </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides
a five-year period of non-patent data exclusivity within the U.S. to the first applicant to obtain approval of an NDA for a new
chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the
FDA may not accept for review an abbreviated new drug application (ANDA) or 505(b)(2) NDA, submitted by another company for another
drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative
drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for
approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement
to one of the patents listed with the FDA by the innovator NDA holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year
exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations
and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication
or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an
applicant submitting a full NDA would be required to conduct, or obtain a right of reference to, all of the preclinical studies
and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
exclusivity is another type of marketing exclusivity available in the U.S. Pediatric exclusivity provides for an additional six
months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in
response to a Written Request from the FDA. The issuance of a Written Request does not require the sponsor to undertake the described
clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Laws &amp; Regulations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject
to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare &amp;
Medicaid Services (&#8220;CMS&#8221;), other divisions of the U.S. Department of Health and Human Services (e.g., the Office of
Inspector General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission,
the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, state Attorneys General and other state
and local government agencies. For example, sales, marketing, and scientific/educational grant programs must comply with the federal
Anti-Kickback Statute, the federal False Claims Act, the privacy regulations promulgated under the Health Information Portability
and Accountability Act of 1996 (&#8220;HIPAA&#8221;), and similar state laws. Pricing and rebate programs must also comply with
the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, provisions of the
Inflation Reduction Act of 2022, and the Veterans Health Care Act of 1992, as amended. The handling of any controlled substances
must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable
child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. All of these activities are also potentially
subject to federal and state consumer protection and unfair competition laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare Modernization Act (MMA) established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare
beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will
provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription
drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary
that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include
drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category
or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee.
Government payment for some of the costs of prescription drugs may increase demand for products for which Vivani may receive regulatory
approval. However, any negotiated prices for Vivani&#8217;s products (if covered by a Part D prescription drug plan) will likely
be lower than the prices Vivani might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries,
private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction
in payment that results from the MMA may result in a similar reduction in payments from non-government payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping,
licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for
its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product,
or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of Vivani&#8217;s products. Historically, products
launched in the European Union do not follow price structures of the U.S. and generally tend to be priced significantly lower
than in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., once Vivani has products on the market, the company will be subject to complex laws and regulations pertaining to healthcare
&#8220;fraud and abuse,&#8221; including, but not limited to, the federal Anti-Kickback Statute, the federal False Claims Act,
and other state and federal laws and regulations. The federal Anti-Kickback Statute makes it illegal for any person, including
a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any
remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular
drug, or other good or service for which payment in whole or in part may be made under a federal healthcare program, such as Medicare
or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties
and exclusion from participation in federal healthcare programs. In addition, many states have adopted laws similar to the federal
Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by
any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth of these federal and state
anti-kickback laws, the absence of guidance in the form of regulations or court decisions and the potential for additional legal
or regulatory change in this area, it is possible that Vivani&#8217;s future sales and marketing practices or Vivani&#8217;s future
relationships with medical professionals might be challenged under anti-kickback laws, which could harm Vivani.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal False Claims Act prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal programs
(including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items
or services not provided as claimed or claims for medically unnecessary items or services. Although Vivani would not submit claims
directly to payors, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission
of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a
product off-label. In addition, Vivani&#8217;s future activities relating to the reporting of wholesaler or estimated retail prices
for Vivani&#8217;s products, the reporting of prices used to calculate Medicaid rebate information and other information affecting
federal, state, and third-party reimbursement for Vivani&#8217;s products, and the sale and marketing of Vivani&#8217;s products,
are subject to scrutiny under this law. For example, pharmaceutical companies have been found liable under the federal False Claims
Act in connection with their off-label promotion of drugs. Penalties for a federal False Claims Act violation include three times
the actual damages sustained by the government, plus mandatory civil penalties of between $11,181 and $22,363 for each separate
false claim, the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims
Act is a civil statute, conduct those results in a federal False Claims Act violation may also implicate various federal criminal
statutes. If the government were to allege that Vivani was, or convict Vivani of, violating these false claims laws, Vivani could
be subject to a substantial fine. In addition, private individuals could bring actions under the federal False Claims Act and
certain states have enacted laws modelled after the federal False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among
other things, executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare
benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
of the statute or specific intent to violate it in order to have committed a violation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the ACA require
certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the
Children&#8217;s Health Insurance Program to report to HHS information related to payments and other transfers of value made to
physician (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care
practitioners and teaching hospitals; as well as the ownership and investment interests of such physicians and their immediate
family members;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations,
also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as
their business associates that perform certain services involving the use or disclosure of individually identifiable health information,
as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended
HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority
to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S.
laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ
from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and
claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and
may be broader in scope than their federal equivalents; some state laws require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in
addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers
or marketing expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
laws governing the privacy and security of health information in certain circumstances may also apply, many of which differ from
each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts, and analogous foreign
laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that
potentially harm consumers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
healthcare laws and regulations in the European Union and other non-U.S. jurisdictions, including reporting requirements detailing
interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information,
such as the General Data Protection Regulation, (&#8220;GDPR&#8221;), which imposes obligations and restrictions on the collection
and use of personal data relating to individuals located in the EU (including health data). There are also an increasing number
of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain
ambiguities as to what is required to comply with the laws. In addition, as discussed below, a similar federal requirement requires
manufacturers to track and report to the federal government certain payments made to physicians and teaching hospitals in the
previous calendar year. These laws may affect Vivani&#8217;s sales, marketing and other promotional activities by imposing administrative
and compliance burdens on Vivani. In addition, given the lack of clarity with respect to these laws and their implementation,
Vivani&#8217;s reporting actions could be subject to the penalty provisions of the pertinent state, and soon federal, authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with regulatory requirements subjects companies to possible legal or regulatory action. Depending on the circumstances,
failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions,
recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal
to allow a company to enter into supply contracts, including government contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in regulations, statutes or the interpretation of existing regulations could impact Vivani&#8217;s business in the future by requiring,
for example: (1) changes to Vivani&#8217;s manufacturing facility; (2) additions or modifications to product labeling; (3) the
recall or discontinuation of Vivani&#8217;s products; or (4) additional record-keeping requirements. If any such changes were
to be imposed, they could adversely affect the operation of Vivani&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform &amp; the Patient Protection and Affordable Care Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payors,
whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare
costs, and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing
rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a
number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of
2010, collectively the PPACA, was enacted, which includes measures that significantly change the way healthcare is financed by
both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical industry
are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and
                                         have in effect a national rebate agreement with the Secretary of the Department of Health
                                         and Human Services as a condition for states to receive federal matching funds for the
                                         manufacturer&#8217;s covered outpatient drugs furnished to Medicaid patients. Effective
                                         in 2010, the PPACA made several changes to the Medicaid Drug Rebate Program, including
                                         increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum
                                         basic Medicaid rebate on most branded prescription drugs and biologic agents to 23.1%
                                         of the AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (<i>i.e.</i>,
                                         new formulations, such as extended release formulations) of solid oral dosage forms of
                                         branded products, as well as potentially impacting their rebate liability by modifying
                                         the statutory definition of AMP. The PPACA also expanded the universe of Medicaid utilization
                                         subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid
                                         managed care utilization and by expanding the population potentially eligible for Medicaid
                                         drug benefits.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         order for a pharmaceutical product to receive federal reimbursement under the Medicare
                                         Part B and Medicaid programs or to be sold directly to U.S. government agencies, the
                                         manufacturer must extend discounts to entities eligible to participate in the 340B drug
                                         pricing program. The required 340B discount on a given product is calculated based on
                                         the AMP and Medicaid rebate amounts reported by the manufacturer. The PPACA expanded
                                         the types of entities eligible to receive discounted 340B pricing, although, under the
                                         current state of the law, with the exception of children&#8217;s hospitals, these newly
                                         eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs
                                         when used for the orphan indication. In addition, as 340B drug pricing is determined
                                         based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and
                                         AMP definition described above could cause the required 340B discount to increase.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         PPACA imposes a requirement on manufacturers of branded drugs and biologic agents to
                                         provide a 50% discount off the negotiated price of branded drugs dispensed to Medicare
                                         Part D patients in the coverage gap (<i>i.e.</i>, &#8220;donut hole&#8221;). This requirement
                                         was later increased to a 70% discount.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         PPACA imposes an annual, non-deductible fee on any entity that manufactures or imports
                                         certain branded prescription drugs and biologic agents, apportioned among these entities
                                         according to their market share in certain government healthcare programs, although this
                                         fee would not apply to sales of certain products approved exclusively for orphan indications.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there have also been executive, judicial, and Congressional challenges to certain aspects of the PPACA. In June
2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the PPACA, dismissing
the case without specifically ruling on the constitutionality of the PPACA. Accordingly, the PPACA remains in effect in its current
form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration
will impact our business, financial condition, and results of operations. Complying with any new legislation or changes in healthcare
regulation could be time-intensive and expensive, resulting in material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget
Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions
of Medicare payments to providers up to 2% per fiscal year. Subsequent legislation extended the 2% payment reduction which remains
in effect through 20310. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to
4% in the final fiscal year of this sequester. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases
resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further
reduced starting in 2025 absent further legislation. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments
to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain
patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing
investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical
trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical
manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically,
there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review
the relationship between pricing and manufacturer patient programs. President Biden has issued multiple executive orders that
have sought to reduce prescription drug costs. Although a number of these and other proposed measures may require authorization
through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures,
both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control
drug costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inflation Reduction Act of 2022, or IRA includes several provisions that may impact our business to varying degrees, including
provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025 (thereby effectively
eliminating the so-called &#8220;donut hole&#8221;); impose new manufacturer financial liability on certain drugs under Medicare
Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics
without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase
faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. The effects
of the IRA on our business and the healthcare industry in general is not yet known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
healthcare reform measures have been the subject to several executive orders of the Biden Administration, including orders that
address pharmaceutical pricing. In July 2021, for example, the Biden administration released an executive order, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition for prescription drugs. In
response to this executive order, the Department of Health and Human Services (&#8220;HHS&#8221;) has released a Comprehensive
Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and potential legislative policies that
Congress could pursue to advance these principles. In addition, Congress is considering legislation that, if passed, could have
significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases, which may
adversely affect our profitability. At the state level, a number of states are considering or have recently enacted state drug
price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability
under such state laws if and when we begin commercialization after obtaining regulatory approval for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal offices and facilities are located at 5858 Horton Street, Emeryville, CA 94608 and 13170 Telfair Avenue, Sylmar CA 91342
and are both leased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, Vivani signed a long-term lease for a new facility at 1350 South Loop Road, Alameda, CA 94502 to accommodate office
space, R&amp;D, analytical labs and a GMP manufacturing suite to support our research and development activities for our Biopharm
Division. We plan to initiate our move into the new facility in September 2023 and have it completed by the end of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2023 our Neuromodulation division entered into a lease agreement, effective March 1, 2023, to sublease office space
to replace their existing headquarters</span>, which lease expired March 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">As of December 31, 2022, we had 14 employees in our Neuromodulation
division and 36 employees in our Biopharm Division. Of these persons, all are employed in the United States. We believe that the
continued success of our business will depend, in part, on our ability to attract and retain qualified personnel, and we are committed
to developing our people and providing them with opportunities to contribute to our growth and success. None of these employees
is covered by a collective bargaining agreement, and we believe our relationship with our employees is good to excellent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Our website address
is www.vivani.com. We make available free of charge through a link provided at our website our Forms 10-K, 10-Q and 8-K as well
as any amendments thereto. These reports are available as soon as reasonably practicable after they are filed with the Securities
and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a003_v1"></span>Item 1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>This Form 10-K contains forward-looking information based
on our current expectations. Because our business is subject to many risks and our actual results may differ materially from any
forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect
our business, operating results, financial condition and the trading price of our common stock. You should carefully consider
these risk factors, together with all of the other information included in this Form 10-K as well as our other publicly available
filings with the SEC.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Financial Position and Need for
Additional Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are a preclinical-stage company with a limited operating
history, and have no products approved for commercial sale.</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We are
a preclinical-stage biopharmaceutical company. In August 2022, we completed a business combination of Second Sight Medical Products,
Inc. (Second Sight) and Nano Precision Medical, Inc. (Nano Precision Medical), to form our current company. Following the business
combination, we are focusing primarily on the development of our proprietary NanoPortal technology and the development of miniaturized,
subdermal drug implants capable of the long-term delivery of medicine in patients with chronic diseases with high unmet medical
need. Our pipeline includes our current product candidates NPM-119, NPM-159, NPM-139 and OKV-119, which we have partnered with
Okava Pharmaceuticals, Inc. All of our product candidates are in early-stage development and none of our product candidates have
entered into clinical-stage testing, been approved for marketing, or are being marketed or commercialized. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">As
a result, we have no meaningful historical operations upon which to evaluate our business and prospects and we have not yet demonstrated
an ability to successfully initiate and conduct clinical trials or obtain marketing approval for any of our product candidates
or otherwise successfully overcome the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry.
We have not generated any revenues to date, and we continue to incur significant research and development and other expenses.
As a result, we have not been profitable and have incurred operating losses in every reporting period since our inception. For
the years ended 2021 and 2022, we reported net losses of $12.8 million and $13.9 million, respectively, and had an accumulated
deficit of $72.8 million as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">For the foreseeable future, we expect to
continue to incur significant and increasing losses as we expand our research and development activities, seek regulatory approvals
for our product candidates and begin to commercialize them if they are approved by the U.S. Food and Drug Administration (the
&#8220;FDA&#8221;) the European Medicines Agency (the &#8220;EMA&#8221;) or comparable foreign authorities. Even if one or more
of our product candidates complete their clinical development, achieve marketing approval and are commercialized, we may never
become profitable.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In
addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks
frequently experienced biopharmaceutical companies in rapidly evolving fields. If one or more of our product candidates receive
marketing approval, we also may need to transition from a company with a research and development focus to a company capable of
supporting commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties,
or to make such a transition.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We
do not anticipate generating revenue from product sales for the foreseeable future and may never be profitable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The
viability of our business depends on our ability to generate revenue from product sales. Vivani&#8217;s current pipeline is focused
on the development of our proprietary NanoPortal&#8482; technology and the development of miniaturized, subdermal drug implants
capable of the long-term delivery of medicine in patients with chronic diseases with high unmet medical need. However, we may
never be able to develop or commercialize marketable products from our current pipeline or achieve profitability. Revenue from
the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets
in the territories for which regulatory approval is obtained, the accepted price for the product, the acceptance of the product
by physicians and patients, the ability to obtain reimbursement at any price and whether we own the commercial rights for that
territory. In addition, if the market size for our product candidates is smaller than estimated, the indication or intended use
approved by regulatory authorities is narrower than expected, or the target patient population for treatment is narrowed by competition,
physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.
Even if we are able to generate revenue from the sale of any approved products, we may not become profitable. Even if we achieve
profitability in the future, such profitability may not be sustained in subsequent periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our ability to generate revenue and achieve
profitability depends significantly on our ability, either independently or in collaboration with third parties, to achieve several
objectives, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successful completion of preclinical studies resulting
in data that is supportive of advancing to an IND submission;</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successful submission and acceptance of INDs or comparable
applications;</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">successful initiation of clinical trials;</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>successful and timely completion of nonclinical and clinical development of our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>establishing and maintaining relationships with contract
                                         research organizations (CROs) and clinical sites for the clinical development of our
                                         product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>timely receipt of marketing approvals from applicable
                                         regulatory authorities for any product candidates for which we successfully complete
                                         clinical development;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>developing an efficient and scalable manufacturing
                                         process for our candidates, including obtaining finished products that are appropriately
                                         packaged for sale;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>establishing and maintaining commercially viable supply
                                         and manufacturing relationships with third parties that can provide adequate, in both
                                         amount and quality, products and services to support clinical development and meet the
                                         market demand for our product candidates, if approved;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>successful commercial launch following any marketing
                                         approval, including the development of a commercial infrastructure, whether in-house
                                         or with one or more collaborators;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>a continued acceptable safety profile following any
                                         marketing approval of our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>commercial acceptance of our product candidates by
                                         patients, the medical community and third-party payors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>satisfying any required post-marketing approval commitments
                                         to applicable regulatory authorities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></div>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>identifying, assessing, and developing new product
                                         candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>obtaining,
                                         maintaining, and expanding patent protection, trade secret protection and regulatory
                                         exclusivity in the United States and target international markets;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>protecting our rights in our intellectual property
                                         portfolio;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>defending against third-party interference or infringement
                                         claims, if any;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>entering into, on favorable terms, any collaboration,
                                         licensing, or other arrangements that may be necessary or desirable to develop, manufacture
                                         or commercialize our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>obtaining coverage and adequate reimbursement by third-party
                                         payors for our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>addressing any competing therapies and technological
                                         and market developments; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>attracting, hiring, and retaining qualified personnel.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We may never be successful in achieving
its objectives and, even if we do, may never generate revenue that is significant or large enough to achieve or maintain profitability.
Any failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or
further our research and development efforts, raise additional necessary capital, grow our business, and continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We will require substantial additional financing to
pursue our business objectives, which may not be available on acceptable terms, or at all. A failure to obtain this necessary
capital when needed could force us to delay, limit, reduce or terminate our product development, commercialization efforts or
other operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Developing
pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and
uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash, and we expect our expenses
to increase in connection with our ongoing activities, particularly as we conduct clinical trials of our product candidates. Even
if one or more of our product candidates is approved for commercial sale, we will incur significant costs associated with sales,
marketing, manufacturing, and distribution activities. Our expenses could increase beyond expectations if required by the FDA,
the European Medicines Agency (EMA) or other regulatory agencies to perform clinical trials or preclinical studies in addition
to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned
and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding
that will be necessary to successfully complete the development and commercialization of any product candidate. We are not permitted
to market or promote any product candidate before it receives marketing approval from the regulatory authorities. Accordingly,
we will need to obtain substantial additional funding in order to continue our operations and pursue our business objectives. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">There can be no assurance that we will
be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing is not available on
satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit, or eliminate one or more of
our business objectives, and our competitiveness, and business, financial condition and results of operations may be materially
adversely affected. If we are unable to continue our business, including due to inadequate funding, you could lose your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vivani&#8217;s
future capital requirements will depend on many factors, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the scope, rate of progress, results and cost of its
                                         clinical trials, preclinical studies, and other related activities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>its ability to establish and maintain strategic collaborations,
                                         licensing or other arrangements and the financial terms of such arrangements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the timing of, and the costs involved in, obtaining
                                         regulatory approvals for any of its current or future product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the number and characteristics of the product candidates
                                         it seeks to develop or commercialize;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></div>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the cost of manufacturing clinical supplies, and establishing
                                         commercial supplies, of its product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the cost of commercialization activities if any of
                                         its current or future product candidates are approved for sale, including marketing,
                                         sales, and distribution costs;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the expenses needed to attract and retain skilled personnel;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the costs associated with being a public company;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the amount of revenue, if any, received from commercial
                                         sales of its product candidates, should any of its product candidates receive marketing
                                         approval; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the costs involved in preparing, filing, prosecuting,
                                         maintaining, defending, and enforcing possible patent claims, including litigation costs
                                         and the outcome of any such litigation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We
may raise capital in the form of equity or debt financing, partnerships, collaborations, licensing, spin-offs or other strategic
transactions. If we raise additional capital by issuing equity securities, the ownership of our existing shareholders may be reduced,
and accordingly these shareholders may experience substantial dilution. We may also issue equity securities that provide for rights,
preferences, and privileges senior to those of its common stock. If we raise funding through debt instruments or facilities, lenders
may require us to pledge some or all of our assets as collateral. We may also be required to observe financial, operational and
other covenants that constrain our business and operations. If we enter into partnerships, collaborations, licensing or other
strategic transactions, we may be required to grant rights to third parties, including rights to develop and market product candidates,
that we would otherwise have retained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Our ability to utilize
its net operating loss (NOL) carry-forwards and certain other tax attributes may be limited.</i></b></span><span style="letter-spacing: 0.2pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Under Section 382 of the Code, if a corporation
undergoes an &#8220;ownership change&#8221; &#8203;(generally defined as a greater than 50% change (by value) in its equity ownership
over a three-year period), the corporation&#8217;s ability to use its pre-change NOL carry-forwards and other pre-change tax attributes
to offset its post-change income may be limited. We have not completed a study to assess whether any ownership changes, as defined
by Section 382 of the Code, have occurred. Past, current and future ownership changes may limit our ability to utilize remaining
tax attributes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, our parent which comprises the Legacy SSMP business, and our subsidiary, Nano Precision Medical, each
had the following carry-forwards available to offset future taxable income and income taxes (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31, 2022</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>NPM</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>SSMP</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">24,647</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">29,095</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Post TCJA period federal NOL carry-forward, with no carry-forward limitation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,113</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">86,412</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total federal NOL carry-forward</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">57,760</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">115,508</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State NOL carry-forward, begin expiring 2030</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">66,514</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,439</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal R&amp;D tax credit carry-forward, begin expiring in 2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State R&amp;D carry-forward, begin expiring in 2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,973</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,989</td><td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
Legacy SSMP and NPM file separate tax returns, the carry-forwards of one filer are not available to offset the taxable income or
income taxes of the other filer.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Furthermore, under recently enacted U.S. tax legislation, although the treatment of tax losses
generated in taxable years ending before December 31, 2017, has generally not changed, tax losses generated in taxable years beginning
after December 31, 2017 may only be utilized to offset 80 % of taxable income annually. This change may require us to pay federal
income taxes in future years despite generating a loss for federal income tax purposes in prior years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Product Development, Clinical Testing
and Commercialization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on the successful development, regulatory approval and commercialization of one or more of our product candidates,
there can be no assurance that we may achieve any of these objectives.</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We have spent significant time, money and
effort on the licensing and development of our core assets, including NPM-119 (exenatide implant) in preclinical stage development,
NPM-139 and NPM-159 (undisclosed drug molecules) in initial feasibility testing with our proprietary NanoPortal implant technology.
To date, we have not commenced clinical testing of any of our product candidates. All of our product candidates will require additional
development, including clinical trials as well as further preclinical studies to evaluate their safety, tolerability and pharmacokinetics,
and to optimize their formulation. Our product candidates may require significant additional testing before advancing to pivotal
clinical trials that are designed to generate sufficient safety and efficacy data to support a marketing application. Even if we
conduct and complete such testing of our product candidates, there can be no assurance that we will obtain marketing approval for
one or more of these candidates. Positive results obtained during early development do not necessarily mean later development will
succeed or that regulatory approvals will be obtained. Our drug development efforts may not lead to commercially-viable products
for any number of reasons, including because our product candidates fail to demonstrate safety and efficacy to the satisfaction
of applicable regulatory authorities to support marketing approval, or because we have inadequate financial or other resources
to advance our product candidates through development and approval processes. If any of our product candidates fail to demonstrate
sufficient safety or efficacy data at any time to support their continued development, or we encounter other challenges in the
development of our product candidates, we would experience potentially significant delays in, or be required to abandon, development
of the product candidate.</p>



<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate that any of our product candidates will be eligible to receive regulatory approval from the FDA, the EMA or
comparable foreign authorities and begin commercialization for a number of years, if ever. Even if we ultimately receive regulatory
approval for any of these product candidates, we may be unable to commercialize them successfully for a variety of reasons, either
independently or in collaboration with third parties. These include, for example, the availability of alternative treatments,
lack of cost-effectiveness, the cost of manufacturing the product on a commercial scale and competition with other drugs. The
success of our product candidates may also be limited by the prevalence and severity of any adverse side effects or the willingness
of patients and healthcare providers to use or administer our drug implants. If we fail to develop, obtain approval for and commercialize
one or more of our product candidates, our business would be materially and adversely impacted. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Clinical development involves a lengthy and expensive
process with uncertain outcomes. We may incur additional costs and experience delays in developing our product candidates, and
our clinical development efforts may not yield favorable results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">To receive
regulatory approval for our product candidates, adequate and well-controlled clinical trials must be conducted to demonstrate safety
and efficacy in humans to the satisfaction of the FDA, the EMA, and comparable foreign authorities. We have not yet conducted clinical
trials for our current product candidates and clinical testing of such product candidates may not yield results to support continued
development or seeking regulatory approval. The development process is expensive, can take many years and has an uncertain outcome.
Failure can occur at any stage of the process. We may experience numerous unforeseen events during, or as a result of, the development
process that could delay or prevent development and approval of our product candidates, including the following: </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>we may be unable to initiate or conduct planned clinical
                                         trials on our anticipated timelines, including as a result of failing to obtain any clearances
                                         necessary to conduct clinical trials or being subject to clinical holds that prevent
                                         continuation of such trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>clinical trials may produce negative or inconclusive
                                         results;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td><span style="font-size: 10pt">&#8203;</span>preclinical
                                         studies conducted with product candidates during clinical development to, among other
                                         things, evaluate their safety, tolerability and pharmacokinetics and optimize
                                         their formulation may produce unfavorable results;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>patient recruitment and enrollment in clinical trials
                                         may be slower than anticipated;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>costs of development may be greater than anticipated;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>our product candidates may cause undesirable side effects
                                         that delay or preclude regulatory approval or limit their commercial use or market acceptance,
                                         if approved;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>if one or more product candidates are developed in
                                         collaboration with third parties, such parties may not devote sufficient resources to
                                         these clinical trials or other preclinical studies of these candidates or conduct them
                                         in a timely manner;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>we
                                         may face delays or other challenges associated with the availability and sourcing key
                                         raw materials and/or key components; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>we
                                         may encounter difficulties in developing product candidates related to our proprietary
                                         NanoPortal implant technology or difficulties associated with the long-term purity, potency,
                                         safety, or stability of our product candidates.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Even
if we experience success in early development for any product candidate, that experience may not be replicated in later development
or with respect to any other product candidates. For example, in our industry, product candidates in later-stage clinical trials
routinely fail to demonstrate adequate safety and efficacy despite having progressed through initial clinical trials or preclinical
testing. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-size: 10pt"></span>Even
if our clinical trials generate data that we believe are promising, such data may not be sufficient to support seeking marketing
approval by the FDA, the EMA, or comparable foreign authorities. Further, data generated during development can be interpreted
in different ways, and the FDA, the EMA or comparable foreign authorities may interpret such data in different ways than we do.
If we fail to generate data that adequately demonstrate the safety and efficacy of our product candidates to support marketing
approval from regulatory authorities, we will not be able to market and commercialize these product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">From
time to time, in addition to or as an alternative to raising capital through equity or debt offerings, we may seek to selectively
and opportunistically enter into collaborations with third parties to assist in the development and potential future commercialization
of some or all of our product candidates. However, there can be no assurance that we will be able to establish such collaborations
on acceptable terms, if at all, or it may take longer than expected to establish new collaborations. Even if we enter into one
or more of such collaborations, the risks associated with the development of product candidates still remain, and there can be
no assurance that our potential collaborators will successfully develop, seek approval for and commercialize any of our product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Vivani&#8217;s <span style="letter-spacing: -0.2pt">product
candidates may have serious adverse, undesirable or unacceptable side effects that could delay, pause or terminate our clinical
trials, or prevent us from obtaining regulatory approval for or commercialize such product candidates.&#160;If such side effects
are identified during the development of our product candidates or following approval, if any, we may need to abandon our development
of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant
negative consequences following marketing approval, if any.</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Undesirable
side effects observed in preclinical studies or clinical trials of our product candidates could interrupt, delay, or halt their
development and could result in the denial of regulatory approval by the FDA, the EMA, or comparable foreign authorities for any
or all targeted indications or adversely affect the marketability of any such product candidates that receive regulatory approval.
</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates may exhibit adverse effects in preclinical toxicology studies and adverse interactions with other drugs. Our
product candidates may require a risk management program that could include patient and healthcare provider education, usage guidelines,
appropriate promotional activities, a post-marketing observational study, and ongoing safety and reporting mechanisms, among other
requirements. Prescribing could be limited to physician specialists or physicians trained in the use of the drug or could be limited
to a more restricted patient population. Any risk management program required for approval of our product candidates could potentially
have an adverse effect on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Undesirable side effects involving our
product candidates may have other significant adverse implications on our business, financial condition, and results of operations.
For example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>our
                                         collaborators may terminate any development agreements covering these product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>if
                                         any development agreements are terminated, we may determine not to further develop the
                                         affected product candidates due to resource constraints and may not be able to establish
                                         additional collaborations for their further development on acceptable terms, if at all;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>if
                                         we were to later continue the development of these product candidates and receive regulatory
                                         approval, earlier findings may significantly limit their marketability and thus significantly
                                         lower our potential future revenues from their commercialization; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>we
                                         may be subject to product liability or shareholder litigation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">In addition,
even if any of our product candidates receive marketing approval and we or others later identify undesirable side effects caused
by such products (or any other similar products) after such approval, a number of potentially significant negative consequences
could result, including: </span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">regulatory authorities may withdraw or limit their approval of the product, or we may decide
to cease marketing and sale of the product voluntarily; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221;
warning or a contraindication;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>regulatory authorities may impose conditions under a risk evaluation and mitigation strategy, or REMS, including distribution
of a medication guide to patients outlining the risks of such side effects or imposing distribution or use restrictions and/or
requiring special training for prescribers of the product;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">change the way the product is administered, conduct additional clinical trials or preclinical
studies regarding the product, change the labeling of the product, or change the product&#8217;s manufacturing facilities; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">we may be subject to regulatory investigations and government enforcement actions; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">we may decide to recall or remove such products from the marketplace; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">we could be sued and held liable for injury caused to individuals exposed to or taking
our product candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">we may fail to secure acceptance of our product candidates from physicians, healthcare
payers, patients and the medical community; and </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="letter-spacing: 0.2pt">&#9679;</span></td><td><span style="letter-spacing: 0.2pt">our reputation may suffer. </span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially
increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating significant
revenues from the sale of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our efforts to identify and develop product candidates
beyond those in our current pipeline may not succeed, and any product candidates that we select for clinical development may not
actually begin clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We intend
to expand our current pipeline of core assets by advancing drug implants from future and ongoing feasibility programs into preclinical
and clinical development. However, the process of identifying and developing drug implants is expensive, time-consuming, and unpredictable.
Data from our current preclinical programs may not support the clinical development of its lead compounds or other compounds from
these programs, and we may not identify any additional drug compounds suitable for recommendation for clinical development. Moreover,
any drug compounds that we select for clinical development may not generate sufficient safety and efficacy data that would support
advancement into clinical trials or to continue clinical trials that are ongoing. Such findings would potentially impede our ability
to maintain or expand our development pipeline. Our ability to identify new drug implants and advance them into preclinical and
clinical development also depends upon our ability to fund our research and development operations, and there can be no assurance
that additional funding will be available on acceptable terms, or at all. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We could experience delays in the commencement or
completion of clinical trials, which could result in increased costs or otherwise impair our research and development efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Delays in the commencement or completion
of clinical trials could significantly impact our drug development costs and otherwise impair our research and development efforts.
We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. The commencement of
clinical trials can be delayed for a variety of reasons, including, but not limited to, delays related to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>obtaining regulatory approval to commence one or more
                                         clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>reaching agreement on acceptable terms with prospective third-party contract research organizations (CROs)
and clinical trial sites;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>manufacturing sufficient quantities of a product candidate
                                         or other materials necessary to conduct clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>obtaining institutional review board approval to conduct
                                         one or more clinical trials at a prospective site;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>recruiting and enrolling patients to participate in
                                         one or more clinical trials; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the failure of our collaborators to adequately resource
                                         our product candidates.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, once a clinical trial has
begun, it may be suspended or terminated by us or our collaborators, institutional review boards, or, if applicable, data safety
monitoring boards charged with overseeing our clinical trials, the FDA, the EMA, or comparable foreign authorities due to a number
of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>failure to conduct the clinical trial in accordance
                                         with regulatory requirements or clinical protocols;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>inspection of the clinical trial operations or clinical
                                         trial site by the FDA, the EMA or comparable foreign authorities resulting in the imposition
                                         of a clinical hold;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>unforeseen safety issues; or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>lack of adequate funding to continue the clinical trial.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">If we experience delays in the completion
or termination of any clinical trial of our product candidates, the development of product candidates will be impaired. In addition,
any delays in completing our clinical trials will increase our costs and slow down our product candidate development process and
our anticipated timelines for seeking marketing approval. Such delays could also allow our competitors to obtain marketing approval
for their own product candidates before we do or may shorten the patent protection period during which we may have the exclusive
right to commercialize our product, if approved. Any of these occurrences may harm our business, financial condition, and prospects
significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results
of preclinical trials may not be predictive of the results of later-stage clinical trials, and many product candidates fail to
achieve regulatory approval despite showing initial promise in early-stage testing.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The
results of preclinical studies of product candidates may not be predictive of the results of clinical trials, and results from
early-stage clinical testing may not be replicated in later-stage clinical trials. Product candidates in later stages of clinical
trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial
clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier studies. We may experience similar
setbacks in our development programs for these or other reasons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">As product candidates are developed through
preclinical, early-stage clinical and late-stage clinical trials towards approval and commercialization, it is customary that
various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in
an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product
candidates for late-stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve
these intended objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Any of these changes could make the results
of our planned clinical trials or other future clinical trials less predictable and could cause our product candidates to perform
differently, including causing toxicities, which could delay completion of our clinical trials, delay approval of our product
candidates, and/or jeopardize our ability to commence product sales and generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Interim, topline
and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">From
time to time, we may publicly disclose interim, topline or preliminary data from our clinical trials, which is based on a preliminary
analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive
review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions
as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.
As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or
considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain
subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, topline data should be viewed with caution until the final data are available. From
time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more
patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm
our business prospects. Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates,
calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value
of the particular program, the approvability or commercialization of the particular product candidate or product and our company
in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based
on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise
appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed
significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate
or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed,
which could harm our business, operating results, prospects or financial condition. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may experience delays in the enrollment of patients
in our clinical trials, which would adversely affect our ability to initiate, conduct and complete such trials on our anticipated
timelines.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints
and the process for identifying patients;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">identifying and enrolling eligible patients, including those willing to discontinue use
of their existing medications;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the design of the clinical protocol and the patient eligibility and exclusion criteria
for the trial;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">safety profile, to date, of the therapeutic candidate under study;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the willingness or availability of patients to participate in our trials, including due
to the perceived risks and benefits, stigma or other side effects of use of a controlled substance;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the willingness or availability of patients to participate in our trials, including due
to any public health crisis such as the COVID-19 pandemic and the emergence of new COVID-19 variants;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">perceived risks and benefits of our approach to treatment of indication;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the proximity of patients to clinical sites;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">our ability to recruit clinical trial investigators with the appropriate competencies and
experience;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the availability of competing clinical trials;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the availability of new drugs approved for the indication the clinical trial is investigating;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">clinicians&#8217; and patients&#8217; perceptions of the potential advantages of the drug
being studied in relation to other available therapies, including any new therapies that may be approved for the indications we
are investigating; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="letter-spacing: 0.2pt">our ability to obtain and maintain patient informed consents.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Even
once enrolled we must retain a sufficient number of patients to complete any of our trials.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">If we fail to enroll and maintain the
number of patients for which the clinical trial was designed, the statistical power of that clinical trial may be reduced, which
may impair the significance of such results and cause regulatory authorities to require additional testing. Additionally, enrollment
delays in our clinical trials may result in increased development costs for our product candidates, delay our development timelines
or force us to abandon one or more of our programs altogether.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may experience difficulty identifying, training
and/or certifying an adequate number of healthcare professionals to properly implant and, when appropriate, explant our drug implants
candidates, which may impair our ability to conduct our clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our drug implant candidates require properly
trained healthcare professionals, which may include doctors, nurse practitioners and nurses, for sub-dermal placement into patients.
These healthcare professionals would also be responsible for removal and replacement of a new drug implant. There can be no assurance
that sufficient numbers of trained and/or certified healthcare professionals will be available or that the training or certification
requirements will not be more burdensome than anticipated. Both factors could lead to difficulties in conducting our clinical
trials and impair our development efforts for our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If our competitors have product candidates that are
approved faster, marketed more effectively, are better tolerated, have a more favorable safety profile, or are demonstrated to
be more effective than our own, our commercial opportunity may be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The biopharmaceutical industry is characterized
by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our
technology, knowledge, experience, and scientific resources enable us to compete in our industry, we face competition from many
different sources, including commercial biopharmaceutical enterprises, academic institutions, government agencies and private
and public research institutions. Any product candidates that we develop and, if approved, commercialize will compete with existing
therapies and new therapies that may become available in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical
studies, clinical trials, regulatory approvals, and marketing approved products. Some of our competitors with the GLP-1 receptor
agonist drug class include companies such as Novo Nordisk, AstraZeneca, and Eli Lilly. Smaller or early-stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our
competitors may succeed in developing technologies and therapies that are more effective, better tolerated or less costly than
those of our own, or that would render our product candidates obsolete and noncompetitive. Even if we obtain regulatory approval
for any of our product candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than
we do. We will also face competition from these third parties in recruiting and retaining qualified scientific and management
personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing
technologies and products complementary to our programs or advantageous to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We believe that the key competitive factors
affecting the viability of product candidates, if approved, are likely to be their efficacy, safety, tolerability, frequency and
route of administration, convenience and price, the level of branded and generic competition and the availability of coverage
and reimbursement from government and other third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Multiple
GLP-1 receptor agonist products have been proven effective to reduce cardiovascular morbidity and mortality, including Trulicity
(dulaglutide), Ozempic (semaglutide injection), and Victoza (liraglutide), Medical Guidelines may recommend preferential use of
GLP-1 receptor agonists that have positive cardiovascular morbidity and mortality data in the products approved labeling. Since
Bydureon, the NPM-119 reference drug, did not demonstrate a reduction in cardiovascular morbidity and mortality, NPM-119 will not
have this claim in the approved product label unless we generate positive cardiovascular outcomes data with NPM-119. The lack of
a cardiovascular outcomes benefit in the NPM-119 label may decrease its market potential, if approved. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: 0.2pt"><b><i>If the FDA or other
applicable regulatory authorities approve generic products that compete with any of our product candidates, the sales of our product
candidates, if approved, could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Once
an NDA, including a Section 505(b)(2) application, is approved, the product covered becomes a &#8220;listed drug&#8221; which can
be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. FDA regulations and other
applicable regulations and policies provide incentives to manufacturers to create modified versions of a drug to facilitate the
approval of an ANDA or other application for similar substitutes. If these manufacturers demonstrate that their product has the
same active ingredient(s), dosage form, strength, route of administration, and conditions of use, or labeling, as our product candidate,
they might only be required to conduct a relatively inexpensive study to show that their generic product is absorbed in the body
at the same rate and to the same extent as, or is bioequivalent to, our product candidate (and in some cases even this limited
bioequivalence testing can be waived by the FDA). Competition from generic equivalents to our product candidates could substantially
limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our product candidates.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are subject to a multitude of manufacturing risks,
any of which could substantially increase our costs and limit supply of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The process of manufacturing our product
candidates is complex, highly regulated, and subject to numerous risks. For example, the process of manufacturing our product
candidates is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment,
or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our product candidates could
result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations
are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing
facilities may need to be closed for an extended period to investigate and remedy the contamination. In addition, the manufacturing
facilities in which its product candidates are made could be adversely affected by equipment failures, labor shortages, natural
disasters, power failures and numerous other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, any adverse developments
affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures,
withdrawals or recalls, or other interruptions in the supply of our product candidates. We also may need to take inventory write-offs
and incur other charges and expenses for product candidates that fail to meet specifications, undertake costly remediation efforts,
or seek costlier manufacturing alternatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The commercial success of our product candidates,
if approved, depends upon their market acceptance among physicians, patients, healthcare payors, and the medical community.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Even if our product candidates obtain
regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community.
The degree of market acceptance of any of our product candidates, if approved, will depend on several factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the effectiveness of our approved product candidates
                                         as compared to competitive products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>adequately
                                         trained healthcare professionals willing to administer our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>patient willingness to adopt our approved product candidates
                                         rather than competitive therapies;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></div>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>our ability to provide acceptable evidence of safety
                                         and efficacy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>relative convenience and ease of administration;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the prevalence and severity of any adverse side effects;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>restrictions on use in combination with other products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>availability of alternative treatments;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>pricing and cost-effectiveness assuming either competitive
                                         or potential premium pricing requirements, based on the profile of our product candidates
                                         and target markets;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>effectiveness of our sales and marketing strategy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>our ability to obtain sufficient third-party coverage
                                         or reimbursement; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>potential product liability claims.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In
addition, the potential market opportunity for our product candidates is difficult to estimate. Our estimates of the potential
market opportunity for our product candidates include several key assumptions based on our industry knowledge, industry publications,
third-party research reports and other surveys. Independent sources have not verified all of our assumptions. If any of these
assumptions proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of
their potential market opportunity. If the actual market for our product candidates is smaller than we expect, the market potential
for our product candidates may be limited. If we fail to achieve market acceptance of our product candidates, the viability of
our business may be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we fail to obtain and sustain an adequate level
of reimbursement by third-party payors for our product candidates, if approved, potential future sales would be materially adversely
affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Even
if our product candidates receive marketing approval, there will be no viable commercial market without reimbursement from third-party
payors. Reimbursement policies may be affected by future healthcare reform measures. We cannot be certain that reimbursement will
be available for our product candidates. Additionally, even if there is a viable commercial market, if the level of reimbursement
is below our expectations, our anticipated revenue and gross margins will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Third-party payors, such as government
or private healthcare insurers, carefully review and increasingly question and challenge the coverage of and the prices charged
for drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan, and
other factors. Reimbursement rates may be based on reimbursement levels already set for lower cost drugs and may be incorporated
into existing payments for other services. There is a current trend in the U.S. healthcare industry toward cost containment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Large public and private payors,
managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on
decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors,
including Medicare, may question the coverage of, and challenge the prices charged for, medical products and services, and
many third-party payors limit coverage of or reimbursement for newly approved healthcare products. Third-party payors may
also limit the covered indications. Cost-control initiatives could decrease the price that we might establish for products,
which could result in product revenues being lower than anticipated. If we are unable to show a significant benefit over
existing therapies, Medicare, Medicaid, and private payors may not be willing to provide reimbursement for our product
candidates, if approved, which would significantly reduce the likelihood of such product candidates gaining market
acceptance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We
expect that private insurers will consider the efficacy, cost-effectiveness, safety, and tolerability of our product candidates
in determining whether to approve reimbursement for such product candidates and at what level. Obtaining these approvals can be
a time consuming and expensive process. Our business, financial condition and results of operations would be materially adversely
affected if we do not receive adequate reimbursement of our product candidates, if approved, from private insurers on a timely
or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare carrier level or by fiscal intermediaries.
Medicare Part D, which provides a pharmacy benefit to Medicare patients, does not require participating prescription drug plans
to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially
adversely affected if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Reimbursement
systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on
a country-by-country basis. In many countries, the product cannot be commercially launched until reimbursement is approved. In
some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial
approval is granted. The negotiation process in some countries can exceed 12 months. To obtain reimbursement or pricing approval
in some countries, we may be required to conduct a clinical trial that generates cost-effectiveness or health economics data of
our product candidates in comparison to other available therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">If the prices for our product candidates,
if approved, are reduced or if governmental and other third-party payors do not provide adequate coverage and reimbursement of
our products, our future revenue, cash flows and prospects for profitability will suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Since
our product candidates are designed to deliver active medication for up to six months or longer, there may be additional risks
associated with the third-party payor&#8217;s willingness or desire to reimburse the full product cost at the time of purchase.
We may develop customized reimbursement practices or policies to address potential concerns from payors if appropriate. There
are no assurances that customized reimbursement practices or policies, if needed, will be effective and the potential impact on
revenues and profits is difficult to project.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Regulatory Approval and Other Legal
and Compliance Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Our product candidates
are subject to extensive regulation under the FDA, the EMA and comparable foreign authorities, and must undergo extensive clinical
testing that can be costly and time consuming, with no assurance that regulatory approval will be obtained for any of our product
candidates.</i></b></span><span style="letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">The clinical
development, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing, and distribution of our
product candidates are subject to extensive regulation by the FDA and other U.S. regulatory agencies, the EMA, or comparable authorities
in foreign markets. In the U.S., neither we nor any collaborators are permitted to conduct clinical testing in humans with our
product candidates unless and until clearance is received to conduct clinical investigations under an investigational new drug
application (IND) from the FDA or receive similar authorizations abroad. In addition, marketing of such product candidates may
not occur unless and until approval of a new drug application (NDA) from the FDA or similar approvals by comparable foreign regulatory
authorities</span> are secured<span style="letter-spacing: 0.2pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">The process
of obtaining these approvals is expensive, often takes many years, and can vary substantially based upon the type, complexity and
novelty of the product candidates involved. Approval policies or regulations may change and may be influenced by the results of
other similar or competitive products, making it more difficult for us to achieve such approval in a timely manner or at all. Any
guidance that may result from recent FDA advisory panel discussions may make it more expensive to develop and commercialize such
product candidates. In addition, with respect to our current pipeline, we have not previously filed INDs or NDAs with the FDA or
filed similar applications with other foreign regulatory agencies. This lack of experience may impede our ability to obtain FDA
or other foreign regulatory agency approval in a timely manner, if at all, for our product candidates. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Despite the time and expense invested, and
even if we observe promising results from clinical testing of our product candidates, regulatory approval is never guaranteed.
In our industry, many companies have experienced significant setbacks when seeking marketing approval from regulatory agencies,
despite having generated promising data from clinical testing of their product candidates. For example, the FDA has rejected both
original and resubmitted NDAs from Intarcia Therapeutics for its exenatide implant candidate for the treatment of Type II diabetes.
Based on public correspondence from the FDA, the agency asserted that the data submitted in the applications did not show that
the product would be safe under the proposed conditions of use and that the methods used in, and the facilities and controls used
for, the manufacture, processing, or packing of the product were not shown to be adequate to preserve its identity, strength,
quality, and purity. Further correspondence disclosed additional deficiencies, including that data that did not demonstrate adequate
device reliability in regard to dose delivery. While we seek to avoid such outcomes in developing our product candidates based
on our proprietary NanoPortal technology, there can be no assurance that such product candidates will not experience similar setbacks
if and when we apply for regulatory approval. Similar results would significantly jeopardize the approvability of our product
candidates that employ the NanoPortal technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Any
inability to obtain these approvals would prevent us from commercializing our product candidates. The FDA, the EMA or comparable
foreign authorities can delay, limit, or deny approval of a product candidate for many reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">a product candidate may not be deemed safe or effective; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>the FDA could determine that we cannot rely on the Section 505(b)(2) regulatory pathway or other pathways we have selected,
as applicable, for our lead product candidate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">agency officials of the FDA, the EMA or comparable foreign authorities may find the data
from non-clinical or preclinical studies, chemistry, manufacturing, and controls, and/or clinical trials generated during development
is inadequate, contained clinical deficiencies or otherwise failed to demonstrate the safety and effectiveness of our product candidate
for any indication; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>the FDA, the EMA or comparable foreign authorities may not find the data from bioequivalence studies and/or clinical trials
sufficient to support the submission of an NDA or to obtain marketing approval in the U.S., including any findings that the clinical
and other benefits of our product candidate outweigh their safety risks;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>the FDA, the EMA or comparable foreign authorities may determine that we have identified the wrong listed drug or drugs or
that approval of our Section 505(b)(2) application for our product candidate is blocked by patent or non-patent exclusivity of
the listed drug or drugs or of other previously approved drugs with the same conditions of approval as our product candidate, as
applicable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">the FDA, the EMA or comparable foreign authorities may not approve in the manufacturing
processes or facilities of third-party manufacturers with which we enter into agreements for the manufacture of our product candidates;
</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">the FDA, the EMA or comparable foreign authorities </span>may audit some or all of our
clinical research study sites to determine the integrity of our data and may reject any or all of such data;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>the FDA, the EMA, or a comparable foreign authority may approve our lead product candidate for fewer or more limited indications
than we request, or may grant approval contingent on the performance of costly post-approval clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="letter-spacing: 0.2pt">&#9679;</span></td><td><span style="letter-spacing: 0.2pt">the FDA, the EMA or a comparable foreign authority may change its approval policies or
adopt new regulations; or </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>may not approve the labeling claims that we believe are necessary or desirable for the successful commercialization of our
lead product candidate.</td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></div>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">With
respect to one or more of our product candidates, including NPM-119 (exenatide implant), we plan to seek regulatory approval in
the U.S. by filing an NDA under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, which is referred to as the 505(b)(2)
pathway. The 505(b)(2) pathway allows at least some of the information required for NDA approval, such as safety and efficacy information
on the active ingredient, to come from studies not conducted by or for the applicant. For NPM-119, we intend to rely on certain
information from Bydureon</span><span style="letter-spacing: 0.15pt">&#174;</span> <span style="letter-spacing: 0.2pt">and/or Bydureon
BCise</span><span style="letter-spacing: 0.15pt">&#174;</span><span style="letter-spacing: 0.2pt">, AstraZeneca&#8217;s exenatide
extended-release injectable products. If we are unable to reference data generated for Bydureon</span><span style="letter-spacing: 0.15pt">&#174;</span>
<span style="letter-spacing: 0.2pt">and/or Bydureon BCise</span><span style="letter-spacing: 0.15pt">&#174;</span><span style="letter-spacing: 0.2pt">,
additional clinical studies, including a cardiovascular outcomes (CVOT) study, may be required and would add significant additional
costs and a significant delay in our efforts to seek and secure marketing approval. Further, if a CVOT study were conducted, there
can be no assurance that the study would generate favorable results and support U.S. registration.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Although
we have discussed our intention to use the 505(b)(2) regulatory pathway with the FDA, there can be no assurance that this pathway
will be acceptable, and there can be no assurance that the FDA will not require additional testing to support seeking approval
in the U.S. If the 505(b)2 regulatory pathway is not available, the costs of development may significantly increase and the projected
timeline to approval and launch would be significantly delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Even
if a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on
the product labeling or require expensive and time-consuming clinical trials and/or reporting as conditions of approval. Regulators
of other countries and jurisdictions have their own procedures for the approval of product candidates with which we must comply
prior to marketing in those countries or jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Obtaining
regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory
approval in any other country. In addition, delays in approvals or rejections of marketing applications in the U.S. or other countries
may be based upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical
trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period
of product development and the emergence of new information regarding our product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>We intend to utilize
the 505(b)(2) pathway for the regulatory approval of NPM-119 and other of our product candidates. Final marketing approval of NPM-119
or any of our other product candidates by the FDA, or other regulatory authorities may be delayed, limited, or denied, any of which
would adversely affect our ability to generate operating revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We intend
to pursue a regulatory pathway pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, for the approval
of NPM-119 and other of our product candidates, which allows us to rely on existing clinical data for the drug. Section 505(b)(2)
was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, and
permits the submission of an NDA where at least some of the information required for approval comes from preclinical studies or
clinical trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The FDA
interprets Section 505(b)(2) of the FDCA to permit the applicant to rely upon the FDA&#8217;s previous findings of safety and efficacy
for an approved product. The FDA requires submission of information needed to support any changes to a previously approved drug,
such as published data or new studies conducted by the applicant or clinical trials demonstrating safety and efficacy. The FDA
could refuse to file our NDA submissions, request additional information before accepting our submissions for filing or require
additional information to sufficiently demonstrate safety and efficacy to support approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">If the
FDA does not agree that the 505(b)(2) regulatory pathway is appropriate or scientifically justified for our product candidates,
we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory
approval. For example, if we are unable to establish a bridge between our product candidates and the listed drug upon which we
rely to demonstrate that such reliance is justified, we may be required to show safety and efficacy through one or more additional
clinical trials. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates,
and the complications and risks associated with these product candidates, would likely substantially increase. Moreover, an inability
to pursue the 505(b)(2) regulatory pathway would likely result in new competitive products reaching the market more quickly than
our product candidates, which would likely materially adversely impact our competitive position and prospects. Even if we are allowed
to pursue the 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals
for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Notwithstanding
the approval of many products by the FDA pursuant to 505(b)(2), over the last few years some pharmaceutical companies and others
have objected to the FDA&#8217;s interpretation of Section 505(b)(2) to allow reliance on the FDA&#8217;s prior findings of safety
and effectiveness. If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&#8217;s interpretation is successfully
challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) application that we submit.
Moreover, the FDA adopted an interpretation of the three-year exclusivity provisions whereby a 505(b)(2) application can be blocked
by exclusivity even if does not rely on the previously-approved drug that has exclusivity (or any safety or effectiveness information
regarding that drug). Under the FDA&#8217;s interpretation, the approval of NPM-119 or other of our product candidates may be blocked
by exclusivity awarded to a previously-approved drug product that shares certain innovative features with NPM-119 or our other
product candidate, even if our 505(b)(2) application does not identify the previously-approved drug product as a listed drug or
rely upon any of its safety or efficacy data. Any failure to obtain regulatory approval of our product candidates would significantly
limit our ability to generate revenues, and any failure to obtain such approval for all of the indications and labeling claims
we deem desirable could reduce our potential revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Even
if we are successful in pursuing the 505(b)(2) regulatory pathway for NPM-119, or other of our product candidates, we cannot assure
you that we will receive the requisite or timely approval for commercialization of NPM-119 or other of our product candidates.
Although the Section 505(b)(2) pathway allows us to rely in part on the FDA&#8217;s prior findings of safety or efficacy for approved
listed drugs or on published literature for which we do not have a right of reference, the FDA may determine that prior findings
by the FDA or the published literature that we believe supports the safety or efficacy of NPM-119 or other of our product candidates
is insufficient or not applicable to our application or that additional studies will need to be conducted. To the extent that we
are relying on the 505(b)(2) regulatory pathway based on the approval of a listed drug for a similar indication, the FDA may require
that we include in the labeling of NPM-119 or another of our product candidates, if approved, some or all of the safety information
that is included in the labeling of the approved listed drug. Moreover, even if any of our product candidates are approved via
the 505(b)(2) regulatory pathway, the approval may be subject to limitations on the indicated uses for which the product may be
marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to
monitor the safety or efficacy of the product, such as a Risk Evaluation and Mitigation Strategy, or REMS, which is a risk mitigation
plan which could include medication guides, physician communication plans, or elements to assure safe use, or ETASU, such as restricted
distribution methods, patient registries and other risk minimization tools.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Additional time may
be required to obtain regulatory approval for our product candidates because they are combination products. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of our product candidates, including NPM-119 which is designed
as a GLP-1 implant for treatment of type 2 diabetes, are drug-device combination products which require coordination within the
FDA and similar foreign regulatory agencies for review of their device and drug components. A combination product generally is
defined as a product comprised of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic).
Each component of a combination product is subject to the requirements established by the FDA for that type of component, whether
a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its
centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination
by the FDA of the primary mode of action of the combination product. Where approval of the drug and device is sought under a single
application, there could be delays in the approval process due to the increased complexity of the review process and the lack of
a well-established review process and criteria. The EMA has a parallel review process in place for combination products, the potential
effects of which in terms of approval and timing could independently affect our ability to market our combination products in Europe.
Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products
such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing
constraints and uncertainties in the product development and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We and our contract manufacturers are subject to significant
regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue
to meet regulatory requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">All entities
involved in the preparation of therapeutics for clinical trials or commercial sale, including our contract manufacturers for our
product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale
or used in clinical trials must be manufactured in accordance with current requirements on good manufacturing practices (cGMP).
These regulations govern manufacturing processes and procedures and the implementation and operation of quality systems to control
and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead
to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may
not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support
of an NDA or marketing authorization application (MAA) on a timely basis and must adhere to good laboratory practices (GLP) and
cGMP regulations enforced by the FDA, the EMA, or comparable foreign authorities through their facilities inspection program. The
facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance
with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities
may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated
quality systems for compliance with the regulations applicable to the activities being conducted. Although we plan to oversee the
contract manufacturers that we use, we cannot control the manufacturing process of, and are completely dependent on, our contract
manufacturers for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection,
regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the
satisfaction of the regulatory authority, if ever. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The
regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our
third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation
of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant
regulatory authority may require remedial measures that may be costly or time consuming for us or a third party to implement,
and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent
closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm
our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

</div>



<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we or any of our third-party manufacturers
fail to maintain regulatory compliance, the FDA, the EMA, or comparable foreign authorities can impose regulatory sanctions including,
among other things, refusal to approve a pending application for a product candidate, withdrawal of an approval, or suspension
of production. As a result, our business, financial condition, and results of operations may be materially and adversely affected.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Additionally, if supply from one manufacturer
is interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent
foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies or
trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and
is likely to result in a delay in our desired clinical and commercial timelines. These factors could cause us to incur higher
costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization
of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one
or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, and
our development efforts would be impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Even if one or more of our product candidates receive
regulatory approval in the U.S., we may never receive comparable approvals outside of the U.S.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed in these risk factors regarding FDA approval in the U.S. as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay seeking or obtaining such approval would impair our ability to commercialize our product candidates in territories outside of the U.S. <span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Even if any of our
product candidates receive regulatory approval, we will be subject to ongoing legal and regulatory compliance requirements, and
regulatory agencies may impose post-approval requirements or, under certain circumstances, withdraw such approval.</i></b></span><span style="letter-spacing: 0.2pt">&#160;<b><i>We
may be subject to substantial penalties regulatory requirements or if we experience unanticipated problems with our products following
approval. </i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Even
if one or more of our product candidates receive regulatory approval, the FDA, the EMA, or comparable foreign authorities may still
impose significant restrictions on the indicated uses or marketing of the product candidates or impose ongoing requirements for
potentially costly post-approval studies and trials. In addition, regulatory agencies subject a product, its manufacturer and the
manufacturer&#8217;s facilities to continual review and periodic inspections. Manufacturers and manufacturers&#8217; facilities
are required to comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality
control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. Manufacturers
and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing
requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that
are otherwise unfit for distribution in the U.S. If a regulatory agency discovers previously unknown problems with a product, including
adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory
agency may impose restrictions on that product, on our company or on any of our collaborators, including requiring withdrawal of
the product from the market. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Our product
candidates will also be subject to ongoing FDA, the EMA, or comparable foreign authorities&#8217; requirements, including those
related to the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market
information on the drug. Any government investigation of alleged violations of law could require us to expend significant time
and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may
significantly and adversely affect our ability to generate revenues from any of our product candidates that are approved for commercialization.
If our product candidates fail to comply with applicable regulatory requirements, or there is later discovery of previously unknown
adverse events or other problems with our products or their manufacturers or manufacturing processes, a regulatory agency may:
</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">issue warning or untitled letters or other notices of possible violations; </span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">impose civil or criminal penalties or fines or seek disgorgement of revenue or profits;
</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">suspend any ongoing clinical trials; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">refuse to approve pending applications or supplements to approved applications filed by
us or our collaborators; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">withdraw any regulatory approvals; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><span style="letter-spacing: 0.2pt">impose restrictions on operations, including costly new manufacturing requirements, or
shut down our manufacturing operations; </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="letter-spacing: 0.2pt">&#9679;</span></td><td><span style="letter-spacing: 0.2pt">refuse to approve pending applications or supplements to approved applications that we
submit;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="letter-spacing: 0.2pt">&#9679;</span></td><td><span style="letter-spacing: 0.2pt">recall our products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="letter-spacing: 0.2pt">&#9679;</span></td><td><span style="letter-spacing: 0.2pt">refuse to permit the import or export of products; or</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="letter-spacing: 0.2pt">&#9679;</span></td><td><span style="letter-spacing: 0.2pt">seize or detain products or require a product recall. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Additionally,
under the Food and Drug Omnibus Reform Act of 2022, sponsors of approved drugs and biologics must provide 6 months&#8217; notice
to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing
the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>
The FDA, the EMA and comparable foreign authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.
</i></b> <span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">The FDA,
the EMA and comparable foreign authorities strictly regulate the promotional claims that may be made about prescription products,
such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the
FDA, the EMA or comparable foreign authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval
for one or more of our product candidates for any particular indications, physicians may nevertheless use our products for their
patients in a manner that is inconsistent with the approved label, if the physicians personally believe in their professional medical
judgment that our products could be used in such manner. However, if we are found to have promoted our products for any off-label
uses, the federal government could levy civil, criminal, or administrative penalties, and seek fines against us. Such enforcement
has become more common in the industry. The FDA, the EMA or comparable foreign authorities could also request that we enter into
a consent decree or a corporate integrity agreement or seek a permanent injunction against us under which specified promotional
conduct is monitored, changed, or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved,
we could become subject to significant liability, which would materially adversely affect our business, financial condition, and
results of operations. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Current and future legislation may increase the difficulty
and cost of commercializing our product candidates and may affect the prices that we may obtain if our product candidates are
approved for commercialization.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict, or regulate post-approval activities and affect our ability to profitably sell any product candidates that obtain regulatory approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any of our collaborators, may receive for any approved products. For more information, see &#8220;<i>Business-Government Regulation &#8211; Healthcare Reform &amp; the Patient Protection and Affordable Care Act.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Current and future legislation may increase
the difficulty and cost to commercialize our product candidates, if approved, and affect the prices obtained, including changes
in coverage and reimbursement policies in certain market segments for our product candidates, which could make it difficult to
sell our product candidates, if approved, profitably. Third-party payors, whether domestic or foreign, or governmental or commercial,
are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign
jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability
to sell our product candidates, if approved, profitably.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Since its enactment, there have been
executive, judicial, and Congressional challenges to certain aspects of the ACA. In June 2021, the United States Supreme Court
held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling
on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme
Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial
condition, and results of operations. Complying with any new legislation or changes in healthcare regulation could be time-intensive
and expensive, resulting in material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, other legislative changes
have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011,
among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked
with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach
required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate
reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and will remain in effect
through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020,
through March 31, 2022, unless additional Congressional action is taken. Under the current legislation, the actual reduction in
Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. The American Taxpayer Relief
Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the demand for our product candidates if approved;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>our ability to receive or set a price that it believes
                                         is fair for its products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>our ability to generate revenue and achieve or maintain
                                         profitability;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the level of taxes that we will be required to pay;
                                         and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the availability of capital.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></div>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We expect that the ACA, the Inflation Reduction Act of 2022, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any product candidates, if approved. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved. </p>

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the state level, individual states are
also increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to
determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs.
These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We expect that additional state and federal
healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments
will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates
or additional pricing pressures. In particular any policy changes through CMS as well as local state Medicaid programs could have
a significant impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Changes in funding for the FDA and other government
agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and
services from being developed or commercialized in a timely manner, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The ability of the FDA to review and
approve new products can be affected by a variety of factors, including (i) government budget and funding levels, (ii) the ability
to hire and retain key personnel and accept the payment of user fees and (iii) statutory, regulatory and policy changes. Average
review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies
that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Disruptions at the FDA and other agencies
may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely
affect its business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government
shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions,
or otherwise impair our interactions with the agency, which could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be exposed to product liability, non-clinical and clinical liability risks which could place a substantial financial burden on our business. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Our business
exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing, and marketing
of medical products and the subsequent sale of these products by. In addition, the use in our clinical trials of pharmaceutical
and related products and the subsequent sale of these products may cause us to bear a portion of or all product liability risks.
If a products liability claim is brought against us, we will be required to expend significant time and resources in defending
against such a claim, and such defense may not ultimately be successful. We do not currently maintain clinical trial liability
insurance, although we intend to seek coverage in connection with initiating our first clinical trial of NPM-119. There can be
no assurance that we will secure clinical trial liability insurance on commercially reasonable terms or at all. As a result, products
liability risks could have a material adverse effect on our business, financial condition, and results of operations. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Our research and
development activities involve the use of hazardous materials, which subjects to regulation, related costs and delays and potential
liabilities.</i></b></span><span style="letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Our research
and development activities may involve the controlled use of hazardous materials and chemicals. If an accident occurs, we could
be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace
safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling
of biohazardous materials. Additional federal, state, and local laws and regulations affecting </span>our <span style="letter-spacing: 0.2pt">operations
may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate any
of these laws or regulations. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Relating to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not be able to adequately protect our proprietary or licensed technology.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our business depends on our ability to protect our proprietary technology. We rely on a combination of trade secret, patent, copyright and trademark laws, and confidentiality, licensing, and other agreements with employees and third parties, all of which offer only limited protection. We may also in-license additional intellectual property rights in the future. We cannot be certain that patent enforcement activities by our current or future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. We also cannot be certain that our current or future licensors will allocate sufficient resources or prioritize enforcement of such patents. Even if we are not a party to these legal actions, an adverse outcome could prevent us from continuing to license intellectual property that we may need to operate our business.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We plan to seek, through prosecution of patent applications covering our owned technology, adequate patent protection for our proprietary drug technology. If we are compelled to spend significant time, money and resources protecting or enforcing our patents and future patents that we may possess, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other proprietary rights held by others, our business, financial condition, and results of operations may be materially and adversely affected. If we are unable to effectively protect the intellectual property that we own or in-license, other companies may be able to offer the same or similar products for sale, which could materially adversely affect our business, financial condition, and results of operations. The patents of others from whom we may license technology, and any future patents we may own, may be challenged, narrowed, invalidated, or circumvented, which could limit our ability to stop competitors from marketing the same or similar products or limit the length of term of patent protection that we may have for our product candidates, if approved.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Obtaining and maintaining patent protection depends
on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection for licensed patents, pending patent applications and potential future patent applications
and patents could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be
due to be paid to the U.S. Patent and Trademark Office (USPTO) and various governmental patent agencies outside of the U.S. in
several stages over the lifetime of the applicable patent and/or patent application. The USPTO and various non-U.S. governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the
patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance
with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent
or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs with
respect to our in-licensed patents or patent applications that we may file in the future, our competitors might be able to use
its technologies, which would have a material adverse effect on our business, financial condition, and results of operations. </span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The patent positions of pharmaceutical products are often complex and uncertain. The breadth of claims allowed in pharmaceutical patents in the U.S. and many jurisdictions outside of the U.S. is not consistent. For example, in many jurisdictions, the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information related to our product candidates may prevent us from obtaining or enforcing patents relating to these product candidates. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Patents that we currently own or license and patents that we may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual property for a number of reasons, including, without limitation, the following:  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the patents may not be broad or strong enough to prevent
                                         competition from other products that are identical or similar to our own product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>there can be no assurance that the term of a patent
                                         can be extended under the provisions of patent term extensions afforded by U.S. law or
                                         similar provisions in foreign countries, where available;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the issued patents and patents that we may obtain
                                         or license in the future may not prevent generic entry into the market for our product
                                         candidates; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>we or our licensors may be required to disclaim part
                                         of the term of one or more patents;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>there may be prior art of which we are not aware
                                         that may affect the validity or enforceability of a patent claim; </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>there may be prior art of which we are aware, which
                                         we do not believe affects the validity or enforceability of a patent claim, but which,
                                         nonetheless, ultimately may be found to affect the validity or enforceability of a patent
                                         claim;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>there may be other patents issued to others that will
                                         affect our freedom to operate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>if the patents are challenged, a court could determine
                                         that they are invalid or unenforceable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>there might be a significant change in the law
                                         that governs patentability, validity and infringement of our licensed patents or any
                                         future patents that we may own that adversely affects the scope of our patent rights;
                                         </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p></div>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>a court could determine that a competitor&#8217;s technology
                                         or product does not infringe our licensed patents, or any future patents we may own;
                                         and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td>the patents could irretrievably lapse due to
                                         failure to pay fees or otherwise comply with regulations or could be subject to compulsory
                                         licensing. If we encounter delays in our development efforts or clinical trials, the
                                         period of time during which we could market our product candidates, if approved, under
                                         patent protection would be reduced. </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our competitors may be able to circumvent our licensed patents or future patents we may own by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors claim that our licensed patents or any future patents we may own are invalid, unenforceable, or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our licensed patents, or any future patents we may own, including by filing lawsuits alleging patent infringement by such third parties. In any of these types of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may own invalid or unenforceable. We may also fail to identify patentable aspects of our research and development efforts before it is too late to obtain patent protection. Even if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity, or enforceability. In this regard, third parties may challenge our licensed patents, or any future patents we may own in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not be successful in obtaining or maintaining necessary rights to develop and commercialize our product candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="margin: 0pt 0; text-indent: 20pt">We utilize our NanoPortal technology to develop long-term drug implant candidates that are designed to
deliver active compounds to patients. Some of our product candidates may deliver active compounds that are proprietary to one or
more third parties. For example, from our current pipeline, NPM 139 and NPM-159 both deliver active ingredients that are proprietary
to another company that have been made available to us for feasibility testing under materials transfer agreements. Similarly,
in the future, we may develop one or more additional product candidates that utilize active ingredients that are proprietary to
another third party. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Our current activities for
NPM-139 and NPM-159 are limited to feasibility testing, but if we advance these programs for further development, we will need
to negotiate and enter into one or more licenses with the relevant third parties in order to conduct such activities. However,
there can be no assurance that we can enter into such agreements on commercially reasonable terms or at all.</span></p>

<p style="margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We may also need to partner, acquire or in-license additional intellectual property in the future with respect to other product candidates. Moreover, we may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. We may face competition with regard to acquiring and in-licensing third-party intellectual property rights, including from a number of more established companies. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property rights to us. We also may be unable to acquire or in-license third-party intellectual property rights on commercially acceptable terms or at all.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">If we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property rights, we may need to abandon development of the related program and our business, financial condition and results of operations could be materially and adversely affected.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may infringe the intellectual property rights of others, which may prevent or delay our development efforts and prevent us from commercializing or increase the costs of commercializing our product candidates, if approved. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our business depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our product candidates infringe. There also could be patents that we believe are not infringed, but that we may ultimately be found to infringe.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Moreover, patent applications are in
some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature
frequently occurs substantially later than the date on which the underlying discoveries were made, and patent applications were
filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that
may later result in issued patents that our product candidates infringe. For example, pending applications may exist that claim
or can be amended to claim subject matter that our product candidates infringe. Competitors may file continuing patent applications
claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part applications, in
order to maintain the pendency of a patent family and attempt to cover our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Third parties may assert that we are
employing their proprietary technology without authorization and may sue us for patent or other intellectual property infringement.
These lawsuits are costly and could adversely affect our business, financial condition and results of operations and divert the
attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate that our
activities either do not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able
to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing
evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we
may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing
these proceedings, which could have a material adverse effect on our business. In addition, we may not have sufficient resources
to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and cover
our activities, the holders of any of these patents may be able to block our ability to commercialize our product candidates,
if approved, unless it we acquire or obtain a license under the applicable patents or until the patents expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We may not be able to enter licensing arrangements or make other arrangements on reasonable terms or at all. Any inability to secure licenses or alternative technology could result in delays in the commercialization of our product candidates, if approved, or lead to the prohibition of their manufacture or sale. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material and adverse effect on our business, financial condition, and results of operations.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: 0.2pt"><b><i>An NDA submitted under
Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the
review or approval of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We expect to submit NDAs under Section 505(b)(2)
of the FDCA for our product candidates. Section 505(b)(2) permits the submission of an NDA where at least some of the information
required for approval comes from preclinical studies or clinical trials that were not conducted by, or for, the applicant and for
which the applicant has not obtained a right of reference. A 505(b)(2) NDA enables the applicant to reference published literature
for which the applicant does not have a right of reference and the FDA&#8217;s previous findings of safety and effectiveness for
a previously approved drug. For 505(b)(2) NDAs, the patent certification and related provisions of the Hatch-Waxman Amendments
apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Accordingly, if the applicant relies for
approval on the safety or effectiveness on information for a previously approved drug, referred to as a listed drug, the applicable
is required to include patent certifications in our 505(b)(2) NDA regarding any applicable patents covering the listed drug. If
there are applicable patents listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly
known as the Orange Book, for the listed drug, and the applicant seeks to obtain approval prior to the expiration of one or more
of those patents, the applicant is required to submit a Paragraph IV certification indicating its belief that the relevant patents
are invalid or unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the
505(b)(2) application. Otherwise, the 505(b)(2) NDA cannot be approved by the FDA until the expiration of any patents listed in
the Orange Book for the listed drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">If we submit any Paragraph IV certification
that may be required, we will be required to provide notice of that certification to the NDA holder and patent owner. Under the
Hatch-Waxman Amendments, the patent owner may file a patent infringement lawsuit after receiving such notice. If a patent infringement
lawsuit is filed within 45 days of the patent owner&#8217;s or NDA holder&#8217;s receipt of notice (whichever is later), a one-time,
automatic stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA is triggered, which typically extends for 30 months unless
patent litigation is resolved in favor of the Paragraph IV filer or the patent expires before that time. Accordingly, we may invest
a significant amount of time and expense in the development of one or more product candidates only to be subject to significant
delay and patent litigation before such product candidates may be commercialized, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, a 505(b)(2) NDA will not be
approved until any applicable non-patent exclusivity listed in the Orange Book for the listed drug, or for any other drug with
the same protected conditions of approval as our product, has expired. The FDA also may require us to perform one or more additional
clinical trials or measurements to support the change from the listed drug, which could be time consuming and could substantially
delay our achievement of regulatory approval. The FDA also may reject any future 505(b)(2) NDAs and require us to submit traditional
NDAs under Section 505(b)(1), which would require extensive data to establish safety and effectiveness of the product for the proposed
use and could cause delay and additional costs. In addition, the FDA could reject any future 505(b)(2) application and require
us to submit a Section 505(b)(1) NDA or a Section 505(j) ANDA if, before the submission of our 505(b)(2) application, the FDA approves
an application for a product that is pharmaceutically equivalent to ours and determines that our product is inappropriate for review
through the 505(b)(2) pathway. These factors, among others, may limit our ability to commercialize our product candidates successfully.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Changes in U.S. patent law could diminish the value
of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">As is the case with other biopharmaceutical companies, our success is heavily dependent on maintaining and protecting our intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming, and inherently uncertain. For example, the U.S. previously enacted and implemented wide-ranging patent reform legislation. Specifically, on September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law and included a number of significant changes to U.S. patent law, and many of the provisions became effective in March 2013. However, it may take the courts years to interpret the provisions of the Leahy-Smith Act, and the implementation of the statute could increase the uncertainties and costs surrounding the prosecution of our patents and future patent applications and the enforcement or defense of our licensed and future patents. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty regarding our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not be able to protect its intellectual property
rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Filing, prosecuting, and defending patents on product candidates in all jurisdictions throughout the world would be prohibitively expensive. Competitors may use our licensed and owned technologies in jurisdictions where we have not licensed or obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain or license patent protection, but where patent enforcement is not as strong as that in the U.S. These products may compete with our product candidates in jurisdictions where we do not have any issued or licensed patents and any future patent claims, or other intellectual property rights may not be effective or sufficient to prevent them from so competing.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our licensed patents and future patents we may own, or marketing of competing products in violation of our proprietary rights generally. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending its licensed and owned intellectual property both in the U.S. and abroad. For example, China currently affords less protection to a company&#8217;s intellectual property than some other jurisdictions. As such, the lack of strong patent and other intellectual property protection in China may significantly increase our vulnerability regarding unauthorized disclosure or use of our intellectual property and undermine our competitive position. Proceedings to enforce our future patent rights, if any, in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be unable to adequately prevent disclosure
of trade secrets and other proprietary information.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">To protect our proprietary and licensed
technology and processes, we rely in part on confidentiality agreements with our corporate partners, employees, consultants, manufacturers,
outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure
of our confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential
information. In addition, others may independently discover our trade secrets and proprietary information. Failure to obtain or
maintain trade secret protection could adversely affect our competitive business position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Although we require all of our employees
to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access
to our proprietary know how, information or technology to enter into confidentiality agreements, we cannot be certain that our
trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain
access to our trade secrets or independently develop substantially equivalent information and techniques.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be subject to claims that our employees, consultants,
or independent contractors have wrongfully used or disclosed confidential information of third parties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We expect to employ individuals who were previously employed at other biopharmaceutical companies. Although we have no knowledge of any such claims against us, and to date none our employees have been subject to such claims, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of such third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>If we do not obtain
additional protection under the Hatch-Waxman Amendments and similar foreign legislation extending the terms of our patents and
any future patents we may own, our business, financial condition and results of operations may be materially and adversely affected.</i></b></span><span style="letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Depending
upon the timing, duration, and specifics of FDA regulatory approval for our product candidates, one or more of our licensed U.S.
patents or future U.S. patents that we may license or own may be eligible for limited patent term restoration under the Drug Price
Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. In certain instances, the Hatch-Waxman
Amendments permit a patent restoration term of up to five years as compensation for patent term lost during drug development and
the FDA regulatory review process. This period is generally one-half the time between the effective date of an investigational
new drug application IND (falling after issuance of the patent), and the submission date of an NDA, plus the time between the
submission date of an NDA and the approval of that application. The patent term extension cannot extend the remaining term of
a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering
the approved drug, a method for using it, or a method of manufacturing it may be extended. However, we may not receive an extension
because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents
or otherwise failing to satisfy applicable requirements. Moreover, the length of the extension could be less than we request.
If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during
which we can enforce our patent rights for that product will not be lengthened and third parties, including our competitors, may
obtain approval to market competing therapies sooner than we expect. As a result, our revenue from applicable therapies could
be materially reduced and our business, financial condition, results of operations, and prospects could be materially harmed.</span>&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Reliance on Third Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>Use of third parties
to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates,
products, or necessary quantities at an acceptable cost. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We do
not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates,
and we lack the resources and the capabilities to do so. As a result, we currently rely on third parties for supply of the active
pharmaceutical ingredients, or API, in our product candidates, and our other drug components, as well as the device components
of our drug-device combination product candidates. Our current strategy is to outsource all manufacturing of our product candidates
and products to third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We currently
engage, or plan to engage, third-party manufacturers to manufacture our product candidates and related supplies and packaging.
There is no guarantee that we can maintain our relationships with these manufacturers and we may incur added costs and delays in
identifying and qualifying any replacements for such manufacturers. There is no assurance that we will be able to timely secure
further needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed ability
to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Reliance
on third-party manufacturers entails additional risks, including:</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td>reliance on third parties for manufacturing process development, regulatory compliance and quality assurance;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td>limitations on supply availability resulting from capacity and scheduling constraints of third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td>the possible breach of manufacturing agreements by third parties because of factors beyond our control; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span>&#9679;</span></td><td>the possible termination or non-renewal of the manufacturing agreements by the third party, at a time that is costly or inconvenient
to us.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">If we
do not maintain our key manufacturing relationships or if our third-party manufactures fail to comply with applicable regulations,
we may need to find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability
to obtain regulatory approval for our products. If we do find replacement manufacturers and enter into agreements with them on
terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered
with the FDA and other foreign regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">If any
third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to manufacture the materials
ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different third-party manufacturer,
which we may not be able to do on reasonable terms, if at all. In either scenario, our product supply could be delayed significantly
as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product
candidates may be unique or proprietary to the original third-party manufacturer and we may have difficulty, or there may be contractual
restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer
such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be required to
verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable
regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process
will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority.
The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates
or commercialize our products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology
related to the manufacture of our product candidate that such manufacturer owns independently. This would increase our reliance
on such third-party manufacturer or require us to obtain a license from such manufacturer in order to have another third party
manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and
processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and
that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require
the conduct of additional clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">Third-party
manufacturers may not be able to comply with the regulatory requirements, known as cGMP, applicable to drug-device combination
products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR
or similar regulatory requirements outside the United States. Our failure, third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and
criminal prosecutions, any of which could significantly affect supplies of our product candidates. The facilities used by our contract
manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted
after we submit our NDA to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We do
not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with
cGMPs and QSRs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and
the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for
their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate
quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve
these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which could cause significant delays in our operating timelines and would significantly
impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Contract manufacturers
may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the
contractor may not be able to maintain compliance with the applicable cGMP and QSR requirements. Any failure to comply with cGMP
or QSR requirements or other FDA, EMA and comparable foreign regulatory requirements could adversely affect our clinical research
activities and our ability to develop our product candidates and market our products following approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">The FDA
and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding
foreign regulators also inspect these facilities to confirm compliance with applicable cGMPs and QSRs. Contract manufacturers may
face manufacturing or quality control problems causing drug substance or device component production and shipment delays or a situation
where the contractor may not be able to maintain compliance with the applicable cGMP or QSR requirements. Any failure to comply
with cGMP or QSR requirements or other FDA, EMA and comparable foreign regulatory requirements could adversely affect our clinical
research activities and our ability to develop our product candidates and market our products following approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: -0.2pt"><b><i>We rely, and expect
to continue to rely, on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these
third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements,
we may not be able to obtain regulatory approval for or commercialize our product candidates on the timelines that we anticipate
or at all.</i></b></span><span style="letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We have
relied and intend to continue to rely upon third-party CROs, medical institutions, clinical investigators, and contract laboratories
to monitor and manage data for our ongoing research and development efforts. Nevertheless, we remain responsible for ensuring that
each of our clinical trials and preclinical studies is conducted in accordance with the applicable protocol, legal, regulatory,
and scientific standards, and our reliance on these third parties does not relieve us of our responsibilities. We and our CROs
and other vendors are required to comply with cGMP, good clinical practices (GCP) and GLP, which are a collection of laws and regulations
enforced by the FDA, the EMA, and comparable foreign authorities for all of our product candidates in clinical development. Regulatory
authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal
investigators, preclinical study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fails to
comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable
and the FDA, the EMA or comparable foreign authorities may require us to perform additional preclinical studies and clinical trials.
We cannot guarantee that upon inspection by a given regulatory authority, such regulatory authority will determine that any of
our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent
with cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the
development and regulatory approval processes. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We may not be able to enter into arrangements with CROs on commercially reasonable terms, or at all. In addition, our CROs are not our own employees, and except for remedies available to us under our agreements with such CROs, we will not be able to control whether they devote sufficient time and resources to our ongoing research and development activities. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated and our development activities will be impaired. CROs may also generate higher costs than anticipated. As a result, our business, financial condition and results of operations and the commercial prospects for our product candidates could be materially and adversely affected, our costs could increase, and our ability to generate revenue could be harmed.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Switching or adding additional CROs, medical institutions, clinical investigators or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition, or results of operations.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our efforts to seek, secure and maintain partnerships,
collaborations or other strategic initiatives with respect to one or more of our programs may not be successful.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">As part of our business strategy, we have entered into, and seek to enter into partnerships, collaborations and other strategic initiatives with respect to one or more of our programs, with the goal of maximizing the value of such assets. For example, we have a collaboration with Okava Pharmaceuticals, Inc. with respect to OKV-119. In March 2023, we announced that our wholly owned subsidiary Cortigent, Inc., which was created to continue the historical business of Second Sight, has filed a registration statement for a potential initial public offering of common stock. However, there can be no assurance that these arrangements will yield their intended benefits or that we will receive any return on our efforts and resources invested into these arrangements. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, we may from time to time
in the future enter into additional arrangements with biopharmaceutical companies for the development or commercialization of
our product candidates. We face significant competition in seeking such transactions with such collaborators. Moreover, collaboration
arrangements are complex, and time consuming to negotiate, execute and implement. We may not be successful in our efforts to establish
and implement collaborations or other alternative arrangements, and the terms of these arrangements may not be favorable to us.
If collaborate with a third party for development and commercialization of a product candidate, we may be required to relinquish
some or all of the control over that product candidate to the third party. The success of our collaboration arrangements will
depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining
the efforts and resources that they will apply to these collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Disagreements between parties to a collaboration
arrangement can lead to delays in developing or commercializing the applicable product candidate and can be difficult to resolve
in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical companies and other third parties are terminated
or allowed to expire by the other party. Any such termination or expiration would adversely affect our business, financial condition,
and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we are unable to develop our own commercial organization
or enter into agreements with third parties to sell and market our product candidates, if approved, we may be unable to generate
significant revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We currently do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing, and distribution of approved products. If any of our product candidates are approved for commercialization, we may be required to develop its sales, marketing, and distribution capabilities, or make arrangements with a third party to perform sales and marketing services. Developing a sales force is expensive and time consuming and could delay any product launch. We may be unable to establish and manage an effective sales force in a timely or cost-effective manner, if at all, and any sales force that we do establish may not be capable of generating sufficient demand for our product candidates, if approved. To the extent that we enter into arrangements with collaborators or other third parties to perform sales and marketing services, we may be required to relinquish a portion of the revenues from product sales to those third parties. If we are unable to establish adequate sales and marketing capabilities, independently or with others, we may not be able to generate significant revenues and may not become profitable.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our <span style="letter-spacing: -0.2pt">current and future
relationships with investigators, healthcare professionals, consultants, third-party payors, and customers will be subject to applicable
healthcare regulatory laws. Failure to comply with those laws could have a material adverse effect on our results of operations
and financial condition.</span></i></b><span style="letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Although we do not currently have any products on the market, our operations may be directly, or indirectly through our prescribers, consultants, customers, and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how it researches, markets, sells and distributes its product candidates for which it obtains marketing approval. For more information, see &#8220;<i>Business &#8211; Government Regulation &#8211; Healthcare Laws &amp; Reimbursement.&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current
environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement
bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a
number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations
and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial
costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future
statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p>

<p style="margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">If we are found to be in violation of
any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal
penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and
state healthcare programs or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations
to resolve allegations of non-compliance, and individual imprisonment, any of which could adversely affect our ability to operate
our business and our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Ownership of Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our principal stockholders and management own a significant
percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">As of March 29, 2023, our executive officers,
directors and principal stockholders, together with their respective affiliates, beneficially owned approximately 33% of
our common stock. Accordingly, these stockholders will be able to exert a significant degree of influence over our management and
affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant
corporate transactions. This concentration of ownership could have the effect of entrenching our management and/or the board of
directors, delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain
control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Because we became a reporting company under the Exchange
Act by means other than a traditional underwritten initial public offering, we may not be able to attract the attention of research
analysts at major brokerage firms.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Vivani resulted from the August 2022 business
combination of Second Sight Medical Products (Second Sight) and Nano Precision Medical (NPM). Since inception, Vivani&#8217;s main
priority has been the further development of the company&#8217;s lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate
for the treatment of patients with type 2 diabetes under the company&#8217;s Biopharm Division (formerly NPM). In parallel, Vivani&#8217;s
new management team remained committed to identifying and exploring strategic options for the Neuromodulation Division (formerly
Second Sight) that will enable further development of its pioneering neurostimulation systems to help patients recover critical
body functions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Because the NPM business did not become a
reporting company by conducting an underwritten initial public offering of our common stock, security analysts of brokerage firms
may not provide coverage of our company. In addition, investment banks may be less likely to agree to underwrite secondary offerings
on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because
they may be less familiar with our company as a result of more limited coverage by analysts and the media, and because we became
public at an early stage in our development. The failure to receive research coverage or support in the market for our shares will
have an adverse effect on our ability to develop a liquid market for our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Because we do not anticipate paying any cash dividends
on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">You should not rely on an investment in our
common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock
in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. In addition, any future
debt financing arrangement we enter into may contain, terms prohibiting or limiting the amount of dividends that may be declared
or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may
never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not
purchase our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The designation of our common stock as &#8220;penny stock&#8221;
would limit the liquidity of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our common stock may be deemed a &#8220;penny
stock&#8221; (as that term is defined under Rule 3a51-1 of the Exchange Act) in any market that may develop in the future. Generally,
a &#8220;penny stock&#8221; is a common stock that is not listed on a securities exchange and trades for less than $5.00 a share.
Prices often are not available to buyers and sellers and the market may be very limited. Penny stock in start-up companies is among
the riskiest equity investments. Broker-dealers who sell penny stock must provide purchasers with a standardized risk-disclosure
document prepared by the SEC. The document provides information about penny stock and the nature and level of risks involved in
investing in the penny stock market. A broker must also provide purchasers with bid and offer quotations and information regarding
broker and salesperson compensation and make a written determination that the penny stock is a suitable investment for the purchaser
and obtain the purchaser&#8217;s written agreement to the purchase. Many brokers choose not to participate in penny stock transactions.
If our common stock is deemed &#8220;penny stock&#8221;, because of penny stock rules, there may be less trading activity in any
market that develops for our common stock in the future and stockholders are likely to have difficulty selling their shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>



<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FINRA sales practice requirements may limit a stockholder&#8217;s
ability to buy and sell our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The Financial Industry Regulatory Authority
(FINRA) has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds
for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to
their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s
financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated
its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers.
If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend
that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our
common stock and could have an adverse effect on the market for and price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The market price of our common stock may be highly volatile,
and may be influenced by numerous factors, some of which are beyond our control.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The market price for our common stock may
from time to time fluctuate substantially due to a variety of factors, including market perception of our ability to meet our growth
projections and expectations, quarterly operating results of other companies in the same industry, trading volume in our common
stock, changes in general conditions in the economy and the financial markets or other developments affecting our business and
the business of others in our industry. In addition, the stock market itself is subject to extreme price and volume fluctuations.
This volatility has had a significant effect on the market price of securities issued by many companies for reasons related and
unrelated to their operating performance and could have the same effect on our common stock. The market price of shares of our
common stock could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our
control, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>results of clinical trials of our product candidates;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>the timing of the release of results of our clinical
trials;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>results of clinical trials of our competitors&#8217;
products;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>safety issues with respect to our products or our
competitors&#8217; products;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>regulatory actions with respect to our products or
our competitors&#8217; products;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>actual or anticipated fluctuations in our financial
condition and operating results;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>publication of research reports by securities analysts
about us or our competitors or our industry;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>our failure or the failure of our competitors to meet
analysts&#8217; projections or guidance that we or our competitors may give to the market;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>additions and departures of key personnel;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>strategic decisions by us or our competitors, such
as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>the passage of legislation or other regulatory developments
affecting us or our industry;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>fluctuations in the valuation of companies perceived
by investors to be comparable to us;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>sales of our common stock by us, our insiders or our
other stockholders;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>speculation in the press or investment community;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>announcement or expectation of additional financing
efforts;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>changes in accounting principles;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>terrorist acts, acts of war or periods of widespread
civil unrest;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>natural disasters and other calamities;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>changes in market conditions for biopharmaceutical
stocks; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>changes in general market and economic conditions.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, the stock market has recently
experienced significant volatility, including as a result of the ongoing COVID-19 pandemic and particularly with respect to pharmaceutical,
biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company
stocks often does not relate to the operating performance of the companies represented by the stock. As we operate in a single
industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products, or to a lesser
extent our markets. In the past, securities class action litigation has often been initiated against companies following periods
of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s
attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we fail to retain current members of our senior
management and scientific personnel, or to attract and keep additional key personnel, our ability to conduct our business will
be impaired.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our business depends on our ability to
attract, retain, and motivate highly qualified management and scientific personnel. However, competition for qualified personnel
is intense. We may not be successful in attracting qualified personnel to fulfill our current or future needs and there is no
guarantee that any of these individuals will join our company. In the event we are unable to fill critical open employment positions,
we may need to delay our operational activities and goals, including the development of our product candidates, and may have difficulty
in meeting our obligations as a public company. We currently do not maintain &#8220;key person&#8221; insurance on any of our
employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, competitors and others are
likely in the future to attempt to recruit our employees. The loss of the services of any of our key personnel, the inability
to attract or retain highly qualified personnel in the future or delays in hiring such personnel, particularly senior management,
and other technical personnel, could materially and adversely affect our business, financial condition and results of operations.
In addition, the replacement of key personnel likely would involve significant time and costs and may significantly delay or prevent
the achievement of our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p></div>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">From time to time, our management seeks the advice and guidance of certain scientific advisors and consultants regarding clinical and regulatory development programs and other customary matters. These scientific advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to our company. In addition, our scientific advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with us.  </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We will need to increase the size of our organization
and may not successfully manage our growth.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We are an early-stage biopharmaceutical company with a relatively small number of employees, and our management systems currently in place are not likely to be adequate to support our growth in the future. Our ability to grow and to manage that growth effectively will require us to hire, train, retain, manage, and motivate additional employees and to implement and improve our operational, financial and management systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems, it could have a material adverse effect on our business, financial condition, and results of operations. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="letter-spacing: 0.2pt"><b><i>Our employees, independent
contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including
non-compliance with regulatory standards and requirements and insider trading.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="letter-spacing: 0.2pt">We are
exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants </span>may
<span style="letter-spacing: 0.2pt">engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include
intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the
FDA and comparable foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate
information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that
require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in
the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws
also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical
studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted
a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees
and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud
or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions , including the imposition of civil, criminal and administrative penalties, damages,
monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual
damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely
affect our ability to operate our business and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are subject to certain U.S. and foreign anti-corruption,
anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Among other matters, U.S. and foreign anti-corruption,
anti-money laundering, export control, sanctions and other trade laws and regulations, or, collectively, Trade Laws, prohibit companies
and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners
from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments
or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial
criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract
and fraud litigation, reputational harm and other consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our business is heavily regulated and therefore
involves significant interaction with public officials. We have direct or indirect interactions with officials and employees of
government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities
to increase in time. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed
by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers
and purchasers are subject to regulation under the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA). We plan to engage
third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals
and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not
explicitly authorize or have prior knowledge of such activities. In particular, our operations will be subject to FCPA, which prohibits,
among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly
or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international
organizations and foreign government-owned or affiliated entities, candidates for foreign political office, and foreign political
parties or officials thereof. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with
respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers,
contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given
the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions
against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers,
requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance
programs and prohibitions on the conduct of our business. Any such violations could also result in prohibitions on our ability
to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products,
and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees
and our business, prospects, operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we fail to maintain proper and effective internal control
over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose
confidence in our financial reporting and the trading price of our common stock may decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Pursuant to Section 404 of the Sarbanes-Oxley
Act, our management is required to annually report upon the effectiveness of our internal control over financial reporting. If
we lose our status as a &#8220;smaller reporting company&#8221; and reach an accelerated filer threshold, our independent registered
public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules
governing the standards that must be met for management to assess our internal control over financial reporting are complex and
require significant documentation, testing and possible remediation. As we grow, we expect to hire additional personnel and may
utilize external temporary resources to implement, document and modify policies and procedures to maintain effective internal controls.
However, it is possible that we may identify significant deficiencies and/or material weaknesses in our internal controls. If we
or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors
may lose confidence in our financial reporting and the trading price of our common stock may decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Although we have determined that our internal
control over financial reporting was effective as of December 31, 2022, we cannot assure you that there will not be material weaknesses
or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control
over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations
or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent
registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over
financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness
of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations
by the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting,
or to implement or maintain other effective control systems required of public companies, could also restrict our future access
to the capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our disclosure controls and procedures may not prevent
or detect all errors or acts of fraud.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We are subject to the periodic reporting
requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must
disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed,
summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls
and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">These inherent limitations include the realities
that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally,
controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override
of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may
occur and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We will continue to incur increased costs as a result
of being a public company and our management will be required to devote substantial time to new compliance initiatives and corporate
governance practices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">As a public company, we will continue to
incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which
will require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business
and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC to implement provisions
of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance
of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank
Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act), was enacted. Stockholder activism, the current political environment
and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure
obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot
currently anticipate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We expect the rules and regulations applicable
to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming
and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could
have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss and may require
us to reduce costs in other areas of our business. For example, we expect that these rules and regulations may make it more difficult
and more expensive for us to obtain director and officer liability insurance and we may be required to accept reduced coverage
or incur substantially higher costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional
costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us
to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover,
these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and,
as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.
This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are a smaller reporting company, and we cannot be certain
if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We are a smaller reporting company and for
as long as we remain a smaller reporting company, we may take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not smaller reporting companies, including the ability to present only the
two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, not being required to comply with
the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act) and
reduced disclosure obligations regarding executive compensation in our registration statements, if applicable, and our periodic
reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on
these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
for our common stock and our stock price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">We will remain a &#8220;smaller reporting
company,&#8221; for so long as the market value of our stock held by non-affiliates is less than $700.0 million and our annual
revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a &#8220;smaller reporting
company&#8221; until (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue
is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates
is less than $700.0 million as of the prior June 30.</p>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p></div>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Adverse developments affecting the financial services
industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional
counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition
and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Actual events involving limited liquidity, defaults, non-performance
or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial
services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other
similar risks, have in the past and may in the future lead to market-wide liquidity problems.&#160; For example, on March 10, 2023,
SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance
Corporation, or the FDIC, as receiver.&#160; Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each
swept into receivership.&#160; Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC indicated
that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held
in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with
SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn
amounts thereunder. In addition, if any of our contract organizations, vendors, suppliers or other parties with whom we conduct
business are unable to access funds pursuant to their own arrangements with such a financial institution, such parties&#8217; ability
to perform their obligations could be adversely affected. In this regard, counterparties to credit agreements and arrangements
with distressed financial institutions, and third parties such as beneficiaries of letters of credit (among others), may experience
direct impacts and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have
occurred in the past, such as during the 2008-2010 financial crisis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inflation and rapid increases in interest rates have led to
a decline in the trading value of previously issued government securities with interest rates below current market interest rates.
Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion
of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate
the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs
of financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee
that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the
event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we assess our banking relationships as we believe necessary
or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current
and projected future business operations could be significantly impaired by factors that affect our company, the financial institutions
with which we have credit agreements or arrangements directly, or the financial services industry or economy in general.&#160;
These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations
under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services
industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services
industry.&#160; These factors could involve financial institutions or financial services industry companies with which we have
financial or business relationships, but could also include factors involving financial markets or the financial services industry
generally.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The results of events or concerns that involve one or more of
these factors could include a variety of material and adverse impacts on our current and projected business operations and our
financial condition and results of operations.&#160; These could include, but may not be limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>Delayed access to deposits or other financial assets
or the uninsured loss of deposits or other financial assets;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>Impairment in the ability to enter into new credit
facilities or other working capital resources;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>Potential or actual breach of contractual obligations
that require the Company to maintain letters of credit or other credit support arrangements; or</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td>Termination of cash management arrangements and/or
delays in accessing or actual loss of funds subject to cash management arrangements.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></div>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, investor concerns regarding the U.S. or international
financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter
financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult
for us to acquire financing on acceptable terms or at all.&#160; Any decline in available funding or access to our cash and liquidity
resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill
our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or
state wage and hour laws.&#160; Any of these impacts, or any other impacts resulting from the factors described above or other
related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected
business operations and financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, any further deterioration in the macroeconomic
economy or financial services industry could lead to losses or defaults by our contract organizations, vendors, suppliers or other
parties with whom we conduct business, which in turn, could have a material adverse effect on our current and/or projected business
operations and results of operations and financial condition.&#160; For example, contract organizations, vendors, suppliers or
other parties with whom we conduct business could be adversely affected by any of the liquidity or other risks that are described
above as factors that could result in material adverse impacts on our company, including but not limited to delayed access or loss
of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial
institution. Any bankruptcy or insolvency involving our contract organizations, vendors, suppliers or other parties with whom we
conduct business, or any breach or default by such parties, or the loss of any significant relationships with such parties, could
result in a material adverse impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our business, results of operations and future growth
prospects could be materially and adversely affected by the ongoing COVID-19 pandemic or the future outbreak of other highly infectious
or contagious diseases.</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Our business could be adversely affected
by health epidemics in regions where we have concentrations of clinical trial sites or other business activities and could cause
significant disruption in the operations of third-parties on which we rely. We cannot precisely determine or quantify the impact
the COVID-19 pandemic, or the future outbreak of any other highly infectious our contagious diseases, will have on our business
operations in the future, which will depend on a variety of factors and future developments, which are highly uncertain and cannot
be predicted with confidence, including the ultimate geographic spread of the disease, the duration, scope and severity of the
pandemic, the duration and extent of travel restrictions and social distancing in the United States and other countries, business
closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and
the pandemic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rising
inflation rates could negatively impact our expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
rates, particularly in the United States, have increased recently to levels not seen in years. Increased inflation may result
in increased operating costs (including our labor costs), reduced liquidity, and
limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal
Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates,
especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing
economic uncertainty and heightening these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on sophisticated information technology systems and data processing to operate our business. If we experience security
or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential
data, employee data or personal data, we may face costs, significant liabilities, harm to our brand and business disruption.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology systems and data processing that we or our service providers, collaborators, consultants, contractors
or partners operate to collect, process, transmit and store electronic information in our day-to-day operations, including a variety
of personal data, such as name, mailing address, email addresses, phone number and potentially clinical trial information. Additionally,
we, and our service providers, collaborators, consultants, contractors or partners, do or will collect, receive, store, process,
generate, use, transfer, disclose, make accessible, protect and share personal information, health information and other information
to host or otherwise process some of our anticipated future clinical data and that of users, develop our products, to operate
our business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes. Our internal
computer systems and data processing and those of our third-party vendors, consultants, collaborators, contractors or partners,
including future CROs may be vulnerable to a cyber-attack (including supply chain cyber-attacks), malicious intrusion, breakdown,
destruction, loss of data privacy, actions or inactions by our employees or contractors that expose security vulnerabilities,
theft or destruction of intellectual property or other confidential or proprietary information, business interruption or other
significant security incidents. As the cyber-threat landscape evolves, these attacks are growing in frequency, level of persistence,
sophistication and intensity, and are becoming increasingly difficult to detect. In addition to traditional computer &#8220;hackers,&#8221;
threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse, denial-of-service attacks
(such as credential stuffing), phishing and ransomware attacks, sophisticated nation-state and nation-state supported actors now
engage in attacks (including advanced persistent threat intrusions). These risks may be increased as a result of the COVID-19
pandemic, owing to an increase in personnel working remotely and higher reliance on internet technology. Furthermore, because
the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until
launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may
also experience security breaches that may remain undetected for an extended period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we, our service providers, collaborators, consultants, contractors or partners will be successful in
efforts to detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of
systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data. Any failure
by us or our service providers, collaborators, consultants, contractors or partners to detect, prevent, respond to or mitigate
security breaches or improper access to, use of, or inappropriate disclosure of any of this information or other confidential
or sensitive information, including patients&#8217; personal data, or the perception that any such failure has occurred, could
result in claims, litigation, regulatory investigations and other proceedings, significant liability under state, federal and
international law, and other financial, legal or reputational harm to us. Further, such failures or perceived failures could result
in liability and a material disruption of our development programs and our business operations, which could lead to significant
delays or setbacks in our research, delays to commercialization of our product candidates, lost revenues or other adverse consequences,
any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cashflow.
For example, the loss or alteration of clinical trial data from future clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
applicable laws and regulations relating to privacy, data protection or cybersecurity, external contractual commitments and internal
privacy and security policies may require us to notify relevant stakeholders if there has been a security breach, including affected
individuals, business partners and regulators. Such disclosures are costly, and the disclosures or any actual or alleged failure
to comply with such requirements could lead to a materially adverse impact on the business, including negative publicity, a loss
of confidence in our services or security measures by our business partners or breach of contract claims. There can be no assurance
that the <span style="background-color: white">limitations of liability in our contracts would be enforceable or adequate or would
otherwise protect us from liabilities or damages if we fail to comply with applicable data protection laws, privacy policies or
other data protection obligations related to information security or security breaches.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a004_v1"></span>Item 1B. Unresolved Staff Comments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a005_v1"></span>Item 2. Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our principal offices
and facilities are located at 5858 Horton Street, Emeryville, CA 94608 and 13170 Telfair Avenue, Sylmar CA 91342.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a006_v1"></span>Item 3. Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Three oppositions
filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us.
The outcomes of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing
our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell
our products, or otherwise have a material effect on our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As described in the Company&#8217;s 10-K
for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (&#8220;MOU&#8221;) for a proposed
business combination with Pixium Vision SA (&#8220;Pixium&#8221;). In response to a press release by Pixium dated March 24, 2021,
and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium
was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between
the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an
amicable resolution will be reached. We accrued $1,000,000 of liquidated damages as contemplated by the MOU in accounts payable
as of March 31, 2021 and remitted that amount to Pixium in April 2021. Pixium indicated that it considered this termination wrongful,
rejected the Company&#8217;s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial
Court, and currently claim damages of approximately &#8364;5.1 million or about $5.6 million. We believe we have fulfilled our obligations
to Pixium with the liquidated damages payment of $1,000,000. On December 9, 2022, the Company received notice that the Paris Commercial
Court has rendered its judgement, including finding that the Company&#8217;s termination of the MOU was not valid. In the judgement,
the Company was ordered to pay to Pixium the amount of &#8364;2,500,000 minus a &#8364;947,780 credit for the $1,000,000 already
paid for, a net amount payable of approximately &#8364;1,552,220. The Company may appeal the decision within three months from the
date of service. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to raise any and all legal
challenges to this preliminary judgement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.6pt">We are party to litigation
arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect
on our financial statements, however the results of litigation and claims are inherently unpredictable. Regardless of outcome,
litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other
factors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.6pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a007_v1"></span>Item 4. Mine Safety Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a008_v1"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a009_v1"></span>Item 5. Market for Registrant&#8217;s Common Equity, Related
Shareholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Market Information</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Vivani&#8217;s common stock is traded on the Nasdaq
Capital Market under the symbol &#8220;VANI.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">On March 24, 2023 there were approximately 123 shareholders
of record.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">We have never declared or paid cash dividends on
our common stock and do not anticipate paying any dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12
of Part III of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a010_v1"></span>Item 6. Reserved</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a011_v1"></span>Item 7. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following discussion
contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements as a result of many factors. The consolidated results of operations for the years
ended December 31, 2022 and 2021 are not necessarily indicative of the results that may be expected for any future period. The
following discussion should be read in conjunction with the consolidated financial statements and the notes thereto included in
Part IV, Item 15 of this Form 10-K and in conjunction with the &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Form
10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani Medical, Inc. (&#8220;Vivani,&#8221;
the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar terms) is a preclinical stage biopharmaceutical
company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal&#8482; technology to enable long-term,
near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop
and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners to address
a leading cause of poor clinical outcomes in the treatment of chronic disease, medication non-adherence. For example, approximately
50% of patients treated for type 2 diabetes are non-adherent to their medicines, which can lead to poor clinical outcomes. We are
developing a portfolio of miniature, sub-dermal drug implant candidates that, unlike most oral and injectable medicines, are designed
with the goal of guaranteeing adherence by delivering therapeutic drug levels for up to 6 months or the life of the implant. In
addition, the minimal fluctuations of drug levels dictated by our NanoPortal technology may improve the tolerability profiles for
medicines that produce side effects associated with fluctuating drug levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani resulted from the business combination
of Second Sight Medical Products (Second Sight) and Nano Precision Medical (NPM). Since inception, Vivani&#8217;s main priority
has been the further development of the company&#8217;s lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate for
the treatment of patients with type 2 diabetes under the company&#8217;s Biopharm Division (formerly NPM). In parallel, Vivani&#8217;s
new management team remained committed to identifying and exploring strategic options for the Neuromodulation Division (formerly
Second Sight) that will enable further development of its pioneering neurostimulation systems to help patients recover critical
body functions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In February 2022, we announced the signing
of a definitive merger agreement between Nano Precision Medical, Inc. (&#8220;NPM&#8221;) and Second Sight Medical Products, Inc.
(&#8220;Second Sight&#8221;), pursuant to which NPM became a wholly-owned subsidiary of Second Sight. On August 30, 2022, the two
companies completed the merger, concurrent with which Second Sight changed its name to Vivani Medical, Inc. and now conducts the
present business of the Company. In September 2022, we announced the formation of the Company&#8217;s Biopharm Division to advance
the assets of the former NPM which includes the further development of the Company&#8217;s lead program, NPM-119, a miniature,
6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes. Vivani&#8217;s new management team remains
committed to identifying and exploring strategic options for the Neuromodulation Division (formerly Second Sight) that will enable
further development of its pioneering neurostimulation systems to help patients recover critical body functions. On December 28,
2022, the assets and liabilities of this segment were contributed to Cortigent, Inc. a newly formed wholly owned subsidiary of
Vivani, in exchange for 20 million shares of common stock of Cortigent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2023, Vivani announced the filing
of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for the proposed initial
public offering of Cortigent. Vivani, is expected to continue to be majority-owned by Vivani immediately following the initial
public offering.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0"><b>Funding and Liquidity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Capital Funding</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From inception, our
operations have been funded primarily through the sales of our common stock and warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Non-Capital Funding</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We were awarded a $1.6 million grant (with the intent
to fund $6.4 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund
the &#8220;Early Feasibility Clinical Trial of a Visual Cortical Prosthesis&#8221; that commenced in January 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Liquidity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have experienced
recurring operating losses and negative operating cash flows since inception and have financed our working capital requirements
through the recurring sale of our equity securities and receipt of grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to
meet its planned obligations into the second half of 2024. Our ability to continue as a going concern is dependent on our ability
to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there
can be no assurances that we will be able to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Adopted Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that recently
issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material impact on our financial
statement presentation or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following discussion
and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been
prepared in conformity with accounting principles generally accepted in the United States of America. Certain accounting policies
and estimates are particularly important to the understanding of our financial position and results of operations and require the
application of significant judgment by our management or can be materially affected by changes from period to period in economic
factors or conditions that are outside of our control. As a result, they are subject to an inherent degree of uncertainty. In applying
these policies, our management uses their judgment to determine the appropriate assumptions to be used in the determination of
certain estimates. Those estimates are based on our historical operations, our future business plans and projected financial results,
the terms of existing contracts, our observance of trends in the industry, information provided by our customers and information
available from other outside sources, as appropriate. See Note 2 of notes to our consolidated financial statements for a more complete
description of our significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock-Based Compensation.
</i>Pursuant to Financial Accounting Standards Board ASC 718 Share-Based Payment (&#8220;ASC 718&#8221;), we record stock-based
compensation expense for all stock-based awards. Under ASC 718, we estimate the fair value of stock options granted using the Black-Scholes
option pricing model. The fair value for awards that are expected to vest is then amortized on a straight-line basis over the requisite
service period of the award, which is generally the option vesting term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The grant price of the issuances is determined based on the fair value of the shares at the date of grant.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The risk free interest rate for periods within the contractual life of the option is based on the U.S. treasury yield in effect at the time of grant.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Volatility is determined based on our average historical volatilities since our trading history began in November 2014 and supplemented with average historical volatilities of comparable companies in our industry.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>




<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 1pt"><span style="font-size: 10pt">Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in"><i>Operating
Expenses. </i>We recognize our operating expenses as incurred in two general operational categories: research and
development, and general and administrative. Our operating expenses also include a non-cash component related to
the amortization of stock-based compensation for research and development, and general and
administrative personnel. From time-to-time we have received grants from institutions or agencies, such as the National
Institutes of Health, to help fund the some of the cost of our development efforts. We have recorded these grants as
reductions to operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>




<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Research and development expenses consist primarily of employee
    compensation and consulting costs related to the design, development, and enhancements of our current and potential future
    products, as well as internal and external costs associated with conducting clinical trials and maintaining relationships
    with regulatory agencies offset by grant revenue received in support of specific research projects. We expense our research
    and development costs as they are incurred. We expect research and development expenses to increase in the future as we
    pursue further enhancements of our existing product and develop technology for our potential future products. We also expect
    to receive additional grants in the future that will primarily offset research and development costs.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">General and administrative expenses consist primarily of salaries and related expenses for executive, legal, finance, human resources, information technology and administrative personnel, as well as recruiting and professional fees, patent filing and annuity costs, insurance costs and other general corporate expenses, including rent. We expect general and administrative expenses to increase as we add personnel and incur additional costs related to the growth of our business and operate as a public company.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the Years Ended December 31, 2022 and 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in"><i>Research
and development expense. </i>Research and development expense increased from $11.0 million in 2021 to $14.2 million in 2022,
an increase of $3.2 million, or 29%. The increase from the prior year was primarily due to increased use of
outside contractors associated with product design, development and manufacturing associated with our products, increased
headcount and professional fees, along with inclusion of new neuromodulation division costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>General
and administrative expense. </i>General and administrative expense increased from $2.3 million in 2021 to $7.1 million in
2022, an increase of $4.8 million, or 205%. The increase is related to a provision for a legal claim of $1.7 million and
increased accounting and legal costs and other expenses related to our merger of approximately $1.5 million and the general
and administrative costs of the neuromodulation division since the merger of $1.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Net loss. </i>The
net loss was $13.9 million in 2022, as compared to $12.8 million in 2021. The $1.1 million increase in net loss from 2021 to 2022
was primarily attributable to a $7.9 million increase in operating expenses offset by a $6.9 million gain on the bargain purchase
and increased interest income due to rate increases on cash investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have experienced
recurring operating losses and negative operating cash flows since inception and have financed our working capital requirements
through the recurring sale of our equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to
meet its planned obligations into the second half of 2024. Our ability to continue as a going concern is dependent on our ability
to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there
can be no assurances that we will be able to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Working capital was $40.7 million at December
31, 2022, as compared to $0.4 million at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows from Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During 2022,
we used $18.8 million of cash in operating activities, consisting primarily of a net loss of $13.9 million, offset by $0.4
million from a net change in operating assets and liabilities and non-cash items including $5.3 million for gain on
bargain purchase, depreciation and amortization of property and equipment and stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During 2021, we used
$11.0 million of cash in operating activities, consisting primarily of a net loss of $12.8 million, offset by a $0.4 million net
change in operating assets and liabilities and non-cash charges of $1.4 million for depreciation and amortization of property and
equipment, stock-based compensation and PPP loan forgiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows from Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investing activities
in 2022 and 2021 used $0.3 million and $0.6 million, respectively, of cash for the purchase of equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash Flows from Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financing activities
provided $63.4 million of cash in 2022, including $55.4 million from cash acquired in merger for stock consideration and $8.0 million
proceeds from SAFE note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financing activities
provided $11.6 million of cash in 2021 from the net proceeds from the issuance of common stock and warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At December 31, 2022, we did not have any
transactions, obligations or relationships that could be considered off-balance sheet arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a012_v1"></span>Item 7A. Quantitative and Qualitative Disclosures about Market
Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Interest Rate Sensitivity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
primary objective of our investment activities is to maintain the safety of principal and preserve liquidity without
incurring significant risk. We invest cash in excess of our current needs in money market funds. In general, money market
funds are not considered to be subject to interest rate risk because the interest paid on such funds fluctuates with the
prevailing interest rate. As of December 31, 2022 and 2021, our cash equivalents consisted solely of money market funds
deposited at Merrill Lynch and restricted cash as collateral for our lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exchange Rate Sensitivity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In 2022 and 2021,
the majority of our operating expenses were denominated in U.S. dollars. We have not entered into foreign currency forward contracts
to hedge our operating expense exposure to foreign currencies, but we may do so in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a013_v1"></span>Item 8. Financial Statements and Supplementary Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
and supplementary data required by this Item are provided in the consolidated financial statements included in this Form 10-K as
listed in Item 15(a) of this Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a014_v1"></span>Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a015_v1"></span>Item 9A. Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Evaluation of Disclosure Controls and Procedures</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Disclosure controls
and procedures are designed to ensure that information required to be disclosed by us in reports filed or submitted under the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized and reported within the time
periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls
and procedures designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act
is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons
performing similar functions, as appropriate to allow for timely decisions regarding required disclosure. Due to inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Further, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree
of compliance with the policies and procedures may deteriorate. Accordingly, even effective disclosure controls and procedures
can only provide reasonable assurance of achieving their control objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31,
2022, management has concluded that our disclosure controls and procedures were effective based upon testing of our key internal
controls. Our management, including our CEO and CFO, has concluded that the consolidated financial statements included in this
Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows
for the periods presented in this Annual Report on Form 10-K in conformity with GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Annual Report
does not include an attestation report from our independent registered public accounting firm regarding internal control over financial
reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm pursuant
to our non-accelerated filer status.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Report on Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">Our management
is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures
that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">1. &#160;&#160;&#160;&#160;&#160;&#160;Pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our
assets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">2.&#160;&#160;&#160;&#160;&#160;&#160;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with GAAP, and that our receipts and expenditures are being made only in accordance with the authorization of our management and
directors; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">3.&#160;&#160;&#160;&#160;&#160;&#160;
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets
that could have a material effect on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31,
2022, based on the criteria established in &#8220;Internal Control &#8212; Integrated Framework&#8221; (2013 Framework) issued
by the Committee of Sponsoring Organizations of the Treadway Commission, management has completed written documentation of its
internal control policies, procedures and controls and has completed its testing of its key controls. Based upon the results of
this testing we have concluded that our internal control over financial reporting was effective as of the end of the period covered
by this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">There has
been no change in our internal control over financial reporting that occurred during or subsequent to our fourth quarter of the
year ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inherent Limitations on Effectiveness of Controls</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The design of any
system of control is based upon certain assumptions about the likelihood of future events. There can be no assurance that any design
will succeed in achieving its stated objectives under all future events, no matter how remote, or that the degree of compliance
with the policies or procedures may not deteriorate. Because of its inherent limitations, disclosure controls and procedures may
not prevent or detect all misstatements. Accordingly, even effective disclosure controls and procedures can provide only reasonable
assurance of achieving their control objectives. In addition, the design of disclosure controls and procedures must reflect the
fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible
controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies
and procedures may deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a016_v1"></span>Item 9B. Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a017_v1"></span>Item 9C. Disclosure regarding foreign jurisdictions that
prevent inspections</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not Applicable.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a018_v1"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain
information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated by reference from our
definitive proxy statement relating to our 2023 annual meeting of stockholders, pursuant to Regulation 14A of the Securities
Exchange Act of 1934, as amended, also referred to in this Annual Report on Form 10-K as our 2023 Proxy Statement, which we
will file with the SEC not later than 120 days after the end of the fiscal year covered by this Annual Report on Form
10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a019_v1"></span>Item 10. Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Information regarding
our directors, including the audit committee and audit committee financial experts, and executive officers, and compliance with
Section 16(a) of the Exchange Act will be included in an amendment to this Form 10-K or in our 2023 Proxy Statement and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a020_v1"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">The information
required by this item regarding executive compensation will be included in an amendment to this Form 10-K or in our 2023 Proxy
Statement and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a021_v1"></span>Item 12. Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this item regarding security ownership of certain beneficial owners and management will be included in an amendment to this
Form 10-K or in our 2023 Proxy Statement and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a022_v1"></span>Item 13. Certain Relationships and Related Transactions,
and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this item regarding certain relationships and related transactions and director independence will be included in an amendment
to this Form 10-K or in our 2023 Proxy Statement and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a023_v1"></span>Item 14. Principal Accounting Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information required by this item regarding
principal accounting fees and services will be included in an amendment to this Form 10-K or in our 2023 Proxy Statement and is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a024_v1"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a025_v1"></span>Item 15. Exhibits, Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 27px">&#160;</td>
    <td style="width: 27px"><span style="font-size: 10pt">(a)</span></td>
    <td><span style="font-size: 10pt">The following documents are included in this Annual Report on Form 10-K:</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 25px">&#160;</td>
    <td style="width: 26px"><span style="font-size: 10pt">1.</span></td>
    <td><span style="font-size: 10pt">The consolidated financial statements listed in the accompanying Index to Consolidated Financial Statements are filed as part of this report.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 25px">&#160;</td>
    <td style="width: 26px"><span style="font-size: 10pt">2.</span></td>
    <td style="padding-right: 10pt"><span style="font-size: 10pt">All financial schedules have been omitted because the required information is either presented in the consolidated financial statements or the notes thereto or is not applicable or required.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 25px">&#160;</td>
    <td style="width: 26px"><span style="font-size: 10pt">3.</span></td>
    <td style="padding-right: 10pt; text-align: justify"><span style="font-size: 10pt">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the exhibits and are incorporated herein. We have identified in the Exhibit Index each management contract and compensation plan filed as an exhibit to this Annual Report on Form 10-K in response to Item 15(a)(3) of Form 10-K.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>




<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-size: 10pt"><b>EXHIBIT INDEX</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 7%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 92%; text-align: center"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td></tr>

<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000169/g082604_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000169/g082604_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Merger Agreement dated February 4, 2022 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed with the SEC on February 8, 2022).</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000879/g083060_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2.2</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000879/g083060_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Waiver of Available Cash Requirement to the Merger Agreement dated June 15, 2022 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 21, 2022).</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Restated Articles of Incorporation of the Registrant as amended (incorporated by reference to Exhibit 3.1 in the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on September August 12, 2014)</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt; width: 7%"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex3-1.htm"><span style="font-size: 10pt">3.1(a)</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt; width: 92%"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex3-1.htm"><span style="font-size: 10pt">Restated Articles of Incorporation of the Registrant as amended (incorporated by reference to the registrant&#8217;s registration statement on Form S-1, file no. 333-198073, originally filed with the Securities and Exchange Commission on August 12, 2014, as amended)</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000110465922060457/eyes-20211231xex3d2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.2</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000110465922060457/eyes-20211231xex3d2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment to Restated Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 in the Company&#8217;s Registration Statement on Form S-4 filed with the SEC on September May 13, 2022)</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000156459020000154/eyes-ex31_15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.3</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000156459020000154/eyes-ex31_15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Second Amendment to Restated Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 in the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 3, 2020)</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622001222/g083173_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.4</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622001222/g083173_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment, filed August 25, 2022, and effective August 30, 2022 changing the name of the Company to &#8220;Vivani Medical, Inc.&#8221; (incorporated by reference Exhibit 3.1 in the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 2, 2022)</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">3.5</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 in the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on September August 12, 2014)</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000172/s100332_ex4-1.htm"><span style="font-size: 10pt">4.1</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000172/s100332_ex4-1.htm"><span style="font-size: 10pt">Form of the Registrant&#8217;s common stock certificate (incorporated by reference to the registrant&#8217;s registration statement on Form S-1, file no. 333-198073, originally filed with the Securities and Exchange Commission on August 12, 2014, as amended)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex4-2.htm"><span style="font-size: 10pt">4.2</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000022/s100275_ex4-2.htm"><span style="font-size: 10pt">Form of Underwriter&#8217;s Warrant (incorporated by reference to the registrant&#8217;s registration statement on Form S-1, file no. 333-198073, originally filed with the Securities and Exchange Commission on August 12, 2014, as amended)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577417000258/s105120_ex4-4.htm"><span style="font-size: 10pt">4.3</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577417000258/s105120_ex4-4.htm"><span style="font-size: 10pt">Form of Warrant Agreement and Form of Warrant Certificate (incorporated by reference to the registrant&#8217;s registration statement on Form S-1, file no. 333-215463, originally filed with the Securities and Exchange Commission on January 9, 2017, as amended)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000156459019003814/eyes-ex992_6.htm"><span style="font-size: 10pt">4.4</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000156459019003814/eyes-ex992_6.htm"><span style="font-size: 10pt">Form of Amendment No.1 to Warrant Agreement (incorporated by reference to registrant&#8217;s current report on Form 8-K filed with the Securities and Exchange Commission on February 22, 2019)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000156459021018750/eyes-ex45_9.htm"><span style="font-size: 10pt">4.5</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000156459021018750/eyes-ex45_9.htm"><span style="font-size: 10pt">Description of Capital Stock (incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on April 14, 2021)</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000110465922060457/eyes-20211231xex10d15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000110465922060457/eyes-20211231xex10d15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Lock-Up Agreement (incorporated by reference to the registrant&#8217;s proxy statement/prospectus on Form S-4, file no. 333-264959, originally filed with the Securities and Exchange Commission on May 13, 2022)</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622001464/g083247_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">10.2</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622001464/g083247_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Non-Employee Director Compensation Policy*</span></a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1958489/000175392623000293/g083409_ex10-2.htm">10.3</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1958489/000175392623000293/g083409_ex10-2.htm">Transition funding, support and services agreement dated March 23, 2023</a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1958489/000175392623000293/g083409_ex10-4.htm">10.4</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1958489/000175392623000293/g083409_ex10-4.htm">Employment terms- Cortigent CEO</a></td></tr>
<tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622001508/g083273_ex10-1.htm">10.5</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622001508/g083273_ex10-1.htm">New Alameda Lease Agreement</a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000172/s100332_ex10-12.htm"><span style="font-size: 10pt">10.7</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000161577414000172/s100332_ex10-12.htm"><span style="font-size: 10pt">Cost Reimbursement Consortium Research Agreement between Registrant and Doheny Eye Institute (incorporated by reference to the registrant&#8217;s registration statement on Form S-1, file no. 333-198073, originally filed with the Securities and Exchange Commission on August 12, 2014, as amended)</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt; width: 7%"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000169/g082604_ex2-1.htm"><span style="font-size: 10pt">10.21</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt; width: 92%"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000169/g082604_ex2-1.htm"><span style="font-size: 10pt">Merger Agreement, dated February 4, 2022, between Registrant and Nano Precision Medical, Inc. (incorporated by reference to registrant&#8217;s current report on Form 8-K filed with the Securities and Exchange Commission on February 8, 2022)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000169/g082604_ex10-1.htm"><span style="font-size: 10pt">10.22</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><a href="http://www.sec.gov/Archives/edgar/data/1266806/000175392622000169/g082604_ex10-1.htm"><span style="font-size: 10pt">SAFE Agreement, dated February 4, 2022, between Registrant and Nano Precision Medical, Inc. (incorporated by reference to registrant&#8217;s current report on Form 8-K filed with the Securities and Exchange Commission on February 8, 2022)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><span style="font-size: 10pt"><a href="g083419_ex23-1.htm">23.1*</a></span></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><span style="font-size: 10pt"><a href="g083419_ex23-1.htm">Consent of BPM LLP, Independent Registered Public Accounting Firm</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt; width: 7%"><a href="#poa"><span style="font-size: 10pt">24.1</span></a></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt; width: 92%"><a href="#poa"><span style="font-size: 10pt">Power of Attorney (included in the signature page to this report)</span></a></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><span style="font-size: 10pt"><a href="g083419_ex31-1.htm">31.1*</a></span></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><span style="font-size: 10pt"><a href="g083419_ex31-1.htm">Certification of Principal Executive Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><span style="font-size: 10pt"><a href="g083419_ex31-2.htm">31.2*</a></span></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><span style="font-size: 10pt"><a href="g083419_ex31-2.htm">Certification of Principal Financial and Accounting Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt"><span style="font-size: 10pt"><a href="g083419_ex32-1.htm">32.1*</a></span></td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><span style="font-size: 10pt"><a href="g083419_ex32-1.htm">Certifications of Principal Executive Officer and Principal Financial and Accounting Officer of Second Sight Medical Products, Inc.</a></span></td></tr>
<tr>
    <td style="vertical-align: top; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt">&#160;</td>
    <td style="vertical-align: bottom; padding-top: 1pt; padding-bottom: 3pt; padding-left: 1pt"><span style="font-size: 10pt"><a href="g083419_ex32-1.htm">pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 27px"><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">Filed or furnished herein, as applicable.</span></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">+</span></td>
    <td><span style="font-size: 10pt">Indicates management contract or compensatory plan.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 8%"><span style="font-size: 10pt">101.INS</span></td>
    <td style="width: 92%"><span style="font-size: 10pt">XBRL Instance Document</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">101.SCH</span></td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Schema Document</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">101.CAL</span></td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">101.DEF</span></td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 8%"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="width: 92%"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">101.PRE</span></td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a026_v1"></span>Item 16. &#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 10-K
Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a027_v1"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-size: 10pt">Dated: March 31, 2023</span></td>
    <td style="width: 50%"><span style="font-size: 10pt">Vivani Medical, Inc.</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Adam Mendelsohn</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Adam Mendelsohn</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="poa"></span>POWER OF ATTORNEY AND SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.25in">The undersigned officers and directors
of Vivani Medical, Inc., each hereby severally constitutes and appoints Scott Dunbar as his true and lawful attorney-in-fact and
agent, with full power of substitution to sign and execute on behalf of the undersigned any and all amendments to this Annual Report
on Form 10-K, and to perform any acts necessary in order to file the same, with all exhibits thereto and other documents in connection
therewith with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to
do and perform each and every act and thing requested and necessary to be done in connection therewith, as fully to all intents
and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their
or his or her substitutes, shall do or cause to be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0; text-indent: 0.3in">Pursuant to the requirements of
the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and
in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15pt 0pt 0; text-indent: 0.3in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 36%; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Adam Mendelsohn</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt"><span style="font-size: 10pt">March 31, 2023</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Adam Mendelsohn</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Brigid Makes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt"><span style="font-size: 10pt">March 31, 2023</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Brigid Makes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman of the Board</span></td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt"><span style="font-size: 10pt">March 31, 2023</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Gregg Williams</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt"><span style="font-size: 10pt">March 31, 2023</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Aaron Mendelsohn</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt"><span style="font-size: 10pt">March 31, 2023</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Dean Baker</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="padding-left: 5pt">&#160;</td>
    <td style="padding-left: 5pt"><span style="font-size: 10pt">March 31, 2023</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Alexandra Larson</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 36%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* By /s/
    Scott Dunbar&#160;</span></td>
    <td style="width: 64%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Dunbar</span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</span></td>
    <td>&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 95%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: right"><span style="font-size: 10pt">Page</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b001_v1"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID:<span id="xdx_903_edei--AuditorFirmId_c20220101__20221231_zKVbqQ1BrfA2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">207</ix:nonNumeric></span>)</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-2</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td><a href="#b002_v1"><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-3</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b003_v1"><span style="font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-4</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td><a href="#b004_v1"><span style="font-size: 10pt">Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-5</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b005_v1"><span style="font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-6</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td><a href="#b006_v1"><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-7</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b007_v1"><span style="font-size: 10pt">Notes to Consolidated Financial Statements for the Years Ended December 31, 2022 and 2021</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">F-8</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 75; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="b001_v1"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b><span style="color: windowtext">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors and Shareholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vivani Medical, Inc. and Subsidiaries</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets
of Vivani Medical, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021 and the related consolidated
statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows, for each of the two years in the period
ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2022 and 2021, and the results of their operations and their cash flows for each of the two years in the period
ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform an audit of its internal control over financial reporting. As part of our audit, we are required to
obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks
of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in
the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Critical Audit Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the current
period audit of the financial statements that were communicated or required to be communicated to the audit committee and that:
(1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <span id="xdx_907_edei--AuditorName_c20220101__20221231_z89VpoiaK8Uh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">BPM LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span id="xdx_903_edei--AuditorLocation_c20220101__20221231_zNqg2GHUZ2C3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Walnut Creek, California</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 31, 2023</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&#160;</p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="b002_v1"></span>Consolidated Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands)</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_pn3n3_zj8bZapBcf13" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zS2issHG1KRe" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zfbUpd1Ui17c" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AssetsAbstract_iB_zS1WkfKeP2Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zJCinRbuTUzh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--CashEquivalentsAtCarryingValue_i02I_maACzUeP_zEiMkckjIKn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,178</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzUeP_zX9THiG7fZX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,452</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtACzUeP_maAz2u1_z48YWkLULXif" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,469</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAz2u1_zH4G1cIJT185" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAz2u1_zVDlo9G4A9Sd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,611</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>



<tr id="xdx_40A_eus-gaap--OtherAssetsNoncurrent_i01I_maAz2u1_zXmunTsQeUg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,366</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0073">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--DepositsAndOtherAssets_i01I_maAz2u1_zIOEjvXgwHm" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Deposits and other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:DepositsAndOtherAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:DepositsAndOtherAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--Assets_i01TI_mtAz2u1_zTyNu425OS5g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.125in; text-indent: -0.125in">Total assets</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,130</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,453</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_i01B_zrybdD3lBTFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_zcKc4byDxmxe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_i02I_maLCz8Hf_zHiw42z5ZT77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCz8Hf_zbbgraLpNST7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">895</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LitigationReserveNoncurrent_i02I_maLCz8Hf_zyLrkiSS9aj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
    accrual</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LitigationReserveNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0094">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCz8Hf_zibWtRNrOc09" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Accrued compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">657</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCz8Hf_zRn1hmYYyoqc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Current operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">955</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">910</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz8Hf_maLz06z_zAXOIeEk3Fml" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,086</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maLz06z_zHbybNFConhb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Long term operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">902</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--Liabilities_iTI_mtLz06z_maLASEzZwA_zBz3jOpQ6ONl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,822</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CommitmentsAndContingencies_iI_zAY86MtQLgH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Commitments and contingencies (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_iB_zi6epxGYkWsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--PreferredStockValue_i01I_maSEzA5r_z0tFzU3KwPb2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Preferred stock, <span id="xdx_90B_eus-gaap--PreferredStockNoParValue_iI_pid_do_uUSDPShares_c20211231_zDyHyo5m9jui" title="Preferred stock, no par value (in dollars per share)"><span id="xdx_90E_eus-gaap--PreferredStockNoParValue_iI_pid_do_uUSDPShares_c20221231_zI8i0jXPu2L8" title="Preferred stock, no par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_uShares_c20211231_z07VZ4livbC6" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pn3n3_uShares_c20221231_zTpEuK5uNL95" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_uShares_c20211231_zzEOf3ltbqY3" title="Preferred stock, shares outstanding"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_uShares_c20221231_zqCAIxlzEvqc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></span></span> outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CommonStockValue_i01I_maSEzA5r_zF5kLLNMhZAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Common stock, <span id="xdx_906_eus-gaap--CommonStockNoParValue_iI_pid_do_uUSDPShares_c20211231_zfNkqHqaqwY6" title="Common stock, no par value (in dollars per share)"><span id="xdx_900_eus-gaap--CommonStockNoParValue_iI_pid_do_uUSDPShares_c20221231_znT5h2Rcdrdb" title="Common stock, no par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_uShares_c20211231_zfFIys6KDlVg" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_uShares_c20221231_zMMfnPfNc7g3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">300,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; shares issued and outstanding: <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pn3n3_uShares_c20221231_zYdEYXWjTt6l" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_uShares_c20221231_zZCoHeXmxmc" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">50,736</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pn3n3_uShares_c20211231_zCUZ0qGMaND7" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_uShares_c20211231_z5IweJP4Aa9g" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">36,803</ix:nonFraction></ix:nonFraction></span></span> at December 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i01I_maSEzA5r_zo22XyG9C9ui" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,713</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maSEzA5r_z46i30G7Ldx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzA5r_zjkGwg4Scpo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72,786</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,897</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--StockholdersEquity_i01TI_mtSEzA5r_maLASEzZwA_zlJ7lZCNExD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,465</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_iI_mtLASEzZwA_zrM2XuB8rLfa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.125in; text-indent: -0.125in">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,130</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,453</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="b003_v1"></span>Consolidated Statements of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except per share data)</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_pn3n3_zCkVA47Qf1X1" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: 0in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zzo3h2UHaJ6j" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_z4zDl2V09ori" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.25in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="text-align: center; vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zAehP2zmh7ed" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzFPM_zIZVDwyFYCff" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Research and development, net of grants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,002</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzFPM_zTwNSlGPxUNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">General and administrative, net of grants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,072</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,321</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_mtOEzFPM_msNILzQTu_msOILzHc0_zut7hs2gasce" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.375in">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,241</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,323</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_maNILzQTu_mtOILzHc0_maNILzMct_zAdhHVB00XY8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,241</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--InterestIncomeOperating_maNILzQTu_maNILzMct_znfsxDSHZYI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">475</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">550</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--GainLossOnRepurchaseOfDebtInstrument_maNILzQTu_maNILzMct_zOEiomA7jcWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Gain on bargain purchase</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnRepurchaseOfDebtInstrument" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,877</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0185">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtNILzMct_zmxx5tR6yUUj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
<tr id="xdx_40F_ecustom--NetLossPerCommonShareBasicAndDiluted_pid_uUSDPShares_zV1MfoMiqCSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:NetLossPerCommonShareBasicAndDiluted" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.36</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:NetLossPerCommonShareBasicAndDiluted" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_ecustom--WeightedAverageSharesOutstandingBasicAndDiluted_pid_uShares_zY8aRIu8GIFd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Weighted average shares outstanding &#8211; basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:WeightedAverageSharesOutstandingBasicAndDiluted" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:WeightedAverageSharesOutstandingBasicAndDiluted" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="b004_v1"></span>Consolidated Statements of Comprehensive
Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands)</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_pn3n3_z4M48DLtuPvf" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zlPhwKF9Ieb4" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_znb8pLQsIQcf" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_maCINOTzaGp_zQb49CUiaxjk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_iB_zVm66iD0CCTh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Other comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_i01_maCINOTzaGp_zwl31jFoAoW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_i01_mtCINOTzaGp_zLOr4W9VDvKk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.125in; text-indent: -0.125in">Comprehensive loss</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,854</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: center"><b><span id="b005_v1"></span>Condensed Consolidated Statements
of Stockholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_pn3n3_zbIWgHkFHdJ6" summary="xdx: Statement - Condensed Consolidated Statements of Stockholder&apos;s Equity (Deficit) (unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zkQYglL2C9R1" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zbcaKLPcLSJ4" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zjNizJTwgYp2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zPv03QW6sDOe" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BA_zj3mEwNRny3" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Other</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Total</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Paid-in</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Comprehensive</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Loss</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Equity</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_437_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zjmWgyGho9fk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.125in; padding-left: 0.125in">Balance, December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20210101__20211230__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj7qDuCqJ2qh" title="Balance beginning (in shares)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,029</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,045</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46,124</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,950</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_zcsHj4mW09nh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of shares of common stock and warrants, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPVxgOUgNVL4" title="Issuance of shares of common stock and warrants, net of issuance costs (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,684</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20210101__20211231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zz6pxOwBlWi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2txgECl8h69" title="Options exercised (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueStockWarrantsExercised_zqeIZuxg2G23" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvqRKjHUh9pl" title="Warrants exercised (in shares)" style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20210101__20211231_ecustom--StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_zjNCS6n7deU1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255); visibility: hidden">
    <td style="display: none; text-align: left; text-indent: -0.125in; padding-left: 0.125in; visibility: hidden">Options and warrants exercised, net of partial shares adjustment</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td title="Repurchase of common stock (in shares)" style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td></tr>
<tr id="xdx_438_c20210101__20211231_eus-gaap--StockRepurchasedDuringPeriodValue_zPWE7KWeohV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Repurchase of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockRepurchasedDuringPeriodShares_iN_pid_di_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNck8CycOYUh" title="Repurchase of common stock (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20210101__20211231_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_zKdIlrqGoOl2" style="display: none; vertical-align: bottom; background-color: White; visibility: hidden">
    <td style="display: none; text-align: left; text-indent: -0.125in; padding-left: 0.125in; visibility: hidden">Shares issued for SSMP net assets</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; visibility: hidden">&#160;</td>
    <td style="display: none; text-align: left; visibility: hidden">&#160;</td><td style="display: none; text-align: right; visibility: hidden">&#160;</td><td style="display: none; text-align: left; visibility: hidden">&#160;</td></tr>
<tr id="xdx_43D_c20210101__20211231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zHN9nPVDLGqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20210101__20211231_eus-gaap--NetIncomeLoss_z6Zrg9YGYgTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_434_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zDshDzv6pYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; text-indent: -0.125in; padding-left: 0.125in">Balance, December 31, 2021</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--CommonStockSharesOutstanding_iE_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zodVM9znr91d" title="Balance ending (in shares)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,803</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,649</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,713</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,897</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,465</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zVuMLV5TJbG5" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z7dPCpNuLFik" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zArIUkdtJQzh" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_ztaknGgYBl63" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BA_zdlWMSICGsYg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Other</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Total</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Paid-in</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Comprehensive</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.25in; text-indent: -0.25in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Loss</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Equity</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_43A_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zDhXfPXz4C4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.25in; padding-left: 0.25in">Balance, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesOutstanding_iS_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4KkbImG6wU5" title="Balance beginning (in shares)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,803</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,713</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,897</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20220101__20221231_ecustom--StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_zeHXUxvGaOJe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Options and warrants exercised, net of partial shares adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_iP3custom--StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziUTkhqpUyde" title="Options and warrants exercised, net of partial shares adjustment (in shares)" style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43B_c20220101__20221231_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_zus2ByZTh4Di" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Shares issued for SSMP net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_iP3us-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE8T00UgBWee" title="Shares issued for SSMP net assets (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,385</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,385</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20220101__20221231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zy1c1MyMKYcd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20220101__20221231_eus-gaap--NetIncomeLoss_zTTetuFOGmIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_432_c20220101__20221231_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zg188mkanHK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zOmRC50phn9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; text-indent: -0.25in; padding-left: 0.25in">Balance, December 31, 2022</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--CommonStockSharesOutstanding_iE_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPAjZZU5LfJ2" title="Balance ending (in shares)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,736</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109,050</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,009</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72,786</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,308</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="b006_v1"></span>Consolidated Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_pn3n3_zXDBHjlLNJD6" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: 0in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zUJsYxWRJNfi" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zCWSsOcosFzh" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.25in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.25in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNnKDbkkmtF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_maNCPBUzc3G_zM3oP9g38ank" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zsvWhb476x23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzc3G_zCVIEBqaD5Df" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Depreciation and amortization of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">345</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maNCPBUzc3G_zipOmBo6gzzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--GainFromBargainPurchase_i02N_di_msNCPBUzc3G_z1yIMbShcB2j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Gain on bargain purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="eyes:GainFromBargainPurchase" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,877</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--PppLoanForgiveness_i02N_di_msNCPBUzc3G_zRSFlvgjUwm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">PPP loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="eyes:PppLoanForgiveness" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--OtherNoncashIncomeExpense_i02N_di_msNCPBUzc3G_znpZqWAQMFO7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zB9O7pEPvSpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUzc3G_zQJwDfJXc5f9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">476</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUzc3G_zrrHQWFWlbTc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,941</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maNCPBUzc3G_zDhiAPuARn78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_maNCPBUzc3G_zSD7suf71431" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.375in">Accrued compensation expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">204</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtNCPBUzc3G_maEOEROzLDZ_maCCERCzMdg_zQficyGg1mTj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.5in">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,787</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,951</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zYTl2SEqIRij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzuqp_z8pf8GH1oTB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">572</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzuqp_maEOEROzLDZ_maCCERCzMdg_z47iQd41oOnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.5in">Net cash used in investing
    activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">338</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">572</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zf0pSIv0j8qd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--CashAcquiredInMergerForStockConsideration_i01_maNCPBUzLQk_zt0Hf69t2M7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Cash acquired in merger for stock consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:CashAcquiredInMergerForStockConsideration" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--CancellationOfSafeBorrowing_i01_maNCPBUzLQk_zZuK3s378jy9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Proceeds from SAFE note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:CancellationOfSafeBorrowing" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--ProceedsFromIssuanceOfCommonStockAndWarrants_i01_maNCPBUzLQk_z6yqADgBIGsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Net proceeds from sale of
    common stock and exercise of options and warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:ProceedsFromIssuanceOfCommonStockAndWarrants" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:ProceedsFromIssuanceOfCommonStockAndWarrants" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,620</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzLQk_maEOEROzLDZ_maCCERCzMdg_zFdppmbxJ861" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.5in">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,390</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,620</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzMdg_zmjzRB3DiJ7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Effect of exchange rate changes on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB_z9QLPZqiGbMa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash, cash equivalents and restricted cash:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_mtCCERCzMdg_zC9SBaPFo8vi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net Increase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zirov3J3AHJd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Balance at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,178</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,081</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zqHse1ocWWw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2pt; text-indent: -0.125in; padding-left: 0.125in">Balance at end of year</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,442</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,178</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zdJgUt9LfEwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Supplemental disclosure of cash flow information;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash paid during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zRyVrOCq81Rh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z2Y10CPStQD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--EstimateOfCancellations_i01_zq6glLuLmrte" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Cancellation of SAFE indebtedness in merger</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EstimateOfCancellations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--BusinessCombinationConsiderationTransferredLiabilitiesIncurred_i01_zUld9b8eQkN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net liabilities acquired in merger for stock consideration</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>VIVANI MEDICAL, INC.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="b007_v1"></span>Notes to Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_809_eus-gaap--NatureOfOperations_z7DSZPSG9EB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><b>1. <span id="xdx_828_z2nn8HHDb18i">Organization and Business Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani Medical, Inc. (&#8220;Vivani,&#8221;
the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar terms) is a preclinical stage biopharmaceutical
company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal&#8482; technology to enable long-term,
near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop
and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners to address
a leading cause of poor clinical outcomes in the treatment of chronic disease, medication non-adherence. For example, approximately
50% of patients treated for type 2 diabetes are non-adherent to their medicines, which can lead to poor clinical outcomes. We are
developing a portfolio of miniature, sub-dermal drug implant candidates that, unlike most oral and injectable medicines, are designed
with the goal of guaranteeing adherence by delivering therapeutic drug levels for up to 6 months or the life of the implant. In
addition, the minimal fluctuations of drug levels dictated by our NanoPortal technology may improve the tolerability profiles for
medicines that produce side effects associated with fluctuating drug levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani resulted from the business combination
of Second Sight Medical Products (Second Sight) and Nano Precision Medical (NPM). Since inception, Vivani&#8217;s main priority
has been the further development of the company&#8217;s lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate for
the treatment of patients with type 2 diabetes under the company&#8217;s Biopharm Division (formerly NPM). In parallel, Vivani&#8217;s
new management team remained committed to identifying and exploring strategic options for the Neuromodulation Division (formerly
Second Sight) that will enable further development of its pioneering neurostimulation systems to help patients recover critical
body functions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In February 2022, we announced the signing
of a definitive merger agreement between Nano Precision Medical, Inc. (&#8220;NPM&#8221;) and Second Sight Medical Products, Inc.
(&#8220;Second Sight&#8221;), pursuant to which NPM became a wholly-owned subsidiary of Second Sight. On August 30, 2022, the two
companies completed the merger, concurrent with which Second Sight changed its name to Vivani Medical, Inc. and now conducts the
present business of the Company. In September 2022, we announced the formation of the Company&#8217;s Biopharm Division to advance
the assets of the former NPM which includes the further development of the company&#8217;s lead program, NPM-119, a miniature,
6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes. Vivani&#8217;s new management team remains
committed to identifying and exploring strategic options for the Neuromodulation Division (formerly Second Sight) that will enable
further development of its pioneering neurostimulation systems to help patients recover critical body functions. On December 28,
2022, the assets and liabilities of this segment were contributed to Cortigent, Inc. a newly formed wholly owned subsidiary of
Vivani, in exchange for 20 million shares of common stock of Cortigent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2023, Vivani announced the filing
of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for the proposed initial
public offering of Cortigent. Cortigent is expected to continue to be majority-owned by Vivani immediately following the initial
public offering.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Agreement and Plan of Merger with Nano
Precision Medical, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, Second Sight Medical
Products, Inc. (&#8220;Second Sight&#8221;) entered into an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) with
Nano Precision Medical, Inc. (&#8220;NPM&#8221;). The Merger was approved by the shareholders of Second Sight on July 27, 2022
and closed on August 30, 2022. Upon consummation of the Merger, NPM became a wholly-owned subsidiary of Second Sight. Concurrent
with to the Merger, Second Sight changed its name to Vivani Medical, Inc. and changed its trading symbol from EYES to VANI, and
trades under the ticker VANI on the NASDAQ market. Certain investors and members of the NPM board of directors are also investors
and members of the board of directors of Second Sight.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms and conditions of the Merger
Agreement, the securities of NPM converted into the right to receive shares of Second Sight&#8217;s common stock representing <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SecondSightSwitzerlandSarlMember_zEhkKwQhbbl4" title="Ownership interest (in percentage)"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_SecondSightSwitzerlandSarlMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.32</ix:nonFraction></span>%
of the total issued and outstanding shares of common stock of Second Sight on a fully converted basis, including, without limitation,
giving effect to the conversion of all options, warrants, and any and all other convertible securities assuming net settlement.
Second Sight filed a Registration Statement on Form S-4 on May 13, 2022 in connection with the Merger to register the merger shares
effective June 24, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_z7nPN5SkEh01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, in connection with
the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) whereby Second Sight
provided to NPM an investment advance of $8 million. The Merger Agreement provided that the SAFE would terminate if the Merger
were to be successfully completed. Under the terms of the SAFE, upon successfully completion of the Merger on August 30, 2022,
the investment advance was eliminated. Under the accounting for a business combination, the $<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20220101__20221231_zxOCogm3q4Rj" title="Purchase consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million adjusted the purchase consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Merger involved a change of control
and was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;). Under this method of accounting, Second Sight was treated as the &#8220;acquired&#8221; company for financial
reporting purposes with NPM as the acquirer. The assets acquired and liabilities assumed by NPM were recorded at fair value under
Accounting Codification Standard (&#8220;ASC 805&#8221;), <i>Business </i>Combinations. Accordingly, <span id="xdx_901_eus-gaap--CommonStockVotingRights_c20220828__20220830_zjvZDQvoEdLg" title="Common stock, voting rights"><ix:nonNumeric contextRef="From2022-08-282022-08-30" name="us-gaap:CommonStockVotingRights">on August 30, 2022 (the &#8220;Acquisition
Date&#8221;), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest
of Second Sight, Medical, Inc.</ix:nonNumeric></span> The results of Second Sight&#8217;s operations have been included in the consolidated financial
statements since that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The acquisition-date fair value of consideration
transferred totaled $<span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_c20220828__20220830__us-gaap--BusinessAcquisitionAxis__us-gaap--SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_zEyzoFQn1Q21" title="Fair value of the consideration transferred"><ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" contextRef="From2022-08-282022-08-30_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">54.4</ix:nonFraction></span> million, which consisted of the fair value of the <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pn3n3_uShares_c20220830_zQLXF9RCF7E6" title="Common stock issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,136</ix:nonFraction></span> common shares deemed issued to Second Sight
shareholders, was determined based on the per share closing price of the Company&#8217;s common shares on the acquisition date
of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220830_zKt7kqpPSGj3" title="Common stock, par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.14</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zPFaoS5J1C76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B8_z58FvJxliqwj">The following table summarizes the fair
values of the assets acquired and liabilities assumed at the acquisition date (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration: underline">At August 30, 2022</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220830_zi8sjoqtX2x2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_404_ecustom--CashAndCashEquivalentsFairValue_iI_pn3n3_zgfRx0eOio1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="eyes:CashAndCashEquivalentsFairValue" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,374</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentFairValueDisclosure_iI_pn3n3_zIF25wJjlbg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn3n3_zb02uyamcnt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,657</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetOne_iI_pn3n3_zxvvNVFFlJhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:OperatingLeaseRightOfUseAssetOne" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherAssetsFairValueDisclosure_iI_pn3n3_zrFmwaFlh3Ic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--FairValueOfAssetsAcquired1_iI_pn3n3_zmvfOPgBpoZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total identifiable assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="eyes:FairValueOfAssetsAcquired1" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_iNI_pn3n3_di_z5SR75EewP79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,913</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iNI_pn3n3_di_ztiNfqcnij33" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_ecustom--FairValueOfLiabilitesAcquired_iNI_pn3n3_di_znkiSdASaQr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:FairValueOfLiabilitesAcquired" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_zk5rigypYHTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt">Net identifiable assets acquired</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53,262</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A0_zvYfOWBDVPy1" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SAFE loan of $<span id="xdx_908_eus-gaap--AssetsFairValueAdjustment_pn6n6_c20220828__20220830_z6VMbERzzti9" title="Assets, fair value adjustment"><ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="From2022-08-282022-08-30" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8.0</ix:nonFraction></span> million was cancelled
in the Merger which adjusted the fair value of net assets acquired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GainLossOnInvestmentsTextBlock"><p id="xdx_893_eus-gaap--GainLossOnInvestmentsTextBlock_zCDd6WSGUaO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B9_z5QPe5U54zy">The following table summarizes the calculation
of the gain on bargain purchase (in thousands)</span>:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220830_znOwAxta2wH6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--TotalConsideration_iNI_pn3n3_di_zCGZuZhdzGRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Total consideration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="eyes:TotalConsideration" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,385</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdvancesFairValueDisclosure_iNI_pn3n3_di_zRq62IKMKht8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SAFE loan forgiven</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdvancesFairValueDisclosure" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_zmQKf8dlIVY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less net identifiable assets acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">53,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_ecustom--GainOnBargainPurchase_iI_pn3n3_zVQzq5qGIrHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt">Gain on bargain purchase</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="eyes:GainOnBargainPurchase" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,877</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AF_zvU2iI6PVVR1" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because NPM purchased <span id="xdx_90A_eus-gaap--SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_pid_dp_uPure_c20220101__20221231_zwkLpQuWZGD4" title="Fair value of identifiable assets acquired and liabilities"><ix:nonFraction name="us-gaap:SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of Second Sight
and the fair value of identifiable assets acquired and liabilities assumed exceeded the fair value of the consideration, we reassessed
the recognition and measurement of identifiable assets acquired and liabilities assumed and concluded that all acquired assets
and assumed liabilities were properly recognized and that the valuation procedures and resulting measures were appropriate. As
a result, we recognized a gain of $<span id="xdx_906_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_pn5n6_c20220101__20221231_zWqxnyNHkMgj" title="Gain of other income expenses"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We recognized $<span id="xdx_907_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_dm_c20220101__20221231_ztylsSOPj3Gj"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.7</ix:nonFraction> million</span> of acquisition
related costs that were expensed in the twelve months ended December 31, 2022. These costs are included in the consolidated income
statement in the line item entitled &#8220;General and administrative costs.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zEHgrDrPhiuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Operating expenses of Second
Sight included in the consolidated statements of operations from the acquisition date August 30, 2022 to the period ending
December 30, 2022 were $2.1 million. Pro forma consolidated net loss as if Second Sight had been included in the consolidated
results was $<span id="xdx_90A_eus-gaap--NetIncomeLoss_pn5n6_c20210101__20211231__srt--StatementScenarioAxis__srt--ProFormaMember_zgx0tDJgGOKi"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_srt_ProFormaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">21.7</ix:nonFraction></span>
million for the year ended December 31, 2021, and $<span id="xdx_90F_eus-gaap--NetIncomeLoss_pn5n6_c20220101__20221231__srt--StatementScenarioAxis__srt--ProFormaMember_zByRXgAXvtGi"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_ProFormaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">28.3</ix:nonFraction></span>
million for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SAFE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, in connection with
the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) whereby Second Sight
provided to NPM an investment advance of $8 million. The agreement provided that the SAFE would terminate if the Merger were to
be successfully completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the SAFE, upon successfully
completion of the Merger on August 30, 2022, the investment advance was eliminated. Under the accounting for a business combination,
the $8.0 million adjusted the purchase consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in">From inception, our operations
have been funded primarily through the sales of our common stock as well as from warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in">&#160;&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zlZyCqP2D9Ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to
meet its planned obligations into the second half of 2024. Our ability to continue as a going concern is dependent on our ability
to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there
can be no assurances that we will be able to do so.</p>



</ix:nonNumeric><p id="xdx_815_zGtzGSclB82c" style="font: 1pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweA1Z8ZaAQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><b>2.</b></td><td><b><span id="xdx_829_zYsauKEln6i">Summary of Significant Accounting</span></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_znEgoZDJUKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zrcVI8rpnEAe">Policies Principles of Consolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The
accompanying consolidated financial statements have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of the Biopharm Division (formerly NPM) and
the Neuromodulation Division (formerly Second Sight including Second Sight Switzerland) each of which is a reporting segment. <span id="xdx_905_esrt--DescriptionOfMaterialContingenciesOfParentCompany_c20220101__20221231_zGkXOkC4mHQc" title="Description of consolidation"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Intercompany balances
and transactions have been eliminated in consolidation.</p>

</ix:nonNumeric><p id="xdx_856_znwldDyGnyBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zGTbltjWTJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_z3hNNmjQ10Rg">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the
financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the
key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted
accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used
in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred
tax assets. Actual results could differ from those estimates.</p>

</ix:nonNumeric><p id="xdx_85A_zUBvWNxGrey3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zLQGIsZ9I9Yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:Reclassifications"><p id="xdx_84C_eus-gaap--Reclassifications_zxlY4h6kXL28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zBKeHb84olkk">Reclassifications</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;&#160; Certain items in prior period financial
statements have been reclassified to conform to the presentation in the current period financial statements. &#160;Such reclassification
did not impact our previously reported net loss or financial position.</p>

</ix:nonNumeric><p id="xdx_852_zxwGis14PGG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zC9pExJxK9F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zhyIEFd2ioY">Cash,
Cash Equivalents and Restricted Cash</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We consider all
highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is
carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds
that are in excess of current needs in high credit quality instruments such as money market funds. Restricted cash of $<span id="xdx_901_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zSRdOuWFbTOc" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million as of December 31, 2022 relates to the lease guarantee requirements of our new lease.</p>

</ix:nonNumeric><p id="xdx_85B_zpFLXIb8trjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAhl0NK6dxw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zETNP9KMVFIj">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Property and equipment
are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures
for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property
accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated
statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Depreciation is provided
for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service
lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful
lives of the principal classes of assets are as follows:</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden">Schedule of estimated useful lives of principal classes of assets</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 46%"><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0503">5</span></span></span></td>
    <td style="width: 53%; padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0505">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Computer hardware and software</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0507">3</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0509">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0511">2</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0512">5</span></span> years or the term of the lease, if shorter</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Furniture, fixtures and equipment</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0514">5</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">10</span></span> years</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_zmoUmQlLehW" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">We review our property
and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets
may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">Depreciation and
amortization of property and equipment amounted to $<span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zHQ24bSGMYEa" title="Depreciation and amortization of property and equipment"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.4</ix:nonFraction> million</span> and $<span id="xdx_90F_eus-gaap--DepreciationAndAmortization_dm_c20210101__20211231_zkxqHBnx92Th" title="Depreciation and amortization of property and equipment"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.3</ix:nonFraction> million</span> for the years ended December 31, 2022 and 2021,
respectively.</p>

</ix:nonNumeric><p id="xdx_854_zM7443DwzLce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zJw3FjN8p46a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LessorLeasesPolicyTextBlock"><p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zUv62FoDlg9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86B_z61llJSlxVL2">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Leases are accounted for under FASB ASC
842,&#160;<i>Leases</i>&#160;(&#8220;ASC 842&#8221;). Under ASC 842, the Company determines if an arrangement contains a lease
at inception. Right of use assets (&#8220;ROU assets&#8221;) represent the right to use an underlying asset for the lease term
while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either
finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive
loss.&#160;All leases greater than 12 months result in the recognition of a ROU asset and liability at the lease commencement date
based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using
the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the
lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated.
The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#8217;s
applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available
to finance assets similar to the assets under lease in their related geographical location.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has elected not to separate
non-lease components from lease components and instead to account for each separate lease component and the non-lease components
associated with a lease as a single lease component. It also elected to exempt from capitalization all leases with an initial term
of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain leases include one or more options
to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#8217;s
discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of
being exercised.</p>

</ix:nonNumeric><p id="xdx_85E_zVq2i5u7Vn0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zdPzi06hHrqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zK2GRWwJyXri">Research and Development</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt">Research
and development costs are charged to operations in the period incurred and amounted to $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zub41g2rEOT8" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">14.2</ix:nonFraction> million</span>, and $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20210101__20211231_zicqqpOfOfA3" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">11.0</ix:nonFraction> million</span> net of
grant revenue, for the years ended December 31, 2022 and 2021, respectively.</p>

</ix:nonNumeric><p id="xdx_851_zLgOSqT6uvFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPoWCpd71C3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_z3kk7jubLX7h">Patent Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt">Due to the uncertainty
associated with the successful development of one or more commercially viable products based on our research efforts and any related
patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated
costs, are expensed as incurred. Patent costs were $<span id="xdx_909_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zCQ4zF0Yq81" title="Patent costs"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.4</ix:nonFraction> million</span> and $<span id="xdx_90F_eus-gaap--OtherGeneralExpense_dm_c20210101__20211231_zN8Rz8SUxRs9" title="Patent costs"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.1</ix:nonFraction> million</span> for the years ended December 31, 2022 and 2021,
respectively, and are included in general and administrative expenses in the consolidated statements of operations.</p>

</ix:nonNumeric><p id="xdx_859_zmB8TcOt9Vad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:NhGrant"><p id="xdx_843_ecustom--NhGrant_zijw8PxQlXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><b><span id="xdx_86B_zlhyRiK7RCc4">NIH Grant </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">From time to
time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset
against the related operating expenses as the costs are incurred. During the year ended December 31, 2022 grants offset
against operating expenses were $<span id="xdx_908_ecustom--GrantsAgainstOperatingExpense_pn5n6_c20220101__20221231_zpObuW9eb3D4" title="Grants offset against operating expenses"><ix:nonFraction name="eyes:GrantsAgainstOperatingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million of which $0.4 million were offset against research and development expenses and $0.1 million were offset against general and
administrative expenses.</p>

</ix:nonNumeric><p id="xdx_857_zW8YOHPzBsV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZWhS4kMrJZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zcPsyB9iOWu">Concentration of Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><i>Credit Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Financial instruments
that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market
funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and
SIPC insurance limits of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zyCtHu3HhL87" title="FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> and $<span id="xdx_908_ecustom--CashSPICInsuredAmount_iI_c20221231_ztjuDBb59ADh" title="SPIC insured amount"><ix:nonFraction name="eyes:CashSPICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> (including cash of $<span id="xdx_906_ecustom--SPICCashLimitCoverage_iI_c20221231_z8MmcFRleYO2" title="SPIC cash limit coverage"><ix:nonFraction name="eyes:SPICCashLimitCoverage" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>), respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We also maintain cash
at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.</p>

</ix:nonNumeric><p id="xdx_85C_z0djLVf0Hzc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zIv7TtBguVxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:ForeignOperationsPolicyTextBlock"><p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_zROto3X0xny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zxt2Q6KVffqf">Foreign Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The accompanying consolidated
financial statements as of December 31, 2022 include assets amounting to approximately $<span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zqmACCOke6fb" title="Assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_custom_CountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> relating to our operations in Switzerland.
Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.</p>

</ix:nonNumeric><p id="xdx_859_zXWD41PlPVk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zWilQ5HPZabf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zrgG5Uj6iJK">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The authoritative guidance
with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one
of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 1. Observable
inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the
measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based
derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 2. Inputs, other
than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through
corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 3. Unobservable
inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its
own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives
and commingled investment funds, and are measured using present value pricing models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We determine the level
in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of
the assets and liabilities at each reporting period end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Cash equivalents, which
include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our
consolidated balance sheet, and they are valued using Level 1 inputs.</p>

</ix:nonNumeric><p id="xdx_850_ztpuyKAXvhEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0jKFcx7iYUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zyYMVTXxDr8g">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">Pursuant to FASB ASC 718 Share-Based Payment (&#8220;ASC
718&#8221;), we record stock-based compensation expense for all stock-based awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Under ASC 718, we estimate
the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected
to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option
vesting term. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The fair value of each
stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the
Black-Scholes valuation model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The grant price of the issuances is determined based on the fair value of the shares at the date of grant.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The risk-free interest rate for periods within the contractual life of the option is based
    on the U.S. treasury yield in effect at the time of grant.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 1pt"><span style="font-size: 10pt">Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_851_z7GbH8TiGw55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>




<ix:exclude><p id="xdx_231_zzy3A1XPQIIf" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zvKuWlpntfEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z4fiOjDQqe6c">Comprehensive Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
comply with provisions of FASB ASC 220, <i>Comprehensive Income</i>, which requires companies to report all changes in equity
during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are
recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner
sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss is reported on the face of the financial statements. For the year ended December 31, 2022
comprehensive loss is the total of net loss and other comprehensive income which, for us, consists entirely
of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net
loss during the year ended December 31, 2022.</span></p>

</ix:nonNumeric><p id="xdx_850_zW0sVKyiGEH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zIwwocQAdPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z9hLzXwHvL19">Foreign
Currency Translation and Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and transactions of the subsidiary&#8217;s operations are reported in the local (functional) currency of
Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are
translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency
financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange
rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions
denominated in a currency other than the foreign operations&#8217; functional currencies are included in expenses in the consolidated
statements of operations.</span></p>

</ix:nonNumeric><p id="xdx_85F_zZcBA8wjQ7C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zOBGA5krpw1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzwzJ11dx4ag">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the
tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the
event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount,
an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise,
should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for
tax purposes since inception and have significant tax losses and tax credit carry-forwards.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

</ix:nonNumeric><p id="xdx_85A_z9OLxp5VSMw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zTDujomcMpg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StandardProductWarrantyPolicy"><p id="xdx_84C_eus-gaap--StandardProductWarrantyPolicy_zXrB223ADMa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zk8HhCPHBf0e">Product
Warranties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed
parts. We also provide a three-year manufacturer&#8217;s warranty covering implant failure by providing a functionally-equivalent
replacement implant. Accruals for product warranties are estimated based on historical warranty experience and current product
performance trends and are recorded at the time revenue is recognized as a component of cost of sales. The warranty liabilities
are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred.
We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The warranty liabilities
are included in accrued expenses in the consolidated balance sheets and amount to $<span id="xdx_909_ecustom--AccruedLiabilitiesCurrent1_iI_c20221231_zdFhT1GUh3Qc" title="Accrued expenses"><ix:nonFraction name="eyes:AccruedLiabilitiesCurrent1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> at December 31, 2022.</span></p>

</ix:nonNumeric><p id="xdx_851_zlODTqFPEZPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z9RjjhyGeCi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuPP9OcACdCd">Net
Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
computation of earnings per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss)
available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS
is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes
payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning
of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those
that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock
warrants and common stock options outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, and 2021, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately
acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in
thousands).</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden">&#160;Schedule
of net loss per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Shares underlying warrants outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,311</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,074</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,272</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,542</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="eyes:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,583</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="eyes:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_z8MB0HtPdyii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</ix:nonNumeric><p id="xdx_85F_zR4Cq4Pa8jYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTTq7qoh0hKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_ztxpnYyQsXIe">Operating
Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our
chief operating decision-maker, our CEO, reviews financial information presented for each of our segments. We consider ourselves to
have two reporting segments, specifically the Biopharm Division and the Neuromodulation Division. Neither division is revenue
producing. The Neuromodulation Division<span></span> <span title="Consolidated"></span>and the Biopharm Division incurred $<span id="xdx_90D_ecustom--DivisionIncurred_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zZweoZ0OV1al"><ix:nonFraction name="eyes:DivisionIncurred" contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span>
million, and $<span id="xdx_904_ecustom--DivisionIncurred_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zq091xoeefyf"><ix:nonFraction name="eyes:DivisionIncurred" contextRef="From2021-01-012021-12-31_custom_BiopharmDivisionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.1</ix:nonFraction></span>
million respectively in operating expenses. The Neuromodulation Division incurred $<span id="xdx_900_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zmcjDfT5FJ67" title="Operating loss"><ix:nonFraction name="eyes:OperatingIncomeLoss1" contextRef="From2022-01-012022-12-31_custom_NeuromodulationDivisionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million and the Biopharm Division $<span id="xdx_90A_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zpom3CTHmlJb" title="Operating loss"><ix:nonFraction name="eyes:OperatingIncomeLoss1" contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.4</ix:nonFraction></span>
million of the $<span id="xdx_90F_ecustom--OperatingIncomeLoss2_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zbX12ji9k7Ii" title="Operating loss"><ix:nonFraction name="eyes:OperatingIncomeLoss2" contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.9</ix:nonFraction></span>
million consolidated net loss, inclusive of the $<span id="xdx_90E_ecustom--OperatingIncomeLoss3_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zLuOkTO7VF64" title="Operating loss"><ix:nonFraction name="eyes:OperatingIncomeLoss3" contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction> </span>million
gain on bargain purchase<span title="Operating expenses"></span>. The Neuromodulation Division includes $<span id="xdx_907_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zeQYdZiuAzLl" title="Division incurred"><ix:nonFraction name="eyes:DivisionIncurredOfAssets" contextRef="From2022-01-012022-12-31_custom_NeuromodulationDivisionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.1</ix:nonFraction>
million</span> of total assets. The Biopharm Division includes $<span id="xdx_90E_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zxDeeAdzHsU"><ix:nonFraction name="eyes:DivisionIncurredOfAssets" contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">49.0</ix:nonFraction>
million</span> in total assets.</span></p>

</ix:nonNumeric><p id="xdx_858_zWUUA3QwVlPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zwzXUnGUThm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqraudtqBEL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z577Pw1dWBV1">Recently
Adopted Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material
impact on our financial statement presentation or disclosures.</span></p>

</ix:nonNumeric><p id="xdx_85D_zxL6OB0J9M65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><p id="xdx_81E_zzWd9YuRqhPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_801_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zsefGKma3kqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82B_zpj7N4PYzeUd">Money Market Funds</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
market funds included in cash equivalents at December 31, 2022 were $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zGglWQYyvs1j" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">44.4</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zWsAqf5BoKS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
following table presents money market funds at their level within the fair value hierarchy at December 31, 2022 and 2021 (in thousands).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zOPtffOgbctf" style="display: none; visibility: hidden">Schedule of Money Market Funds at their Level within the Fair Value Hierarchy</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">December 31, 2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; text-align: left; padding-bottom: 1pt">Money market funds</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20221231_zRysV9MvISUl" title="Money market funds" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,417</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWHzCoiivLB6" title="Money market funds" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,417</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTRUEe7wKfrg" title="Money market funds" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zde2sAraGg8c" title="Money market funds" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">December 31, 2021:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Money market funds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20211231_zBGhRpK0g3J8" title="Money market funds" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeyQYp5i1Vue" title="Money market funds" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoIaFTcfPhud" title="Money market funds" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zh7TluyGlx61" title="Money market funds" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_zQc0WLpPwoNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</ix:nonNumeric><p id="xdx_817_zPW7gO0zzk37" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p id="xdx_807_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_z7bz7WqXa2xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<b><span id="xdx_822_zXC1Hq08lBwd">Selected Balance Sheet Detail </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and equipment, net of accumulated depreciation and amortization</b> &#160; &#160; &#160; &#160; &#160; &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjC0DyuWb6Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zRzYQ4bz5yYe">Property
and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zv6HeXdASRD9" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,520</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zh99CLf6UYte" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,174</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhBX8h3qlb11" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxnkfGZPZ7Ne" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Computer software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_pn3n3" title="Property and equipment, gross" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputerHardwareAndSoftwareMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_zu0eqEiR6114" title="Property and equipment, gross" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ComputerHardwareAndSoftwareMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_z4VDJ4qMb2b5" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zmuXJCwkl7q8" title="Accumulated depreciation and amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,411</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zO4j6AB8io87" title="Accumulated depreciation and amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,031</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pn3n3" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_ziL4I3Sc0IS3" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,173</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zx9pQOzFZOol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
liabilities amounted to $<span id="xdx_90F_ecustom--ContractLiabilitiesOther_iI_c20221231_zJBTKDaxdY6b" title="Contract liabilities"><ix:nonFraction name="eyes:ContractLiabilitiesOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,000</ix:nonFraction></span> at December 31, 2022 and are included in accrued expenses on the balance sheet.</span></p>

</ix:nonNumeric><p id="xdx_819_zxTygwkS1gSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"></p>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:GrantsTextBlock"><p id="xdx_800_ecustom--GrantsTextBlock_z42oqYMLsIx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82E_zqK05YYs7od">Grants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received an award for $<span id="xdx_904_ecustom--GrantReceivedToSupportClinicalDevelopment_pn5n6_c20180101__20181231_zsoWI8JUye7c" title="Received grant"><ix:nonFraction name="eyes:GrantReceivedToSupportClinicalDevelopment" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million grant (with the intent to fund $<span id="xdx_901_ecustom--GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_pn5n6_c20180101__20181231_zEhTZFyhfHSi" title="Grant receivable with intent to fund early feasibility clinical trial for five years"><ix:nonFraction name="eyes:GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span>
million over <span id="xdx_905_ecustom--GrantReceivedFundingPeriod_dxL_c20180101__20181231_zTBYD37GtAne" title="Grant received funding period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0660">five</span></span>
years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the &#8220;Early
Feasibility Clinical Trial of a Visual Cortical Prosthesis&#8221; that commenced in January 2018. The NIH grant funds ongoing
and planned clinical activities and are being used to conduct and support clinical testing of six subjects implanted with the
Orion&#8482; Cortical Visual Prosthesis (Orion), submit and obtain Investigational Device Exemption approval from the U.S.
Food and Drug Administration (FDA). During the year ended December 31, 2022 grants offset against operating expenses were
$<span id="xdx_906_ecustom--GrantsAgainstOperatingExpenses_pn5n6_c20220101__20221231_zPguaR21NJn9" title="Grants against operating expenses"><ix:nonFraction name="eyes:GrantsAgainstOperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million of which $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_dxL_c20220101__20221231_zfItUoydTwse" title="Research and development expenses::XDX::14169"><span style="-sec-ix-hidden: xdx2ixbrl0664">0.4</span></span> million were offset against research and development expenses and $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_dxL_c20220101__20221231_z6axLnCVGif7" title="General and administrative expenses.::XDX::7072"><span style="-sec-ix-hidden: xdx2ixbrl0666">0.1</span></span> million were offset against
general and administrative expenses.</span></p>

</ix:nonNumeric><p id="xdx_817_zbiwihGjN1qa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zSOq78OI2Gvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;6.
<span id="xdx_823_zm11uf6n8cI2">Equity Securities&#160;&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkiZW3dde77"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></span> shares of common stock with <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FDOknATFMl"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,735,770</ix:nonFraction></span> issued as of December 31, 2022. In addition, we are
authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrGF0soLlDhl"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred stock with <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znSBIiffqci4"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></span> issued. On August 19, 2022 the Company initiated a reverse
stock split of one share for every three shares. All share numbers have been retroactively adjusted for the split. On August 30,
2022, <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesMergerAcquisitions_iI_pid_uShares_c20220830_zJ0Vwxl57vDi" title="Stock issued during period shares merger acquisitions"><ix:nonFraction name="eyes:StockIssuedDuringPeriodSharesMergerAcquisitions" contextRef="AsOf2022-08-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,136,362</ix:nonFraction></span> shares were deemed issued for the merger acquisition.</span></p>

</ix:nonNumeric><p id="xdx_81C_z1wXukfo0E2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:WarrantDisclosureTextBlock"><p id="xdx_806_ecustom--WarrantDisclosureTextBlock_zMKstc3ZFCv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_825_zx1DeKZIKU1h">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM,
prior to the Merger, issued common stock and warrants (collectively, the &#8220;unit&#8221; or &#8220;units&#8221;) in 2019,
2020 and 2021 for $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z8gG6RdoWIXa" title="Share price (in dollars per share)"><span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zrcjsVLaBPrc" title="Share price (in dollars per share)"><span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z8lxdk6prppa" title="Share price (in dollars per share)"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2019-12-31_custom_RightOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2020-12-31_custom_RightOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-12-31_custom_RightOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
per unit. Outstanding warrants to purchase common stock are shown in the table below and generally expire <span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsTerm_dxL_c20221228__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zIxXjNiUV1l4" title="Term of warrants::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0684">5</span></span>
years from the date of issuance at $3.15 per share exercise price, are exercisable for one share of common stock and
may be exercised on a cashless basis. The warrants qualified for an exception to derivative accounting and, accordingly,
their value was not bifurcated from the total purchase price. Warrants outstanding associated with these units totaled 7,747,213 as of December 31, 2022 and are not registered or tradeable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
other adjustment for <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zhRZkiB5nOXe" title="Warrants granted"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-12-31_custom_RightOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,563,688</ix:nonFraction></span> warrants in the table below were outstanding Second Sight warrants exchanged as part of the Merger
for Vivani warrants on a like-for-like basis. The warrants are tradeable on the open market. Under accounting standards in a business
combination, these warrants were measured at fair value as of the Merger date; however, the warrants were substantially out-of-the-money
and were assigned no value.</span></p>

<ix:exclude><p id="xdx_238_zlGBVfjoqv0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjY8AwJpseL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zwkhgZqovQ7g">A
summary of warrant activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zttlQCtP8VPl" style="display: none; visibility: hidden">Summary of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share&#160;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)&#160;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%">Warrants outstanding as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEGqAedIP7W2" title="Outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,402</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zv1eVTrc1d16" title="Outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;&#160;&#160;Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqVhoxQ0zcdi" title="Issued" style="text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightIssued" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7EkoCazMLS4" title="Class of warrant or right exercise issued" style="text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightExerciseIssued" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znMfsDsK0vci" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2h8DpHJ1Uqa" title="Forfeited or expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zi70I13cg8z5" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,074</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6MHehZVgxyb" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaVPY4vfYiMa" title="Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zd8UlA9P8thf" title="Class of warrant or right exercise issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhqepYaOnrne" title="Exercised" style="text-align: right">(<ix:nonFraction name="eyes:ClassOfWarrantOrRightExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">1,327</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQIqnjNC5a18" title="Class of warrant or right to be exercised" style="text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightToBeExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="Shares">3,15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Forfeited or expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuS9ZPI4H3j3" title="Forfeited or expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOtherAdjustments_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJsR55UOQaU5" title="Other adjustments" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightOtherAdjustments" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,564</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOtherAdjustment_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zcHbRVwesco3" title="Class of warrant or right other adjustment" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightOtherAdjustment" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.24</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWwwuvTOloD3" title="Other adjustments (in years)::XDX::P1Y5M16D" style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">1.46</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zVsAaEkTYhS2" title="Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMc7aeem6TJ6" title="Outstanding at ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zETl6FD27PJ4" title="Outstanding at ending (in years)::XDX::P2Y3M22D" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">2.31</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsrL7AZWik24" title="Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zChkBds5Pxjl" title="Exercisable at ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="eyes:ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh1z8YdtMeca" title="Exercisable at ending (in years)::XDX::P2Y3M22D" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">2.31</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zQNawRGChg4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants outstanding as of December 31, 2022 have</span> no intrinsic value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><p id="xdx_81C_z3upicXf6V73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zJ2csz9HLB6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_826_zO2bfl7F4yX2">Employee Benefit Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a 401(k) Savings Retirement Plan (the &#8220;Plan&#8221;) that covers substantially all full-time employees who meet the
Plan&#8217;s eligibility requirements and provides for an employee elective contribution. The Plan provides for employer matching
contributions. Employer contributions are discretionary and determined annually by the Board of Directors. For the years ended
December 31, 2022 and 2021, employer contributions to the Plan totaled $<span id="xdx_90D_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pn5n6_c20220101__20221231_zJWE77VVxxhh" title="Employer contributions to plan"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pn5n6_c20210101__20211231_zRzEfNPuaz67"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively.</span></p>

</ix:nonNumeric><p id="xdx_81F_zThcO5W5l9Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></p>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuHyPTlhonAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_823_zJtooUUzdtjc">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
initiated a new Incentive Plan at the time of the Merger. Under the 2022 Omnibus Plan we were authorized to issue options covering
up to 20% of the outstanding shares of common stock. The maximum number of shares with respect to which options could be granted
was approximately 10,147,000 shares at December 31, 2022, which is offset and reduced by options previously granted under the Plan.
The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date.
Generally, the options vest ratably over four years and expire ten years from the grant date. The plan provides for accelerated
vesting if there is a change of control, as defined in the Plan.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zzjDNw9ffAT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized stock-based compensation cost of $<span id="xdx_906_ecustom--ShareBasedCompensation1_dxL_c20220101__20221231_z8VpJhbYUYe8" title="stock based compensation cost::XDX::1470000"><span style="-sec-ix-hidden: xdx2ixbrl0742">1.3</span></span> million and $<span id="xdx_90E_ecustom--ShareBasedCompensation1_dxL_c20210101__20211231_z3PyTOn5Qiwh" title="::XDX::1668000"><span style="-sec-ix-hidden: xdx2ixbrl0743">1.7</span></span> million during 2022 and 2021, respectively. The calculated value
of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zaEStGAOm7m4" style="display: none; visibility: hidden">Summary of Option Grant using the Black-Scholes Option-pricing Model</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zM1VFRmlrsD7" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.42</ix:nonFraction></span>% &#8211; <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zVd946XQ434d" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.45</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zvAXpD4SbRUb" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.7</ix:nonFraction></span>% &#8211; <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zvwkKdMHCbuc" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.9</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_z4nxWKRXhusj" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zczCJihV88Sf" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zrf3O4uhs7Ce" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zE27Sy97wy1f" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Expected term</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zUDoygePn4z3"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.25</ix:nonNumeric></span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zgHGX0qnM573" title="Expected term::XDX::P6Y0M29D"><span style="-sec-ix-hidden: xdx2ixbrl0762">6.08</span></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zyY3OekL5h5l" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0764">5</span></span>-<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zs6Oex5mheV6" title="Expected term::XDX::P6Y0M29D"><span style="-sec-ix-hidden: xdx2ixbrl0766">6.08</span></span> years</span></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_z2iI9dvb0lsc" style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"></p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z7oBTzFtD6Fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zahKLqv7z9Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zj01Vx6A5a3d" style="display: none; visibility: hidden">Summary of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (in Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%">Options outstanding at December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAq3dvCRueP4" title="Options outstanding, number of shares (in shares)" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,888</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zotkEN4Z8A9e" title="Options outstanding, weighted average exercise price (in dollars per share)" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO47jeZyLfe" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaOmFHF99Och" title="Granted, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPt2m0inTWN6" title="Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,020</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJy5Ox6CHsNi" title="Exercised, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGGJ0RhXpFz" title="Forfeited or expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">875</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS2mkehgpYhc" title="Forfeited or expired, weighted average exercise price (in dollars per share)" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.82</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPyG8b7gHeD3" title="Options outstanding, number of shares (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPjpcsFgvk23" title="Options outstanding, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZIQwcJ86x4f" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXM35BSQwxml" title="Granted, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z74HFrTaoNK1" title="Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">73</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa6okzzYMid" title="Exercised, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited or expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLSgc4UlujS5" title="Forfeited or expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">335</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmplEwphIV1e" title="Forfeited or expired, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC0Nce0vksEe" title="Other adjustments" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="eyes:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">272</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcoan5IqPKj" title="Other adjustments , weighted average exercise price (in dollars per share)" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">8.70</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding, vested and expected to vest at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVV42Ik6nYa8" title="Options outstanding, number of shares (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,272</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDRb9YqGwUh" title="Options outstanding, vested and expected to vest (in dollars per share)" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.07</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zavW5A2be8n6" title="Options outstanding, vested and expected to vest (in years)::XDX::P7Y1M24D" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">7.15</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOfbPGH9Eie" title="Options exercisable, number of shares (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT1q0jnevKVa" title="Options exercisable, weighted average exercise price (in dollars per share)" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsupd8sSKsd6" title="Options exercisable period (in years)::XDX::P6Y6M18D" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">6.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_z2XO29eymG2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated aggregate intrinsic value of stock options exercisable as of December 31, 2022 was $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231_z6FpaTKWVOWb" title="Stock options exercisable"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,000</ix:nonFraction></span>.
As of December 31, 2022, there was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_dm_c20221231_zowRhijOxWKg" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.1</ix:nonFraction>
million</span> of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted
average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20220101__20221231_zDrzeVJvCFPh" title="Weighted average period (in years)::XDX::P1Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0823">1.2 </span></span>years.
Other adjustment represents a prior period true-up and Second Sight options exchanged as part of the Merger for Vivani options on a
like-for-like basis. Under accounting standards in a business combination, these options were measured at fair value as of the
Merger date; however, the options were substantially out-of-the-money and were assigned no value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z9SzNUjW711j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the
years ended December 31, 2022 and 2021 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5E5xaTBjh83" style="display: none; visibility: hidden">Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUwCT72f93V4" title="Allocated share-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">896</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z35zALM8DjS1" title="Allocated share-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,329</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwmYPOrrbxF8" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPff0Tqq0N86" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">339</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zVNroePLEmzl" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zhh55aUb3Zz" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zOb5ZfWGScV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z9dUSXJyMtel" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_820_zwOrBIqjiv4">Income taxes</span></b></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in <i>Note 1, Business</i>, Nano Precision Medical, Inc. and Second Sight Medical Products, Inc. merged on August 30, 2022. The transaction was accounted for as a reverse
merger business combination under GAAP. Accordingly, the consolidated income tax provision includes NPM for all periods presented,
and the legacy Second Sight business of Vivani (the &#8220;Legacy SSMP&#8221;) since the date of the merger. Further, NPM (the
major subsidiary of Vivani) and Legacy SSMP will not elect to consolidate their tax returns for income tax filing purposes. For
the purposes of accounting for income taxes under GAAP, the Legacy SSMP tax provision, deferred taxes and liabilities, and various
other matters such as net operation loss and R&amp;D carry-forwards have been prepared as if it filed a separate tax return for
the period from August 30, 2022 to December 31, 2022.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the net losses in 2022 and 2021, the provision for income taxes consists only of minimum California franchise taxes presented
in general and administrative expenses.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOKWsQU7nvP1" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zbKs38QJmLP">The
components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zhBNNNbVEkzi" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLfxWR3YG7Eb" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zwXrDoYiCHv1" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVwGkpHftDn9">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31, 2022</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of <br /> December 31, <br /> 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NPM</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Legacy SSMP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Combined</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NPM</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;Deferred Tax :</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zmQMyRQ8hCSc" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">&#160;Accruals/reserves</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,475</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_zReRcK54dMZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Capitalized R&amp;E &#167;174</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_z4nEoMQlRdg1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Lease ROU</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zexQfnaMWIo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Stock Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z28JT53TZaRk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Net operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,974</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,749</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_zTSpWO3W4hNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;R&amp;D credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,358</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,961</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,319</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,671</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zryEUe5YTfnk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Gross Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,982</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33,564</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,546</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,698</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zhx89EXOrBHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Investment in Sub</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,510</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,510</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_iI_pn3n3_zfuK6Ucv2SG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Accumulated depreciation/amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">52</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">202</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zOKU14AVwRi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,660</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,712</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--TaxCreditCarryforwardValuationAllowance1_iI_pn3n3_zsY5DO2zilY" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:TaxCreditCarryforwardValuationAllowance1" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,322</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:TaxCreditCarryforwardValuationAllowance1" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33,512</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:TaxCreditCarryforwardValuationAllowance1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,834</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="eyes:TaxCreditCarryforwardValuationAllowance1" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,804</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zpdkLC6KkpIb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Total Deferred Tax Assets, Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zpGd0eDQucMk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Change in valuation allowance for the year ended</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,519</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">461</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,980</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,204</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>





<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

</ix:nonNumeric><p id="xdx_8A1_zSsI6Y9jA8xb" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwtCrr7WOmJ3" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0mHY8d5OAgb">The
reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and
the corresponding rate from operations consist of the following (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year Ended December 31, 2022</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    SSMP</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combined</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pre-Tax
    Loss <sup id="xdx_F49_zGmS0pPvS0ah">(a)</sup></span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_fKGEp_zHzGdXL01v9l" title="Pre-Tax Income (Loss)" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" contextRef="From2022-01-012022-12-31_custom_NPMMember" id="Fact000906" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_fKGEp_zWCTbOGinBvc" title="Pre-Tax Income (Loss)" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" id="Fact000908" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,479</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zua3UZboUDw8" title="Pre-Tax Income (Loss)" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" contextRef="From2022-01-01to2022-12-31" id="Fact000910" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,889</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Federal
    tax (benefit) at statutory rate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zncslZ6DXQck" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zrbiY7wKWQ2k" title="Federal tax (benefit) at statutory rate (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLRDFlBXZNOf" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">311</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z8PnshO8R8o5"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z5q8hVYFGA1" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zrAoBkAO3O05"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State
    tax (benefit), net of federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFQOLbuhoitf" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">970</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zD1eAPRL6576" title="State tax (benefit), net of federal tax benefit (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zlw0ckYWhjoc" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zMvh0e3gAc95"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zenX8q6pqWT3" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,073</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zRCHgDBN6hnk"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.7</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;R&amp;D
    tax credit from current year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zYSxRUdYx7kk" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">687</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zHtF5TCrGin" title="R&amp;D tax credit from current year (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.9</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zjpNWYaVx6A9" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zgfCkLAAkdYg"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_zuDwWdXE50hd" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">707</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zDN2HLZPgYH7"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.1</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;Impact on effective rate of SSMP loss eliminated in consolidation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zg4ZopIGFyqf" style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Pre-Tax Income (Loss)" id="xdx_98E_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z7407CXbAdx7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Pre-Tax Income (Loss)" id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zOqFyhnDf6Ze" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">311</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zPODuwsCotR8"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.2</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zEaiJaSJG7oe" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z6Hygoi7XCaf" title="Other (percent)">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.4</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zIwosWd83wRh" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvubkJAIpfvd"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.8</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_zBMC6AulFCY8" title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zZqmHqWoOHhg">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.2</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Change
    in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFkC1XoH0tde" title="Pre-Tax Income (Loss)" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,519</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z2ZLLbff7oH1" title="Change in valuation allowance (percent)">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">32.5</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvc749oR8kRc" title="Pre-Tax Income (Loss)" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">462</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zTSngbE0cer8">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">31.2</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zFVL4pyxdznj" title="Pre-Tax Income (Loss)" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,980</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zavBeFvSroH9">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">35.9</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Pre-Tax Income (Loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    provision for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zsKXGl0USTZa" title="Pre-Tax Income (Loss)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zBkzXlJPSPQi" title="Total provision for income taxes (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zW7xByvT8XIg" title="Pre-Tax Income (Loss)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zRmu271TSLd7" title="Total provision for income taxes">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.1</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zfe3Ewm9pWQj" title="Pre-Tax Income (Loss)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zeca7nMC5lzc" title="Total provision for income taxes"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F0B_zYjnvwWfePwl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F1B_zXoPwEsGRYk5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000979" xml:lang="en-US">The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#8217;s interest in
                                                                                                                                                                 Legacy SSMP&#8217;s pre-tax loss.</ix:footnote></span></td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPM</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2021 </b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 59%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; width: 1%; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pre-tax
    income (loss)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zIFEVggs4Vc5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,773</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Federal
    tax (benefit) at statutory rate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_znk23RLyjb73" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,682</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zCditIAbu0w2" title="Federal tax (benefit) at statutory rate (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State
    tax (benefit), net of federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zP7JJ3t5UThf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">893</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zENdvgyn1FBb" title="State tax (benefit), net of federal tax benefit (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;R&amp;D
    tax credit from current year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zPdxEEyF5vxf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">475</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVOtVlxUes3i" title="R&amp;D tax credit from current year (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zDCw1WYbBTRd" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">163</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z9qwsOanWJg5" title="Other (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.3</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Change
    in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zozPAyMDDaEb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,214</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zf12XN9xRLCg" title="Change in valuation allowance (percent)">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">33.0</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    provision for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z3pRQx6eCr3b" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zoVjvEkxEPc9" title="Total provision for income taxes (percent)"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zrNn2XPHoQ38" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-tax losses for NPM and Legacy SSMP in the preceding table are presented as if each entity filed separate returns;
and accordingly, the information does not reflect elimination of intercompany transactions or balances. The combined pre-tax
loss in the table reflects elimination of intercompany transactions
and balances.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
NPM and Legacy SSMP file as separate taxpayers, deferred tax assets and liabilities and attributes such as NOL and R&amp;D carry-forwards
of one taxpayer are not available to offset those of the other taxpayer. The combined data is presented for disclosure purposes
only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize
the existing deferred tax assets. Based on this evaluation, as of December&#160;31, 2022 and 2021, a full valuation allowance
has been recorded because deferred tax assets have been assessed to be less than &#8220;more likely than not&#8221; to be realized.
</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><p id="xdx_89A_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z1x7zifKh8Tc" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zRHHnjqmtF79">As
of December&#160;31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and
state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zGsn3kKIHJh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zkWy5QjDEc04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    SSMP</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zyEmcgMFwV1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre TCJA
    (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,257</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,095</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_z6bkqeUeSoO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post
    TCJA period federal NOL carry-forward, with no carry-forward limitation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,503</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">86,412</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zLMKKvhr7KAb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    federal NOL carry-forward</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,760</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115,508</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_z6Ez4bIX1poh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State NOL carry-forward,
    begin expiring 2030</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66,514</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_z61WgtTZchY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal R&amp;D tax
    credit carry-forward, begin expiring in 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,586</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--DeferredTaxAssetsStateTaxes1_iI_pn3n3_zvGm8u83tYC4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State R&amp;D carry-forward,
    begin expiring in 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="eyes:DeferredTaxAssetsStateTaxes1" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,973</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="eyes:DeferredTaxAssetsStateTaxes1" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,989</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zKwUUYRHHkz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total R&amp;E related
    deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2022-12-31_custom_NPMMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,997</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2022-12-31_custom_LegacySSMPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserve for uncertain
    income tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_znBnu9YcQ0k5" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
recently enacted U.S. tax legislation, although the treatment of tax losses generated in taxable years ending before December
31, 2017, has generally not changed, tax losses generated in taxable years beginning after December 31, 2017, may only be utilized
to offset 80% of taxable income annually. This change may require NPM and Legacy SSMP to pay federal income taxes in future years
despite generating a loss for federal income tax purposes in prior years.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that each of the tax filers continue to generate taxable losses, unused losses will carry-forward to offset future
taxable income, if any, until these unused losses expire. However, the tax filers may be unable to use these losses to offset
taxable income before our unused losses expire at various dates that range from 2030 through 2038 for federal net operating losses
generated before 2018. Federal net operating losses generated for year 2018 and forward do not expire. State net operating losses
expire from 2030 through 2042. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation
undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its
equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss, or NOL, carry-forwards
to offset its post-change taxable income may be limited. Limitations may also apply to the utilization of other pre-change tax
attributes as a result of an ownership change.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legal subsidiary, NPM experienced an &#8220;ownership change&#8221; within the meaning of Section 382(g) of the Internal
Revenue Code of 1986, as amended, during the third quarter of 2022 as a result of the merger. The ownership change will
subject its net operating loss carry-forwards to an annual limitation, which will significantly restrict its ability to use
them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the
aggregate value of stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the
Internal Revenue Service. We have not yet fully analyzed the available information to determine the amount of the annual
limitation. </span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically review the uncertainties and judgments related to the application of complex income tax regulations to determine
income tax liabilities in several jurisdictions. We use a &#8220;more likely than not&#8221; criterion for recognizing the
income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. We have
evaluated the impact of these positions and believe tax filing positions and deductions will more likely than not
be sustained upon examination. Accordingly, no reserve for uncertain income tax positions has been recorded as of December
31, 2022.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the cumulative unrecognized tax benefit is recognized, there will be no effect on our effective tax rate due to the full
valuation allowance. Due to the nature of the unrecognized tax benefits and the existence of tax attributes, we have not
accrued any interest or penalties associated with unrecognized tax benefits in the Consolidated Statement of Operations
nor recognized a liability in the Consolidated Balance Sheet. We do not believe the total amount
of unrecognized benefit as of December 31, 2022, will increase or decrease significantly in the next twelve
months.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
January 1, 2022, we are required to capitalize certain research and development expenditures in accordance with section 174 of
the Internal Revenue Code, as amended by the Tax Cuts and Jobs Act of 2017, instead of previously being allowed to expense. Amortization
of such capitalized expenditures are allowed over a 5-year period if incurred in the U.S. or a 15-year period if incurred outside
the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file income tax returns in the U.S. federal jurisdiction and various states and are subject to income tax examinations by federal
tax authorities for tax years ended 2017 and later and by state authorities for tax years ended 2016 and later. We currently are
not under examination by any tax authority. Our policy is to record interest and penalties on uncertain tax positions as income
tax expense. As of December 31, 2021, and 2020, we have no accrued interest or penalties related to uncertain tax positions. Second
Sight Switzerland, our foreign subsidiary, has not had any taxable income in the prior and current years.</span></p>

</ix:nonNumeric><p id="xdx_812_zYmgGpjib2Y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock"><p id="xdx_800_ecustom--RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_z2q5w2eKDAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82E_z6F3qsOLl1ml">Right-of-use Assets and Operating Lease Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the
balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is
computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets
and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value
guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental
borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zq8oKKab9gji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_za0Kr6KDHsHe">The
Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use
assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Year ending December 31:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left; padding-bottom: 1pt">2023</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20220101__20221231_zpX4ZUs9dsml" title="2023" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="eyes:LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">975</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--OperatingLeasePayment_pn3n3_c20220101__20221231_zF2Q9QG9LCGh" title="Total lease payments" style="text-align: right"><ix:nonFraction name="eyes:OperatingLeasePayment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseCost_iN_pn3n3_di_c20220101__20221231_zYsFQ1WevWGh" title="Imputed interest" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_zbDVMgvUGY29" title="Total lease liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">955</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other supplemental information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--OperatingLeasePayments1_pn3n3_c20220101__20221231_zWQ9TPCyUn19" title="Current operating lease liabilities" style="text-align: right"><ix:nonFraction name="eyes:OperatingLeasePayments1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Long term operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zXCADKZZDPzh" title="Long term operating lease liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_z3qyK37DPtHa" title="Total lease liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">955</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 1pt">&#160;</span></td><td><span style="font-size: 1pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 1pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 1pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 1pt">&#160;</span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%">
<tr>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended</b><br />
    <b>&#160;December 31,</b><br />
    <b>2022</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended</b><br />
    <b>&#160;December 31,</b><br />
    <b>2021</b></span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for operating lease liabilities</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20221231_zMSIGN02zZJa" title="Cash paid for operating lease liabilities"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="9" unitRef="USD">1.0</ix:nonFraction> million</span></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20211231_zPg1JFTUxMG1" title="Cash paid for operating lease liabilities"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="9" unitRef="USD">0.9</ix:nonFraction>
    million</span></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A7_znxkihANCFw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense, including common area maintenance charges, was $<span id="xdx_903_ecustom--LeaseAndRentalExpense1_dm_c20220101__20221231_zmAsfNpToRP1" title="Rent expense"><ix:nonFraction name="eyes:LeaseAndRentalExpense1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.9</ix:nonFraction> million</span> and $<span id="xdx_905_ecustom--LeaseAndRentalExpense1_dm_c20210101__20211231_zfuhVpEF1YMi" title="Rent expense"><ix:nonFraction name="eyes:LeaseAndRentalExpense1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.8</ix:nonFraction> million</span> during 2022 and 2021, respectively.</span></p>

</ix:nonNumeric><p id="xdx_81B_zKTMEv7TT6Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4LxlbWYOsR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_825_zv9mtsWGmpbe">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain indemnification agreements with our directors and officers that may require us to indemnify them against liabilities
that arise by reason of their status or service as directors or officers, except as prohibited by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">Based upon FDA approval of Argus II, which was obtained in February
2013, we were required to collect follow-up data from subjects enrolled in our pre-approval trial for a period of up to ten years
post-implant, which was extended through the year 2019. This requirement to collect follow-up data was halted in 2020 with FDA
approval.&#160;In addition, we conducted three post-market studies to comply with U.S. FDA, French, and European post-market surveillance
regulations and requirements and are conducting an early feasibility clinical study of Orion. We have contracted with various universities,
hospitals, and medical practices to provide these services. Payments are based on procedures performed for each subject and are
charged to clinical and regulatory expense as incurred. Total amounts charged to expense for the year ended December 31, 2022 were
$<span id="xdx_90C_ecustom--ClinicalAndRegulatoryExpense_pn5n6_c20220101__20221231_zxe40tu4oKEa" title="Clinical and regulatory expense"><ix:nonFraction name="eyes:ClinicalAndRegulatoryExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation,
Claims and Assessments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent
owned by us. The outcomes of the challenges are not certain, however, if successful, they may affect our ability to block competitors
from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture
and sell our products, or otherwise have a material effect on our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in the Company&#8217;s 10-K
for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (&#8220;MOU&#8221;) for a proposed
business combination with Pixium Vision SA (&#8220;Pixium&#8221;). In response to a press release by Pixium dated March 24, 2021,
and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium
was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between
the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an
amicable resolution will be reached. We accrued $<span id="xdx_908_ecustom--LiquidatedDamagesPaidValue_iI_c20210331_zXn3eedxF3li" title="Liquidated damage"><ix:nonFraction name="eyes:LiquidatedDamagesPaidValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> of liquidated damages as contemplated by the MOU in accounts payable
as of March 31, 2021 and remitted that amount to Pixium in April 2021. <span id="xdx_903_eus-gaap--ContractTerminationClaimsDescription_c20220101__20221231_zwt4juUsdCwc" title="Description of contract termination and claims"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:ContractTerminationClaimsDescription">Pixium indicated that it considered this termination wrongful,
rejected the Company&#8217;s offers, but retained the $<span id="xdx_903_eus-gaap--LossContingencyDamagesPaidValue_c20220101__20221231_zeiefDIQN3ak" title="Loss contingency, damages paid, value"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> payment. On May 19, 2021, Pixium filed suit in the Paris Commercial
Court, and currently claim damages of approximately &#8364;5.1 million or about $5.6 million. We believe we have fulfilled our obligations
to Pixium with the liquidated damages payment of $1,000,000.</ix:nonNumeric></span> <span id="xdx_90F_eus-gaap--LossContingencySettlementAgreementCourt_c20221207__20221209_zjbv0ZbtFJ3k" title="Description of legal settlement"><ix:nonNumeric contextRef="From2022-12-072022-12-09" name="us-gaap:LossContingencySettlementAgreementCourt">On December 9, 2022, the Company received notice that the Paris Commercial
Court has rendered its judgement, including finding that the Company&#8217;s termination of the MOU was not valid. In the judgement,
the Company was ordered to pay to Pixium the amount of &#8364;2,500,000 minus a &#8364;947,780 credit for the $1,000,000 already
paid for, a net amount payable of approximately &#8364;1,552,220. The Company may appeal the decision within three months from the
date of service. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to raise any and all legal
challenges to this preliminary judgement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not
have a material effect on our financial statements, however the results of litigation and claims are inherently unpredictable.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.</span></p>

</ix:nonNumeric><p id="xdx_818_zmS5qB2N4T8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></p>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zcRd8mM2weRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_827_zv2yh86PzQEh">Subsequent Event</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2023 Cortigent entered into a lease agreement, effective March 1, 2023, to sublease office space to replace our
existing headquarters. Our rental payments amount to $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230226__20230303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9D29ezjR4d9" title="Rental payments amount"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-262023-03-03_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,158</ix:nonFraction></span>
per month plus operating expenses, to <span id="xdx_90D_eus-gaap--SubsequentEventDescription_c20230226__20230303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUwfrGIISAJf" title="Description of lease agreement"><ix:nonNumeric contextRef="From2023-02-262023-03-03_us-gaap_SubsequentEventMember" name="us-gaap:SubsequentEventDescription">lease
14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355. The sub-lease has a term of two years
and two months. We also entered into a lease for storage space on January 25, 2023 in the same building at a cost of $6,775
per month for a term of two years and one month.</ix:nonNumeric></span> As a material inducement for the lessor to execute the lease with us
Vivani guaranteed the prompt payment of all rents and all other sums payable under the lease together with all other terms
and conditions to be kept and performed under the lease by the lessee.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 2023, Cortigent commenced to pay <span id="xdx_907_eus-gaap--SubsequentEventDescription_c20230101__20230131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__custom--MrAdamsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5ld5Rty6y2b" title="Description of lease agreement"><ix:nonNumeric contextRef="From2023-01-012023-01-31_us-gaap_SubsequentEventMember_custom_MrAdamsMember_srt_ChiefExecutiveOfficerMember" name="us-gaap:SubsequentEventDescription">Mr.
Adams $25,000 per month for his services to us. In March 2023 we entered into an at will letter agreement with Jonathan Adams
by which we appointed him President and Chief Executive Officer of Cortigent at a base salary of $350,000 per year commencing
as of March 1, 2023. He may also receive a onetime signing bonus of up to $50,000 upon Board approval. Upon Board approval following
completion of the initial public offering of securities, Mr. Adams may also be issued an option to purchase 400,000 shares of
our common stock at a strike price equal to the price per share at which shares initially are sold to the public in this
offering. Of these, options to purchase 100,000 shares will vest on November 10, 2023 and the balance shall vest in
approximately equal monthly instalments over the ensuing 36 months.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 Cortigent entered into a Transition Funding, Support and Services Agreement with Vivani whereby Vivani will advance
funds and provide or cause to be provided to the Company the services and funding that will cover salaries and related costs,
rent and other overhead in order to permit the Company to operate in substantially the same manner in which business operations
of the Company were previously operated by Second Sight, prior to the formation of Cortigent, which obligations will continue,
in the case of the funding obligations, until the earlier of December 31, 2024 or receipt of proceeds from this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_900_eus-gaap--SubsequentEventDescription_c20230301__20230331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWIyWrRGAIb9" title="Description of lease agreement"><ix:nonNumeric contextRef="From2023-03-012023-03-31_us-gaap_SubsequentEventMember" name="us-gaap:SubsequentEventDescription">Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California on November
21, 2022. The stated term of the lease commences on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months.
Payments increase annually from $2,676,311 to $3,596,784, or 124 payments less the first four which are abated, totalling approximately
$31 million.</ix:nonNumeric></span> Vivani will be responsible for insurance, property taxes and CAM charges. The current lease expires on September 30, 2023.</span></p>

</ix:nonNumeric><p id="xdx_81B_zm42126dEdc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></p>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt">&#160;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


</div>



</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>g083419_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (333-221228, 333-255267 and 333-256904)
and Form S-8 (Nos. 333-204241, 333-213184, 333-218016, 333-219737, 333-237266 and 333-267271) of our report dated March 31, 2023, relating
to the consolidated financial statements of Vivani Medical, Inc. as of and for the years ended December 31, 2022 and 2021, which
appears in this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
BPM LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Walnut Creek, California&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>g083419_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 45pt 0pt 17pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 45pt 0pt 17pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Adam Mendelsohn, hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Vivani Medical, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Adam Mendelsohn</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Mendelsohn</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>g083419_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF THE CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Brigid Makes, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Vivani Medical, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-indent: 0.25in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Brigid Makes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brigid
    Makes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>g083419_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certifications
of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant To Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), Adam Mendelsohn Chief Executive Officer (Principal Executive
Officer) and Brigid Makes, Chief Financial Officer (Principal Financial and Accounting Officer) of Vivani Medical, Inc.
(the &ldquo;Company&rdquo;), each hereby certifies that, to the best of his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Annual Report of the Company on Form 10-K (the &ldquo;Report&rdquo;) for the fiscal year ended December 31, 2022, to which
    this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities
    Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Adam Mendelsohn</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Mendelsohn</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Brigid Makes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brigid
    Makes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial and Accounting Officer)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and
is not to be incorporated by reference into any filing of Vivani Medical, Inc. under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any
general incorporation language contained in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img001_v15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &9 G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK,CC;"I]VPHHHKF/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D)VC)I:\#_ ."C7[18_9]_9TU VDWEZ[XA#:=IX!^9-P_>2?\
M 5_4B@#\_?\ @I+^T<?C_P#M$7_V.X,N@^',Z=IX!^5BI_>2#_>;/X 5\X7,
MF35J]F+$DG))R23U-47.]J  #"U'C<U/E.!20IEJ )[9.*NPI4-LF15N),4
M2Q+4\:U'$.*G04 .4<4\#BFBG8H 0FHW.*>3Q4,AH KW3X4UR/C#4/*@;YJZ
M;4I=D)]>U>>^,YWNY5@C!>25@BA1DL2<  ?6JCN95961^F/_  ;_ /P6_LGX
M8>+O']S$?.U^]&G6;,.L,/+D'W=L?\!K]#Z\M_8K^"Z?L_?LM^"_"JHJ3:?I
ML;W.!]Z>0>9(?^^F->I4F[LJFK12"BBBD6%%%% %#Q1K*^'?#E_?O]VSMWF/
M_ 5)KX^\%QM>*T[_ #/<NTC'UW$DU]%?M4>(/[$^#6H1J<2ZBR6D?_ F!/Z
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M$>*AB3+5<@3I0!/;I@5:B%0VZ\59B7% $B+4RBF)TJ11D4 *.*<:0#BD(P*
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M)4$_J:Z.O%J.\VS[_"QY:,(]DOR"BBBH-PHHHH **** "BBB@ HHHH ****
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MVWS6_GN?2-%%%>.?=A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M98KT,ORHDG=N :\,_P""=?Q%UKQ=9ZCI3W5C!HFA6^T:7%8>2]O*TA )?^+
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MS:JU_P#(_L*^$_B2X\9?"SPUJ]WM^U:KI5K>3;1A=\D*NV!Z9)KH*X_]GO\
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MBC_B)L_99_Z"OCG_ ,)>XK3ZM5_E9S_VAAO^?B^\\L_X.Q_^34/A7_V.;_\
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M%S+%&@.7"=.*Y\4FXKV?]?Y[GIY+)1G-XB]]KV=K._E9+3N^FNIYY\'/V?\
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MW2UAMHPTB&Y(&Y P[ G&37;5C*5G8\7"3I4DXN6B>K>UV]K[==%Z'H429&"
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M^%?^"S?C2W_8$D_9V\6^"?"7Q \("QDTVUOM6N+A+^RASNM]C(<;K=MIC;J
MB@Y Y=/#2@U.VMR*^8TZL94F[)I6?FNC\C];O^"I4WP"\(_L$_"NU^+X^)@^
M%\7V&+3V\#R2Q0AUL\6_VDPLH\LIG9GY=V.^*^-/^"@O_!63X3_&K]E#X/>'
MO@WI_P 3=>\3_##QIHVI>'+SQ+H\S_V@UBK P-=$LTTSJ4!49=LYZUX/^QC_
M ,' 7Q6_91^!]G\-]:\.^%OBAX1TN!;73X==WI<VD"_=@,BY62->-H="5  !
MP !SW[8/_!;+QW^UEXU^&&IIX+\$^#K'X2>((_$NB:?IT<LB2W<94KYQ+*"G
MRXVHJ]3S13P\HNTE>WG^@8C,:<X-P=FTE;EU^^_W'Z3>$?V@/V:O^"]&M:-H
ME_?>/OA7\>?#-G*^GP6NHW&EZOIA3YY?(D0^3<1HX#$.H< ?=7FJ?_!!C]FN
M7]EO]M;]K3PCXEUS_A*/&_A_4=*B;5YO^/K5+2X6XN?M#;B6W2%XRX)/SCJ>
M#7RQ=_\ !T7X\4R:G8_!3X667BR:%H6UCS)W;GV #D9P=IDYQUKY ^$'_!3[
MXQ?!;]L36OCEIGB&&X\;>*)G;7$N;?=8:O"Q7_1Y(5(Q$H1 FT@IL7!ZY2P]
M1QE#9>MRGF&'52%5^])/5I6TM;;N?IC^S7_P4=_9 _8<_::\=WGA[_AI6Z\>
M^)KR>Q\0:9K%K=ZFT]VMP79OLS.2)0X8 @9VL0.#75?\&]?Q"TG4/#W[77BS
MPM!,FAW/CBXUC2H;F+RI%@:&::-73^$X(!7MTKYCU;_@Z-\?RQSW^F_!CX7:
M=XJN(MC:PSSS,#C&[;A7;'8&2OF[]@7_ (*Y^,O^"?7P\^('AW0/"?AGQ%!\
M1;LWE]-J4T\3VSF)HB(Q&<8PQ/--X>3@U;5VZBCF%*-6#YKQ5]HVM='#:1_P
M4O\ C!>_M+^$_BGXI\=>)_%.H>%O$47B.*RO=0D>RB(8B2.&#/EQ*T+21 *H
M^5L5^]/B_P#8B\/_ +4__!1_X$_M.Z1]FO/#FG^$+BZD?:,74Y5&TV4^X2[N
M#[>4E?S/1IY:!?08K[H^ '_!??XM?L[_ +%D'P6TK0?#5Y96&DW6CZ?K]S-<
M#4;"&;S-A4*=A:$283/9%STK7$4)2LZ>^WR.7 8V$.:.(U6C^:/N#_@FQ^U1
MI'[9W_!P'\;_ !9)/!=6NC^%9] \(%SG%I:WD$4LD6>\A\R0X[2&O*?V8/B9
M\:+K_@YC\2Z7?:GXODLSKNK6^IV$\TYL(]#2WD-J1&3Y8B&+8QL!RQ&#DFOS
M _9V_: \6_LI?%_0_'?@75I='\2^'Y"]M<;1(LBL-KQ2H>'C=2593U!['!'Z
M):E_P=5?%VY\*2Q6OPT^'-EXDEM_(.KB2YD13C[XA)R<'D*9"/K43H23?(KI
MJQK0QU.45[:334N;3J?8_P $]/TK3_\ @YK^+G]F+ DD_P ,[2;4!$ /]*+6
M8);'\1C$1/UKS#_@D7_RG_\ VP/KJ/\ Z=(:_-O]CO\ X*H?$']D;]K3Q7\9
MWL],\>^,O&EG/:ZG)K<LD:2M-+%*T@\K&"/*554#:%X &!6_^S-_P6"\9_LO
M?MI_$_XWZ5X1\+ZGKOQ4,YO]-NYYUM+'S;A9SY3*=YPR ?-V-)X:=FEV2+AF
M%'FC)Z>\W\F5O^"K_P"VK\4?CE^V3\7/#^N^-_$DWA/3O$UYI-GX?2_DCTN"
MVM;@I"OV=2(V(\L,68$EN<]*[#_@W2_Y2W> /^P9K/\ Z02U\D?&KXH77QO^
M,GBSQI?6MM87OB[5[K6+BVMV9H;>2>5I&1"WS%06P,\X%?77_!N;;23_ /!6
MOP(R(S+#I.L/(0,[%^Q2+D^@RP'U(KHJ14:+2['!AZCGC(R;O[R_,_I/HHHK
MY\^\"BBB@ HHHH **** "BBB@ HHHH *\C_:<\=QV%I#I6_]VH^U7F/[H^XO
MXGG\!7JFJZG%HVF3W<[;8;>,R.?0 9KY=^*,[^++&\O[MV$FH2^:5!Y"=%7\
M!BO0RVDIUXN6USYKBK%SI8&<*7Q23^X^7/VO?'.EZKI$]W!=O'?6XX09&17S
MKX2_:MU;PGX1^R?VC<QSQ2%XV^\"N<@&OI'XL^&=&T'[;<ZO:O<Q3QE5!&0@
M-?%/Q0TS3M&\:LNG>9)ISN'C#C''=?I7Z7B%-1C*!_*E.G"K*5&O%NSO=GO>
MO:-J/[2_@>QUVZ^:.T&60ME7]37@'Q"\"ZCHOCVXL]-L[AR5#K'!&6V@U[9^
MQ9XFU"VU#4Y!"\WAFW.V:W#CASZ*:[SQY^V7X>^$6OR7EGX<CNO-'DD,56?/
MT]*V]A3G#GD['DPQ.)PV(EAZ$.==%MOT9\A1:+%IG^MNWM9)$*W,9)5P?[I%
M3^$?"\NO^(+7[+(@>%PP,HR..E;?C74O^%R>/+_Q'-#%#)?ON6UB&!$.V:TO
MB'XALO!^MPVMG8FWN;>T42;""K2$<'(K&RC'5Z'L.M-VC;WFM?+_ #/7?@-\
M3=(\2+?^%]:T?3;^^U"Y1%:= 1&PXPIZXKW/XS_L;^#-1^&=U<1:#:PZW9P^
M9%);+M+N/X<=Q7YZ^%==U"'6GO899QJ,!\U'7^$Y[U]C? G_ (*#:O\ V-]E
M\;^'[BX6% $OK-1^\ X^93_,5K1F[<DCYW-\NQ-*:KX1^JO;[O(^6]<\&-I>
MK740C$;1-M:.1<%#Z5Z=^S'\<O#?PRLY=-U[3[MHW=G$ZQA]A],?6NW^.?PI
MN/V@OB[I.K::L>F:%J48=KH<.?;']ZN6_:1_9.7X6:5IDFG7MQ-<7TOE[)3P
MWICWI^RG&7/'8[_KN'Q-..'KNTI=.S7F=A\*/'UI\3_%=_IT:2Q666-N9%Y"
M^GTJU\7_ (9VD7@PVUJD:_9LOYA7 8DUE?LT>%+S3;+4$U"(V^I6"F191_$@
M'2K/Q?2_U3X8S:I#>% [8*@Y)YKT7;V5SS+*.,4:3LDT>6>,? 5MX3TF&ZNK
ML?:0HG22)N5[C%?,/QA^*=YKGQVTB26XD=H)X]XS\TC.0.?^ UZUXYUW48--
M+7\S"*(%LGOQS7SI\,M%N/B9\7A>E6,,%Q]JF<]%53\H_E7YWQ)B^9JE'8_H
MGPQRCD;Q=366R?J?</[$7P*_X:!_;&\ Z-)#YNG6=Z=3O^,KY, \S!_WB /Q
MK]SP,"O@/_@B#\ 3IGASQ#\1[ZV*2ZHW]EZ:SKC]RA#2NOLS[1G_ &#7W[7R
M"1^UA1113 **** "BBB@#G_BMX@_X1;X;ZU?YPUO:2%?=B,#]37SC\.=.\C3
M8L]2 3[UZS^UQK?V+X=VU@I^?5+V.+C^ZN6/\A7 >$[+R[:,#T'X5WX96A<^
M9S6?/B5#LOS'_$.V\4R^"9%\&S:9!KK21B)K_P#U6S<-_P".*[!_".G^(5TZ
M;5=.L+Z[TXK-!)+"'^SS8Y>,G[ISFO!/VI5MO%/Q'\'^'-!UV;2OB;;&34="
M49:V4#AOM  .T,. 2*[;Q'\=]6_9V_9J_P"$G^(\>F2^)+1=DEG83!5NW+80
M)GN1R<5T2IR<8\N[^_\ X8XJ>)A&I4]JO=BM]XZ:_)Z[=59FS\=/"6M_$_7-
M(\(2^';+5_A_K\<B>(KJ2X,4UIM^:+9@@_?"],U\_2R^/O#_ (QTWX>?$;3]
M*N=+T:\;4M"UE=@C:!$V)!'D Y4,/?BOHKX9_'Z\\?\ Q(BT)_"&NZ7:R:)!
MJXU&YCQ!ND /DYZ;AG]#7SO_ ,%*?"MO\6?BWX<TMQ>/_8@B60QG;#&)6+.7
M;^'Y57GZUMA>;G5&:25OZ>^_0X\V4/J[QE*3;O:VUUI[NU[=5YWL]34\1WWB
M*\OIG\.ZAHTM@+9D4R-N:.<'DDCL*S+3X+:=XT\:Z5XOU&\35M3TZS\B)XV#
M6IDY^8 =<$FN6^'GP%\;6?C:*\76],TWPO:7DC0V-HQF6_MG&,L<X)(XYZ=J
M[OP7\1/"6@:KX@\,Z=%-IL7A!//O3*A$**W)(8]>M=,ERZ4W?T_4\.'OM.NK
M:]7U6NB^_>QYK\*-4F\%_&C6+7Q)XOE\.ZUK6L6MC*L5N9DUFT96WVX5?NKR
MOS8XK[C\%?#[2/A;X6MM"T.S%AI5CN$-N'+A,G)Y//6ODWX(_"/2/VLO%-]J
MS:?KFA7N@ZNNK:=XHA4B+4X"5'V=,\'&P\C..:^RYOG/'>N7'33:BM^J_(][
M(:#A3E)JZ^R];VZ[^?96>^NYY/X0T+Q/XWTGQ)8?$S2?#]W8OJ)_LVVC02Q2
MVHY4N#WS^->?_'OQMX[L?&NG>&_!?AZ%;3RTGGU2X_X]HH@<-$HQ@''X^E>\
M76J6]W<W,$5Q!)/;$":)'!:(GH&'45Y-\2O^$R_X6?I#Z=+IR^$$A?\ M))/
M]>TG\.W]/UJ:4KRNTO3H7C:7+248REONK7WZOM^1W/[)]C]K^*>L79 )M[!8
M\CL6<$_^@U]#UX9^QQ:&2^\37>/^6D4(/T!/]:]SKS<4_P!XSZ;)E;"Q?>_Y
MA1117.>H%%%% !1110 4444 %%%% #9$$J%6 96&"",@BOR<_:N_X-8O"_Q2
M^+&I^(OAI\0W\!:7K%P]U+H=YI']H6UD[G<PMW66-ECR3A&W;>@., ?K+16E
M.K.F[P9SXC"TJZM55S\3/^(27Q%_T7/1O_"4D_\ DJC_ (A)?$7_ $7/1O\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!^.?B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !112,X122< #))[4 <5\;/$3VFB1:5;MBZU9MAQU6(??/\ 3\:XF[LU
MM]-\A?E&W:,=JL76K'QEXMO=5/-NI^SVH/:->I_$\U1\122&TD\K[V.#7I4H
M<L5'J?(XNO[>K*INEHOZ\SQ_XAZ3;ZO<R6))+J=S#MBO&_'9TCPG++)+91 Q
MH5$L7WA^'K7O,OAMKG4,O,H>0GS&SVKQGXW^&;7[)<0_\M=Y*N!DFOO\DG%)
MTI.Y^$<<8>J^3%4HM69\]:E^TO:>$M4ELQ#<0#.[S93]\>U:NF>.GUJPM=9B
M6&VAU(E%BE8;V'3I7'>/?A79^,9'F-Q*MQ: AI",# [5P?ADV\M^LSZM<_VI
MHLI"0.N894'0@=J]*IB9TY>]L?$TZ6'J4IO6[W]3Z_\ #5AINBV%I/Y%OYNW
MYV*_I7 ?'O28=+@NKEE22TNFW2@IG:N.@KS.Z_;#?3+$6AM$F#?>=3_*NWTG
MQQIWBO08I;B8SHZ9,3MD#/:NM8FE6BXTV?/?4<1AYJK46A\IWEU,?$5Q+823
M0QAB(R@(& :U8M6U+Q_X@TVRN)3<2%Q$O&*]<\(:;_PFGQ3.@RV<4.FEV>&1
M8N/H35/]HSX)7?PD\16-[;1"Q,K"2WE3Y0Q'((]Z\^K2G"+J1=UV/JH8^G*K
M&C)6DUH8LW@K6QXIT^WL8)7E@?>&AC^:-0>2<=J^@?"GB'6=$@@2PEDU.69P
M#%.?E+'C@]JZ7]@34;'XJZWK+.DEUJ36L,$LDT?.1G<<].<_I7TZG[+.G+.K
M6]LL# 90A<?-ZUA+,:.$7O/<ZLKX=QV<3E#V5HPMJUHV^WH?-/Q$\87>A:9;
M6VJ(MI]H&&(&X*:YKPWJ2Z/KL<;+(MG,N'<C&&_O?C7OW[27PEL-&\*8N[-Y
M[D$8D!Y&*\=^'7@"Y\>>+GRLOV2"/Y4?@-773S*E7I.L]$B*O#&*R[$QP<=9
MRWMTUT/?OA-=J?AM T$BK']X@'.1[U[)^QQX;\^#7/$4@R;R?[) Q_N)]['_
M  (_I7S[X?\ "-W\/=!N5\QB9E\N&'L"> !7V=\(_""^!/AQI.F 8>"W4R\=
M7;YF_4FOS3,YKG?*]V?TKPM1DX0<TURKKWV.DHHHKR#[8**** "BBB@ HHHH
M Q_B#KP\+^!]6U D+]EM9'4G^]M./UQ7YCQZI]I?Q#J\G_+S=,H;/9 3_,U]
MW_MR>,AX2^ FH -A[UA$.>PRQ_D/SK\[?B/J)\)_!"67I)):M*?]Z0D_U%?B
MOB-B?;YC2PD?LI??)W_)(]_*X\M)S_K0R/@:?L_PYUO6Y/OZOJ,]P&/>-!L7
M\,[JK_L_J8? .OZV_P![5M3F<-ZI$-H/YDUKZSX=O?A]^S;9V_V:59+?2ED8
M;>2SJ9&./J35S0OA[<>&_P!GW0M/BFMOMMYI@GCB\T;F:7+\^_S"OB*M6#C.
M5_CFE\E_2/0BFFEV1S_[-UL9_#&N:NWWM7UB3:?5(AM'\ZP?^"ANN-H7[*CV
M2$B77;R*U [MN?G]*Z?P1X_\%_"'X7^&-%U?5Q::TR.MY!+^[,<S.Q(YZG&*
MY#]O:VL_BOJOPLT/PQ=C6(+S4/M<R1#+1+$,DL.PYKIP7O9Q"I--14F[M:6@
MO\D1/2@TM[?F<O\ $+2/[$^!/A?P_$-K7I@M]H[[F45]+^%=+$=U96H'"M'$
M !_= ']*\C\4> +KQ#\>OA_HKH(K9)S,[/\ *F(HRW7IUQ7T'\-?#T6K^,XH
M(;ZTFEMW+,HD')]O6N+.<4O80UU?-)_-V_0TH1]Y_)'SG^T?<?\ "9_\%$M'
ML!\\?AO14XS]UI"2?Y"O2_VI=<_X1#]B+QS= [9;VV-HG;)<A0*\H\%*_C;]
MN_XFZRP+1V-TEBC?W?+0 C\\UV'_  47U Z=^RMX?T<'#Z]KEM$5_O '>?Y5
MTSHIXO 83LJ=_P#TMD)_NZD_7_(W?V)_#']E?#CPS;8 Q&K'\JX71+C_ (2_
M]OWXA:C]Y=.\JR4^FQ?_ *]>X_LW:0-,TW2DQM%M:!C[<5X#^R5)_P )3\5/
MB-KI^;[=K5P$;U ?:/Y5A1J<]7&8A_RV_P# I?\  *:LH1_K1'?_ /!1#5_[
M!_8BO80<-J,L46,XSN<5)^P-H_V'PWI7'^JMMWZ5S/\ P5=U#[+\#O!^D*1O
MO]6M\KW*C)/]*]*_9 T[^S/!Y?&/)L<_I63]SAU/^><G^2'OBO1(_0#]DF[^
MV? W3',K3'S9P23RN)&X_"O2J\D_8EO6O/@#I^Y0 EQ,JGNPWDY/OS^E>MU_
M1W#;OE.&:_DC^2/EL5_&EZL****]HP"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH SO$GBNP\(VD,^H3B".XG2VBR"3)(YPJ
M@#N:C\(>-](\?Z7)>Z)J5GJEI%<2VCS6T@D19HG*2(2/XE8$$=B#7@W[>OQA
MMOAK:07=QDV_A'2;[Q5<+G^*&(I;CZM(Q KM/V%?A9)\&OV1? 6A7";-072H
M[W4,KAFN[C-Q.3[^;*]1S>_RE\ON\QZU1115D!1110 4444 %%%% !1110 5
MQ_QG\2/I/AE;&W8K>:L_V=".J+_&WX#^==@3@5X]K.LCQCXYN]0+@6=GFUM=
MQP" ?F8?4_RK>A#FEKT/-S3$>RH\L=Y:?YBV]JFE:6D2\*BA0*Q=5NW<,L8R
MQK8O[V*1\"6(]N'%,AL$F]#GKBNWF2E=G@QHR<+1=CD]*\/E[J0M'N$OWO:N
M3^*?P4EFMVOK.*&=44GRY&Q7M&FZ<FG0L=H;=TS7&_&2ZN=/\*S7$4<GEQ F
M0(,D#Z5Z>"QU55TJ;L?/YWD>%G@9_6(\VC;2W^1^7?[4'B#5/!WBB^L)X&L#
M>DON1<*ZYQQ74?L\_L'WNL6MKXH\6WRZ;I5Y&)4MXY<2S*1E=Q/0$<U;_;"L
M;GXP>-;&2SMH(;60?94N990$!'.:\Y^(WC#Q;?:)9Z1_PE%U<66B((HXTDP@
M*C'!'7\:^TQ"]YN2O8_FI5*E6A&GAVJ=[WZM+_,\Z^.7AFQ\'?%[6--L)/.L
M()\1$'/![9J30;ZZTYLPB\AM1SN=#MQ]>E7O"'@6_P#$OC.RNM2C:6&2XC25
MSW4D _I7Z-^-O#_AKP'\$KUI]/L$TNTL,,AB7##;_B:QP^&;?.W8US/-XX54
MZ'+SMZ?E^)\@_LW^/)M.\5V=GY]C_I4X>-YR, _W?QKZI_:,TKP=XX^%MS#X
MBN--\VVA,D02=?,CD Z+SGK7YRK:V]SJ-_<HQ6UAE9HHXW*[1G@ UL_!SPC=
M?$[Q]^ZBN[N*-U+*TC.5!/<UTRQ/+%<VHWP\\7BHSIS<6NR_X)^B7_!+;X3V
M?PW^$>JZS-Y8OM4NOE+'++$OW<CMFOJ^+55U!!Y;*>/QKXZ_9UL]<\ V<UE/
M,KZ;(?DC+;6C]J^FOA/?MKOAT7+J\91R@#<YQZ'N*^+S;!RA)UY_:V/Z%X1S
MBC5@LOPV]/27?1ZO[R7QYX&M/%]D\-U\^>5)_AK@(/ADG@*9IK>)&4\$CL*]
M6OGRY]JY/Q??B&T<GT[UYE.O44>6^A]-B\'1E/VMO>[G,^#-&_X6-\9]#L"I
M:WMI/MMPI_NQ\@'ZG%?5E>&?L>>'3>7.O>(I5_U\HLK<D=47EO\ QXBO<Z\_
M$2O.Q]!E-+EH<[WD%%%%8'J!1110 4444 %%%% 'R)_P5+\8O;>'+/3H@SBW
M@>YD"]"3Q@_@/UKX6\8?M+:I\0?#FF3WGPWU-_!^KHUM'=VRJR(T1V'/.X'(
MXXK[7_X*R^"?%^G^%+/Q1X6U;0HXD80W6GZL?)BG('&V4 X)'&T\<5^>GC&?
MQ%J6G6]W?>(!\/M$LX&G\RQE6[@GN"P.T(.%!YSZ]J_!N(\-*6<5I8A+FYKK
M5Z1Y5;1:W=DUH^I]'A9)4(J.UC1G^+'Q,\8:]+JUGJFE1Z!:SBP2SU<^1>3H
MJCHIX '3D<UR'Q)TZ/0YFUOQ;XPU+PA>-<#^S[737$MF(0!N))Z@GM_#47B>
M3PUXSTU=<\1:J?',<D"V5E:Z6[6\QG+##,H^9FXP/2G:%J5E8W&FS>'_  [K
M5UX@ESIMOIOB.%C#;[^&?+C"$ =3U%<E*C&.L(V6VD4MNEW^+<58MMO=_P!?
MUYCO$2^&-=E%[=VO_"VM1UNW6"PMX4Q+;1H-Q.P''/9R:O\ A3Q1)I-I!/X-
M\-:KX8\5ZIMT[;J2DPQIDEMSDD1XQV/.*7R_&FDZ3=JWAKP_HNJQN8!J^CW*
MLMK&Q 9R!AF7'5<50L;JY6?5?#:_%:TUCSA\Z7]MY,RJ?O;<XP>NUNW%5;FA
MO=+3=M6](KEMMV;U%=)^?]=]3I1<?$[6?"]]I&K2Z!JTL<FV._T^?Y[0$X,J
M+G=N49R >:YCP?<>%O#?Q+DMM$^+6L1:C)'D1W@#A9!UD1<\<]1G\*PM*O?
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M)Y#,1\K'J*J^!_C'XGTSX;ZCH^IP_P!M:=?0^5"]TN38YZ[3Z'TKT/\ 8?\
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MFM[X2J!N99#\K;ASMQV-?,7B2XU#0M!8VZ>&O#6E6LBS!=;03->RO]_;*.<
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MCT'C*25M_P"O,^'?V;?V/=7^.NK1_P#".VB>&;N>P=(!KB?;K92HR=@R2F>
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MM//-5/VA;[QC\/=!U?P9JGC:7Q):^,O"FIW8NA:1PW>ESV\:N9%V_+]G<$J
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M=Y)I6RSL?<X'8 5U(&T8' '04M &7XUUE?#WA'4KULXMK:23@\Y"G'ZUY_\
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MVQ]$&D>(?[!NFN5V&P\16:(P_P!UG&W\FKAEE_+K1E;UU-/:7^(_E=U'P9)
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MM/[S^JZN1^,?QGTCX*>&5O\ 4O/N;J[D%MIVG6J>9=ZI<'[L,*=68]ST Y)
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MUO<#U20?*PK]ZJR?&G@31OB-H,VEZ[I=EJVGS@J\%U")$/X'H?<4 ?SMWOQ
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MB 0)R?WTWT[*/U]Z^:?$_C'Q+\6_$-K=WCO%9P2$MYLA>>93_#_L@^]=+;:
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M 0%BQ"@>I-?N7^PI\'1\"_V4_!V@M'Y=V+%+N\&.?.E_>/GZ;L?A7S1\,_\
M@AYI'AKQKIVHZYXRN=4LM/N$N#:0V:QBXV,&V,Q)PIQSBOO&.,11A5&%48 '
M84 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$V?V9\=;].VJ:
M3'.?=HY"G\C6SXE\00>%M!NM0N/]5;(6VCJY[*/<G _&LCXCC^S?B1X1O@,"
M:6>QD/J'CRH_[Z6H-2@_X6!\1;?2Q\^EZ 5N[WTEN/\ EE'^'WC^%=::Y4V>
M15B_:.*W;_,V/A3X9GT307O+\?\ $VUB0WEV?[I;[J?15P/SKJ***Y9-MW9Z
ME."A%170****184444 %%%% !1110 4444 %%%% '.?%CQ6_@OP!J-]"5%PL
M9C@+=%D;A2?H3G\*^);CX7>'M2U$W.LR76KSS,7<S2%4=CR<*#7UC^UJ3_PI
MFYP^S-U ,_\  Q7QW?Z];:;*YG?S".Y? 6O&S*7O)/8^LX>I^XYK=L[;0M+\
M,:'#BPTG3K81\*5@7/Y]:M7GC);<'RT"1'H<8_*O+[CXB6DC8@NK>/'9<L?P
MQ34\1?VC+''Y6I7@?[H1"B@^^<5Y,K,^XHTVE[QV\GC'RO,8R(G8]!^-<_JG
MQ1MR9%\TDYP2AW9_GS45MX6N9(/,DM;:VX.[<WFM_P#KKEOB7XTT_P"&>A2S
M22'S$4D;<* /H.]<=5V/3I&)\0?C0^F*L5I;7<]S<R>7$@&-Y_'''O6SX6^&
M3W&EQ:OXC:34)MN]8@O^CP#TST9JI?L]_!*[\?:D/%_B6(,LJEK"SD&4B4_Q
MOZGT%>N^(+:"S8"4^<RC" C"I]%' K.E0;=Y#GBW)\D3C5U&]U...'3]/BL+
M+;S-,,EOHHQ_,5+'97>G0)<,9)(AQ*2/O'N5Z\>V:9X@UB2(OV';'85UGP[N
MK?Q#X7-FW,D>6.XC#>P]^M>FH)JQQ8B4X^\MBC:7\DD*R9^5AD+[5;T\?NV8
MGN#G'2L"UA-AJ=U;1ELYR@)_A[5;M[UX6$4A[_-CI7'4.B+4E<W_ +?Y* ,>
M!U)]*H?\)"))94C?[IR,=:R-3U-';;DX[US<^O+I=WM#YB)X)[&N21>CW/0+
MK6X599T9@V01]*BU#QJWEL&<[O4&O/;SQT"H21@J(>QZBN=\4?$A8K=W,JHA
MR<GC%<VM[FW+H>C2>.'LXCND.3R.:YOQ9\:+?P_8237$\:)"-SN[8'TKYN^(
M'[7T5OJ_]AZ%;WWB;7Y#B/3=/'F2+[R-]V)?=C6W\,_V.O%G[0&I6^J?$V?R
M]-5Q+%H-E*PMXSV:5^#*1Z<*/0UG.I?2.IT0P]ES5-$=3IO[0.L?$[4Y+;P9
MI$VMW!.UKUSY5C;G_?\ XS[*#7J?@']F#Q#XK\F]\2^)[ER?O6=@HMX8_P >
M7)]R:[WP%\,+#X?6<5I:00IL4)%LPJA?3 XKK;&Y;3;KS,,J'ATSR/<^AK-8
M64M:CN93K1AI Y6X_8T\-ZO8&$2ZO;SXRLZ7C/M/NK9!KW;]ACX&Z;\%_#VI
M@WL=_KM[+B63;M*P+]P >_4^^/2LKP_<?:(!C^+GGO3H-9N_#VO17-LYCDC.
MX'T^OL:]++Z\<+54[71\SFU"ICJ4L/S6Z^OJ?1]%8_@?Q;%XRT&.Z3"R#Y)D
M'\#CK^'I6Q7W].<9Q4X[,_*JM*=*;IS5F@HHHJS,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH XGX]V5^_@B._TNSDU#4=%O(;Z"VC&6F*G&T?@Q_*M;X:
M^$F\(^&E2=O,U"[<W5Y*>KROR?P'0?2N@HJ^=\O*9>R7M/:=0HHHJ#4****
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M2O=:Z/=>H4445[!\^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img002_v15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %@ G # 2(  A$! Q$!_\0
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M;!)[.N?VI?VD?'7[*#?&>R\4^&=$T#0)4LI+"#34,^JE9%BDNG#*RXWN!L!
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M2_\ !0[5?B!?V^FR> ]6\)2:!.?M0-RSR6_E,/)QG;UYS7FO[&'_  3L\:?
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M$OXH_L3>.O"^K^'_ (=:'XT\374+V=CX?CCLK&.".2)@LTBKAG&V3DYZ@9K
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MIO\ A2_C#_H5O$'_ ( R?X4?\*7\8?\ 0K>(/_ &3_"@/J];^5_<<S173?\
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MA6\0?^ ,G^% ?5ZW\K^XYFBNF_X4OXP_Z%;Q!_X R?X4?\*7\8?]"MX@_P#
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M%FV@U]I ;161+X&TF;QI:^(&T^V;6K.SDT^"[*_O(;>1T>2-?0,T:$^NP>E
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M?XB@UR]BU";5[9;J>VTV%I#(D 8E6;8W[N3#8QWR!] :Q^SWX#\1:U:ZC?\
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MIX/^'GA6]T/0O"WA_1M%U3S/MEC9V$4,%WO7:_F(J@/E>#G/''2@#YL\/_\
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M>[8KZ&\5?L_^!?'6M7^I:UX0\-ZMJ&J6Z6EY<W6G132W$2%65&9E)(!52/\
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M@5_M\/\ ST_0T?;X?^>GZ&K%%&H%?[?#_P ]/T-']IPMG$@.#@X[58JCI/\
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M#NM>$5I91:2\@N9)+H1')^154*F"T@YP,T ?7U%?%.H?\%=VU;PWI_B;PYX
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MU% $/V*'_GC%_P!\"C[%#_SQB_[X%344 4;^RA%S:?NHO]=_<']QZL?8H?\
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M ,%(M!^#?[2'_"O[KPWK%Y]CNM-L]0U&*X@5H'OPS1/#;%O.N(D5"99(U(C
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M7_PX^*GQ*U+PGX?\5Z7JFLZ9$D[K!*&AN%;KY,OW)2F5WA"=NX9ZU\^CQO\
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M(NTH?BC[;S1G_.:^*H_^"B/QP)_Y-WO?PU:7_P"1JG3_ (*"_'"7_FW;4/\
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M_"OP#)X'LYK?4X[P^(I'NXY/M2JG,48CA4XDP^^0\8&:^T7^X?I2TC_</TH
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MPDVH6#:I%"+&8P&W4E6<S!?+&",8+9R5'<5TS#/B5?\ KU;_ -"%?%6L?\%
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MOO/O[.1UK%OM?LO"NDZSJ6I7$-EI^GF2YN;B1ML<,:1JS.Q[  $GZ5\\1?\
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M=5U+0_B$CZ[K-]#JHVM/JTPLX+1O^/>9N&L)>/*B:*,AMV17Z0_$S4?$6D>
M]4N/"NF:?K/B*& M865]=FTM[F7(PKRA7*#KSM-?G;\+?",>L?MU1ZEJVA^
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M^C]?D7_:JS]BOO\ G]B_\!__ +*@"]15'[%??\_L7_@/_P#94?8K[_G]B_\
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M65LD-SJD\$<$E_(!@RLD8"*6/.%&*T-2U2VTBU,UU<0VL((!DFD"*">G)XH
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MKS@F3C/?'6KUO_P27^#+1J9M-\2760"?.\2W[9_\BBOI#65_XE%U_P!<7_\
M034MLO[A/]T4?4L/_(ON'_K'F?\ S_G][/G2'_@D]\"81\W@^XF_ZZZS?/\
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M:N44 4_M-[_SZQ?]_P#_ .QH^TWO_/K%_P!__P#[&KE% &6DD[^((/.B6/\
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M_KU;_P!#%5_[3UK_ *!-K_X'_P#VNJ[3:T=3%Q_9=G\L1CV_;CW(.?\ 5^U
M'045C_VGK7_0)M?_  /_ /M=']IZU_T";7_P/_\ M= &Q16/_:>M?] FU_\
M _\ ^UT?VGK7_0)M?_ __P"UT ;%%8_]IZU_T";7_P #_P#[71_:>M?] FU_
M\#__ +70!;T'_D#V_P#N_P!:NU@Z?<:U8V4<7]EV;;!C/V\\_P#D.IO[3UK_
M *!-K_X'_P#VN@#8HK'_ +3UK_H$VO\ X'__ &NC^T]:_P"@3:_^!_\ ]KH
MV**Q_P"T]:_Z!-K_ .!__P!KH_M/6O\ H$VO_@?_ /:Z +U__P ?-G_UV_\
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MP3@$)R02.A- '62:Y90V\<S7=JL,S!(Y#*NV1CT .<$U)+J5O!?1V[30K<3
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M#GQ+XFO'U+7-4TD/<WDB!6O=KNB3$  9=%5C@<[J]MH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBOC7]M7]F[P;XX_;O^!,V
MI>'UO&\97NK0:Z?/G5;^.VTPM;B0*X&$8 CIR.] 'V):W4=Y'OBD21,E=R,&
M&0<$<>A&*FK\N_"W[07Q0\%?":ZL/ >N:;X'L/#_ (8\;^,YK:U\-03I?SZ=
MKLD44&''R"1&P[#+-R0,G-=%XN_;>^-OPST+7M/U#Q-#JD:ZEX5N+CQ$-&MK
M >'K+5;2>>=!N5X51)(DC6697VB3YLG% 'Z+ZGJEOHFFS7EY<0VMK;(99IIG
M$<<2@9+,QX  ZDTCZO:QFVW7-NOVP[;?,@'G'&["<_-P">.PKXA^/OQ'\4?%
M/_@D[IM_XPU;0]8N/$&OZ9IFNZGH\JR6=WIKZY% \FY%5/FA #[ $)+X^4UY
M9\5?VC/$?C3]M#PY;Z]XFE\SX?\ Q*UB"R\&V?AL&;1["UTN[%I?K* &F,RD
ME49MKEP%QM- 'Z>U6OKZ'2K&:YN9HK>WMT:6661PJ1(HR68G@  9)-?F;\.?
M^"D_Q0_X1'Q5XT7Q%<^*/!OP]F\/>(-7CN--L/M]UI5Z)XKZ#-L@B22%A%)M
M!+Q['5W;!KL_A+^U-\2/%/QO^'GA'XG^)+35-*^)>A^?>>'=+L+/SK 7<%U<
M&/48FC\T6PMC"BSPN &0K(I+&@#] +2\BO[6.:WDCFAF42)(C!ED4C(((X((
M[U8KY_\ ^"6>JW>L_P#!/KX62WDLMP\6C_9H9)#EFMXI9(X/P\I(\>V*^@*
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MXRZ,WW@"",8(!^BU>=V?[*'PQT[3?$%G;_#[P?;VWBPG^VHH](@5=4^??^^
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M&21&(!]Q?$OX6Z#\8OA[JGA3Q)IL.I^']:MS:WEFY9%EC.#@%2&4@@$%2""
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M'&3(Y<+@,[,)D I:K\?_ -I*X^&?@/4/%GCKQ#HL;7OP_P#%>MZMH_@5K?\
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M0_AWX=D\1:QJ'B*%Y;+58-*D_LERFGV^HM&9VQAQ:W=J_*X_TA%SNW 5(/\
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MJ&BW'B+2=8M6U'2);._N=+NI[^:QL-?36OLET)KR2V8-(FS,$$(W$R%225H
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MP>$(WA\1_;/'>I6=T))6C,JA=*\JX_<LI&]9B=I(;TK]KKQ'^T#/^TCJ%KX
M\5:]X;\(Z?<>#=/AM[3PG:ZE%=C5-3N[75;HSS1LV;2V6&8!3LC8*T@9&*D
MK_LS?\$K=2_9>_;0N/B#H'C*VA\+2(+5M/\ LCR7U]81Z7;6%M82R.S*J0M:
MQ3>='AY&158 9)[_ ,0?\$MOAKXBL?'=BUUXJM=%^(%Y)J5]I=OJ"+:VMY)>
MQ7\EQ#F,N"US$)#&[/%\\B^7M8K7SUH'[1W[4L_Q>^&/A_4+NXTJPD$4%QJ.
MI^%9UA\52Q^(KRSNEN1;6,PMY#ID%M,FV2TC#W7F[FB!1.1UC]MO]I#4+;XG
MWFGP_$C2-&TB73[S3H=4\&_\3EW%]J45WI-H\6F/;I/)!#9M&98[N-2RAK@&
M?<@!]:>!_P#@EY\._AA+X?D\/:MX\T>71;>\LKI[377C_P"$@MKJ_GU&2"^
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MOX/>:\\&+-JUQ%>-";BQ2UEMA9+%M<RW15@LI<I)MH ^TC^QCX(;]EV3X/\
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MX)O#>CZ3?>,;KP:ECIEWK %Z8==TZ6\E=4V R>1Y3J"HPX5B=N"*Z/1/V_\
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MSRV:AU3X;> -<N[&:]T'P?=SZ7?'5+*2>QMI'M+L@ W$9*Y27"K\ZX;@<\4
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MPVL-:A\(Z3X+\1:E;Z]!H6FL=;>>WO9W\-Q:R(6^SH[+)+-)]D1C^[4_.[
MK75?MY?M+_$3X)?%#X0Z],R0^&M!\#^*/'WBKP_I&J2PSZU<Z596DHM$D6-A
M+"&N& #$*V=S9VJ#Z?\ %;_@G'\#_BMX;T/3AHNG^%5\/P26=K<>&Y8M+F:V
ME@>WE@D,:[9$:.1Q\P)4L2I4DD^P^%/!/@_P3X;\/Z1IUGHUO8>%M-72-)1B
MLK6-HL:1>2CN2^TI'&#S\VP9SB@#Y'\#?\%+/B3X_P#C)X?^&^F^&_A7JGB?
M4O$J:9=ZUIOB2XNM %D='&K.T$BP>9)<I&#&8B O[R&0L%?:*?[<?[5WQ>\$
M_&CXI>%/#6L>#;'3_#]KX O?#L+7<MKJ<T^I>(OL=PLS!&S;2+$\4A4,41DV
M@L[8^O\ P?\ #OP#\/+.QM= T'PCH=MILLLUI#I]E;6R6DDHVRO&J* C.#AB
M,%AUS5C6O!_@SQ'XDCUC4M+\,7VL0P+:I?W%M!+<I"LJS+&)&!8()420+G =
M%;J : /BV^_X*Z^/H/'?A_PA9_"W3=;\46]QJ</B.*QU<K:R_8?$,FBR_899
ME0?\LFN,S8VAHXR,OO'5_M:_MF^*?V=?VXGT+2[O3;BTU_PQX=T[3K/7=0-E
MHNF7]]JNJ1-?7,BJS@>7;+& /]8_E("N[-?3>O\ PQ^'OBJZT^;4_#O@W49=
M*O9-2LGNK"VF:SNI'\R2>,LI*2LX#%UPQ;DG-7/%WA#P9X_MKZ'7=+\,:U#J
M5LEG>1ZA;07*W4".9%BD#@AT#DL%.0&).,T ?!VK?\%W;KP%8>%[KQ-X"TZ/
M3]9$.IWM_INJO=6MKHEK?ZA8:WJ\;>4#+;VLMI;2QX&9(=0A/!'/K'BS_@I/
MXJ\/_ GP+JEQ\._^$;\6>.[O1+*&Z\1W+67A?3WU-&F3?>A2[M%&NQD$:DS.
MB C.:^E;[P+X'U/38K&XT?PK<6=OITFD102VEN\4=E($#VJJ1@0L(X\QCY3L
M7(X%7/%6C>%_'GA6;0]<M- UC1;I52;3[Z*&XM9E4AE#1."I *@@$<$#TH _
M/+]F_P#X*S>,M&^#WA'^V%\'^*9K6'3K_7[JZ\0M_:&O)J_B74-,@31E6';=
M);+;@EFV[U\M %)+5M>(_P#@L]XXTFRBT:S^'>@ZE\0I];U2SDT.#4I&@TZ&
MTLDO(87NL>3/+=1R(T4T+&(1[W8 QLE?;T?PM^'D.IZ'>KX;\&+>>&0XT:<6
M%L)=)#DE_L[;<P[B3G9C.>:IS_ ?X5W/A"3P_)X-^'\F@S7IU*336TFS-H]T
M1@W!BV;#+C^/&[WH Z+X>>/K7X@Z##.GV>WU*&*!M3TU;N*XGTB>6".?[/-Y
M9(#A)$/N&5AD$&NBK#TJ+0=!N;N:Q71[.;4)%ENGA$<;7+K&L:LY&"Q$:(@)
MSA44= *T/^$@L/\ G]M?^_Z_XT 7**I_\)!8?\_MK_W_ %_QH_X2"P_Y_;7_
M +_K_C0!<HJG_P )!8?\_MK_ -_U_P :/^$@L/\ G]M?^_Z_XT 7**I_\)!8
M?\_MK_W_ %_QH_X2"P_Y_;7_ +_K_C0!<HJG_P )!8?\_MK_ -_U_P :/^$@
ML/\ G]M?^_Z_XT 7**I_\)!8?\_MK_W_ %_QH_X2"P_Y_;7_ +_K_C0!<HJG
M_P )!8?\_MK_ -_U_P :/^$@L/\ G]M?^_Z_XT 7**I_\)!8?\_MK_W_ %_Q
MH_X2"P_Y_;7_ +_K_C0!<HJG_P )!8?\_MK_ -_U_P :/^$@L/\ G]M?^_Z_
MXT 7**I_\)!8?\_MK_W_ %_QH_X2"P_Y_;7_ +_K_C0!<HJG_P )!8?\_MK_
M -_U_P :/^$@L/\ G]M?^_Z_XT 7**I_\)!8?\_MK_W_ %_QH_X2"P_Y_;7_
M +_K_C0!<HJG_P )!8?\_MK_ -_U_P :/^$@L/\ G]M?^_Z_XT 7**I_\)!8
M?\_MK_W_ %_QH_X2"P_Y_;7_ +_K_C0!<HJG_P )!8?\_MK_ -_U_P :/^$@
ML/\ G]M?^_Z_XT 7**I_\)!8?\_MK_W_ %_QH_X2"P_Y_;7_ +_K_C0!<HJG
@_P )!8?\_MK_ -_U_P :/^$@L/\ G]M?^_Z_XT ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img003_v15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img003_v15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %/ G # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[0HHKS_\
M:B^/=I^S+\"M>\9W5O\ ;&TR-4M+4MM%U<R,$BC)[*6.2?[H-:I-NR/S,] H
MKX-^%'@K]JG]J7X>P_$2V^*UIX2BU@-<:3HZQF&&:($A3M5&"(Q!QOW$CD]:
M^F=?^/=I^RE^SWH&K?&'Q';-KOV=(+V6SMPSZA>8W.D$2 ;MHZD # R<9K65
M&SLG=C/6:*\*_9]_X*-_"W]I+QDGAW0]2U&QUR<$VUIJEI]F-Y@9(C;+*6QS
MMR"0#@&K'Q<_X*%?"_X&?$36O"WB;5-2L=7T*UCNYD6P:1)Q($9(XF!^>0AP
M=O'0\\5/LIWY;:@>VT5\TZ)_P5L^"NL>$]1U1]7UBPDTYD7^S[G3F%Y=EB0/
M)525?D<_,-O>N_\ V8/VT/ G[73:A#X1N[X7^EA'N;*_MOL\Z(QVK(.2K+GC
M(/!QGK0Z4TKM >KT5\W^)_\ @JW\'/":ZPESJ6N&^T74'TV6Q33&^T32(6#M
M&"=IC4H06)'4>M>H_ []ISP=^T3\-;GQ5X6OY[O3; NMY%);LEU9NB[RKQ#+
M9V\C&=W;-)TII7: [^BOEN'_ (+#?!B;5DA\_P 5I8O)Y8U)]&86H/J?FWX]
M?ES[5ZW\;OVLO!'[/OA#P[K_ (AU"X.C>*;A+?3KNR@-S')O3S%D8@C$>PYW
M4W1FG9H#TFBOF[2?^"L'P8UGXBQ>'8M9U5?/N1:1:G)I[)I[N6V@^9G<$)_C
M*X_"O0XOVN_!K?M*/\)I9-6M?&*H9$CGLBEK.OE><#'+G#93)''.".U#I36Z
M ].HKS'4?VN_!FG?M(VWPH\W5;GQC<HLGE6]D9+:!6B,O[R7.%P@R>.,CUJ;
M]L3QAJGP^_94^(&N:)>S:;J^E:-+<6=W#CS+>0%<,N01GGN*GD=TGU ](I4C
M:3[JDXY.!TK\T?#OQ3_:5T_]D]/CA;?%9=1T*UN&BN-*OH(Y)%59_(W$&/8X
M+$<!@<'CD5Z7^TM^T#IOQM_9=^"OC'7?''BOX9W&O7KRR1^';22Y6\GB(CD4
M[9$*@,NY"Q8?.<@XK?ZLT[7\@L?<5%>4?&[]M;X>_LY_$#2_#?C#5+S3+W5;
M$W\5P;1I+98EWC+NO1B4( QR2/6L3]GK_@HE\,?VF/';>&O#U]JEOK)1Y+>#
M4K(VWVU4&6\LY(+ <[3@X!..*Q]E.W-;0#W*A06.!R3V%>(?M ?\%"_AK^SA
MXT/AS6;S5=2U^-!)/8Z18F[DM%(W#S#D*IV\[<YP02!47BG]ICPO^T3^QA\0
M_$W@;69IX[30[Z.3 :VN]/F$#, Z_>1L8((.#U!I^REHVM&![L87$FW:V[^[
MCFFD;3@\&O@+X,>+SJ?_  2 U&^\1^-_%/A[?KDL+ZW9^;?7T?\ I,86/&]7
M*,?E.'& ?PKZ \/_ +4_@K]F[]E7X7ZMXC\1>(=9TGQ!:P6%CK-U9,UU>MM+
M>;<+N)C&!R23@ 9)JY4&M%KK8#WVBOF[2?\ @K!\&-9^(L7AV+6=57S[D6D6
MIR:>R:>[EMH/F9W!"?XRN/PKT[]HO]J7P5^RMX<MM2\8ZF]K]OD:*SM+:(SW
M5XR\ML0?PC(RQ( R.>:CV4TTFMP/0Z*\;_9S_;P^'?[4'B*YT7P]>:E9Z]:Q
M&=M-U6S-K<21C[S(,D-C() .0#G&*]DJ)1<7:0@HHHI %%%% !1110 4444
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MD@C^*$ X(R54\5](:W_P39^!_B#7WU&?X?:8L\KF1XX+B>&!F)R?W:.%'T
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MK&GRZI:6OV=RDEO&2'8R8V@C:>"<FNK,3 #Y6YZ<=:_._P"#GB#PM\-/VQ/
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MIOQ=M=!TW5(M5:]E@M9HVQ'YY -Q&#\R[AANN,&E##RDK@?IH(7+8VMGKC%
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MI@N9O"T5LI)LY(Y98A->DX)WLB@9V@T?5Y!8^R:='$TOW59OH,U\=>'?CO\
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MY2#)$_\ >1BJ\'T&*\F_X;!\3_\ /GHW_?I__BJ/^&P?$_\ SYZ-_P!^G_\
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MX;X\0_\ 0 T/_OY-_C1_PWQXA_Z &A_]_)O\:\)HHY4'M)=SW;_AOGQ#_P!
M#0_^_DW^-'_#?/B'_H :'_W\F_QKWG_@AQ\._@]XHOOCCXA^-OA/2_%7A#P5
MX7L]0D-Y!YITU'NFCEG3D%2J')(.<)Q76_';_@FGHO[('[(W[5=OK.C:?KFH
M>%O$_AFX\#>*)8P\TNBWUP-KQ2 X^9-T<F,@LC>U8NI!2Y&NQUQH594U43TU
M_"_YV9\L_P##?/B$_P#,!T/_ +^3?XT?\-\^(?\ H :'_P!_)O\ &OU2_;?_
M .">WPB\*?#?XT-KWP+^'_PT^'/ACX?)K'A/XAZ?J"VFIWFO& N+18 Y+C>
M,,N&SMP2V1XU^WS_ ,$R?!/Q&_8N_9\NOA)X3TK0?B'<GPK8^*1IMIMEO8]=
MMECBNYB#SMN8V.3_ 'GK..(INVAM4P-:-_>O8^"8/VY=>@U>YO!H>BE[F..-
ME\R7"A-V,<_[1JS_ ,-\^(?^@!H?_?R;_&OLW_@LW^P+X0W?!'1_V:?AD^JW
MFHVFNPWX\-::UQ>:L-.N+>T>XE"9+A9 _P _K)[URO\ P1P_9P^"7BOXB>-/
MA_\ %?X>^(]<^,]CI>L2SZ9K]L(=*\,P6D2%6\K(=[MW?!WC]WL.,9R;]K!P
MY[&7U6K&M[&_SZ:Z_J?+G_#?/B'_ * &A_\ ?R;_ !H_X;Y\0_\ 0 T/_OY-
M_C7T9_P0L^$'[/OQS\1Z[X>\?>$]6\;_ !*N]'U2]M8-1C7^P='LK:!&6=0&
MW2W+R.5^8?(%R,9R?2_^"4/['?@SXA?L2^!_%EA\%/"'QR\1>+/B!)H'CN;6
M]1$+^"]&!*B:)6==C; LFX#<3)CGC!.K&-[K8*6&J5%%J6]_PMY>9\4?\-\>
M(?\ H :'_P!_)O\ &C_AOCQ#_P! #0_^_DW^-97_  4$^!.C_LQ?MO?%'X?^
M'GG?0?"VO2VFGB:3S)(X&5)4C9NK%!($R>3MYYKQZMDHM71RRE.,G%O8]V_X
M;X\0_P#0 T/_ +^3?XT?\-\>(?\ H :'_P!_)O\ &O":*?*B?:2[GNW_  WQ
MXA_Z &A_]_)O\:/^&^/$/_0 T/\ [^3?XUX311RH/:2[GNW_  WQXA_Z &A_
M]_)O\:='^WSKX<;_  _HI7N!+*#_ #KP>BCE0>TEW/L3X._M<:'\3]2BTV\@
M;0]5F.V))9 \%PW]U7XPWH".>Q->LCAJ_.,,58$$@@Y!!P0?45]P_LU_$*?X
ME_"+3;^[<R7T!:SN7/61X^-Q]RI4GWS42C;8WI5')V9T7@?_ )!$_P#U_77_
M *.>MBL?P-_R!)?^OVZ_]'/6Q4/<JE\"] HHHH+"BBB@ HHHH **** "BBB@
M ILW^I?_ '3_ "IU-E_U+_[I_E0!E?#[_D1-'_Z\X_Y5KUC_  \.? >C_P#7
MI'_*MBF]R*7P1]$%%%.B"M,@<E4+ ,P&=HSR:18VC.*]Y^)?[ ?B/2O#,GB?
MX?:IIOQ5\&@;C?Z"V^[M!R<3VN2ZD <[<X[@5[!_P3-_8<\(?%GP;'\0O%T6
MHZ]]DUMM+AT*"%6MX2JJ#)=JW++\^=O   //;*5:*CS'5#"5)3Y+'Q-17OVJ
MV_[.-A^T'I!A_P"%C-X"6TG?5[2X4)>6]ZI/EPC@/Y9Q\V&SEEPP&ZO2_B#\
M#OA%\??V*O$/Q*^'G@_5_A_J7AK5(]-MHKN]>>+6&:6&/:=SL,GSARO(9<<B
MAU4K73%'#.2=I+0^-J*_0Y?V/O@/X-^,7AOX$ZOX=UJ_\::_H;7TWBE+]T,%
MP$=MJINVC/E.0-A &T'.2:X;]F+]DGP-H7P8^+^J^//!>I>.M:^&_B.;2H[7
M3+B:.XNTC$:XC2-@"26+<@\?2I^L1M<T^HSO:Z_RL?%5%?6/[=/[+?@#X=?L
M]^"/B'X3T?Q!X(OO$]V;>;PUK4S-<HFQVW[')92I09YP5E7@&ODZM(34E='/
M5I.G+ED?8/P5_P"21>'/^O"/^M=/7,?!7_DD7AS_ *\(_P"M=/7D3^)GD3^)
MA1114DA1110 4444 %%%% '*_'+_ )(SXH_[!LO\J^*:^UOCE_R1GQ1_V#9?
MY5\4T'S^<?Q(^@C_ ':^O/VE/^2#7G_;K_Z&E?(;_=KZ\_:4_P"2#7G_ &Z_
M^AI6E+XT;Y#\<OE^IY3^SO\ #3PIXTT#Q]KGC&;Q FD>"=&BU1H]&>%+B<O<
MQP8S*"O&_...G6O2?&_[ J:,7LM(U*YOYKWQ)IVGZ??2PREX[*[TYKU3-:11
MN^]0,,5;C'W<'(\6^$?QR\3? R_U&Y\,WMO9R:M;"TNUGL8+N.>,.'"E)D9>
M& .<9XKH-%_;)^)F@Z[=:G#XJNI+^^U/^V+F:X@BG,]S]G:VRVY2"GDNR>7]
MS&..!7I2C.]TS[>$Z/*E):GK%G_P3C73;'Q)I&M^+=%TSQ#!J6AVVB:C*TXT
M^]CU%9MD;1B,R"5G15&0 N"2<5D^&/\ @F?XNU+0-'U+5M<T#18]2U"*UFMI
M#*\]O"]Y]D,P(38[;^1&#G!!.!G'':5^WA\4]%U>>^M_$5LD]S':Q,#I%FT:
M+:AQ;[$,6U#'YC;2H!''H*PA^U1X[/AJRTM]:CGCTVX%U9W4]A;RWUHXG^T#
MR[ED,JKYWS[0V,D\8.*GEJ]R^?#?RL],7_@G'K7B >,KSP[XM\.:GH_AC4[O
M2K6YF6>W;4KBV0O-%\R;8F3A"SD(TG"DCFO/OVB/V7=0_9VTSPU<:AK6D:TO
MB>U^UPMIT<S0(NU&^69D$4OW\9C8X*G('&9-5_;)^(.NKK2WFJ:9<Q:_,UU=
MPR:+9-$L[1^4T\2&+$4K)PTB89NI)/-8/Q.^/WBKXP:+I&FZ[?6LNG:$7:RM
M;6P@LX87? =]L2*"[;1ECR?QJHJI?5Z$3E0<7R)W.-QSGOTS1116QRA1110!
M\T?M]^'IEUOP[JP4FV>"2S9NRN&W@?B"?RKYZK[M^+_@6P^)-CIFC:DK&UO+
MB0%D.'B80N5=?<'FOE_XA_LF>+_ ]_)]EL9-=L,_N[FR7<Q7MNC^\I^F1[UK
M%Z')4BW)M?UH>945T/\ PJ3Q5_T+6N_^ ,G^%'_"I?%7_0M:[_X R?X55T9V
M9SU%=#_PJ7Q5_P!"UKO_ ( R?X4?\*E\5?\ 0M:[_P" ,G^%%T%F<]170_\
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MD3('I?\ #W_!9?XJ>'M2TVZA^#-XDR6L\&IR+J5ZSSM+965H7L_,C=; #[!
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M,_X49XQ_Z%O5/^_8_P :/^%&>,?^A;U3_OV/\:UA^U%XT/\ S$K?_P  X_\
M"C_AJ'QI_P!!*W_\ X_\*/WWD+]YY&3_ ,*,\8_]"WJG_?L?XT?\*,\8_P#0
MMZI_W['^-:W_  U#XT_Z"5O_ . <?^%'_#4/C3_H)6__ (!Q_P"%'[[R#]YY
M''>*/@UXKM/$OAJ.3P_J227-[*D2F,9D(MY&('/H"?PK;_X4;XQ'_,MZI_W[
M'^-5_%G[1WBZ^\4>%YI-0@,EE?2R0D6L8VL;:53VYX)K>_X:A\:?]!*W_P#
M./\ PIOVMEL1'VEWM_21E?\ "C_&7_0N:K_W['^-'_"C_&7_ $+FJ_\ ?L?X
MUJ_\-0^-/^@E;_\ @''_ (4O_#4/C4_\Q&W_ / ./_"E^^\B[U/(R?\ A1_C
M+_H7-5_[]C_&C_A1_C+_ *%S5?\ OV/\:UO^&H/&O_01M_\ P#C_ ,*/^&H/
M&O\ T$;?_P  X_\ "C]]Y!>IY&3_ ,*/\9?]"YJO_?L?XT?\*/\ &7_0N:K_
M -^Q_C6M_P -0>-?^@C;_P#@''_A1_PT_P"-O^@C!_X!Q_X4?OO(+U/(R?\
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M_O/(R?\ A1_C+_H7-5_[]C_&C_A1_C+_ *%S5?\ OV/\:U?^&H?&G_02M_\
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M'3.1BNG\<_M8?!F_\$?$:PT.RT6&36[W4)TCNM%F5=66>VC6%HMD9\MXY5;
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M/_%":3_U[+_6MBL;X=?\B'I/_7LO\S6PY(0X&3C@>M-[F=+^''T0M!.T<U]
MZM^P;<>._"*^(?A'XGTOXEV"0)+>:7 PM]:TY]H+J]NQ!<!B0"N"<< ]:]5_
MX)@_L7^%_B?!JOBSQ=I^I:MK'A3Q!;Z>OATA8A:G,9,UU%)@N@W,2AXVQ/\
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M9X=^).JZ1X*\.7Z6VG>#]0%TTFH%+;3VN3.0X2&9GO-RQ21GY5VELXKQ:/\
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M"C \D8[]*/WG\R%[*LE=_D:?_#(/B[^]H_\ X%-_\11_PR#XN_O:/_X%-_\
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M(H_X9!\7?WM'_P# IO\ XBN*_P"%A^)?^@YK7_@4_P#C1_PL/Q+_ -!S6O\
MP*?_ !HM5[H+3[G:_P##(/B[^]H__@4W_P 11_PR#XN_O:/_ .!3?_$5Q7_"
MP_$O_0<UK_P*?_&C_A8?B7_H.:U_X%/_ (T6J]T%I]SM?^&0?%W][1__  *;
M_P"(H_X9!\7?WM'_ / IO_B*XK_A8?B7_H.:U_X%/_C33\1_$:GG7=8'_;V_
M^-%JO=!:?<UKS]ECQ1%\6M.L"VE>?/H]S<+_ *2=NU)H5/.WKEA70_\ #(/B
M[^]H_P#X%-_\17EUY\0->/Q'T^;^VM5\U=-N(P_VI]P4R1$C.>G _*MK_A9'
MB+_H/:Q_X%O_ (TVJG=&<%.[UZ_HCM_^&0?%W][1_P#P*;_XBC_AD'Q=_>T?
M_P "F_\ B*XC_A9'B+_H/:Q_X%O_ (T?\+(\1?\ 0>UC_P "W_QI6J]T:6GW
M.W_X9!\7?WM'_P# IO\ XBC_ (9!\7?WM'_\"F_^(KB/^%D>(O\ H/:Q_P"!
M;_XT?\+(\1?]![6/_ M_\:+5>Z"T^YV__#(/B[^]H_\ X%-_\11_PR#XN_O:
M/_X%-_\ $5Q'_"R/$7_0>UC_ ,"W_P :/^%D>(O^@]K'_@6_^-%JO=!:?<[?
M_AD'Q=_>T?\ \"F_^(H_X9!\7?WM'_\  IO_ (BN(_X61XB_Z#VL?^!;_P"-
M'_"R/$7_ $'M8_\  M_\:+5>Z"T^YV__  R#XN_O:/\ ^!3?_$4?\,@^+O[V
MC_\ @4W_ ,17$?\ "R/$7_0>UC_P+?\ QH_X61XB_P"@]K'_ (%O_C1:KW06
MGW.W_P"&0?%W][1__ IO_B*?;_L?^+GG0;M'Y8#_ (^F_P#B*X7_ (61XB_Z
M#VL?^!;_ .-.A^)/B(3+_P 3[6/O#_E[?_&E:KW06GW-3X4?LK^*-=^'FFW<
M#:5Y4_FE=]RP/$TBGC;Z@UT/_#(/B[^]H_\ X%-_\17EWPZ\?Z]:>"-/CBUK
M58HU5\*MTX S(Y/&?4FMK_A9'B+_ *#VL?\ @6_^-5)5+[HSIJ?(M>B.W_X9
M!\7?WM'_ / IO_B*/^&0?%W][1__  *;_P"(KB/^%D>(O^@]K'_@6_\ C1_P
MLCQ%_P!![6/_  +?_&E:KW1I:?<[?_AD'Q=_>T?_ ,"F_P#B*/\ AD'Q=_>T
M?_P*;_XBN(_X61XB_P"@]K'_ (%O_C1_PLCQ%_T'M8_\"W_QHM5[H+3[G;_\
M,@^+O[VC_P#@4W_Q%'_#(/B[^]H__@4W_P 17$?\+(\1?]![6/\ P+?_ !H_
MX61XB_Z#VL?^!;_XT6J]T%I]SM_^&0?%W][1_P#P*;_XBC_AD'Q=_>T?_P "
MF_\ B*XC_A9'B+_H/:Q_X%O_ (T?\+(\1?\ 0>UC_P "W_QHM5[H+3[G;_\
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M (%O_C1:KW06GW.W_P"&0?%W][1__ IO_B*/^&0?%W][1_\ P*;_ .(KB/\
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M*UTOT/S%_;(^#/B[]BW]I+Q3\,]<\6RZQJ7A22*.XO;&ZG2WF\R".8%0YW#
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MW_H;5KUD> C_ ,49IW_7(_\ H1K7IO<SI?!'T04444BPHHHH **** "BBB@
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M-^ <L^_X'KW_  Q;K'_0;TS_ +\R4?\ #%NL?]!O3/\ OS)7D/VJY_Y[7/\
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M "BBB@ I)#B-O]TTM-F/[E_]T_RH R_ 7'@G2?\ KUC_ )5K5E>!./!.D_\
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MIK-UK>HVME,GV22%=*6>Y>V#7#D%4;?&^U,_/M.#6O-7-_:S[D__  QKH?\
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M6/\ OF+_  H_X8UT/_H,:Q_WS%_A3+;]N?P'=6US=JVN?V3:Z1!J[Z@=.?R
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MI+<:WYUE<M9KLTB=A>S+<QVKQVY Q,RS31*0O3S%/KA\]8/:S[E3_AC70_\
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M:-,E8XXU9V;. HS6#8_M<QWVF>.-87PW>GPWX+UJUTAM0,^W[:DK1"6Z52H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img004_v15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img004_v15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $$ G # 2(  A$! Q$!_\0
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M,B8#RCT$BD_H#0!V/]B0;OOW?_@5)_\ %4G]C6_]Z\_\"I/_ (JN</Q ^?\
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MJ]10!1_L&'^_=_\ @3)_\55;1])2YTV-Y);MG;.3]IDYY/O6O5'P[_R!H?\
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MY;)RHQ7MOC_QOIOPS\"ZSXCUB?[-I.@V,VH7LVW=Y<,2%W..^%4\5Y3^RO\
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MJ']J:?F.QSYC[<2-_<;_ &:WJHZG_P A;3?^NC_^BVH /,U/_GE8_P#?U_\
MXFCS-3_YY6/_ ']?_P")J]FB@"CYFI_\\K'_ +^O_P#$T>9J?_/*Q_[^O_\
M$U>HH H^9J?_ #RL?^_K_P#Q-'F:G_SRL?\ OZ__ ,35ZC- %'S-3_YY6/\
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M[5Y+^PW!I5K^RAX-CT63P7+I2VD@MW\(B8:*R^=)G[,)F:3;G.=Q)W;J]:H
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MFM>-?!,>GO:-?:)X9U_5X(':\:;R52UMV*DOY$[%8@"%C9B ,&OJ3]FGX1>
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MFD^IPPISDG**;2U;2VZ:]CM:;-_JF^AIV:;-_JF^AIBCN>(?\$X?^3*/ O\
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M !-7J* */_"0VO\ T\?^ TG_ ,31_P )#:_]/'_@-)_\35ZB@"C_ ,)#:_\
M3Q_X#2?_ !-'_"0VO_3Q_P" TG_Q-7J* */_  D-K_T\?^ TG_Q-'_"0VO\
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M@ #H !VJPO-=5&CR)MZR>[_KIV1X>89@\1)0@N6G'2,5LE^K>[?5^0ZJ:_\
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M&EA!P<'_ %J=Z -6BJ?]AV__ $]?^!,G_P 51_8=O_T]?^!,G_Q5 %RBJ?\
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M\UU:_NG^::=L$9+N2>>V!VKCJ?O*BI]%J_T7ZL][!VP6$EC'\<[QAY+:4O\
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M_P# F3_XJC^P[?\ Z>O_  )D_P#BJ +E%4_[#M_^GK_P)D_^*H_L.W_Z>O\
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M&GX.^%O'5UIDGANUUB"2^6VN;E)3!#L<J[.ORC* -[9YZ5Z)K2YTFZ_ZY/\
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M;KU+X2:IIO@6^M8=/O=0>;P]K$MW=Z!Y$R1QPWX=%3S90P.V/[AX.0,UL?\
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MP_'OM[[Q5<R74LS_ &@YW1VJLY 4??QGT8??>;X_PVO_ 'TW^%'^G8^[:_\
M?3?X5QU,'3G5YW\UT?K]Q[V$XBQ.'P?U2*3UO&37O1WV^]V[-MJS9%X5\)Z?
MX*T"TTO2K.VT_3K&)8+>VMHQ'%"BC 55' %2Z;_Q_7__ %V7_P!%I3B;[/W;
M7_OIO\*IV!O/ME]\MK_KAGEO^>:>U=FVB/#E)M\TM6S58AN/:OC_ .,GAO4/
M^">/QFN_BIX8M9[KX5^*KA3XXT6V3=_9,[':-4@0=!D_O5'7KW&WZU)OF_AM
M?^^F_P *K:MH[>(-,N+&]M;&ZM;J)H9H907CE1@0P8$8(()!'O6-:GSK1V:V
M?9_UN=V7X[ZM-J2YH25I1[K_ #6Z?1DOAGQ/I_C+P]9ZMI=W#?:;J$*7%M<0
M.'CFC8 JRD=00:T-V:^'9/$'CS_@EYXZ'AW2?">M^/\ X.^(KW[1I":<DMQ>
M>%&9BT]L%56+Q\[HPQ4'D;@<Y[Z7_@HQX@U"'_B2_ /XQ:DQ^Z9M*2S0_4NW
M'Y5C3Q<?AJ:26ZL_P[H]#$</5[JIA6ITY:Q?-%:=FFU9K9KOY'U&6R:\,^&G
M_*0+XH9_Z%;0O_1VH5R.G_M??'3Q"H:P_9KU>W5NAU'Q39VY_$;<UP5M\>OB
M7^SM\>?$'Q*^*7PGOM'\,^*=.LM+N;O0M076/[$6U>9EEG2,;MK>><D# V=\
MXK.IBH-QWLGJ[-+9^1U8')<1"G5C)PYI1M%*<&V^:+LDF[NR9]OGYC0*XOX4
M?&70_CAX5AUSPEK6BZ]I<WW9[2<N ?[K#&5;U5@"/2NH#7O]VU_[Z;_"NZ,E
M)7CL?+U*<Z<G":::W3T:^1>HJF&OCVM/^^V_PHS??W;7_OIO\*HDN51\._\
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MG,S0Z20D07R'WMYC8WOQ\PQ7LWQ^^*:? [X'>,/&<EN;Q/"NC7>JFW#;?/\
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M:S_8<L:R-X>U$VW]JG4 T4NW[7N^S"PRC1[MYGPX<)\E>O?\)[IG_/6X_P#
M67_XFC_A/=,_YZW'_@++_P#$T >>W>D?&Y_$,S6^N?#)-+.L:B\4;Z/>_:%T
MUK+;I\;,+C:;A+W+S.!L>'Y45'^>JND:)\?%MK7[=XB^$\DBQZ +DP:'?JK.
MC'^W"@-T<"5=OV0'/E'/F^;7IG_">Z9_SUN/_ 67_P")H_X3W3/^>MQ_X"R_
M_$T >6W>B?M!OH]T+?Q%\(5OFT[5UMW?0M0\I;UKD'2G<"ZR88[;*W"@AI),
M-&T:_+5S4-)^,3>/;)_[<^&_]B_V\LBQ'2+S[4=*_LTK+%O\_;]I-]EUDQL$
M'R%"_P ]>C?\)[IG_/6X_P# 67_XFJ5_XST^34K&19+@K&[EC]EEX!0C^[ZT
M ><6VB?M"GPQ;K-XC^$/]L?V/IB32)H.H"V;4EO2VHR*INMPMWL]J0H3O2;+
M.SI\E6+W1?CV9[O[-X@^$ZQM)KQM1+H=^Q1'"_V&'Q<C)B._[7C'F@KY7DX.
M?3/^$]TS_GK<?^ LO_Q-'_">Z9_SUN/_  %E_P#B: /.8-&^.B^(+5I/$'PM
M;3/[3TAKA%T6^$[6*VI&JHK?:=HFDN=K6[$%8X\JZR-\U9<F@_M'#P@R+XF^
M#/\ ;W]AO&)?^$?U'[)_:OV_<LNS[7N^S?8?D,>[?Y_S[]GR5ZU_PGNF?\];
MC_P%E_\ B:/^$]TS_GK<?^ LO_Q- 'GLFE?&T^(KAEUSX8KI1U?4W@C.CWOV
MA=-:S TZ-F^T;3<)>9>=P CPX5%1OGJKINB?'T"T^U^(?A.^$T#[5Y6AWZ[V
M0G^W-F;HX$HV_9,Y\KGS?.KTS_A/=,_YZW'_ ("R_P#Q-'_">Z9_SUN/_ 67
M_P")H \OU'1/V@#H=PMIXB^$B:D=-U98'ET*_:%;YKL'2W91= F&.TRMPH(:
M27#(T:_+6O#I7QB'BG=)K7PY;1?[;$GE+I-X+G^RO[/*F+=]HV_:?M^'W[=G
MD?)LW_/7<_\ ">Z9_P ];C_P%E_^)H_X3W3/^>MQ_P" LO\ \30!Y58Z)^T,
MN@P+<>(_@^VIC2M+2:2/0=0$#:@MX3J3JINMP@>SPL"$EHY?F=I%^2K.L:-\
M?)'NOL/B'X3QJ6\0?9O/T._8J' _L+?BY&?*^;[7C'G<>5Y->F?\)[IG_/6X
M_P# 67_XFC_A/=,_YZW'_@++_P#$T >>6^C?' :Y;M+KWPO.F_VII3W")HMZ
M)FL%M"-316^TX$\EUAH'(*QQ?*ZR-\U<]!H'[1PT5D?Q/\&3X@_X1X1F5?#V
MH_9?[4_M%F$NS[5N^S?8?D\O?O\ /^?=L^2O9/\ A/=,_P">MQ_X"R__ !-5
ME\::>-7:3S)]AA50?LLO7<?]F@#@KK1OCHWB6X:'7_A:NDG5-5>WC?1;XW"Z
M>UFHTQ&;[3M,\=WN:=P LD1"HL;?/45EHOQZ5;3[1X@^$[8_L#[5Y>B7XW[-
MW]N;,W)QYOR_9,Y\K!\WSLUZ7_PGNF?\];C_ ,!9?_B:/^$]TS_GK<?^ LO_
M ,30!Y7-HG[0I\.7"IXD^$']K'2=5CAD;0=0^SKJ+78.F2,OVK<8$M,K.@.Z
M27#(T:_+6O'I/QH'B_S&UOX:_P!@_P!N&3RAI%Y]K_LK[!M$6_[1M^T_;OGW
M[=GD?)LW_/7>_P#">Z9_SUN/_ 67_P")H_X3W3/^>MQ_X"R__$T >50:%^T-
M_85LLGB/X/\ ]I?V7I27$BZ#J'DM?K=$ZFZK]JR('M<+ A):.7+.TB_+5O4]
M%^/+Q7?V/Q#\*4<C7_LIFT2^8(7*_P!A[\7(SY0W?:\8\W(\KR:]*_X3W3/^
M>MQ_X"R__$T?\)[IG_/6X_\  67_ .)H \ZL=)^.2>(X6NM>^%K:2-5TMYHX
MM%OEN#IZV1&I1JQN2HG>\P\#D;8X<JZR-\]9#Z!^TD?"VQ?$_P &/[:_L18_
M-/A[4?LW]J_VAN:79]KW?9OL'R"/=O\ /^??L^2O7/\ A/=,_P">MQ_X"R__
M !-'_">Z9_SUN/\ P%E_^)H \[O]'^.3ZY<-:Z_\+ET\ZCJS0)+HM\TRV36H
M&EHS"Y ,T=UEKA@ LD6%18V^:HM(T7X\1O9_;_$'PKD56T#[5Y&B7REU0'^W
M-F;DX,IV_9,Y\KGS?.KTG_A/=,_YZW'_ ("R_P#Q-'_">Z9_SUN/_ 67_P")
MH \IGT/]H@^'IUC\2?!\:H=(U-(';0-0\E=1:\SILC+]JW&W2SRLZ AWF^9&
M1?DK4BTKXPMXVNY(=:^'"Z)_PD+R&)])O#=#2O[-18XM_GA?M0OOG,FW88/D
M"!_GKT+_ (3W3/\ GK<?^ LO_P 356Q\:Z=%=WC-).!)*&7_ $67D;%']WU!
MH \[L=&^/R>'[5;CQ%\)6U1=.T=;B2/0[\0->K=,=5=5-UN$,EKM6W4DM'*"
MTC2+\M+?:+\?&BO/L_B'X3J_EZ^+0R:'?D([E?[#+XNAD1#=]K QYI(\KRL5
MZ;_PGNF?\];C_P !9?\ XFC_ (3W3/\ GK<?^ LO_P 30!Y\-)^-@\4Q2-KW
MPQ_L7^V=->2(:/>_:3IJV9&H1A_M&W[0]YAX7V[$ARKJ[?/6+)H7[1W_  B
M1?$WP9_M[^PXHS*?#^H_9/[5^W[I)=GVO=]F-C\BQ[MXG^<N4^2O6_\ A/=,
M_P">MQ_X"R__ !-'_">Z9_SUN/\ P%E_^)H \ZNM'^.7]LW30Z]\+5T]M1U=
MK=&T6^,RV36P&E([?:<&:.XRUPP 62/"QK&WS56TG1?CVEW9_;/$'PG>!9=!
M-TL.B7ZL\:JW]N!";D@-*^TVA.?* /F^;G->G?\ ">Z9_P ];C_P%E_^)H_X
M3W3/^>MQ_P" LO\ \30!Y3>Z%^T0_AF9;?Q+\'UUC^R-12.230-0:W&I-?!M
M/D*BZ#&W2RRDR9WO-AT9$^2MS^ROC-_PE#-_;?PW_L7^W)I%C_LB\^TC238;
M88BWVC;]J%_\[2;=A@^0('^>NZ_X3W3/^>MQ_P" LO\ \31_PGNF?\];C_P%
ME_\ B: /+-.T;]H%-)MENO$7PB>^^PZ.MP\.A:@L37:W).K,@-T2(I+?"VZD
MEHY,M(9%^6LKXG_"?XQ?$[POJFCZG=_!76-/O(->CCM=3\.7MQ 7=A_8AD7[
M3R(DW?:L8,A(,1AKV8>.]-_Y[7'_ ("R_P#Q-!\>::?^6UQ_X"R__$TFDU9E
M0J2@U*#LUU/@_P ??\$T/CIX&\+^+M)^%_Q%\)6/@_Q$8+8^#;^SNYK&.S>S
M5;X0S22NT,S76]H2!M6)@K[F&ZI#^TW^VE\*O!\-MX@^%/@F[EM=&M[9=2\/
MV=QJ=NU^E[F:<P+="3[.;+Y%C!WB8;RY0[!]V'QWIN?];<?^ LO_ ,3532/&
M>GP:=&DCS;ESP;67U/\ LUR?5;:TVX_=;[G^A[2SR52/)C*<:G6[NGT6Z:N]
M%O<^,H?^"GFL?\))=0:QXR\%^ U%[J[0V?BCP/J]G<):R6X&D(\GGF,RQ7 9
MKELA98R!&(R"U;VN_ML?$NU\5?#VU\-^)?@KX^L_&&N:#IMW+HPE5K",0L^L
MMAKLMF7:QM21B$1E9?-9EKZLUK5/#?B6P:UU"VBOK:08:*?3WD1A[JR$5X_X
MZ_8<_9_^(5V;B^\ Z/!='_EOI]E/82#WS $HE'$I:-/Y6_S_ "-*%;)Y3YJM
M.<5KI=26VG\CT>N[[&L^D_M#-X2D6/Q/\&SKG]BZ@D<IT#4/LHU1KX-8R%/M
M>[[,EEE)4W;WFPZNB?)6]'I7QF_X2YI#K?PU_L'^W;B1(AI%Y]J&DFQVP1%_
MM&W[4+[YWDV[#!\@0/\ /7C)_P"">WA/PPC?\(;\3OC!X+YS'%9:U<S6\?\
MVSE1N/QH;X2?'?P,BCPY\?H=>C4\0>)?" ;</>6$*WZ57MJJ^*#^33_.QC_9
MN#J?PL2E_BC)?DI+\3U"UT?]H!-+M5G\1?"-KU;'11<M'H5^(C=K.3J[(#=9
M$4D.T6RDEHWR9#*.*FU/1?CT]A>?8_$/PH2Z:WUT6IFT2_9$F>53HI<"Y!*1
M1;A= $&5B#&8@,5\]Z;X<_:B\-_'#4/%RWWP]UI[[3X['[++JVJ0Z3"5(S,E
MJ5^65@J@GIU(Y8UV@\4_M3W8)-]\$['=Z6^JS%?_ !W%3'%7W@_N-*V1QA9Q
MKTVFEUZ]5;5Z>B]#UVSTGXT)XGADN-:^&C:-_;-B\D<>D7HN3I8L"M[&&-P5
M^TM?;7B?;L2#*,CO\]4O@98?%:'X@!O'.N?#O4K./PU:QZFN@:9=6TDFK_:;
M@F6(RSR!;7[/Y:B-MTGF!FW[2%KRR<_M07Z'=XY^$=GNX_<^']0DQ_WT:Z/]
M@;X&3?LO^&O$&F:Q?:7?ZKX@U0ZB]QIFF7%M;L9"V(@),\)T'0!2H[9K2%:;
MDH\K2[LPK9;0HT)5'7BY75HQN[]VVTDK?.Y[UX^\$Z;\3/ VL>&]8M_M6DZ]
M93:?>PY(\V&5"CKD<C*L>:\+^%'_  3?T/X12Q75CX\^)5SJT,VEQKJ<^J1"
MZ_LW3F8V^E$I$H-H=[;UQN?C+<5ZU^T-\5?^%&_ ?QEXR^RB\;PKHMWJJVY;
M:)VAA:0(3V!*@9]Z\*_8B_::^(OCKXQWG@OXB77AW5KJ]\%:3XYL+S2;![);
M1+UG22S=6D??Y;*NV3(+#.170>0=[X+_ &+[/P5^U#K'Q63QSX\O]8UZ,VUY
MIMU=6S:=); R&&WV+ '\N$RN4^?/J6KVRBB@#Y*_;+_:D_:.^$7[4?PY\,_#
M?X&V_BWX:^(+](M<\6MJHEDMB49A;FV4!K4,X5/M4GF1KOY48%>HV/Q@^+T]
MS9K-\&K2".:30$N''C.V?[,MV&.JMCR?F_L\A0 ,?:MWR;,5[)10!XE=?&CX
MS1>&9;J/X(V<FIKI&IW:6/\ PF]LHDO8+T165GYGDX NK8FX,N,0D>6P8G=6
MU'\4/B<WBHVI^%=JNE_VY)8B_P#^$I@).G+8><E_Y7E9RUW_ *-Y&=P'[W=M
M^6O4Z* /-_@]\0_B%XOU6WA\7_#FW\&6LF@V=_)<1^)(=3,6I2-(+C3]J1J2
M(0L9$^=LGF8"C:<^/_M0_&+3?VROV-/CMH_PS72?%%_X&U&Y\,ZQ:ZYI<K:9
M?7-B\$VH6(#1/YN8?,AWQH^V4_*=R9'U17X6_%SXC^!;[]K+XE>$O"_[27Q
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MW[*_[3/B"QN]8M]8\/6V@Z[JT6FZEX6?2+426UL)K*"ROF<F^D)8>;MX 5\
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M$6DQF&R-GXBNK:VM(V55D1(48(JR!%W@#YR.:Y?P-_P3&^&'@'X>:YX0M?\
MA,+SPCXBLI[*\T6^\1W=Q8GSI%E>98F?"S[U#"4?.#GGFOHBB@#SG]GK]F7P
MS^S3I.K6_A\ZQ?7FOW8OM4U/5]0DU"_U&58UB0RS2$L0L:*JCH .!R:]&HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZO#KVLSS>%_%^N>,88Y%BVSSZHLPEA;"\1IYQVXYX&2:]]HH ^4_B1^P3?\
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M ?#?_!4#_@HKXS_9"@^'J^'&M(?$6K6"ZS>Z/-I:75AJD:W5E#-;1WCSQ.9
M+ERL=O%)*5'FD*D;!O)_VL?VU_VB+3P-\5&T;Q)I.BV%Q/X\TKP__9?A>5M3
MT)?#[K)#=><TS+,\\23H1Y:@ HR9*D-^GVT$CCIR/:G4 ?ES^T%^TUK6G?&_
MPWJT?Q:\/^&M&T[QCHF/B%<:=<7>AWT-UX+U21KDVGVD6ZQR2A FUUC5V0L7
M<*:VO '_  5+^,WB[QIX"34['P[H.NZI#X0 ^'LFA7/]I^,H-5A5]1U*TG:0
M&WAM=TCA61A&+619F!=<?I5L&S;@;<8QCC%&/FZ<],T ?D;\,/\ @HW\0K+X
MA^)/CAK'BC2?%&E^&/A[X:UOQOH.E:#=6Z>$K"36+]=6TX1M,V^_L8G60N0L
MA6W*L@W(:^BOB_\ MT?&CX1_L8>'/&'BK1?#?@'4-;N_#GVOQ9J"+=Z5I<6K
M:G!%+"UBLRW DM+:YPSNRHTD+'[IK['^*7PL\/\ QK\ :IX5\4Z9#K'AW6HA
M!?6,K,L=U'N#;&VD$J2!D9P1D'()%+\0/AGH?Q2TZQL_$&FPZG:Z9J5IJ]K'
M*6 AN[69)[>48(Y25$8=LKR"* /S<\2_\%7/C!IO@FQNK;5O!ZW%CIVIWWAJ
MXD\,W+I\:YK;7KC3[:VTY%F_T8S6L4$OR&5B;V.11Y*G/8^/?VT/'WC+]HSQ
M)X!FU32+RYT3XH:#8Z3)HML\UAHVGW%[<VR&XG@N5D>^1HLS6ERB1_)N7S(F
M!'Z);!QP/EZ<=*%15.1CYCDX'4]* /RK_9\_;H^*?A?X(>$O'%]XA'Q)U?PG
M\,;7Q'XRNVTRX2Y-O;:Y!%K%BUM'+Y0OK>S^T-O\OS3)$ 5VMMKM/"7_  4E
M^.WBO]HGX<:+/IW@?P]I/C*WTCQ%:6>LM'I\NM:5JNIW:B")IIA*]W::>EJ2
MD,;DW$I\Q41EK](0-O3ZTC(&()'*\@D=* /B?X__ /!0+Q3\/?\ @IGX+^%.
MAW<5QH^HZA9:;K.F7>CQQLD5W8WUPMW;W'VCSYMCVT:LRV_D(6,;.788\S^&
M?[9WQD\;:9\.%\>3Z%K$WBQ/A_XQ@;2=&O-(725U74;VWN;)]MPQF$:VT3@R
M$ EW#QE=H'Z28^;ISTS3J /S5^%/[<O[26I:/X1\1ZYKG@6\TW4] \#^+;[2
M[;P?<VTSQZ_K3:7/IZS&Z;9]GC7SQ*4+%VPR!!7,Z=_P4 \9_M1_'Y?"_P!N
MNKSPQHGQ#\)ZCI]Q%I8TJ^L_^*CN;&XL;F**XF*IL@C?9<;)<$LZ!9% _5"D
M7C\>: /B#]G;_@H1XF\1?L9?&[QIXNUBUU#Q%\,9+II[[PSH"ZGI$8^S+/%_
M9YCN1]OC574L)7@EC8LDH3;NKSWX!_\ !0SXZ_'FT\&V>DW7AFXFCUWQ?'J-
MW#HBWC^)K+1HK&>U@MV@N6MHY;DW31&:-Y(\+N0$U^CZ(L?08Y/;N>32JH10
M , < #M0!\+_ + ?[>7Q4_: _9K^)GC+Q8_@>\NM!\,6^O:9;Z3+$UWIE])9
MW$UQI]W;132-&(9(HU02E)SF0.@*@G@=*_X*(?&KPSX8T_2_&WBKP/H UR7P
MI>WOCN3PM/!IOA&TUC2=0O)(Y;=[@JVVZL8K9)9)%4&\7>,A0?TF6,1] !N.
M3@=30PWK@C(Z$'O0!\$_L4_M7_%+XV?M>_#N3QQXJMM!T;QG\+GU:W\+_P!B
M/:V^OWD&IW4#7]JTS>;'YELMM=>4VYDBG13TW5ROC[]LKXR> M)\6OX+N-!T
MNU\*V_Q$\7WL6J:->:J^K_V1XC2UM[-':X4P+-#*^2NX#"^6BJ,#]("@)!QR
M.GM3J /SC^)_[5WB[XV>--8T74O%VEZ;J'AWXR>'])@\!6&ES6^L:5I]OXFT
M^&*_N;KS<R0W<+^9CRQ&R3J%8['SBZ?_ ,%??'7B[P=9I8ZEX4TN]L_#GA\>
M,M5FT2XEM_ VIWNOOIU_+<QF10!;0+N,+.-C,KR,$//Z:!0&SCGIFE(R* /R
M0^#O_!0#XS_#C1_!N@>']8\&ZM!XEU[Q/K8\1>(A_96G>,)3XPN;;[):FZG#
MP1_9&$L<<7G2CSH=JF-3N]>^$'[47B_X\?\ !5+P3I^L>*M-%OH%]X\TN?P7
M8Z5<6MUX<AM)K>VLIKZ<R,DYNH4%PFY$'[X&,LH)K]$&C$AY .TY&1T-.H _
M-'QY^V]\9OAQJOQ';P>V@V.E^!6\8^++NVU+1[W4I==%AXE^QQ6<<K7 \A98
M"Y)0,%.TQH%!%>H?\%2/B=XT\"?&3POIFG^/)?#G@_Q1\./&T5QHRZ>&_MS4
MH+2UDMH8[D,&CN"CS-'M&X""7 ;<=OV]32N?YB@#\S_AQ^U)\7/ >@^"/"_B
MC5/#&LZAX9_L._L-<FL+_2K"".\\':W=>5>A)W,D<-S81[Y7W924DQB148>H
M>$/V^_&VI?\ !+/6OB@M]8WGC+1]631-0U:XT96TK3B=1@M+K4(EM9Y$O+*U
MCEEG6:.4+(D'S;"' ^XJ:D8C0*H 4#  ' % 'Y Z?_P4H\>?LT?"G5-0T7QE
M9^--8USXE^)-1BNY=!V:5XKL8+_3;8+;/-=!X<I<,4AM1.S?/*N(D.[?^,'_
M  4R^*G[*WP[^(2/\1+7Q5XUT?X@^+%LM*OO#$$<5O8V$Z/;6$LK74;+YT,T
M;0)$DD\L9)C!6)B?U?V@XXZ<CCI1M&[/?.<X_"@#Y5_;-_:]\4? /]H7X,:9
MI]]I,7AKQA=+;ZIIMM;)?>(+Z>:XMX;=8+=Y(R;7]Y()I81))"3'(T9C5S7R
M7H?_  46^/GQN^ ,?BO5?&O@OX9VNG^*_",VLSV5M!=WGA:.\U62VO\ 3M0M
MA.S0VT2B',EQY4I*3*P52&'ZO% S D#*]#CI33"I#?*/G^]_M<8Y_"@##\$?
M$;1OB$NJKHNHP:DV@ZA+I&H&($?9[N(*9(FR/O#<O3(YZUT%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img005_v15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img005_v15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $E G # 2(  A$! Q$!_\0
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M\1ZAI_[5FF6WAOXR2Q>)XK:;PW+"UYNOKQ;9H6$$GF!E@^TE3L!5/*&<;>*
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN"^/W[2'AO\
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M]_X$O_C5ZBLC0H_V#'_S\7W_ ($O_C1_8,?_ #\7W_@2_P#C5ZB@"C_8,?\
MS\7W_@2_^-']@Q_\_%]_X$O_ (U>HH H_P!@Q_\ /Q??^!+_ .-']@Q_\_%]
M_P"!+_XU>HH RK/1UFFN0;B^Q'+M7_27X&U3Z^YJ?^P8_P#GXOO_  )?_&I-
M._X^+S_KO_[(E6J */\ 8,?_ #\7W_@2_P#C1_8,?_/Q??\ @2_^-7J* */]
M@Q_\_%]_X$O_ (T?V#'_ ,_%]_X$O_C5ZB@"C_8,?_/Q??\ @2_^-']@Q_\
M/Q??^!+_ .-7J* */]@Q_P#/Q??^!+_XU5UG219Z5<2I<WP=$+*?M+\'\ZV*
MI>(_^0%=_P#7(T )_8,?_/Q??^!+_P"-']@Q_P#/Q??^!+_XU>HH H_V#'_S
M\7W_ ($O_C1_8,?_ #\7W_@2_P#C5ZB@"C_8,?\ S\7W_@2_^-']@Q_\_%]_
MX$O_ (U>HH H_P!@Q_\ /Q??^!+_ .-']@Q_\_%]_P"!+_XU>HH H_V#'_S\
M7W_@2_\ C51M* UM(?M-]Y9@9R/M+]0RCU]ZV:H/_P C-'_UZO\ ^AK0 O\
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MM_W]7_&C^V[/_G[MO^_J_P"-2_8X?^>4?_?(H^QP_P#/*/\ [Y% $7]MV?\
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MA/\ 9!^)6I+8:!JILO#M[+]CUPC^SKH")LI-DC*'IC(SP,C- '%_LK?M[/\
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M .*H MT54_M.3_GRN_\ QS_XJC^TY/\ GRN__'/_ (J@"W153^TY/^?*[_\
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M7SK>$!4D\O&<C=T+?-FO$?VROA_^RCX ^)M^/&_PGT_6O&5S9VNI+::-H_\
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M3K<WB[1O VCS6%Q'';+X:\4+KB2JRDL966-/+8$# YR.:\]_X*??';Q)\#O
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M#_\ %4>1>?\ /Q!_WX/_ ,55JB@"KY%Y_P _$'_?@_\ Q5'D7G_/Q!_WX/\
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MH_MDZ9JTWB#4?^%V-\;WT"^TE=4F+Q^%UL-SI]DW;!:A/W@?9C><[LU];_\
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M(-&\0_"70=$OOB L'B/5-06_T_P/:6\FO7T45F6#0R3J8TC0G]XN075_12*
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M3Z+;?\)'&NQL?9F/^L;^\OO0!LT53_L*V_N-_P!_&_QH_L*V_N-_W\;_ !H
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M:7_@K/XCLO!/A_X>^($U7QMI/B7PYJE[JNDS>%M*L[Z\2.*QE-V[_:F$:0I
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MI;_]N[KIL]S+!XZA7Q=2-*5[*/Z[=]SN:*H_\)%:?\]&_P"_;?X4?\)%:?\
M/1O^_3?X5X9ZQ>HJC_PD5I_ST;_OTW^%>1_LP_$77]?\8?%*#Q)XD;6K;0_%
M+Z9I<?\ 9J6_V2W6"*;&8QES^^VY;G]V#_$:WIT'.G.HG\-OQ=M#*=51G&#7
MQ?Y7/:J*H_\ "16G_/1O^_3?X4?\)%:?\]&_[]-_A6!J7J*H_P#"16G_ #T;
M_OTW^%'_  D5I_ST;_OTW^% %ZJ#_P#(S1_]>K_^AK2_\)%:?\]&_P"_3?X5
M2?7K7_A(HV\QL?9F'^K;^\OM0!MT51_X2*T_YZ-_WZ;_  H_X2*T_P">C?\
M?IO\* +U%4?^$BM/^>C?]^F_PH_X2*T_YZ-_WZ;_  H O451_P"$BM/^>C?]
M^F_PH_X2*T_YZ-_WZ;_"@"]15'_A(K3_ )Z-_P!^F_PH_P"$BM/^>C?]^F_P
MH O52\/_ /()C^K?^A&D_P"$BM/^>C?]^V_PJIH>OVL>EQ@R-U;_ )9M_>/M
M0!LT51_X2*T_YZ-_WZ;_  H_X2*T_P">C?\ ?IO\* +U%4?^$BM/^>C?]^F_
MPH_X2*T_YZ-_WZ;_  H O451_P"$BM/^>C?]^F_PH_X2*T_YZ-_WZ;_"@"]1
M5'_A(K3_ )Z-_P!^F_PH_P"$BM/^>C?]^F_PH -8_P"/K3_^OG_VF]7JQ=5U
MZU>YL,2-\MQD_NV_N/[5<_X2*T_YZ-_WZ;_"@"]15'_A(K3_ )Z-_P!^F_PH
M_P"$BM/^>C?]^F_PH O451_X2*T_YZ-_WZ;_  H_X2*T_P">C?\ ?IO\* +U
M8G@:[EET2"-K66)$4[969"K_ #'H 2?S%7?^$BM/^>C?]^V_PJ'P6P?PO9D=
M"A(_,T >6?MUV/B:\^"+MX4D^(#:K;W'FBT\'7UC9:C> 1N #+=_*L2L5=@G
MSG:  1D5\ Z?^V=\3_B-\ ]4\51?%K68=3^%'PVT?Q%$ME!%;0^(M4FOYXKA
M+R-X\S*H@6W(7:"S%ARPS^F'QP_9U\%?M(^';;2O&_A^S\06-E/]IMXYV=##
M)M*EE9&5AE6(.#R#@US&L?L%_!O7[WPO<77PY\,._@N".VT8+:[$LXHW\Q(]
MBD*ZK)\X#A@&);J2: /E+P]^T=\0]6^/>E>,I/&VM1QW_P :C\-Y?!A\K^S8
M=+^Q;B_E[/,\]6_>F3=TXZ5]C_M3:NUA\!_%%M:S:J-7U#3+F'3K?28;>XU*
M\F\IF$=M#/\ NY9" ?D8%2 <\9J.U_9'^&MC\<I/B5%X,T6/QS*2S:N(CYQ<
MIY9DQG:)"GREPNXCC.*Y[]K[]G/Q1\=9O!&I^#/%6E^$O$7@C5IM3M;K4-)_
MM*&02V<]JZF/S$YV3M@YH ^=_P#@E?\ "OQU\'?CIXDL?'O@WP_X!O=6\/0W
MMGIWA?2=/MM*OXA*BM<7$D#M+]L5FV^7Q"H9]E>U_P#!3?1].U[]EU[>]O-=
ML[TZ[I<FC_V)ID6HZE/J*7<;6T=O%*RQEVD &7(4#=GBL#]B3]A'QC^S/X_T
M[5O%7CW2/%MIX?\ !Z>#M'M[/0S826]LMPD^Z20ROYC97'0=:Z__ (*,:3<:
MW^R_?6Z>$9?&E@VIZ>VJV%M:RW-[#8BZC-Q<6L<3I(;B*,%TV,&!7(SC! ,3
M_@GK\6]3^)6D:Y'K/CKQ#XTOOL.DZRBZKX?L=);3K>^MFFB1?LI*R$[6#%NC
M(<9!!-3_ (*3?#GQ%XRTKP#JOA/3OB+<^(/#&LRWEI=^#1IOVVQWVTD3%S>D
M)Y;*Y4A<Y)&1@5D?\$M_#.A^&8/B-'X+\#Z[X5^'TFI69T.^UZRN[75=8(M0
ML_F"Z8R-'$X"QG"C#, /ER>/_P""LD'B_4I-$6Z\-_#/Q'X*CU;3K+3X]1\1
M:KIFJPWU[+]E\QQ:.BF!3(IR6.!N.,B@#V?_ ()S?$;4_B5^S[<W&M:EXTU+
M6-,UZ_TN]_X2M+)-4M9H)-CPR+: 1*%(..-V#D\$5[U7C7["/P=N_@7\ (/#
M][HG@C0)XK^YG-OX5O;J]LI-[9\QIKG,SRM_$6)[8->RT %%%% !1110 5^?
M7[<-_P#&'2?VM==U;PUX:^+.IV.A#2'\.6OA[1;.Z\/ZO&2'U%=0,G[QY&4M
M&FW[NU>G6OT%KYB_X*;?M8>,?V4?!'AG4?"_]FV-IJ%W,-1U2_TN>_A@$2*\
M=J%B(\M[CYU61_E78>Y% 'M/P!^( ^)OPVM]67P;XB\!B6:6/^R-;LH[.[BV
ML1O,<;,H#=0<\@U\B?&[P=^SE\1/VF/$?C36/VF-2T#5+VR_L*^TS3/'R6 M
M#&Y#P@JVY(\@Y@^[O+-C)-?3G[('QOU']H;X4W?B>\@"6%UKFHPZ+<"SEM/[
M1TV.Y=+6X\N3YQOC .3C=C( !Q7R]^W]\/-'TO\ :[\*P^$[_P -:;XN\8Z&
MWA^\TW4? ?\ ;NG6]O=7+[+V1T:,02R2AH@6W>;LQC@T ?8/[._A;PGX(^!G
MA32/ D]O<^#=.TR&WT>:"Y^TQS6RJ C"3)WY'.[/.:[.O+/V(+31M/\ V0OA
MQ;^'M;O_ !'HEMH%K#9ZG>VYM[B\C6,*&>,\H>,;>=N,9.,UZG0!YO\ M$_L
MPZ'^TC;^'Y-0U'Q!H&L>%+\ZCH^L:'>"UO\ 3Y6B:*38Y5EVO&[*RLI!'TK<
M^!WP6T']G?X4Z-X-\,P36^BZ'"8H!-,9I9"S,[R.YY9W=F9CW+&NLHH Y;XM
MW/V+PN9LX\GSGSZ8MIC7P]_P24LAX<^,FD+C8?$?PNM-0(_OM'J,T>?R(K[+
M_:9OO[,^#NLW/_/"QO)/RLYS7Q_^Q58MX6^-7[,\X)4:[\*[RR8>ICF%P/\
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M:G6<:T8/9J3?R<?\SUWQK\0(?ASX3U#7=<:PTS2-*@:YN[J>[VI"BC))^7\
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MI])MY+6UTVT@MK9EBBBCGVI$BQH%50%X  &*O_:[_P#Y\H/_  )_^QJ33O\
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MB25"'EWD,!]G<\(/]8/[O.U*A*HI-?95_P 4OU,JE50<4^KM^#?Z'I7VN_\
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M'6D?VM9:?#87UZEL8FF@NH8(C:R?.0/*4^83COMSQ73_ /!9WXEZ;X4_9/\
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M -!&[_[YC_\ B* +U%4?[*G_ .@C=_\ ?,?_ ,11_94__01N_P#OF/\ ^(H
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MO_!1_P")G[._PRO'\5_!VZ\.^(BZ6]AJ1O$O] FE+9PTB,KKE V%ZD_C73?
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MP I)+"MW]E7]H.S_ &I_@#X=\=V6GW.DQZ["YDL;AP\EG-'*\4L18<-MDC8
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M+7/[,.AR>&S'_P )7J^_["]]]O:/S/M6_?\ :?F\W=Y@7]V'$?R5[1_:5O\
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MWVI7=W)H^L&>]N];O9F'B34U#2ZQ$L6H$ 7&%#HH"* %@/,(C))KU;^TK?\
MY[P_]]BC^TK?_GO#_P!]B@#RFT_87^&=CJ=K>1Z/K N+*[T2^A8^)-3(671X
MFBT\E3<8(1&(=2"LQYF$A -4I/\ @GM\*)?"4NAG0];_ +-FT2]\.O'_ ,)3
MJV\V5W>B^GC\S[3O#M< ,)0WF(OR(RQ_)7L?]I6__/>'_OL4?VE;_P#/>'_O
ML4 >:O\ L:?#R3Q<^N'2M4_M.36[GQ"TG]OZCL-[<6(L)G\OS]FPVX"B+;Y:
MM\ZJ)/GK.M_V"_A?:Z1;6*:+K(MK2PT;3(E/B75"5@TF<SV"EC<;B4D8EG)+
M3#Y93(O%>M_VE;_\]X?^^Q1_:5O_ ,]X?^^Q0!Y/>_L)?#'4+*[MY=&U@Q7U
MOKEK,!XEU-2T>LNKZB 1<94R,HV$8,'2$Q D5:MOV*?AS9^*8M9CTG5AJ,.L
M:=KR2'Q#J107EA9&QM7V&?856W)5HR/+D;YY%=_GKT[^TK?_ )[P_P#?8H_M
M*W_Y[P_]]B@#QB7_ ()U_"6;PB-#;0]<_LP:'%X;$8\5ZN'^PQWWV](_,^U;
M]XN?F\W=YA7Y"YC^2K5U^Q1\.;GQW)>OI.K&YN[G6=7E8>(=2 -SJD*6UZP7
MS\!7B "H $B/S1+&WS5Z[_:5O_SWA_[[%47U&W_X26,^?#_Q[/\ QC^\M 'F
MFG?L'_##2I[22#1M95[)M!:$GQ+JC;3H@8:;D&X.[RPS;\Y\_/[[S<"HKG]@
M/X67GAR;29-%UHV-QI6IZ)(@\3ZJ&-IJ-X+V[3>+G<&><!ED!WQ#Y(V1/EKU
M[^TK?_GO#_WV*/[2M_\ GO#_ -]B@#SB+]COX?P>+/[;72]4&I?VW_PD7F?V
M]J!3[=]A^P>9Y?G[-GV;Y?*V^7N_>;?,^>L:+_@G[\*H=!M],71-:^QVNE:9
MHL:?\)1JI86NG79O+1"_VG<62<[FD)WRCY)&=/EKV#^TK?\ Y[P_]]BC^TK?
M_GO#_P!]B@#RK4OV&?AIJPN_/T?6&^VG7FFQXDU-=QUL :CC%P-OF;1LQCR/
M^6/E9I]A^Q!\-M,UNWU&'2-76[MM1TG58V/B+4F47&EVIM+)BIN"I5(259"-
MDI^:42/\U>I?VE;_ //>'_OL4?VE;_\ />'_ +[% 'B\_P#P3J^$EQX7;1GT
M+7#I[:')X<,8\5ZN&^PR7XU!H]_VK?O^T@-YN?,"_NPXC^2MZ;]C3X>W'B.;
M56TK53?3ZOJ.NNXU_40IN[^R^PW3[//VA6M_E6,#RXV^>-4?YJ]*_M*W_P">
M\/\ WV*/[2M_^>\/_?8H \ETS]@WX8:/!:1V^C:RJ6,.AV\(;Q+JC[4T9R^G
M DW!+&-B=Y.3/TF,HJK;_L)_#'7?"\EG<Z-K#V]U9:UILJKXDU-"8-5NOM%\
MH9;@$%Y0"K AH1\L1C7BO9/[2M_^>\/_ 'V*IZ!J-N-*C_?P]6_C']XT <):
M_L>?#^R\4QZU'I>J#48M;M_$*R'7M0*"]@L#I\3[#/L*"V)4Q8\MF_>,ID^>
ML&W_ .">'PFM?#46D)H>N"P@T2R\/(A\5:L6%E9WQO[=-YN=Y=;D[C*3YCK\
MCLT?R5[+_:5O_P ]X?\ OL4?VE;_ //>'_OL4 >5ZI^PY\--9OKFXN-'U=I;
MNYUN[E*^(]30-)K$0BU @"X  =  BC A/,(C/-&E_L-_#31KZUN;?1]76:SN
MM%O(BWB/4W"RZ/$8; D&X((1"0ZD$3'F42'FO5/[2M_^>\/_ 'V*/[2M_P#G
MO#_WV* /&9_^"=_PFN?#<FD/H>N&PET6]\/,@\5:L&-E>7PO[A-_VG>&:Y&X
M2Y\Q%_=HRQ_)6AJO["7PJUSX@1>*;WPL;OQ#!K5SX@AOIM3O'D@O;BR%C*Z9
MEPB&W4 1*!&C_O%59/GKU;^TK?\ Y[P_]]BC^TK?_GO#_P!]BFFUL)I/<\FT
M[]A#X8Z5IMO:0Z/K(@M;+1M/B#>)M4<B'2;@W%@I9K@DE)22S$EIA\LID7BC
M5?V$/ACK5M=0W.C:P\=Y!KEM*%\2ZHFY-9<2:B 5N 09& *$8,'2$Q#BO6?[
M2M_^>\/_ 'V*/[2M_P#GO#_WV*0SRJ[_ &//A_8>*M+U2/2]4%['K^GZVKG7
MM0*B[L=/>RMGV&<J56W^5H\;)&^=U=_FK-M_^"=OPEMO"R:,FAZX-/30XO#B
MH?%6KEQ8QWQU!(]YNM^\7)W>;GS"O[LN8_DKUK5]1MS=:?\ OX?^/G^^/^>;
MU=_M*W_Y[P_]]B@#RV__ &(?AMJ6MSZC-I&KM=W.H:MJDC#Q%J2J;C5+86MZ
MVT7 4*\( 5 -L1^:(1M\U8GBW_@FU\&O'GA0Z)K/A6\U/3#'HL0ANM?U*4(-
M(1DL""UP2&C5V#-UFS^],F!7MO\ :5O_ ,]X?^^Q1_:5O_SWA_[[%5&4HM2B
M[-"E%27++8_-WX:_\$&=3\,?$'Q=;-\1_$&A>#=7TZ\T6"32];OI-2O["YG$
MS03&23"%=H D5BZXPA1217M</_!%OX8ZOJ$E[XH\4_%KQ=>W%_\ VG<-?^,[
MU(IKCR!;[C'&ZKCR@%V_=XSC=S7UO_:5O_SWA_[[%']I6_\ SWA_[[%>I7SK
M%59<UTGIM%+;;5*YP4LKP]-<NK6N[;W\F['YX_&3_@E7\"?@O^U-^S_I?ASP
M;<Z?8:M>265[%_;VHR?:4TY1>6;,SSEMZ3_,6SEQ\KEEXKZ[^%7[)O@3PCK>
MC>*+#3=3CUK3;[6-4MYI-<OYHUN-4D5[UC$\QC8.T:[492L6"(A&"<^"?MX_
MM6^"_AS^VA\'(]3OYQ_P@\]YJ>L/!;M,+:*YMC%"!MY9B5R0 < @]Z^J_@MX
M\TCXD?#'1M9T2^AU#3=2MA<6\L9^^C$]0>01T(/(((K?-:6(^JX:M53LXO5_
MXI-:^EGZ&&7U*/UBO2IM74EHO\,5MZ_B7/BA\-='^,?P\UCPMX@@N+G1=>M7
ML[V*"[FM))(G&&"RPLDB'W1@?>OF3]E?_@BE\$_V3OA#K_@?1X/%NJZ!KHU*
MUV7OB*\AFMK*_EMII[57MY(L_O+:,K.1YZC*^9@G/KW[5O[3%W^S]!X2TS0O
M#G_"6^,/'FL?V-HFEM?"QAD<0R32RRS%6V1I'&Q.%))( '-:?[)G[15O^U1\
M"M*\90Z7/H<UW+<VEYITTHE>QNK>>2":+>  P#QMAL#((.!7A'KE<?L;_#T>
M+6US^RM4_M)M;F\1&3^W]0V?;9K'[!(_E^?LV&V&T1;?+5OG"B3YZRX/V!?A
M;;:-;6":+K(M;33M(TJ)3XFU0LMOI=P;FR4M]IW%DE)+.27E'RRM(ORU[)10
M!Y#??L*_#+4K>ZBFT?6&2]BUV&8#Q)J:[EUIE;4<$7 (\PJ-A&#!_P L?*R:
MYK]MO]JRR_X)X? SP'=6>DV5SINJ^+-!\"Q3:KJKVMEHMO=S+;_;+JY<2-Y<
M4:DEFR6;;EADFOH.ODW_ (+*^)-2\/?LHZ.L7P_U'XH^%-1\9:/9>-?#=AX8
M_P"$CNM1T!YB;T16H!/F!54K(N&1@K!@0#0!\_\ [:/[.O@']HS_ (*M^'_A
M]JGBK5-;M_C#X.U77X;*PU&UN(_!FK:?:VEI;:PL'E&2.4V\TGV>8RX65'*J
M2<U^F$2>5$JY9MH RQR3]:_&W_@A_:V?@?\ :H\$:;X%_9<\6_ ]M5L/%;_$
M/5M6\ 7^G6UW;K>1'08+>^O9)9$/V<;IHD=5:49(.T8_92@ HHHH **** "B
MBB@ HHHH **** "BBB@#Q?\ :T_9GU[XV:[X%\4>#?$]EX5\:?#N_N+S3+F_
MTXW]E,ES;M;SQ2Q!T8Y0@@AA@J.N:Z7]E3]GZV_9;^ 'ASP+:ZA-JPT.%Q-?
M31B-[R>65YI92HR%W22.0N3@8&3C->AT4 0WMA!J5N8KB&*>(G)21 RG\#5/
M_A#](_Z!>G?^ R?X5Y5^U9^T[K?P5\4>"/"GA#PM:^+/&?CZ>]73[6\U+^S[
M2&&SMS<3R22['(^7:J@+RS=0!73_ ++/Q]M/VH_V?/"WCZRL9]+A\26?VAK.
M9P[VDBLT<D98<-MD1AG SC.!F@#KO^$/TC_H%Z=_X#)_A1_PA^D?] O3O_ 9
M/\*TJ* ,W_A#](_Z!>G?^ R?X4?\(?I'_0+T[_P&3_"M*B@#-_X0_2/^@7IW
M_@,G^%'_  A^D?\ 0+T[_P !D_PK2HH S?\ A#](_P"@7IW_ (#)_A1_PA^D
M?] O3O\ P&3_  K2KE_C1XXO?AK\+-;U[3K/3+Z\TNV,Z1:EJ::99X!&YIKE
MP5BC5<LS$'A3@9H UO\ A#M(_P"@7IW_ (#)_A1_PA^D?] O3O\ P&3_  KX
M^\&?\%3_ !/\3= TC3O#7PYT?6/&VL:]K.DVJ0^) =!OK?2X(YKB\M[T0DRQ
MMYJ1KB/ER<D"OI?]F+X\V/[3W[/_ (4\?:=:3V%KXHL$O!:S-NDM7Y5XR1P=
MKJRY[XSWH ZK_A#](_Z!>G?^ R?X4?\ "'Z1_P! O3O_  &3_"M*B@#-_P"$
M/TC_ *!>G?\ @,G^%'_"'Z1_T"]._P# 9/\ "M*B@#-_X0_2/^@7IW_@,G^%
M'_"'Z1_T"]._\!D_PK2HH S?^$/TC_H%Z=_X#)_A1_PAVD?] K3O_ 9/\*TJ
M^;?VD_V_X_@Y^T?I7PRTFU\(-K%QI\.J7MWXF\2IHEI''-.88H("8W::X<JY
M"@!0 ,GYJ /H#_A#](_Z!>G?^ R?X4?\(?I'_0+T[_P&3_"OF?X4?\%(;WXD
M?'G0-&E\$I8>!?&NO:QX:\.Z\-4\RZN;O30YE::V\L>7%(8I0A#L?E&0,U]5
M4 9O_"'Z1_T"]._\!D_PH_X0_2/^@7IW_@,G^%:5% &;_P (?I'_ $"]._\
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M?))(@;*JJ\L3T')K(M?VV_@[?2(L/Q1\ RM)>1Z>@37;8[KB0;DC'S\LPZ4
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MW[X"TO\ :*T/X>V.M:%J\UY!JL^M7]OJ\!B\,_8(DE<72Y.S<&89)7;Y;9H
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M7NH9)+1M+O%FE:&+$;PS,Y;:$01J.-H->X^!/V'_ !'^RE\?-,\6^$$TG1_
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MD\7A'3+KQ3IFAZE8^((;JZUJ\T*98I%DM_+46T4^\;)6D8+@[PJLK-9\9?\
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MP/JEKX8UWXD?!_X;:'X0\+1VESY1FFO(+>]MH?$2)N"SRZ>9-KPL,11WK2Q
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MG;Q4.I?L(_![5?&T'B.3X=^&8]=M]2?5UO8+7R)6N7:)G=BA&\,\$3E6RI9
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M^%Y_#GA*&>VT?3);"-[6PBGMI;69$0C&V2">:-@>&61LYS7HE% 'AP_X)I?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img006_v15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img006_v15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %# G # 2(  A$! Q$!_\0
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MTOA^T\/KK,&K03/)/.QBB< 8)C*?O#R/04XTY.]N@KH]WW4;J**@8;J-U%%
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MU,0/Q->4?$[]I7XV_$[X)_$/1O&_P3?P7X;N/"FIO/JS22L(72 F-,,<?.P
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M_"+XJ>.;W7Y['7=&N-5E,VH6VD:D;6UO6+;F+1[2%R<D[<#))P#7?>.OV0?
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M?)G>N,;.IW5^K8^&NA-XX;QP]G;Q^*Y-'73AJTK%FM(,%R$!.Q!N.YB "P4
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MRC;BY);=Y:,0?XER,4GA4EJ]=?P'SL^Z-3UBST2%)+Z]LK&.0[4>YN$A5SZ
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M'."?:OSC_8[^ 7A/]KKX>_&+XE?$;5-0E\;:;J%S)'J(U)[>70 D+2I,,$8
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M\9>#OAKXKT_QS)?+?V_Q!E\5VL5MJ4GF/F,1R2*0<K@ G>2C;L@D5[G^T_\
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M_P# "7_XFC_A6WB/_H7M=_\  "7_ .)H+]G/L8M%;7_"MO$?_0O:[_X 2_\
MQ-'_  K;Q'_T+VN_^ $O_P 30'LY]C%HK:_X5MXC_P"A>UW_ , )?_B:/^%;
M>(_^A>UW_P  )?\ XF@/9S[&+16U_P *V\1_]"]KO_@!+_\ $T?\*V\1_P#0
MO:[_ . $O_Q- >SGV,6BMK_A6WB/_H7M=_\  "7_ .)H_P"%;>(_^A>UW_P
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M@5=X5SRRAL$DXQFOI[_A6WB/_H7M=_\  "7_ .)H_P"%;>(_^A>UW_P E_\
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M  K;Q'_T+VN_^ $O_P 31_PK;Q'_ -"]KO\ X 2__$U3KS;NV+V#_E/CQ_\
M@D-\.+[PF-&U#Q'\1M3L[5LZ8D^L@IHZEMSK!'Y?EC=W)7/IBOJ"STU+;1H;
M&0F[BCMUMG,X#&=0@0[QC!W#KQ@Y/%='_P *V\1_]"]KO_@!+_\ $T?\*V\1
M_P#0O:[_ . $O_Q-3.K*?Q,:HR6R/D74O^"3'PYDGU"VTO7OB!X=\-:M/Y]Y
MX=TW6?+TV<YSMV%2=O' ).   >!7T7X'\$Z5\-O!NF>']#LH].T?1K=;6SMH
M\E88UZ#)Y)ZDD\DDD]:Z_P#X5MXC_P"A>UW_ , )?_B:/^%;>(_^A>UW_P
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MM(LO"48BT.?2I?L]QI2  ;$8@@J=H)# Y(#=>:]X_P"%;>(_^A>UW_P E_\
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MO_Q-/'P]\3A-O]@^(-OI]AFQ_P"@UK2Q+AOJ*6'D^GX'R]X._8<T3X@_L0^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)!&-W!4DC."<^=?%S]B'Q^++Q<GC[]G/Q;\:=?\ B)\)O#/A_P  ZM"T$I\
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M"?A'J%^=.T?4?%FCV_PEF^+MKJFGW,2P7^GQW"0"! QR)&WALD8 !!YKX_\
M"_[-'BSXR?L2^,/A3I7AX>)?%O@3]IYM0\3:?(\2F73VU1;]KJ02LH>)[2=&
M[EER #6%XZ_X)%?&3X0_%K]H;PWX2T2[\4_"_4?A'KN@_#4_;+<&R?4+^"\&
MC8DD#CRY?M&UG^385^8$D5WJE1V?];'A2Q6+WBKI^6SU_P"&]?4^LO 7_!:2
M*^\3:;I/CCX+?$7X<7/BGPIJ/BSPK-J4]G<6OB2"QLS>2Q1R0R-Y<AAPP#@=
M1G&1GEI_^#ASX>P_\$\H?V@/^$*\2FWF\5-X2_X1O[5;_;Q<B$W!?=G9L\C$
MGT(K1^%?_!'CPM\*OV<[GQ2+;QSXG^,G_"L[O0=/C\1^)IM371+JYTQHIK6S
M21_)A!=C&,?*%X! KX=N/^"+7QT;PI<Z/_PA]VWAS_A3PUN+2?MUIC_A.6T5
M-)>W'[W'F;07W_ZO_;S3A##R)JUL?!*RO?RVVWT]3]:/V=/VX=*^/OQJU_P(
M^B7WA[6M+\.:/XML!=3)(NL:7J,&X3Q[>AAG62"13G#*I!(<8]QKX(_9L\(:
MC=_\%8O"D*PO;3?"K]GO2] \4J"&%O?W=XLD%J[*2I8);2OU/!R."*^]ZXZL
M4GH>MA:DIQ;GW?\ 7Z!11169TA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65J_@?1M?\2:3K
M%]I.G7FKZ 96TR]FMD>XT\RIY<OE.1N3>GRMM(W#@YK5HH#?<**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4WI_7<^N?V6?B'HUE\3O&]IJ%TR:CH+VF@RSO&PA:5(OM-R0_P!WFYNI0?\
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MBE6Q/+':.@4445Z)XH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>9_M1?%AOAO\/9H+*4+K.K*8+8#EH5/#
MRX]@>/<BNW\9^,;'P'X>GU+4)?+MX!T_BD8]%4=R37RA\0=;N?B1K\VKWYQ-
M,VV.+<<6\8^Z@(_R3FO$SO,?JU%QI_&]O+S/7RC ^WJJ4_A7X^1RWA<76FV
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M4)6+RW#@S2)N/4$YVC/9<5N>'KZ-+MH69> &4@8R*L:[-I[:?/;*8?WF5)Z
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M))8#'KS7F<7[1>M_%/79-)\!:7/X@O-Y26\5BNGVA]9)NAQ_=3)^E>Q>'_\
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MHH **** "BBB@ HHHH **CENXH)8D>2-'F)6-68 R$ D@#OP"?PJ2@ HHHH
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MQLJO*X/RCTI<\>Q?L:EG[W7S_I'Q[X(_;0^(6I:CX2\5W/C'0KJW\>^+=?\
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MMI<><C1"$J$'EI)E@P? .1UOA/\ X*D^/YO^"B'@SP3I7B3P]KOPXUSQO<>
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MIN-#M?\ B7M<@BX,/R?NS+N;?MQOW'=G--5X6VU_X%B7@*O-I/2^VO\ -?\
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M(F+113%E/F(C$E5;(4DD 4O:PYKVT-/JM;D<7/6[:?;1H^>?V"_V@_B9XO\
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M^%/ Z^&-+\">#=.\-I=I?KI-MHMM%9"X1U=9O)5 GF!E5@^,@J#G(IR_L[^
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M[/P#\$/"GPLUR_U'P[H=GH]UJ5C8Z;/]FW)&;:R1X[6)8\[$6-)'4!0.#SG
MHG4@[NVH4J%:+2<M%_EZ=_O/G+QS^WU\0[W]K?QKX)\!^ O"6K^$_A/?:'8>
M,-2UOQ.-)O7;5%616LD>,PL(8V4GS9%,K?(G.,_.?P&_;1\;6$'PBN-:\1^*
M_$%QJ?Q*^)5G)OU?R(+FVTR'4);:WN(_+8S1((45%W)L(!RV,5]M?%C_ ()W
M_!GXY?&ZP^(OBKP)INK^+K![607;SSI'=M:OOMFN($<0W)A;E#,C[<#&,"K&
MF_L"?"+2%T46_@RU3_A'M3U?6=/_ -,N3]FN]525-0E&9.3,LTH(;(7?\H7
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M%]'TJ/P2S1Z%XC3Q9:7<FLW\FH#5%18A</=M.9Y#Y:JA5W92@"[<<50_8?\
MV$;W]FGXM_%KXE>+-<T/Q+\0OB_JL%WJ5UI&C_V996=M;Q>5!!%&TDC$GYGD
M=G^=VSCCE2G2<=$53HXN,US2NF]?33R\K?-GC?[4?[>'C+]FK]JKXY_\(WX<
M\1^.IO"?ACPG-:Z,=1EFT^T%]=W<4UXMG#"TW[M4#2>49'D"J JX)K@_&O\
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MCO\ X+#:SH'[<>K?#K1_AS-K?@_PMXKT[P9K.H0"]DU,75W&CM=QHELUJMM
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MC#X:_'7QJOB#Q1X;_M'4FMX;2Z*7US;0:K!#(98H;R&*18KN-'9F5)U=1N;
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MPV3[6+#1)_#MW_9VJ:/I,][JM]'8QV$TM[ C.8))H9'FA4J\3DJJD8/TY?\
M[-W@75OC%>^/[KPSIMSXNU+03X8N]0F4N;G33(9#;.A/ELI8G)*Y(X)QQ7+^
M&_V#_A=X7^'NN^$XM O;OPQXALH]-NM+U#6[^_M8;:,DQPV\<\SBV5"<KY&S
M:0I&-JX.>E;8'2Q-])::_P# Z'"_L:^*?'^J_M9_'?2_B!=Z5-?Z-'X=6WBT
M>XN&TQ4DM+AS)%%,2T+,>'7)R8P=QR,><?!?]L?XI>//"O@3P]X%TCPHU]JW
M@[5_%EY?^+=7OKXQ?9-5^RK;AU'F2&3S/OL1Y87H^ I^H/@A^R_X*_9VO=<N
M_"NF7=MJ'B=X)-7OKS4[K4;O4GA0QQ-+-<R2.Q5#M!)Z #H!@\ _LL^ ?A?=
M:?-H/AV#3Y=+TBXT&U9;B9_)LKBX%S-"-SG(:8!\GYAT! XI<\+O3M^12H5;
M)7[W^;OV['FGCS]L[7C^QI\,?B3X4\.Z3+K?Q.NO#=I:Z;JMZ\=K9/J\L$7S
MRQH6(B,^<A?FV]!FN,U?]MOXLZ9XAC^'\7AGP#>?$N/QY%X,N+H7EU'HGDSZ
M'+K$-\JD&8%(X]CP$DEE.V0!PP],_:(_8JT;XL_L[>#?AAHUO9:7X2\+:WH5
MQ]@EEGV_V=IUS#(;=)%;S _EQ!4?=D, =V1FNF\!?L??#OX:QZ7_ &5H#+/H
M^N2^)8+NZU"ZN[N34I;9[22ZFGED:2>0V\C1YE9L+M  VK@4J:6P.G7<M]-/
M^#T/!O"?_!1#QWKOQYN=(7P)-JWA'0?%,O@[6[K2M!U:::VEMX,W.J"X$36@
MMDN 4%N9#-L*ODL?+KM-7_;%\1_&7XLZ!X1^#UCHN^\T*?Q+J&I>,M/U'3A%
M;1W8M%@BM&CBG,CR>8=[A4544@/O&/2(_P!DGP';?&*;QW;:7?V'B*[NUO[L
MV6L7MK97UTL0B6XGLXY5MII1& N]XV8A5R3M&+/QC_9?\%?'C7=)U7Q'IEX^
MKZ''+#9:AIVJ7>EWD4,I0RP&:UEC=H7,:%HV)0E0<9 -+FIWV!4Z_*TY=?P]
M>GXGRKX&_:5USX?>,V,\^JZPR^*OBA<QBXU><0)'IMPSP0/""5DC PJ!O]4!
M\HYJMX\_;Q^)MO\ !(7/C/0/#-B?&/@&T\=Z./#&M7MK=::GV_3();2><J&9
ML:A$1)%M!V2*5P0Q^JY/V1/AS+=><WAFW,OG:Q<;OM$_^LU;G46^_P#\MN_]
MW^';3/$W['WPW\8Z%INFZEX8M[JQTC01X8LXC<SJ(=-$MK,+<$."1YEG;-N)
M+?NAS@MF_:4[W:(^KU^5I2_JR\O4\\T']K'Q9XF\2?$KQ,__  @/AGX2_#+4
M=3T2^O-8N;@:C/<64 ,ERS(/*A@$YV[2'=D4N""RK7C6F?MG^-OC%\8/ WAG
M6TBTF\T+XB:"\EWI-EJFCPZQ8W^D:S((9+:^2.<JLEJ3E@4DPA !4@?3/B[]
MAOX7^.O%OB/6=3\-R33>,()8-<M4U2\AT_5_,M_LSR3V:2BWDF\D!/-:/S %
M4ALJI#/ _P"PK\+_ (>Z^FKV'AZYGUE=2M-7;4M0UB]U"]GN[6&X@MY9)IYG
M>0QQ74Z ,2-KXQ\JXE3II;#E1Q#:UTOK_5CD_P!K#]JGQA\!_C1X7TJ"Q\.Z
M%X&U."%KOQ7KUK>W&GFZ>Z6'["TML"ED_ED.LUS^Z=G"#D&N,_9S_:W^*%]\
M3="T3QI_PB&JV/B_XC^*?"MI/I\,]O<:?;Z6NI2*"&)5^;2- >#M+%B6KW?X
MO_LJ^"?CSX@M=0\56&I:F;:*.![,:S>P:?>1QR^<B7%I'*L%P!)\V)4;T.1Q
M6#XA_8(^%WB6]U:YGT/4H+C6-;_X2222SU[4+1K34BLB275J8IU^RR2+-*)#
M!L\W>V_=FA2I\MFBI4J_M.:+T]?^ ><Q_MN^-OB#=^%_#?A'1/"D/BSQ9XM\
M5:-#<ZK/.VFV5CH=W+ \S+'B22:7;" BLH!=VSA,'Q;X5_MR^(?@+\%++Q3X
MILM2UW5M-\+^.M:N;*+7+B>WEN[?Q;#90VH4J1(BM<*B3%2\<2E57#%:^LF_
M8+^%,?PST7PE:^&&TS1_#>I7&KZ4=/U2\L[S3KNX,IGEBNHI5G0R^=+O DPP
MD8$$59\/?L._"CPMX/M_#]GX*TM=$M=%U'P['8RO+/#]@U"X6YO(&5W8,LLR
M*Y+9((X('%-3IK2W]:F;H8AN_-K;_+R\F>"7O[>/QHTOP)J<MW\./L[Z/K5O
M;7GBA_">NII4&GRV<TS7(TYXDOY?*GB$$AC!51*DI(7<H^L/A'XS7XC?"SP[
MKZW^BZJ-9TVWO?MFCRM+I]T9(U8O S?,8CG*D\XQGFN!M_V%_A]9^$QHT7_"
M;16BW2WB2+XXUO[5&RQ&$(L_VOS1%Y;%?+#;.^W< :]*\">!=(^&'@O2O#OA
M_3[;2=#T.UCL;"SMUVQ6T,:A411Z  5$Y0:]U'10A5B_WCNC6HHHK(Z0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH<[6 (Z=:^5_^"H/_!.;XG?M=_%75;O2O"WP6\=:)J>BQ6'A_4/$<ESHVO\
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M3]J?P9X9^&%OXFM/$/A_4H=8T:]UO0D_M2&WBUJ&UMFN9&CF<[ BQKEI#\J
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MWV3_ (05=,$G]J+\G[_[3GC[WZXQQ7BW_!4CQQJ_PP\?:1XF\/7ITOQ#X?\
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M7P;_ .%J:%X=?QUIFEVUY'X5T6;0VN)9(7>%TV37R"/[1*KJN[@X(KR77_\
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M(\[6_'5[>Z_KMTQR=0O99F224K]U<K'&NU0% 48 KZ)LO#]AIUK%#;V5I!#
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/110%D6J*** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>eyes-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9qw5o7xRiXgen8uEZ3ZcSaGKSaOdz511yZlBtWl6HTlaXyoiHvdt5CSPPIQ2wcQD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:eyes="http://secondsight.com/20221231" elementFormDefault="qualified" targetNamespace="http://secondsight.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://secondsight.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/OrganizationAndBusinessOperations" id="OrganizationAndBusinessOperations">
	  <link:definition>00000008 - Disclosure - Organization and Business Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfSignificantAccounting" id="SummaryOfSignificantAccounting">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/MoneyMarketFunds" id="MoneyMarketFunds">
	  <link:definition>00000010 - Disclosure - Money Market Funds</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SelectedBalanceSheetDetail" id="SelectedBalanceSheetDetail">
	  <link:definition>00000011 - Disclosure - Selected Balance Sheet Detail</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Grants" id="Grants">
	  <link:definition>00000012 - Disclosure - Grants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/EquitySecurities" id="EquitySecurities">
	  <link:definition>00000013 - Disclosure - Equity Securities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Warrants" id="Warrants">
	  <link:definition>00000014 - Disclosure - Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
	  <link:definition>00000015 - Disclosure - Employee Benefit Plans</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000016 - Disclosure - Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - Income taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" id="Right-of-useAssetsAndOperatingLeaseLiabilities">
	  <link:definition>00000018 - Disclosure - Right-of-use Assets and Operating Lease Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000019 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SubsequentEvent" id="SubsequentEvent">
	  <link:definition>00000020 - Disclosure - Subsequent Event</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000021 - Disclosure - Summary of Significant Accounting (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" id="OrganizationAndBusinessOperationsTables">
	  <link:definition>00000022 - Disclosure - Organization and Business Operations (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingTables" id="SummaryOfSignificantAccountingTables">
	  <link:definition>00000023 - Disclosure - Summary of Significant Accounting (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/MoneyMarketFundsTables" id="MoneyMarketFundsTables">
	  <link:definition>00000024 - Disclosure - Money Market Funds (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailTables" id="SelectedBalanceSheetDetailTables">
	  <link:definition>00000025 - Disclosure - Selected Balance Sheet Detail (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000026 - Disclosure - Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000027 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000028 - Disclosure - Income taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" id="Right-of-useAssetsAndOperatingLeaseLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" id="FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails">
	  <link:definition>00000030 - Disclosure - The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" id="FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails">
	  <link:definition>00000031 - Disclosure - The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" id="OrganizationAndBusinessOperationsDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Organization and Business Operations (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" id="ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails">
	  <link:definition>00000033 - Disclosure - Schedule of estimated useful lives of principal classes of assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" id="ScheduleOfNetLossPerShareDetails">
	  <link:definition>00000034 - Disclosure -  Schedule of net loss per share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" id="SummaryOfSignificantAccountingDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Summary of Significant Accounting (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" id="ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" id="MoneyMarketFundsDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Money Market Funds (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" id="PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails">
	  <link:definition>00000038 - Disclosure - Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" id="SelectedBalanceSheetDetailDetailsNarrative">
	  <link:definition>00000039 - Disclosure - Selected Balance Sheet Detail (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/GrantsDetailsNarrative" id="GrantsDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Grants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" id="EquitySecuritiesDetailsNarrative">
	  <link:definition>00000041 - Disclosure - Equity Securities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfWarrantActivityDetails" id="SummaryOfWarrantActivityDetails">
	  <link:definition>00000042 - Disclosure - Summary of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
	  <link:definition>00000043 - Disclosure - Warrants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" id="EmployeeBenefitPlansDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Employee Benefit Plans (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" id="SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails">
	  <link:definition>00000045 - Disclosure - Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" id="SummaryOfStockOptionActivityDetails">
	  <link:definition>00000046 - Disclosure - Summary of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" id="Stock-basedCompensationExpenseDetails">
	  <link:definition>00000047 - Disclosure - Stock-based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000048 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" id="ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails">
	  <link:definition>00000049 - Disclosure - The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" id="ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails">
	  <link:definition>00000050 - Disclosure - The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" id="AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails">
	  <link:definition>00000051 - Disclosure - As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" id="CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails">
	  <link:definition>00000052 - Disclosure - The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" id="Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000054 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://secondsight.com/role/SubsequentEventDetailsNarrative" id="SubsequentEventDetailsNarrative">
	  <link:definition>00000055 - Disclosure - Subsequent Event (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="eyes-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="eyes-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="eyes-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="eyes-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="eyes_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_SecondSightSwitzerlandSarlMember" name="SecondSightSwitzerlandSarlMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_CountryMember" name="CountryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_BiopharmDivisionMember" name="BiopharmDivisionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_NeuromodulationDivisionMember" name="NeuromodulationDivisionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ComputerHardwareAndSoftwareMember" name="ComputerHardwareAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_RightOfferingMember" name="RightOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_NPMMember" name="NPMMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LegacySSMPMember" name="LegacySSMPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_MrAdamsMember" name="MrAdamsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DepositsAndOtherAssets" name="DepositsAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_NetLossPerCommonShareBasicAndDiluted" name="NetLossPerCommonShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_WeightedAverageSharesOutstandingBasicAndDiluted" name="WeightedAverageSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" name="StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" name="StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GainFromBargainPurchase" name="GainFromBargainPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_PppLoanForgiveness" name="PppLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_CashAcquiredInMergerForStockConsideration" name="CashAcquiredInMergerForStockConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_CancellationOfSafeBorrowing" name="CancellationOfSafeBorrowing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DisclosureGrantsAbstract" name="DisclosureGrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GrantsTextBlock" name="GrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_WarrantDisclosureTextBlock" name="WarrantDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" name="DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" name="RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_NhGrant" name="NhGrant" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ForeignOperationsPolicyTextBlock" name="ForeignOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" name="ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_CashAndCashEquivalentsFairValue" name="CashAndCashEquivalentsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingLeaseRightOfUseAssetOne" name="OperatingLeaseRightOfUseAssetOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_FairValueOfAssetsAcquired1" name="FairValueOfAssetsAcquired1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_FairValueOfLiabilitesAcquired" name="FairValueOfLiabilitesAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_TotalConsideration" name="TotalConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GainOnBargainPurchase" name="GainOnBargainPurchase" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GrantsAgainstOperatingExpense" name="GrantsAgainstOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_CashSPICInsuredAmount" name="CashSPICInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_SPICCashLimitCoverage" name="SPICCashLimitCoverage" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_AccruedLiabilitiesCurrent1" name="AccruedLiabilitiesCurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DivisionIncurred" name="DivisionIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingIncomeLoss1" name="OperatingIncomeLoss1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingIncomeLoss2" name="OperatingIncomeLoss2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingIncomeLoss3" name="OperatingIncomeLoss3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DivisionIncurredOfAssets" name="DivisionIncurredOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ContractLiabilitiesOther" name="ContractLiabilitiesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GrantReceivedToSupportClinicalDevelopment" name="GrantReceivedToSupportClinicalDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" name="GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GrantReceivedFundingPeriod" name="GrantReceivedFundingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_GrantsAgainstOperatingExpenses" name="GrantsAgainstOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" name="StockIssuedDuringPeriodSharesMergerAcquisitions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightExerciseIssued" name="ClassOfWarrantOrRightExerciseIssued" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightForfeitedOrExpired" name="ClassOfWarrantOrRightForfeitedOrExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightToBeExercised" name="ClassOfWarrantOrRightToBeExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightOtherAdjustments" name="ClassOfWarrantOrRightOtherAdjustments" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightOtherAdjustment" name="ClassOfWarrantOrRightOtherAdjustment" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" name="ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" name="ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantsOrRightsTerm" name="ClassOfWarrantsOrRightsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ShareBasedCompensation1" name="ShareBasedCompensation1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" name="IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_TaxCreditCarryforwardValuationAllowance1" name="TaxCreditCarryforwardValuationAllowance1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DeferredTaxAssetsStateTaxes1" name="DeferredTaxAssetsStateTaxes1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" name="LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingLeasePayment" name="OperatingLeasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingLeasePayments1" name="OperatingLeasePayments1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LeaseAndRentalExpense1" name="LeaseAndRentalExpense1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClinicalAndRegulatoryExpense" name="ClinicalAndRegulatoryExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LiquidatedDamagesPaidValue" name="LiquidatedDamagesPaidValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClinicalAndRegulatoryExpenseNetOfGrants" name="ClinicalAndRegulatoryExpenseNetOfGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodValueStockOptionsWarrantsExercised" name="StockIssuedDuringPeriodValueStockOptionsWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ValueOfConsolidated" name="ValueOfConsolidated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_The2011EquityIncentivePlanMember" name="The2011EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClinicalAndRegulatoryMember" name="ClinicalAndRegulatoryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DeferredTaxAssetsResearchCredits" name="DeferredTaxAssetsResearchCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_DeferredTaxAssetsDepreciation" name="DeferredTaxAssetsDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LimitationArisingFromEstimatedOwnershipChange" name="LimitationArisingFromEstimatedOwnershipChange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_ClinicalTrialAgreementsExpenses" name="ClinicalTrialAgreementsExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LossContingencyPayable" name="LossContingencyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_NetOperatingLossCarryforwardsExpiringUnusedMember" name="NetOperatingLossCarryforwardsExpiringUnusedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_OperatingExpenses1" name="OperatingExpenses1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LegacyNMPMember" name="LegacyNMPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_SSMPMember" name="SSMPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_NMPMember" name="NMPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="eyes_LegacySSMPOneMember" name="LegacySSMPOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>eyes-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://secondsight.com/role/Cover" xlink:href="eyes-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/BalanceSheets" xlink:href="eyes-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/BalanceSheetsParenthetical" xlink:href="eyes-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfOperations" xlink:href="eyes-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfComprehensiveLoss" xlink:href="eyes-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eyes-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfCashFlows" xlink:href="eyes-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperations" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccounting" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccounting" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFunds" xlink:href="eyes-20221231.xsd#MoneyMarketFunds" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetail" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Grants" xlink:href="eyes-20221231.xsd#Grants" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EquitySecurities" xlink:href="eyes-20221231.xsd#EquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Warrants" xlink:href="eyes-20221231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EmployeeBenefitPlans" xlink:href="eyes-20221231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensation" xlink:href="eyes-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/IncomeTaxes" xlink:href="eyes-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CommitmentsAndContingencies" xlink:href="eyes-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SubsequentEvent" xlink:href="eyes-20221231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingTables" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFundsTables" xlink:href="eyes-20221231.xsd#MoneyMarketFundsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailTables" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/WarrantsTables" xlink:href="eyes-20221231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationTables" xlink:href="eyes-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/IncomeTaxesTables" xlink:href="eyes-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:href="eyes-20221231.xsd#FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:href="eyes-20221231.xsd#FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:href="eyes-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" xlink:href="eyes-20221231.xsd#ScheduleOfNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:href="eyes-20221231.xsd#ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" xlink:href="eyes-20221231.xsd#MoneyMarketFundsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:href="eyes-20221231.xsd#PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetailDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/GrantsDetailsNarrative" xlink:href="eyes-20221231.xsd#GrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" xlink:href="eyes-20221231.xsd#EquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfWarrantActivityDetails" xlink:href="eyes-20221231.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/WarrantsDetailsNarrative" xlink:href="eyes-20221231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:href="eyes-20221231.xsd#EmployeeBenefitPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:href="eyes-20221231.xsd#SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" xlink:href="eyes-20221231.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" xlink:href="eyes-20221231.xsd#Stock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="eyes-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:href="eyes-20221231.xsd#ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:href="eyes-20221231.xsd#ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:href="eyes-20221231.xsd#AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:href="eyes-20221231.xsd#CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="eyes-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SubsequentEventDetailsNarrative" xlink:href="eyes-20221231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DepositsAndOtherAssets" xlink:label="loc_eyesDepositsAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_eyesDepositsAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="loc_us-gaapLitigationReserveNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLitigationReserveNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaapInterestIncomeOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:label="loc_us-gaapGainLossOnRepurchaseOfDebtInstrument" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainLossOnRepurchaseOfDebtInstrument" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholder&apos;s Equity (Deficit) (unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GainFromBargainPurchase" xlink:label="loc_eyesGainFromBargainPurchase" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_eyesGainFromBargainPurchase" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_PppLoanForgiveness" xlink:label="loc_eyesPppLoanForgiveness" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_eyesPppLoanForgiveness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashAcquiredInMergerForStockConsideration" xlink:label="loc_eyesCashAcquiredInMergerForStockConsideration" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_eyesCashAcquiredInMergerForStockConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CancellationOfSafeBorrowing" xlink:label="loc_eyesCancellationOfSafeBorrowing" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_eyesCancellationOfSafeBorrowing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_eyesProceedsFromIssuanceOfCommonStockAndWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_eyesProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperations" xlink:title="00000008 - Disclosure - Organization and Business Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccounting" xlink:title="00000009 - Disclosure - Summary of Significant Accounting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFunds" xlink:title="00000010 - Disclosure - Money Market Funds" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetail" xlink:title="00000011 - Disclosure - Selected Balance Sheet Detail" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Grants" xlink:title="00000012 - Disclosure - Grants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EquitySecurities" xlink:title="00000013 - Disclosure - Equity Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Warrants" xlink:title="00000014 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EmployeeBenefitPlans" xlink:title="00000015 - Disclosure - Employee Benefit Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensation" xlink:title="00000016 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:title="00000018 - Disclosure - Right-of-use Assets and Operating Lease Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SubsequentEvent" xlink:title="00000020 - Disclosure - Subsequent Event" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000021 - Disclosure - Summary of Significant Accounting (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" xlink:title="00000022 - Disclosure - Organization and Business Operations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingTables" xlink:title="00000023 - Disclosure - Summary of Significant Accounting (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFundsTables" xlink:title="00000024 - Disclosure - Money Market Funds (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetailTables" xlink:title="00000025 - Disclosure - Selected Balance Sheet Detail (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/WarrantsTables" xlink:title="00000026 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:title="00000029 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:title="00000030 - Disclosure - The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:title="00000031 - Disclosure - The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" xlink:title="00000032 - Disclosure - Organization and Business Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of estimated useful lives of principal classes of assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" xlink:title="00000034 - Disclosure -  Schedule of net loss per share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" xlink:title="00000035 - Disclosure - Summary of Significant Accounting (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:title="00000036 - Disclosure - Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" xlink:title="00000037 - Disclosure - Money Market Funds (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:title="00000038 - Disclosure - Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" xlink:title="00000039 - Disclosure - Selected Balance Sheet Detail (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/GrantsDetailsNarrative" xlink:title="00000040 - Disclosure - Grants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" xlink:title="00000041 - Disclosure - Equity Securities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000042 - Disclosure - Summary of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/WarrantsDetailsNarrative" xlink:title="00000043 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="00000044 - Disclosure - Employee Benefit Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:title="00000045 - Disclosure - Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000046 - Disclosure - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" xlink:title="00000047 - Disclosure - Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000048 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:title="00000049 - Disclosure - The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:title="00000050 - Disclosure - The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:title="00000051 - Disclosure - As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:title="00000052 - Disclosure - The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:title="00000053 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000054 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SubsequentEventDetailsNarrative" xlink:title="00000055 - Disclosure - Subsequent Event (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>eyes-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://secondsight.com/role/Cover" xlink:href="eyes-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/BalanceSheets" xlink:href="eyes-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/BalanceSheetsParenthetical" xlink:href="eyes-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfOperations" xlink:href="eyes-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfComprehensiveLoss" xlink:href="eyes-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eyes-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfCashFlows" xlink:href="eyes-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperations" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccounting" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccounting" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFunds" xlink:href="eyes-20221231.xsd#MoneyMarketFunds" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetail" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Grants" xlink:href="eyes-20221231.xsd#Grants" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EquitySecurities" xlink:href="eyes-20221231.xsd#EquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Warrants" xlink:href="eyes-20221231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EmployeeBenefitPlans" xlink:href="eyes-20221231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensation" xlink:href="eyes-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/IncomeTaxes" xlink:href="eyes-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CommitmentsAndContingencies" xlink:href="eyes-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SubsequentEvent" xlink:href="eyes-20221231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingTables" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFundsTables" xlink:href="eyes-20221231.xsd#MoneyMarketFundsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailTables" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/WarrantsTables" xlink:href="eyes-20221231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationTables" xlink:href="eyes-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/IncomeTaxesTables" xlink:href="eyes-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:href="eyes-20221231.xsd#FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:href="eyes-20221231.xsd#FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:href="eyes-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" xlink:href="eyes-20221231.xsd#ScheduleOfNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:href="eyes-20221231.xsd#ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" xlink:href="eyes-20221231.xsd#MoneyMarketFundsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:href="eyes-20221231.xsd#PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetailDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/GrantsDetailsNarrative" xlink:href="eyes-20221231.xsd#GrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" xlink:href="eyes-20221231.xsd#EquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfWarrantActivityDetails" xlink:href="eyes-20221231.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/WarrantsDetailsNarrative" xlink:href="eyes-20221231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:href="eyes-20221231.xsd#EmployeeBenefitPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:href="eyes-20221231.xsd#SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" xlink:href="eyes-20221231.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" xlink:href="eyes-20221231.xsd#Stock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="eyes-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:href="eyes-20221231.xsd#ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:href="eyes-20221231.xsd#ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:href="eyes-20221231.xsd#AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:href="eyes-20221231.xsd#CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="eyes-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SubsequentEventDetailsNarrative" xlink:href="eyes-20221231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WarrantsMember" xlink:label="loc_eyesWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_eyesWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_70" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_70" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_70" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_70" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_70" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_70" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_70" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_70" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_70" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_70" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_70" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_70" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_70" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_70" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_70" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_70" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_70" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_70" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_70" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_70" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_70" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_70" xlink:type="arc" order="60" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholder&apos;s Equity (Deficit) (unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" xlink:label="loc_eyesStockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodValueStockWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodValueStockWarrantsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodSharesStockWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodSharesStockWarrantsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperations" xlink:title="00000008 - Disclosure - Organization and Business Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccounting" xlink:title="00000009 - Disclosure - Summary of Significant Accounting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFunds" xlink:title="00000010 - Disclosure - Money Market Funds" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetail" xlink:title="00000011 - Disclosure - Selected Balance Sheet Detail" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Grants" xlink:title="00000012 - Disclosure - Grants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/EquitySecurities" xlink:title="00000013 - Disclosure - Equity Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Warrants" xlink:title="00000014 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/EmployeeBenefitPlans" xlink:title="00000015 - Disclosure - Employee Benefit Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensation" xlink:title="00000016 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:title="00000018 - Disclosure - Right-of-use Assets and Operating Lease Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SubsequentEvent" xlink:title="00000020 - Disclosure - Subsequent Event" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000021 - Disclosure - Summary of Significant Accounting (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" xlink:title="00000022 - Disclosure - Organization and Business Operations (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingTables" xlink:title="00000023 - Disclosure - Summary of Significant Accounting (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFundsTables" xlink:title="00000024 - Disclosure - Money Market Funds (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetailTables" xlink:title="00000025 - Disclosure - Selected Balance Sheet Detail (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/WarrantsTables" xlink:title="00000026 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:title="00000029 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:title="00000030 - Disclosure - The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:title="00000031 - Disclosure - The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" xlink:title="00000032 - Disclosure - Organization and Business Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SecondSightSwitzerlandSarlMember" xlink:label="loc_eyesSecondSightSwitzerlandSarlMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_eyesSecondSightSwitzerlandSarlMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaapSeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_us-gaapSeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProFormaMember" xlink:label="loc_srtProFormaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtProFormaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaapAssetsFairValueAdjustment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapAssetsFairValueAdjustment_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" xlink:label="loc_us-gaapSensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapSensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of estimated useful lives of principal classes of assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" xlink:title="00000034 - Disclosure -  Schedule of net loss per share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" xlink:title="00000035 - Disclosure - Summary of Significant Accounting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CountryMember" xlink:label="loc_eyesCountryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_eyesCountryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_BiopharmDivisionMember" xlink:label="loc_eyesBiopharmDivisionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_eyesBiopharmDivisionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NeuromodulationDivisionMember" xlink:label="loc_eyesNeuromodulationDivisionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_eyesNeuromodulationDivisionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DescriptionOfMaterialContingenciesOfParentCompany" xlink:label="loc_srtDescriptionOfMaterialContingenciesOfParentCompany_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_srtDescriptionOfMaterialContingenciesOfParentCompany_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralExpense_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsAgainstOperatingExpense" xlink:label="loc_eyesGrantsAgainstOperatingExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesGrantsAgainstOperatingExpense_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashSPICInsuredAmount" xlink:label="loc_eyesCashSPICInsuredAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesCashSPICInsuredAmount_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SPICCashLimitCoverage" xlink:label="loc_eyesSPICCashLimitCoverage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesSPICCashLimitCoverage_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_AccruedLiabilitiesCurrent1" xlink:label="loc_eyesAccruedLiabilitiesCurrent1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesAccruedLiabilitiesCurrent1_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DivisionIncurred" xlink:label="loc_eyesDivisionIncurred_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesDivisionIncurred_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss1" xlink:label="loc_eyesOperatingIncomeLoss1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesOperatingIncomeLoss1_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss2" xlink:label="loc_eyesOperatingIncomeLoss2_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesOperatingIncomeLoss2_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss3" xlink:label="loc_eyesOperatingIncomeLoss3_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesOperatingIncomeLoss3_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DivisionIncurredOfAssets" xlink:label="loc_eyesDivisionIncurredOfAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesDivisionIncurredOfAssets_80" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:title="00000036 - Disclosure - Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:label="loc_us-gaapImpairmentEffectsOnEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapMoneyMarketFundsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" xlink:title="00000037 - Disclosure - Money Market Funds (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaapCashAndCashEquivalentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:title="00000038 - Disclosure - Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ComputerHardwareAndSoftwareMember" xlink:label="loc_eyesComputerHardwareAndSoftwareMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_eyesComputerHardwareAndSoftwareMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" xlink:title="00000039 - Disclosure - Selected Balance Sheet Detail (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/GrantsDetailsNarrative" xlink:title="00000040 - Disclosure - Grants (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" xlink:title="00000041 - Disclosure - Equity Securities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" xlink:label="loc_eyesStockIssuedDuringPeriodSharesMergerAcquisitions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodSharesMergerAcquisitions_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000042 - Disclosure - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightIssued" xlink:label="loc_eyesClassOfWarrantOrRightIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightIssued_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightExerciseIssued" xlink:label="loc_eyesClassOfWarrantOrRightExerciseIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightExerciseIssued_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightExercised" xlink:label="loc_eyesClassOfWarrantOrRightExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightForfeitedOrExpired" xlink:label="loc_eyesClassOfWarrantOrRightForfeitedOrExpired_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightForfeitedOrExpired_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightToBeExercised" xlink:label="loc_eyesClassOfWarrantOrRightToBeExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightToBeExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightOtherAdjustments" xlink:label="loc_eyesClassOfWarrantOrRightOtherAdjustments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightOtherAdjustments_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightOtherAdjustment" xlink:label="loc_eyesClassOfWarrantOrRightOtherAdjustment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightOtherAdjustment_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" xlink:label="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" xlink:label="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:label="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:label="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" xlink:label="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/WarrantsDetailsNarrative" xlink:title="00000043 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_RightOfferingMember" xlink:label="loc_eyesRightOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_eyesRightOfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantsOrRightsTerm" xlink:label="loc_eyesClassOfWarrantsOrRightsTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_eyesClassOfWarrantsOrRightsTerm_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="00000044 - Disclosure - Employee Benefit Plans (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:title="00000045 - Disclosure - Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ShareBasedCompensation1" xlink:label="loc_eyesShareBasedCompensation1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_eyesShareBasedCompensation1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000046 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:label="loc_eyesShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_eyesShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" xlink:title="00000047 - Disclosure - Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000048 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:title="00000049 - Disclosure - The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="loc_eyesNPMMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesNPMMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="loc_eyesLegacySSMPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesLegacySSMPMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsRegulatoryAssetsAndLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsRegulatoryAssetsAndLiabilities_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaapDeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" xlink:label="loc_eyesIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_eyesIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_TaxCreditCarryforwardValuationAllowance1" xlink:label="loc_eyesTaxCreditCarryforwardValuationAllowance1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_eyesTaxCreditCarryforwardValuationAllowance1_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaapOperatingLossCarryforwardsValuationAllowance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsValuationAllowance_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:title="00000050 - Disclosure - The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="loc_eyesNPMMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesNPMMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="loc_eyesLegacySSMPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesLegacySSMPMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxExemptIncome_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxExemptIncome_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_50" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:title="00000051 - Disclosure - As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="loc_eyesNPMMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesNPMMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="loc_eyesLegacySSMPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesLegacySSMPMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DeferredTaxAssetsStateTaxes1" xlink:label="loc_eyesDeferredTaxAssetsStateTaxes1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_eyesDeferredTaxAssetsStateTaxes1_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:title="00000052 - Disclosure - The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:title="00000053 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000054 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://secondsight.com/role/SubsequentEventDetailsNarrative" xlink:title="00000055 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_MrAdamsMember" xlink:label="loc_eyesMrAdamsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_eyesMrAdamsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForRent_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription_40" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>eyes-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WarrantsMember" xlink:label="eyes_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WarrantsMember" xlink:to="eyes_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SecondSightSwitzerlandSarlMember" xlink:label="eyes_SecondSightSwitzerlandSarlMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_SecondSightSwitzerlandSarlMember" xlink:to="eyes_SecondSightSwitzerlandSarlMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_SecondSightSwitzerlandSarlMember_lbl" xml:lang="en-US">Second Sight Switzerland Sarl [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProFormaMember" xlink:to="srt_ProFormaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProFormaMember_lbl" xml:lang="en-US">Pro Forma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CountryMember" xlink:label="eyes_CountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CountryMember" xlink:to="eyes_CountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_CountryMember_lbl" xml:lang="en-US">Country [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_BiopharmDivisionMember" xlink:label="eyes_BiopharmDivisionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_BiopharmDivisionMember" xlink:to="eyes_BiopharmDivisionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_BiopharmDivisionMember_lbl" xml:lang="en-US">Biopharm Division [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NeuromodulationDivisionMember" xlink:label="eyes_NeuromodulationDivisionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NeuromodulationDivisionMember" xlink:to="eyes_NeuromodulationDivisionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_NeuromodulationDivisionMember_lbl" xml:lang="en-US">Neuromodulation Division [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ComputerHardwareAndSoftwareMember" xlink:label="eyes_ComputerHardwareAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ComputerHardwareAndSoftwareMember" xlink:to="eyes_ComputerHardwareAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US">Computer Hardware And Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_RightOfferingMember" xlink:label="eyes_RightOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_RightOfferingMember" xlink:to="eyes_RightOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_RightOfferingMember_lbl" xml:lang="en-US">Right Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="eyes_NPMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NPMMember" xlink:to="eyes_NPMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_NPMMember_lbl" xml:lang="en-US">NPM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="eyes_LegacySSMPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LegacySSMPMember" xlink:to="eyes_LegacySSMPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_LegacySSMPMember_lbl" xml:lang="en-US">Legacy SSMP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_MrAdamsMember" xlink:label="eyes_MrAdamsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_MrAdamsMember" xlink:to="eyes_MrAdamsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_MrAdamsMember_lbl" xml:lang="en-US">Mr dams [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DepositsAndOtherAssets" xlink:label="eyes_DepositsAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DepositsAndOtherAssets" xlink:to="eyes_DepositsAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DepositsAndOtherAssets_lbl" xml:lang="en-US">Deposits and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveNoncurrent" xlink:to="us-gaap_LitigationReserveNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US">Litigation accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long term operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, no par value, 10,000 shares authorized; none outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 50,736 and 36,803 at December 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred stock, no par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock, no par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative, net of grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating" xlink:label="us-gaap_InterestIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOperating" xlink:to="us-gaap_InterestIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOperating_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:label="us-gaap_GainLossOnRepurchaseOfDebtInstrument" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:to="us-gaap_GainLossOnRepurchaseOfDebtInstrument_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnRepurchaseOfDebtInstrument_lbl" xml:lang="en-US">Gain on bargain purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NetLossPerCommonShareBasicAndDiluted" xlink:label="eyes_NetLossPerCommonShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NetLossPerCommonShareBasicAndDiluted" xlink:to="eyes_NetLossPerCommonShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_NetLossPerCommonShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:label="eyes_WeightedAverageSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:to="eyes_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares outstanding &#8211; basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Balance beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" xlink:label="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" xlink:to="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of shares of common stock and warrants, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares of common stock and warrants, net of issuance costs (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Options and warrants exercised, net of partial shares adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" xlink:label="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_lbl" xml:lang="en-US">Options and warrants exercised, net of partial shares adjustment (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Repurchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Shares issued for SSMP net assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Shares issued for SSMP net assets (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Balance ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GainFromBargainPurchase" xlink:label="eyes_GainFromBargainPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GainFromBargainPurchase" xlink:to="eyes_GainFromBargainPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyes_GainFromBargainPurchase_lbl" xml:lang="en-US">Gain on bargain purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_PppLoanForgiveness" xlink:label="eyes_PppLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_PppLoanForgiveness" xlink:to="eyes_PppLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyes_PppLoanForgiveness_lbl" xml:lang="en-US">PPP loan forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashAcquiredInMergerForStockConsideration" xlink:label="eyes_CashAcquiredInMergerForStockConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CashAcquiredInMergerForStockConsideration" xlink:to="eyes_CashAcquiredInMergerForStockConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_CashAcquiredInMergerForStockConsideration_lbl" xml:lang="en-US">Cash acquired in merger for stock consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CancellationOfSafeBorrowing" xlink:label="eyes_CancellationOfSafeBorrowing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CancellationOfSafeBorrowing" xlink:to="eyes_CancellationOfSafeBorrowing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_CancellationOfSafeBorrowing_lbl" xml:lang="en-US">Proceeds from SAFE note</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Net proceeds from sale of common stock and exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Balance at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Balance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfCancellations" xlink:label="us-gaap_EstimateOfCancellations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfCancellations" xlink:to="us-gaap_EstimateOfCancellations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfCancellations_lbl" xml:lang="en-US">Cancellation of SAFE indebtedness in merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US">Net liabilities acquired in merger for stock consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Business Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Money Market Funds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Selected Balance Sheet Detail</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureGrantsAbstract" xlink:label="eyes_DisclosureGrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DisclosureGrantsAbstract" xlink:to="eyes_DisclosureGrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DisclosureGrantsAbstract_lbl" xml:lang="en-US">Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsTextBlock" xlink:label="eyes_GrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsTextBlock" xlink:to="eyes_GrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_GrantsTextBlock_lbl" xml:lang="en-US">Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureWarrantsAbstract" xlink:label="eyes_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DisclosureWarrantsAbstract" xlink:to="eyes_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WarrantDisclosureTextBlock" xlink:label="eyes_WarrantDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WarrantDisclosureTextBlock" xlink:to="eyes_WarrantDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_WarrantDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:label="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Right-of-use Assets And Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" xlink:label="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" xlink:to="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_lbl" xml:lang="en-US">Right-of-use Assets and Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Policies Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NhGrant" xlink:label="eyes_NhGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NhGrant" xlink:to="eyes_NhGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_NhGrant_lbl" xml:lang="en-US">NIH Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ForeignOperationsPolicyTextBlock" xlink:label="eyes_ForeignOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ForeignOperationsPolicyTextBlock" xlink:to="eyes_ForeignOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ForeignOperationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation and Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyPolicy" xlink:to="us-gaap_StandardProductWarrantyPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US">Product Warranties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Operating Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="us-gaap_GainLossOnInvestmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock_lbl" xml:lang="en-US">The following table summarizes the calculation of the gain on bargain purchase (in thousands)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:label="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:to="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated useful lives of principal classes of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Money Market Funds at their Level within the Fair Value Hierarchy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" xlink:label="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" xlink:to="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_lbl" xml:lang="en-US">Summary of Option Grant using the Black-Scholes Option-pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashAndCashEquivalentsFairValue" xlink:label="eyes_CashAndCashEquivalentsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CashAndCashEquivalentsFairValue" xlink:to="eyes_CashAndCashEquivalentsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_CashAndCashEquivalentsFairValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLeaseRightOfUseAssetOne" xlink:label="eyes_OperatingLeaseRightOfUseAssetOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeaseRightOfUseAssetOne" xlink:to="eyes_OperatingLeaseRightOfUseAssetOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_OperatingLeaseRightOfUseAssetOne_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="us-gaap_OtherAssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_FairValueOfAssetsAcquired1" xlink:label="eyes_FairValueOfAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_FairValueOfAssetsAcquired1" xlink:to="eyes_FairValueOfAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_FairValueOfAssetsAcquired1_lbl" xml:lang="en-US">Total identifiable assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Right of use liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_FairValueOfLiabilitesAcquired" xlink:label="eyes_FairValueOfLiabilitesAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_FairValueOfLiabilitesAcquired" xlink:to="eyes_FairValueOfLiabilitesAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyes_FairValueOfLiabilitesAcquired_lbl" xml:lang="en-US">Total liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net identifiable assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_TotalConsideration" xlink:label="eyes_TotalConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_TotalConsideration" xlink:to="eyes_TotalConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyes_TotalConsideration_lbl" xml:lang="en-US">Total consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesFairValueDisclosure" xlink:label="us-gaap_AdvancesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesFairValueDisclosure" xlink:to="us-gaap_AdvancesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdvancesFairValueDisclosure_lbl" xml:lang="en-US">SAFE loan forgiven</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_lbl" xml:lang="en-US">Less net identifiable assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GainOnBargainPurchase" xlink:label="eyes_GainOnBargainPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GainOnBargainPurchase" xlink:to="eyes_GainOnBargainPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_GainOnBargainPurchase_lbl" xml:lang="en-US">Gain on bargain purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Ownership interest (in percentage)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Purchase consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock, voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xml:lang="en-US">Fair value of the consideration transferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xml:lang="en-US">Assets, fair value adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" xlink:label="us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" xlink:to="us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_lbl" xml:lang="en-US">Fair value of identifiable assets acquired and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_lbl" xml:lang="en-US">Gain of other income expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Shares underlying warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:label="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:to="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DescriptionOfMaterialContingenciesOfParentCompany" xlink:label="srt_DescriptionOfMaterialContingenciesOfParentCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DescriptionOfMaterialContingenciesOfParentCompany" xlink:to="srt_DescriptionOfMaterialContingenciesOfParentCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DescriptionOfMaterialContingenciesOfParentCompany_lbl" xml:lang="en-US">Description of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsAgainstOperatingExpense" xlink:label="eyes_GrantsAgainstOperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsAgainstOperatingExpense" xlink:to="eyes_GrantsAgainstOperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GrantsAgainstOperatingExpense_lbl" xml:lang="en-US">Grants offset against operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashSPICInsuredAmount" xlink:label="eyes_CashSPICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CashSPICInsuredAmount" xlink:to="eyes_CashSPICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_CashSPICInsuredAmount_lbl" xml:lang="en-US">SPIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SPICCashLimitCoverage" xlink:label="eyes_SPICCashLimitCoverage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_SPICCashLimitCoverage" xlink:to="eyes_SPICCashLimitCoverage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_SPICCashLimitCoverage_lbl" xml:lang="en-US">SPIC cash limit coverage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_AccruedLiabilitiesCurrent1" xlink:label="eyes_AccruedLiabilitiesCurrent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_AccruedLiabilitiesCurrent1" xlink:to="eyes_AccruedLiabilitiesCurrent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_AccruedLiabilitiesCurrent1_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DivisionIncurred" xlink:label="eyes_DivisionIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DivisionIncurred" xlink:to="eyes_DivisionIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DivisionIncurred_lbl" xml:lang="en-US">Division Incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss1" xlink:label="eyes_OperatingIncomeLoss1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss1" xlink:to="eyes_OperatingIncomeLoss1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_OperatingIncomeLoss1_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss2" xlink:label="eyes_OperatingIncomeLoss2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss2" xlink:to="eyes_OperatingIncomeLoss2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_OperatingIncomeLoss2_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss3" xlink:label="eyes_OperatingIncomeLoss3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss3" xlink:to="eyes_OperatingIncomeLoss3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_OperatingIncomeLoss3_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DivisionIncurredOfAssets" xlink:label="eyes_DivisionIncurredOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DivisionIncurredOfAssets" xlink:to="eyes_DivisionIncurredOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DivisionIncurredOfAssets_lbl" xml:lang="en-US">Division incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable_lbl" xml:lang="en-US">Impairment Effects on Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems_lbl" xml:lang="en-US">Impairment Effects on Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Money market funds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ContractLiabilitiesOther" xlink:label="eyes_ContractLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ContractLiabilitiesOther" xlink:to="eyes_ContractLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ContractLiabilitiesOther_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantReceivedToSupportClinicalDevelopment" xlink:label="eyes_GrantReceivedToSupportClinicalDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantReceivedToSupportClinicalDevelopment" xlink:to="eyes_GrantReceivedToSupportClinicalDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GrantReceivedToSupportClinicalDevelopment_lbl" xml:lang="en-US">Received grant</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" xlink:label="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" xlink:to="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_lbl" xml:lang="en-US">Grant receivable with intent to fund early feasibility clinical trial for five years</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantReceivedFundingPeriod" xlink:label="eyes_GrantReceivedFundingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantReceivedFundingPeriod" xlink:to="eyes_GrantReceivedFundingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GrantReceivedFundingPeriod_lbl" xml:lang="en-US">Grant received funding period</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsAgainstOperatingExpenses" xlink:label="eyes_GrantsAgainstOperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsAgainstOperatingExpenses" xlink:to="eyes_GrantsAgainstOperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GrantsAgainstOperatingExpenses_lbl" xml:lang="en-US">Grants against operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expenses.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_3_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" xlink:label="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" xlink:to="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions_lbl" xml:lang="en-US">Stock issued during period shares merger acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightIssued" xlink:label="eyes_ClassOfWarrantOrRightIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightIssued" xlink:to="eyes_ClassOfWarrantOrRightIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightExerciseIssued" xlink:label="eyes_ClassOfWarrantOrRightExerciseIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightExerciseIssued" xlink:to="eyes_ClassOfWarrantOrRightExerciseIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightExerciseIssued_lbl" xml:lang="en-US">Class of warrant or right exercise issued</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightExercised" xlink:label="eyes_ClassOfWarrantOrRightExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightExercised" xlink:to="eyes_ClassOfWarrantOrRightExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightForfeitedOrExpired" xlink:label="eyes_ClassOfWarrantOrRightForfeitedOrExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightForfeitedOrExpired" xlink:to="eyes_ClassOfWarrantOrRightForfeitedOrExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightForfeitedOrExpired_lbl" xml:lang="en-US">Forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightToBeExercised" xlink:label="eyes_ClassOfWarrantOrRightToBeExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightToBeExercised" xlink:to="eyes_ClassOfWarrantOrRightToBeExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightToBeExercised_lbl" xml:lang="en-US">Class of warrant or right to be exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightOtherAdjustments" xlink:label="eyes_ClassOfWarrantOrRightOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightOtherAdjustments" xlink:to="eyes_ClassOfWarrantOrRightOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightOtherAdjustment" xlink:label="eyes_ClassOfWarrantOrRightOtherAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightOtherAdjustment" xlink:to="eyes_ClassOfWarrantOrRightOtherAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightOtherAdjustment_lbl" xml:lang="en-US">Class of warrant or right other adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_lbl" xml:lang="en-US">Other adjustments (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_lbl" xml:lang="en-US">Outstanding at ending (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:to="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:to="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_lbl" xml:lang="en-US">Exercisable at ending (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantsOrRightsTerm" xlink:label="eyes_ClassOfWarrantsOrRightsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantsOrRightsTerm" xlink:to="eyes_ClassOfWarrantsOrRightsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantsOrRightsTerm_lbl" xml:lang="en-US">Term of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Employer contributions to plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ShareBasedCompensation1" xlink:label="eyes_ShareBasedCompensation1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ShareBasedCompensation1" xlink:to="eyes_ShareBasedCompensation1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ShareBasedCompensation1_lbl" xml:lang="en-US">stock based compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, number of shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited or expired, weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:label="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:to="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Other adjustments , weighted average exercise price (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, number of shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, vested and expected to vest (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, vested and expected to vest (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, number of shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable period (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US">&#160;Accruals/reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">&#160;Capitalized R&amp;E &#167;174</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xml:lang="en-US">&#160;Lease ROU</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">&#160;Stock Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">&#160;Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">&#160;R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">&#160;Gross Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_lbl" xml:lang="en-US">&#160;Investment in Sub</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" xlink:label="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" xlink:to="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_lbl" xml:lang="en-US">&#160;Accumulated depreciation/amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">&#160;Gross deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_TaxCreditCarryforwardValuationAllowance1" xlink:label="eyes_TaxCreditCarryforwardValuationAllowance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_TaxCreditCarryforwardValuationAllowance1" xlink:to="eyes_TaxCreditCarryforwardValuationAllowance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_TaxCreditCarryforwardValuationAllowance1_lbl" xml:lang="en-US">&#160;Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US">&#160;Total Deferred Tax Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">&#160;Change in valuation allowance for the year ended</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax (benefit) at statutory rate (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax (benefit), net of federal tax benefit (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">R&amp;D tax credit from current year (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Other (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Change in valuation allowance (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total provision for income taxes (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Post TCJA period federal NOL carry-forward, with no carry-forward limitation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Total federal NOL carry-forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xml:lang="en-US">&#160;State NOL carry-forward, begin expiring 2030</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Federal R&amp;D tax credit carry-forward, begin expiring in 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DeferredTaxAssetsStateTaxes1" xlink:label="eyes_DeferredTaxAssetsStateTaxes1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DeferredTaxAssetsStateTaxes1" xlink:to="eyes_DeferredTaxAssetsStateTaxes1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_DeferredTaxAssetsStateTaxes1_lbl" xml:lang="en-US">State R&amp;D carry-forward, begin expiring in 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">Total R&amp;E related deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract_2_lbl" xml:lang="en-US">Company Evaluated Lease Amendment Under Provisions Of Asc 842. Information Related To Companys Right-of-use Assets And Related Lease Liabilities Are As Followings In Thousands Except For Remaining Lease Term And Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLeasePayment" xlink:label="eyes_OperatingLeasePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeasePayment" xlink:to="eyes_OperatingLeasePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_OperatingLeasePayment_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLeasePayments1" xlink:label="eyes_OperatingLeasePayments1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeasePayments1" xlink:to="eyes_OperatingLeasePayments1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyes_OperatingLeasePayments1_lbl" xml:lang="en-US">Current operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Long term operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LeaseAndRentalExpense1" xlink:label="eyes_LeaseAndRentalExpense1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LeaseAndRentalExpense1" xlink:to="eyes_LeaseAndRentalExpense1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_LeaseAndRentalExpense1_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClinicalAndRegulatoryExpense" xlink:label="eyes_ClinicalAndRegulatoryExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClinicalAndRegulatoryExpense" xlink:to="eyes_ClinicalAndRegulatoryExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClinicalAndRegulatoryExpense_lbl" xml:lang="en-US">Clinical and regulatory expense</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LiquidatedDamagesPaidValue" xlink:label="eyes_LiquidatedDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LiquidatedDamagesPaidValue" xlink:to="eyes_LiquidatedDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_LiquidatedDamagesPaidValue_lbl" xml:lang="en-US">Liquidated damage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractTerminationClaimsDescription" xlink:label="us-gaap_ContractTerminationClaimsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationClaimsDescription" xlink:to="us-gaap_ContractTerminationClaimsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationClaimsDescription_lbl" xml:lang="en-US">Description of contract termination and claims</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Loss contingency, damages paid, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementCourt" xlink:label="us-gaap_LossContingencySettlementAgreementCourt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencySettlementAgreementCourt" xlink:to="us-gaap_LossContingencySettlementAgreementCourt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencySettlementAgreementCourt_lbl" xml:lang="en-US">Description of legal settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rental payments amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Description of lease agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WarrantsMember" xlink:to="eyes_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_WarrantsMember_doc" xml:lang="en-US">The element represents warrants member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DepositsAndOtherAssets" xlink:to="eyes_DepositsAndOtherAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_DepositsAndOtherAssets_doc" xml:lang="en-US">The element represents deposits and other assets.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClinicalAndRegulatoryExpenseNetOfGrants" xlink:label="eyes_ClinicalAndRegulatoryExpenseNetOfGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClinicalAndRegulatoryExpenseNetOfGrants" xlink:to="eyes_ClinicalAndRegulatoryExpenseNetOfGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClinicalAndRegulatoryExpenseNetOfGrants_doc" xml:lang="en-US">The element represents clinical and regulatory expense net of grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" xlink:to="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts_doc" xml:lang="en-US">The element represents stock issued during period value common stock and warrants in connection with rights offering net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GainFromBargainPurchase" xlink:to="eyes_GainFromBargainPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GainFromBargainPurchase_doc" xml:lang="en-US">The element represents gain from bargain purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CancellationOfSafeBorrowing" xlink:to="eyes_CancellationOfSafeBorrowing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_CancellationOfSafeBorrowing_doc" xml:lang="en-US">The element represents cancellation of safe borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CashAcquiredInMergerForStockConsideration" xlink:to="eyes_CashAcquiredInMergerForStockConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_CashAcquiredInMergerForStockConsideration_doc" xml:lang="en-US">The element represents cash acquired in merger for stock consideration.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockOptionsWarrantsExercised" xlink:label="eyes_StockIssuedDuringPeriodValueStockOptionsWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueStockOptionsWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodValueStockOptionsWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodValueStockOptionsWarrantsExercised_doc" xml:lang="en-US">The element represents stock issued during period value stock options warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised_doc" xml:lang="en-US">The element represents stock issued during period shares stock options warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xml:lang="en-US">The element represents stock issued during period value stock warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xml:lang="en-US">The element represents stock issued during period shares stock warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_doc" xml:lang="en-US">The element represents stock issued during period value stock options and warrants exercised.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="eyes_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="eyes_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_doc" xml:lang="en-US">The element represents stock issued during period shares stock options and warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_FairValueOfAssetsAcquired1" xlink:to="eyes_FairValueOfAssetsAcquired1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_FairValueOfAssetsAcquired1_doc" xml:lang="en-US">The element represents fair value of assets acquired1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_FairValueOfLiabilitesAcquired" xlink:to="eyes_FairValueOfLiabilitesAcquired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_FairValueOfLiabilitesAcquired_doc" xml:lang="en-US">The element represents fair value of liabilites acquired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_TotalConsideration" xlink:to="eyes_TotalConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_TotalConsideration_doc" xml:lang="en-US">The element represents total consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GainOnBargainPurchase" xlink:to="eyes_GainOnBargainPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GainOnBargainPurchase_doc" xml:lang="en-US">The element represents gain on bargain purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:to="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">The element represents schedule of estimated useful life of property and equipment table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NhGrant" xlink:to="eyes_NhGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_NhGrant_doc" xml:lang="en-US">The element represents nh grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsAgainstOperatingExpense" xlink:to="eyes_GrantsAgainstOperatingExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GrantsAgainstOperatingExpense_doc" xml:lang="en-US">The element represents grants against operating expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CashSPICInsuredAmount" xlink:to="eyes_CashSPICInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_CashSPICInsuredAmount_doc" xml:lang="en-US">The element represents cash s p i c insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_SPICCashLimitCoverage" xlink:to="eyes_SPICCashLimitCoverage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_SPICCashLimitCoverage_doc" xml:lang="en-US">The element represents s p i c cash limit coverage.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLossCarryforwardsExpirationYear" xlink:label="eyes_OperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLossCarryforwardsExpirationYear" xlink:to="eyes_OperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">The element represents operating loss carryforwards expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:to="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_doc" xml:lang="en-US">The element represents antidilutive securities excluded from computation of earnings per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DivisionIncurred" xlink:to="eyes_DivisionIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_DivisionIncurred_doc" xml:lang="en-US">The element represents division incurred.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ValueOfConsolidated" xlink:label="eyes_ValueOfConsolidated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ValueOfConsolidated" xlink:to="eyes_ValueOfConsolidated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ValueOfConsolidated_doc" xml:lang="en-US">The element represents value of consolidated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ContractLiabilitiesOther" xlink:to="eyes_ContractLiabilitiesOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ContractLiabilitiesOther_doc" xml:lang="en-US">The element represents contract liabilities other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsTextBlock" xlink:to="eyes_GrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GrantsTextBlock_doc" xml:lang="en-US">The element represents grants text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantReceivedToSupportClinicalDevelopment" xlink:to="eyes_GrantReceivedToSupportClinicalDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GrantReceivedToSupportClinicalDevelopment_doc" xml:lang="en-US">The element represents grant received to support clinical development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" xlink:to="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_doc" xml:lang="en-US">The element represents grant receivable to fund early feasibility clinical trial for five years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantReceivedFundingPeriod" xlink:to="eyes_GrantReceivedFundingPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GrantReceivedFundingPeriod_doc" xml:lang="en-US">The element represents grant received funding period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsAgainstOperatingExpenses" xlink:to="eyes_GrantsAgainstOperatingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_GrantsAgainstOperatingExpenses_doc" xml:lang="en-US">The element represents grants against operating expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" xlink:to="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_StockIssuedDuringPeriodSharesMergerAcquisitions_doc" xml:lang="en-US">The element represents stock issued during period shares merger acquisitions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_RightOfferingMember" xlink:to="eyes_RightOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_RightOfferingMember_doc" xml:lang="en-US">The element represents right offering member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WarrantDisclosureTextBlock" xlink:to="eyes_WarrantDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_WarrantDisclosureTextBlock_doc" xml:lang="en-US">The element represents warrant disclosure text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantsOrRightsTerm" xlink:to="eyes_ClassOfWarrantsOrRightsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantsOrRightsTerm_doc" xml:lang="en-US">The element represents class of warrants or rights term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightIssued" xlink:to="eyes_ClassOfWarrantOrRightIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightIssued_doc" xml:lang="en-US">The element represents class of warrant or right issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightExercised" xlink:to="eyes_ClassOfWarrantOrRightExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightExercised_doc" xml:lang="en-US">The element represents class of warrant or right exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightForfeitedOrExpired" xlink:to="eyes_ClassOfWarrantOrRightForfeitedOrExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightForfeitedOrExpired_doc" xml:lang="en-US">The element represents class of warrant or right forfeited or expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightOtherAdjustments" xlink:to="eyes_ClassOfWarrantOrRightOtherAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightOtherAdjustments_doc" xml:lang="en-US">The element represents class of warrant or right other adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:to="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_doc" xml:lang="en-US">The element represents class of warrant or right weighted exercise price exercisable of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightExerciseIssued" xlink:to="eyes_ClassOfWarrantOrRightExerciseIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightExerciseIssued_doc" xml:lang="en-US">The element represents class of warrant or right exercise issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightToBeExercised" xlink:to="eyes_ClassOfWarrantOrRightToBeExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightToBeExercised_doc" xml:lang="en-US">The element represents class of warrant or right to be exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:to="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_doc" xml:lang="en-US">The element represents class of warrant or right weighted exercise price exercisable of warrants or rights11.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1_doc" xml:lang="en-US">The element represents class of warrant or right weighted average remaining contractual life of warrants or rights1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_doc" xml:lang="en-US">The element represents class of warrant or right weighted average remaining contractual life of warrants or rights one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_doc" xml:lang="en-US">The element represents class of warrant or right weighted average remaining contractual life of warrants or rights2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" xlink:to="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_doc" xml:lang="en-US">The element represents class of warrant or right weighted average remaining contractual life of warrants or rights exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" xlink:to="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_doc" xml:lang="en-US">The element represents schedule of share based compensation arrangement by share based payment award options grants in period table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightOtherAdjustment" xlink:to="eyes_ClassOfWarrantOrRightOtherAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClassOfWarrantOrRightOtherAdjustment_doc" xml:lang="en-US">The element represents class of warrant or right other adjustment.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_The2011EquityIncentivePlanMember" xlink:label="eyes_The2011EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_The2011EquityIncentivePlanMember" xlink:to="eyes_The2011EquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_The2011EquityIncentivePlanMember_doc" xml:lang="en-US">The element represents the 2011 equity incentive plan member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:to="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options other adjustments in period.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClinicalAndRegulatoryMember" xlink:label="eyes_ClinicalAndRegulatoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClinicalAndRegulatoryMember" xlink:to="eyes_ClinicalAndRegulatoryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClinicalAndRegulatoryMember_doc" xml:lang="en-US">The element represents clinical and regulatory member.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DeferredTaxAssetsResearchCredits" xlink:label="eyes_DeferredTaxAssetsResearchCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DeferredTaxAssetsResearchCredits" xlink:to="eyes_DeferredTaxAssetsResearchCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_DeferredTaxAssetsResearchCredits_doc" xml:lang="en-US">The element represents deferred tax assets research credits.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DeferredTaxAssetsDepreciation" xlink:label="eyes_DeferredTaxAssetsDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DeferredTaxAssetsDepreciation" xlink:to="eyes_DeferredTaxAssetsDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_DeferredTaxAssetsDepreciation_doc" xml:lang="en-US">The element represents deferred tax assets depreciation.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LimitationArisingFromEstimatedOwnershipChange" xlink:label="eyes_LimitationArisingFromEstimatedOwnershipChange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LimitationArisingFromEstimatedOwnershipChange" xlink:to="eyes_LimitationArisingFromEstimatedOwnershipChange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LimitationArisingFromEstimatedOwnershipChange_doc" xml:lang="en-US">The element represents limitation arising from estimated ownership change.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" xlink:to="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_doc" xml:lang="en-US">The element represents right of use assets and operating lease liabilities text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_doc" xml:lang="en-US">The element represents lessee discounted operating lease liability payments due year three.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeasePayment" xlink:to="eyes_OperatingLeasePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingLeasePayment_doc" xml:lang="en-US">The element represents operating lease payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeasePayments1" xlink:to="eyes_OperatingLeasePayments1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingLeasePayments1_doc" xml:lang="en-US">The element represents operating lease payments1.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClinicalTrialAgreementsExpenses" xlink:label="eyes_ClinicalTrialAgreementsExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClinicalTrialAgreementsExpenses" xlink:to="eyes_ClinicalTrialAgreementsExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClinicalTrialAgreementsExpenses_doc" xml:lang="en-US">The element represents clinical trial agreements expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LiquidatedDamagesPaidValue" xlink:to="eyes_LiquidatedDamagesPaidValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LiquidatedDamagesPaidValue_doc" xml:lang="en-US">The element represents liquidated damages paid value.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LossContingencyPayable" xlink:label="eyes_LossContingencyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LossContingencyPayable" xlink:to="eyes_LossContingencyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LossContingencyPayable_doc" xml:lang="en-US">The element represents loss contingency payable.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NetOperatingLossCarryforwardsExpiringUnusedMember" xlink:label="eyes_NetOperatingLossCarryforwardsExpiringUnusedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NetOperatingLossCarryforwardsExpiringUnusedMember" xlink:to="eyes_NetOperatingLossCarryforwardsExpiringUnusedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_NetOperatingLossCarryforwardsExpiringUnusedMember_doc" xml:lang="en-US">The element represents net operating loss carryforwards expiring unused member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NetLossPerCommonShareBasicAndDiluted" xlink:to="eyes_NetLossPerCommonShareBasicAndDiluted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_NetLossPerCommonShareBasicAndDiluted_doc" xml:lang="en-US">The element represents net loss per common share basic and diluted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:to="eyes_WeightedAverageSharesOutstandingBasicAndDiluted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_WeightedAverageSharesOutstandingBasicAndDiluted_doc" xml:lang="en-US">The element represents weighted average shares outstanding basic and diluted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ProceedsFromIssuanceOfCommonStockAndWarrants_doc" xml:lang="en-US">The element represents proceeds from issuance of common stock and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ForeignOperationsPolicyTextBlock" xlink:to="eyes_ForeignOperationsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ForeignOperationsPolicyTextBlock_doc" xml:lang="en-US">The element represents foreign operations policy text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_AccruedLiabilitiesCurrent1" xlink:to="eyes_AccruedLiabilitiesCurrent1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_AccruedLiabilitiesCurrent1_doc" xml:lang="en-US">The element represents accrued liabilities current.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingExpenses1" xlink:label="eyes_OperatingExpenses1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingExpenses1" xlink:to="eyes_OperatingExpenses1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingExpenses1_doc" xml:lang="en-US">The element represents Operating expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss1" xlink:to="eyes_OperatingIncomeLoss1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingIncomeLoss1_doc" xml:lang="en-US">The element represents Operating income loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_PppLoanForgiveness" xlink:to="eyes_PppLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_PppLoanForgiveness_doc" xml:lang="en-US">The element represents ppp loan forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LeaseAndRentalExpense1" xlink:to="eyes_LeaseAndRentalExpense1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LeaseAndRentalExpense1_doc" xml:lang="en-US">The element represents Lease and rental expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ShareBasedCompensation1" xlink:to="eyes_ShareBasedCompensation1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ShareBasedCompensation1_doc" xml:lang="en-US">The element represents share based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeaseRightOfUseAssetOne" xlink:to="eyes_OperatingLeaseRightOfUseAssetOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingLeaseRightOfUseAssetOne_doc" xml:lang="en-US">The element represents Operating lease right of use asset one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_CashAndCashEquivalentsFairValue" xlink:to="eyes_CashAndCashEquivalentsFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_CashAndCashEquivalentsFairValue_doc" xml:lang="en-US">The element represents Cash and cash equivalents fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DivisionIncurredOfAssets" xlink:to="eyes_DivisionIncurredOfAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_DivisionIncurredOfAssets_doc" xml:lang="en-US">The element represents division incurred of assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NeuromodulationDivisionMember" xlink:to="eyes_NeuromodulationDivisionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_NeuromodulationDivisionMember_doc" xml:lang="en-US">The element represents neuromodulation division member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_BiopharmDivisionMember" xlink:to="eyes_BiopharmDivisionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_BiopharmDivisionMember_doc" xml:lang="en-US">The element represents biopharm division member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NPMMember" xlink:to="eyes_NPMMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_NPMMember_doc" xml:lang="en-US">The element represents NPM member.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacyNMPMember" xlink:label="eyes_LegacyNMPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LegacyNMPMember" xlink:to="eyes_LegacyNMPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LegacyNMPMember_doc" xml:lang="en-US">The element represents legacy NMP member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_DeferredTaxAssetsStateTaxes1" xlink:to="eyes_DeferredTaxAssetsStateTaxes1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_DeferredTaxAssetsStateTaxes1_doc" xml:lang="en-US">The element represents deferred tax assets state taxes.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SSMPMember" xlink:label="eyes_SSMPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_SSMPMember" xlink:to="eyes_SSMPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_SSMPMember_doc" xml:lang="en-US">The element represents SSMP member.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LeaseAgreementMember" xlink:label="eyes_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LeaseAgreementMember" xlink:to="eyes_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LeaseAgreementMember_doc" xml:lang="en-US">The element represents lease agreement member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_MrAdamsMember" xlink:to="eyes_MrAdamsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_MrAdamsMember_doc" xml:lang="en-US">The element represents mr adams member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" xlink:to="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_doc" xml:lang="en-US">The elemnt represents accumulated depreciation and amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LegacySSMPMember" xlink:to="eyes_LegacySSMPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LegacySSMPMember_doc" xml:lang="en-US">The element represents Legacy SSMP member.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NMPMember" xlink:label="eyes_NMPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_NMPMember" xlink:to="eyes_NMPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_NMPMember_doc" xml:lang="en-US">The element represents NMP member.</link:label>
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPOneMember" xlink:label="eyes_LegacySSMPOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_LegacySSMPOneMember" xlink:to="eyes_LegacySSMPOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_LegacySSMPOneMember_doc" xml:lang="en-US">The element represents legacy SSMP member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClinicalAndRegulatoryExpense" xlink:to="eyes_ClinicalAndRegulatoryExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_ClinicalAndRegulatoryExpense_doc" xml:lang="en-US">The element represents clinical and regulatory expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss2" xlink:to="eyes_OperatingIncomeLoss2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingIncomeLoss2_doc" xml:lang="en-US">The element represents Operating income loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss3" xlink:to="eyes_OperatingIncomeLoss3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyes_OperatingIncomeLoss3_doc" xml:lang="en-US">The element represents Operating income loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GainFromBargainPurchase" xlink:to="eyes_GainFromBargainPurchase_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GainFromBargainPurchase_3_lbl" xml:lang="en-US">Gain from Bargain Purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_PppLoanForgiveness" xlink:to="eyes_PppLoanForgiveness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_PppLoanForgiveness_3_lbl" xml:lang="en-US">Ppp Loan Forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_2_lbl" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GrantsTextBlock" xlink:to="eyes_GrantsTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GrantsTextBlock_3_lbl" xml:lang="en-US">Grants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_WarrantDisclosureTextBlock" xlink:to="eyes_WarrantDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_WarrantDisclosureTextBlock_3_lbl" xml:lang="en-US">Warrant Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_FairValueOfLiabilitesAcquired" xlink:to="eyes_FairValueOfLiabilitesAcquired_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_FairValueOfLiabilitesAcquired_3_lbl" xml:lang="en-US">Fair Value of Liabilites Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_TotalConsideration" xlink:to="eyes_TotalConsideration_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_TotalConsideration_3_lbl" xml:lang="en-US">Total Consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesFairValueDisclosure" xlink:to="us-gaap_AdvancesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesFairValueDisclosure_2_lbl" xml:lang="en-US">Advances, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_GainOnBargainPurchase" xlink:to="eyes_GainOnBargainPurchase_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_GainOnBargainPurchase_3_lbl" xml:lang="en-US">Gain on Bargain Purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_AccruedLiabilitiesCurrent1" xlink:to="eyes_AccruedLiabilitiesCurrent1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_AccruedLiabilitiesCurrent1_3_lbl" xml:lang="en-US">Accrued Liabilities Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss2" xlink:to="eyes_OperatingIncomeLoss2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_OperatingIncomeLoss2_3_lbl" xml:lang="en-US">Operating Income Loss two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingIncomeLoss3" xlink:to="eyes_OperatingIncomeLoss3_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_OperatingIncomeLoss3_3_lbl" xml:lang="en-US">Operating Income Loss three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:to="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_3_lbl" xml:lang="en-US">Class of Warrant or Right Weighted Exercise Price Exercisable of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:to="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_3_lbl" xml:lang="en-US">Class of Warrant or Right Weighted Exercise Price Exercisable of Warrants or Rights11</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:to="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Other Adjustments in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesOther_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_2_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyes_OperatingLeasePayments1" xlink:to="eyes_OperatingLeasePayments1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyes_OperatingLeasePayments1_3_lbl" xml:lang="en-US">Operating Lease Payments1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>eyes-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://secondsight.com/role/Cover" xlink:href="eyes-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/BalanceSheets" xlink:href="eyes-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/BalanceSheetsParenthetical" xlink:href="eyes-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfOperations" xlink:href="eyes-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfComprehensiveLoss" xlink:href="eyes-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eyes-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/StatementsOfCashFlows" xlink:href="eyes-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperations" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccounting" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccounting" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFunds" xlink:href="eyes-20221231.xsd#MoneyMarketFunds" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetail" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Grants" xlink:href="eyes-20221231.xsd#Grants" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EquitySecurities" xlink:href="eyes-20221231.xsd#EquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Warrants" xlink:href="eyes-20221231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EmployeeBenefitPlans" xlink:href="eyes-20221231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensation" xlink:href="eyes-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/IncomeTaxes" xlink:href="eyes-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CommitmentsAndContingencies" xlink:href="eyes-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SubsequentEvent" xlink:href="eyes-20221231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingTables" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFundsTables" xlink:href="eyes-20221231.xsd#MoneyMarketFundsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailTables" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/WarrantsTables" xlink:href="eyes-20221231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationTables" xlink:href="eyes-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/IncomeTaxesTables" xlink:href="eyes-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:href="eyes-20221231.xsd#FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:href="eyes-20221231.xsd#FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" xlink:href="eyes-20221231.xsd#OrganizationAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:href="eyes-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" xlink:href="eyes-20221231.xsd#ScheduleOfNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" xlink:href="eyes-20221231.xsd#SummaryOfSignificantAccountingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:href="eyes-20221231.xsd#ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" xlink:href="eyes-20221231.xsd#MoneyMarketFundsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:href="eyes-20221231.xsd#PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" xlink:href="eyes-20221231.xsd#SelectedBalanceSheetDetailDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/GrantsDetailsNarrative" xlink:href="eyes-20221231.xsd#GrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" xlink:href="eyes-20221231.xsd#EquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfWarrantActivityDetails" xlink:href="eyes-20221231.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/WarrantsDetailsNarrative" xlink:href="eyes-20221231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:href="eyes-20221231.xsd#EmployeeBenefitPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:href="eyes-20221231.xsd#SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" xlink:href="eyes-20221231.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" xlink:href="eyes-20221231.xsd#Stock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="eyes-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:href="eyes-20221231.xsd#ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:href="eyes-20221231.xsd#ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:href="eyes-20221231.xsd#AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:href="eyes-20221231.xsd#CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:href="eyes-20221231.xsd#Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="eyes-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://secondsight.com/role/SubsequentEventDetailsNarrative" xlink:href="eyes-20221231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WarrantsMember" xlink:label="loc_eyesWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_eyesWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DepositsAndOtherAssets" xlink:label="loc_eyesDepositsAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_eyesDepositsAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="loc_us-gaapLitigationReserveNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLitigationReserveNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaapInterestIncomeOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnRepurchaseOfDebtInstrument" xlink:label="loc_us-gaapGainLossOnRepurchaseOfDebtInstrument" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainLossOnRepurchaseOfDebtInstrument" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NetLossPerCommonShareBasicAndDiluted" xlink:label="loc_eyesNetLossPerCommonShareBasicAndDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_eyesNetLossPerCommonShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:label="loc_eyesWeightedAverageSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_eyesWeightedAverageSharesOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholder&apos;s Equity (Deficit) (unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" xlink:label="loc_eyesStockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodValueStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" xlink:label="loc_eyesStockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodSharesStockOptionsWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GainFromBargainPurchase" xlink:label="loc_eyesGainFromBargainPurchase" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_eyesGainFromBargainPurchase" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_PppLoanForgiveness" xlink:label="loc_eyesPppLoanForgiveness" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_eyesPppLoanForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashAcquiredInMergerForStockConsideration" xlink:label="loc_eyesCashAcquiredInMergerForStockConsideration" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_eyesCashAcquiredInMergerForStockConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CancellationOfSafeBorrowing" xlink:label="loc_eyesCancellationOfSafeBorrowing" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_eyesCancellationOfSafeBorrowing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_eyesProceedsFromIssuanceOfCommonStockAndWarrants" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_eyesProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfCancellations" xlink:label="loc_us-gaapEstimateOfCancellations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapEstimateOfCancellations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperations" xlink:title="00000008 - Disclosure - Organization and Business Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccounting" xlink:title="00000009 - Disclosure - Summary of Significant Accounting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFunds" xlink:title="00000010 - Disclosure - Money Market Funds">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetail" xlink:title="00000011 - Disclosure - Selected Balance Sheet Detail">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Grants" xlink:title="00000012 - Disclosure - Grants">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureGrantsAbstract" xlink:label="loc_eyesDisclosureGrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsTextBlock" xlink:label="loc_eyesGrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_eyesGrantsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EquitySecurities" xlink:title="00000013 - Disclosure - Equity Securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Warrants" xlink:title="00000014 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureWarrantsAbstract" xlink:label="loc_eyesDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_WarrantDisclosureTextBlock" xlink:label="loc_eyesWarrantDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureWarrantsAbstract" xlink:to="loc_eyesWarrantDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EmployeeBenefitPlans" xlink:title="00000015 - Disclosure - Employee Benefit Plans">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensation" xlink:title="00000016 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities" xlink:title="00000018 - Disclosure - Right-of-use Assets and Operating Lease Liabilities">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:label="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" xlink:label="loc_eyesRightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_eyesRightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SubsequentEvent" xlink:title="00000020 - Disclosure - Subsequent Event">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000021 - Disclosure - Summary of Significant Accounting (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Reclassifications" xlink:label="loc_us-gaapReclassifications" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReclassifications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="loc_us-gaapLessorLeasesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLessorLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NhGrant" xlink:label="loc_eyesNhGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_eyesNhGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ForeignOperationsPolicyTextBlock" xlink:label="loc_eyesForeignOperationsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_eyesForeignOperationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaapStandardProductWarrantyPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStandardProductWarrantyPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperationsTables" xlink:title="00000022 - Disclosure - Organization and Business Operations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaapGainLossOnInvestmentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapGainLossOnInvestmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingTables" xlink:title="00000023 - Disclosure - Summary of Significant Accounting (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:label="loc_eyesScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_eyesScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFundsTables" xlink:title="00000024 - Disclosure - Money Market Funds (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetailTables" xlink:title="00000025 - Disclosure - Selected Balance Sheet Detail (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/WarrantsTables" xlink:title="00000026 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureWarrantsAbstract" xlink:label="loc_eyesDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" xlink:label="loc_eyesScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_eyesScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables" xlink:title="00000029 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:label="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails" xlink:title="00000030 - Disclosure - The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashAndCashEquivalentsFairValue" xlink:label="loc_eyesCashAndCashEquivalentsFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesCashAndCashEquivalentsFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="loc_us-gaapPropertyPlantAndEquipmentFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLeaseRightOfUseAssetOne" xlink:label="loc_eyesOperatingLeaseRightOfUseAssetOne" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesOperatingLeaseRightOfUseAssetOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="loc_us-gaapOtherAssetsFairValueDisclosure" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_FairValueOfAssetsAcquired1" xlink:label="loc_eyesFairValueOfAssetsAcquired1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesFairValueOfAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_FairValueOfLiabilitesAcquired" xlink:label="loc_eyesFairValueOfLiabilitesAcquired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesFairValueOfLiabilitesAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails" xlink:title="00000031 - Disclosure - The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_TotalConsideration" xlink:label="loc_eyesTotalConsideration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesTotalConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesFairValueDisclosure" xlink:label="loc_us-gaapAdvancesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAdvancesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GainOnBargainPurchase" xlink:label="loc_eyesGainOnBargainPurchase" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesGainOnBargainPurchase" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative" xlink:title="00000032 - Disclosure - Organization and Business Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtOwnershipAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SecondSightSwitzerlandSarlMember" xlink:label="loc_eyesSecondSightSwitzerlandSarlMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_eyesSecondSightSwitzerlandSarlMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaapSeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_us-gaapSeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProFormaMember" xlink:label="loc_srtProFormaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtProFormaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaapAssetsFairValueAdjustment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapAssetsFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" xlink:label="loc_us-gaapSensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapSensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails" xlink:title="00000033 - Disclosure - Schedule of estimated useful lives of principal classes of assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfNetLossPerShareDetails" xlink:title="00000034 - Disclosure -  Schedule of net loss per share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:label="loc_eyesAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_eyesAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative" xlink:title="00000035 - Disclosure - Summary of Significant Accounting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CountryMember" xlink:label="loc_eyesCountryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_eyesCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_BiopharmDivisionMember" xlink:label="loc_eyesBiopharmDivisionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_eyesBiopharmDivisionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NeuromodulationDivisionMember" xlink:label="loc_eyesNeuromodulationDivisionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_eyesNeuromodulationDivisionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DescriptionOfMaterialContingenciesOfParentCompany" xlink:label="loc_srtDescriptionOfMaterialContingenciesOfParentCompany" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_srtDescriptionOfMaterialContingenciesOfParentCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsAgainstOperatingExpense" xlink:label="loc_eyesGrantsAgainstOperatingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesGrantsAgainstOperatingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_CashSPICInsuredAmount" xlink:label="loc_eyesCashSPICInsuredAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesCashSPICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_SPICCashLimitCoverage" xlink:label="loc_eyesSPICCashLimitCoverage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesSPICCashLimitCoverage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_AccruedLiabilitiesCurrent1" xlink:label="loc_eyesAccruedLiabilitiesCurrent1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesAccruedLiabilitiesCurrent1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DivisionIncurred" xlink:label="loc_eyesDivisionIncurred" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesDivisionIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss1" xlink:label="loc_eyesOperatingIncomeLoss1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesOperatingIncomeLoss1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss2" xlink:label="loc_eyesOperatingIncomeLoss2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesOperatingIncomeLoss2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingIncomeLoss3" xlink:label="loc_eyesOperatingIncomeLoss3" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesOperatingIncomeLoss3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DivisionIncurredOfAssets" xlink:label="loc_eyesDivisionIncurredOfAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_eyesDivisionIncurredOfAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails" xlink:title="00000036 - Disclosure - Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:label="loc_us-gaapImpairmentEffectsOnEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapImpairmentEffectsOnEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/MoneyMarketFundsDetailsNarrative" xlink:title="00000037 - Disclosure - Money Market Funds (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaapCashAndCashEquivalentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapCashAndCashEquivalentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCashAndCashEquivalentsTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails" xlink:title="00000038 - Disclosure - Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ComputerHardwareAndSoftwareMember" xlink:label="loc_eyesComputerHardwareAndSoftwareMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_eyesComputerHardwareAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative" xlink:title="00000039 - Disclosure - Selected Balance Sheet Detail (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ContractLiabilitiesOther" xlink:label="loc_eyesContractLiabilitiesOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_eyesContractLiabilitiesOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/GrantsDetailsNarrative" xlink:title="00000040 - Disclosure - Grants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureGrantsAbstract" xlink:label="loc_eyesDisclosureGrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantReceivedToSupportClinicalDevelopment" xlink:label="loc_eyesGrantReceivedToSupportClinicalDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_eyesGrantReceivedToSupportClinicalDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" xlink:label="loc_eyesGrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_eyesGrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantReceivedFundingPeriod" xlink:label="loc_eyesGrantReceivedFundingPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_eyesGrantReceivedFundingPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_GrantsAgainstOperatingExpenses" xlink:label="loc_eyesGrantsAgainstOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_eyesGrantsAgainstOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureGrantsAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EquitySecuritiesDetailsNarrative" xlink:title="00000041 - Disclosure - Equity Securities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_StockIssuedDuringPeriodSharesMergerAcquisitions" xlink:label="loc_eyesStockIssuedDuringPeriodSharesMergerAcquisitions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_eyesStockIssuedDuringPeriodSharesMergerAcquisitions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000042 - Disclosure - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureWarrantsAbstract" xlink:label="loc_eyesDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightIssued" xlink:label="loc_eyesClassOfWarrantOrRightIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightExerciseIssued" xlink:label="loc_eyesClassOfWarrantOrRightExerciseIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightExerciseIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightExercised" xlink:label="loc_eyesClassOfWarrantOrRightExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightForfeitedOrExpired" xlink:label="loc_eyesClassOfWarrantOrRightForfeitedOrExpired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightForfeitedOrExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightToBeExercised" xlink:label="loc_eyesClassOfWarrantOrRightToBeExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightToBeExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightOtherAdjustments" xlink:label="loc_eyesClassOfWarrantOrRightOtherAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightOtherAdjustment" xlink:label="loc_eyesClassOfWarrantOrRightOtherAdjustment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightOtherAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" xlink:label="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" xlink:label="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:label="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:label="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" xlink:label="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_eyesClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/WarrantsDetailsNarrative" xlink:title="00000043 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureWarrantsAbstract" xlink:label="loc_eyesDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureWarrantsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_RightOfferingMember" xlink:label="loc_eyesRightOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_eyesRightOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClassOfWarrantsOrRightsTerm" xlink:label="loc_eyesClassOfWarrantsOrRightsTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_eyesClassOfWarrantsOrRightsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="00000044 - Disclosure - Employee Benefit Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails" xlink:title="00000045 - Disclosure - Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ShareBasedCompensation1" xlink:label="loc_eyesShareBasedCompensation1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_eyesShareBasedCompensation1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000046 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:label="loc_eyesShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_eyesShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationExpenseDetails" xlink:title="00000047 - Disclosure - Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000048 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails" xlink:title="00000049 - Disclosure - The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="loc_eyesNPMMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesNPMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="loc_eyesLegacySSMPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesLegacySSMPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsRegulatoryAssetsAndLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaapDeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" xlink:label="loc_eyesIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_eyesIncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_TaxCreditCarryforwardValuationAllowance1" xlink:label="loc_eyesTaxCreditCarryforwardValuationAllowance1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_eyesTaxCreditCarryforwardValuationAllowance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaapOperatingLossCarryforwardsValuationAllowance" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsValuationAllowance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails" xlink:title="00000050 - Disclosure - The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="loc_eyesNPMMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesNPMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="loc_eyesLegacySSMPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesLegacySSMPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxExemptIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxExemptIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails" xlink:title="00000051 - Disclosure - As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_NPMMember" xlink:label="loc_eyesNPMMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesNPMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LegacySSMPMember" xlink:label="loc_eyesLegacySSMPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_eyesLegacySSMPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaapDeferredTaxAssetsStateTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsStateTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DeferredTaxAssetsStateTaxes1" xlink:label="loc_eyesDeferredTaxAssetsStateTaxes1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_eyesDeferredTaxAssetsStateTaxes1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails" xlink:title="00000052 - Disclosure - The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:label="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_eyesLesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_eyesLesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLeasePayment" xlink:label="loc_eyesOperatingLeasePayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_eyesOperatingLeasePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_OperatingLeasePayments1" xlink:label="loc_eyesOperatingLeasePayments1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_eyesOperatingLeasePayments1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" xlink:title="00000053 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:label="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LeaseAndRentalExpense1" xlink:label="loc_eyesLeaseAndRentalExpense1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyesDisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="loc_eyesLeaseAndRentalExpense1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000054 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_ClinicalAndRegulatoryExpense" xlink:label="loc_eyesClinicalAndRegulatoryExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_eyesClinicalAndRegulatoryExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_LiquidatedDamagesPaidValue" xlink:label="loc_eyesLiquidatedDamagesPaidValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_eyesLiquidatedDamagesPaidValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractTerminationClaimsDescription" xlink:label="loc_us-gaapContractTerminationClaimsDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractTerminationClaimsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementCourt" xlink:label="loc_us-gaapLossContingencySettlementAgreementCourt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingencySettlementAgreementCourt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://secondsight.com/role/SubsequentEventDetailsNarrative" xlink:title="00000055 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="eyes-20221231.xsd#eyes_MrAdamsMember" xlink:label="loc_eyesMrAdamsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_eyesMrAdamsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271863040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vivani
Medical, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001266806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">02-0692322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5858 Horton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">833-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,735,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions
of the registrant&#8217;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) are
incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Registrant
intends to file a definitive proxy statement pursuant to Regulation 14A with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within
120 days after the end of registrant&#8217;s fiscal year end of December 31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BPM LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Walnut Creek, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,680,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VANI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyes_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VANIW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyes_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyes_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271867120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 45,076<span></span>
</td>
<td class="nump">$ 2,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,528<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">51,130<span></span>
</td>
<td class="nump">5,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,358<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Litigation accrual</a></td>
<td class="nump">1,675<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">657<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,822<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,822<span></span>
</td>
<td class="nump">2,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value, 10,000 shares authorized; none outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 50,736 and 36,803 at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">109,050<span></span>
</td>
<td class="nump">54,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">8,009<span></span>
</td>
<td class="nump">6,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">35<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(72,786)<span></span>
</td>
<td class="num">(58,897)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">44,308<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 51,130<span></span>
</td>
<td class="nump">$ 5,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents deposits and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185272740864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">50,736,000<span></span>
</td>
<td class="nump">36,803,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">50,736,000<span></span>
</td>
<td class="nump">36,803,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185273154352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of grants</a></td>
<td class="nump">$ 14,169<span></span>
</td>
<td class="nump">$ 11,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative, net of grants</a></td>
<td class="nump">7,072<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,241<span></span>
</td>
<td class="nump">13,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(21,241)<span></span>
</td>
<td class="num">(13,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Other income</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnRepurchaseOfDebtInstrument', window );">Gain on bargain purchase</a></td>
<td class="nump">6,877<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,889)<span></span>
</td>
<td class="num">$ (12,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_NetLossPerCommonShareBasicAndDiluted', window );">Net loss per common share &#8211; basic and diluted</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_WeightedAverageSharesOutstandingBasicAndDiluted', window );">Weighted average shares outstanding &#8211; basic and diluted</a></td>
<td class="nump">38,241<span></span>
</td>
<td class="nump">33,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_NetLossPerCommonShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents net loss per common share basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_NetLossPerCommonShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_WeightedAverageSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents weighted average shares outstanding basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_WeightedAverageSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnRepurchaseOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnRepurchaseOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185273173072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,889)<span></span>
</td>
<td class="num">$ (12,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">35<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (13,854)<span></span>
</td>
<td class="num">$ (12,773)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271923664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholder's Equity (Deficit) (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 43,029<span></span>
</td>
<td class="nump">$ 5,045<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (46,124)<span></span>
</td>
<td class="nump">$ 1,950<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">32,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts', window );">Issuance of shares of common stock and warrants, net of issuance costs</a></td>
<td class="nump">$ 11,564<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock and warrants, net of issuance costs (in shares)</a></td>
<td class="nump">3,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="nump">627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,668<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,773)<span></span>
</td>
<td class="num">(12,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 54,649<span></span>
</td>
<td class="nump">6,713<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(58,897)<span></span>
</td>
<td class="nump">$ 2,465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2021</a></td>
<td class="nump">36,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,803,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Options and warrants exercised, net of partial shares adjustment</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised', window );">Options and warrants exercised, net of partial shares adjustment (in shares)</a></td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for SSMP net assets</a></td>
<td class="nump">$ 54,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for SSMP net assets (in shares)</a></td>
<td class="nump">13,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,889)<span></span>
</td>
<td class="num">(13,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 109,050<span></span>
</td>
<td class="nump">$ 8,009<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="num">$ (72,786)<span></span>
</td>
<td class="nump">$ 44,308<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">50,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,736,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares stock options warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period value common stock and warrants in connection with rights offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period value stock options and warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period value stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185269616624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,889)<span></span>
</td>
<td class="num">$ (12,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GainFromBargainPurchase', window );">Gain on bargain purchase</a></td>
<td class="num">(6,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_PppLoanForgiveness', window );">PPP loan forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash lease expense</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(476)<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,941)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation expenses</a></td>
<td class="nump">204<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,787)<span></span>
</td>
<td class="num">(10,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_CashAcquiredInMergerForStockConsideration', window );">Cash acquired in merger for stock consideration</a></td>
<td class="nump">55,374<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_CancellationOfSafeBorrowing', window );">Proceeds from SAFE note</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from sale of common stock and exercise of options and warrants</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">11,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">63,390<span></span>
</td>
<td class="nump">11,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase</a></td>
<td class="nump">44,264<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at beginning of year</a></td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at end of year</a></td>
<td class="nump">46,442<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimateOfCancellations', window );">Cancellation of SAFE indebtedness in merger</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Net liabilities acquired in merger for stock consideration</a></td>
<td class="nump">$ 2,112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_CancellationOfSafeBorrowing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cancellation of safe borrowing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_CancellationOfSafeBorrowing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_CashAcquiredInMergerForStockConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash acquired in merger for stock consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_CashAcquiredInMergerForStockConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GainFromBargainPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents gain from bargain purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GainFromBargainPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_PppLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents ppp loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_PppLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimateOfCancellations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimates of cancellations for refundable service fees, if accounted for by analogy to FASB Statement No. 48.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimateOfCancellations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274789888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business Operations</a></td>
<td class="text"><p id="xdx_809_eus-gaap--NatureOfOperations_z7DSZPSG9EB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><b>1. <span id="xdx_828_z2nn8HHDb18i">Organization and Business Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani Medical, Inc. (&#8220;Vivani,&#8221;
the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar terms) is a preclinical stage biopharmaceutical
company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal&#8482; technology to enable long-term,
near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop
and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners to address
a leading cause of poor clinical outcomes in the treatment of chronic disease, medication non-adherence. For example, approximately
50% of patients treated for type 2 diabetes are non-adherent to their medicines, which can lead to poor clinical outcomes. We are
developing a portfolio of miniature, sub-dermal drug implant candidates that, unlike most oral and injectable medicines, are designed
with the goal of guaranteeing adherence by delivering therapeutic drug levels for up to 6 months or the life of the implant. In
addition, the minimal fluctuations of drug levels dictated by our NanoPortal technology may improve the tolerability profiles for
medicines that produce side effects associated with fluctuating drug levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani resulted from the business combination
of Second Sight Medical Products (Second Sight) and Nano Precision Medical (NPM). Since inception, Vivani&#8217;s main priority
has been the further development of the company&#8217;s lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate for
the treatment of patients with type 2 diabetes under the company&#8217;s Biopharm Division (formerly NPM). In parallel, Vivani&#8217;s
new management team remained committed to identifying and exploring strategic options for the Neuromodulation Division (formerly
Second Sight) that will enable further development of its pioneering neurostimulation systems to help patients recover critical
body functions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In February 2022, we announced the signing
of a definitive merger agreement between Nano Precision Medical, Inc. (&#8220;NPM&#8221;) and Second Sight Medical Products, Inc.
(&#8220;Second Sight&#8221;), pursuant to which NPM became a wholly-owned subsidiary of Second Sight. On August 30, 2022, the two
companies completed the merger, concurrent with which Second Sight changed its name to Vivani Medical, Inc. and now conducts the
present business of the Company. In September 2022, we announced the formation of the Company&#8217;s Biopharm Division to advance
the assets of the former NPM which includes the further development of the company&#8217;s lead program, NPM-119, a miniature,
6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes. Vivani&#8217;s new management team remains
committed to identifying and exploring strategic options for the Neuromodulation Division (formerly Second Sight) that will enable
further development of its pioneering neurostimulation systems to help patients recover critical body functions. On December 28,
2022, the assets and liabilities of this segment were contributed to Cortigent, Inc. a newly formed wholly owned subsidiary of
Vivani, in exchange for 20 million shares of common stock of Cortigent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2023, Vivani announced the filing
of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for the proposed initial
public offering of Cortigent. Cortigent is expected to continue to be majority-owned by Vivani immediately following the initial
public offering.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Agreement and Plan of Merger with Nano
Precision Medical, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, Second Sight Medical
Products, Inc. (&#8220;Second Sight&#8221;) entered into an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) with
Nano Precision Medical, Inc. (&#8220;NPM&#8221;). The Merger was approved by the shareholders of Second Sight on July 27, 2022
and closed on August 30, 2022. Upon consummation of the Merger, NPM became a wholly-owned subsidiary of Second Sight. Concurrent
with to the Merger, Second Sight changed its name to Vivani Medical, Inc. and changed its trading symbol from EYES to VANI, and
trades under the ticker VANI on the NASDAQ market. Certain investors and members of the NPM board of directors are also investors
and members of the board of directors of Second Sight.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms and conditions of the Merger
Agreement, the securities of NPM converted into the right to receive shares of Second Sight&#8217;s common stock representing <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SecondSightSwitzerlandSarlMember_zEhkKwQhbbl4" title="Ownership interest (in percentage)">77.32</span>%
of the total issued and outstanding shares of common stock of Second Sight on a fully converted basis, including, without limitation,
giving effect to the conversion of all options, warrants, and any and all other convertible securities assuming net settlement.
Second Sight filed a Registration Statement on Form S-4 on May 13, 2022 in connection with the Merger to register the merger shares
effective June 24, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, in connection with
the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) whereby Second Sight
provided to NPM an investment advance of $8 million. The Merger Agreement provided that the SAFE would terminate if the Merger
were to be successfully completed. Under the terms of the SAFE, upon successfully completion of the Merger on August 30, 2022,
the investment advance was eliminated. Under the accounting for a business combination, the $<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20220101__20221231_zxOCogm3q4Rj" title="Purchase consideration">8</span> million adjusted the purchase consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Merger involved a change of control
and was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;). Under this method of accounting, Second Sight was treated as the &#8220;acquired&#8221; company for financial
reporting purposes with NPM as the acquirer. The assets acquired and liabilities assumed by NPM were recorded at fair value under
Accounting Codification Standard (&#8220;ASC 805&#8221;), <i>Business </i>Combinations. Accordingly, <span id="xdx_901_eus-gaap--CommonStockVotingRights_c20220828__20220830_zjvZDQvoEdLg" title="Common stock, voting rights">on August 30, 2022 (the &#8220;Acquisition
Date&#8221;), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest
of Second Sight, Medical, Inc.</span> The results of Second Sight&#8217;s operations have been included in the consolidated financial
statements since that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The acquisition-date fair value of consideration
transferred totaled $<span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_c20220828__20220830__us-gaap--BusinessAcquisitionAxis__us-gaap--SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_zEyzoFQn1Q21" title="Fair value of the consideration transferred">54.4</span> million, which consisted of the fair value of the <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pn3n3_uShares_c20220830_zQLXF9RCF7E6" title="Common stock issued">13,136</span> common shares deemed issued to Second Sight
shareholders, was determined based on the per share closing price of the Company&#8217;s common shares on the acquisition date
of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220830_zKt7kqpPSGj3" title="Common stock, par or stated value per share">4.14</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zPFaoS5J1C76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B8_z58FvJxliqwj">The following table summarizes the fair
values of the assets acquired and liabilities assumed at the acquisition date (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration: underline">At August 30, 2022</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220830_zi8sjoqtX2x2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_404_ecustom--CashAndCashEquivalentsFairValue_iI_pn3n3_zgfRx0eOio1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">55,374</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentFairValueDisclosure_iI_pn3n3_zIF25wJjlbg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn3n3_zb02uyamcnt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,657</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetOne_iI_pn3n3_zxvvNVFFlJhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherAssetsFairValueDisclosure_iI_pn3n3_zrFmwaFlh3Ic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--FairValueOfAssetsAcquired1_iI_pn3n3_zmvfOPgBpoZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total identifiable assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,326</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_iNI_pn3n3_di_z5SR75EewP79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,913</td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iNI_pn3n3_di_ztiNfqcnij33" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(151</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_ecustom--FairValueOfLiabilitesAcquired_iNI_pn3n3_di_znkiSdASaQr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_zk5rigypYHTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt">Net identifiable assets acquired</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">53,262</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A0_zvYfOWBDVPy1" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SAFE loan of $<span id="xdx_908_eus-gaap--AssetsFairValueAdjustment_pn6n6_c20220828__20220830_z6VMbERzzti9" title="Assets, fair value adjustment">8.0</span> million was cancelled
in the Merger which adjusted the fair value of net assets acquired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p id="xdx_893_eus-gaap--GainLossOnInvestmentsTextBlock_zCDd6WSGUaO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B9_z5QPe5U54zy">The following table summarizes the calculation
of the gain on bargain purchase (in thousands)</span>:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220830_znOwAxta2wH6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--TotalConsideration_iNI_pn3n3_di_zCGZuZhdzGRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Total consideration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,385</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdvancesFairValueDisclosure_iNI_pn3n3_di_zRq62IKMKht8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SAFE loan forgiven</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_zmQKf8dlIVY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less net identifiable assets acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,262</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_ecustom--GainOnBargainPurchase_iI_pn3n3_zVQzq5qGIrHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt">Gain on bargain purchase</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">6,877</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AF_zvU2iI6PVVR1" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because NPM purchased <span id="xdx_90A_eus-gaap--SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_pid_dp_uPure_c20220101__20221231_zwkLpQuWZGD4" title="Fair value of identifiable assets acquired and liabilities">100</span>% of Second Sight
and the fair value of identifiable assets acquired and liabilities assumed exceeded the fair value of the consideration, we reassessed
the recognition and measurement of identifiable assets acquired and liabilities assumed and concluded that all acquired assets
and assumed liabilities were properly recognized and that the valuation procedures and resulting measures were appropriate. As
a result, we recognized a gain of $<span id="xdx_906_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_pn5n6_c20220101__20221231_zWqxnyNHkMgj" title="Gain of other income expenses">6.9</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We recognized $<span id="xdx_907_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_dm_c20220101__20221231_ztylsSOPj3Gj">0.7 million</span> of acquisition
related costs that were expensed in the twelve months ended December 31, 2022. These costs are included in the consolidated income
statement in the line item entitled &#8220;General and administrative costs.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Operating expenses of Second
Sight included in the consolidated statements of operations from the acquisition date August 30, 2022 to the period ending
December 30, 2022 were $2.1 million. Pro forma consolidated net loss as if Second Sight had been included in the consolidated
results was $<span id="xdx_90A_eus-gaap--NetIncomeLoss_pn5n6_c20210101__20211231__srt--StatementScenarioAxis__srt--ProFormaMember_zgx0tDJgGOKi">21.7</span>
million for the year ended December 31, 2021, and $<span id="xdx_90F_eus-gaap--NetIncomeLoss_pn5n6_c20220101__20221231__srt--StatementScenarioAxis__srt--ProFormaMember_zByRXgAXvtGi">28.3</span>
million for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SAFE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, in connection with
the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) whereby Second Sight
provided to NPM an investment advance of $8 million. The agreement provided that the SAFE would terminate if the Merger were to
be successfully completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the SAFE, upon successfully
completion of the Merger on August 30, 2022, the investment advance was eliminated. Under the accounting for a business combination,
the $8.0 million adjusted the purchase consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in">From inception, our operations
have been funded primarily through the sales of our common stock as well as from warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in">&#160;&#160;</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to
meet its planned obligations into the second half of 2024. Our ability to continue as a going concern is dependent on our ability
to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there
can be no assurances that we will be able to do so.</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274544624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting</a></td>
<td class="text"><p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweA1Z8ZaAQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>2.</b></td><td><b><span id="xdx_829_zYsauKEln6i">Summary of Significant Accounting</span></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_znEgoZDJUKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zrcVI8rpnEAe">Policies Principles of Consolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The
accompanying consolidated financial statements have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of the Biopharm Division (formerly NPM) and
the Neuromodulation Division (formerly Second Sight including Second Sight Switzerland) each of which is a reporting segment. <span id="xdx_905_esrt--DescriptionOfMaterialContingenciesOfParentCompany_c20220101__20221231_zGkXOkC4mHQc" title="Description of consolidation"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Intercompany balances
and transactions have been eliminated in consolidation.</p>

<p id="xdx_856_znwldDyGnyBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_zGTbltjWTJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_z3hNNmjQ10Rg">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the
financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the
key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted
accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used
in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred
tax assets. Actual results could differ from those estimates.</p>

<p id="xdx_85A_zUBvWNxGrey3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>






<p id="xdx_84C_eus-gaap--Reclassifications_zxlY4h6kXL28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zBKeHb84olkk">Reclassifications</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;&#160; Certain items in prior period financial
statements have been reclassified to conform to the presentation in the current period financial statements. &#160;Such reclassification
did not impact our previously reported net loss or financial position.</p>

<p id="xdx_852_zxwGis14PGG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zC9pExJxK9F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zhyIEFd2ioY">Cash,
Cash Equivalents and Restricted Cash</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We consider all
highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is
carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds
that are in excess of current needs in high credit quality instruments such as money market funds. Restricted cash of $<span id="xdx_901_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zSRdOuWFbTOc" title="Restricted cash">1.4</span>
million as of December 31, 2022 relates to the lease guarantee requirements of our new lease.</p>

<p id="xdx_85B_zpFLXIb8trjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAhl0NK6dxw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zETNP9KMVFIj">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Property and equipment
are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures
for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property
accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated
statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Depreciation is provided
for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service
lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful
lives of the principal classes of assets are as follows:</p>

<p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden">Schedule of estimated useful lives of principal classes of assets</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 46%"><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0503">5</span></span></span></td>
    <td style="width: 53%; padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0505">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Computer hardware and software</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0507">3</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0509">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0511">2</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0512">5</span></span> years or the term of the lease, if shorter</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Furniture, fixtures and equipment</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0514">5</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">10</span></span> years</span></td></tr>
</table>

<p id="xdx_8AD_zmoUmQlLehW" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">We review our property
and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets
may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">Depreciation and
amortization of property and equipment amounted to $<span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zHQ24bSGMYEa" title="Depreciation and amortization of property and equipment">0.4 million</span> and $<span id="xdx_90F_eus-gaap--DepreciationAndAmortization_dm_c20210101__20211231_zkxqHBnx92Th" title="Depreciation and amortization of property and equipment">0.3 million</span> for the years ended December 31, 2022 and 2021,
respectively.</p>

<p id="xdx_854_zM7443DwzLce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">&#160;</p>






<p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zUv62FoDlg9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86B_z61llJSlxVL2">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Leases are accounted for under FASB ASC
842,&#160;<i>Leases</i>&#160;(&#8220;ASC 842&#8221;). Under ASC 842, the Company determines if an arrangement contains a lease
at inception. Right of use assets (&#8220;ROU assets&#8221;) represent the right to use an underlying asset for the lease term
while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either
finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive
loss.&#160;All leases greater than 12 months result in the recognition of a ROU asset and liability at the lease commencement date
based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using
the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the
lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated.
The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#8217;s
applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available
to finance assets similar to the assets under lease in their related geographical location.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has elected not to separate
non-lease components from lease components and instead to account for each separate lease component and the non-lease components
associated with a lease as a single lease component. It also elected to exempt from capitalization all leases with an initial term
of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain leases include one or more options
to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#8217;s
discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of
being exercised.</p>

<p id="xdx_85E_zVq2i5u7Vn0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zdPzi06hHrqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zK2GRWwJyXri">Research and Development</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt">Research
and development costs are charged to operations in the period incurred and amounted to $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zub41g2rEOT8" title="Research and development costs">14.2 million</span>, and $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20210101__20211231_zicqqpOfOfA3" title="Research and development costs">11.0 million</span> net of
grant revenue, for the years ended December 31, 2022 and 2021, respectively.</p>

<p id="xdx_851_zLgOSqT6uvFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt">&#160;</p>

<p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPoWCpd71C3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_z3kk7jubLX7h">Patent Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt">Due to the uncertainty
associated with the successful development of one or more commercially viable products based on our research efforts and any related
patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated
costs, are expensed as incurred. Patent costs were $<span id="xdx_909_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zCQ4zF0Yq81" title="Patent costs">0.4 million</span> and $<span id="xdx_90F_eus-gaap--OtherGeneralExpense_dm_c20210101__20211231_zN8Rz8SUxRs9" title="Patent costs">0.1 million</span> for the years ended December 31, 2022 and 2021,
respectively, and are included in general and administrative expenses in the consolidated statements of operations.</p>

<p id="xdx_859_zmB8TcOt9Vad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt">&#160;</p>

<p id="xdx_843_ecustom--NhGrant_zijw8PxQlXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><b><span id="xdx_86B_zlhyRiK7RCc4">NIH Grant </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">From time to
time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset
against the related operating expenses as the costs are incurred. During the year ended December 31, 2022 grants offset
against operating expenses were $<span id="xdx_908_ecustom--GrantsAgainstOperatingExpense_pn5n6_c20220101__20221231_zpObuW9eb3D4" title="Grants offset against operating expenses">0.5</span>
million of which $0.4 million were offset against research and development expenses and $0.1 million were offset against general and
administrative expenses.</p>

<p id="xdx_857_zW8YOHPzBsV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZWhS4kMrJZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zcPsyB9iOWu">Concentration of Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><i>Credit Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Financial instruments
that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market
funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and
SIPC insurance limits of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zyCtHu3HhL87" title="FDIC insured amount">250,000</span> and $<span id="xdx_908_ecustom--CashSPICInsuredAmount_iI_c20221231_ztjuDBb59ADh" title="SPIC insured amount">500,000</span> (including cash of $<span id="xdx_906_ecustom--SPICCashLimitCoverage_iI_c20221231_z8MmcFRleYO2" title="SPIC cash limit coverage">250,000</span>), respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We also maintain cash
at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.</p>

<p id="xdx_85C_z0djLVf0Hzc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>






<p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_zROto3X0xny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zxt2Q6KVffqf">Foreign Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The accompanying consolidated
financial statements as of December 31, 2022 include assets amounting to approximately $<span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zqmACCOke6fb" title="Assets">40,000</span> relating to our operations in Switzerland.
Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.</p>

<p id="xdx_859_zXWD41PlPVk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zWilQ5HPZabf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zrgG5Uj6iJK">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The authoritative guidance
with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one
of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 1. Observable
inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the
measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based
derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 2. Inputs, other
than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through
corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 3. Unobservable
inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its
own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives
and commingled investment funds, and are measured using present value pricing models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We determine the level
in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of
the assets and liabilities at each reporting period end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Cash equivalents, which
include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our
consolidated balance sheet, and they are valued using Level 1 inputs.</p>

<p id="xdx_850_ztpuyKAXvhEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0jKFcx7iYUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zyYMVTXxDr8g">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">Pursuant to FASB ASC 718 Share-Based Payment (&#8220;ASC
718&#8221;), we record stock-based compensation expense for all stock-based awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Under ASC 718, we estimate
the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected
to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option
vesting term. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The fair value of each
stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the
Black-Scholes valuation model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The grant price of the issuances is determined based on the fair value of the shares at the date of grant.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The risk-free interest rate for periods within the contractual life of the option is based
    on the U.S. treasury yield in effect at the time of grant.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 1pt"><span style="font-size: 10pt">Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.</span></td></tr>
</table>


<p id="xdx_851_z7GbH8TiGw55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>









<p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zvKuWlpntfEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z4fiOjDQqe6c">Comprehensive Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
comply with provisions of FASB ASC 220, <i>Comprehensive Income</i>, which requires companies to report all changes in equity
during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are
recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner
sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss is reported on the face of the financial statements. For the year ended December 31, 2022
comprehensive loss is the total of net loss and other comprehensive income which, for us, consists entirely
of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net
loss during the year ended December 31, 2022.</span></p>

<p id="xdx_850_zW0sVKyiGEH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zIwwocQAdPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z9hLzXwHvL19">Foreign
Currency Translation and Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and transactions of the subsidiary&#8217;s operations are reported in the local (functional) currency of
Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are
translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency
financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange
rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions
denominated in a currency other than the foreign operations&#8217; functional currencies are included in expenses in the consolidated
statements of operations.</span></p>

<p id="xdx_85F_zZcBA8wjQ7C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zOBGA5krpw1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzwzJ11dx4ag">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the
tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the
event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount,
an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise,
should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for
tax purposes since inception and have significant tax losses and tax credit carry-forwards.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>

<p id="xdx_85A_z9OLxp5VSMw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>





<p id="xdx_84C_eus-gaap--StandardProductWarrantyPolicy_zXrB223ADMa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zk8HhCPHBf0e">Product
Warranties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed
parts. We also provide a three-year manufacturer&#8217;s warranty covering implant failure by providing a functionally-equivalent
replacement implant. Accruals for product warranties are estimated based on historical warranty experience and current product
performance trends and are recorded at the time revenue is recognized as a component of cost of sales. The warranty liabilities
are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred.
We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The warranty liabilities
are included in accrued expenses in the consolidated balance sheets and amount to $<span id="xdx_909_ecustom--AccruedLiabilitiesCurrent1_iI_c20221231_zdFhT1GUh3Qc" title="Accrued expenses">50,000</span> at December 31, 2022.</span></p>

<p id="xdx_851_zlODTqFPEZPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z9RjjhyGeCi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuPP9OcACdCd">Net
Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
computation of earnings per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss)
available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS
is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes
payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning
of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those
that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock
warrants and common stock options outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, and 2021, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately
acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in
thousands).</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden">&#160;Schedule
of net loss per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Shares underlying warrants outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">10,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">9,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,272</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,542</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,583</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_z8MB0HtPdyii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<p id="xdx_85F_zR4Cq4Pa8jYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTTq7qoh0hKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_ztxpnYyQsXIe">Operating
Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our
chief operating decision-maker, our CEO, reviews financial information presented for each of our segments. We consider ourselves to
have two reporting segments, specifically the Biopharm Division and the Neuromodulation Division. Neither division is revenue
producing. The Neuromodulation Division<span/> <span title="Consolidated"/>and the Biopharm Division incurred $<span id="xdx_90D_ecustom--DivisionIncurred_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zZweoZ0OV1al">2.1</span>
million, and $<span id="xdx_904_ecustom--DivisionIncurred_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zq091xoeefyf">19.1</span>
million respectively in operating expenses. The Neuromodulation Division incurred $<span id="xdx_900_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zmcjDfT5FJ67" title="Operating loss">1.5</span>
million and the Biopharm Division $<span id="xdx_90A_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zpom3CTHmlJb" title="Operating loss">12.4</span>
million of the $<span id="xdx_90F_ecustom--OperatingIncomeLoss2_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zbX12ji9k7Ii" title="Operating loss">13.9</span>
million consolidated net loss, inclusive of the $<span id="xdx_90E_ecustom--OperatingIncomeLoss3_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zLuOkTO7VF64" title="Operating loss">6.9 </span>million
gain on bargain purchase<span title="Operating expenses"/>. The Neuromodulation Division includes $<span id="xdx_907_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zeQYdZiuAzLl" title="Division incurred">2.1
million</span> of total assets. The Biopharm Division includes $<span id="xdx_90E_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zxDeeAdzHsU">49.0
million</span> in total assets.</span></p>

<p id="xdx_858_zWUUA3QwVlPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"/>





<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqraudtqBEL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z577Pw1dWBV1">Recently
Adopted Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material
impact on our financial statement presentation or disclosures.</span></p>

<p id="xdx_85D_zxL6OB0J9M65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276083232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Money Market Funds<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Money Market Funds</a></td>
<td class="text"><p id="xdx_801_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zsefGKma3kqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82B_zpj7N4PYzeUd">Money Market Funds</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
market funds included in cash equivalents at December 31, 2022 were $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zGglWQYyvs1j" title="Cash equivalents">44.4</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zWsAqf5BoKS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
following table presents money market funds at their level within the fair value hierarchy at December 31, 2022 and 2021 (in thousands).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zOPtffOgbctf" style="display: none; visibility: hidden">Schedule of Money Market Funds at their Level within the Fair Value Hierarchy</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">December 31, 2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; text-align: left; padding-bottom: 1pt">Money market funds</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20221231_zRysV9MvISUl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds">44,417</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWHzCoiivLB6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds">44,417</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTRUEe7wKfrg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zde2sAraGg8c" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">December 31, 2021:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Money market funds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20211231_zBGhRpK0g3J8" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeyQYp5i1Vue" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoIaFTcfPhud" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zh7TluyGlx61" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zQc0WLpPwoNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274542624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected Balance Sheet Detail</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_z7bz7WqXa2xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<b><span id="xdx_822_zXC1Hq08lBwd">Selected Balance Sheet Detail </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and equipment, net of accumulated depreciation and amortization</b> &#160; &#160; &#160; &#160; &#160; &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjC0DyuWb6Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zRzYQ4bz5yYe">Property
and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zv6HeXdASRD9" style="width: 10%; text-align: right">3,520</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zh99CLf6UYte" style="width: 10%; text-align: right">3,174</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="text-align: right" title="Property and equipment, gross">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhBX8h3qlb11" style="text-align: right" title="Property and equipment, gross">10</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" style="text-align: right" title="Property and equipment, gross">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxnkfGZPZ7Ne" style="text-align: right" title="Property and equipment, gross">12</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Computer software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_zu0eqEiR6114" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property and equipment, gross">3,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_z4VDJ4qMb2b5" style="text-align: right" title="Property and equipment, gross">3,204</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zmuXJCwkl7q8" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization">(2,411</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zO4j6AB8io87" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization">(2,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">1,182</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_ziL4I3Sc0IS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">1,173</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zx9pQOzFZOol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract
Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
liabilities amounted to $<span id="xdx_90F_ecustom--ContractLiabilitiesOther_iI_c20221231_zJBTKDaxdY6b" title="Contract liabilities">335,000</span> at December 31, 2022 and are included in accrued expenses on the balance sheet.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274717744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureGrantsAbstract', window );"><strong>Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GrantsTextBlock', window );">Grants</a></td>
<td class="text"><p id="xdx_800_ecustom--GrantsTextBlock_z42oqYMLsIx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82E_zqK05YYs7od">Grants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received an award for $<span id="xdx_904_ecustom--GrantReceivedToSupportClinicalDevelopment_pn5n6_c20180101__20181231_zsoWI8JUye7c" title="Received grant">1.6</span>
million grant (with the intent to fund $<span id="xdx_901_ecustom--GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_pn5n6_c20180101__20181231_zEhTZFyhfHSi" title="Grant receivable with intent to fund early feasibility clinical trial for five years">6.4</span>
million over <span id="xdx_905_ecustom--GrantReceivedFundingPeriod_dxL_c20180101__20181231_zTBYD37GtAne" title="Grant received funding period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0660">five</span></span>
years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the &#8220;Early
Feasibility Clinical Trial of a Visual Cortical Prosthesis&#8221; that commenced in January 2018. The NIH grant funds ongoing
and planned clinical activities and are being used to conduct and support clinical testing of six subjects implanted with the
Orion&#8482; Cortical Visual Prosthesis (Orion), submit and obtain Investigational Device Exemption approval from the U.S.
Food and Drug Administration (FDA). During the year ended December 31, 2022 grants offset against operating expenses were
$<span id="xdx_906_ecustom--GrantsAgainstOperatingExpenses_pn5n6_c20220101__20221231_zPguaR21NJn9" title="Grants against operating expenses">0.5</span>
million of which $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_dxL_c20220101__20221231_zfItUoydTwse" title="Research and development expenses::XDX::14169"><span style="-sec-ix-hidden: xdx2ixbrl0664">0.4</span></span> million were offset against research and development expenses and $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_dxL_c20220101__20221231_z6axLnCVGif7" title="General and administrative expenses.::XDX::7072"><span style="-sec-ix-hidden: xdx2ixbrl0666">0.1</span></span> million were offset against
general and administrative expenses.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents grants text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274546208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Securities</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zSOq78OI2Gvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;6.
<span id="xdx_823_zm11uf6n8cI2">Equity Securities&#160;&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkiZW3dde77">300,000,000</span> shares of common stock with <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FDOknATFMl">50,735,770</span> issued as of December 31, 2022. In addition, we are
authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrGF0soLlDhl">10,000,000</span> shares of preferred stock with <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znSBIiffqci4">none</span> issued. On August 19, 2022 the Company initiated a reverse
stock split of one share for every three shares. All share numbers have been retroactively adjusted for the split. On August 30,
2022, <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesMergerAcquisitions_iI_pid_uShares_c20220830_zJ0Vwxl57vDi" title="Stock issued during period shares merger acquisitions">13,136,362</span> shares were deemed issued for the merger acquisition.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276083232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_WarrantDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_806_ecustom--WarrantDisclosureTextBlock_zMKstc3ZFCv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_825_zx1DeKZIKU1h">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM,
prior to the Merger, issued common stock and warrants (collectively, the &#8220;unit&#8221; or &#8220;units&#8221;) in 2019,
2020 and 2021 for $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z8gG6RdoWIXa" title="Share price (in dollars per share)"><span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zrcjsVLaBPrc" title="Share price (in dollars per share)"><span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z8lxdk6prppa" title="Share price (in dollars per share)">3.15</span></span></span>
per unit. Outstanding warrants to purchase common stock are shown in the table below and generally expire <span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsTerm_dxL_c20221228__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zIxXjNiUV1l4" title="Term of warrants::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0684">5</span></span>
years from the date of issuance at $3.15 per share exercise price, are exercisable for one share of common stock and
may be exercised on a cashless basis. The warrants qualified for an exception to derivative accounting and, accordingly,
their value was not bifurcated from the total purchase price. Warrants outstanding associated with these units totaled 7,747,213 as of December 31, 2022 and are not registered or tradeable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
other adjustment for <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zhRZkiB5nOXe" title="Warrants granted">2,563,688</span> warrants in the table below were outstanding Second Sight warrants exchanged as part of the Merger
for Vivani warrants on a like-for-like basis. The warrants are tradeable on the open market. Under accounting standards in a business
combination, these warrants were measured at fair value as of the Merger date; however, the warrants were substantially out-of-the-money
and were assigned no value.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/>



<p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjY8AwJpseL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zwkhgZqovQ7g">A
summary of warrant activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zttlQCtP8VPl" style="display: none; visibility: hidden">Summary of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share&#160;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)&#160;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%">Warrants outstanding as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEGqAedIP7W2" style="width: 10%; text-align: right" title="Outstanding at beginning">5,402</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zv1eVTrc1d16" style="width: 10%; text-align: right" title="Outstanding at beginning">3.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;&#160;&#160;Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqVhoxQ0zcdi" style="text-align: right" title="Issued">3,672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7EkoCazMLS4" style="text-align: right" title="Class of warrant or right exercise issued">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znMfsDsK0vci" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2h8DpHJ1Uqa" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zi70I13cg8z5" style="text-align: right">9,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6MHehZVgxyb" style="text-align: right">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaVPY4vfYiMa" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zd8UlA9P8thf" style="text-align: right" title="Class of warrant or right exercise issued"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhqepYaOnrne" style="text-align: right" title="Exercised">(1,327</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQIqnjNC5a18" style="text-align: right" title="Class of warrant or right to be exercised">3,15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Forfeited or expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuS9ZPI4H3j3" style="text-align: right" title="Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOtherAdjustments_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJsR55UOQaU5" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments">2,564</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOtherAdjustment_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zcHbRVwesco3" style="padding-bottom: 1pt; text-align: right" title="Class of warrant or right other adjustment">35.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWwwuvTOloD3" style="padding-bottom: 1pt; text-align: right" title="Other adjustments (in years)::XDX::P1Y5M16D"><span style="-sec-ix-hidden: xdx2ixbrl0719">1.46</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zVsAaEkTYhS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending">10,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMc7aeem6TJ6" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending">11.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zETl6FD27PJ4" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending (in years)::XDX::P2Y3M22D"><span style="-sec-ix-hidden: xdx2ixbrl0725">2.31</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsrL7AZWik24" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable at ending">10,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zChkBds5Pxjl" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending">11.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh1z8YdtMeca" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending (in years)::XDX::P2Y3M22D"><span style="-sec-ix-hidden: xdx2ixbrl0731">2.31</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zQNawRGChg4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants outstanding as of December 31, 2022 have</span> no intrinsic value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_WarrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents warrant disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_WarrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274671152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zJ2csz9HLB6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_826_zO2bfl7F4yX2">Employee Benefit Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a 401(k) Savings Retirement Plan (the &#8220;Plan&#8221;) that covers substantially all full-time employees who meet the
Plan&#8217;s eligibility requirements and provides for an employee elective contribution. The Plan provides for employer matching
contributions. Employer contributions are discretionary and determined annually by the Board of Directors. For the years ended
December 31, 2022 and 2021, employer contributions to the Plan totaled $<span id="xdx_90D_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pn5n6_c20220101__20221231_zJWE77VVxxhh" title="Employer contributions to plan">0.2</span> million and $<span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pn5n6_c20210101__20211231_zRzEfNPuaz67">0.2</span> million, respectively.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271719136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuHyPTlhonAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_823_zJtooUUzdtjc">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
initiated a new Incentive Plan at the time of the Merger. Under the 2022 Omnibus Plan we were authorized to issue options covering
up to 20% of the outstanding shares of common stock. The maximum number of shares with respect to which options could be granted
was approximately 10,147,000 shares at December 31, 2022, which is offset and reduced by options previously granted under the Plan.
The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date.
Generally, the options vest ratably over four years and expire ten years from the grant date. The plan provides for accelerated
vesting if there is a change of control, as defined in the Plan.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zzjDNw9ffAT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized stock-based compensation cost of $<span id="xdx_906_ecustom--ShareBasedCompensation1_dxL_c20220101__20221231_z8VpJhbYUYe8" title="stock based compensation cost::XDX::1470000"><span style="-sec-ix-hidden: xdx2ixbrl0742">1.3</span></span> million and $<span id="xdx_90E_ecustom--ShareBasedCompensation1_dxL_c20210101__20211231_z3PyTOn5Qiwh" title="::XDX::1668000"><span style="-sec-ix-hidden: xdx2ixbrl0743">1.7</span></span> million during 2022 and 2021, respectively. The calculated value
of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zaEStGAOm7m4" style="display: none; visibility: hidden">Summary of Option Grant using the Black-Scholes Option-pricing Model</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zM1VFRmlrsD7" title="Risk-free interest rate">3.42</span>% &#8211; <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zVd946XQ434d" title="Risk-free interest rate">4.45</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zvAXpD4SbRUb" title="Risk-free interest rate">0.7</span>% &#8211; <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zvwkKdMHCbuc" title="Risk-free interest rate">0.9</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_z4nxWKRXhusj" title="Expected dividend yield">0</span>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zczCJihV88Sf" title="Expected dividend yield">0</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zrf3O4uhs7Ce" title="Expected volatility">100</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zE27Sy97wy1f" title="Expected volatility">100</span>%</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Expected term</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zUDoygePn4z3">4.25</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zgHGX0qnM573" title="Expected term::XDX::P6Y0M29D"><span style="-sec-ix-hidden: xdx2ixbrl0762">6.08</span></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zyY3OekL5h5l" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0764">5</span></span>-<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zs6Oex5mheV6" title="Expected term::XDX::P6Y0M29D"><span style="-sec-ix-hidden: xdx2ixbrl0766">6.08</span></span> years</span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AD_z2iI9dvb0lsc" style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"/>





<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zahKLqv7z9Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zj01Vx6A5a3d" style="display: none; visibility: hidden">Summary of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (in Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%">Options outstanding at December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAq3dvCRueP4" style="width: 10%; text-align: right" title="Options outstanding, number of shares (in shares)">5,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zotkEN4Z8A9e" style="width: 10%; text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)">2.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO47jeZyLfe" style="text-align: right" title="Granted">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaOmFHF99Och" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPt2m0inTWN6" style="text-align: right" title="Exercised">(1,020</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJy5Ox6CHsNi" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGGJ0RhXpFz" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired">(875</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS2mkehgpYhc" style="padding-bottom: 1pt; text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)">2.82</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPyG8b7gHeD3" style="text-align: right" title="Options outstanding, number of shares (in shares)">4,542</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPjpcsFgvk23" style="text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)">2.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZIQwcJ86x4f" style="text-align: right" title="Granted">866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXM35BSQwxml" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)">2.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z74HFrTaoNK1" style="text-align: right" title="Exercised">(73</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa6okzzYMid" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)">1.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited or expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLSgc4UlujS5" style="text-align: right" title="Forfeited or expired">(335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmplEwphIV1e" style="text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)">4.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC0Nce0vksEe" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments">272</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcoan5IqPKj" style="padding-bottom: 1pt; text-align: right" title="Other adjustments , weighted average exercise price (in dollars per share)">8.70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding, vested and expected to vest at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVV42Ik6nYa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, number of shares (in shares)">5,272</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDRb9YqGwUh" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in dollars per share)">3.07</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zavW5A2be8n6" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in years)::XDX::P7Y1M24D"><span style="-sec-ix-hidden: xdx2ixbrl0811">7.15</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOfbPGH9Eie" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, number of shares (in shares)">3,819</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT1q0jnevKVa" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable, weighted average exercise price (in dollars per share)">3.24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsupd8sSKsd6" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable period (in years)::XDX::P6Y6M18D"><span style="-sec-ix-hidden: xdx2ixbrl0817">6.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AF_z2XO29eymG2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated aggregate intrinsic value of stock options exercisable as of December 31, 2022 was $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231_z6FpaTKWVOWb" title="Stock options exercisable">151,000</span>.
As of December 31, 2022, there was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_dm_c20221231_zowRhijOxWKg" title="Unrecognized compensation cost">2.1
million</span> of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted
average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20220101__20221231_zDrzeVJvCFPh" title="Weighted average period (in years)::XDX::P1Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0823">1.2 </span></span>years.
Other adjustment represents a prior period true-up and Second Sight options exchanged as part of the Merger for Vivani options on a
like-for-like basis. Under accounting standards in a business combination, these options were measured at fair value as of the
Merger date; however, the options were substantially out-of-the-money and were assigned no value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z9SzNUjW711j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the
years ended December 31, 2022 and 2021 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5E5xaTBjh83" style="display: none; visibility: hidden">Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUwCT72f93V4" style="width: 10%; text-align: right" title="Allocated share-based compensation expense">896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z35zALM8DjS1" style="width: 10%; text-align: right" title="Allocated share-based compensation expense">1,329</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwmYPOrrbxF8" style="border-bottom: Black 1pt solid; text-align: right">400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPff0Tqq0N86" style="border-bottom: Black 1pt solid; text-align: right">339</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zVNroePLEmzl" style="border-bottom: Black 2.5pt double; text-align: right">1,296</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zhh55aUb3Zz" style="border-bottom: Black 2.5pt double; text-align: right">1,668</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zOb5ZfWGScV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274663056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z9dUSXJyMtel" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_820_zwOrBIqjiv4">Income taxes</span></b></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in <i>Note 1, Business</i>, Nano Precision Medical, Inc. and Second Sight Medical Products, Inc. merged on August 30, 2022. The transaction was accounted for as a reverse
merger business combination under GAAP. Accordingly, the consolidated income tax provision includes NPM for all periods presented,
and the legacy Second Sight business of Vivani (the &#8220;Legacy SSMP&#8221;) since the date of the merger. Further, NPM (the
major subsidiary of Vivani) and Legacy SSMP will not elect to consolidate their tax returns for income tax filing purposes. For
the purposes of accounting for income taxes under GAAP, the Legacy SSMP tax provision, deferred taxes and liabilities, and various
other matters such as net operation loss and R&amp;D carry-forwards have been prepared as if it filed a separate tax return for
the period from August 30, 2022 to December 31, 2022.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the net losses in 2022 and 2021, the provision for income taxes consists only of minimum California franchise taxes presented
in general and administrative expenses.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOKWsQU7nvP1" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zbKs38QJmLP">The
components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"/>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zhBNNNbVEkzi" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLfxWR3YG7Eb" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zwXrDoYiCHv1" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVwGkpHftDn9">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31, 2022</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of <br/> December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NPM</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Legacy SSMP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Combined</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NPM</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;Deferred Tax :</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zmQMyRQ8hCSc" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">&#160;Accruals/reserves</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">226</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_zReRcK54dMZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Capitalized R&amp;E &#167;174</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_z4nEoMQlRdg1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Lease ROU</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zexQfnaMWIo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Stock Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">776</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z28JT53TZaRk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Net operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,194</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_zTSpWO3W4hNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;R&amp;D credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,358</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,961</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,319</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,671</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zryEUe5YTfnk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Gross Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,982</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,564</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">56,546</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,698</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zhx89EXOrBHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Investment in Sub</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_iI_pn3n3_zfuK6Ucv2SG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Accumulated depreciation/amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(202</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(120</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zOKU14AVwRi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,660</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,712</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(120</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--TaxCreditCarryforwardValuationAllowance1_iI_pn3n3_zsY5DO2zilY" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21,322</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(33,512</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(54,834</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,804</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zpdkLC6KkpIb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Total Deferred Tax Assets, Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zpGd0eDQucMk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Change in valuation allowance for the year ended</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,519</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">461</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,204</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>





<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p id="xdx_8A1_zSsI6Y9jA8xb" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwtCrr7WOmJ3" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0mHY8d5OAgb">The
reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and
the corresponding rate from operations consist of the following (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year Ended December 31, 2022</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    SSMP</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combined</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pre-Tax
    Loss <sup id="xdx_F49_zGmS0pPvS0ah">(a)</sup></span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_fKGEp_zHzGdXL01v9l" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,889</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_fKGEp_zWCTbOGinBvc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,479</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zua3UZboUDw8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,889</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Federal
    tax (benefit) at statutory rate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zncslZ6DXQck" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zrbiY7wKWQ2k" title="Federal tax (benefit) at statutory rate (percent)">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLRDFlBXZNOf" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(311</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z8PnshO8R8o5">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z5q8hVYFGA1" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zrAoBkAO3O05">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State
    tax (benefit), net of federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFQOLbuhoitf" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zD1eAPRL6576" title="State tax (benefit), net of federal tax benefit (percent)">7.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zlw0ckYWhjoc" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zMvh0e3gAc95">7.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zenX8q6pqWT3" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,073</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zRCHgDBN6hnk">7.7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;R&amp;D
    tax credit from current year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zYSxRUdYx7kk" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(687</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zHtF5TCrGin" title="R&amp;D tax credit from current year (percent)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zjpNWYaVx6A9" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zgfCkLAAkdYg">0.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_zuDwWdXE50hd" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(707</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zDN2HLZPgYH7">5.1</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;Impact on effective rate of SSMP loss eliminated in consolidation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zg4ZopIGFyqf" style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z7407CXbAdx7" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zOqFyhnDf6Ze" style="text-align: right" title="Pre-Tax Income (Loss)">(311</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zPODuwsCotR8">2.2</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zEaiJaSJG7oe" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z6Hygoi7XCaf" title="Other (percent)">-0.4</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zIwosWd83wRh" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvubkJAIpfvd">1.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_zBMC6AulFCY8" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zZqmHqWoOHhg">-0.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Change
    in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFkC1XoH0tde" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,519</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z2ZLLbff7oH1" title="Change in valuation allowance (percent)">-32.5</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvc749oR8kRc" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">462</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zTSngbE0cer8">-31.2</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zFVL4pyxdznj" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,980</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zavBeFvSroH9">-35.9</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    provision for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zsKXGl0USTZa" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zBkzXlJPSPQi" title="Total provision for income taxes (percent)">0.0</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zW7xByvT8XIg" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zRmu271TSLd7" title="Total provision for income taxes">-0.1</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zfe3Ewm9pWQj" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zeca7nMC5lzc" title="Total provision for income taxes">0.0</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F0B_zYjnvwWfePwl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F1B_zXoPwEsGRYk5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#8217;s interest in
                                                                                                                                                                 Legacy SSMP&#8217;s pre-tax loss.</span></td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPM</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2021 </b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 59%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; width: 1%; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pre-tax
    income (loss)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zIFEVggs4Vc5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,773</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Federal
    tax (benefit) at statutory rate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_znk23RLyjb73" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,682</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zCditIAbu0w2" title="Federal tax (benefit) at statutory rate (percent)">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State
    tax (benefit), net of federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zP7JJ3t5UThf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zENdvgyn1FBb" title="State tax (benefit), net of federal tax benefit (percent)">7.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;R&amp;D
    tax credit from current year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zPdxEEyF5vxf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(475</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVOtVlxUes3i" title="R&amp;D tax credit from current year (percent)">3.7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zDCw1WYbBTRd" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(163</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z9qwsOanWJg5" title="Other (percent)">1.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Change
    in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zozPAyMDDaEb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,214</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zf12XN9xRLCg" title="Change in valuation allowance (percent)">-33.0</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    provision for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z3pRQx6eCr3b" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zoVjvEkxEPc9" title="Total provision for income taxes (percent)">0.0</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
</table>

<p id="xdx_8A7_zrNn2XPHoQ38" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-tax losses for NPM and Legacy SSMP in the preceding table are presented as if each entity filed separate returns;
and accordingly, the information does not reflect elimination of intercompany transactions or balances. The combined pre-tax
loss in the table reflects elimination of intercompany transactions
and balances.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
NPM and Legacy SSMP file as separate taxpayers, deferred tax assets and liabilities and attributes such as NOL and R&amp;D carry-forwards
of one taxpayer are not available to offset those of the other taxpayer. The combined data is presented for disclosure purposes
only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize
the existing deferred tax assets. Based on this evaluation, as of December&#160;31, 2022 and 2021, a full valuation allowance
has been recorded because deferred tax assets have been assessed to be less than &#8220;more likely than not&#8221; to be realized.
</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z1x7zifKh8Tc" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zRHHnjqmtF79">As
of December&#160;31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and
state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zGsn3kKIHJh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zkWy5QjDEc04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    SSMP</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zyEmcgMFwV1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre TCJA
    (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,257</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,095</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_z6bkqeUeSoO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post
    TCJA period federal NOL carry-forward, with no carry-forward limitation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,503</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,412</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zLMKKvhr7KAb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    federal NOL carry-forward</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,760</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,508</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_z6Ez4bIX1poh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State NOL carry-forward,
    begin expiring 2030</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,514</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,439</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_z61WgtTZchY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal R&amp;D tax
    credit carry-forward, begin expiring in 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--DeferredTaxAssetsStateTaxes1_iI_pn3n3_zvGm8u83tYC4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State R&amp;D carry-forward,
    begin expiring in 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,973</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,989</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zKwUUYRHHkz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total R&amp;E related
    deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserve for uncertain
    income tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8A9_znBnu9YcQ0k5" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
recently enacted U.S. tax legislation, although the treatment of tax losses generated in taxable years ending before December
31, 2017, has generally not changed, tax losses generated in taxable years beginning after December 31, 2017, may only be utilized
to offset 80% of taxable income annually. This change may require NPM and Legacy SSMP to pay federal income taxes in future years
despite generating a loss for federal income tax purposes in prior years.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that each of the tax filers continue to generate taxable losses, unused losses will carry-forward to offset future
taxable income, if any, until these unused losses expire. However, the tax filers may be unable to use these losses to offset
taxable income before our unused losses expire at various dates that range from 2030 through 2038 for federal net operating losses
generated before 2018. Federal net operating losses generated for year 2018 and forward do not expire. State net operating losses
expire from 2030 through 2042. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation
undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its
equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss, or NOL, carry-forwards
to offset its post-change taxable income may be limited. Limitations may also apply to the utilization of other pre-change tax
attributes as a result of an ownership change.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legal subsidiary, NPM experienced an &#8220;ownership change&#8221; within the meaning of Section 382(g) of the Internal
Revenue Code of 1986, as amended, during the third quarter of 2022 as a result of the merger. The ownership change will
subject its net operating loss carry-forwards to an annual limitation, which will significantly restrict its ability to use
them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the
aggregate value of stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the
Internal Revenue Service. We have not yet fully analyzed the available information to determine the amount of the annual
limitation. </span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically review the uncertainties and judgments related to the application of complex income tax regulations to determine
income tax liabilities in several jurisdictions. We use a &#8220;more likely than not&#8221; criterion for recognizing the
income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. We have
evaluated the impact of these positions and believe tax filing positions and deductions will more likely than not
be sustained upon examination. Accordingly, no reserve for uncertain income tax positions has been recorded as of December
31, 2022.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the cumulative unrecognized tax benefit is recognized, there will be no effect on our effective tax rate due to the full
valuation allowance. Due to the nature of the unrecognized tax benefits and the existence of tax attributes, we have not
accrued any interest or penalties associated with unrecognized tax benefits in the Consolidated Statement of Operations
nor recognized a liability in the Consolidated Balance Sheet. We do not believe the total amount
of unrecognized benefit as of December 31, 2022, will increase or decrease significantly in the next twelve
months.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
January 1, 2022, we are required to capitalize certain research and development expenditures in accordance with section 174 of
the Internal Revenue Code, as amended by the Tax Cuts and Jobs Act of 2017, instead of previously being allowed to expense. Amortization
of such capitalized expenditures are allowed over a 5-year period if incurred in the U.S. or a 15-year period if incurred outside
the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file income tax returns in the U.S. federal jurisdiction and various states and are subject to income tax examinations by federal
tax authorities for tax years ended 2017 and later and by state authorities for tax years ended 2016 and later. We currently are
not under examination by any tax authority. Our policy is to record interest and penalties on uncertain tax positions as income
tax expense. As of December 31, 2021, and 2020, we have no accrued interest or penalties related to uncertain tax positions. Second
Sight Switzerland, our foreign subsidiary, has not had any taxable income in the prior and current years.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276033216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use Assets and Operating Lease Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract', window );"><strong>Right-of-use Assets And Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock', window );">Right-of-use Assets and Operating Lease Liabilities</a></td>
<td class="text"><p id="xdx_800_ecustom--RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_z2q5w2eKDAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82E_z6F3qsOLl1ml">Right-of-use Assets and Operating Lease Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the
balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is
computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets
and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value
guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental
borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zq8oKKab9gji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_za0Kr6KDHsHe">The
Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use
assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Year ending December 31:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left; padding-bottom: 1pt">2023</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20220101__20221231_zpX4ZUs9dsml" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="2023">975</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--OperatingLeasePayment_pn3n3_c20220101__20221231_zF2Q9QG9LCGh" style="text-align: right" title="Total lease payments">975</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseCost_iN_pn3n3_di_c20220101__20221231_zYsFQ1WevWGh" style="border-bottom: Black 1pt solid; text-align: right" title="Imputed interest">(20</td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_zbDVMgvUGY29" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other supplemental information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--OperatingLeasePayments1_pn3n3_c20220101__20221231_zWQ9TPCyUn19" style="text-align: right" title="Current operating lease liabilities">955</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Long term operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zXCADKZZDPzh" style="border-bottom: Black 1pt solid; text-align: right" title="Long term operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_z3qyK37DPtHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 1pt">&#160;</span></td><td><span style="font-size: 1pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 1pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 1pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 1pt">&#160;</span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%">
<tr>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended</b><br/>
    <b>&#160;December 31,</b><br/>
    <b>2022</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended</b><br/>
    <b>&#160;December 31,</b><br/>
    <b>2021</b></span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for operating lease liabilities</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20221231_zMSIGN02zZJa" title="Cash paid for operating lease liabilities">1.0 million</span></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20211231_zPg1JFTUxMG1" title="Cash paid for operating lease liabilities">0.9
    million</span></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td></tr>
</table>
<p id="xdx_8A7_znxkihANCFw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense, including common area maintenance charges, was $<span id="xdx_903_ecustom--LeaseAndRentalExpense1_dm_c20220101__20221231_zmAsfNpToRP1" title="Rent expense">0.9 million</span> and $<span id="xdx_905_ecustom--LeaseAndRentalExpense1_dm_c20210101__20211231_zfuhVpEF1YMi" title="Rent expense">0.8 million</span> during 2022 and 2021, respectively.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents right of use assets and operating lease liabilities text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274544624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4LxlbWYOsR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_825_zv9mtsWGmpbe">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain indemnification agreements with our directors and officers that may require us to indemnify them against liabilities
that arise by reason of their status or service as directors or officers, except as prohibited by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">Based upon FDA approval of Argus II, which was obtained in February
2013, we were required to collect follow-up data from subjects enrolled in our pre-approval trial for a period of up to ten years
post-implant, which was extended through the year 2019. This requirement to collect follow-up data was halted in 2020 with FDA
approval.&#160;In addition, we conducted three post-market studies to comply with U.S. FDA, French, and European post-market surveillance
regulations and requirements and are conducting an early feasibility clinical study of Orion. We have contracted with various universities,
hospitals, and medical practices to provide these services. Payments are based on procedures performed for each subject and are
charged to clinical and regulatory expense as incurred. Total amounts charged to expense for the year ended December 31, 2022 were
$<span id="xdx_90C_ecustom--ClinicalAndRegulatoryExpense_pn5n6_c20220101__20221231_zxe40tu4oKEa" title="Clinical and regulatory expense">0.2</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation,
Claims and Assessments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent
owned by us. The outcomes of the challenges are not certain, however, if successful, they may affect our ability to block competitors
from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture
and sell our products, or otherwise have a material effect on our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in the Company&#8217;s 10-K
for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (&#8220;MOU&#8221;) for a proposed
business combination with Pixium Vision SA (&#8220;Pixium&#8221;). In response to a press release by Pixium dated March 24, 2021,
and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium
was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between
the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an
amicable resolution will be reached. We accrued $<span id="xdx_908_ecustom--LiquidatedDamagesPaidValue_iI_c20210331_zXn3eedxF3li" title="Liquidated damage">1,000,000</span> of liquidated damages as contemplated by the MOU in accounts payable
as of March 31, 2021 and remitted that amount to Pixium in April 2021. <span id="xdx_903_eus-gaap--ContractTerminationClaimsDescription_c20220101__20221231_zwt4juUsdCwc" title="Description of contract termination and claims">Pixium indicated that it considered this termination wrongful,
rejected the Company&#8217;s offers, but retained the $<span id="xdx_903_eus-gaap--LossContingencyDamagesPaidValue_c20220101__20221231_zeiefDIQN3ak" title="Loss contingency, damages paid, value">1,000,000</span> payment. On May 19, 2021, Pixium filed suit in the Paris Commercial
Court, and currently claim damages of approximately &#8364;5.1 million or about $5.6 million. We believe we have fulfilled our obligations
to Pixium with the liquidated damages payment of $1,000,000.</span> <span id="xdx_90F_eus-gaap--LossContingencySettlementAgreementCourt_c20221207__20221209_zjbv0ZbtFJ3k" title="Description of legal settlement">On December 9, 2022, the Company received notice that the Paris Commercial
Court has rendered its judgement, including finding that the Company&#8217;s termination of the MOU was not valid. In the judgement,
the Company was ordered to pay to Pixium the amount of &#8364;2,500,000 minus a &#8364;947,780 credit for the $1,000,000 already
paid for, a net amount payable of approximately &#8364;1,552,220. The Company may appeal the decision within three months from the
date of service. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to raise any and all legal
challenges to this preliminary judgement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not
have a material effect on our financial statements, however the results of litigation and claims are inherently unpredictable.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274717744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zcRd8mM2weRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_827_zv2yh86PzQEh">Subsequent Event</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2023 Cortigent entered into a lease agreement, effective March 1, 2023, to sublease office space to replace our
existing headquarters. Our rental payments amount to $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230226__20230303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9D29ezjR4d9" title="Rental payments amount">22,158</span>
per month plus operating expenses, to <span id="xdx_90D_eus-gaap--SubsequentEventDescription_c20230226__20230303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUwfrGIISAJf" title="Description of lease agreement">lease
14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355. The sub-lease has a term of two years
and two months. We also entered into a lease for storage space on January 25, 2023 in the same building at a cost of $6,775
per month for a term of two years and one month.</span> As a material inducement for the lessor to execute the lease with us
Vivani guaranteed the prompt payment of all rents and all other sums payable under the lease together with all other terms
and conditions to be kept and performed under the lease by the lessee.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 2023, Cortigent commenced to pay <span id="xdx_907_eus-gaap--SubsequentEventDescription_c20230101__20230131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__custom--MrAdamsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5ld5Rty6y2b" title="Description of lease agreement">Mr.
Adams $25,000 per month for his services to us. In March 2023 we entered into an at will letter agreement with Jonathan Adams
by which we appointed him President and Chief Executive Officer of Cortigent at a base salary of $350,000 per year commencing
as of March 1, 2023. He may also receive a onetime signing bonus of up to $50,000 upon Board approval. Upon Board approval following
completion of the initial public offering of securities, Mr. Adams may also be issued an option to purchase 400,000 shares of
our common stock at a strike price equal to the price per share at which shares initially are sold to the public in this
offering. Of these, options to purchase 100,000 shares will vest on November 10, 2023 and the balance shall vest in
approximately equal monthly instalments over the ensuing 36 months.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 Cortigent entered into a Transition Funding, Support and Services Agreement with Vivani whereby Vivani will advance
funds and provide or cause to be provided to the Company the services and funding that will cover salaries and related costs,
rent and other overhead in order to permit the Company to operate in substantially the same manner in which business operations
of the Company were previously operated by Second Sight, prior to the formation of Cortigent, which obligations will continue,
in the case of the funding obligations, until the earlier of December 31, 2024 or receipt of proceeds from this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_900_eus-gaap--SubsequentEventDescription_c20230301__20230331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWIyWrRGAIb9" title="Description of lease agreement">Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California on November
21, 2022. The stated term of the lease commences on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months.
Payments increase annually from $2,676,311 to $3,596,784, or 124 payments less the first four which are abated, totalling approximately
$31 million.</span> Vivani will be responsible for insurance, property taxes and CAM charges. The current lease expires on September 30, 2023.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185269555392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Policies Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_znEgoZDJUKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zrcVI8rpnEAe">Policies Principles of Consolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The
accompanying consolidated financial statements have been prepared in accordance with United States generally accepted
accounting principles (&#8220;GAAP&#8221;) and include the financial statements of the Biopharm Division (formerly NPM) and
the Neuromodulation Division (formerly Second Sight including Second Sight Switzerland) each of which is a reporting segment. <span id="xdx_905_esrt--DescriptionOfMaterialContingenciesOfParentCompany_c20220101__20221231_zGkXOkC4mHQc" title="Description of consolidation"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Intercompany balances
and transactions have been eliminated in consolidation.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zGTbltjWTJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_z3hNNmjQ10Rg">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the
financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the
key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted
accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used
in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred
tax assets. Actual results could differ from those estimates.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--Reclassifications_zxlY4h6kXL28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zBKeHb84olkk">Reclassifications</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;&#160; Certain items in prior period financial
statements have been reclassified to conform to the presentation in the current period financial statements. &#160;Such reclassification
did not impact our previously reported net loss or financial position.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zC9pExJxK9F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zhyIEFd2ioY">Cash,
Cash Equivalents and Restricted Cash</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We consider all
highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is
carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds
that are in excess of current needs in high credit quality instruments such as money market funds. Restricted cash of $<span id="xdx_901_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zSRdOuWFbTOc" title="Restricted cash">1.4</span>
million as of December 31, 2022 relates to the lease guarantee requirements of our new lease.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAhl0NK6dxw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zETNP9KMVFIj">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Property and equipment
are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures
for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property
accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated
statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Depreciation is provided
for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service
lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful
lives of the principal classes of assets are as follows:</p>

<p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden">Schedule of estimated useful lives of principal classes of assets</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 46%"><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0503">5</span></span></span></td>
    <td style="width: 53%; padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0505">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Computer hardware and software</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0507">3</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0509">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0511">2</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0512">5</span></span> years or the term of the lease, if shorter</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Furniture, fixtures and equipment</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0514">5</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">10</span></span> years</span></td></tr>
</table>

<p id="xdx_8AD_zmoUmQlLehW" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">We review our property
and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets
may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt">Depreciation and
amortization of property and equipment amounted to $<span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zHQ24bSGMYEa" title="Depreciation and amortization of property and equipment">0.4 million</span> and $<span id="xdx_90F_eus-gaap--DepreciationAndAmortization_dm_c20210101__20211231_zkxqHBnx92Th" title="Depreciation and amortization of property and equipment">0.3 million</span> for the years ended December 31, 2022 and 2021,
respectively.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zUv62FoDlg9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86B_z61llJSlxVL2">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Leases are accounted for under FASB ASC
842,&#160;<i>Leases</i>&#160;(&#8220;ASC 842&#8221;). Under ASC 842, the Company determines if an arrangement contains a lease
at inception. Right of use assets (&#8220;ROU assets&#8221;) represent the right to use an underlying asset for the lease term
while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either
finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive
loss.&#160;All leases greater than 12 months result in the recognition of a ROU asset and liability at the lease commencement date
based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using
the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the
lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated.
The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#8217;s
applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available
to finance assets similar to the assets under lease in their related geographical location.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has elected not to separate
non-lease components from lease components and instead to account for each separate lease component and the non-lease components
associated with a lease as a single lease component. It also elected to exempt from capitalization all leases with an initial term
of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain leases include one or more options
to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#8217;s
discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of
being exercised.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zdPzi06hHrqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zK2GRWwJyXri">Research and Development</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt">Research
and development costs are charged to operations in the period incurred and amounted to $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zub41g2rEOT8" title="Research and development costs">14.2 million</span>, and $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20210101__20211231_zicqqpOfOfA3" title="Research and development costs">11.0 million</span> net of
grant revenue, for the years ended December 31, 2022 and 2021, respectively.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent Costs</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPoWCpd71C3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_z3kk7jubLX7h">Patent Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt">Due to the uncertainty
associated with the successful development of one or more commercially viable products based on our research efforts and any related
patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated
costs, are expensed as incurred. Patent costs were $<span id="xdx_909_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zCQ4zF0Yq81" title="Patent costs">0.4 million</span> and $<span id="xdx_90F_eus-gaap--OtherGeneralExpense_dm_c20210101__20211231_zN8Rz8SUxRs9" title="Patent costs">0.1 million</span> for the years ended December 31, 2022 and 2021,
respectively, and are included in general and administrative expenses in the consolidated statements of operations.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_NhGrant', window );">NIH Grant</a></td>
<td class="text"><p id="xdx_843_ecustom--NhGrant_zijw8PxQlXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><b><span id="xdx_86B_zlhyRiK7RCc4">NIH Grant </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">From time to
time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset
against the related operating expenses as the costs are incurred. During the year ended December 31, 2022 grants offset
against operating expenses were $<span id="xdx_908_ecustom--GrantsAgainstOperatingExpense_pn5n6_c20220101__20221231_zpObuW9eb3D4" title="Grants offset against operating expenses">0.5</span>
million of which $0.4 million were offset against research and development expenses and $0.1 million were offset against general and
administrative expenses.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZWhS4kMrJZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zcPsyB9iOWu">Concentration of Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><i>Credit Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Financial instruments
that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market
funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and
SIPC insurance limits of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zyCtHu3HhL87" title="FDIC insured amount">250,000</span> and $<span id="xdx_908_ecustom--CashSPICInsuredAmount_iI_c20221231_ztjuDBb59ADh" title="SPIC insured amount">500,000</span> (including cash of $<span id="xdx_906_ecustom--SPICCashLimitCoverage_iI_c20221231_z8MmcFRleYO2" title="SPIC cash limit coverage">250,000</span>), respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We also maintain cash
at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ForeignOperationsPolicyTextBlock', window );">Foreign Operations</a></td>
<td class="text"><p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_zROto3X0xny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zxt2Q6KVffqf">Foreign Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The accompanying consolidated
financial statements as of December 31, 2022 include assets amounting to approximately $<span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zqmACCOke6fb" title="Assets">40,000</span> relating to our operations in Switzerland.
Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zWilQ5HPZabf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zrgG5Uj6iJK">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The authoritative guidance
with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one
of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 1. Observable
inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the
measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based
derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 2. Inputs, other
than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through
corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Level 3. Unobservable
inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its
own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives
and commingled investment funds, and are measured using present value pricing models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">We determine the level
in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of
the assets and liabilities at each reporting period end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Cash equivalents, which
include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our
consolidated balance sheet, and they are valued using Level 1 inputs.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0jKFcx7iYUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zyYMVTXxDr8g">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">Pursuant to FASB ASC 718 Share-Based Payment (&#8220;ASC
718&#8221;), we record stock-based compensation expense for all stock-based awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Under ASC 718, we estimate
the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected
to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option
vesting term. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The fair value of each
stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the
Black-Scholes valuation model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The grant price of the issuances is determined based on the fair value of the shares at the date of grant.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">The risk-free interest rate for periods within the contractual life of the option is based
    on the U.S. treasury yield in effect at the time of grant.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 29px">&#160;</td>
    <td style="width: 29px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 1pt"><span style="font-size: 10pt">Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zvKuWlpntfEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z4fiOjDQqe6c">Comprehensive Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
comply with provisions of FASB ASC 220, <i>Comprehensive Income</i>, which requires companies to report all changes in equity
during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are
recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner
sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss is reported on the face of the financial statements. For the year ended December 31, 2022
comprehensive loss is the total of net loss and other comprehensive income which, for us, consists entirely
of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net
loss during the year ended December 31, 2022.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zIwwocQAdPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z9hLzXwHvL19">Foreign
Currency Translation and Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and transactions of the subsidiary&#8217;s operations are reported in the local (functional) currency of
Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are
translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency
financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange
rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions
denominated in a currency other than the foreign operations&#8217; functional currencies are included in expenses in the consolidated
statements of operations.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zOBGA5krpw1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zzwzJ11dx4ag">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the
tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the
event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount,
an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise,
should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for
tax purposes since inception and have significant tax losses and tax credit carry-forwards.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Warranties</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--StandardProductWarrantyPolicy_zXrB223ADMa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zk8HhCPHBf0e">Product
Warranties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed
parts. We also provide a three-year manufacturer&#8217;s warranty covering implant failure by providing a functionally-equivalent
replacement implant. Accruals for product warranties are estimated based on historical warranty experience and current product
performance trends and are recorded at the time revenue is recognized as a component of cost of sales. The warranty liabilities
are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred.
We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The warranty liabilities
are included in accrued expenses in the consolidated balance sheets and amount to $<span id="xdx_909_ecustom--AccruedLiabilitiesCurrent1_iI_c20221231_zdFhT1GUh3Qc" title="Accrued expenses">50,000</span> at December 31, 2022.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z9RjjhyGeCi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zuPP9OcACdCd">Net
Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
computation of earnings per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss)
available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS
is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes
payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning
of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those
that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock
warrants and common stock options outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, and 2021, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately
acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in
thousands).</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden">&#160;Schedule
of net loss per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Shares underlying warrants outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">10,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">9,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,272</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,542</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,583</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_z8MB0HtPdyii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTTq7qoh0hKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_ztxpnYyQsXIe">Operating
Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our
chief operating decision-maker, our CEO, reviews financial information presented for each of our segments. We consider ourselves to
have two reporting segments, specifically the Biopharm Division and the Neuromodulation Division. Neither division is revenue
producing. The Neuromodulation Division<span/> <span title="Consolidated"/>and the Biopharm Division incurred $<span id="xdx_90D_ecustom--DivisionIncurred_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zZweoZ0OV1al">2.1</span>
million, and $<span id="xdx_904_ecustom--DivisionIncurred_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zq091xoeefyf">19.1</span>
million respectively in operating expenses. The Neuromodulation Division incurred $<span id="xdx_900_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zmcjDfT5FJ67" title="Operating loss">1.5</span>
million and the Biopharm Division $<span id="xdx_90A_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zpom3CTHmlJb" title="Operating loss">12.4</span>
million of the $<span id="xdx_90F_ecustom--OperatingIncomeLoss2_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zbX12ji9k7Ii" title="Operating loss">13.9</span>
million consolidated net loss, inclusive of the $<span id="xdx_90E_ecustom--OperatingIncomeLoss3_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zLuOkTO7VF64" title="Operating loss">6.9 </span>million
gain on bargain purchase<span title="Operating expenses"/>. The Neuromodulation Division includes $<span id="xdx_907_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zeQYdZiuAzLl" title="Division incurred">2.1
million</span> of total assets. The Biopharm Division includes $<span id="xdx_90E_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zxDeeAdzHsU">49.0
million</span> in total assets.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqraudtqBEL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z577Pw1dWBV1">Recently
Adopted Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material
impact on our financial statement presentation or disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ForeignOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents foreign operations policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ForeignOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_NhGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nh grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_NhGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274593824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zPFaoS5J1C76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B8_z58FvJxliqwj">The following table summarizes the fair
values of the assets acquired and liabilities assumed at the acquisition date (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration: underline">At August 30, 2022</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220830_zi8sjoqtX2x2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_404_ecustom--CashAndCashEquivalentsFairValue_iI_pn3n3_zgfRx0eOio1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">55,374</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentFairValueDisclosure_iI_pn3n3_zIF25wJjlbg2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn3n3_zb02uyamcnt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,657</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetOne_iI_pn3n3_zxvvNVFFlJhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherAssetsFairValueDisclosure_iI_pn3n3_zrFmwaFlh3Ic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--FairValueOfAssetsAcquired1_iI_pn3n3_zmvfOPgBpoZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total identifiable assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,326</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_iNI_pn3n3_di_z5SR75EewP79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,913</td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iNI_pn3n3_di_ztiNfqcnij33" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(151</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_ecustom--FairValueOfLiabilitesAcquired_iNI_pn3n3_di_znkiSdASaQr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_zk5rigypYHTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt">Net identifiable assets acquired</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">53,262</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">The following table summarizes the calculation of the gain on bargain purchase (in thousands)</a></td>
<td class="text"><p id="xdx_893_eus-gaap--GainLossOnInvestmentsTextBlock_zCDd6WSGUaO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B9_z5QPe5U54zy">The following table summarizes the calculation
of the gain on bargain purchase (in thousands)</span>:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220830_znOwAxta2wH6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--TotalConsideration_iNI_pn3n3_di_zCGZuZhdzGRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Total consideration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,385</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdvancesFairValueDisclosure_iNI_pn3n3_di_zRq62IKMKht8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SAFE loan forgiven</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_zmQKf8dlIVY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less net identifiable assets acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,262</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_ecustom--GainOnBargainPurchase_iI_pn3n3_zVQzq5qGIrHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2pt">Gain on bargain purchase</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">6,877</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274558464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives of principal classes of assets</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden">Schedule of estimated useful lives of principal classes of assets</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 46%"><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0503">5</span></span></span></td>
    <td style="width: 53%; padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0505">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Computer hardware and software</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0507">3</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0509">7</span></span> years</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0511">2</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0512">5</span></span> years or the term of the lease, if shorter</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Furniture, fixtures and equipment</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0514">5</span></span></span></td>
    <td style="padding-left: 1pt"><span style="font-size: 10pt">&#8211; <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">10</span></span> years</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden">&#160;Schedule
of net loss per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Shares underlying warrants outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">10,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">9,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,272</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,542</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,583</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of estimated useful life of property and equipment table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274501312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Money Market Funds (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Money Market Funds at their Level within the Fair Value Hierarchy</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zWsAqf5BoKS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
following table presents money market funds at their level within the fair value hierarchy at December 31, 2022 and 2021 (in thousands).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zOPtffOgbctf" style="display: none; visibility: hidden">Schedule of Money Market Funds at their Level within the Fair Value Hierarchy</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">December 31, 2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; text-align: left; padding-bottom: 1pt">Money market funds</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20221231_zRysV9MvISUl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds">44,417</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWHzCoiivLB6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds">44,417</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTRUEe7wKfrg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zde2sAraGg8c" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">December 31, 2021:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Money market funds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20211231_zBGhRpK0g3J8" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeyQYp5i1Vue" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoIaFTcfPhud" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zh7TluyGlx61" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276095328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjC0DyuWb6Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zRzYQ4bz5yYe">Property
and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zv6HeXdASRD9" style="width: 10%; text-align: right">3,520</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zh99CLf6UYte" style="width: 10%; text-align: right">3,174</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="text-align: right" title="Property and equipment, gross">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhBX8h3qlb11" style="text-align: right" title="Property and equipment, gross">10</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" style="text-align: right" title="Property and equipment, gross">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxnkfGZPZ7Ne" style="text-align: right" title="Property and equipment, gross">12</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Computer software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_zu0eqEiR6114" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property and equipment, gross">3,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_z4VDJ4qMb2b5" style="text-align: right" title="Property and equipment, gross">3,204</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zmuXJCwkl7q8" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization">(2,411</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zO4j6AB8io87" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization">(2,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">1,182</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_ziL4I3Sc0IS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">1,173</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271719136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjY8AwJpseL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zwkhgZqovQ7g">A
summary of warrant activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zttlQCtP8VPl" style="display: none; visibility: hidden">Summary of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share&#160;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)&#160;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%">Warrants outstanding as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEGqAedIP7W2" style="width: 10%; text-align: right" title="Outstanding at beginning">5,402</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zv1eVTrc1d16" style="width: 10%; text-align: right" title="Outstanding at beginning">3.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;&#160;&#160;Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqVhoxQ0zcdi" style="text-align: right" title="Issued">3,672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7EkoCazMLS4" style="text-align: right" title="Class of warrant or right exercise issued">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znMfsDsK0vci" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;&#160;Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2h8DpHJ1Uqa" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants outstanding as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zi70I13cg8z5" style="text-align: right">9,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6MHehZVgxyb" style="text-align: right">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaVPY4vfYiMa" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zd8UlA9P8thf" style="text-align: right" title="Class of warrant or right exercise issued"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhqepYaOnrne" style="text-align: right" title="Exercised">(1,327</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQIqnjNC5a18" style="text-align: right" title="Class of warrant or right to be exercised">3,15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Forfeited or expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuS9ZPI4H3j3" style="text-align: right" title="Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOtherAdjustments_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJsR55UOQaU5" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments">2,564</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOtherAdjustment_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zcHbRVwesco3" style="padding-bottom: 1pt; text-align: right" title="Class of warrant or right other adjustment">35.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWwwuvTOloD3" style="padding-bottom: 1pt; text-align: right" title="Other adjustments (in years)::XDX::P1Y5M16D"><span style="-sec-ix-hidden: xdx2ixbrl0719">1.46</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zVsAaEkTYhS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending">10,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMc7aeem6TJ6" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending">11.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zETl6FD27PJ4" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending (in years)::XDX::P2Y3M22D"><span style="-sec-ix-hidden: xdx2ixbrl0725">2.31</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable as of December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsrL7AZWik24" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable at ending">10,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zChkBds5Pxjl" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending">11.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh1z8YdtMeca" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending (in years)::XDX::P2Y3M22D"><span style="-sec-ix-hidden: xdx2ixbrl0731">2.31</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185272718256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock', window );">Summary of Option Grant using the Black-Scholes Option-pricing Model</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zzjDNw9ffAT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized stock-based compensation cost of $<span id="xdx_906_ecustom--ShareBasedCompensation1_dxL_c20220101__20221231_z8VpJhbYUYe8" title="stock based compensation cost::XDX::1470000"><span style="-sec-ix-hidden: xdx2ixbrl0742">1.3</span></span> million and $<span id="xdx_90E_ecustom--ShareBasedCompensation1_dxL_c20210101__20211231_z3PyTOn5Qiwh" title="::XDX::1668000"><span style="-sec-ix-hidden: xdx2ixbrl0743">1.7</span></span> million during 2022 and 2021, respectively. The calculated value
of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zaEStGAOm7m4" style="display: none; visibility: hidden">Summary of Option Grant using the Black-Scholes Option-pricing Model</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zM1VFRmlrsD7" title="Risk-free interest rate">3.42</span>% &#8211; <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zVd946XQ434d" title="Risk-free interest rate">4.45</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zvAXpD4SbRUb" title="Risk-free interest rate">0.7</span>% &#8211; <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zvwkKdMHCbuc" title="Risk-free interest rate">0.9</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_z4nxWKRXhusj" title="Expected dividend yield">0</span>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zczCJihV88Sf" title="Expected dividend yield">0</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zrf3O4uhs7Ce" title="Expected volatility">100</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zE27Sy97wy1f" title="Expected volatility">100</span>%</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Expected term</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zUDoygePn4z3">4.25</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zgHGX0qnM573" title="Expected term::XDX::P6Y0M29D"><span style="-sec-ix-hidden: xdx2ixbrl0762">6.08</span></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zyY3OekL5h5l" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0764">5</span></span>-<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zs6Oex5mheV6" title="Expected term::XDX::P6Y0M29D"><span style="-sec-ix-hidden: xdx2ixbrl0766">6.08</span></span> years</span></td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zahKLqv7z9Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zj01Vx6A5a3d" style="display: none; visibility: hidden">Summary of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Life (in Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%">Options outstanding at December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAq3dvCRueP4" style="width: 10%; text-align: right" title="Options outstanding, number of shares (in shares)">5,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zotkEN4Z8A9e" style="width: 10%; text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)">2.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO47jeZyLfe" style="text-align: right" title="Granted">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaOmFHF99Och" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPt2m0inTWN6" style="text-align: right" title="Exercised">(1,020</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJy5Ox6CHsNi" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)">0.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGGJ0RhXpFz" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired">(875</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS2mkehgpYhc" style="padding-bottom: 1pt; text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)">2.82</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options outstanding at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPyG8b7gHeD3" style="text-align: right" title="Options outstanding, number of shares (in shares)">4,542</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPjpcsFgvk23" style="text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)">2.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZIQwcJ86x4f" style="text-align: right" title="Granted">866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXM35BSQwxml" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)">2.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z74HFrTaoNK1" style="text-align: right" title="Exercised">(73</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa6okzzYMid" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)">1.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited or expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLSgc4UlujS5" style="text-align: right" title="Forfeited or expired">(335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmplEwphIV1e" style="text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)">4.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC0Nce0vksEe" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments">272</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcoan5IqPKj" style="padding-bottom: 1pt; text-align: right" title="Other adjustments , weighted average exercise price (in dollars per share)">8.70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding, vested and expected to vest at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVV42Ik6nYa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, number of shares (in shares)">5,272</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDRb9YqGwUh" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in dollars per share)">3.07</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zavW5A2be8n6" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in years)::XDX::P7Y1M24D"><span style="-sec-ix-hidden: xdx2ixbrl0811">7.15</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOfbPGH9Eie" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, number of shares (in shares)">3,819</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT1q0jnevKVa" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable, weighted average exercise price (in dollars per share)">3.24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsupd8sSKsd6" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable period (in years)::XDX::P6Y6M18D"><span style="-sec-ix-hidden: xdx2ixbrl0817">6.55</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z9SzNUjW711j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the
years ended December 31, 2022 and 2021 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5E5xaTBjh83" style="display: none; visibility: hidden">Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUwCT72f93V4" style="width: 10%; text-align: right" title="Allocated share-based compensation expense">896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z35zALM8DjS1" style="width: 10%; text-align: right" title="Allocated share-based compensation expense">1,329</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwmYPOrrbxF8" style="border-bottom: Black 1pt solid; text-align: right">400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPff0Tqq0N86" style="border-bottom: Black 1pt solid; text-align: right">339</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zVNroePLEmzl" style="border-bottom: Black 2.5pt double; text-align: right">1,296</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zhh55aUb3Zz" style="border-bottom: Black 2.5pt double; text-align: right">1,668</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of share based compensation arrangement by share based payment award options grants in period table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185272749280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOKWsQU7nvP1" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zbKs38QJmLP">The
components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"/>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zhBNNNbVEkzi" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLfxWR3YG7Eb" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zwXrDoYiCHv1" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVwGkpHftDn9">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31, 2022</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of <br/> December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NPM</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Legacy SSMP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Combined</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NPM</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;Deferred Tax :</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zmQMyRQ8hCSc" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%">&#160;Accruals/reserves</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">226</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_zReRcK54dMZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Capitalized R&amp;E &#167;174</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">459</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_z4nEoMQlRdg1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Lease ROU</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zexQfnaMWIo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Stock Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">776</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z28JT53TZaRk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Net operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,194</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_zTSpWO3W4hNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;R&amp;D credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,358</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,961</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,319</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,671</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zryEUe5YTfnk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Gross Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,982</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,564</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">56,546</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,698</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zhx89EXOrBHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Investment in Sub</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_iI_pn3n3_zfuK6Ucv2SG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Accumulated depreciation/amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(202</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(120</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zOKU14AVwRi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,660</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,712</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(120</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--TaxCreditCarryforwardValuationAllowance1_iI_pn3n3_zsY5DO2zilY" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21,322</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(33,512</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(54,834</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,804</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zpdkLC6KkpIb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Total Deferred Tax Assets, Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zpGd0eDQucMk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Change in valuation allowance for the year ended</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,519</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">461</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,204</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>





<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands):</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwtCrr7WOmJ3" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0mHY8d5OAgb">The
reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and
the corresponding rate from operations consist of the following (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year Ended December 31, 2022</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    SSMP</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combined</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pre-Tax
    Loss <sup id="xdx_F49_zGmS0pPvS0ah">(a)</sup></span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_fKGEp_zHzGdXL01v9l" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,889</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_fKGEp_zWCTbOGinBvc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,479</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zua3UZboUDw8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,889</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Federal
    tax (benefit) at statutory rate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zncslZ6DXQck" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zrbiY7wKWQ2k" title="Federal tax (benefit) at statutory rate (percent)">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLRDFlBXZNOf" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(311</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z8PnshO8R8o5">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z5q8hVYFGA1" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zrAoBkAO3O05">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State
    tax (benefit), net of federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFQOLbuhoitf" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zD1eAPRL6576" title="State tax (benefit), net of federal tax benefit (percent)">7.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zlw0ckYWhjoc" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zMvh0e3gAc95">7.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zenX8q6pqWT3" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,073</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zRCHgDBN6hnk">7.7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;R&amp;D
    tax credit from current year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zYSxRUdYx7kk" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(687</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zHtF5TCrGin" title="R&amp;D tax credit from current year (percent)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zjpNWYaVx6A9" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zgfCkLAAkdYg">0.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_zuDwWdXE50hd" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(707</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zDN2HLZPgYH7">5.1</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;Impact on effective rate of SSMP loss eliminated in consolidation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zg4ZopIGFyqf" style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z7407CXbAdx7" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zOqFyhnDf6Ze" style="text-align: right" title="Pre-Tax Income (Loss)">(311</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zPODuwsCotR8">2.2</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zEaiJaSJG7oe" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z6Hygoi7XCaf" title="Other (percent)">-0.4</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zIwosWd83wRh" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvubkJAIpfvd">1.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_zBMC6AulFCY8" style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zZqmHqWoOHhg">-0.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Change
    in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFkC1XoH0tde" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,519</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z2ZLLbff7oH1" title="Change in valuation allowance (percent)">-32.5</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvc749oR8kRc" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">462</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zTSngbE0cer8">-31.2</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zFVL4pyxdznj" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,980</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zavBeFvSroH9">-35.9</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    provision for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zsKXGl0USTZa" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zBkzXlJPSPQi" title="Total provision for income taxes (percent)">0.0</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zW7xByvT8XIg" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zRmu271TSLd7" title="Total provision for income taxes">-0.1</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zfe3Ewm9pWQj" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zeca7nMC5lzc" title="Total provision for income taxes">0.0</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F0B_zYjnvwWfePwl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F1B_zXoPwEsGRYk5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#8217;s interest in
                                                                                                                                                                 Legacy SSMP&#8217;s pre-tax loss.</span></td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPM</b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended December 31, 2021 </b></span></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 59%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; width: 1%; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Pre-tax
    income (loss)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zIFEVggs4Vc5" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,773</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Federal
    tax (benefit) at statutory rate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_znk23RLyjb73" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,682</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zCditIAbu0w2" title="Federal tax (benefit) at statutory rate (percent)">21.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State
    tax (benefit), net of federal tax benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zP7JJ3t5UThf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zENdvgyn1FBb" title="State tax (benefit), net of federal tax benefit (percent)">7.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;R&amp;D
    tax credit from current year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zPdxEEyF5vxf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(475</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVOtVlxUes3i" title="R&amp;D tax credit from current year (percent)">3.7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zDCw1WYbBTRd" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(163</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z9qwsOanWJg5" title="Other (percent)">1.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Change
    in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zozPAyMDDaEb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,214</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zf12XN9xRLCg" title="Change in valuation allowance (percent)">-33.0</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; padding-bottom: 1pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="display: none; text-align: left; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    provision for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z3pRQx6eCr3b" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zoVjvEkxEPc9" title="Total provision for income taxes (percent)">0.0</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z1x7zifKh8Tc" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zRHHnjqmtF79">As
of December&#160;31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and
state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):</span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zGsn3kKIHJh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zkWy5QjDEc04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NPM</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    SSMP</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zyEmcgMFwV1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre TCJA
    (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,257</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,095</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_z6bkqeUeSoO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post
    TCJA period federal NOL carry-forward, with no carry-forward limitation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,503</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,412</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zLMKKvhr7KAb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    federal NOL carry-forward</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,760</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,508</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_z6Ez4bIX1poh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;State NOL carry-forward,
    begin expiring 2030</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,514</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,439</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_z61WgtTZchY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal R&amp;D tax
    credit carry-forward, begin expiring in 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--DeferredTaxAssetsStateTaxes1_iI_pn3n3_zvGm8u83tYC4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State R&amp;D carry-forward,
    begin expiring in 2026</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,973</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,989</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zKwUUYRHHkz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total R&amp;E related
    deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">459</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserve for uncertain
    income tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274695712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use Assets and Operating Lease Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract', window );"><strong>Right-of-use Assets And Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):</a></td>
<td class="text"><p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zq8oKKab9gji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_za0Kr6KDHsHe">The
Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use
assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Year ending December 31:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left; padding-bottom: 1pt">2023</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20220101__20221231_zpX4ZUs9dsml" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="2023">975</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--OperatingLeasePayment_pn3n3_c20220101__20221231_zF2Q9QG9LCGh" style="text-align: right" title="Total lease payments">975</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseCost_iN_pn3n3_di_c20220101__20221231_zYsFQ1WevWGh" style="border-bottom: Black 1pt solid; text-align: right" title="Imputed interest">(20</td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_zbDVMgvUGY29" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other supplemental information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--OperatingLeasePayments1_pn3n3_c20220101__20221231_zWQ9TPCyUn19" style="text-align: right" title="Current operating lease liabilities">955</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Long term operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zXCADKZZDPzh" style="border-bottom: Black 1pt solid; text-align: right" title="Long term operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_z3qyK37DPtHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities">955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 1pt">&#160;</span></td><td><span style="font-size: 1pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 1pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 1pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 1pt">&#160;</span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%">
<tr>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended</b><br/>
    <b>&#160;December 31,</b><br/>
    <b>2022</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the year ended</b><br/>
    <b>&#160;December 31,</b><br/>
    <b>2021</b></span></td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for operating lease liabilities</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20221231_zMSIGN02zZJa" title="Cash paid for operating lease liabilities">1.0 million</span></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20211231_zPg1JFTUxMG1" title="Cash paid for operating lease liabilities">0.9
    million</span></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271753408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_CashAndCashEquivalentsFairValue', window );">Cash</a></td>
<td class="nump">$ 55,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Property and equipment</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingLeaseRightOfUseAssetOne', window );">Right of use assets</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_FairValueOfAssetsAcquired1', window );">Total identifiable assets acquired</a></td>
<td class="nump">57,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Current liabilities</a></td>
<td class="num">(3,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Right of use liabilities</a></td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_FairValueOfLiabilitesAcquired', window );">Total liabilities assumed</a></td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="nump">$ 53,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_CashAndCashEquivalentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents Cash and cash equivalents fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_CashAndCashEquivalentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_FairValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents fair value of assets acquired1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_FairValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_FairValueOfLiabilitesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents fair value of liabilites acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_FairValueOfLiabilitesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_OperatingLeaseRightOfUseAssetOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents Operating lease right of use asset one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_OperatingLeaseRightOfUseAssetOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276913168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_TotalConsideration', window );">Total consideration</a></td>
<td class="nump">$ 54,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesFairValueDisclosure', window );">SAFE loan forgiven</a></td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Less net identifiable assets acquired</a></td>
<td class="num">(53,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GainOnBargainPurchase', window );">Gain on bargain purchase</a></td>
<td class="nump">$ 6,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GainOnBargainPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents gain on bargain purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GainOnBargainPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_TotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents total consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_TotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of Federal Home Loan Bank (FHLBank) advances carried under the fair value option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271524496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Operations (Details Narrative) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">on August 30, 2022 (the &#8220;Acquisition
Date&#8221;), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest
of Second Sight, Medical, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">13,136<span></span>
</td>
<td class="nump">50,736<span></span>
</td>
<td class="nump">36,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Assets, fair value adjustment</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent', window );">Fair value of identifiable assets acquired and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax', window );">Gain of other income expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business Combination, Acquisition Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,889,000)<span></span>
</td>
<td class="num">$ (12,773,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ProFormaMember', window );">Pro Forma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300,000<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of the consideration transferred</a></td>
<td class="nump">$ 54,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=eyes_SecondSightSwitzerlandSarlMember', window );">Second Sight Switzerland Sarl [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A specified percentage variance in the prepayment speed assumption in the determination of fair value of transferor's interests in transferred financial assets (including any servicing assets or servicing liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=d3e107314-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eyes_SecondSightSwitzerlandSarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eyes_SecondSightSwitzerlandSarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185269634432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of estimated useful lives of principal classes of assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276907216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of net loss per share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares underlying warrants outstanding</a></td>
<td class="nump">10,311<span></span>
</td>
<td class="nump">9,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Common stock options</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare', window );">Total</a></td>
<td class="nump">15,583<span></span>
</td>
<td class="nump">13,616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents antidilutive securities excluded from computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271526096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">11,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Patent costs</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GrantsAgainstOperatingExpense', window );">Grants offset against operating expenses</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured amount</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_CashSPICInsuredAmount', window );">SPIC insured amount</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_SPICCashLimitCoverage', window );">SPIC cash limit coverage</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">51,130,000<span></span>
</td>
<td class="nump">5,453,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_AccruedLiabilitiesCurrent1', window );">Accrued expenses</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eyes_BiopharmDivisionMember', window );">Biopharm Division [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DivisionIncurred', window );">Division Incurred</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingIncomeLoss1', window );">Operating loss</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingIncomeLoss2', window );">Operating loss</a></td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingIncomeLoss3', window );">Operating loss</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DivisionIncurredOfAssets', window );">Division incurred</a></td>
<td class="nump">49,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eyes_NeuromodulationDivisionMember', window );">Neuromodulation Division [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingIncomeLoss1', window );">Operating loss</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DivisionIncurredOfAssets', window );">Division incurred</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eyes_CountryMember', window );">Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_AccruedLiabilitiesCurrent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents accrued liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_AccruedLiabilitiesCurrent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_CashSPICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash s p i c insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_CashSPICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DivisionIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents division incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DivisionIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DivisionIncurredOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents division incurred of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DivisionIncurredOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GrantsAgainstOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents grants against operating expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GrantsAgainstOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_OperatingIncomeLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents Operating income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_OperatingIncomeLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_OperatingIncomeLoss2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents Operating income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_OperatingIncomeLoss2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_OperatingIncomeLoss3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents Operating income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_OperatingIncomeLoss3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_SPICCashLimitCoverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents s p i c cash limit coverage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_SPICCashLimitCoverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eyes_BiopharmDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eyes_BiopharmDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eyes_NeuromodulationDivisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eyes_NeuromodulationDivisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=eyes_CountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=eyes_CountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185273081680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 44,417<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">44,417<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274571376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Money Market Funds (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 44.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185272768224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,593<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(2,411)<span></span>
</td>
<td class="num">(2,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,520<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyes_ComputerHardwareAndSoftwareMember', window );">Computer Hardware And Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyes_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyes_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185274694112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Detail (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ContractLiabilitiesOther', window );">Contract liabilities</a></td>
<td class="nump">$ 335,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ContractLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents contract liabilities other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ContractLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185272512896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grants (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureGrantsAbstract', window );"><strong>Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GrantReceivedToSupportClinicalDevelopment', window );">Received grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears', window );">Grant receivable with intent to fund early feasibility clinical trial for five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GrantReceivedFundingPeriod', window );">Grant received funding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_GrantsAgainstOperatingExpenses', window );">Grants against operating expenses</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">14,169<span></span>
</td>
<td class="nump">$ 11,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses.</a></td>
<td class="nump">$ 7,072<span></span>
</td>
<td class="nump">$ 2,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents grant receivable to fund early feasibility clinical trial for five years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GrantReceivedFundingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents grant received funding period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GrantReceivedFundingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GrantReceivedToSupportClinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents grant received to support clinical development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GrantReceivedToSupportClinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_GrantsAgainstOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents grants against operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_GrantsAgainstOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271617056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Securities (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">50,736,000<span></span>
</td>
<td class="nump">13,136,000<span></span>
</td>
<td class="nump">36,803,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_StockIssuedDuringPeriodSharesMergerAcquisitions', window );">Stock issued during period shares merger acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,136,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">50,735,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_StockIssuedDuringPeriodSharesMergerAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares merger acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_StockIssuedDuringPeriodSharesMergerAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185268258416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Warrant Activity (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at beginning</a></td>
<td class="nump">9,074,000<span></span>
</td>
<td class="nump">5,402,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightIssued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,672,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightExerciseIssued', window );">Class of warrant or right exercise issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(1,327,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightForfeitedOrExpired', window );">Forfeited or expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightToBeExercised', window );">Class of warrant or right to be exercised</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">2,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightOtherAdjustment', window );">Class of warrant or right other adjustment</a></td>
<td class="nump">$ 35.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne', window );">Other adjustments (in years)</a></td>
<td class="text">1 year 5 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at ending</a></td>
<td class="nump">10,311,000<span></span>
</td>
<td class="nump">9,074,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding at ending</a></td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2', window );">Outstanding at ending (in years)</a></td>
<td class="text">2 years 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights', window );">Exercisable at ending</a></td>
<td class="nump">10,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11', window );">Exercisable at ending</a></td>
<td class="nump">11.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise', window );">Exercisable at ending (in years)</a></td>
<td class="text">2 years 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightExerciseIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right exercise issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightExerciseIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightForfeitedOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightForfeitedOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightOtherAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right other adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightOtherAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right to be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right weighted average remaining contractual life of warrants or rights2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right weighted average remaining contractual life of warrants or rights exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right weighted average remaining contractual life of warrants or rights one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right weighted exercise price exercisable of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right weighted exercise price exercisable of warrants or rights11.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271552944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - Right Offering [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClassOfWarrantsOrRightsTerm', window );">Term of warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,563,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClassOfWarrantsOrRightsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrants or rights term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClassOfWarrantsOrRightsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eyes_RightOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eyes_RightOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185277663856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions to plan</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271813120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Option Grant using the Black-Scholes Option-pricing Model (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ShareBasedCompensation1', window );">stock based compensation cost</a></td>
<td class="nump">$ 1,470,000<span></span>
</td>
<td class="nump">$ 1,668,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 3 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ShareBasedCompensation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ShareBasedCompensation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271497856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of shares (in shares)</a></td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">5,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.89<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(1,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired</a></td>
<td class="num">(335)<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod', window );">Other adjustments</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Other adjustments , weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number of shares (in shares)</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Options outstanding, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, vested and expected to vest (in years)</a></td>
<td class="text">7 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, number of shares (in shares)</a></td>
<td class="nump">3,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable period (in years)</a></td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options other adjustments in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185268260784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 1,296<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271861424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options exercisable</a></td>
<td class="nump">$ 151,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185268937312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">&#160;Accruals/reserves</a></td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">&#160;Capitalized R&amp;E &#167;174</a></td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities', window );">&#160;Lease ROU</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">&#160;Stock Compensation</a></td>
<td class="nump">1,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">&#160;Net operating loss</a></td>
<td class="nump">44,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">&#160;R&amp;D credit</a></td>
<td class="nump">6,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">&#160;Gross Deferred Tax Assets</a></td>
<td class="nump">56,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">&#160;Investment in Sub</a></td>
<td class="num">(1,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1', window );">&#160;Accumulated depreciation/amortization</a></td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">&#160;Gross deferred tax liabilities</a></td>
<td class="num">(1,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_TaxCreditCarryforwardValuationAllowance1', window );">&#160;Valuation Allowance</a></td>
<td class="num">(54,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">&#160;Total Deferred Tax Assets, Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">&#160;Change in valuation allowance for the year ended</a></td>
<td class="nump">4,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember', window );">NPM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">&#160;Accruals/reserves</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">&#160;Capitalized R&amp;E &#167;174</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities', window );">&#160;Lease ROU</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">&#160;Stock Compensation</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">&#160;Net operating loss</a></td>
<td class="nump">16,775<span></span>
</td>
<td class="nump">14,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">&#160;R&amp;D credit</a></td>
<td class="nump">2,358<span></span>
</td>
<td class="nump">1,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">&#160;Gross Deferred Tax Assets</a></td>
<td class="nump">22,982<span></span>
</td>
<td class="nump">16,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">&#160;Investment in Sub</a></td>
<td class="num">(1,510)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1', window );">&#160;Accumulated depreciation/amortization</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">&#160;Gross deferred tax liabilities</a></td>
<td class="num">(1,660)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_TaxCreditCarryforwardValuationAllowance1', window );">&#160;Valuation Allowance</a></td>
<td class="num">(21,322)<span></span>
</td>
<td class="num">(16,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">&#160;Total Deferred Tax Assets, Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">&#160;Change in valuation allowance for the year ended</a></td>
<td class="nump">4,519<span></span>
</td>
<td class="nump">$ 4,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember', window );">Legacy SSMP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">&#160;Accruals/reserves</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">&#160;Capitalized R&amp;E &#167;174</a></td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities', window );">&#160;Lease ROU</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">&#160;Stock Compensation</a></td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">&#160;Net operating loss</a></td>
<td class="nump">27,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">&#160;R&amp;D credit</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">&#160;Gross Deferred Tax Assets</a></td>
<td class="nump">33,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">&#160;Investment in Sub</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1', window );">&#160;Accumulated depreciation/amortization</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">&#160;Gross deferred tax liabilities</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_TaxCreditCarryforwardValuationAllowance1', window );">&#160;Valuation Allowance</a></td>
<td class="num">(33,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">&#160;Total Deferred Tax Assets, Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">&#160;Change in valuation allowance for the year ended</a></td>
<td class="nump">$ 461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The elemnt represents accumulated depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_TaxCreditCarryforwardValuationAllowance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_TaxCreditCarryforwardValuationAllowance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185268039120">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (13,889)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,916)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax (benefit) at statutory rate (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,073)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax (benefit), net of federal tax benefit (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.70%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (707)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit from current year (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (311)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Change in valuation allowance (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35.90%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember', window );">NPM [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (13,889)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (12,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,916)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax (benefit) at statutory rate (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (970)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax (benefit), net of federal tax benefit (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (687)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit from current year (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Change in valuation allowance (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32.50%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(33.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember', window );">Legacy SSMP [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,479)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (311)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax (benefit) at statutory rate (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (103)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax (benefit), net of federal tax benefit (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit from current year (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Change in valuation allowance (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Pre-Tax Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes (percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#8217;s interest in
                                                                                                                                                                 Legacy SSMP&#8217;s pre-tax loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276781360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>As of December 31, 2022, we had federal and apportioned state net operating loss (&#8220;NOL&#8221;) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember', window );">NPM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</a></td>
<td class="nump">$ 18,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Post TCJA period federal NOL carry-forward, with no carry-forward limitation</a></td>
<td class="nump">39,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Total federal NOL carry-forward</a></td>
<td class="nump">57,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">&#160;State NOL carry-forward, begin expiring 2030</a></td>
<td class="nump">66,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Federal R&amp;D tax credit carry-forward, begin expiring in 2026</a></td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DeferredTaxAssetsStateTaxes1', window );">State R&amp;D carry-forward, begin expiring in 2026</a></td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Total R&amp;E related deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was</a></td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember', window );">Legacy SSMP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030</a></td>
<td class="nump">29,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Post TCJA period federal NOL carry-forward, with no carry-forward limitation</a></td>
<td class="nump">86,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Total federal NOL carry-forward</a></td>
<td class="nump">115,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">&#160;State NOL carry-forward, begin expiring 2030</a></td>
<td class="nump">30,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Federal R&amp;D tax credit carry-forward, begin expiring in 2026</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DeferredTaxAssetsStateTaxes1', window );">State R&amp;D carry-forward, begin expiring in 2026</a></td>
<td class="nump">4,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Total R&amp;E related deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was</a></td>
<td class="nump">$ 459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DeferredTaxAssetsStateTaxes1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents deferred tax assets state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DeferredTaxAssetsStateTaxes1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=eyes_NPMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=eyes_LegacySSMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185276730288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#8217;s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract', window );"><strong>Right-of-use Assets And Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingLeasePayment', window );">Total lease payments</a></td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Imputed interest</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease liabilities</a></td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_OperatingLeasePayments1', window );">Current operating lease liabilities</a></td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Long term operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee discounted operating lease liability payments due year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_OperatingLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents operating lease payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_OperatingLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_OperatingLeasePayments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents operating lease payments1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_OperatingLeasePayments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185273155312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use Assets and Operating Lease Liabilities (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract', window );"><strong>Right-of-use Assets And Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_LeaseAndRentalExpense1', window );">Rent expense</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_LeaseAndRentalExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents Lease and rental expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_LeaseAndRentalExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185268249104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_ClinicalAndRegulatoryExpense', window );">Clinical and regulatory expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eyes_LiquidatedDamagesPaidValue', window );">Liquidated damage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractTerminationClaimsDescription', window );">Description of contract termination and claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pixium indicated that it considered this termination wrongful,
rejected the Company&#8217;s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial
Court, and currently claim damages of approximately &#8364;5.1 million or about $5.6 million. We believe we have fulfilled our obligations
to Pixium with the liquidated damages payment of $1,000,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency, damages paid, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementCourt', window );">Description of legal settlement</a></td>
<td class="text">On December 9, 2022, the Company received notice that the Paris Commercial
Court has rendered its judgement, including finding that the Company&#8217;s termination of the MOU was not valid. In the judgement,
the Company was ordered to pay to Pixium the amount of &#8364;2,500,000 minus a &#8364;947,780 credit for the $1,000,000 already
paid for, a net amount payable of approximately &#8364;1,552,220. The Company may appeal the decision within three months from the
date of service. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to raise any and all legal
challenges to this preliminary judgement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_ClinicalAndRegulatoryExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents clinical and regulatory expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_ClinicalAndRegulatoryExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyes_LiquidatedDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents liquidated damages paid value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyes_LiquidatedDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyes_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractTerminationClaimsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84167097&amp;loc=d3e55541-109407<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167097&amp;loc=d3e55538-109407<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54672-109401<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938335&amp;loc=d3e56414-109416<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54708-109401<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126938335&amp;loc=d3e56417-109416<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54658-109401<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractTerminationClaimsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencySettlementAgreementCourt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the name of the court, if applicable, which approved the terms of the settlement agreement resolving the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencySettlementAgreementCourt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140185271704240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rental payments amount</a></td>
<td class="nump">$ 22,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Description of lease agreement</a></td>
<td class="text">lease
14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355. The sub-lease has a term of two years
and two months. We also entered into a lease for storage space on January 25, 2023 in the same building at a cost of $6,775
per month for a term of two years and one month.<span></span>
</td>
<td class="text">Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California on November
21, 2022. The stated term of the lease commences on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months.
Payments increase annually from $2,676,311 to $3,596,784, or 124 payments less the first four which are abated, totalling approximately
$31 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Mr dams [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Description of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mr.
Adams $25,000 per month for his services to us. In March 2023 we entered into an at will letter agreement with Jonathan Adams
by which we appointed him President and Chief Executive Officer of Cortigent at a base salary of $350,000 per year commencing
as of March 1, 2023. He may also receive a onetime signing bonus of up to $50,000 upon Board approval. Upon Board approval following
completion of the initial public offering of securities, Mr. Adams may also be issued an option to purchase 400,000 shares of
our common stock at a strike price equal to the price per share at which shares initially are sold to the public in this
offering. Of these, options to purchase 100,000 shares will vest on November 10, 2023 and the balance shall vest in
approximately equal monthly instalments over the ensuing 36 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyes_MrAdamsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyes_MrAdamsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>g083419_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:eyes="http://secondsight.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eyes-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyes:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="AsOf2023-03-27_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SecondSightSwitzerlandSarlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">eyes:SecondSightSwitzerlandSarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-282022-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2022-08-28</startDate>
            <endDate>2022-08-30</endDate>
        </period>
    </context>
    <context id="From2022-08-282022-08-30_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-28</startDate>
            <endDate>2022-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2022-08-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_ProFormaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_ProFormaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eyes:CountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BiopharmDivisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eyes:BiopharmDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_BiopharmDivisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eyes:BiopharmDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NeuromodulationDivisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eyes:NeuromodulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyes:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyes:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_RightOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RightOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RightOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-12-282022-12-31_custom_RightOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RightOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyes:RightOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NPMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LegacySSMPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:LegacySSMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NPMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NPMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LegacySSMPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:LegacySSMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NPMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">eyes:NPMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-12-072022-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2022-12-07</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="From2023-02-262023-03-03_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-26</startDate>
            <endDate>2023-03-03</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_us-gaap_SubsequentEventMember_custom_MrAdamsMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyes:MrAdamsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001266806</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0019">CA</dei:EntityIncorporationStateCountryCode>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnRepurchaseOfDebtInstrument
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:GainFromBargainPurchase
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:PppLoanForgiveness
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:CashAcquiredInMergerForStockConsideration
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:CancellationOfSafeBorrowing
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EstimateOfCancellations
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MinimumMember"
      id="xdx2ixbrl0503">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_EquipmentMember_srt_MaximumMember"
      id="xdx2ixbrl0505">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember"
      id="xdx2ixbrl0507">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember"
      id="xdx2ixbrl0509">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      id="xdx2ixbrl0511">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      id="xdx2ixbrl0512">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember"
      id="xdx2ixbrl0514">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember"
      id="xdx2ixbrl0515">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <eyes:GrantReceivedFundingPeriod contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0660">P5Y</eyes:GrantReceivedFundingPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      id="xdx2ixbrl0664"
      unitRef="USD">14169000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      id="xdx2ixbrl0666"
      unitRef="USD">7072000</us-gaap:GeneralAndAdministrativeExpense>
    <eyes:ClassOfWarrantsOrRightsTerm
      contextRef="From2022-12-282022-12-31_custom_RightOfferingMember"
      id="xdx2ixbrl0684">P5Y</eyes:ClassOfWarrantsOrRightsTerm>
    <eyes:ClassOfWarrantOrRightExercised
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0699"
      unitRef="Shares"
      xsi:nil="true"/>
    <eyes:ClassOfWarrantOrRightForfeitedOrExpired
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0701"
      unitRef="Shares"
      xsi:nil="true"/>
    <eyes:ClassOfWarrantOrRightIssued
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0705"
      unitRef="Shares"
      xsi:nil="true"/>
    <eyes:ClassOfWarrantOrRightExerciseIssued
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0707"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <eyes:ClassOfWarrantOrRightForfeitedOrExpired
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0713"
      unitRef="Shares"
      xsi:nil="true"/>
    <eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0719">P1Y5M16D</eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne>
    <eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0725">P2Y3M22D</eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2>
    <eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0731">P2Y3M22D</eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise>
    <eyes:ShareBasedCompensation1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="xdx2ixbrl0742"
      unitRef="USD">1470000</eyes:ShareBasedCompensation1>
    <eyes:ShareBasedCompensation1
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="xdx2ixbrl0743"
      unitRef="USD">1668000</eyes:ShareBasedCompensation1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      id="xdx2ixbrl0762">P6Y0M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-012021-12-31_srt_MinimumMember"
      id="xdx2ixbrl0764">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-012021-12-31_srt_MaximumMember"
      id="xdx2ixbrl0766">P6Y0M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0811">P7Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0817">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0823">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      id="xdx2ixbrl0875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="AsOf2021-12-31_custom_NPMMember"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="AsOf2022-12-31_custom_NPMMember"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      id="xdx2ixbrl0895"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0896"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="AsOf2021-12-31_custom_NPMMember"
      id="xdx2ixbrl0897"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1037"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-36747</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">Vivani Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">02-0692322</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">5858 Horton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite     280</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">818</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">833-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember">VANI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2022-01-012022-12-31_custom_WarrantsMember">Warrants</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-12-31_custom_WarrantsMember">VANIW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-12-31_custom_WarrantsMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">57100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-27" decimals="INF" unitRef="Shares">50735770</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2023-03-27_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">7680938</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2022-01-01to2022-12-31">Portions
of the registrant&#x2019;s Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;) are
incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Registrant
intends to file a definitive proxy statement pursuant to Regulation 14A with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within
120 days after the end of registrant&#x2019;s fiscal year end of December 31, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">207</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">BPM LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Walnut Creek, California</dei:AuditorLocation>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">45076000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2178000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2452000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">291000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">47528000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2469000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1182000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1173000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">779000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1611000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1366000</us-gaap:OtherAssetsNoncurrent>
    <eyes:DepositsAndOtherAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">275000</eyes:DepositsAndOtherAssets>
    <eyes:DepositsAndOtherAssets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">200000</eyes:DepositsAndOtherAssets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">51130000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5453000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1177000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2358000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">895000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserveNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1675000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">657000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">955000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">910000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6822000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2086000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">902000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6822000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2988000</us-gaap:Liabilities>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">50736000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">50736000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">36803000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">36803000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">109050000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">54649000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8009000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6713000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">35000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-72786000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-58897000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">44308000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2465000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">51130000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5453000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">14169000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">11002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">7072000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2321000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">21241000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">13323000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-21241000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-13323000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">475000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">550000</us-gaap:InterestIncomeOperating>
    <us-gaap:GainLossOnRepurchaseOfDebtInstrument
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6877000</us-gaap:GainLossOnRepurchaseOfDebtInstrument>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-13889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:NetIncomeLoss>
    <eyes:NetLossPerCommonShareBasicAndDiluted
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.36</eyes:NetLossPerCommonShareBasicAndDiluted>
    <eyes:NetLossPerCommonShareBasicAndDiluted
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.39</eyes:NetLossPerCommonShareBasicAndDiluted>
    <eyes:WeightedAverageSharesOutstandingBasicAndDiluted
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">38241</eyes:WeightedAverageSharesOutstandingBasicAndDiluted>
    <eyes:WeightedAverageSharesOutstandingBasicAndDiluted
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">33092</eyes:WeightedAverageSharesOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-13889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-13854000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">32197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">43029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">5045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-46124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1950000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3684</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">11564000</eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts>
    <eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">11564000</eyes:StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">355</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eyes:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">627</eyes:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <eyes:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32000</eyes:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <eyes:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">32000</eyes:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">36803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">54649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">6713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-58897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2465000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">36803</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">54649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">6713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-58897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2465000</us-gaap:StockholdersEquity>
    <eyes:StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      decimals="INF"
      unitRef="Shares">797</eyes:StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised>
    <eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      decimals="-3"
      unitRef="USD">16000</eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">16000</eyes:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      decimals="INF"
      unitRef="Shares">13136</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember347418515"
      decimals="-3"
      unitRef="USD">54385000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">54385000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-13889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-13889000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">50736</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">109050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">8009000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-72786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">44308000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-13889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">381000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">345000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1296000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:ShareBasedCompensation>
    <eyes:GainFromBargainPurchase
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6877000</eyes:GainFromBargainPurchase>
    <eyes:PppLoanForgiveness
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">641000</eyes:PppLoanForgiveness>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">36000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-14000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">476000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-102000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-1941000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">13000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2551000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">321000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">204000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-18787000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-10951000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">338000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">572000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-338000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-572000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <eyes:CashAcquiredInMergerForStockConsideration
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">55374000</eyes:CashAcquiredInMergerForStockConsideration>
    <eyes:CancellationOfSafeBorrowing
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8000000</eyes:CancellationOfSafeBorrowing>
    <eyes:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">16000</eyes:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <eyes:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">11620000</eyes:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">63390000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">11620000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">44264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">97000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2081000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">46442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:EstimateOfCancellations
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8000000</us-gaap:EstimateOfCancellations>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2112000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:NatureOfOperations contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--NatureOfOperations_z7DSZPSG9EB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;b&gt;1. &lt;span id="xdx_828_z2nn8HHDb18i"&gt;Organization and Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Vivani Medical, Inc. (&#x201c;Vivani,&#x201d;
the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; or similar terms) is a preclinical stage biopharmaceutical
company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal&#x2122; technology to enable long-term,
near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop
and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners to address
a leading cause of poor clinical outcomes in the treatment of chronic disease, medication non-adherence. For example, approximately
50% of patients treated for type 2 diabetes are non-adherent to their medicines, which can lead to poor clinical outcomes. We are
developing a portfolio of miniature, sub-dermal drug implant candidates that, unlike most oral and injectable medicines, are designed
with the goal of guaranteeing adherence by delivering therapeutic drug levels for up to 6 months or the life of the implant. In
addition, the minimal fluctuations of drug levels dictated by our NanoPortal technology may improve the tolerability profiles for
medicines that produce side effects associated with fluctuating drug levels.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Vivani resulted from the business combination
of Second Sight Medical Products (Second Sight) and Nano Precision Medical (NPM). Since inception, Vivani&#x2019;s main priority
has been the further development of the company&#x2019;s lead program, NPM-119, a miniature, 6-month, GLP-1 implant candidate for
the treatment of patients with type 2 diabetes under the company&#x2019;s Biopharm Division (formerly NPM). In parallel, Vivani&#x2019;s
new management team remained committed to identifying and exploring strategic options for the Neuromodulation Division (formerly
Second Sight) that will enable further development of its pioneering neurostimulation systems to help patients recover critical
body functions.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In February 2022, we announced the signing
of a definitive merger agreement between Nano Precision Medical, Inc. (&#x201c;NPM&#x201d;) and Second Sight Medical Products, Inc.
(&#x201c;Second Sight&#x201d;), pursuant to which NPM became a wholly-owned subsidiary of Second Sight. On August 30, 2022, the two
companies completed the merger, concurrent with which Second Sight changed its name to Vivani Medical, Inc. and now conducts the
present business of the Company. In September 2022, we announced the formation of the Company&#x2019;s Biopharm Division to advance
the assets of the former NPM which includes the further development of the company&#x2019;s lead program, NPM-119, a miniature,
6-month, GLP-1 implant candidate for the treatment of patients with type 2 diabetes. Vivani&#x2019;s new management team remains
committed to identifying and exploring strategic options for the Neuromodulation Division (formerly Second Sight) that will enable
further development of its pioneering neurostimulation systems to help patients recover critical body functions. On December 28,
2022, the assets and liabilities of this segment were contributed to Cortigent, Inc. a newly formed wholly owned subsidiary of
Vivani, in exchange for 20 million shares of common stock of Cortigent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In March 2023, Vivani announced the filing
of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) for the proposed initial
public offering of Cortigent. Cortigent is expected to continue to be majority-owned by Vivani immediately following the initial
public offering.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Agreement and Plan of Merger with Nano
Precision Medical, Inc.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On February 4, 2022, Second Sight Medical
Products, Inc. (&#x201c;Second Sight&#x201d;) entered into an agreement and plan of merger (the &#x201c;Merger Agreement&#x201d;) with
Nano Precision Medical, Inc. (&#x201c;NPM&#x201d;). The Merger was approved by the shareholders of Second Sight on July 27, 2022
and closed on August 30, 2022. Upon consummation of the Merger, NPM became a wholly-owned subsidiary of Second Sight. Concurrent
with to the Merger, Second Sight changed its name to Vivani Medical, Inc. and changed its trading symbol from EYES to VANI, and
trades under the ticker VANI on the NASDAQ market. Certain investors and members of the NPM board of directors are also investors
and members of the board of directors of Second Sight.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Under the terms and conditions of the Merger
Agreement, the securities of NPM converted into the right to receive shares of Second Sight&#x2019;s common stock representing &lt;span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SecondSightSwitzerlandSarlMember_zEhkKwQhbbl4" title="Ownership interest (in percentage)"&gt;77.32&lt;/span&gt;%
of the total issued and outstanding shares of common stock of Second Sight on a fully converted basis, including, without limitation,
giving effect to the conversion of all options, warrants, and any and all other convertible securities assuming net settlement.
Second Sight filed a Registration Statement on Form S-4 on May 13, 2022 in connection with the Merger to register the merger shares
effective June 24, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On February 4, 2022, in connection with
the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) whereby Second Sight
provided to NPM an investment advance of $8 million. The Merger Agreement provided that the SAFE would terminate if the Merger
were to be successfully completed. Under the terms of the SAFE, upon successfully completion of the Merger on August 30, 2022,
the investment advance was eliminated. Under the accounting for a business combination, the $&lt;span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20220101__20221231_zxOCogm3q4Rj" title="Purchase consideration"&gt;8&lt;/span&gt; million adjusted the purchase consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Merger involved a change of control
and was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;). Under this method of accounting, Second Sight was treated as the &#x201c;acquired&#x201d; company for financial
reporting purposes with NPM as the acquirer. The assets acquired and liabilities assumed by NPM were recorded at fair value under
Accounting Codification Standard (&#x201c;ASC 805&#x201d;), &lt;i&gt;Business &lt;/i&gt;Combinations. Accordingly, &lt;span id="xdx_901_eus-gaap--CommonStockVotingRights_c20220828__20220830_zjvZDQvoEdLg" title="Common stock, voting rights"&gt;on August 30, 2022 (the &#x201c;Acquisition
Date&#x201d;), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest
of Second Sight, Medical, Inc.&lt;/span&gt; The results of Second Sight&#x2019;s operations have been included in the consolidated financial
statements since that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The acquisition-date fair value of consideration
transferred totaled $&lt;span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn5n6_c20220828__20220830__us-gaap--BusinessAcquisitionAxis__us-gaap--SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_zEyzoFQn1Q21" title="Fair value of the consideration transferred"&gt;54.4&lt;/span&gt; million, which consisted of the fair value of the &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pn3n3_uShares_c20220830_zQLXF9RCF7E6" title="Common stock issued"&gt;13,136&lt;/span&gt; common shares deemed issued to Second Sight
shareholders, was determined based on the per share closing price of the Company&#x2019;s common shares on the acquisition date
of $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220830_zKt7kqpPSGj3" title="Common stock, par or stated value per share"&gt;4.14&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zPFaoS5J1C76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span id="xdx_8B8_z58FvJxliqwj"&gt;The following table summarizes the fair
values of the assets acquired and liabilities assumed at the acquisition date (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration: underline"&gt;At August 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220830_zi8sjoqtX2x2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--CashAndCashEquivalentsFairValue_iI_pn3n3_zgfRx0eOio1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;55,374&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentFairValueDisclosure_iI_pn3n3_zIF25wJjlbg2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn3n3_zb02uyamcnt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetOne_iI_pn3n3_zxvvNVFFlJhj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherAssetsFairValueDisclosure_iI_pn3n3_zrFmwaFlh3Ic" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--FairValueOfAssetsAcquired1_iI_pn3n3_zmvfOPgBpoZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total identifiable assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_iNI_pn3n3_di_z5SR75EewP79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,913&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iNI_pn3n3_di_ztiNfqcnij33" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of use liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(151&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--FairValueOfLiabilitesAcquired_iNI_pn3n3_di_znkiSdASaQr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_zk5rigypYHTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2pt"&gt;Net identifiable assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;53,262&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A0_zvYfOWBDVPy1" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The SAFE loan of $&lt;span id="xdx_908_eus-gaap--AssetsFairValueAdjustment_pn6n6_c20220828__20220830_z6VMbERzzti9" title="Assets, fair value adjustment"&gt;8.0&lt;/span&gt; million was cancelled
in the Merger which adjusted the fair value of net assets acquired.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--GainLossOnInvestmentsTextBlock_zCDd6WSGUaO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span id="xdx_8B9_z5QPe5U54zy"&gt;The following table summarizes the calculation
of the gain on bargain purchase (in thousands)&lt;/span&gt;:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220830_znOwAxta2wH6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--TotalConsideration_iNI_pn3n3_di_zCGZuZhdzGRb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Total consideration&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,385&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AdvancesFairValueDisclosure_iNI_pn3n3_di_zRq62IKMKht8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;SAFE loan forgiven&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_zmQKf8dlIVY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less net identifiable assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,262&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--GainOnBargainPurchase_iI_pn3n3_zVQzq5qGIrHg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2pt"&gt;Gain on bargain purchase&lt;/td&gt;&lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;6,877&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AF_zvU2iI6PVVR1" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Because NPM purchased &lt;span id="xdx_90A_eus-gaap--SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_pid_dp_uPure_c20220101__20221231_zwkLpQuWZGD4" title="Fair value of identifiable assets acquired and liabilities"&gt;100&lt;/span&gt;% of Second Sight
and the fair value of identifiable assets acquired and liabilities assumed exceeded the fair value of the consideration, we reassessed
the recognition and measurement of identifiable assets acquired and liabilities assumed and concluded that all acquired assets
and assumed liabilities were properly recognized and that the valuation procedures and resulting measures were appropriate. As
a result, we recognized a gain of $&lt;span id="xdx_906_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_pn5n6_c20220101__20221231_zWqxnyNHkMgj" title="Gain of other income expenses"&gt;6.9&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;We recognized $&lt;span id="xdx_907_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_dm_c20220101__20221231_ztylsSOPj3Gj"&gt;0.7 million&lt;/span&gt; of acquisition
related costs that were expensed in the twelve months ended December 31, 2022. These costs are included in the consolidated income
statement in the line item entitled &#x201c;General and administrative costs.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Operating expenses of Second
Sight included in the consolidated statements of operations from the acquisition date August 30, 2022 to the period ending
December 30, 2022 were $2.1 million. Pro forma consolidated net loss as if Second Sight had been included in the consolidated
results was $&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_pn5n6_c20210101__20211231__srt--StatementScenarioAxis__srt--ProFormaMember_zgx0tDJgGOKi"&gt;21.7&lt;/span&gt;
million for the year ended December 31, 2021, and $&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_pn5n6_c20220101__20221231__srt--StatementScenarioAxis__srt--ProFormaMember_zByRXgAXvtGi"&gt;28.3&lt;/span&gt;
million for the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;SAFE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On February 4, 2022, in connection with
the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) whereby Second Sight
provided to NPM an investment advance of $8 million. The agreement provided that the SAFE would terminate if the Merger were to
be successfully completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Under the terms of the SAFE, upon successfully
completion of the Merger on August 30, 2022, the investment advance was eliminated. Under the accounting for a business combination,
the $8.0 million adjusted the purchase consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in"&gt;From inception, our operations
have been funded primarily through the sales of our common stock as well as from warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in"&gt;&#160;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Our financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in
the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to
meet its planned obligations into the second half of 2024. Our ability to continue as a going concern is dependent on our ability
to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there
can be no assurances that we will be able to do so.&lt;/p&gt;



</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_SecondSightSwitzerlandSarlMember"
      decimals="INF"
      unitRef="Pure">0.7732</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-01-01to2022-12-31"
      decimals="-6"
      unitRef="USD">8000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CommonStockVotingRights contextRef="From2022-08-282022-08-30">on August 30, 2022 (the &#x201c;Acquisition
Date&#x201d;), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest
of Second Sight, Medical, Inc.</us-gaap:CommonStockVotingRights>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="From2022-08-282022-08-30_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"
      decimals="-5"
      unitRef="USD">54400000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-08-30" decimals="-3" unitRef="Shares">13136000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-08-30"
      decimals="INF"
      unitRef="USDPShares">4.14</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zPFaoS5J1C76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span id="xdx_8B8_z58FvJxliqwj"&gt;The following table summarizes the fair
values of the assets acquired and liabilities assumed at the acquisition date (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="text-decoration: underline"&gt;At August 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220830_zi8sjoqtX2x2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--CashAndCashEquivalentsFairValue_iI_pn3n3_zgfRx0eOio1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;55,374&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentFairValueDisclosure_iI_pn3n3_zIF25wJjlbg2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn3n3_zb02uyamcnt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetOne_iI_pn3n3_zxvvNVFFlJhj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherAssetsFairValueDisclosure_iI_pn3n3_zrFmwaFlh3Ic" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--FairValueOfAssetsAcquired1_iI_pn3n3_zmvfOPgBpoZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total identifiable assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_iNI_pn3n3_di_z5SR75EewP79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,913&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iNI_pn3n3_di_ztiNfqcnij33" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of use liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(151&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--FairValueOfLiabilitesAcquired_iNI_pn3n3_di_znkiSdASaQr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_zk5rigypYHTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2pt"&gt;Net identifiable assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;53,262&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <eyes:CashAndCashEquivalentsFairValue contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">55374000</eyes:CashAndCashEquivalentsFairValue>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">99000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">1657000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <eyes:OperatingLeaseRightOfUseAssetOne contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">140000</eyes:OperatingLeaseRightOfUseAssetOne>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">56000</us-gaap:OtherAssetsFairValueDisclosure>
    <eyes:FairValueOfAssetsAcquired1 contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">57326000</eyes:FairValueOfAssetsAcquired1>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">3913000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">151000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <eyes:FairValueOfLiabilitesAcquired contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">-4064000</eyes:FairValueOfLiabilitesAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">53262000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="From2022-08-282022-08-30"
      decimals="-6"
      unitRef="USD">8000000.0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--GainLossOnInvestmentsTextBlock_zCDd6WSGUaO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span id="xdx_8B9_z5QPe5U54zy"&gt;The following table summarizes the calculation
of the gain on bargain purchase (in thousands)&lt;/span&gt;:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220830_znOwAxta2wH6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--TotalConsideration_iNI_pn3n3_di_zCGZuZhdzGRb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Total consideration&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,385&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AdvancesFairValueDisclosure_iNI_pn3n3_di_zRq62IKMKht8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;SAFE loan forgiven&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_zmQKf8dlIVY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less net identifiable assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,262&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--GainOnBargainPurchase_iI_pn3n3_zVQzq5qGIrHg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2pt"&gt;Gain on bargain purchase&lt;/td&gt;&lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;6,877&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:GainLossOnInvestmentsTextBlock>
    <eyes:TotalConsideration contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">-54385000</eyes:TotalConsideration>
    <us-gaap:AdvancesFairValueDisclosure contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">8000000</us-gaap:AdvancesFairValueDisclosure>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">-53262000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <eyes:GainOnBargainPurchase contextRef="AsOf2022-08-30" decimals="-3" unitRef="USD">6877000</eyes:GainOnBargainPurchase>
    <us-gaap:SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">6900000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_srt_ProFormaMember"
      decimals="-5"
      unitRef="USD">21700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_ProFormaMember"
      decimals="-5"
      unitRef="USD">28300000</us-gaap:NetIncomeLoss>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zweA1Z8ZaAQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&lt;span id="xdx_829_zYsauKEln6i"&gt;Summary of Significant Accounting&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_znEgoZDJUKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zrcVI8rpnEAe"&gt;Policies Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"&gt;The
accompanying consolidated financial statements have been prepared in accordance with United States generally accepted
accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of the Biopharm Division (formerly NPM) and
the Neuromodulation Division (formerly Second Sight including Second Sight Switzerland) each of which is a reporting segment. &lt;span id="xdx_905_esrt--DescriptionOfMaterialContingenciesOfParentCompany_c20220101__20221231_zGkXOkC4mHQc" title="Description of consolidation"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Intercompany balances
and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p id="xdx_856_znwldDyGnyBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zGTbltjWTJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_868_z3hNNmjQ10Rg"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the
financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the
key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted
accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used
in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred
tax assets. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p id="xdx_85A_zUBvWNxGrey3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;






&lt;p id="xdx_84C_eus-gaap--Reclassifications_zxlY4h6kXL28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_865_zBKeHb84olkk"&gt;Reclassifications&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&#160; Certain items in prior period financial
statements have been reclassified to conform to the presentation in the current period financial statements. &#160;Such reclassification
did not impact our previously reported net loss or financial position.&lt;/p&gt;

&lt;p id="xdx_852_zxwGis14PGG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zC9pExJxK9F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zhyIEFd2ioY"&gt;Cash,
Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;We consider all
highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is
carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds
that are in excess of current needs in high credit quality instruments such as money market funds. Restricted cash of $&lt;span id="xdx_901_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zSRdOuWFbTOc" title="Restricted cash"&gt;1.4&lt;/span&gt;
million as of December 31, 2022 relates to the lease guarantee requirements of our new lease.&lt;/p&gt;

&lt;p id="xdx_85B_zpFLXIb8trjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAhl0NK6dxw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_865_zETNP9KMVFIj"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Property and equipment
are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures
for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property
accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated
statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Depreciation is provided
for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service
lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful
lives of the principal classes of assets are as follows:&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden"&gt;Schedule of estimated useful lives of principal classes of assets&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0503"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 53%; padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;7&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;7&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0512"&gt;5&lt;/span&gt;&lt;/span&gt; years or the term of the lease, if shorter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;10&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_zmoUmQlLehW" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;We review our property
and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets
may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;Depreciation and
amortization of property and equipment amounted to $&lt;span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zHQ24bSGMYEa" title="Depreciation and amortization of property and equipment"&gt;0.4 million&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--DepreciationAndAmortization_dm_c20210101__20211231_zkxqHBnx92Th" title="Depreciation and amortization of property and equipment"&gt;0.3 million&lt;/span&gt; for the years ended December 31, 2022 and 2021,
respectively.&lt;/p&gt;

&lt;p id="xdx_854_zM7443DwzLce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;&#160;&lt;/p&gt;






&lt;p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zUv62FoDlg9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_z61llJSlxVL2"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Leases are accounted for under FASB ASC
842,&#160;&lt;i&gt;Leases&lt;/i&gt;&#160;(&#x201c;ASC 842&#x201d;). Under ASC 842, the Company determines if an arrangement contains a lease
at inception. Right of use assets (&#x201c;ROU assets&#x201d;) represent the right to use an underlying asset for the lease term
while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either
finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive
loss.&#160;All leases greater than 12 months result in the recognition of a ROU asset and liability at the lease commencement date
based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using
the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the
lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated.
The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#x2019;s
applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available
to finance assets similar to the assets under lease in their related geographical location.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company has elected not to separate
non-lease components from lease components and instead to account for each separate lease component and the non-lease components
associated with a lease as a single lease component. It also elected to exempt from capitalization all leases with an initial term
of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Certain leases include one or more options
to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#x2019;s
discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of
being exercised.&lt;/p&gt;

&lt;p id="xdx_85E_zVq2i5u7Vn0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zdPzi06hHrqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zK2GRWwJyXri"&gt;Research and Development&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt"&gt;Research
and development costs are charged to operations in the period incurred and amounted to $&lt;span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zub41g2rEOT8" title="Research and development costs"&gt;14.2 million&lt;/span&gt;, and $&lt;span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20210101__20211231_zicqqpOfOfA3" title="Research and development costs"&gt;11.0 million&lt;/span&gt; net of
grant revenue, for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p id="xdx_851_zLgOSqT6uvFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPoWCpd71C3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_868_z3kk7jubLX7h"&gt;Patent Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt"&gt;Due to the uncertainty
associated with the successful development of one or more commercially viable products based on our research efforts and any related
patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated
costs, are expensed as incurred. Patent costs were $&lt;span id="xdx_909_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zCQ4zF0Yq81" title="Patent costs"&gt;0.4 million&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OtherGeneralExpense_dm_c20210101__20211231_zN8Rz8SUxRs9" title="Patent costs"&gt;0.1 million&lt;/span&gt; for the years ended December 31, 2022 and 2021,
respectively, and are included in general and administrative expenses in the consolidated statements of operations.&lt;/p&gt;

&lt;p id="xdx_859_zmB8TcOt9Vad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--NhGrant_zijw8PxQlXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zlhyRiK7RCc4"&gt;NIH Grant &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;From time to
time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset
against the related operating expenses as the costs are incurred. During the year ended December 31, 2022 grants offset
against operating expenses were $&lt;span id="xdx_908_ecustom--GrantsAgainstOperatingExpense_pn5n6_c20220101__20221231_zpObuW9eb3D4" title="Grants offset against operating expenses"&gt;0.5&lt;/span&gt;
million of which $0.4 million were offset against research and development expenses and $0.1 million were offset against general and
administrative expenses.&lt;/p&gt;

&lt;p id="xdx_857_zW8YOHPzBsV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZWhS4kMrJZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zcPsyB9iOWu"&gt;Concentration of Risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Financial instruments
that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market
funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and
SIPC insurance limits of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zyCtHu3HhL87" title="FDIC insured amount"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--CashSPICInsuredAmount_iI_c20221231_ztjuDBb59ADh" title="SPIC insured amount"&gt;500,000&lt;/span&gt; (including cash of $&lt;span id="xdx_906_ecustom--SPICCashLimitCoverage_iI_c20221231_z8MmcFRleYO2" title="SPIC cash limit coverage"&gt;250,000&lt;/span&gt;), respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;We also maintain cash
at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.&lt;/p&gt;

&lt;p id="xdx_85C_z0djLVf0Hzc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;






&lt;p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_zROto3X0xny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zxt2Q6KVffqf"&gt;Foreign Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The accompanying consolidated
financial statements as of December 31, 2022 include assets amounting to approximately $&lt;span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zqmACCOke6fb" title="Assets"&gt;40,000&lt;/span&gt; relating to our operations in Switzerland.
Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.&lt;/p&gt;

&lt;p id="xdx_859_zXWD41PlPVk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zWilQ5HPZabf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86A_zrgG5Uj6iJK"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The authoritative guidance
with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one
of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Level 1. Observable
inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the
measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based
derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Level 2. Inputs, other
than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through
corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Level 3. Unobservable
inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its
own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives
and commingled investment funds, and are measured using present value pricing models.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;We determine the level
in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of
the assets and liabilities at each reporting period end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Cash equivalents, which
include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our
consolidated balance sheet, and they are valued using Level 1 inputs.&lt;/p&gt;

&lt;p id="xdx_850_ztpuyKAXvhEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0jKFcx7iYUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_867_zyYMVTXxDr8g"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;Pursuant to FASB ASC 718 Share-Based Payment (&#x201c;ASC
718&#x201d;), we record stock-based compensation expense for all stock-based awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Under ASC 718, we estimate
the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected
to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option
vesting term. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The fair value of each
stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the
Black-Scholes valuation model are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The grant price of the issuances is determined based on the fair value of the shares at the date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The risk-free interest rate for periods within the contractual life of the option is based
    on the U.S. treasury yield in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-right: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_851_z7GbH8TiGw55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;









&lt;p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zvKuWlpntfEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z4fiOjDQqe6c"&gt;Comprehensive Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
comply with provisions of FASB ASC 220, &lt;i&gt;Comprehensive Income&lt;/i&gt;, which requires companies to report all changes in equity
during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are
recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner
sources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive loss is reported on the face of the financial statements. For the year ended December 31, 2022
comprehensive loss is the total of net loss and other comprehensive income which, for us, consists entirely
of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net
loss during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zW0sVKyiGEH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zIwwocQAdPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z9hLzXwHvL19"&gt;Foreign
Currency Translation and Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and transactions of the subsidiary&#x2019;s operations are reported in the local (functional) currency of
Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are
translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency
financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange
rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions
denominated in a currency other than the foreign operations&#x2019; functional currencies are included in expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85F_zZcBA8wjQ7C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zOBGA5krpw1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zzwzJ11dx4ag"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the
tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the
event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount,
an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise,
should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for
tax purposes since inception and have significant tax losses and tax credit carry-forwards.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;p id="xdx_85A_z9OLxp5VSMw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;





&lt;p id="xdx_84C_eus-gaap--StandardProductWarrantyPolicy_zXrB223ADMa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zk8HhCPHBf0e"&gt;Product
Warranties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed
parts. We also provide a three-year manufacturer&#x2019;s warranty covering implant failure by providing a functionally-equivalent
replacement implant. Accruals for product warranties are estimated based on historical warranty experience and current product
performance trends and are recorded at the time revenue is recognized as a component of cost of sales. The warranty liabilities
are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred.
We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The warranty liabilities
are included in accrued expenses in the consolidated balance sheets and amount to $&lt;span id="xdx_909_ecustom--AccruedLiabilitiesCurrent1_iI_c20221231_zdFhT1GUh3Qc" title="Accrued expenses"&gt;50,000&lt;/span&gt; at December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_851_zlODTqFPEZPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z9RjjhyGeCi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zuPP9OcACdCd"&gt;Net
Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
computation of earnings per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as the income (loss)
available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS
is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes
payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning
of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those
that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock
warrants and common stock options outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, and 2021, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately
acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in
thousands).&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden"&gt;&#160;Schedule
of net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Shares underlying warrants outstanding&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;10,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;9,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,272&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,542&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_z8MB0HtPdyii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p id="xdx_85F_zR4Cq4Pa8jYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTTq7qoh0hKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_ztxpnYyQsXIe"&gt;Operating
Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our
chief operating decision-maker, our CEO, reviews financial information presented for each of our segments. We consider ourselves to
have two reporting segments, specifically the Biopharm Division and the Neuromodulation Division. Neither division is revenue
producing. The Neuromodulation Division&lt;span/&gt; &lt;span title="Consolidated"/&gt;and the Biopharm Division incurred $&lt;span id="xdx_90D_ecustom--DivisionIncurred_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zZweoZ0OV1al"&gt;2.1&lt;/span&gt;
million, and $&lt;span id="xdx_904_ecustom--DivisionIncurred_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zq091xoeefyf"&gt;19.1&lt;/span&gt;
million respectively in operating expenses. The Neuromodulation Division incurred $&lt;span id="xdx_900_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zmcjDfT5FJ67" title="Operating loss"&gt;1.5&lt;/span&gt;
million and the Biopharm Division $&lt;span id="xdx_90A_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zpom3CTHmlJb" title="Operating loss"&gt;12.4&lt;/span&gt;
million of the $&lt;span id="xdx_90F_ecustom--OperatingIncomeLoss2_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zbX12ji9k7Ii" title="Operating loss"&gt;13.9&lt;/span&gt;
million consolidated net loss, inclusive of the $&lt;span id="xdx_90E_ecustom--OperatingIncomeLoss3_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zLuOkTO7VF64" title="Operating loss"&gt;6.9 &lt;/span&gt;million
gain on bargain purchase&lt;span title="Operating expenses"/&gt;. The Neuromodulation Division includes $&lt;span id="xdx_907_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zeQYdZiuAzLl" title="Division incurred"&gt;2.1
million&lt;/span&gt; of total assets. The Biopharm Division includes $&lt;span id="xdx_90E_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zxDeeAdzHsU"&gt;49.0
million&lt;/span&gt; in total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_858_zWUUA3QwVlPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"/&gt;





&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqraudtqBEL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z577Pw1dWBV1"&gt;Recently
Adopted Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material
impact on our financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85D_zxL6OB0J9M65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_znEgoZDJUKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zrcVI8rpnEAe"&gt;Policies Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"&gt;The
accompanying consolidated financial statements have been prepared in accordance with United States generally accepted
accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of the Biopharm Division (formerly NPM) and
the Neuromodulation Division (formerly Second Sight including Second Sight Switzerland) each of which is a reporting segment. &lt;span id="xdx_905_esrt--DescriptionOfMaterialContingenciesOfParentCompany_c20220101__20221231_zGkXOkC4mHQc" title="Description of consolidation"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Intercompany balances
and transactions have been eliminated in consolidation.&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zGTbltjWTJkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_868_z3hNNmjQ10Rg"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the
financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the
key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted
accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used
in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred
tax assets. Actual results could differ from those estimates.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:Reclassifications contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--Reclassifications_zxlY4h6kXL28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_865_zBKeHb84olkk"&gt;Reclassifications&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&#160; Certain items in prior period financial
statements have been reclassified to conform to the presentation in the current period financial statements. &#160;Such reclassification
did not impact our previously reported net loss or financial position.&lt;/p&gt;

</us-gaap:Reclassifications>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zC9pExJxK9F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zhyIEFd2ioY"&gt;Cash,
Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;We consider all
highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is
carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds
that are in excess of current needs in high credit quality instruments such as money market funds. Restricted cash of $&lt;span id="xdx_901_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zSRdOuWFbTOc" title="Restricted cash"&gt;1.4&lt;/span&gt;
million as of December 31, 2022 relates to the lease guarantee requirements of our new lease.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">1400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAhl0NK6dxw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_865_zETNP9KMVFIj"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Property and equipment
are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures
for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property
accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated
statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Depreciation is provided
for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service
lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful
lives of the principal classes of assets are as follows:&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden"&gt;Schedule of estimated useful lives of principal classes of assets&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0503"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 53%; padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;7&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;7&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0512"&gt;5&lt;/span&gt;&lt;/span&gt; years or the term of the lease, if shorter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;10&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_zmoUmQlLehW" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;We review our property
and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets
may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.25pt"&gt;Depreciation and
amortization of property and equipment amounted to $&lt;span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zHQ24bSGMYEa" title="Depreciation and amortization of property and equipment"&gt;0.4 million&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--DepreciationAndAmortization_dm_c20210101__20211231_zkxqHBnx92Th" title="Depreciation and amortization of property and equipment"&gt;0.3 million&lt;/span&gt; for the years ended December 31, 2022 and 2021,
respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <eyes:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_ecustom--ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_zi6xaIuGSOKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span id="xdx_8B8_z8KNwCjrKUmb" style="display: none; visibility: hidden"&gt;Schedule of estimated useful lives of principal classes of assets&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 46%"&gt;&lt;span style="font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRq2ugTDr1e2" title="Estimated useful lives::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0503"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 53%; padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z1t9v7tsywvl" title="Estimated useful lives::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;7&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzbZqV1I5FR" title="Estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zqeNlpAvLjUc" title="Estimated useful lives::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0509"&gt;7&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zmMxMemWLAz6" title="Estimated useful lives::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zXSbKkDkNgB7" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0512"&gt;5&lt;/span&gt;&lt;/span&gt; years or the term of the lease, if shorter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zqz4lqRpWEZc" title="Estimated useful lives::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-left: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtxL_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zhV0bJp1xGXf" title="::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;10&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</eyes:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zUv62FoDlg9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86B_z61llJSlxVL2"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Leases are accounted for under FASB ASC
842,&#160;&lt;i&gt;Leases&lt;/i&gt;&#160;(&#x201c;ASC 842&#x201d;). Under ASC 842, the Company determines if an arrangement contains a lease
at inception. Right of use assets (&#x201c;ROU assets&#x201d;) represent the right to use an underlying asset for the lease term
while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either
finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive
loss.&#160;All leases greater than 12 months result in the recognition of a ROU asset and liability at the lease commencement date
based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using
the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the
lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated.
The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#x2019;s
applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available
to finance assets similar to the assets under lease in their related geographical location.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company has elected not to separate
non-lease components from lease components and instead to account for each separate lease component and the non-lease components
associated with a lease as a single lease component. It also elected to exempt from capitalization all leases with an initial term
of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Certain leases include one or more options
to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#x2019;s
discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of
being exercised.&lt;/p&gt;

</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zdPzi06hHrqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zK2GRWwJyXri"&gt;Research and Development&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 15.75pt"&gt;Research
and development costs are charged to operations in the period incurred and amounted to $&lt;span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zub41g2rEOT8" title="Research and development costs"&gt;14.2 million&lt;/span&gt;, and $&lt;span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20210101__20211231_zicqqpOfOfA3" title="Research and development costs"&gt;11.0 million&lt;/span&gt; net of
grant revenue, for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">14200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">11000000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zPoWCpd71C3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_868_z3kk7jubLX7h"&gt;Patent Costs&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.85pt"&gt;Due to the uncertainty
associated with the successful development of one or more commercially viable products based on our research efforts and any related
patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated
costs, are expensed as incurred. Patent costs were $&lt;span id="xdx_909_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zCQ4zF0Yq81" title="Patent costs"&gt;0.4 million&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OtherGeneralExpense_dm_c20210101__20211231_zN8Rz8SUxRs9" title="Patent costs"&gt;0.1 million&lt;/span&gt; for the years ended December 31, 2022 and 2021,
respectively, and are included in general and administrative expenses in the consolidated statements of operations.&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:OtherGeneralExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">400000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">100000</us-gaap:OtherGeneralExpense>
    <eyes:NhGrant contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_ecustom--NhGrant_zijw8PxQlXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zlhyRiK7RCc4"&gt;NIH Grant &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;From time to
time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset
against the related operating expenses as the costs are incurred. During the year ended December 31, 2022 grants offset
against operating expenses were $&lt;span id="xdx_908_ecustom--GrantsAgainstOperatingExpense_pn5n6_c20220101__20221231_zpObuW9eb3D4" title="Grants offset against operating expenses"&gt;0.5&lt;/span&gt;
million of which $0.4 million were offset against research and development expenses and $0.1 million were offset against general and
administrative expenses.&lt;/p&gt;

</eyes:NhGrant>
    <eyes:GrantsAgainstOperatingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">500000</eyes:GrantsAgainstOperatingExpense>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZWhS4kMrJZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zcPsyB9iOWu"&gt;Concentration of Risk&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Financial instruments
that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market
funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and
SIPC insurance limits of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zyCtHu3HhL87" title="FDIC insured amount"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--CashSPICInsuredAmount_iI_c20221231_ztjuDBb59ADh" title="SPIC insured amount"&gt;500,000&lt;/span&gt; (including cash of $&lt;span id="xdx_906_ecustom--SPICCashLimitCoverage_iI_c20221231_z8MmcFRleYO2" title="SPIC cash limit coverage"&gt;250,000&lt;/span&gt;), respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;We also maintain cash
at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <eyes:CashSPICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">500000</eyes:CashSPICInsuredAmount>
    <eyes:SPICCashLimitCoverage contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</eyes:SPICCashLimitCoverage>
    <eyes:ForeignOperationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_zROto3X0xny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_860_zxt2Q6KVffqf"&gt;Foreign Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The accompanying consolidated
financial statements as of December 31, 2022 include assets amounting to approximately $&lt;span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zqmACCOke6fb" title="Assets"&gt;40,000&lt;/span&gt; relating to our operations in Switzerland.
Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.&lt;/p&gt;

</eyes:ForeignOperationsPolicyTextBlock>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_custom_CountryMember"
      decimals="0"
      unitRef="USD">40000</us-gaap:Assets>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zWilQ5HPZabf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86A_zrgG5Uj6iJK"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The authoritative guidance
with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one
of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Level 1. Observable
inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the
measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based
derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Level 2. Inputs, other
than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through
corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Level 3. Unobservable
inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its
own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives
and commingled investment funds, and are measured using present value pricing models.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;We determine the level
in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of
the assets and liabilities at each reporting period end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Cash equivalents, which
include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our
consolidated balance sheet, and they are valued using Level 1 inputs.&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0jKFcx7iYUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_867_zyYMVTXxDr8g"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;Pursuant to FASB ASC 718 Share-Based Payment (&#x201c;ASC
718&#x201d;), we record stock-based compensation expense for all stock-based awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;Under ASC 718, we estimate
the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected
to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option
vesting term. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;The fair value of each
stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the
Black-Scholes valuation model are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The grant price of the issuances is determined based on the fair value of the shares at the date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;The risk-free interest rate for periods within the contractual life of the option is based
    on the U.S. treasury yield in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 29px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-right: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zvKuWlpntfEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z4fiOjDQqe6c"&gt;Comprehensive Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
comply with provisions of FASB ASC 220, &lt;i&gt;Comprehensive Income&lt;/i&gt;, which requires companies to report all changes in equity
during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are
recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner
sources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive loss is reported on the face of the financial statements. For the year ended December 31, 2022
comprehensive loss is the total of net loss and other comprehensive income which, for us, consists entirely
of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net
loss during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zIwwocQAdPnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z9hLzXwHvL19"&gt;Foreign
Currency Translation and Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and transactions of the subsidiary&#x2019;s operations are reported in the local (functional) currency of
Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are
translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency
financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange
rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions
denominated in a currency other than the foreign operations&#x2019; functional currencies are included in expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zOBGA5krpw1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zzwzJ11dx4ag"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the
tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the
event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount,
an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise,
should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for
tax purposes since inception and have significant tax losses and tax credit carry-forwards.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--StandardProductWarrantyPolicy_zXrB223ADMa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zk8HhCPHBf0e"&gt;Product
Warranties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed
parts. We also provide a three-year manufacturer&#x2019;s warranty covering implant failure by providing a functionally-equivalent
replacement implant. Accruals for product warranties are estimated based on historical warranty experience and current product
performance trends and are recorded at the time revenue is recognized as a component of cost of sales. The warranty liabilities
are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred.
We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The warranty liabilities
are included in accrued expenses in the consolidated balance sheets and amount to $&lt;span id="xdx_909_ecustom--AccruedLiabilitiesCurrent1_iI_c20221231_zdFhT1GUh3Qc" title="Accrued expenses"&gt;50,000&lt;/span&gt; at December 31, 2022.&lt;/span&gt;&lt;/p&gt;

</us-gaap:StandardProductWarrantyPolicy>
    <eyes:AccruedLiabilitiesCurrent1 contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">50000</eyes:AccruedLiabilitiesCurrent1>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z9RjjhyGeCi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zuPP9OcACdCd"&gt;Net
Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
computation of earnings per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as the income (loss)
available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS
is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes
payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning
of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those
that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock
warrants and common stock options outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, and 2021, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately
acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in
thousands).&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden"&gt;&#160;Schedule
of net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Shares underlying warrants outstanding&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;10,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;9,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,272&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,542&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_z8MB0HtPdyii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zXbCrkO4qsOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zI2ut21xkljb" style="display: none; visibility: hidden"&gt;&#160;Schedule
of net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zc5Tr3YwRmKe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zpoXtPvpdNV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pn3n3_uShares_znwBnwITOBOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Shares underlying warrants outstanding&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;10,311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;9,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn3n3_uShares_zSqp9X3p8Nbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,272&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,542&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare_iI_pn3n3_uShares_ziP4XCZpxEr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">10311000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">9074000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">5272000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">4542000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <eyes:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">15583000</eyes:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare>
    <eyes:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">13616000</eyes:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTTq7qoh0hKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_ztxpnYyQsXIe"&gt;Operating
Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our
chief operating decision-maker, our CEO, reviews financial information presented for each of our segments. We consider ourselves to
have two reporting segments, specifically the Biopharm Division and the Neuromodulation Division. Neither division is revenue
producing. The Neuromodulation Division&lt;span/&gt; &lt;span title="Consolidated"/&gt;and the Biopharm Division incurred $&lt;span id="xdx_90D_ecustom--DivisionIncurred_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zZweoZ0OV1al"&gt;2.1&lt;/span&gt;
million, and $&lt;span id="xdx_904_ecustom--DivisionIncurred_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zq091xoeefyf"&gt;19.1&lt;/span&gt;
million respectively in operating expenses. The Neuromodulation Division incurred $&lt;span id="xdx_900_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zmcjDfT5FJ67" title="Operating loss"&gt;1.5&lt;/span&gt;
million and the Biopharm Division $&lt;span id="xdx_90A_ecustom--OperatingIncomeLoss1_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zpom3CTHmlJb" title="Operating loss"&gt;12.4&lt;/span&gt;
million of the $&lt;span id="xdx_90F_ecustom--OperatingIncomeLoss2_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zbX12ji9k7Ii" title="Operating loss"&gt;13.9&lt;/span&gt;
million consolidated net loss, inclusive of the $&lt;span id="xdx_90E_ecustom--OperatingIncomeLoss3_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zLuOkTO7VF64" title="Operating loss"&gt;6.9 &lt;/span&gt;million
gain on bargain purchase&lt;span title="Operating expenses"/&gt;. The Neuromodulation Division includes $&lt;span id="xdx_907_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--NeuromodulationDivisionMember_zeQYdZiuAzLl" title="Division incurred"&gt;2.1
million&lt;/span&gt; of total assets. The Biopharm Division includes $&lt;span id="xdx_90E_ecustom--DivisionIncurredOfAssets_dm_c20220101__20221231__dei--LegalEntityAxis__custom--BiopharmDivisionMember_zxDeeAdzHsU"&gt;49.0
million&lt;/span&gt; in total assets.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <eyes:DivisionIncurred
      contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember"
      decimals="-5"
      unitRef="USD">2100000</eyes:DivisionIncurred>
    <eyes:DivisionIncurred
      contextRef="From2021-01-012021-12-31_custom_BiopharmDivisionMember"
      decimals="-5"
      unitRef="USD">19100000</eyes:DivisionIncurred>
    <eyes:OperatingIncomeLoss1
      contextRef="From2022-01-012022-12-31_custom_NeuromodulationDivisionMember"
      decimals="-5"
      unitRef="USD">1500000</eyes:OperatingIncomeLoss1>
    <eyes:OperatingIncomeLoss1
      contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember"
      decimals="-5"
      unitRef="USD">12400000</eyes:OperatingIncomeLoss1>
    <eyes:OperatingIncomeLoss2
      contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember"
      decimals="-5"
      unitRef="USD">13900000</eyes:OperatingIncomeLoss2>
    <eyes:OperatingIncomeLoss3
      contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember"
      decimals="-5"
      unitRef="USD">6900000</eyes:OperatingIncomeLoss3>
    <eyes:DivisionIncurredOfAssets
      contextRef="From2022-01-012022-12-31_custom_NeuromodulationDivisionMember"
      decimals="0"
      unitRef="USD">2100000</eyes:DivisionIncurredOfAssets>
    <eyes:DivisionIncurredOfAssets
      contextRef="From2022-01-012022-12-31_custom_BiopharmDivisionMember"
      decimals="0"
      unitRef="USD">49000000.0</eyes:DivisionIncurredOfAssets>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqraudtqBEL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z577Pw1dWBV1"&gt;Recently
Adopted Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material
impact on our financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zsefGKma3kqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82B_zpj7N4PYzeUd"&gt;Money Market Funds&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money
market funds included in cash equivalents at December 31, 2022 were $&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zGglWQYyvs1j" title="Cash equivalents"&gt;44.4&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zWsAqf5BoKS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;The
following table presents money market funds at their level within the fair value hierarchy at December 31, 2022 and 2021 (in thousands).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zOPtffOgbctf" style="display: none; visibility: hidden"&gt;Schedule of Money Market Funds at their Level within the Fair Value Hierarchy&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;December 31, 2022:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 48%; text-align: left; padding-bottom: 1pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20221231_zRysV9MvISUl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;44,417&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWHzCoiivLB6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;44,417&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTRUEe7wKfrg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zde2sAraGg8c" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0612"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;December 31, 2021:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20211231_zBGhRpK0g3J8" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0614"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeyQYp5i1Vue" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoIaFTcfPhud" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zh7TluyGlx61" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zQc0WLpPwoNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      unitRef="USD">44400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zWsAqf5BoKS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;The
following table presents money market funds at their level within the fair value hierarchy at December 31, 2022 and 2021 (in thousands).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zOPtffOgbctf" style="display: none; visibility: hidden"&gt;Schedule of Money Market Funds at their Level within the Fair Value Hierarchy&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;December 31, 2022:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 48%; text-align: left; padding-bottom: 1pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20221231_zRysV9MvISUl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;44,417&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zWHzCoiivLB6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;44,417&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTRUEe7wKfrg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zde2sAraGg8c" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0612"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;December 31, 2021:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20211231_zBGhRpK0g3J8" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0614"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeyQYp5i1Vue" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoIaFTcfPhud" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0618"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_pn3n3_c20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zh7TluyGlx61" style="border-bottom: Black 2.5pt double; text-align: right" title="Money market funds"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">44417000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">44417000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_z7bz7WqXa2xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.
&lt;b&gt;&lt;span id="xdx_822_zXC1Hq08lBwd"&gt;Selected Balance Sheet Detail &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property
and equipment, net of accumulated depreciation and amortization&lt;/b&gt; &#160; &#160; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjC0DyuWb6Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zRzYQ4bz5yYe"&gt;Property
and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zv6HeXdASRD9" style="width: 10%; text-align: right"&gt;3,520&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zh99CLf6UYte" style="width: 10%; text-align: right"&gt;3,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="text-align: right" title="Property and equipment, gross"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhBX8h3qlb11" style="text-align: right" title="Property and equipment, gross"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" style="text-align: right" title="Property and equipment, gross"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxnkfGZPZ7Ne" style="text-align: right" title="Property and equipment, gross"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_zu0eqEiR6114" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property and equipment, gross"&gt;3,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_z4VDJ4qMb2b5" style="text-align: right" title="Property and equipment, gross"&gt;3,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zmuXJCwkl7q8" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization"&gt;(2,411&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zO4j6AB8io87" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization"&gt;(2,031&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;1,182&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_ziL4I3Sc0IS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;1,173&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zx9pQOzFZOol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contract
Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
liabilities amounted to $&lt;span id="xdx_90F_ecustom--ContractLiabilitiesOther_iI_c20221231_zJBTKDaxdY6b" title="Contract liabilities"&gt;335,000&lt;/span&gt; at December 31, 2022 and are included in accrued expenses on the balance sheet.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjC0DyuWb6Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zRzYQ4bz5yYe"&gt;Property
and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zv6HeXdASRD9" style="width: 10%; text-align: right"&gt;3,520&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zh99CLf6UYte" style="width: 10%; text-align: right"&gt;3,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="text-align: right" title="Property and equipment, gross"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhBX8h3qlb11" style="text-align: right" title="Property and equipment, gross"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pn3n3" style="text-align: right" title="Property and equipment, gross"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxnkfGZPZ7Ne" style="text-align: right" title="Property and equipment, gross"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Computer software&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_zu0eqEiR6114" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property and equipment, gross"&gt;3,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_z4VDJ4qMb2b5" style="text-align: right" title="Property and equipment, gross"&gt;3,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zmuXJCwkl7q8" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization"&gt;(2,411&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zO4j6AB8io87" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation and amortization"&gt;(2,031&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;1,182&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_ziL4I3Sc0IS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;1,173&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_EquipmentMember"
      decimals="-3"
      unitRef="USD">3520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_EquipmentMember"
      decimals="-3"
      unitRef="USD">3174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      unitRef="USD">51000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      unitRef="USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3593000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">3204000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2411000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2031000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1182000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1173000</us-gaap:PropertyPlantAndEquipmentNet>
    <eyes:ContractLiabilitiesOther contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">335000</eyes:ContractLiabilitiesOther>
    <eyes:GrantsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_ecustom--GrantsTextBlock_z42oqYMLsIx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82E_zqK05YYs7od"&gt;Grants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
received an award for $&lt;span id="xdx_904_ecustom--GrantReceivedToSupportClinicalDevelopment_pn5n6_c20180101__20181231_zsoWI8JUye7c" title="Received grant"&gt;1.6&lt;/span&gt;
million grant (with the intent to fund $&lt;span id="xdx_901_ecustom--GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_pn5n6_c20180101__20181231_zEhTZFyhfHSi" title="Grant receivable with intent to fund early feasibility clinical trial for five years"&gt;6.4&lt;/span&gt;
million over &lt;span id="xdx_905_ecustom--GrantReceivedFundingPeriod_dxL_c20180101__20181231_zTBYD37GtAne" title="Grant received funding period::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0660"&gt;five&lt;/span&gt;&lt;/span&gt;
years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the &#x201c;Early
Feasibility Clinical Trial of a Visual Cortical Prosthesis&#x201d; that commenced in January 2018. The NIH grant funds ongoing
and planned clinical activities and are being used to conduct and support clinical testing of six subjects implanted with the
Orion&#x2122; Cortical Visual Prosthesis (Orion), submit and obtain Investigational Device Exemption approval from the U.S.
Food and Drug Administration (FDA). During the year ended December 31, 2022 grants offset against operating expenses were
$&lt;span id="xdx_906_ecustom--GrantsAgainstOperatingExpenses_pn5n6_c20220101__20221231_zPguaR21NJn9" title="Grants against operating expenses"&gt;0.5&lt;/span&gt;
million of which $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_dxL_c20220101__20221231_zfItUoydTwse" title="Research and development expenses::XDX::14169"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0664"&gt;0.4&lt;/span&gt;&lt;/span&gt; million were offset against research and development expenses and $&lt;span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_dxL_c20220101__20221231_z6axLnCVGif7" title="General and administrative expenses.::XDX::7072"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;0.1&lt;/span&gt;&lt;/span&gt; million were offset against
general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

</eyes:GrantsTextBlock>
    <eyes:GrantReceivedToSupportClinicalDevelopment
      contextRef="From2018-01-012018-12-31"
      decimals="-5"
      unitRef="USD">1600000</eyes:GrantReceivedToSupportClinicalDevelopment>
    <eyes:GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears
      contextRef="From2018-01-012018-12-31"
      decimals="-5"
      unitRef="USD">6400000</eyes:GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears>
    <eyes:GrantsAgainstOperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">500000</eyes:GrantsAgainstOperatingExpenses>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zSOq78OI2Gvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;6.
&lt;span id="xdx_823_zm11uf6n8cI2"&gt;Equity Securities&#160;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are authorized to issue &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkiZW3dde77"&gt;300,000,000&lt;/span&gt; shares of common stock with &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7FDOknATFMl"&gt;50,735,770&lt;/span&gt; issued as of December 31, 2022. In addition, we are
authorized to issue &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrGF0soLlDhl"&gt;10,000,000&lt;/span&gt; shares of preferred stock with &lt;span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_uShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znSBIiffqci4"&gt;none&lt;/span&gt; issued. On August 19, 2022 the Company initiated a reverse
stock split of one share for every three shares. All share numbers have been retroactively adjusted for the split. On August 30,
2022, &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesMergerAcquisitions_iI_pid_uShares_c20220830_zJ0Vwxl57vDi" title="Stock issued during period shares merger acquisitions"&gt;13,136,362&lt;/span&gt; shares were deemed issued for the merger acquisition.&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">50735770</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <eyes:StockIssuedDuringPeriodSharesMergerAcquisitions contextRef="AsOf2022-08-30" decimals="INF" unitRef="Shares">13136362</eyes:StockIssuedDuringPeriodSharesMergerAcquisitions>
    <eyes:WarrantDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_ecustom--WarrantDisclosureTextBlock_zMKstc3ZFCv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_825_zx1DeKZIKU1h"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NPM,
prior to the Merger, issued common stock and warrants (collectively, the &#x201c;unit&#x201d; or &#x201c;units&#x201d;) in 2019,
2020 and 2021 for $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z8gG6RdoWIXa" title="Share price (in dollars per share)"&gt;&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zrcjsVLaBPrc" title="Share price (in dollars per share)"&gt;&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z8lxdk6prppa" title="Share price (in dollars per share)"&gt;3.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
per unit. Outstanding warrants to purchase common stock are shown in the table below and generally expire &lt;span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsTerm_dxL_c20221228__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zIxXjNiUV1l4" title="Term of warrants::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;5&lt;/span&gt;&lt;/span&gt;
years from the date of issuance at $3.15 per share exercise price, are exercisable for one share of common stock and
may be exercised on a cashless basis. The warrants qualified for an exception to derivative accounting and, accordingly,
their value was not bifurcated from the total purchase price. Warrants outstanding associated with these units totaled 7,747,213 as of December 31, 2022 and are not registered or tradeable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
other adjustment for &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zhRZkiB5nOXe" title="Warrants granted"&gt;2,563,688&lt;/span&gt; warrants in the table below were outstanding Second Sight warrants exchanged as part of the Merger
for Vivani warrants on a like-for-like basis. The warrants are tradeable on the open market. Under accounting standards in a business
combination, these warrants were measured at fair value as of the Merger date; however, the warrants were substantially out-of-the-money
and were assigned no value.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/&gt;



&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjY8AwJpseL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zwkhgZqovQ7g"&gt;A
summary of warrant activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zttlQCtP8VPl" style="display: none; visibility: hidden"&gt;Summary of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Per Share&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%"&gt;Warrants outstanding as of December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEGqAedIP7W2" style="width: 10%; text-align: right" title="Outstanding at beginning"&gt;5,402&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zv1eVTrc1d16" style="width: 10%; text-align: right" title="Outstanding at beginning"&gt;3.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"/&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&#160;&#160;&#160;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqVhoxQ0zcdi" style="text-align: right" title="Issued"&gt;3,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7EkoCazMLS4" style="text-align: right" title="Class of warrant or right exercise issued"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&#160;&#160;&#160;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znMfsDsK0vci" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2h8DpHJ1Uqa" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zi70I13cg8z5" style="text-align: right"&gt;9,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6MHehZVgxyb" style="text-align: right"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaVPY4vfYiMa" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zd8UlA9P8thf" style="text-align: right" title="Class of warrant or right exercise issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhqepYaOnrne" style="text-align: right" title="Exercised"&gt;(1,327&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQIqnjNC5a18" style="text-align: right" title="Class of warrant or right to be exercised"&gt;3,15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuS9ZPI4H3j3" style="text-align: right" title="Forfeited or expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightOtherAdjustments_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJsR55UOQaU5" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments"&gt;2,564&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightOtherAdjustment_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zcHbRVwesco3" style="padding-bottom: 1pt; text-align: right" title="Class of warrant or right other adjustment"&gt;35.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWwwuvTOloD3" style="padding-bottom: 1pt; text-align: right" title="Other adjustments (in years)::XDX::P1Y5M16D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;1.46&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zVsAaEkTYhS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"&gt;10,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMc7aeem6TJ6" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending"&gt;11.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zETl6FD27PJ4" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending (in years)::XDX::P2Y3M22D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsrL7AZWik24" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable at ending"&gt;10,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zChkBds5Pxjl" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending"&gt;11.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh1z8YdtMeca" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending (in years)::XDX::P2Y3M22D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zQNawRGChg4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants outstanding as of December 31, 2022 have&lt;/span&gt; no intrinsic value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</eyes:WarrantDisclosureTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2019-12-31_custom_RightOfferingMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-12-31_custom_RightOfferingMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-12-31_custom_RightOfferingMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-01-012022-12-31_custom_RightOfferingMember"
      decimals="INF"
      unitRef="Shares">2563688</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zjY8AwJpseL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zwkhgZqovQ7g"&gt;A
summary of warrant activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zttlQCtP8VPl" style="display: none; visibility: hidden"&gt;Summary of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Per Share&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%"&gt;Warrants outstanding as of December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zEGqAedIP7W2" style="width: 10%; text-align: right" title="Outstanding at beginning"&gt;5,402&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zv1eVTrc1d16" style="width: 10%; text-align: right" title="Outstanding at beginning"&gt;3.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"/&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&#160;&#160;&#160;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqVhoxQ0zcdi" style="text-align: right" title="Issued"&gt;3,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z7EkoCazMLS4" style="text-align: right" title="Class of warrant or right exercise issued"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&#160;&#160;&#160;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znMfsDsK0vci" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2h8DpHJ1Uqa" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants outstanding as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zi70I13cg8z5" style="text-align: right"&gt;9,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6MHehZVgxyb" style="text-align: right"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zaVPY4vfYiMa" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightExerciseIssued_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zd8UlA9P8thf" style="text-align: right" title="Class of warrant or right exercise issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhqepYaOnrne" style="text-align: right" title="Exercised"&gt;(1,327&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQIqnjNC5a18" style="text-align: right" title="Class of warrant or right to be exercised"&gt;3,15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuS9ZPI4H3j3" style="text-align: right" title="Forfeited or expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightOtherAdjustments_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJsR55UOQaU5" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments"&gt;2,564&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightOtherAdjustment_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zcHbRVwesco3" style="padding-bottom: 1pt; text-align: right" title="Class of warrant or right other adjustment"&gt;35.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWwwuvTOloD3" style="padding-bottom: 1pt; text-align: right" title="Other adjustments (in years)::XDX::P1Y5M16D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0719"&gt;1.46&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zVsAaEkTYhS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"&gt;10,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMc7aeem6TJ6" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending"&gt;11.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zETl6FD27PJ4" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at ending (in years)::XDX::P2Y3M22D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsrL7AZWik24" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable at ending"&gt;10,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zChkBds5Pxjl" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending"&gt;11.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh1z8YdtMeca" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at ending (in years)::XDX::P2Y3M22D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0731"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">5402000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eyes:ClassOfWarrantOrRightIssued
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">3672000</eyes:ClassOfWarrantOrRightIssued>
    <eyes:ClassOfWarrantOrRightExerciseIssued
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.15</eyes:ClassOfWarrantOrRightExerciseIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">9074000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eyes:ClassOfWarrantOrRightExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">-1327000</eyes:ClassOfWarrantOrRightExercised>
    <eyes:ClassOfWarrantOrRightToBeExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3.15</eyes:ClassOfWarrantOrRightToBeExercised>
    <eyes:ClassOfWarrantOrRightOtherAdjustments
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">2564000</eyes:ClassOfWarrantOrRightOtherAdjustments>
    <eyes:ClassOfWarrantOrRightOtherAdjustment
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">35.24</eyes:ClassOfWarrantOrRightOtherAdjustment>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">10311000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">11.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eyes:ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">10311000</eyes:ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights>
    <eyes:ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">11.13</eyes:ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zJ2csz9HLB6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_826_zO2bfl7F4yX2"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have a 401(k) Savings Retirement Plan (the &#x201c;Plan&#x201d;) that covers substantially all full-time employees who meet the
Plan&#x2019;s eligibility requirements and provides for an employee elective contribution. The Plan provides for employer matching
contributions. Employer contributions are discretionary and determined annually by the Board of Directors. For the years ended
December 31, 2022 and 2021, employer contributions to the Plan totaled $&lt;span id="xdx_90D_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pn5n6_c20220101__20221231_zJWE77VVxxhh" title="Employer contributions to plan"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pn5n6_c20210101__20211231_zRzEfNPuaz67"&gt;0.2&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2021-01-012021-12-31"
      decimals="-5"
      unitRef="USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuHyPTlhonAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_823_zJtooUUzdtjc"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company
initiated a new Incentive Plan at the time of the Merger. Under the 2022 Omnibus Plan we were authorized to issue options covering
up to 20% of the outstanding shares of common stock. The maximum number of shares with respect to which options could be granted
was approximately 10,147,000 shares at December 31, 2022, which is offset and reduced by options previously granted under the Plan.
The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date.
Generally, the options vest ratably over four years and expire ten years from the grant date. The plan provides for accelerated
vesting if there is a change of control, as defined in the Plan.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zzjDNw9ffAT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognized stock-based compensation cost of $&lt;span id="xdx_906_ecustom--ShareBasedCompensation1_dxL_c20220101__20221231_z8VpJhbYUYe8" title="stock based compensation cost::XDX::1470000"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;1.3&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90E_ecustom--ShareBasedCompensation1_dxL_c20210101__20211231_z3PyTOn5Qiwh" title="::XDX::1668000"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;1.7&lt;/span&gt;&lt;/span&gt; million during 2022 and 2021, respectively. The calculated value
of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zaEStGAOm7m4" style="display: none; visibility: hidden"&gt;Summary of Option Grant using the Black-Scholes Option-pricing Model&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zM1VFRmlrsD7" title="Risk-free interest rate"&gt;3.42&lt;/span&gt;% &#x2013; &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zVd946XQ434d" title="Risk-free interest rate"&gt;4.45&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zvAXpD4SbRUb" title="Risk-free interest rate"&gt;0.7&lt;/span&gt;% &#x2013; &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zvwkKdMHCbuc" title="Risk-free interest rate"&gt;0.9&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_z4nxWKRXhusj" title="Expected dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zczCJihV88Sf" title="Expected dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zrf3O4uhs7Ce" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zE27Sy97wy1f" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zUDoygePn4z3"&gt;4.25&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zgHGX0qnM573" title="Expected term::XDX::P6Y0M29D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;6.08&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zyY3OekL5h5l" title="Expected term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;5&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zs6Oex5mheV6" title="Expected term::XDX::P6Y0M29D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;6.08&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_z2iI9dvb0lsc" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"/&gt;





&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zahKLqv7z9Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zj01Vx6A5a3d" style="display: none; visibility: hidden"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%"&gt;Options outstanding at December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAq3dvCRueP4" style="width: 10%; text-align: right" title="Options outstanding, number of shares (in shares)"&gt;5,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zotkEN4Z8A9e" style="width: 10%; text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)"&gt;2.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO47jeZyLfe" style="text-align: right" title="Granted"&gt;549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaOmFHF99Och" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPt2m0inTWN6" style="text-align: right" title="Exercised"&gt;(1,020&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJy5Ox6CHsNi" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGGJ0RhXpFz" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"&gt;(875&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS2mkehgpYhc" style="padding-bottom: 1pt; text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)"&gt;2.82&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPyG8b7gHeD3" style="text-align: right" title="Options outstanding, number of shares (in shares)"&gt;4,542&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPjpcsFgvk23" style="text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)"&gt;2.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZIQwcJ86x4f" style="text-align: right" title="Granted"&gt;866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXM35BSQwxml" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)"&gt;2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z74HFrTaoNK1" style="text-align: right" title="Exercised"&gt;(73&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa6okzzYMid" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)"&gt;1.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Forfeited or expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLSgc4UlujS5" style="text-align: right" title="Forfeited or expired"&gt;(335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmplEwphIV1e" style="text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)"&gt;4.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC0Nce0vksEe" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments"&gt;272&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcoan5IqPKj" style="padding-bottom: 1pt; text-align: right" title="Other adjustments , weighted average exercise price (in dollars per share)"&gt;8.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options outstanding, vested and expected to vest at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVV42Ik6nYa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, number of shares (in shares)"&gt;5,272&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDRb9YqGwUh" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in dollars per share)"&gt;3.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zavW5A2be8n6" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in years)::XDX::P7Y1M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOfbPGH9Eie" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, number of shares (in shares)"&gt;3,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT1q0jnevKVa" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable, weighted average exercise price (in dollars per share)"&gt;3.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsupd8sSKsd6" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable period (in years)::XDX::P6Y6M18D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;6.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_z2XO29eymG2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated aggregate intrinsic value of stock options exercisable as of December 31, 2022 was $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231_z6FpaTKWVOWb" title="Stock options exercisable"&gt;151,000&lt;/span&gt;.
As of December 31, 2022, there was $&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_dm_c20221231_zowRhijOxWKg" title="Unrecognized compensation cost"&gt;2.1
million&lt;/span&gt; of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted
average period of &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20220101__20221231_zDrzeVJvCFPh" title="Weighted average period (in years)::XDX::P1Y2M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;1.2 &lt;/span&gt;&lt;/span&gt;years.
Other adjustment represents a prior period true-up and Second Sight options exchanged as part of the Merger for Vivani options on a
like-for-like basis. Under accounting standards in a business combination, these options were measured at fair value as of the
Merger date; however, the options were substantially out-of-the-money and were assigned no value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z9SzNUjW711j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the
years ended December 31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z5E5xaTBjh83" style="display: none; visibility: hidden"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUwCT72f93V4" style="width: 10%; text-align: right" title="Allocated share-based compensation expense"&gt;896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z35zALM8DjS1" style="width: 10%; text-align: right" title="Allocated share-based compensation expense"&gt;1,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwmYPOrrbxF8" style="border-bottom: Black 1pt solid; text-align: right"&gt;400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPff0Tqq0N86" style="border-bottom: Black 1pt solid; text-align: right"&gt;339&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zVNroePLEmzl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zhh55aUb3Zz" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zOb5ZfWGScV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zzjDNw9ffAT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognized stock-based compensation cost of $&lt;span id="xdx_906_ecustom--ShareBasedCompensation1_dxL_c20220101__20221231_z8VpJhbYUYe8" title="stock based compensation cost::XDX::1470000"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;1.3&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90E_ecustom--ShareBasedCompensation1_dxL_c20210101__20211231_z3PyTOn5Qiwh" title="::XDX::1668000"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;1.7&lt;/span&gt;&lt;/span&gt; million during 2022 and 2021, respectively. The calculated value
of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zaEStGAOm7m4" style="display: none; visibility: hidden"&gt;Summary of Option Grant using the Black-Scholes Option-pricing Model&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zM1VFRmlrsD7" title="Risk-free interest rate"&gt;3.42&lt;/span&gt;% &#x2013; &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zVd946XQ434d" title="Risk-free interest rate"&gt;4.45&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zvAXpD4SbRUb" title="Risk-free interest rate"&gt;0.7&lt;/span&gt;% &#x2013; &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zvwkKdMHCbuc" title="Risk-free interest rate"&gt;0.9&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231_z4nxWKRXhusj" title="Expected dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zczCJihV88Sf" title="Expected dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231_zrf3O4uhs7Ce" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_zE27Sy97wy1f" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zUDoygePn4z3"&gt;4.25&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zgHGX0qnM573" title="Expected term::XDX::P6Y0M29D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;6.08&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zyY3OekL5h5l" title="Expected term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;5&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zs6Oex5mheV6" title="Expected term::XDX::P6Y0M29D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;6.08&lt;/span&gt;&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_srt_MinimumMember">P4Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zahKLqv7z9Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity for the years ended December 31, 2022 and 2021 is presented below (in thousands, except per share
and contractual life data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zj01Vx6A5a3d" style="display: none; visibility: hidden"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%"&gt;Options outstanding at December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAq3dvCRueP4" style="width: 10%; text-align: right" title="Options outstanding, number of shares (in shares)"&gt;5,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zotkEN4Z8A9e" style="width: 10%; text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)"&gt;2.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYO47jeZyLfe" style="text-align: right" title="Granted"&gt;549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaOmFHF99Och" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPt2m0inTWN6" style="text-align: right" title="Exercised"&gt;(1,020&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJy5Ox6CHsNi" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)"&gt;0.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGGJ0RhXpFz" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"&gt;(875&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS2mkehgpYhc" style="padding-bottom: 1pt; text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)"&gt;2.82&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Options outstanding at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPyG8b7gHeD3" style="text-align: right" title="Options outstanding, number of shares (in shares)"&gt;4,542&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPjpcsFgvk23" style="text-align: right" title="Options outstanding, weighted average exercise price (in dollars per share)"&gt;2.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZIQwcJ86x4f" style="text-align: right" title="Granted"&gt;866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXM35BSQwxml" style="text-align: right" title="Granted, weighted average exercise price (in dollars per share)"&gt;2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z74HFrTaoNK1" style="text-align: right" title="Exercised"&gt;(73&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa6okzzYMid" style="text-align: right" title="Exercised, weighted average exercise price (in dollars per share)"&gt;1.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Forfeited or expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLSgc4UlujS5" style="text-align: right" title="Forfeited or expired"&gt;(335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmplEwphIV1e" style="text-align: right" title="Forfeited or expired, weighted average exercise price (in dollars per share)"&gt;4.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC0Nce0vksEe" style="border-bottom: Black 1pt solid; text-align: right" title="Other adjustments"&gt;272&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcoan5IqPKj" style="padding-bottom: 1pt; text-align: right" title="Other adjustments , weighted average exercise price (in dollars per share)"&gt;8.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options outstanding, vested and expected to vest at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVV42Ik6nYa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, number of shares (in shares)"&gt;5,272&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDRb9YqGwUh" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in dollars per share)"&gt;3.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zavW5A2be8n6" style="padding-bottom: 2.5pt; text-align: right" title="Options outstanding, vested and expected to vest (in years)::XDX::P7Y1M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOfbPGH9Eie" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, number of shares (in shares)"&gt;3,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT1q0jnevKVa" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable, weighted average exercise price (in dollars per share)"&gt;3.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsupd8sSKsd6" style="padding-bottom: 2.5pt; text-align: right" title="Options exercisable period (in years)::XDX::P6Y6M18D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;6.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">5888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">1020000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">875000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">4542000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">335000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <eyes:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">272000</eyes:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">8.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">5272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="Shares">3819000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">151000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z9SzNUjW711j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the
years ended December 31, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z5E5xaTBjh83" style="display: none; visibility: hidden"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUwCT72f93V4" style="width: 10%; text-align: right" title="Allocated share-based compensation expense"&gt;896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z35zALM8DjS1" style="width: 10%; text-align: right" title="Allocated share-based compensation expense"&gt;1,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwmYPOrrbxF8" style="border-bottom: Black 1pt solid; text-align: right"&gt;400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPff0Tqq0N86" style="border-bottom: Black 1pt solid; text-align: right"&gt;339&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zVNroePLEmzl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231_zhh55aUb3Zz" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">1329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">339000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_z9dUSXJyMtel" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_820_zwOrBIqjiv4"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in &lt;i&gt;Note 1, Business&lt;/i&gt;, Nano Precision Medical, Inc. and Second Sight Medical Products, Inc. merged on August 30, 2022. The transaction was accounted for as a reverse
merger business combination under GAAP. Accordingly, the consolidated income tax provision includes NPM for all periods presented,
and the legacy Second Sight business of Vivani (the &#x201c;Legacy SSMP&#x201d;) since the date of the merger. Further, NPM (the
major subsidiary of Vivani) and Legacy SSMP will not elect to consolidate their tax returns for income tax filing purposes. For
the purposes of accounting for income taxes under GAAP, the Legacy SSMP tax provision, deferred taxes and liabilities, and various
other matters such as net operation loss and R&amp;amp;D carry-forwards have been prepared as if it filed a separate tax return for
the period from August 30, 2022 to December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the net losses in 2022 and 2021, the provision for income taxes consists only of minimum California franchise taxes presented
in general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOKWsQU7nvP1" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zbKs38QJmLP"&gt;The
components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"/&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zhBNNNbVEkzi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLfxWR3YG7Eb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zwXrDoYiCHv1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVwGkpHftDn9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of December 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NPM&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Legacy SSMP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Combined&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NPM&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;Deferred Tax :&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zmQMyRQ8hCSc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;&#160;Accruals/reserves&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;226&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_zReRcK54dMZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;Capitalized R&amp;amp;E &#xa7;174&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_z4nEoMQlRdg1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;Lease ROU&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zexQfnaMWIo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;Stock Compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;776&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z28JT53TZaRk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;Net operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,974&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_zTSpWO3W4hNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;R&amp;amp;D credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,358&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,961&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,671&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zryEUe5YTfnk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;Gross Deferred Tax Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,982&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,564&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;56,546&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zhx89EXOrBHk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;Investment in Sub&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,510&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,510&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_iI_pn3n3_zfuK6Ucv2SG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;Accumulated depreciation/amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(202&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zOKU14AVwRi1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,660&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,712&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--TaxCreditCarryforwardValuationAllowance1_iI_pn3n3_zsY5DO2zilY" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&#160;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,322&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(33,512&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54,834&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,804&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zpdkLC6KkpIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total Deferred Tax Assets, Net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zpGd0eDQucMk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Change in valuation allowance for the year ended&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,519&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;461&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;





&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A1_zSsI6Y9jA8xb" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwtCrr7WOmJ3" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z0mHY8d5OAgb"&gt;The
reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and
the corresponding rate from operations consist of the following (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the Year Ended December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NPM&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legacy
    SSMP&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Combined&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Pre-Tax
    Loss &lt;sup id="xdx_F49_zGmS0pPvS0ah"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_fKGEp_zHzGdXL01v9l" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,889&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_fKGEp_zWCTbOGinBvc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,479&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zua3UZboUDw8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,889&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal
    tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zncslZ6DXQck" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zrbiY7wKWQ2k" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLRDFlBXZNOf" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(311&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z8PnshO8R8o5"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z5q8hVYFGA1" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zrAoBkAO3O05"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State
    tax (benefit), net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFQOLbuhoitf" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(970&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zD1eAPRL6576" title="State tax (benefit), net of federal tax benefit (percent)"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zlw0ckYWhjoc" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zMvh0e3gAc95"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zenX8q6pqWT3" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,073&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zRCHgDBN6hnk"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;R&amp;amp;D
    tax credit from current year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zYSxRUdYx7kk" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(687&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zHtF5TCrGin" title="R&amp;amp;D tax credit from current year (percent)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zjpNWYaVx6A9" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zgfCkLAAkdYg"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_zuDwWdXE50hd" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(707&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zDN2HLZPgYH7"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;Impact on effective rate of SSMP loss eliminated in consolidation &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zg4ZopIGFyqf" style="text-align: right"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"/&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z7407CXbAdx7" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zOqFyhnDf6Ze" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;(311&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zPODuwsCotR8"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zEaiJaSJG7oe" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z6Hygoi7XCaf" title="Other (percent)"&gt;-0.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zIwosWd83wRh" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvubkJAIpfvd"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_zBMC6AulFCY8" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zZqmHqWoOHhg"&gt;-0.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFkC1XoH0tde" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,519&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z2ZLLbff7oH1" title="Change in valuation allowance (percent)"&gt;-32.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvc749oR8kRc" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;462&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zTSngbE0cer8"&gt;-31.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zFVL4pyxdznj" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,980&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zavBeFvSroH9"&gt;-35.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Total
    provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zsKXGl0USTZa" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zBkzXlJPSPQi" title="Total provision for income taxes (percent)"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zW7xByvT8XIg" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zRmu271TSLd7" title="Total provision for income taxes"&gt;-0.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zfe3Ewm9pWQj" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zeca7nMC5lzc" title="Total provision for income taxes"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0B_zYjnvwWfePwl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zXoPwEsGRYk5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#x2019;s interest in
                                                                                                                                                                 Legacy SSMP&#x2019;s pre-tax loss.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NPM&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended December 31, 2021 &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 59%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 6%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; width: 1%; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Pre-tax
    income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zIFEVggs4Vc5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(12,773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal
    tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_znk23RLyjb73" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,682&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zCditIAbu0w2" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State
    tax (benefit), net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zP7JJ3t5UThf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(893&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zENdvgyn1FBb" title="State tax (benefit), net of federal tax benefit (percent)"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;R&amp;amp;D
    tax credit from current year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zPdxEEyF5vxf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(475&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVOtVlxUes3i" title="R&amp;amp;D tax credit from current year (percent)"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zDCw1WYbBTRd" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(163&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z9qwsOanWJg5" title="Other (percent)"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zozPAyMDDaEb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,214&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zf12XN9xRLCg" title="Change in valuation allowance (percent)"&gt;-33.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Total
    provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z3pRQx6eCr3b" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zoVjvEkxEPc9" title="Total provision for income taxes (percent)"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zrNn2XPHoQ38" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
pre-tax losses for NPM and Legacy SSMP in the preceding table are presented as if each entity filed separate returns;
and accordingly, the information does not reflect elimination of intercompany transactions or balances. The combined pre-tax
loss in the table reflects elimination of intercompany transactions
and balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
NPM and Legacy SSMP file as separate taxpayers, deferred tax assets and liabilities and attributes such as NOL and R&amp;amp;D carry-forwards
of one taxpayer are not available to offset those of the other taxpayer. The combined data is presented for disclosure purposes
only.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize
the existing deferred tax assets. Based on this evaluation, as of December&#160;31, 2022 and 2021, a full valuation allowance
has been recorded because deferred tax assets have been assessed to be less than &#x201c;more likely than not&#x201d; to be realized.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z1x7zifKh8Tc" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zRHHnjqmtF79"&gt;As
of December&#160;31, 2022, we had federal and apportioned state net operating loss (&#x201c;NOL&#x201d;) and federal and
state R&amp;amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zGsn3kKIHJh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zkWy5QjDEc04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NPM&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legacy
    SSMP&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zyEmcgMFwV1a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre TCJA
    (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,257&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;29,095&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_z6bkqeUeSoO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post
    TCJA period federal NOL carry-forward, with no carry-forward limitation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;39,503&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,412&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zLMKKvhr7KAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    federal NOL carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;57,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115,508&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_z6Ez4bIX1poh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State NOL carry-forward,
    begin expiring 2030&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;66,514&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,439&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_z61WgtTZchY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal R&amp;amp;D tax
    credit carry-forward, begin expiring in 2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,586&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--DeferredTaxAssetsStateTaxes1_iI_pn3n3_zvGm8u83tYC4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State R&amp;amp;D carry-forward,
    begin expiring in 2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,989&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zKwUUYRHHkz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total R&amp;amp;E related
    deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,997&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;459&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reserve for uncertain
    income tax positions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_znBnu9YcQ0k5" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
recently enacted U.S. tax legislation, although the treatment of tax losses generated in taxable years ending before December
31, 2017, has generally not changed, tax losses generated in taxable years beginning after December 31, 2017, may only be utilized
to offset 80% of taxable income annually. This change may require NPM and Legacy SSMP to pay federal income taxes in future years
despite generating a loss for federal income tax purposes in prior years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
the extent that each of the tax filers continue to generate taxable losses, unused losses will carry-forward to offset future
taxable income, if any, until these unused losses expire. However, the tax filers may be unable to use these losses to offset
taxable income before our unused losses expire at various dates that range from 2030 through 2038 for federal net operating losses
generated before 2018. Federal net operating losses generated for year 2018 and forward do not expire. State net operating losses
expire from 2030 through 2042. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation
undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50 percentage point change (by value) in its
equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change net operating loss, or NOL, carry-forwards
to offset its post-change taxable income may be limited. Limitations may also apply to the utilization of other pre-change tax
attributes as a result of an ownership change.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
legal subsidiary, NPM experienced an &#x201c;ownership change&#x201d; within the meaning of Section 382(g) of the Internal
Revenue Code of 1986, as amended, during the third quarter of 2022 as a result of the merger. The ownership change will
subject its net operating loss carry-forwards to an annual limitation, which will significantly restrict its ability to use
them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the
aggregate value of stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the
Internal Revenue Service. We have not yet fully analyzed the available information to determine the amount of the annual
limitation. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
periodically review the uncertainties and judgments related to the application of complex income tax regulations to determine
income tax liabilities in several jurisdictions. We use a &#x201c;more likely than not&#x201d; criterion for recognizing the
income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. We have
evaluated the impact of these positions and believe tax filing positions and deductions will more likely than not
be sustained upon examination. Accordingly, no reserve for uncertain income tax positions has been recorded as of December
31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the cumulative unrecognized tax benefit is recognized, there will be no effect on our effective tax rate due to the full
valuation allowance. Due to the nature of the unrecognized tax benefits and the existence of tax attributes, we have not
accrued any interest or penalties associated with unrecognized tax benefits in the Consolidated Statement of Operations
nor recognized a liability in the Consolidated Balance Sheet. We do not believe the total amount
of unrecognized benefit as of December 31, 2022, will increase or decrease significantly in the next twelve
months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
January 1, 2022, we are required to capitalize certain research and development expenditures in accordance with section 174 of
the Internal Revenue Code, as amended by the Tax Cuts and Jobs Act of 2017, instead of previously being allowed to expense. Amortization
of such capitalized expenditures are allowed over a 5-year period if incurred in the U.S. or a 15-year period if incurred outside
the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
file income tax returns in the U.S. federal jurisdiction and various states and are subject to income tax examinations by federal
tax authorities for tax years ended 2017 and later and by state authorities for tax years ended 2016 and later. We currently are
not under examination by any tax authority. Our policy is to record interest and penalties on uncertain tax positions as income
tax expense. As of December 31, 2021, and 2020, we have no accrued interest or penalties related to uncertain tax positions. Second
Sight Switzerland, our foreign subsidiary, has not had any taxable income in the prior and current years.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOKWsQU7nvP1" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zbKs38QJmLP"&gt;The
components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"/&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zhBNNNbVEkzi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLfxWR3YG7Eb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zwXrDoYiCHv1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVwGkpHftDn9"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of December 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NPM&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Legacy SSMP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Combined&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NPM&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;Deferred Tax :&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zmQMyRQ8hCSc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%"&gt;&#160;Accruals/reserves&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;226&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_zReRcK54dMZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;Capitalized R&amp;amp;E &#xa7;174&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;459&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_z4nEoMQlRdg1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;Lease ROU&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zexQfnaMWIo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;Stock Compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;776&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z28JT53TZaRk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;Net operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,974&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_zTSpWO3W4hNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;R&amp;amp;D credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,358&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,961&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,671&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zryEUe5YTfnk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;Gross Deferred Tax Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,982&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,564&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;56,546&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zhx89EXOrBHk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;Investment in Sub&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,510&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,510&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1_iI_pn3n3_zfuK6Ucv2SG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;Accumulated depreciation/amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(202&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zOKU14AVwRi1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,660&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,712&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--TaxCreditCarryforwardValuationAllowance1_iI_pn3n3_zsY5DO2zilY" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;&#160;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,322&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(33,512&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54,834&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,804&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zpdkLC6KkpIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total Deferred Tax Assets, Net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0897"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zpGd0eDQucMk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Change in valuation allowance for the year ended&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,519&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;461&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;





&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">725000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">750000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1475000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">226000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1997000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">459000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2456000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">48000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">48000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">56000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1079000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">420000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1499000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">776000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">16775000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">27974000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">44749000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">14194000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">2358000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">3961000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">6319000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1671000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">22982000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">33564000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">56546000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">16698000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1510000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1510000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-150000</eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1>
    <eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">-52000</eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1>
    <eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1 contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-202000</eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1>
    <eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-120000</eyes:IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1660000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">52000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1712000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">120000</us-gaap:DeferredIncomeTaxLiabilities>
    <eyes:TaxCreditCarryforwardValuationAllowance1
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-21322000</eyes:TaxCreditCarryforwardValuationAllowance1>
    <eyes:TaxCreditCarryforwardValuationAllowance1
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">-33512000</eyes:TaxCreditCarryforwardValuationAllowance1>
    <eyes:TaxCreditCarryforwardValuationAllowance1 contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-54834000</eyes:TaxCreditCarryforwardValuationAllowance1>
    <eyes:TaxCreditCarryforwardValuationAllowance1
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-16804000</eyes:TaxCreditCarryforwardValuationAllowance1>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">4519000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">461000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4980000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="AsOf2021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">4204000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwtCrr7WOmJ3" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z0mHY8d5OAgb"&gt;The
reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and
the corresponding rate from operations consist of the following (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the Year Ended December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NPM&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legacy
    SSMP&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Combined&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Pre-Tax
    Loss &lt;sup id="xdx_F49_zGmS0pPvS0ah"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_fKGEp_zHzGdXL01v9l" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,889&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_fKGEp_zWCTbOGinBvc" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,479&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zua3UZboUDw8" style="border-bottom: Black 2.5pt double; width: 6%; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,889&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal
    tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zncslZ6DXQck" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zrbiY7wKWQ2k" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zLRDFlBXZNOf" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(311&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z8PnshO8R8o5"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z5q8hVYFGA1" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zrAoBkAO3O05"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State
    tax (benefit), net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFQOLbuhoitf" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(970&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zD1eAPRL6576" title="State tax (benefit), net of federal tax benefit (percent)"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zlw0ckYWhjoc" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zMvh0e3gAc95"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zenX8q6pqWT3" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,073&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zRCHgDBN6hnk"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;R&amp;amp;D
    tax credit from current year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zYSxRUdYx7kk" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(687&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zHtF5TCrGin" title="R&amp;amp;D tax credit from current year (percent)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zjpNWYaVx6A9" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zgfCkLAAkdYg"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_zuDwWdXE50hd" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(707&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zDN2HLZPgYH7"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;Impact on effective rate of SSMP loss eliminated in consolidation &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zg4ZopIGFyqf" style="text-align: right"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"/&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_z7407CXbAdx7" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zOqFyhnDf6Ze" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;(311&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zPODuwsCotR8"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zEaiJaSJG7oe" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z6Hygoi7XCaf" title="Other (percent)"&gt;-0.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zIwosWd83wRh" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvubkJAIpfvd"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_zBMC6AulFCY8" style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zZqmHqWoOHhg"&gt;-0.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zFkC1XoH0tde" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,519&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z2ZLLbff7oH1" title="Change in valuation allowance (percent)"&gt;-32.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zvc749oR8kRc" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;462&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zTSngbE0cer8"&gt;-31.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zFVL4pyxdznj" style="border-bottom: Black 1pt solid; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,980&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zavBeFvSroH9"&gt;-35.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Total
    provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zsKXGl0USTZa" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zBkzXlJPSPQi" title="Total provision for income taxes (percent)"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zW7xByvT8XIg" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zRmu271TSLd7" title="Total provision for income taxes"&gt;-0.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zfe3Ewm9pWQj" style="border-bottom: Black 2.5pt double; text-align: right" title="Pre-Tax Income (Loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zeca7nMC5lzc" title="Total provision for income taxes"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0B_zYjnvwWfePwl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zXoPwEsGRYk5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#x2019;s interest in
                                                                                                                                                                 Legacy SSMP&#x2019;s pre-tax loss.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NPM&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended December 31, 2021 &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: center; vertical-align: bottom; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 59%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 6%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; width: 1%; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Pre-tax
    income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zIFEVggs4Vc5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(12,773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Federal
    tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_znk23RLyjb73" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,682&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zCditIAbu0w2" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State
    tax (benefit), net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zP7JJ3t5UThf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(893&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zENdvgyn1FBb" title="State tax (benefit), net of federal tax benefit (percent)"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;R&amp;amp;D
    tax credit from current year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zPdxEEyF5vxf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(475&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zVOtVlxUes3i" title="R&amp;amp;D tax credit from current year (percent)"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zDCw1WYbBTRd" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(163&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z9qwsOanWJg5" title="Other (percent)"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zozPAyMDDaEb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,214&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zf12XN9xRLCg" title="Change in valuation allowance (percent)"&gt;-33.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; text-align: left; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Total
    provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_z3pRQx6eCr3b" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zoVjvEkxEPc9" title="Total provision for income taxes (percent)"&gt;0.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt; text-align: left; background-color: White; visibility: hidden"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      id="Fact000906"
      unitRef="USD">-13889000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">-1479000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      id="Fact000910"
      unitRef="USD">-13889000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-2916000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">-311000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2916000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-970000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">-103000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="INF"
      unitRef="Pure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-1073000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-687000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">-20000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-707000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-311000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">55000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">-27000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="INF"
      unitRef="Pure">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">28000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">4519000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">-0.325</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">462000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="INF"
      unitRef="Pure">-0.312</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4980000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.359</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31_custom_LegacySSMPMember"
      decimals="INF"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-12773000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-2682000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-893000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-475000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">-163000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">4214000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">-0.330</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31_custom_NPMMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z1x7zifKh8Tc" style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zRHHnjqmtF79"&gt;As
of December&#160;31, 2022, we had federal and apportioned state net operating loss (&#x201c;NOL&#x201d;) and federal and
state R&amp;amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--NPMMember_zGsn3kKIHJh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20221231__us-gaap--IncomeTaxAuthorityAxis__custom--LegacySSMPMember_zkWy5QjDEc04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NPM&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legacy
    SSMP&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zyEmcgMFwV1a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pre TCJA
    (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,257&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;29,095&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_z6bkqeUeSoO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post
    TCJA period federal NOL carry-forward, with no carry-forward limitation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;39,503&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,412&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zLMKKvhr7KAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    federal NOL carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;57,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115,508&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_z6Ez4bIX1poh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;State NOL carry-forward,
    begin expiring 2030&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;66,514&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,439&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_z61WgtTZchY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal R&amp;amp;D tax
    credit carry-forward, begin expiring in 2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,586&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--DeferredTaxAssetsStateTaxes1_iI_pn3n3_zvGm8u83tYC4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State R&amp;amp;D carry-forward,
    begin expiring in 2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,989&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zKwUUYRHHkz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total R&amp;amp;E related
    deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,997&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;459&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reserve for uncertain
    income tax positions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">18257000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">29095000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">39503000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">86412000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">57760000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">115508000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">66514000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">30439000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1586000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">20000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <eyes:DeferredTaxAssetsStateTaxes1
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1973000</eyes:DeferredTaxAssetsStateTaxes1>
    <eyes:DeferredTaxAssetsStateTaxes1
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">4989000</eyes:DeferredTaxAssetsStateTaxes1>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2022-12-31_custom_NPMMember"
      decimals="-3"
      unitRef="USD">1997000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2022-12-31_custom_LegacySSMPMember"
      decimals="-3"
      unitRef="USD">459000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_ecustom--RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_z2q5w2eKDAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_82E_z6F3qsOLl1ml"&gt;Right-of-use Assets and Operating Lease Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the
balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is
computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets
and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value
guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental
borrowing rate based on the information available at commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zq8oKKab9gji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_za0Kr6KDHsHe"&gt;The
Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#x2019;s right-of-use
assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Year ending December 31:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; text-align: left; padding-bottom: 1pt"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20220101__20221231_zpX4ZUs9dsml" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="2023"&gt;975&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OperatingLeasePayment_pn3n3_c20220101__20221231_zF2Q9QG9LCGh" style="text-align: right" title="Total lease payments"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseCost_iN_pn3n3_di_c20220101__20221231_zYsFQ1WevWGh" style="border-bottom: Black 1pt solid; text-align: right" title="Imputed interest"&gt;(20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_zbDVMgvUGY29" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;955&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other supplemental information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--OperatingLeasePayments1_pn3n3_c20220101__20221231_zWQ9TPCyUn19" style="text-align: right" title="Current operating lease liabilities"&gt;955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Long term operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zXCADKZZDPzh" style="border-bottom: Black 1pt solid; text-align: right" title="Long term operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_z3qyK37DPtHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;955&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;
&lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;&#160;December 31,&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;&#160;December 31,&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20221231_zMSIGN02zZJa" title="Cash paid for operating lease liabilities"&gt;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20211231_zPg1JFTUxMG1" title="Cash paid for operating lease liabilities"&gt;0.9
    million&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A7_znxkihANCFw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense, including common area maintenance charges, was $&lt;span id="xdx_903_ecustom--LeaseAndRentalExpense1_dm_c20220101__20221231_zmAsfNpToRP1" title="Rent expense"&gt;0.9 million&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--LeaseAndRentalExpense1_dm_c20210101__20211231_zfuhVpEF1YMi" title="Rent expense"&gt;0.8 million&lt;/span&gt; during 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

</eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zq8oKKab9gji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_za0Kr6KDHsHe"&gt;The
Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company&#x2019;s right-of-use
assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Year ending December 31:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; text-align: left; padding-bottom: 1pt"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20220101__20221231_zpX4ZUs9dsml" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="2023"&gt;975&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OperatingLeasePayment_pn3n3_c20220101__20221231_zF2Q9QG9LCGh" style="text-align: right" title="Total lease payments"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseCost_iN_pn3n3_di_c20220101__20221231_zYsFQ1WevWGh" style="border-bottom: Black 1pt solid; text-align: right" title="Imputed interest"&gt;(20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_zbDVMgvUGY29" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;955&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other supplemental information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--OperatingLeasePayments1_pn3n3_c20220101__20221231_zWQ9TPCyUn19" style="text-align: right" title="Current operating lease liabilities"&gt;955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Long term operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20221231_zXCADKZZDPzh" style="border-bottom: Black 1pt solid; text-align: right" title="Long term operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LeaseCost_pn3n3_c20220101__20221231_z3qyK37DPtHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;955&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;
&lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;&#160;December 31,&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
    the year ended&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;&#160;December 31,&lt;/b&gt;&lt;br/&gt;
    &lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20221231_zMSIGN02zZJa" title="Cash paid for operating lease liabilities"&gt;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_dm_c20211231_zPg1JFTUxMG1" title="Cash paid for operating lease liabilities"&gt;0.9
    million&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <eyes:LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">975000</eyes:LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree>
    <eyes:OperatingLeasePayment
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">975000</eyes:OperatingLeasePayment>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">20000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">955000</us-gaap:LeaseCost>
    <eyes:OperatingLeasePayments1
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">955000</eyes:OperatingLeasePayments1>
    <us-gaap:LeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">955000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1000000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">900000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <eyes:LeaseAndRentalExpense1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">900000</eyes:LeaseAndRentalExpense1>
    <eyes:LeaseAndRentalExpense1
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">800000</eyes:LeaseAndRentalExpense1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4LxlbWYOsR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_825_zv9mtsWGmpbe"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Indemnification
Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
maintain indemnification agreements with our directors and officers that may require us to indemnify them against liabilities
that arise by reason of their status or service as directors or officers, except as prohibited by applicable law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
Trial Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"&gt;Based upon FDA approval of Argus II, which was obtained in February
2013, we were required to collect follow-up data from subjects enrolled in our pre-approval trial for a period of up to ten years
post-implant, which was extended through the year 2019. This requirement to collect follow-up data was halted in 2020 with FDA
approval.&#160;In addition, we conducted three post-market studies to comply with U.S. FDA, French, and European post-market surveillance
regulations and requirements and are conducting an early feasibility clinical study of Orion. We have contracted with various universities,
hospitals, and medical practices to provide these services. Payments are based on procedures performed for each subject and are
charged to clinical and regulatory expense as incurred. Total amounts charged to expense for the year ended December 31, 2022 were
$&lt;span id="xdx_90C_ecustom--ClinicalAndRegulatoryExpense_pn5n6_c20220101__20221231_zxe40tu4oKEa" title="Clinical and regulatory expense"&gt;0.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Litigation,
Claims and Assessments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three
oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent
owned by us. The outcomes of the challenges are not certain, however, if successful, they may affect our ability to block competitors
from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture
and sell our products, or otherwise have a material effect on our operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As described in the Company&#x2019;s 10-K
for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (&#x201c;MOU&#x201d;) for a proposed
business combination with Pixium Vision SA (&#x201c;Pixium&#x201d;). In response to a press release by Pixium dated March 24, 2021,
and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium
was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between
the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an
amicable resolution will be reached. We accrued $&lt;span id="xdx_908_ecustom--LiquidatedDamagesPaidValue_iI_c20210331_zXn3eedxF3li" title="Liquidated damage"&gt;1,000,000&lt;/span&gt; of liquidated damages as contemplated by the MOU in accounts payable
as of March 31, 2021 and remitted that amount to Pixium in April 2021. &lt;span id="xdx_903_eus-gaap--ContractTerminationClaimsDescription_c20220101__20221231_zwt4juUsdCwc" title="Description of contract termination and claims"&gt;Pixium indicated that it considered this termination wrongful,
rejected the Company&#x2019;s offers, but retained the $&lt;span id="xdx_903_eus-gaap--LossContingencyDamagesPaidValue_c20220101__20221231_zeiefDIQN3ak" title="Loss contingency, damages paid, value"&gt;1,000,000&lt;/span&gt; payment. On May 19, 2021, Pixium filed suit in the Paris Commercial
Court, and currently claim damages of approximately &#x20ac;5.1 million or about $5.6 million. We believe we have fulfilled our obligations
to Pixium with the liquidated damages payment of $1,000,000.&lt;/span&gt; &lt;span id="xdx_90F_eus-gaap--LossContingencySettlementAgreementCourt_c20221207__20221209_zjbv0ZbtFJ3k" title="Description of legal settlement"&gt;On December 9, 2022, the Company received notice that the Paris Commercial
Court has rendered its judgement, including finding that the Company&#x2019;s termination of the MOU was not valid. In the judgement,
the Company was ordered to pay to Pixium the amount of &#x20ac;2,500,000 minus a &#x20ac;947,780 credit for the $1,000,000 already
paid for, a net amount payable of approximately &#x20ac;1,552,220. The Company may appeal the decision within three months from the
date of service. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to raise any and all legal
challenges to this preliminary judgement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not
have a material effect on our financial statements, however the results of litigation and claims are inherently unpredictable.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <eyes:ClinicalAndRegulatoryExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">200000</eyes:ClinicalAndRegulatoryExpense>
    <eyes:LiquidatedDamagesPaidValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1000000</eyes:LiquidatedDamagesPaidValue>
    <us-gaap:ContractTerminationClaimsDescription contextRef="From2022-01-01to2022-12-31">Pixium indicated that it considered this termination wrongful,
rejected the Company&#x2019;s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial
Court, and currently claim damages of approximately &#x20ac;5.1 million or about $5.6 million. We believe we have fulfilled our obligations
to Pixium with the liquidated damages payment of $1,000,000.</us-gaap:ContractTerminationClaimsDescription>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1000000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencySettlementAgreementCourt contextRef="From2022-12-072022-12-09">On December 9, 2022, the Company received notice that the Paris Commercial
Court has rendered its judgement, including finding that the Company&#x2019;s termination of the MOU was not valid. In the judgement,
the Company was ordered to pay to Pixium the amount of &#x20ac;2,500,000 minus a &#x20ac;947,780 credit for the $1,000,000 already
paid for, a net amount payable of approximately &#x20ac;1,552,220. The Company may appeal the decision within three months from the
date of service. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to raise any and all legal
challenges to this preliminary judgement.</us-gaap:LossContingencySettlementAgreementCourt>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zcRd8mM2weRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_827_zv2yh86PzQEh"&gt;Subsequent Event&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25pt"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 1, 2023 Cortigent entered into a lease agreement, effective March 1, 2023, to sublease office space to replace our
existing headquarters. Our rental payments amount to $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_c20230226__20230303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9D29ezjR4d9" title="Rental payments amount"&gt;22,158&lt;/span&gt;
per month plus operating expenses, to &lt;span id="xdx_90D_eus-gaap--SubsequentEventDescription_c20230226__20230303__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUwfrGIISAJf" title="Description of lease agreement"&gt;lease
14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355. The sub-lease has a term of two years
and two months. We also entered into a lease for storage space on January 25, 2023 in the same building at a cost of $6,775
per month for a term of two years and one month.&lt;/span&gt; As a material inducement for the lessor to execute the lease with us
Vivani guaranteed the prompt payment of all rents and all other sums payable under the lease together with all other terms
and conditions to be kept and performed under the lease by the lessee.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of January 2023, Cortigent commenced to pay &lt;span id="xdx_907_eus-gaap--SubsequentEventDescription_c20230101__20230131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__custom--MrAdamsMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5ld5Rty6y2b" title="Description of lease agreement"&gt;Mr.
Adams $25,000 per month for his services to us. In March 2023 we entered into an at will letter agreement with Jonathan Adams
by which we appointed him President and Chief Executive Officer of Cortigent at a base salary of $350,000 per year commencing
as of March 1, 2023. He may also receive a onetime signing bonus of up to $50,000 upon Board approval. Upon Board approval following
completion of the initial public offering of securities, Mr. Adams may also be issued an option to purchase 400,000 shares of
our common stock at a strike price equal to the price per share at which shares initially are sold to the public in this
offering. Of these, options to purchase 100,000 shares will vest on November 10, 2023 and the balance shall vest in
approximately equal monthly instalments over the ensuing 36 months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2023 Cortigent entered into a Transition Funding, Support and Services Agreement with Vivani whereby Vivani will advance
funds and provide or cause to be provided to the Company the services and funding that will cover salaries and related costs,
rent and other overhead in order to permit the Company to operate in substantially the same manner in which business operations
of the Company were previously operated by Second Sight, prior to the formation of Cortigent, which obligations will continue,
in the case of the funding obligations, until the earlier of December 31, 2024 or receipt of proceeds from this offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_900_eus-gaap--SubsequentEventDescription_c20230301__20230331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWIyWrRGAIb9" title="Description of lease agreement"&gt;Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California on November
21, 2022. The stated term of the lease commences on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months.
Payments increase annually from $2,676,311 to $3,596,784, or 124 payments less the first four which are abated, totalling approximately
$31 million.&lt;/span&gt; Vivani will be responsible for insurance, property taxes and CAM charges. The current lease expires on September 30, 2023.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-262023-03-03_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">22158</us-gaap:PaymentsForRent>
    <us-gaap:SubsequentEventDescription contextRef="From2023-02-262023-03-03_us-gaap_SubsequentEventMember">lease
14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355. The sub-lease has a term of two years
and two months. We also entered into a lease for storage space on January 25, 2023 in the same building at a cost of $6,775
per month for a term of two years and one month.</us-gaap:SubsequentEventDescription>
    <us-gaap:SubsequentEventDescription contextRef="From2023-01-012023-01-31_us-gaap_SubsequentEventMember_custom_MrAdamsMember_srt_ChiefExecutiveOfficerMember">Mr.
Adams $25,000 per month for his services to us. In March 2023 we entered into an at will letter agreement with Jonathan Adams
by which we appointed him President and Chief Executive Officer of Cortigent at a base salary of $350,000 per year commencing
as of March 1, 2023. He may also receive a onetime signing bonus of up to $50,000 upon Board approval. Upon Board approval following
completion of the initial public offering of securities, Mr. Adams may also be issued an option to purchase 400,000 shares of
our common stock at a strike price equal to the price per share at which shares initially are sold to the public in this
offering. Of these, options to purchase 100,000 shares will vest on November 10, 2023 and the balance shall vest in
approximately equal monthly instalments over the ensuing 36 months.</us-gaap:SubsequentEventDescription>
    <us-gaap:SubsequentEventDescription contextRef="From2023-03-012023-03-31_us-gaap_SubsequentEventMember">Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California on November
21, 2022. The stated term of the lease commences on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months.
Payments increase annually from $2,676,311 to $3,596,784, or 124 payments less the first four which are abated, totalling approximately
$31 million.</us-gaap:SubsequentEventDescription>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000906"
          xlink:label="Fact000906"
          xlink:type="locator"/>
        <link:footnote id="Footnote000979" xlink:label="Footnote000979" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                                                                                                                                                 pre-tax losses for NPM and Legacy SSMP are presented on a stand-alone basis and do not
                                                                                                                                                                 reflect elimination of intercompany balances and transactions; specifically, the net loss recognized by NPM on its investment in Legacy SSMP. The
                                                                                                                                                                 combined pre-tax loss reflects the elimination of intercompany balances and transactions, including NPM&#x2019;s interest in
                                                                                                                                                                 Legacy SSMP&#x2019;s pre-tax loss.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000906"
          xlink:to="Footnote000979"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000908"
          xlink:label="Fact000908"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000908"
          xlink:to="Footnote000979"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000910"
          xlink:label="Fact000910"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000910"
          xlink:to="Footnote000979"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MMRK7!Y*O]'N&#UQ*OM0?%XS&3*@3X/<YYW)SH"ZP?;?UZG]02P,$%     @
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MM%FMM(-V;;OS;G1!$Q@YN+4TJ!4X\;LWG=#[T&;\/XDUEB&HER$XIAY/<->
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M7B8$""KAF0R8#M77HSX0(:<"&7T?LS1.UUR'%>BQ/E/YA'6S@1P:Y?A Y?A
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MY %:+H"7@\A7SD)146BO0%A^V#JD\31L!7M \$",OB=.4CDCQ]8V .1 O-E
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M5F(ZRHCJX[GNVIZM2;,.?)%@_99",(Y$Q4R0=6CQ38,<FQ\7$$%1;;:EO_T
MX?RVPXE.I:*"/'!^/IQ.;@]+/@VHJG0.RQ%Q)Q*X?X&L;+_=<,0(JIQZS$%T
M]ZJA["Y>_MI0V]9%]^S5RVT,4H<ZWTV.&044DC#3'&_8^CJ&>RQ9R X/+MK<
ML!.66RFV*U&Z)<UH=[&VC2G8;]3+@0EWG,5Y+;*J;_(<!=FB22<ML3J\Z?SD
M;5H<S3P%[6TS;\3O+3$_R"(UWU"7N 8M?)1X1P29Y\AM[&FRNKRU6XW >R N
M^H;"-M80=\D4N3&W(J-;PW'!!!>73Z<K= /H EA]URWHB@>Y(@I*C-*3"?UJ
ME>N:&G;D,>7XU K/J: MVC.BC\A%N.+\R^:<86V02]<>?#^;O=]R<*L\<F*I
MPLIRL&[WW ,N:=&>$,E8OZ9590YL L;M 65[[D6:+MICY0S!1%F8=&D<)>]4
M<3(V??(!+^0B#ML"*JU^HY+"\Z:,*8/K:P(<U6N.H J@+J1VXEH:9'<FQFRV
M->>E+?2B/3&#O:J"N*HUT^SJ4ER,3K<-5'<&?!-J.UER1K)Z)J_L!2RU78$D
M/ 1 I%&TE]@HZ8X4U<40*&P>LGD+"C@.V)6\5EO-QZ-X4D<[V2;0R6D\.DQD
M%2F-['-M63W-O.+#_NG*8"_;_-@:/<I\%+N$K=TBD.D8*)9VE&@JCPK'L9@!
MVA0(A].3X8D83P?CZ9DX&8Y/>-U>F<0-?'PKIK^TO0]VR7B7+O"_UN&)A'J"
M"Q;\D,/ -AX3_</OLEG8=U9V*?V*!#X=3,]/J'*JD2\VL4'!:K%A>/2(JK):
M:NY:5$50'0_.3L^S#['^6-!!<RON^&24O>.F(]TX/<M^)-.T+9!F]?>5.ST?
M3"=GV67JB?MZ'DX'C\93\7!WNYT1X],QGL=M;C/1R6!T=I*]5>%^(6")Z6!R
M-F&',:D;&TM <-QP]#5^!)CRU$9ER8]+JBO@E+ET_!/Q#F+T^PY*XN\ C,$T
MF%Z<9EMI0"-+9&XT!!>#T6@$O7^@4*S^DW*'2;>'V?=W"?1 G TNSL_%<Q5/
MX2E*VX<<=N)L^(@.JXE7EA6]'\&<T?"\ZZ;22R%8IX-*%W-9),[4\G<LG7?O
MXJC W+YLPSR[?<74G9K>@/D^ :5*!U.U)3XA:LBZIK0;QOSX8#(<;[,]\!]/
M/'9E(LNBFB8T45+?R0(K6<3CTONTRN+9KV=2>R F8QAL<C&<1HC]'Y10\K^J
MG42JG;(_K';*?DOM)/ZDVHD=^H!HI0T>6?R"G=-Q0A>4.X0P%#]HN*W0B:4O
M9:V)-3XH;S$!X?:* J5WVD_O0[9QE'$F9<0NJ J@0S1-_&6HT72V6<9#"2]-
M#%V:OM,$0.NU,H;^<TRNI:.70W3VT_3JFUXD]_:L*8^XV)=*L;0Q:T-81VSD
M]?:E&>I%10=V(?$J*BW3OH:FLFQ[FA3%#=HO9-X^[N< 7;&E*\NOS. 9%]\O
MMD[AMV^*CK\(>8S+U,=227DMM6$ZS2E5\ME:PC 0M4#-I#FJ8$O?>[_;.RHE
MX);TM0T?NAE941]MYT8O$[-UO9F/L;:29D'R 7PGT:CM.ZK^ 0V7S+L&U%0Q
M@72+=-1DMU.S[;O>^*8KYJX>O[;.9[XH^U]"T#(=@./Q#IWJL_&/ 6\G-67_
M]-*.3!PQ.1 KNZ::GB/(J8Q>A,[)$9R6'051>L&V5M&R>!K-!VFM\'9XVY<1
MQ[V/7[A7H$]\*+00<O$[F.YN]Q71+'X\LQT>/T%Z@P2H*SI-7F J\MCI0>R0
MVXM@:_Z49FY#L"7_7"F)8*0!>+ZP-K07M$'W;=6S?P-02P,$%     @ "6U_
M5LLS[A1P%P  JD   !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R=7%ES
MVT82?L>OF%)2*;N*HD1*\A$?5;9L;UR50V79R</6/@R!(3DQ"# 80#3SZ_?K
M[IG!@(>TFX=8) ',=/?T\?6!O-S4S5>W-*95WU9EY5Z=+-MV_>/9F<N79J7=
MN%Z;"E?F=;/2+;XVBS.W;HPN^*%5>38]/W]RMM*V.GG]DG^[:5Z_K+NVM)6Y
M:93K5BO=;-^:LMZ\.IF<A!\^V<6RI1_.7K]<ZX6Y->V7]4V#;V=QE<*N3.5L
M7:G&S%^=O)G\^/:2[N<;?K=FXY+/BCB9U?57^O*Q>'5R3@29TN0MK:#QY\Y<
MF[*DA4#&7W[-D[@E/9A^#JM_8-[!RTP[<UV7?]BB7;XZ>7:B"C/77=E^JC<_
M&<_/%:V7UZ7C?]5&[KVX/%%YY]IZY1\&!2M;R5_]S<LA>>#9^9$'IOZ!*=,M
M&S&5[W2K7[]LZHUJZ&ZL1A^857X:Q-F*#N6V;7#5XKGV]:T<AJKGZM8N*CNW
MN:Y:]2;/ZZYJ;;5X>=9B&[KY+/=+OI4EIT>6G$S5+W75+IUZ7Q6F&"YP!OHB
MD=- Y-OIO2N^,_E874Q&:GH^G=ZSWD5D^H+7>W)DO9X[=5.7-K?&J7^_F;FV
M@9+\YQ#'LM[%X?7(<'YT:YV;5R>P#&>:.W/R^H?O)D_.7]Q#[66D]O*^U?_9
M$=V[Y&&"IV/UX%:]O&X:6^5V7>(C[KZN*X<KA693^[PTF<8SJ[6NMO14'B^;
M0LUMI?&H+I5K\0,LO'5JJ>^,FAE3*1"TU@WNLV2S>=T4N-O +-JE^E)96N&6
MGG-J82K3Z++<TGUFC2N\JZ=TW1/XZ(?OGDVGYR_^]>;-#7^<O'BL=$5;Y&57
M&-4NS6&RP!I=>VOK]5(W*_7.WEGV1X_('YH&>_]Z\PLOEM&-OYJNJ5=UT94B
MB0/WWQI(HR#Y+EM/ )$[^/D6W/Z-N['L8V5TOB1"-DN+#]8I#6^XKAOFTID%
M43I6'ZO6-%[D\%,E"<UEQ"2TNG*:G6 J9U-:^!,^$4@Z3P]PK+XX0UN^=ZU=
ML:QQI/YDA+%ZGAT4F"Q%S-IV*X=&4@?%?W46J@;?5<'9T\VJK?'MJU$F[D+D
M:H< L19JVZ5NE9[/X<+Y'(1O4*Q7=,PN XVXW[3R:&GUS):V)?W4\@2I7#C%
M@P2SA XL30^9;XA]#HL574/"[N]C!3.-K8MQ]H?AN*#JKDE8@8R6%NZ[@0F5
MO%)C#2DR;8B+=QI/=^X NPT=4&G-'8B!B&:TIW9UI6>E(?DVQBL7+H*BP^?0
M0K"P'U*6S;+&@QU\<<,<Y+;)NQ7N)0T9>:8<HICKM8P.D*^ ,V@<OM)1$==_
M=L7"2VZ&(,\4Y+IIV,[O=-F)0SAR*I'#JFZ)K<*2]:[)X*$0<]B.JK$B4 .D
M"?+&ZI=>7QJS@%V1#1G:B,5,VW\U6S6'@M?-O@9U3J180)QEO6:>^D/J6A#V
M-WNHKB$2B)H[;4LO:P$]6&BD\J6N%H85G/:2G8:BS(X?>'*""75C]6;>$K,=
M1.YYHM]'RLY!,;@N2#A-#5\&>NFL:C>P%TA2%W\")GC?UY O*;=8.&\[D!$.
M%EZQ+%1A84J-B'EGJ?' X?<[]!Z2;F?5$X'N"CD3=]U@5]&7==U"H*26B0*,
M6$5(X.0/X"%LA:C;]:8( >9?3\F>(%UX,]B?/X#>4#7.+'@A0F &1P?WJ[]Y
MK?LGW'\R>8FG60#"U+5I6H!:A8BSXF/'(1!;;/6]+\D.!K$F+B?2\C[1FZSB
MH%NUP@269K,4#=S;(+%J"M#0E&:'UJRP!1N4A?>'IR1'A!WNR+] H:-GJX#Q
MR]K!/IMD^77MK#C]:^V6HXS^5>]Q.CBI>"R?("HH-JW"U^'S*&)8\BF(P-#\
MQ1);E1;/43RYP_TB$PX!&MZCA0]MM^*+&V/42C B:$&(WO/7:YC_DKRJ>,"<
M-C4]44(L@B'['A(RGL]KUXZ\ V.S^>:5>*YM([Y)U&AW-;:C9*'^_C%QVN,,
M84S-X4Q=%GT9#M!\RXD)$!Z.L3*F8+4AT:@<&FI;]1>T<E?KV?CAJ"$/^#'
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M[2_GV:N8PT+?J4@I=W'Q();'WM_<QC<^/(V<X=G<=YW*CJC!;6/UEG_&1XY
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M?3I5EZ.KRVGVF6LYDZO1U;,+-;D8/9D\"=,;T+=;XU\SZG]RX2?6)^Z7R_B
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M)?U?4#L#.E\I9;<;%Z#_8TW_ E!+ P04    "  );7]6E^L8_0<"  ">!
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MPX2&X7!$$8Q&X2QX^\ $A8.YXIP@F5LE0<V(HL=W:UW \4(Y9F7$G\=W3 ]
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M'VE8 .\76KO=#1O8_YBZ^!=02P,$%     @ "6U_5DC^2;!T#P  6"@  !D
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MA%['GJJ=Q<G:^>N^^K!F3YJ:'4&Y#'<4X>Z)9@QUU1F7=L] =P>I',)V/UB
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MO=GPXQI!K2PMP/=+8WSS@1BT/R9\]E]02P,$%     @ "6U_5@M$A(FV!
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M:4?KDW\L:%]%PP)TO];:[0YLH-N %W\!4$L#!!0    (  EM?U9.[$&_C0@
M !T3   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)U8VV[<1A)]YU<T
M)D:P"]!SD^2;+H DQXBQ:UCP)7E8[$.3[!EVU.QF^J+1Y.MSJIJD1EE'FUW
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M930.A2L/)SZ !#N-89!,6PD44;&6J &*_2.:3MJT 4%!LH*2A#G,#(+DJ&A
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M<+VH(8AQ7W"#\ *LU_\%4$L#!!0    (  EM?U90FF8K=0,  .4(   9
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M0NL5^+PRQNT%[V!XWY:_ 5!+ P04    "  );7]6#R*XZJH"  "#!@  &0
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MH[7IIH5KC:%$/?/MST"J*FGK'M%ZVPY[43>6C_"Z/=.1SK@T5,"<H+WNZ7$
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MQI@KVW^FS0%A!EN$&5QJ<0BQ'[S#/!SS XC$,8W#HBB)'P,[;H;=X^ G[X<
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M--1&NF\;L876UR5+<.A3)6E4"_1'.UO147BV(83#-H3#3>BCAPQA(O.2%<^
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M 647H'TII=D-[/W:/(_2OU!+ P04    "  );7]6OV9CFZ@"   @!@  &0
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MIIEMCKT^U(<]?GE]9G9#U9+E&G%8V-#D:&S;I^ICJ/K"R*(Z^KF3QDA1#5=
M,U!N@;V_D-(\7;@$S6'@["]02P,$%     @ "6U_5M#SD MZ @  5@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULK55=;],P%/TK5I 02+!\MZ.T
MD;9."!Z0JG7  ^+!36X;JXX=;*?9_CW73AIU:S;M@9?XZY[C<Z[MFWDKU5Z7
M (;<5USHA5<:4\]\7^<E5%1?R!H$KFREJJC!H=KYNE9 "P>JN!\%P<2O*!->
M-G=S*Y7-96,X$[!21#=51=7#-7#9+KS0.T[<LEUI[(2?S6NZ@S68'_5*X<@?
M6 I6@=!,"J)@N_"NPMDRM?$NX">#5I_TB76RD7)O!]^*A1=80< A-Y:!8G.
M)7!NB5#&WY[3&[:TP-/^D?V+\XY>-E3#4O)?K##EPKOT2 %;VG!S*]NOT/MQ
M G/)M?N2MHN=!A[)&VUDU8-10<5$U]+[/@\G@#!Y!A#U@.BU@+@'Q,YHI\S9
MNJ&&9G,E6Z)L-++9CLN-0Z,;)NPIKHW"588XDZWQ6A0-!R*W1."EX5)K4@.>
M<TD5D'<W8"CC^CWYV,WH8\,$N2MEHZDH]-PW*,42^GF_[76W;?3,MC>07Y X
M_$"B((I&X,O7P\/'<!\3,&0A&K(0.;[),WQ7>2X;89C8D97D+&=H\/?51AN%
MU^S/F+V.+Q[GLT]OIFN:P\+#MZ5!'<#+WKX))\'G,;/_B>R1]7BP'K_$GJV[
MXVQ$ 8H_V RT5"DJC";XZ+7!\\7)L11TO*GCM<7BD(5!'.)Q'$Z]G4=]"J;)
M$/1(<S)H3E[4O)15A24 'T>^)[*V]6#T#B9G>Z?1-'HB\#PH29-H7& Z"$Q?
M%'@G#>5CBM+SG*7I9?Q$TDA4/ DG3S3Y)Z_>5MSO5.V8T(3#%G'!Q10)5%?%
MNH&1M2L$&VFPK+ANB84?E W ]:V4YCBPM67XE63_ %!+ P04    "  );7]6
MF3:T!6,$  "[%   &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6RU6%US
MXC84_2L:M]/9G6EC2WPDI,!, MUM'K)EPFS[T.F#8E] L[;%2C(D_?659&-#
M+!3*)#R /W3O/4>Z5^>BX9:+;W(%H-!3EN9R%*R46E^'H8Q7D%%YP=>0ZS<+
M+C*J]*U8AG(M@";6*$M#$D7],*,L#\9#^VPFQD->J)3E,!-(%EE&Q?,MI'P[
M"G"P>_# EBME'H3CX9HN80[JZWHF]%U8>TE8!KED/$<"%J/@!E]/2,<8V!%_
M,MC*O6MDJ#QR_LW<W"6C(#*(((58&1=4_VQ@ FEJ/&D<WRNG01W3&.Y?[[Q_
MLN0UF4<J8<+3OUBB5J/@*D )+&B1J@>^_1TJ0CWC+^:IM-]H6X[M=P,4%U+Q
MK#+6"#*6E[_TJ9J(/0/</V) *@/RTN!8A$YE8&<N+)%96E.JZ'@H^!8),UI[
M,Q=V;JRU9L-RLXQS)?1;INW4>%XN'^(+-&?+G"U83'.%;N*8%[EB^1)]F(*B
M+)7H"Q6"FDG_B'Y!7^=3].''C\-0:1#&51A7 6_+@.1(0$S0/<_52J+?\@22
M0P>A1E]3(#L*M\3K<0KQ!>K@GQ&)"'$ FIQNCCUP.O6,=JR_SA%_#R"58+&"
M!,54KEPS5#KH6@>FSC9CW(W,9QAN]H%[ YD"OY9K&L,HT!4L06P@&/_T ^Y'
MOWIH=&L:72^-*6BG,:-EL>4)HAD7BOU;/M#ILA9Z+Q'JV;Z$[P5;Z^I6+KIE
MH-X>72?;;FM6.H?##GCT:AZ]UY8#J(A7%F8"&[UQ6: HYE))%]Q>"R[N$A=@
MQT <>2#W:\A]+^0955Z _=/FLST,>\!=UN NO> ^"[T_2)T "ZE%ABZU4DB%
M3"I0NUW DU88"4[@ERU$/1=P+X ST_ZJIG?EI?=I>C=!FE(AP*9\X4[IJQ83
MTG,P\<8ZD\F@9C+P,IG/3F(R.&U-O+'.9(*C1J2BU[F8W12E+&.F-#8ZWY;@
ME)_HM+7QASR7TI[N8B^E&ZGKQUDEE>'!DF#<<5%PC.SV.D=K'),&'?&CBV-1
MZ+SQ57/EHI4Z+T%Z(YT[SXT:8[\<WS*^7E&1H2G;,-M\_GT/V2.(?YR<WDAR
M*^KO(>"X47#\BH3O&-_E<2'$RV:K8MQ69X)=.P!NZS,>^!0%-Q*-_1K]1ZT>
M*9?N7'-H+7&JGC_4N7/>2#?V:_<)5!RZW!DXJ7A#G4NE$7KL5_H3J+0%O>]F
M\AZ2CAM-QWY1KPN!^0JAK>G=0>1D\QZRCAM=QWYA_P*%X!E/BK3LQ4_;V-Y(
MP*L9>(]V@#3M /&W Z]G)FDW =C9U_@CG<NDZ0*(OPLX*3-)6^;=6[0_V+ED
MFJ:!^)N&B>DQQ;,W#_TN_F\>OI6W0\)-;T'\O<7Q'HZT_^)W70OVI@U"N'<,
ME(%8VM,QB>Q)3GF<4C^M3^!N[+G3B^>W^'I2GJ,U;LICO7LJEOH_!4IAH5U&
M%Y<Z*45Y4E;>*+ZVATV/7"F>V<L5T 2$&:#?+SA7NQL3H#ZO'/\'4$L#!!0
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MC4O4N<F QGH)+HE:O2=ABG!%D1/N!2]P>(Z2T%!\@^]P-SV'PX-O<  JXE?
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MYV#WMU*:H^%N0O^.9;\!4$L#!!0    (  EM?U9PR)]8LP,  (,1   9
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M+(ZB.6N!2YJG(;?1>:KV5G")&TW,OFU!_UFB4,>,3NDI\<!WC?4)EJ<=[+!
M^]AMM(O8R%+Q%J7A2A*-=4;OIHMEXO>'#=\Y'LW9G'@G6Z6>?/"YRFCD!:'
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M:W-H965T<R]S:&5E=#0Q+GAM;+V8;6_;-A#'OPJA 4,+I-&3+3NI+2"-.BQ
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M;TYJFH9DV_KLXH%)R6A]FP/.@.L.ZOV:,?G4T,<AW7E9_!-02P,$%     @
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M'Y PT1K-G%AO;+960S+S&)=*Z+M$YZG9LGA\B*_1'[DU]E>!,X5VDF0;I%)
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M42%HIF^70&)@RD!^GU,J]@]J@.JX:_(O4$L#!!0    (  EM?U88122I*0,
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M@X=.Q4/G@X7>.215!P+;H,IUGD<*YQVE7H*OOZX;CK.E]1HCW]_6NKTV%J7
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M$H \>9<BN9!L&[\L\,"D9%'\=4.P2OUT ?7[BC'Y<J$KV+_1,OL?4$L#!!0
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M]U'37 +#,M(3<#SF7+UV]*6T^D]A_!=02P,$%     @ "6U_5AXS$^=X P
MC L  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULK59M3^,X$/XKH^QJ
M!=)"7OH*VT8JY4Z'Q.H0L'N?33)MK'7BG.VT\.]O[*2AL"'+5E>I;6S//#//
M,[8SLZU4/W2&:. Q%X6>>YDQY;GOZR3#G.E366)!*RNI<F9HJ-:^+A6RU#GE
MPH^"8.SGC!=>/'-S-RJ>R<H(7N"- EWE.5-/%RCD=NZ%WF[BEJ\S8R?\>%:R
M-=ZA^5;>*!KY+4K*<RPTEP4H7,V]17B^# /KX"R^<]SJO6>P5!ZD_&$'5^G<
M"VQ&*# Q%H+1WP:7*(1%HCS^;4"]-J9UW'_>H?_IR!.9!Z9Q*<4_/#79W)MZ
MD.**5<+<RNU?V! :6;Q$"NU^8=O8!AXDE38R;YPI@YP7]3][;(38<PC';SA$
MC4/TVF'XAL.@<1@XHG5FCM8E,RR>*;D%9:T)S3XX;9PWL>&%+>.=4;3*R<_$
M]QG"4N8E*YX -TQ4S& *AF8%DCK J&0I?0U418K*K91*;KBMHP:Y@L7=$J;#
MZ!2NBGI7U046-9!T'DV$3Q^F43CYHD%9<4_DZJ2R(;1&HX$5:>M6QQ:</7#!
M#4=:5=805E+0QN/%6L,1+PA;5IH<]6? QP1+0P:*4.S^):,&QZ#*'7S*=2(K
MXJ(HRO$Y'%VB85SH8SB!;W>7</3Q&#X"X=[O<&>^(9&M5'[2"'I1"QJ](6@8
MP5=9F$S#'R18^A+ I^JT)8IV);J(>A$O,3F%0?@9HB"*.A):OM\][$EGT.Z8
M@<,;OX%WNU^[15V[!8G[=XDDJU7]VJE^_5R]+A7K((/N(/;R.M<E2W#NT>VD
M46W0BS]]",?!ERX%_B>P%WH,6SV&?>@QR3KH(EA[#9V7O4PW\=ED-/,W^WGW
M(A^8]ZC->]2;][TT3#0GI&1/]HQW%JI&&?7RZ(UT((]QRV/<R^,J+RM[9_""
MSCEJT\5A_!.'DRAXQ:$WRH$<)BV'R;MK(?K/S>3G<HQ>EZ,WV(%4IBV5:2^5
M9:64?5W(]CIX%ZWI.VCU!CZ0UEE+ZZR7UK4D)NY%\IO$>F&[DX:N*^X G%^2
M#X/G+B'HKRK3&=T2/'4OV-^4H,'>OPK#P'U>%;C#\.RE79V^O]?OY*C6K@W4
MX-[M=>O3SK:MYL(U6/ZS>=VG?F5JS:F1$;@BU^!T0EM0U:U?/3"R=-W3@S34
MB[G'C-IE5-: UE=2FMW !F@;\/@_4$L#!!0    (  EM?U97,>NL5P(  - %
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;*U4;6_3,!#^*R>#T":Q
MY:5=&2.-U!<FD#:H5@T^N\FUL>;8P7;:\N^QG32THZM HA\:GWW/X^>YY"[9
M2/6D"T0#VY(+/22%,=5-$.BLP)+J2UFAL"=+J4IJ;*A6@:X4TMR#2A[$83@(
M2LH$21._-U-I(FO#F<"9 EV7)54_Q\CE9D@BLMMX8*O"N(T@32JZPCF:QVJF
M;!1T+#DK46@F!2A<#LDHNIGT7;Y/^,9PH_?6X)PLI'QRP>=\2$(G"#EFQC%0
M^UCC!#EW1%;&CY:3=%<ZX/YZQW[KO5LO"ZIQ(OEWEIMB2*X)Y+BD-3</<O,)
M6S]7CB^37/M_V+2Y(8&LUD:6+=@J*)EHGG3;UF$/$ U> ,0M('X.Z+\ Z+6
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M#[5;0/-+I>SNPRFHK^K3?P!02P,$%     @ "6U_5LM\\;_G!0  S1$  !D
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MHJA^#^Z]C\+U>RK<_'=K_ -02P,$%     @ "6U_5I>*NQS     $P(   L
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M9$% %B\(.8\0<0<O[%)<MH-;71*0Y:M!GMBF32"G!.24';(&XY%P)VX">4!
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ML.W2?+:RWO['9OO_H(__ E!+ P04    "  );7]6O '6P> !  #L(   &@
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M4$L! A0#%     @ "6U_5B=4$I76 @  6PD  !@              ("!X!8
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  EM?U9+M[L(
MG@,  $L+   8              " @>P9  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  );7]6RKPPY\<"   :"   &
M@(' '0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ "6U_
M5NRSV*:=!@  %2P  !@              ("!O2   'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    (  EM?U9V!/S@DP8  $0>   8
M      " @9 G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M"  );7]6YVV@BMP-  !G)0  &               @(%9+@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ "6U_5LLS[A1P%P  JD   !@
M             ("!:SP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    (  EM?U;9R$0-P0(  *8&   9              " @1%4  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ "6U_5A$E1/0  P
MO08  !D              ("!"5<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    "  );7]6E^L8_0<"  ">!   &0              @(%
M6@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  EM?U;\
M0ZV4+@(  /D$   9              " @7Y<  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ "6U_5M791G%^ P  6@@  !D
M     ("!XUX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  EM?U9.[$&_C0@  !T3   9              "
M@9>   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ "6U_
M5KC-G/A<!@  !@X  !D              ("!6XD  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    "  );7]6;TC&Z-<8   ,2P  &0
M        @('NCP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   (  EM?U90FF8K=0,  .4(   9              " @?RH  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ "6U_5BQ8U7_Y @  ZP8
M !D              ("!J*P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    "  );7]6#R*XZJH"  "#!@  &0              @('8KP
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  EM?U;K()LJ
MY (  '0&   9              " @;FR  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ "6U_5E8[(@T@ P  = <  !D
M ("!U+4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  )
M;7]6[R@=S*<$  !T"P  &0              @($KN0  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  EM?U:Y/FDIQ <  #05   9
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M970S,BYX;6Q02P$"% ,4    "  );7]6QHJ!3XP#   8%   &0
M    @('LU0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M  EM?U;0\Y +>@(  %8&   9              " @:_9  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ "6U_5IDVM 5C!   NQ0  !D
M             ("!8-P  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    "  );7]6Z?$IY24#   "#P  &0              @('ZX   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  EM?U;B^> ](@(
M -,$   9              " @5;D  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ "6U_5G#(GUBS P  @Q$  !D              ("!
MK^8  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  );7]6
M@H63>R("  !3!   &0              @(&9Z@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    (  EM?U9\;7Z36 ,  %L,   9
M      " @?+L  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ "6U_5C6>IKZ4 P  .Q,  !D              ("!@?   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  );7]6/LHG5P8$   @$@
M&0              @(%,]   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    (  EM?U:#@!T'_P(  !0,   9              " @8GX  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ "6U_5M.95)EB
M @  N@4  !D              ("!O_L  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    "  );7]6HE8_TJD#  !\#@  &0
M@(%8_@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  EM
M?U;Z(1KC= 0  /H2   9              " @3@" 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ "6U_5AA%)*DI P  RPL  !D
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M=#4Q+GAM;%!+ 0(4 Q0    (  EM?U8>,Q/G> ,  (P+   9
M  " @8P@ 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M"6U_5E<QZZQ7 @  T 4  !D              ("!.R0! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    "  );7]6M2J%'R %  "V#P  &0
M            @('))@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    (  EM?U;+?/&_YP4  ,T1   9              " @2 L 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ "6U_5IW=ZTDU P
MZA(   T              ( !/C(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  );7]6EXJ[',     3 @  "P              @ &>-0$ 7W)E;',O+G)E
M;'-02P$"% ,4    "  );7]6'/<?O>,$  "C)   #P              @ &'
M-@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "6U_5KP!UL'@ 0  ["
M !H              ( !ESL! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ "6U_5A34<>30 0  K2   !,              ( !KST!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #\ /P P$0  L#\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholder's Equity (Deficit) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/OrganizationAndBusinessOperations</Role>
      <ShortName>Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfSignificantAccounting</Role>
      <ShortName>Summary of Significant Accounting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Money Market Funds</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/MoneyMarketFunds</Role>
      <ShortName>Money Market Funds</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Selected Balance Sheet Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SelectedBalanceSheetDetail</Role>
      <ShortName>Selected Balance Sheet Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Grants</Role>
      <ShortName>Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/EquitySecurities</Role>
      <ShortName>Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Right-of-use Assets and Operating Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities</Role>
      <ShortName>Right-of-use Assets and Operating Lease Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Summary of Significant Accounting (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://secondsight.com/role/SummaryOfSignificantAccounting</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Organization and Business Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/OrganizationAndBusinessOperationsTables</Role>
      <ShortName>Organization and Business Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/OrganizationAndBusinessOperations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Summary of Significant Accounting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfSignificantAccountingTables</Role>
      <ShortName>Summary of Significant Accounting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/SummaryOfSignificantAccounting</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Money Market Funds (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/MoneyMarketFundsTables</Role>
      <ShortName>Money Market Funds (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/MoneyMarketFunds</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Selected Balance Sheet Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SelectedBalanceSheetDetailTables</Role>
      <ShortName>Selected Balance Sheet Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/SelectedBalanceSheetDetail</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/Warrants</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/Stock-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables</Role>
      <ShortName>Right-of-use Assets and Operating Lease Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails</Role>
      <ShortName>The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails</Role>
      <ShortName>The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Organization and Business Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative</Role>
      <ShortName>Organization and Business Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/OrganizationAndBusinessOperationsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of estimated useful lives of principal classes of assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails</Role>
      <ShortName>Schedule of estimated useful lives of principal classes of assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure -  Schedule of net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/ScheduleOfNetLossPerShareDetails</Role>
      <ShortName>Schedule of net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Summary of Significant Accounting (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/SummaryOfSignificantAccountingTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails</Role>
      <ShortName>Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Money Market Funds (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/MoneyMarketFundsDetailsNarrative</Role>
      <ShortName>Money Market Funds (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/MoneyMarketFundsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails</Role>
      <ShortName>Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Selected Balance Sheet Detail (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative</Role>
      <ShortName>Selected Balance Sheet Detail (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/SelectedBalanceSheetDetailTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Grants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/GrantsDetailsNarrative</Role>
      <ShortName>Grants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/Grants</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Equity Securities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/EquitySecuritiesDetailsNarrative</Role>
      <ShortName>Equity Securities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/EquitySecurities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfWarrantActivityDetails</Role>
      <ShortName>Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/WarrantsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Employee Benefit Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative</Role>
      <ShortName>Employee Benefit Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails</Role>
      <ShortName>Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Stock-basedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails</Role>
      <ShortName>The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails</Role>
      <ShortName>The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - As of December 31, 2022, we had federal and apportioned state net operating loss (???NOL???) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails</Role>
      <ShortName>As of December 31, 2022, we had federal and apportioned state net operating loss (???NOL???) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company???s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company???s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative</Role>
      <ShortName>Right-of-use Assets and Operating Lease Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="g083419_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Subsequent Event (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://secondsight.com/role/SubsequentEventDetailsNarrative</Role>
      <ShortName>Subsequent Event (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://secondsight.com/role/SubsequentEvent</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 25 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityIncorporationStateCountryCode, eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2, eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise, eyes:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne, eyes:ClassOfWarrantsOrRightsTerm, eyes:GrantReceivedFundingPeriod, eyes:ShareBasedCompensation1, us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1, us-gaap:GeneralAndAdministrativeExpense, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ResearchAndDevelopmentExpense, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 -  g083419_10k.htm 27, 29, 83, 84, 85, 86, 87, 88, 89, 90, 97, 98, 99, 100, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="g083419_10k.htm">g083419_10k.htm</File>
    <File>eyes-20221231.xsd</File>
    <File>eyes-20221231_cal.xml</File>
    <File>eyes-20221231_def.xml</File>
    <File>eyes-20221231_lab.xml</File>
    <File>eyes-20221231_pre.xml</File>
    <File>g083419_ex23-1.htm</File>
    <File>g083419_ex31-1.htm</File>
    <File>g083419_ex31-2.htm</File>
    <File>g083419_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img001_v15.jpg</File>
    <File>img002_v15.jpg</File>
    <File>img003_v15.jpg</File>
    <File>img004_v15.jpg</File>
    <File>img005_v15.jpg</File>
    <File>img006_v15.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="471">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "g083419_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 471,
    "http://xbrl.sec.gov/dei/2022": 41
   },
   "contextCount": 99,
   "dts": {
    "calculationLink": {
     "local": [
      "eyes-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eyes-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "g083419_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eyes-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eyes-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eyes-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 462,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 72,
    "http://secondsight.com/20221231": 25,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 103
   },
   "keyCustom": 66,
   "keyStandard": 238,
   "memberCustom": 10,
   "memberStandard": 24,
   "nsprefix": "eyes",
   "nsuri": "http://secondsight.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://secondsight.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Money Market Funds",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://secondsight.com/role/MoneyMarketFunds",
     "shortName": "Money Market Funds",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Selected Balance Sheet Detail",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://secondsight.com/role/SelectedBalanceSheetDetail",
     "shortName": "Selected Balance Sheet Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:GrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Grants",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://secondsight.com/role/Grants",
     "shortName": "Grants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:GrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Equity Securities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://secondsight.com/role/EquitySecurities",
     "shortName": "Equity Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:WarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Warrants",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://secondsight.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:WarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://secondsight.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://secondsight.com/role/Stock-basedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://secondsight.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Right-of-use Assets and Operating Lease Liabilities",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities",
     "shortName": "Right-of-use Assets and Operating Lease Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://secondsight.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://secondsight.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://secondsight.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Summary of Significant Accounting (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Organization and Business Operations (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://secondsight.com/role/OrganizationAndBusinessOperationsTables",
     "shortName": "Organization and Business Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Summary of Significant Accounting (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://secondsight.com/role/SummaryOfSignificantAccountingTables",
     "shortName": "Summary of Significant Accounting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Money Market Funds (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://secondsight.com/role/MoneyMarketFundsTables",
     "shortName": "Money Market Funds (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Selected Balance Sheet Detail (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://secondsight.com/role/SelectedBalanceSheetDetailTables",
     "shortName": "Selected Balance Sheet Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "eyes:WarrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Warrants (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://secondsight.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "eyes:WarrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://secondsight.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Income taxes (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://secondsight.com/role/IncomeTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables",
     "shortName": "Right-of-use Assets and Operating Lease Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockNoParValue",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://secondsight.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockNoParValue",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-08-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eyes:CashAndCashEquivalentsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails",
     "shortName": "The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-08-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eyes:CashAndCashEquivalentsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-08-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eyes:TotalConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails",
     "shortName": "The following table summarizes the calculation of the gain on bargain purchase (in thousands) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-08-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eyes:TotalConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Organization and Business Operations (Details Narrative)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative",
     "shortName": "Organization and Business Operations (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Schedule of estimated useful lives of principal classes of assets (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails",
     "shortName": "Schedule of estimated useful lives of principal classes of assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure -  Schedule of net loss per share (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://secondsight.com/role/ScheduleOfNetLossPerShareDetails",
     "shortName": "Schedule of net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Summary of Significant Accounting (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative",
     "shortName": "Summary of Significant Accounting (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails",
     "shortName": "Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_MoneyMarketFundsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Money Market Funds (Details Narrative)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative",
     "shortName": "Money Market Funds (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_MoneyMarketFundsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
     "shortName": "Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyes:ContractLiabilitiesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Selected Balance Sheet Detail (Details Narrative)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative",
     "shortName": "Selected Balance Sheet Detail (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyes:ContractLiabilitiesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://secondsight.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "eyes:GrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2018-01-012018-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "eyes:GrantReceivedToSupportClinicalDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Grants (Details Narrative)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://secondsight.com/role/GrantsDetailsNarrative",
     "shortName": "Grants (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "eyes:GrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2018-01-012018-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "eyes:GrantReceivedToSupportClinicalDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Equity Securities (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://secondsight.com/role/EquitySecuritiesDetailsNarrative",
     "shortName": "Equity Securities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-08-30",
      "decimals": "INF",
      "lang": null,
      "name": "eyes:StockIssuedDuringPeriodSharesMergerAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "eyes:WarrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Summary of Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://secondsight.com/role/SummaryOfWarrantActivityDetails",
     "shortName": "Summary of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "eyes:WarrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SaleOfStockPricePerShare",
       "us-gaap:SaleOfStockPricePerShare",
       "span",
       "span",
       "span",
       "span",
       "p",
       "eyes:WarrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2021-12-31_custom_RightOfferingMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Warrants (Details Narrative)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://secondsight.com/role/WarrantsDetailsNarrative",
     "shortName": "Warrants (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SaleOfStockPricePerShare",
       "us-gaap:SaleOfStockPricePerShare",
       "span",
       "span",
       "span",
       "span",
       "p",
       "eyes:WarrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2021-12-31_custom_RightOfferingMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Employee Benefit Plans (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative",
     "shortName": "Employee Benefit Plans (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails",
     "shortName": "Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "eyes:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://secondsight.com/role/SummaryOfStockOptionActivityDetails",
     "shortName": "Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://secondsight.com/role/Stock-basedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://secondsight.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
     "shortName": "The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://secondsight.com/role/StatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationTaxExemptIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails",
     "shortName": "The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationTaxExemptIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31_custom_NPMMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - As of December 31, 2022, we had federal and apportioned state net operating loss (\u201cNOL\u201d) and federal and state R&D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
     "shortName": "As of December 31, 2022, we had federal and apportioned state net operating loss (\u201cNOL\u201d) and federal and state R&D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2022-12-31_custom_NPMMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eyes:LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company\u2019s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails",
     "shortName": "The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company\u2019s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eyes:LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyes:LeaseAndRentalExpense1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Right-of-use Assets and Operating Lease Liabilities (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative",
     "shortName": "Right-of-use Assets and Operating Lease Liabilities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "eyes:RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyes:LeaseAndRentalExpense1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "eyes:ClinicalAndRegulatoryExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "eyes:ClinicalAndRegulatoryExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2023-02-262023-03-03_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Subsequent Event (Details Narrative)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://secondsight.com/role/SubsequentEventDetailsNarrative",
     "shortName": "Subsequent Event (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2023-02-262023-03-03_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Deficit) (unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholder's Equity (Deficit) (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://secondsight.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Business Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://secondsight.com/role/OrganizationAndBusinessOperations",
     "shortName": "Organization and Business Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://secondsight.com/role/SummaryOfSignificantAccounting",
     "shortName": "Summary of Significant Accounting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "g083419_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r421",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r421",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r421",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r421",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "eyes_AccruedLiabilitiesCurrent1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents accrued liabilities current.",
        "label": "Accrued Liabilities Current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents antidilutive securities excluded from computation of earnings per share.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_BiopharmDivisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents biopharm division member.",
        "label": "Biopharm Division [Member]"
       }
      }
     },
     "localname": "BiopharmDivisionMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_CancellationOfSafeBorrowing": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents cancellation of safe borrowing.",
        "label": "Proceeds from SAFE note"
       }
      }
     },
     "localname": "CancellationOfSafeBorrowing",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_CashAcquiredInMergerForStockConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents cash acquired in merger for stock consideration.",
        "label": "Cash acquired in merger for stock consideration"
       }
      }
     },
     "localname": "CashAcquiredInMergerForStockConsideration",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_CashAndCashEquivalentsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Cash and cash equivalents fair value.",
        "label": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValue",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_CashSPICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents cash s p i c insured amount.",
        "label": "SPIC insured amount"
       }
      }
     },
     "localname": "CashSPICInsuredAmount",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_ClassOfWarrantOrRightExerciseIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right exercise issued.",
        "label": "Class of warrant or right exercise issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExerciseIssued",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyes_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right exercised.",
        "label": "Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantOrRightForfeitedOrExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right forfeited or expired.",
        "label": "Forfeited or expired"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightForfeitedOrExpired",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right issued.",
        "label": "Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantOrRightOtherAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right other adjustment.",
        "label": "Class of warrant or right other adjustment"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOtherAdjustment",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyes_ClassOfWarrantOrRightOtherAdjustments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right other adjustments.",
        "label": "Other adjustments"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOtherAdjustments",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantOrRightToBeExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right to be exercised.",
        "label": "Class of warrant or right to be exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightToBeExercised",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right weighted average remaining contractual life of warrants or rights2.",
        "label": "Outstanding at ending (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right weighted average remaining contractual life of warrants or rights exercise.",
        "label": "Exercisable at ending (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right weighted average remaining contractual life of warrants or rights one.",
        "label": "Other adjustments (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsOne",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right weighted exercise price exercisable of warrants or rights.",
        "label": "Class of Warrant or Right Weighted Exercise Price Exercisable of Warrants or Rights",
        "periodEndLabel": "Exercisable at ending"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right weighted exercise price exercisable of warrants or rights11.",
        "label": "Class of Warrant or Right Weighted Exercise Price Exercisable of Warrants or Rights11",
        "periodEndLabel": "Exercisable at ending"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_ClassOfWarrantsOrRightsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrants or rights term.",
        "label": "Term of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsTerm",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "eyes_ClinicalAndRegulatoryExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents clinical and regulatory expense.",
        "label": "Clinical and regulatory expense"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryExpense",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Hardware And Software [Member]"
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_ContractLiabilitiesOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents contract liabilities other.",
        "label": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilitiesOther",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SelectedBalanceSheetDetailDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_CountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country [Member]"
       }
      }
     },
     "localname": "CountryMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_DeferredTaxAssetsStateTaxes1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents deferred tax assets state taxes.",
        "label": "State R&amp;D carry-forward, begin expiring in 2026"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateTaxes1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_DepositsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents deposits and other assets.",
        "label": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssets",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_DisclosureGrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants"
       }
      }
     },
     "localname": "DisclosureGrantsAbstract",
     "nsuri": "http://secondsight.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eyes_DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use Assets And Operating Lease Liabilities",
        "verboseLabel": "Company Evaluated Lease Amendment Under Provisions Of Asc 842. Information Related To Companys Right-of-use Assets And Related Lease Liabilities Are As Followings In Thousands Except For Remaining Lease Term And Discount Rate"
       }
      }
     },
     "localname": "DisclosureRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://secondsight.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eyes_DisclosureWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "DisclosureWarrantsAbstract",
     "nsuri": "http://secondsight.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eyes_DivisionIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents division incurred.",
        "label": "Division Incurred"
       }
      }
     },
     "localname": "DivisionIncurred",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_DivisionIncurredOfAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents division incurred of assets.",
        "label": "Division incurred"
       }
      }
     },
     "localname": "DivisionIncurredOfAssets",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_FairValueOfAssetsAcquired1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents fair value of assets acquired1.",
        "label": "Total identifiable assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_FairValueOfLiabilitesAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents fair value of liabilites acquired.",
        "label": "Fair Value of Liabilites Acquired",
        "negatedLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "FairValueOfLiabilitesAcquired",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_ForeignOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents foreign operations policy text block.",
        "label": "Foreign Operations"
       }
      }
     },
     "localname": "ForeignOperationsPolicyTextBlock",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_GainFromBargainPurchase": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents gain from bargain purchase.",
        "label": "Gain from Bargain Purchase",
        "negatedLabel": "Gain on bargain purchase"
       }
      }
     },
     "localname": "GainFromBargainPurchase",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_GainOnBargainPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents gain on bargain purchase.",
        "label": "Gain on Bargain Purchase",
        "verboseLabel": "Gain on bargain purchase"
       }
      }
     },
     "localname": "GainOnBargainPurchase",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents grant receivable to fund early feasibility clinical trial for five years.",
        "label": "Grant receivable with intent to fund early feasibility clinical trial for five years"
       }
      }
     },
     "localname": "GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/GrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_GrantReceivedFundingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents grant received funding period.",
        "label": "Grant received funding period"
       }
      }
     },
     "localname": "GrantReceivedFundingPeriod",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/GrantsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "eyes_GrantReceivedToSupportClinicalDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents grant received to support clinical development.",
        "label": "Received grant"
       }
      }
     },
     "localname": "GrantReceivedToSupportClinicalDevelopment",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/GrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_GrantsAgainstOperatingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents grants against operating expense.",
        "label": "Grants offset against operating expenses"
       }
      }
     },
     "localname": "GrantsAgainstOperatingExpense",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_GrantsAgainstOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents grants against operating expenses.",
        "label": "Grants against operating expenses"
       }
      }
     },
     "localname": "GrantsAgainstOperatingExpenses",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/GrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_GrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents grants text block.",
        "label": "Grants [Text Block]",
        "verboseLabel": "Grants"
       }
      }
     },
     "localname": "GrantsTextBlock",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/Grants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The elemnt represents accumulated depreciation and amortization.",
        "label": "Accumulated depreciation/amortization"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_LeaseAndRentalExpense1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Lease and rental expense.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_LegacySSMPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Legacy SSMP member.",
        "label": "Legacy SSMP [Member]"
       }
      }
     },
     "localname": "LegacySSMPMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents lessee discounted operating lease liability payments due year three.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_LiquidatedDamagesPaidValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents liquidated damages paid value.",
        "label": "Liquidated damage"
       }
      }
     },
     "localname": "LiquidatedDamagesPaidValue",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_MrAdamsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents mr adams member.",
        "label": "Mr dams [Member]"
       }
      }
     },
     "localname": "MrAdamsMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_NPMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents NPM member.",
        "label": "NPM [Member]"
       }
      }
     },
     "localname": "NPMMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_NetLossPerCommonShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents net loss per common share basic and diluted.",
        "label": "Net loss per common share \u2013 basic and diluted"
       }
      }
     },
     "localname": "NetLossPerCommonShareBasicAndDiluted",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyes_NeuromodulationDivisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents neuromodulation division member.",
        "label": "Neuromodulation Division [Member]"
       }
      }
     },
     "localname": "NeuromodulationDivisionMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_NhGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents nh grant.",
        "label": "NIH Grant"
       }
      }
     },
     "localname": "NhGrant",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_OperatingIncomeLoss1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Operating income loss.",
        "label": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_OperatingIncomeLoss2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Operating income loss.",
        "label": "Operating Income Loss two",
        "verboseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss2",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_OperatingIncomeLoss3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Operating income loss.",
        "label": "Operating Income Loss three",
        "verboseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss3",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_OperatingLeasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents operating lease payment.",
        "label": "Total lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayment",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_OperatingLeasePayments1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents operating lease payments1.",
        "label": "Operating Lease Payments1",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_OperatingLeaseRightOfUseAssetOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents Operating lease right of use asset one.",
        "label": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetOne",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_PppLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents ppp loan forgiveness.",
        "label": "Ppp Loan Forgiveness",
        "negatedLabel": "PPP loan forgiveness"
       }
      }
     },
     "localname": "PppLoanForgiveness",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents proceeds from issuance of common stock and warrants.",
        "label": "Net proceeds from sale of common stock and exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents right of use assets and operating lease liabilities text block.",
        "label": "Right-of-use Assets and Operating Lease Liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_RightOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents right offering member.",
        "label": "Right Offering [Member]"
       }
      }
     },
     "localname": "RightOfferingMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_SPICCashLimitCoverage": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents s p i c cash limit coverage.",
        "label": "SPIC cash limit coverage"
       }
      }
     },
     "localname": "SPICCashLimitCoverage",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of estimated useful life of property and equipment table text block.",
        "label": "Schedule of estimated useful lives of principal classes of assets"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of share based compensation arrangement by share based payment award options grants in period table text block.",
        "label": "Summary of Option Grant using the Black-Scholes Option-pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_SecondSightSwitzerlandSarlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Sight Switzerland Sarl [Member]"
       }
      }
     },
     "localname": "SecondSightSwitzerlandSarlMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_ShareBasedCompensation1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation.",
        "label": "stock based compensation cost"
       }
      }
     },
     "localname": "ShareBasedCompensation1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options other adjustments in period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Other Adjustments in Period",
        "verboseLabel": "Other adjustments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherAdjustmentsInPeriod",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_StockIssuedDuringPeriodSharesMergerAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares merger acquisitions.",
        "label": "Stock issued during period shares merger acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMergerAcquisitions",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares stock options warrants exercised.",
        "label": "Options and warrants exercised, net of partial shares adjustment (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsWarrantsExercised",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares stock warrants exercised.",
        "label": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period value common stock and warrants in connection with rights offering net of issuance costs.",
        "label": "Issuance of shares of common stock and warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period value stock options and warrants exercised.",
        "label": "Options and warrants exercised, net of partial shares adjustment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period value stock warrants exercised.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_TaxCreditCarryforwardValuationAllowance1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance1",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_TotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents total consideration.",
        "label": "Total Consideration",
        "negatedLabel": "Total consideration"
       }
      }
     },
     "localname": "TotalConsideration",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyes_WarrantDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents warrant disclosure text block.",
        "label": "Warrant Disclosure [Text Block]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantDisclosureTextBlock",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyes_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents warrants member.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "eyes_WeightedAverageSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents weighted average shares outstanding basic and diluted.",
        "label": "Weighted average shares outstanding \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageSharesOutstandingBasicAndDiluted",
     "nsuri": "http://secondsight.com/20221231",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DescriptionOfMaterialContingenciesOfParentCompany": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of consolidation"
       }
      }
     },
     "localname": "DescriptionOfMaterialContingenciesOfParentCompany",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r246",
      "r351",
      "r366",
      "r386",
      "r387",
      "r396",
      "r404",
      "r409",
      "r456",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails",
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r246",
      "r351",
      "r366",
      "r386",
      "r387",
      "r396",
      "r404",
      "r409",
      "r456",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails",
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProFormaMember": {
     "auth_ref": [
      "r170",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro Forma [Member]"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r238",
      "r246",
      "r274",
      "r275",
      "r276",
      "r350",
      "r351",
      "r366",
      "r386",
      "r387",
      "r396",
      "r404",
      "r409",
      "r449",
      "r456",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails",
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r238",
      "r246",
      "r274",
      "r275",
      "r276",
      "r350",
      "r351",
      "r366",
      "r386",
      "r387",
      "r396",
      "r404",
      "r409",
      "r449",
      "r456",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails",
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r170",
      "r247",
      "r431",
      "r444"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r397",
      "r408",
      "r458"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r373",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r397",
      "r408",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r170",
      "r247",
      "r431",
      "r432",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r447",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r407"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r48",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r19",
      "r20",
      "r141",
      "r364",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r149",
      "r150",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r20",
      "r100",
      "r341",
      "r367",
      "r368",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r5",
      "r407"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r441",
      "r442",
      "r443",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r74",
      "r75",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvancesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of Federal Home Loan Bank (FHLBank) advances carried under the fair value option.",
        "label": "Advances, Fair Value Disclosure",
        "negatedLabel": "SAFE loan forgiven"
       }
      }
     },
     "localname": "AdvancesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r120",
      "r137",
      "r155",
      "r187",
      "r195",
      "r197",
      "r201",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r308",
      "r310",
      "r321",
      "r407",
      "r454",
      "r455",
      "r474"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets",
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r131",
      "r143",
      "r155",
      "r201",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r308",
      "r310",
      "r321",
      "r407",
      "r454",
      "r455",
      "r474"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, fair value adjustment"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccounting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r306",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r87",
      "r88",
      "r306",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Net liabilities acquired in merger for stock consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.",
        "label": "Less net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesCalculationOfGainOnBargainPurchaseInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Fair value of the consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r133",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Money Market Funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFunds"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r28",
      "r34",
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r28",
      "r108"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net Increase"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r155",
      "r171",
      "r172",
      "r174",
      "r175",
      "r177",
      "r178",
      "r201",
      "r211",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r228",
      "r234",
      "r321",
      "r388",
      "r430",
      "r439",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r58",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Shares underlying warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r58",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r116",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r50",
      "r205",
      "r206",
      "r374",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r441",
      "r442",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover",
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common stock, no par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical",
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical",
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative",
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding",
        "periodEndLabel": "Balance ending (in shares)",
        "periodStartLabel": "Balance beginning (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r407"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 50,736 and 36,803 at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r145",
      "r147",
      "r152",
      "r362",
      "r365"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r118",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Policies Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractTerminationClaimsDescription": {
     "auth_ref": [
      "r110",
      "r111",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim.",
        "label": "Description of contract termination and claims"
       }
      }
     },
     "localname": "ContractTerminationClaimsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r113",
      "r119",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Capitalized R&amp;E \u00a7174"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Total R&amp;E related deferred income tax assets (net of applicable amortization) as of December 31, 2022, in the table above, was"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Gross Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "R&amp;D credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Total federal NOL carry-forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Post TCJA period federal NOL carry-forward, with no carry-forward limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Pre TCJA (Tax Cuts and Jobs Acts of 2017) period federal NOL carry-forward, begin expiring 2030"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities.",
        "label": "Lease ROU"
       }
      }
     },
     "localname": "DeferredTaxAssetsRegulatoryAssetsAndLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.",
        "label": "State NOL carry-forward, begin expiring 2030"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Total Deferred Tax Assets, Net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Federal R&amp;D tax credit carry-forward, begin expiring in 2026"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Accruals/reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r84",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedLabel": "Investment in Sub"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r237",
      "r239",
      "r245",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Employer contributions to plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r32",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation and amortization of property and equipment"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r32",
      "r186"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization of property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r251",
      "r279",
      "r280",
      "r282",
      "r286",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Total provision for income taxes (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r156",
      "r289",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal tax (benefit) at statutory rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax (benefit), net of federal tax benefit (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Change in valuation allowance (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Other (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "R&amp;D tax credit from current year (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r55",
      "r129",
      "r149",
      "r150",
      "r151",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r176",
      "r202",
      "r236",
      "r283",
      "r284",
      "r285",
      "r298",
      "r299",
      "r313",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r341",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover",
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfCancellations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimates of cancellations for refundable service fees, if accounted for by analogy to FASB Statement No. 48.",
        "label": "Cancellation of SAFE indebtedness in merger"
       }
      }
     },
     "localname": "EstimateOfCancellations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r220",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r316",
      "r347",
      "r348",
      "r349",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r220",
      "r239",
      "r244",
      "r316",
      "r347",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r220",
      "r239",
      "r244",
      "r316",
      "r348",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r220",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r316",
      "r349",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r220",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r347",
      "r348",
      "r349",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "negatedLabel": "Right of use liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Translation and Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "The following table summarizes the calculation of the gain on bargain purchase (in thousands)"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnRepurchaseOfDebtInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase.",
        "label": "Gain on bargain purchase"
       }
      }
     },
     "localname": "GainLossOnRepurchaseOfDebtInstrument",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative, net of grants",
        "verboseLabel": "General and administrative expenses."
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/GrantsDetailsNarrative",
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Impairment Effects on Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "ImpairmentEffectsOnEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentEffectsOnEarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the effects of asset impairment charge on per share or per unit basis.",
        "label": "Impairment Effects on Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ImpairmentEffectsOnEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r290",
      "r291",
      "r296",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r287",
      "r288",
      "r291",
      "r292",
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesOther": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingenciesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "verboseLabel": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Pre-Tax Income (Loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued compensation expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r45",
      "r357",
      "r358",
      "r359",
      "r361",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Patent Costs"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Other income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r335",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company\u2019s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Right-of-useAssetsAndOperatingLeaseLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r155",
      "r201",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r309",
      "r310",
      "r311",
      "r321",
      "r392",
      "r454",
      "r474",
      "r475"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r114",
      "r122",
      "r407",
      "r440",
      "r448",
      "r469"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r132",
      "r155",
      "r201",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r309",
      "r310",
      "r311",
      "r321",
      "r407",
      "r454",
      "r474",
      "r475"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r14",
      "r450"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Litigation accrual"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r450",
      "r451",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss contingency, damages paid, value"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencySettlementAgreementCourt": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the name of the court, if applicable, which approved the terms of the settlement agreement resolving the legal matter.",
        "label": "Description of legal settlement"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementCourt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Ownership interest (in percentage)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative",
      "http://secondsight.com/role/ScheduleOfMoneyMarketFundsAtTheirLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r179",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Organization and Business Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r28",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r33",
      "r117",
      "r126",
      "r130",
      "r144",
      "r146",
      "r151",
      "r155",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r173",
      "r187",
      "r194",
      "r196",
      "r198",
      "r201",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r314",
      "r321",
      "r393",
      "r454"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://secondsight.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Income (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative",
      "http://secondsight.com/role/StatementsOfCashFlows",
      "http://secondsight.com/role/StatementsOfComprehensiveLoss",
      "http://secondsight.com/role/StatementsOfOperations",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r187",
      "r194",
      "r196",
      "r198",
      "r393"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r333",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Long term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/CompanyEvaluatedLeaseAmendmentUnderProvisionsOfAsc842.InformationRelatedToCompanysRight-of-useAssetsAndRelatedLeaseLiabilitiesAreAsFollowingsInThousandsExceptForRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/AsOfDecember312022WeHadFederalAndApportionedStateNetOperatingLossNolAndFederalAndStateRdCreditCarry-forwardsAvailableToOffsetFutureTaxableIncomeAndIncomeTaxesAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails",
      "http://secondsight.com/role/ReconciliationOfIncomeTaxComputedAtExpectedU.s.FederalStatutoryTaxRateOf21ToIncomeTaxExpenseBenefitAndCorrespondingRateFromOperationsConsistOfFollowingInThousandsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Change in valuation allowance for the year ended"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ComponentsOfDeferredIncomeAssetsAndLiabilitiesAsOfDecember312022And2021AreAsFollowsInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other assets.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r96",
      "r97",
      "r99"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfComprehensiveLoss",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Gain of other income expenses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Patent costs"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Research and development costs"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Rental payments amount"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r3",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, no par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical",
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r407"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, no par value, 10,000 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r115",
      "r125",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/FollowingTableSummarizesFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateInThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r47",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r49",
      "r123",
      "r363",
      "r407"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets",
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SelectedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Reclassifications": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.",
        "label": "Reclassifications"
       }
      }
     },
     "localname": "Reclassifications",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r128",
      "r342",
      "r343",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r77",
      "r127",
      "r483"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development, net of grants",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/GrantsDetailsNarrative",
      "http://secondsight.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r37",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r57",
      "r121",
      "r370",
      "r372",
      "r407"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r129",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r202",
      "r283",
      "r284",
      "r285",
      "r298",
      "r299",
      "r313",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Warrants granted"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Money Market Funds at their Level within the Fair Value Hierarchy"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/MoneyMarketFundsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "The components of deferred income assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands):"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands):"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/PropertyAndEquipmentConsistedOfFollowingAtDecember312022And2021InThousandsDetails",
      "http://secondsight.com/role/ScheduleOfEstimatedUsefulLivesOfPrincipalClassesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r248",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails",
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r65",
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r58",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Summary of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A specified percentage variance in the prepayment speed assumption in the determination of fair value of transferor's interests in transferred financial assets (including any servicing assets or servicing liabilities).",
        "label": "Fair value of identifiable assets acquired and liabilities"
       }
      }
     },
     "localname": "SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://secondsight.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Other adjustments , weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodEndLabel": "Options outstanding, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails",
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Options exercisable, number of shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Options exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, number of shares (in shares)",
        "periodStartLabel": "Options outstanding, number of shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Options outstanding, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited or expired, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Common stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/ScheduleOfNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfOptionGrantUsingBlack-scholesOption-pricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Stock options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options outstanding, vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Product Warranties"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r155",
      "r171",
      "r172",
      "r174",
      "r175",
      "r177",
      "r178",
      "r201",
      "r211",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r228",
      "r234",
      "r321",
      "r388",
      "r430",
      "r439",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r55",
      "r129",
      "r149",
      "r150",
      "r151",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r176",
      "r202",
      "r236",
      "r283",
      "r284",
      "r285",
      "r298",
      "r299",
      "r313",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r341",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover",
      "http://secondsight.com/role/EquitySecuritiesDetailsNarrative",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit",
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r176",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit",
      "http://secondsight.com/role/SummaryOfSignificantAccountingDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r55",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of shares of common stock and warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Shares issued for SSMP net assets (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r55",
      "r57",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Shares issued for SSMP net assets"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r55",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r3",
      "r4",
      "r55",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r3",
      "r4",
      "r55",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r44",
      "r407",
      "r440",
      "r448",
      "r469"
     ],
     "calculation": {
      "http://secondsight.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets",
      "http://secondsight.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r154",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Equity Securities"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/EquitySecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Description of lease agreement"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r328",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/WarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "As of December 31, 2022, we had federal and apportioned state net operating loss (\u201cNOL\u201d) and federal and state R&amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Selected Balance Sheet Detail"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SelectedBalanceSheetDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information;"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r180",
      "r181",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://secondsight.com/role/Cover",
      "http://secondsight.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54672-109401",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=84167097&loc=d3e55538-109407",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54658-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54708-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=84167097&loc=d3e55541-109407",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938335&loc=d3e56414-109416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938335&loc=d3e56417-109416",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r418": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r421": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r426": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r427": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r428": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r429": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001753926-23-000344-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001753926-23-000344-xbrl.zip
M4$L#!!0    (  EM?U8>BW!K[A,  "S$   1    97EE<RTR,#(R,3(S,2YX
M<V3M/6M3&SFVGW>K]C]HN75W,U5CP#"924BR6\9 0BW!7DPF<^?+ENB6;6W:
M+4?J!IQ??W7TZ'?+;0-)9^SYD#'2T=%YZG'Z2'K]S_M9@&X)%Y2%;W:ZN_L[
MB(0>\VDX>;/S8=3IC?KGYSOHG__XRY^1_._U7SL==$9)X!^A$^9USL,Q>X4N
M\8P<H;<D)!Q'C+]"O^(@AA)V1@/"49_-Y@&)B*S0/1VAY[O=%QAU.@WP_DI"
MG_$/5^<)WFD4S<71WM[=W=UNR&[Q'>.?Q*['9LT0CB(<Q2+!MG^_;_YKUOP]
M%5[2^.7GN^?LE_LK^MN$A"_BT]\/?_=&^.V_1GC@?WG>[2Y^#XZCC\'/[ZX#
M_-N"T7>W?O2\/QH.S_]]<.?]^T1W^5IX4S+#2"HC%&]V@#_#WMWA+N.3O8/]
M_>[>;^\O1@IN1P,>W0<T_%0%WGWY\N6>JK6@)<C[&QY8U(=[4'V#!4DPRUKJ
M@*>AB'#HY>#]*&F0!7Z^IRMSH+02]&<-2BVH3PIP@GB[$W:[)RLD_,&!!8Q%
M9X+Q/ $>8W&CD H>=40\5\"?#RVX+*T$S>&$IM%B3D0U5E65:^!'O- @)S=9
MO0?5T&:_L]_M''1M2[+(-)(\LM 7=#*-P*15%]V#0PE, C(C873&^.R$C'$<
M2"X^QSB@8TK\'11A/B$1V*B88X\L1VAM'8<ADRXA_=*40-E\3J7-RX(_O0;C
M..(L(->2? 0_I#/6HH?ZO3Z38\H.HOZ;'?T3$$FT"I5/QC2DJC_C>%W4 3>+
M@3WY4S5YO5<$SJ"(!?$'X3_4[SDG0K93#%S( M/0@-0T\G#@Q<%J;5)2*IN8
M BNH=45WC /PK-&4D$AH$>:+W*(\D/*# 8XDL@P%"Z@O2WQD$"&-:2MA*80A
MYI*U*8FH)+A"W/EZM^P/F\L>/<LA_F%3=9&(2PS&@SFL'V2'QNQKZMPZ^,FE
M@Q0C8F.4XMQ*?S"&11HG4Q(*>DLNF*A00AG$K8OGS7610XT ]U8G@_$H8MZG
M*0M\N6P^_1S3:"$G?NK1J*R;>E"WCGXNZ\B76I *<F@KT]G?!=+=H6>FPQ_0
MLSC$L4]EN^VX!FZ#Q?0L8'=5'I54N;7TRPJ>)%$BA7-393_@$QS2+XJT7N@?
MQX*&1(CB]+(<S*V3%[!HE7O!@(F8$_E'%B'"H9SR#<KM3+,WBF<SS!=RG**3
M4&Y8/!Q&/<]C<1C1<&(<PPWCUL;+HC8,-C5<I?A0BG!35?&>A63Q'O-/)#J+
M9:T6?JG4*>[N?E'<JCW2")#"L*GR'<E]NB?'Y>PVXH1$F)KMA:/>+?-NR<0-
MIOS> FEDFRK^MURZN3%J\]LMUH.B6'6K396?7LV-B!=SV1<QDBR5NF5Z6)2I
M62.F"#95O!\QSQAH\I=;G#\5Q6G;;:H43V?S@"T(.2:A["\:RN'/&FI5C5NZ
MSTO&:G @@P0I+)LJ:[79Z\#7 1]VZ7)SJ*BTFYGJ2K?$?R[-9 K-,=;[SA3/
MILK\/)0_R36^M^-OML MVU^*LM5-401M-U6>5_!GAXT[$G-/"!()N>,SN[)P
M<D&DX5U0?$.#S)2W8ANW5DJ;Q2QVI-&K/6/2 5(]H$P7FZH\.2#,:*0"'%(#
M?:9V;R3T$DVY -QJ*>T:,ZB4.G+(-E4!H_A&D,^QY.CT5OYC=^OY0J>@#TK[
MQ;0Y4NTW5[:NH,>0!32U\X:P;DV4=Y'+ B7HF46]L>'<I;'":WP3D*:!10/L
MUE-I6]HDO(B>:=P;JRBWBV2UU C2K:+2+K>!*VVX?HIAQJQ&:NK<.BAMC<N!
MR(T7>GW$,><0RZ#<BBCMHIW1R8W7B8W@9#50*'/+N[2'MJTW7K0U,8F<K3M!
MW((O;;#K@A<;KXA,T"(K_'*Q6^"EO7,VHK'Q0EXM3)'5PUHMW:HJ[:?7"'-L
MO$;/6!"P.[L(U6M*^H6(,TRY2CL7@['1E_<YIISX4F\9 <JZ>"8+(U4M%+TG
M."+GX?64Q4**7^A)V-C!5^S/:3V'I2#!]92@L:5.^KLD#XF$/A1!M202W2HJ
M8=D-1=B8F2%6V5N0L2^LZ44XTN IU0@2:M S&LH*0_D/1Y#8I*C?&F3!0/HI
MQ8/Q6TS#07B,Y2Z5AL.8>U/IUZN:W%H8W495BG<T,*J,*JQ1 0U(_GFCR4%S
M0T_!6K;&LC3Z801T"<O5B-Z2AD&34C.WVM<,GYA>4-+-QNH1CAKY<4 &XU,1
MT1ED&GX09!P'%U(J<D88<AIZ=(Z#?@ #;C)'Y/S\H4C<.B['7TQWX+3$=HAB
MU:.< F[U'#&WG2)/]PJ%9M+8>/=--79)(LC#'A(^FF).:O1: ^567"EHD]-<
M2"(D:P22?HD$8-VJQ1VMK!Y25VSC5EDYO+,\UKD=3,M>50QR]B*Y'J'\@MR2
MX".-IC1,EMWOJ)R7Y"IC4>-Z#T'E5G8Y/R/CGA4!5KV2E@MQU3>Z4YVK91-0
MH,_*HH2&K3<7-5?MOTNAW$HLQ:FJ(N-;%[4Z&7(FYYMH(1>?D*PXAQP .&9!
MA5Q##,;)CJ47G1"/S&X(/^S"45H)+__7K=OI/#Y:M]9+P3)+@%KS$DL"\BP-
M=H.3;HDP!.DU+>BP^R,"<E1K(&B[.V[^=:5F6FX.[U9U^<B#^XO+UM?S.>+5
MZJFI<ZKBIU+DZJWY%+.5>5U>>;7TET*Y]5 *]I3RSK<JJ=A4F$^'/4^*0YT<
MS:XWEP"Y%5(*PV2V#08ALABW4XG]A%OM&[6U;A64HB3IA^*M*[@.%-2,4$T@
MW1HIA3^J#QQL]5,Q5 WFT)6:7C\(N5H]#K#WJ2.\J802NK(SY]235>^93X+J
ML6Q=+&Z]NF(D&JE>%R"(/$_4JEMW/-(=HWS/2'6]'173.!8D6F@9N:<J!Z!;
M@^7 1R;*!4BM'K=SUI)LF]-[^%F(&C<"=6NH)OOFIIQ]8]!N-50C]IK=:4-@
MMY9*48CZ'*GM')<YYS)GH;X8Y(2,">?$UZE.279.+NL"H"I"1CTNX75<2=1%
MI;Y.5VX;*84OX,.\EQ &0ZYO2$-49WSA-($HG] !P(Z8%7Q"DD ZQ"6V(:Q2
M#AD4>E*<)O,BR= #.XDCR.V!T11B2Q]VQ>X9\0G'@;I',V)\(0&O<$0&XX/N
M-4O:FO'7+&G5P2RI2R'5"[>+0H,SSF;IQW<3%<W$1.NL]_LAU^D!SROSG7B.
M.3!LFJ0[*O< !FWN$C%LH@^[HUTTUHPB83E5;3CD-$DT!]W_11'+8B-VAKS1
M3/^@/$8EP&1YUQC&DGO$TE0)$T NAX^WWE7PKO+P^9&\P[XQ2VEIO?F<<:""
M^.HNITL2I6F83(A+!E IO *Z\OMR9*117\Z;B\Z8\3O,?=&[E:*&E*9K-AB/
M!7PYBJ1M2?N&0C/$AWXF!7?I7/']DN_VOE*LL%<]C?R([@B:8C]Q+W 2G/*L
MW(VHK 669+6J_(5G?_N?%P<'^Z\N!Q?J5_>5]K L(MWXZF]X-G]U@CPE$^3E
MA(*PE0KX+U-R06,E&'!C56$GR-#/.+B>&K>SGF.]A</%*62/0J*0RD3NS4CH
MPQ>R#Z%4TI"S6PHW5JO,)._%3P>[<!4TGRE^KD@ [:Z9P20J,ZH-5#&?.K-V
MD@:3-=_3>X_,X9K?*S+#4@XF%_N:\)E$!R8+&18P(Y76='\,=MQ^6PHIPZQI
M2$;$<J\FI4#EEF,K Q2#$%3-/)$$^'QOU$<@#)21AIR( XV(J1:F!W#D[B^O
M!.+9S/;,PM0VTWWGEJG952@(*>^2/\KY&"0E ;C$8F1E\$126@J];^2E)N6M
M%Z]Z_J%ZT_M '&Y[+<7?USH3L=TF-[@.HEJ[JS1PJ[(4N'=>%[%56NT5$G4)
MBVX@MW(JHN_Y*R;^V/J ?R!L=T7&2#W]< 2O#;S9$10>W]@Q95-.QF]VX,&!
MCGT'X#^2M=W[66!! +7CZ0>ESJ(T3,<6!>9>"4OI:0J)1&4F24_9L\1;!!&-
MH/DPTPV"?N129^\Q6):KZ559EDU(\(2\7@#^1V526M^J3!8,]HE8S9SR>52&
MI>NLRG#>VYZ(WY.DDRR[YJ6-O?2I#?-W\3F.UY)QN=E$8>EI#]?#+/I)F0OF
M*52.)O!7Q[;K0%&G>] Y[.[>"S^E=!4B4C&L1H1MMP81-<_#5/4OZL#AAS*F
MIITF#\*8]V>:=%K99H\$D; E#R(A]]K-ZH1\/LPBZNBBE6DIOKK3C [[ (^D
MP2!8MW_)0O9YG@?H0Z%922'+W_RI(V=92_6W6,LAU(Z1+U9QBFP3^\=ZEID^
MK+2:'6@E@"FLV^T:5E#NO-8$S'-,:N4*\]!_;%[5>Q4_W%'$I5E;22D-5"SO
MS4[$8Y@IX*FM(SF#4.9?JXG.CW6,?0?IB2]Y6.K(9Q 5.(_(#" E3W*%*^>8
M6">SL'C^9D>CHQ+$1>I(K=%'L$8?W='H"^&!W+Z,, _RQ#> :P,[?6V?>=J+
MA6T@])BR^13SV0G5T:<\Q;6U;2#]DL2<S9AO%F[5'"P#:@,CYB,A?X>Y?X<Y
M?$\8L7$$/XL&M!RP#0RI>-)@/):]AI,\"]55;2#Z<OB^8#J9@C80>$$FV%N,
M1N^'>3HKRMM [GO>\_&L,/<4"]M Z F9,T%UA#6:$JX#H);BVMJEI.L=3&2K
M;O01&,D"N8'WDC0_NF[&0A)AOGB44=$>?X90( O5(>AC+*BGOFT$\+$^'1P;
MP3Y 27-S"OL1&/M(8.@@?N^6<#PA"JT8Q!$(&9(":GA<O=G*[&H(=2Y</,92
M"#+3SH6(B7\2PS Y5'VK,ZM&3P A:;8KN?.PS\*0>- 5G+-5@ZRPHRQ\_1X#
M/C"_/A.I;7^5GE809\%1]+?G)_,4%_>JSC)]>D^X1T5J4VNU_-[DH#UE+4$L
M:=IF!\LD:HN,W:]N FX<W[$Q&,8>8!,.#-_:-."&)\BJ*]SQ9'FKKVZM0H?S
M^07#X1GC$WI+X'HARTQE36OY@%<$[6UOYW+_QB>$2]*50:G,1Y]8PLQF:84&
MZW/]M(NY/G02V.O'1GA,CAGG*E<C9=,%TE;&AIQYA/@"G,DN&-1SKA5KCL1>
M5VO35M;3+\+Z2'9/XN'8BY(-1VT]-K\L2VN/EA$,RX\Q6NK+@<E]=!Q(^2>C
M9*GX 3N(R*)Y5-%;.ZD7?AFB=>(W)*8TES3AA&B=4M1F@HT;I3S5*VX]+*U3
MK@F4?6AT$VY1[^LV;HE)7$[5$)*$*9(_6T*?7$80.@G3HQ?J.9)%20T-X%K"
MD>-:Q#&!6Q'+=P:IBU)++#\&HM;)Q,;%\B<0>S"V3E2CXT4*,L0+*.I!IKS9
MZ;PUL1.]$UHFN"?NK2725<OST(?_@27<X@!R%I/[X7*K>"=82^.P^?&V," /
MPH3!!G MY3!10O$R[FXR_KD@VL^5G21)0G<%8Y5 +>7MFD4XJ-PL5]:TE(O*
M6[BS$9JJRK5Y>>*P1B^,J ^?'N@M2>^$.KWW@M@G/FQU]4=?L[\_Q1S.8"2W
MVUJV'XZFN8">)O"F-UN@-9$>UC-'8/,;RWJ@MF[Y8?8:#<_[YR%L4/S>#!)!
MLC-<565+O0](!9(OZ(Q&?::_JB6+F)K*EO+2\SQ)3_9B@7[,N01)9C G1%O'
M%)OD<AYZ0&PR:U64M]5C$N?6!VOA*W6WM&+*U[4V<EU![X&#EX/OC)=#!R^'
M;>:EZ YVD5KG+IGZMKH-G/:"*%9FO%))*VD"66U]6P<S->=?$8_(E8U_S4:Q
M.N?>#VA(/1R<P/7>3(41<HN$A@W:JL<,#_KN ;@<6R[:@L69W"52I;N%9>F:
M4QR<,7XF&?X_@KFHD,1Z6%KKNCD= U?)9^9**RA"K!G;M:5/O=P5C=:[;1Z'
MG#D ^E-LYFFN9?E(CF;?>->B'HE)+J(=<!6^T0PD0ZX3Y%OG.U129Q,R&C!2
M FU'KJ"3UF8<M58[<HP>$PIW]7,Y$F2C4LW!6\G8-3LFS714A&PE.SI;V/]O
M+/1Q?"='%<#? U.K\-3NP:&0)IS<#&-7S#$V7[!L7H!I)S*A_*= _.V7*H_+
MU<'3"&O%3?.W$)4=L(:<>G;T GK+S#02T4KHVKA,6IV1;O>1)=-=+8KW]66S
MLA]8WI_&RS+8V^9L"8UPBU<U]T60;\]"]9?^Q,KKJUN[[WM@ZD)Q&623&-P2
M>13\WWJYE=P@F;]+]I*%/O%C+Z*2N.1>\CDGGJZ'VRYG</'CE[SM/!ZZEGZ[
M@<MUT_LZS<V4OZJ[]H /N-$.R$@$L@)\6T.A]EYLR8J.1*M[2]6EHPF;2V!:
MJLP+(FDE]N9%4I.LN# >+4YB%:*\GG*2S'0/0]':2&>>#4-]=>Y06OE]<5/Q
M9:]4W5J.])VF< EI&.' C*C=U"AK:MLZ@=NO 8KF"5R:P/BBD(6Q!*:MK%W0
MSS'U(2'U!,_DLE<,,?5SN89.B+9."BYMJ/.X;W.':)J#MU6/34]>/OCHYA_S
MW.8:AUH;(VFM='*WOV<7@$+%Q!5-L!PH3T1+X=?<-TR@^2-P9K)0(763!7KP
MLDQ45[75K1\W4M$L4K06VF\?-KB>DH/];E>_)"HW>K*2WA)XH2]_V4H#N#;<
MOU(Y)14N/G*"M(&)TK[KB@@"C\OK3:>HW9^5X5JZ1RM1GHT;U+)7 &HI;RI?
MU<22*#R%"!G3R0&FP5U(N)C2>7\*<:9TN;A:HY;RGDL ZDWD?ECMNHJY*,O!
MVCJSJ#D\N08=(@! 9J+%NMJV+OB+C]F4ER>RXD,(%W07K\);O6$;AM92XE,Y
M7I"M::T9JFO:+JMO;[MLV>5MY5OF6G>_G(ZMV(&H*-3*NC:073* MJD^O4YP
M$)*ZFP:S55^7Z-=[^MY<^?/_ 5!+ P04    "  );7]6AE9C, @3  #GM@
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M5/,@HU,B=E>>P2\=(,KDO^N"$+(3A5@5P+6'$<7MOMH_8RY$L[YN<PJ%7,'
M*\B\9MYD?"/6L&:U&BNIGQ^ -!2(!WO!$.!,BL4F%36Q6"H2:R[^'XZ1G:DP
MOY2^L3^H:S@$HJ?+I9!('W-UHP3DEYMB&22:7P6.VHS7@Z[<8UC /#R&7;L:
M>4(^4@EYS@.P@.63&S'S/(490QA)%!5^:99[X*;*BB_843\\8SLU<#18G3Y
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MUE!CQW8N[:ILL.DC^]IJNK%CJB"YVF["*>?#-"WC7Q@YPS?_ E!+ P04
M"  );7]6MTXK0-PP   #R@( %0   &5Y97,M,C R,C$R,S%?9&5F+GAM;.U]
M:W/;N-+F]ZW:_\#-6WMJINHXB>UDKF?V+?DVXWH=RVL[D]W]XJ))R,()16@
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M8 GQ::\HMB>^VML_V#O<?_O,PC<%3E+8E$3H&DT\\2\'>MDK0P&)0X8?IHF
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MG$<L8B6EHR/XZ</!6Q'#2&=2,Z]1).K=DKPE5NM"S4MM.E!+4Q(7;)G?T^<
MS9,S0J_1S,=QX7R]173&FSO!3-K_8IPTF$1?%*.6_.A-5^YV6N_CX+HI9ULT
MU=7!=G.7FE%U%;D^#0J*ZPJ7^P?"<HOH8!&/^U&2->5-T""]1WLAGHD@1A$-
MDG=4%LFR%1PG[WC1=WF9=[4-=$_WLK.]D(A!W(SH:NT>*)8][<WD"MB0W/6J
MW=/J1U$S"F6%[NF*23)J2EI1IU>=1!,_C9*ME;*HODXS_YJO5F)AO. ?U^A&
MSPE?5E%84"X:;!!(G^!$E,]O0NQ[>^+:1"KF6?YG5C*GI* E(L$: 9&X,T!H
M57*L8'GBLWO)=\KV'GQ__DY,C^]0E+#B&SEA2DGF7]PM0X$YP^B<_[E<BOGV
M#D6RV[N\<%W9=W:IEF>3!A3GY3:I7>$]H@7=N;(8CLA,0W_A\"=<0TXCV1O7
M<O0P*P5;3;C9HQ5E+C:BY* L6T[(&X]0OLG[[<W^^Q4M$6$H_.U-0M,:EGL&
M2)XFYGZET3,VT:YJE59AJUU.=3"M2Q^ ".*U!BU;N)1)/,D79@B0NK*M(E'=
M(^A@ "5,M)1#4!R\'R86=_LUA+<%1[$Z[CJ[;8V7Y Z"[- >9-PZ(K&D\U.^
M5001VRS: 6#KFU8 #,5@( 84@U/8MG-8U7 3W]P5!UN@7$6I]4)W=6/7"8D"
MM()SD+7U8#E2L_/:E5/><*VNKS:0]5K%<PU(MC#:(%.W5 #%+:_<2ED3$P;<
M6\#; &80R_BNX#FZFN<SM&XE7RMV]]'.FJ,>%$1#,"3[CZTL/ P%;Q_(X[L0
MX4SL_(^5M/F'N\+7<<M;K!$T+U(N<?>C'1GKC?(Z0B'9MJ+6>M$N3WO.(O^A
M7K9K19P6;I723BWH!M(]02R@>%Z^RPD(N51R&++>)+C3#9#Y7'&-'C!+LDB!
M)4/JR:.VBM,@Z"D'E\U^T1C%<>I'UTA$$*A!*)<<A.PK!$,B_]"OR/]WZM,$
MT6AA(O6-PH,0?!W-X$ZEYXT*WT!E-[M,A+]9>A#2KR4:$O\/_8K_9HJB* ])
M,0&@6GX0$ !D0R#\: ^$+**"LV:.P[+*X*!8IQQ"XZ=^T;A"%!,1DD<-<-@H
M/ @$ZFB&9/^S#=F?QJ&IY/.B Y)[F6+0YNK)I"TH.\,L\*.,OC/^79U#NL1(
MI?@@Q%]/=>NG+CM!\'^13XT!6!8>D/C7:0:%WY,%?)Q2ND::<N:!2CLM?B71
MH/Q[LGE/XP0G"Y%;]S(%7,.\V&8II^5=2RPHYYX,W8RHPO41)R)]L$K6ZR4'
M(.\:@D&9]V3@9H0=<_*I'YW'(7K^+[10"7VCZ "D7D<Q*/:>#-N,LBN*Q37+
M&QSH)Y;-L@,0?"W)H.1[LF8STF[]Y_.0,R$S;0AYZ0$ J@P !Q7E(!P]F;,9
MA>)>&)V3DK_[6%P(HHMC$BJ7 &7% 4"CIQ\$J">;-Z-S%(84,9;_(_C:5\%2
M4WP 8$!4@P=@/=F_$'4'S2 X&"0$!VH(>K)_(>H.FT%P.$@(#M40]&0%KU%W
MS/\<TUOR!)R^ X6'(_X-FD'A]VH"Y[1);L;93>+L(1,= ALUA@-#'>$@%KV:
MR86>9-L%DU&0E1R.[,L$@S+OU4S.";LB+/&C_X?GNMUI7?GAR+]*-HA"3U9S
MKA'"C0*%7:T5<5K654I!\?9D&HLU9T21#ZMUN83;PMTD%)1M3W;N!1&G.E,2
M*WW(FZ6<EG$ML:"<^S)7Q;5L!DX/RY^=ENPZE9!(VPF4UXOT"\4)IT=<!TOC
MW(,$G/S5%G5:U##%H-A[,CEOY!L7(MW*)\X'Q:OWXM9E7BWGM, !<D%I]V1=
M7E$D= #Q3;X,AA.Y'>AX,H%F:KB\T]+7D VBT).9N4'>.6,IHDVQJ-0:$B+U
MQ(.X]&1RYGE[%_L'][<B<0DP$VV4<EKNM<2"<N[)S+PDM]07N1%O%K-[$L%7
M>&H*.BUMB%Y0X#U9E&M4U8MZK8C30JY2"HJW)XNR&&2GS\'4CQ\0'-%15])I
M88,$@S+OR=)<36P/1G/UPY#FZ@>#N;HG2[,@*@O4Y^-N?!_AA[77'>M%7E-A
M$-*'Z(: ^-#7C5=Y7ZN4Q/2,_U$/06U1IX4/4PR*O:^KL&F(15YH2> 9COTX
MP%E&Z.PI:0 !32VWP3 A'L2EUW/2+RB*_BLF3_$-\IG(\)P9%JK3"J"*TXCH
M*0?AZ/7D]$\2I7'B4QER2X&Q45MT .*OHQ@4>Z^'I'E8^7+EDOGJE=*OKS$
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MR+O" H#]]V-Z\#XWJT;A(Q<YRN1['E]1-/<7TDLR1RC,"ZG\Y ,@_UM2_^$
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M+\2HLITY$R9-XZG05G3&Y]  NHW)T% X _$(W/K/HY0/*8J3A8DSH%K>FA_
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MSNT:&[#5BCJ\:."5$+N3>U#ZH#21CHI*+P#"#6; _:8SD-V:I+-M@*91>R\
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M3YH</3#I)HC:%)&L.7B>DC4[=P\A3H,\SA13,X6<JRF:%F8]59,*>6>;"9E
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M5/56#XNK2Y1FY<$<@ZK<J.=2':)YN9+',9?ZO(S2=^=,-,&LULUHA#(,EDU
M+)O_;7K4*X)$C.C"%C%5+"SZ,9,$RWI'L\2])Q]09X7[S0;?Q=I&C5NYMME4
M2:"GG70>Z)VYEZL5#LOEZO(M9/XR]T&)ERFUGOX_W7=X):V2M+%[LC;+X[#$
M$9NII%'_AX[D=1HF6WH/]2(N-AEIU#_FV7;#'@\M".7("F^+HVJSF;1D11U
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M,BBWI GLF$Y.'4M(,J<G_S<JLVYJF ]0Z.LG_I3B-ZPU,B^ C#3I@K3RB*[
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M1A%$!"G!$*NX43?@')6LH8XDX@T@-R&EC>T#GV-+IZL)@H^B*5:$;-7@,U+
M.J3DI?1Y5>_T.Z=+H.6J>DJJ>H3J=DM#Q2Y7#SC<YFPKXSQ($AR=[2Z#\*4O
MJSKAV#]=IV=.<Q5#[T1JWT3!T'XN2X1K>NRXE4=737;4*^1+]1P:RK9E408L
M*K?W1J)XW8:!7VS+EXP^*A[]1*WH/'G#=@8NWW >Q@6^R^,0W]/MQ[K8JB]T
M3E0]D:.:E+G*W>FTVFV1]F;E;K(&TWC=VJMUELBXZ(&NX2W2,H[H>\]D9&T[
MI<NW,-E&.**;>N?L48'J"9SAD]&#XILG26=7^V8ROKD$N&=ZWMD_HQ'2N 6'
M&92*O.P,2.1?[6!$_O'+!2["/-YPM)_);#*/6:@%ZE")TY#81E;N;#.H"CH^
M*)2):;@@\5[F4=9.2L [3?=!/>1E)QUZR!!VK]QXGT/=XZ(DHPC==Y8&)%^4
M[%4+8K(L4/SD5%S.:2::V)V;C$P"VH;V-/A"N+8F%11""$-_@3<Y#ODK1<2F
MQ9J^D?)/6?@@*PV7E+2 WJ6?1AP:U<Q0Q>ZQU>"OW71T:(>Y@1E9GIT]DS:!
M28'3-G6!7W&2,6Q5#'/=X;=!T;EGA)4A@@^#5LO[(#X:JJ3'8SK\H996BXSA
MAM-5=PS\$:?T>2<+R@TEG7-,#E4@55\,%HNDV(1C#C)7G(LDJM V;#=N02.G
M%&43 U]. AL%=Z%N;("W(6]TTMZ980U1\#>J]E+YXVH!U^V\YP;&]8C.$Z\N
MKL^O4QK4C8[F6Z4;M4+6Z7&!#F[O"$ FZ)U/-N@$-U@BAV(N2&=.V_UG1IHG
MQ![N]%S0"3I]+DP)M/=(F"#EG0)&:,)1S9VK^J<Y460W\3HNSS.R%@B>I4.-
M0M!9_6N!-O4OE8)1_SIHTOJGRW&44&DRZ>#BGES_^!4 69?+OSB^9:KK90>
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M]F?G\Q.2;1C,T-:W=W/,T!C9^W9.*E,11D ULG1F7]+<,8&HE*TF'PE#T M
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M,RT=5*C@JMS"L#X]7MD)//XWK)H8 .;>=J^9BEK/#-_9]OVUN>T+>6@T5&T
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MW2WK,!1T]N.^4M7#Y*J <WWL1\+*L:#3)?N9N(/*N,-"+OY6+AXJR>F6(]E
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M^$0_@*)60-WL+OM5UH2F%45E_]HJ*?O';QLB1\^X3:%8FUJ3/YGPFP!47%<
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M,"I5#DD^ORZ?HKO,T+^03Z=LS#;[EP=']A@1*E#0AUC:XD1[@SO0/F27DH(
MB4 E;<&\]F%DI40$?"NR2YVZ<'Y;6S!GNW]A*;AL".O@)3GW%K2!?.W%VK\/
M/IA85=(<W !*?3!I:S#W^(!&L-4C.[Z\NG;>3,WHMCV8QWT@4UI'YJB%GN_
M]/LNE;4U'0',J1_0&-NAYX;7W^JC2R$HO,8[G_*_/VUYV7&UW]==[>I'O-'6
MZ=U\QQ,?\BI?VGBHWN9CK[ZJG:_*PS<\WL*4)2IBN+(E6];XI7F8*DC<F(\7
M9+G$:?Z2/:]97+F&:#;YOJ]/OLJ(8M+MC-G;--N_MHZ"<8M47<MA^IQQ%ZP)
M#D2*^?:-.OG%:]Y'W04X$:231*KSS020H3*K\.\9#KF#>NDO_3E*[GTL7BV0
M!N(4':!3+O86A!X-\)@-YXJ3S\/Z.,YO4$8^7C*KEP04K]1Y-6:]H9,H]I*C
M%:>."%4<F&W87!M,Q7(OK>L(G4_1AR@-T7%-BA.4LOT&9WTTITC\<$$RJHK!
MF0X G3\Q@%1U:+FQZYQDCPGZ/6,C7CVQ_S';:?Y0WVEN1_'$,.YL+FO\J?RX
MHHN\!\PDK-&CN>35WMJ-"PTZ6=3F4SLK\'>Y:G3=ZB]PR7LX*1C5_1\Y*_#W
ML^ILL$^I+VA).QR[6+:<@-_+:J%,=S%+T<5-P=0432^;GNYF]2T<Z5VD=DY<
MN>"E53&U0!R[G%2DR=W[-%U/J1\G;(7D0"HMF;*3FY-&8<V4W%1\=:<$I+-J
MFFYN",E ^<QD->SMTX]T%/K+1'EWLM8&.@1DI#75T%TKC\-8IX2F%<5G_]HJ
M/?O';U/N_/''&4/\A,/,CR2VB+65-'5#N4TLD)R'2F )$/K/.%T(5>*IR N\
MFI*K.%5==F]C2#<(L+CD,M#+2L?:(#LNC1 O%AC-KIY1D/% R'@VPP&B4MO%
M>B@[@!FR+G W!&: !?@.K$S9$#</5%7J&@V!S^UTD8G:TBWA$QS_1DS2X!Q(
MU<<Q_T0G%CW[5J'CXB_\?Q[]!+'?_']02P,$%     @ "6U_5F%J_O+/M (
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MX_5S&@8]I&!DLY5J'-#G:HUN/Q\F!UT)]VWA\=SXD)[/]V\R7<RFU\SAW?A
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MT)./TL[LU<!93V[*P[,S)S'DQV<R,M3=V>D86O?6ZEUT&XRA;[*"HP/30?H
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MJ9D7=5X\ [EBOP+_/#JBZQ&C?-#TO+]3GSQ&Q">9/,9'D<F#9I#]O1&C5'%
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M1X<X>Y/S4X<X-17/,X &&:_?HL.&5Y_K!R%!K\4"U%X9QSN%+>\1!'ZX,_N
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M%WT8?<;B'+(C$G3O,$C@ ^C@5 +:[H!\$<6H%)&II4AK5DI<R2CQVU*@)BP
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M&ADL A*."Q\Y#'.BOK5M_>H.A%+8LNN[OI9F/Y#R!P(UAM?Y3B)R;N<'.ED
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MJ4.K@W3&CMR.[:"51'P=-56\QCAY02%]$=%A7$D/@ZJ :/IN7Z )DO./_6#
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M@NFK.OBOF:F9(; :I 1M!H1?4APS5"+O&^7@ZQP9 TT,_<GP#EIE?%E4S-9
MV?@642$F-W:"$&N?^39<\<,2XU;!Q>F5B<<58D"5Y.5MFG4PRU@%.G9LD$@"
M=.FAR8,&-@JD-%7 TO+MY6NFT]L HP"8P!XD$95?3^!P$FXLS8DS4,% /H^!
MSH<8_T %81C-#3][(@>'Q@*U3NO;MHXDJ\_R9I)0\_!;Q.)WF<4_,/IMZ\+
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M6L\JW25$&)62F-ZE_*@*=BTE+CJ*>M55$K5RN,"@C - K,I!^!2@%3$2<K(
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MQID"E57AM12(JZX6 I09@\1)N3\I[CD&@Z:N 6^H@4@H>YQ]F&@ST?GX1="
M,O326'W,"^/<+05 9_%VP[ P@)/O*1GC(+MA@+DP: O:3XD-(5<"GNNM>.DJ
MRNC'(N9UO6UI[?-8-:0#;1Q8"N3&HXZ'B:M>RBAHQHO62DS6=9D+J<=&"71)
M^EM+:1SGYDC8A50II>R!3*>4QF:4N/@ 'YVL9#92BH 5("F: L,@W'_-+U"!
M5- R60LKRY\DUY _U[,YTB?->*>62RP^2750EA]-J.PZ)G_K19 @(]HL6VR*
M;08%D$9&T!%]+L!JI5V08,2TQ@)Q*3!_6?@)>Z"YZ>X(7#L#P:CV:6+ID%(Y
M.@>\.@YHG!:#43E@@' 3X<*R_593B3+2P@!1/.8!$.X23H7AC53L,-FO.83=
M3/HD0=Y 61\K76\7Z#^HWV,A6\R++M-%1(D;.G'"=QAP !V\E#N-?!Q3-3&F
MA$HDP,DL4ZJGM7EZ]MN6#'G.YO./@*0KW(+,.F9')R^M 5OX44'#E2OGBESA
MBACD0"H&7^MW0<Z0X7EV,U!YT/2,1(PO-+?@-J^OG4&_^K#K<#N)-Q#EZ]TL
M.&M^+;<?3$]F" G/ZR/]^)U?-BH;]'>$24/R[T<O@4P3K58J_YQJ/6"J<:BZ
M =F-"$AYIN'%#4REB!WUA&P^W:S8^3#AYQFNXN'>_F&ZC-SM3,%0_"#Q6\0Z
MK&G_@?4I4_6HT(13-J$15)8!%F(QDLUVLC-Y$X?X+Z2(>=*^<;A6U+=0U/<Y
M=KT4 4KGWEEVLXG@$71S*JB21]#G<_ZCL@11.%'W)@6TW3$H ^,)4=PYN8))
M"-"7( );"(P#8Y.^)R8=D!7U+A;U-DC$>23KS,4B@NP- @H5!4A)J'[((A%[
MS93,-9$T5ISSYZ*]8];''D=\V2A/S-(F*M3JPC"*14^9VS >-I>B;4]*-W_$
M.-#RE(362/A,M!(/5D1N='!N@T8)_X]YXX\@+W'?MRDPO:2\@#&&KT@++RJI
MGB<0E-(C<Z_ LA^Z5/,+D6 VW7;^E#XI2KCZJJ.$JZLHX;'4,6?;]XJ]+A1[
MO1'BV^,$"#.A1ZIE4C+PAP77N41",.W(VFJ9BR]Z]XA10/LO)"?,SC^].AF+
M?#(:CO.X@X%2A,UPJR4L(H!Z(7Z4N54J:<[UL6H9>V^5M,V9I6$4^+[PS)JK
M^LM'6>9TMA=YLR7Z\+BTK]'T.M&&$<8$ :J EY[>O<$N=":A5CC0]=5/FAB.
MR85"2"?A@,GME]4#EH*%O*)0G2/8=1&3+^D5!^J\&K<[159!\TD4AY2#T.K:
M&%XG.+2F.52)!]()2/9=Y89WL65R%%(5"+WQJA)\' ;H..WUNW9$%9DS49S*
M7;R]OO8%T^];HVVDX7_F+[+@8XHS%@5)V.*Q:(:;]292N( ;& $$VK\(VFA'
M^##?EO2AZQ_X;QT0I'_@Z;5LA^#'.<) %F0TP+JC;>N&,O55U*3Q?B@4^V:
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M8ZJ47J9*Z0@BF)T H3CE*27LP#GA/Q#W+;=4Z50=1,QSFPDA&<&ROPE"!M^
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MM=R^8GNY15I?DUN?H54>8"N)8MQRB5(<A+QT"HC0C3*K;R VPN:"5-[# 8%
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M_2_0.X#,+@2N!,A0#@I.2'__$3;^6;*NA2QH ?/Y'1827KI.HLBUM?B3#8N
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MAE1P "6,61B&'L7A\?->==P&&P;X@0'9N@"VLM57HZ"I6'OJ@CNT_AF:U!/
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M.8D5N^GT7'8 (F[.C$$YDOE/#9]3%@0I<XD8T)OV8[Z$X4+$,J'IAS_+0G3
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MP>\N0SLSI!C',O9BHE@B1ZNLZ$[E1(,7G+FRFD)>.)W-T6'MVD[Y2ZT-24\
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MB:4RV@(*H90<D5UH#K="H,4AK [D_./Q\>CX^3&_E#^>G(R>?/5$CA=*T"U
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MIFP'1STVBKFS![ #QK 4$<! KGD! O7NQ_@'W]6N#HL]D4L7E@YB+'$ GB=
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MP_5E40EY51RFOA"R;1NEWD=D!7$/"R@9#5@T<W2\;Q?&L=QNE$0@WXQURW*
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M9R3#R_KN&M!W8(5;MQB!+6),YP6Q, ]G@UWC$="C<*+$D+9LJ\NM<%4]1WS
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M(IVM!Y9)5MX9FS0FV'"T%//L>0/]:!+Z[CPE+)6U7N5PQM:)YBY*:1?!.];
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M2'#]PNJ;<K)(X6VK^W9*=,F9(G^]&VOO#L=].QR:A4,@WZS*90A]B@JQN*:
MNA9U*^XQ]D1:BHJ,GL.Y"SMYN&_R($DY<F6\9M*7F)"L[-[B/7Z+-R3VI1X,
M:*@-C/?)^JV4?[Y,4BA<&!FL26':+;._6%TV5"XTOZ^<6CJ)BV* ;>@-RVG@
M5-Y)XGV3Q,Z<RPV<V*IL&/2[5?AU<]%NI&E4^5?(G=+=ZA3 $T<D8O+N%D>
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MHXA\789KP,5@"28@Z4BAP5?CR(K8$HUZ7*G$2%7LL\!=X^BJS\+WE>J">X#
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ME^%(T!9#;84;1'$#;Q^4!M*8$\!M.\T1/L/E.)]\"6M2C$G..+TV+O(VD5I
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MA1218EDNNZK<OJ\C6!ZJ?:-DZUFJ=L3]E@029%I )CH'4O"OOV>O/9Q]<H!
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M3/ HFS^59'FO(/QWB)TGV0SE2J8C51.;3I=GPJ"?GEP4^QIFN@9$+V6Z+7?
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MZEIA$?!10^>/BL:  5E_F@%R%/;_JF[BM^A]FJ9N)'$=;EFC+E_*80J[5-6
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M('U"?CJ<"9%6Y!HZRSC& 4X4NF,6J50M2OT9\:5EW"V=@CHG'T'VE+DCZ9[
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M7BEO(( Q<SR^:6U'@B[GVJ"XX]>32$[8VD?JP:U]M^;A_@[\?T0>6C7*PAG
M(-L;.E1X/4::?;3I-Q",WY9=ESK*T4V6+1/N==5OD20!>GYF)(1GE-Z0@YCE
MILAY[Y165I^^D].@I*P.VX*\2O\>OJ>T?D;3A^%]],./WSXV5GEEH]2\GQ9\
M9/BLXG/1U/EJP&83:_X'DMDH4I +6A/Z9_S:"8'?)!/AXM&/WYZ/G]B>U(+/
MB_V4\8N+)HQ#7!1B&GA%%N'1BM4QFVS(K?;QFQ2)2UD^9#:Q'=:LI:_#5@SQ
M;P4ZF9;#^WU8VW+VT&G"^8:$/8T+S$I<LNCVNR)3EC"A^:5U%(Q:MS?PW51
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M%<99='0H-2@\E8;PF2<P%/2J3:UPJBZ+R I$GTH73'F(:5T1]+,(H_O;. ?
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MM6DDMAO@'44?JRIHW("((=[_\"A,*<',";Q,&,/V)]:SMF[F^,N)N4W;$JT
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MV5)9BN,D[V$#YFBE*T?=<C!<[*/ZM[ZO@>B'3X0^![U&N:0$%THZ&&;VE4)
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MI<5X)82VZ-D7,0^0_#9MR,H6?-@RCAOM1FDU$!/Z"E+YV@I@\(?9_A'D)+\
M70Q0'GM%.JO#0?20"*4RX5:E86=R%R\M3W;#7<LW8(G:$@=389\"LD#ZN>/.
M;U9NP-.4!K%ZEK.V"FM$UE]1-=IHYVF#&)?+-WVU-"$W.8H:(%AI5:/4_T!;
MMW#TPU%;H(H/Q'['@JT*J'#SPL@09BUO5(DT1PEP)4Q5.B[F^VQN*#QH,;<
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MZ5@AA+ZB,M5F&B?5FMF(0\Y3_Q!MII#HQE!:)!%W'6M+KKN=9QSGG'HNY:"
MX#8T['-3VHT&1+L#\G-MH6[)J$@':ZFJ4XI-,+1[_66M(_PT4Y[21D[CTPI]
M[46U2FN*Q.H>2=D+_YXA>*:9=G6Y3<X&,[HCM=#*(#M0-=A2(4JI%1I0M,9R
M.DGK.6=GW"TRP:A%W6NU\2!%*E*\%"[2HU@F7"X.'PQR\01[3"8FEGM/<7Y8
M?6F;EU[*C"O 3:04YV:LM(8N)0^IA+PJ^_IDR-A .Y"7?#+\L$(OZ/KJ"J'A
MMLO73!T32#ZT^L\ , 6%*#TN]/Q(AKG(%\X=CT51GY'?8*8UV+0MRV6)VW!W
MK?OK\PT)=2=96LH1,C:L)Q 9X)UTCH32JK-N6N()Q,VYRU[$E:9%P>=](8O$
MN ."0GHB/JSDM1[\P;, E99OK08<27T4%8.LGU+)2,JHX,N%0A0^]34[6\!=
M/T)NYQ3E>")<"+ JG**C%KUNX9#0%PTT$A-IXUJPN?33U)*[7)3:/;91M1NA
MHG,,DQ F$*0:.UV3,#:],]@:N 7S+.6^"ZKLR(;=M7 2;-HEK]0Y+YSI+F%R
MC-U.KOUW3Z)(9NK#5L>T($]R 8G4,+'B;KO4Y]:,:>?%YL;&9MQYT?W9QUI=
MQ$?8HG<8\-F@L<,]2(!L9>,O&*XY#<T69I&H6B;L;\#CTK0"!L!^NP2HO\S-
MU[O,E'QD\MJD-]SN#,_7&QH_%/FE H:JU L\""^9UV22A]=<[ WMJ[CV9ETJ
MGQ4-)L4XG,%=71D%JM#P<%TH@SRO3R-[2%#J[Y5C)M$AT4'+2@UA>;(NTF)#
M+*"S%U61F>($[@31JG9:2NKL.9Q34UAH$(#=0WOD]$R9_/AL8V-](QF[\:B/
M3S4N=-0ALL[[GV6M[_2C[PQG'G'&:)AB[DLLAE;;> QN&ZHEP3EW%701$+XK
MDD?YXZN8_^:.G8M;WD>Y>W!8@T26@'#$KV@-?+':9<?>'D1K\WQ$DINH_FM6
M9LG6AC\W5IZ]E"XW \Q'+H&CNW.OJQ=V[G[U0HRC>WDYN%+;?%="+)8.. EL
MP%34%RP2P1ZW%"[<&T@7#@XK52\TTE]"H1U!$\+3BMP9&D/R*(<991FYDPAG
MS-+,'-J6 $5.T9HM=Z4Y@V 00@,S\FX5&Z<%UZ'(X9C(7M!B($#QT5<Q!_Y)
MZ3<#Q!TZ&BG@.6VZPOD<HUD&\'''7 8EP=J--M-NX)B,U,Z-;.VBP<U)NX2,
MK6S>G>[=[L5[G<1;'2KT(KS?2&)75SQ<OF4&ZI;J\!'A[4(JV HR<!IF8ZJ^
M/JQF7"2A\JX!IL\YT7#(T-S[W8H5:<W 23WMB^0[(FVF/O 8(^YK$)ZOIS7"
M$/-K#EEU!NZX66=AB ./[AIZ2U@72(%L;FQN]597#GY_28D+JF+Q2:,]1*^J
MNLS35A/G&[\T)B6"@>X[Z_A$^@ XU._L;?#&<XMG\D: ?-SC #;D/B^AQ]65
M/<GA<*<8;\&;5_M[Y#XP^D56ZX0.>-%H_?UT-F4Z[J]'Q%^8)2^1E\' #O+"
M??T(X<0]J5G$"]>=!4[8/\@'-J<(<;K!5OY]S7$^T7?Z,NXT. 6Z4O'RX#>?
M$ *>U=(+J_/^F''T3ZT+3)#*&:C41]U0BD_3 E7L^M'V&'Q5*L(T&&,<:F.X
ME72$.AIR*]$"& A@TCGCKI%?93W3T0P2"7.&J#]F)06$X8;)+DE"%H4555U7
MIPB0<3'3 'X0D!/J3'TL1HFD8>M?D2T0P![!<XI.<ST+T-TDB@L[R'W5G5\6
M52#%60UC)P\7=U%WBE9<?)=0P"TKZB95IX TXW"SM#;35%M)V3SBUM!6X#9\
MC$?@##VL7B>IDJ(4\>EQ->9Z9&H675TQ\'P=X^0=FY@N+I8 --4NHJ'S!=R]
M;G(]RV#DXHNZ2T5AZQN,.^Z+I]MW*<&<E0PIQSY[KZV:$7EHRPXW[9OA(T7O
MQC^$,T]%;DNO 3Y/%KE!K8Y#IZFI4;T61(1%^7QD4O_-XQZ'ICTK((*ZC"M"
MF0(>91Q'AH_8<!@[Z&!CW9#@$:IF)+X+U\JZZC7_+AQWJ02J0YV>T,_)#(UC
ML[FQ\7P-N6UKA[B+);^^J+,:!#=C=NR7(\$ (9O*:?( ?TTK38D,]-[5Y$B2
MNBPHT@7 1BG_UW74V(=W[E!;BS ALJA-,\N&-M-NZ/Y(+%NO.G2&RVE@-6.W
M,?[,^NJ*OT0\>DE\=81K@Q059MF^.UY2:D@RH,Q;/D3-#3>B2R<MU4?.)OC)
M^<_)(?N?5&=15"DGHI98T#1/-@*\UA:$C^[54$=XR?-@I3#64L811D)6Q&I7
ME!AVGU>L2-X60)KZ5YH+HF>8HCWP.R&T*.(I]@4:7 !%E>-2CR31?]$:+!GJ
MB% ]N%,1ZBQ\E77"(!,[9I "!)DA%EB!\NJW07NF!G?"LXS)-?^M$D !*MWJ
M8!*$ZYMOB=ANY)]65QCT4XL< U*R9-_=I4LKN$S?DGVF[)ILF0RKA(!AG2AJ
MTW;J+MYK;*F_6=5CN_A,+RV6BF/JDFAUMH; +/B":0\0Q#!L@/F9U! Q:=GT
M>X<=(^XLZ6,U*&1R6<:HR(G:*986@O>,2AFD/8? >P(AGJ_1%G]61*/+K0W]
M41%GE3;<TZE7[E7CK1DREU[+E[)R)/>[KPEBVID%LP!K9N<=P'@NX*G!\R%&
M9?*@Q&\3DQ[Y8DL?&Z&.1Q6!@I(T#79%=-$WQ(K!0Y6N1NE+LQD?,:2,";6Z
MPF:T9J? X]I$H-H]78_**K+EBT.XT0+#*,7W*+RS#+)GAFOB0R]M70M.;ID=
M49VL5+!H#(1\7@YN"O(&J^>EWG?' -3;ZMX9+AA8'OHY2Q)L@K<M=;;!L3+5
M1]&I9O!F4Q.B9?0ZRA &65C""XCJZHJ/*MP3E4G !2'NU1'YDY8:J0,QB#6
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M-Z'WG.LZ3]"O)@XQ#R\?1$V_56FL2Y/_"KZ[F!(2&SRDS@XJP5_L[0B-'.F
M;[,P07G1A.\(FB[I.$H?^I1E.;<Q;^'<!8JT!)HJ&WTB-PDZ,!HP8>Y*/(IV
M(FZ5E+1U2 %I0T4,PS1&3YU!@:8:SHE@LQK?VZ27X,[/BE%>%,1NHP#KMBDM
MR 2;!0'S.MK")U6]S%I@:@5]RDF$D*NL,[A2*..;G.)D4FL ]58!5=>LM$_Q
MB^O9B_.6ZI#RZSR!$3F XN,.!0T=)&Q$B^JK!"@0P<#.6C"@7X)3V?JB%KE0
M0&V!B[/E&9NPDA:6!E_Y"<-BL[MLTI(M?_ERKO+]B&Y$R@[;/.(N4X;BRJ66
M03V1<3JH*XY$HM!88Y+GQJRPC5KL$2BUM*9&:6B_(@$=P+R[,M &1I<#99C&
MK"XCR3J7YW69()D>Z)8@=0K,4K#>KO*62RV%>_^YR7C;B[@TX<U@$JH#S)D*
M*&%$C.8[!_R)!6!)Q07;42B]?>N==XQ]O#W<>0@[,8.TQIN281P"J9BGC7)B
M72DD&^+P-"RQ7XU\&\:0?<D9]U-N/>-8A[AHFDSK:G98L"9#J-PF]1$%]O%<
MQ@A$>@7A[('0W32(%#)<G3[S*@LP"'^D)?^BQ-7Q](</6VZ+)WPZ0A>*:-ZB
MQGF;(@JE&7%E(MVWLN<=!TROUU:GZ[4%#MM5R5< =A66]HS3SCDI9B8GE'5)
M*/@S:.#&3=BW=22Q'=JIM_?^]_U7:_T7"0BOR7#3F#R_JYI-R=P/:5#8C-10
M3<6NU4S ("MT&5&^9I@W5'G@ZSBOW)5;W(P;(.XY0\\1 B*SS239)*=U;!CV
MZHBI/1A;5)-Y%7&0UL&HBME4W/F8VLA;%S!_0)BGGAE43!H 2Y_MTHO6"!(I
MJ[P>KOF"4 - 4!,G;=32,\AIKAY*$^/Z%RJL .$[]<W"7,6P($Z],^0I6($+
M,N7U5TNFA"6"EK%UVJ-;,\KOZVTM/>[ #R5/P69+])8QQ\R6W?K"S3K3P?IJ
M)]X+068XS+0-2C#&#)YGN_$-!B_U<A]EJ).8N#<D4L@A-XI,FQ,BPYD6@C8#
M-U5Z+0&]!E8+F"^Z[O8KC$?_9:KE#74*S R%LO3ZI:G(E$!IF3A42_F0%PB7
MPC9(X403Y0QM E;K/!<@P)6?"IV+Y87?+5BSNA4LB+H.=PL6ZN<$_,I.OSM/
M=&U0%57]$P1OFK5(TO'XM5'J7)[Y3^>]@#[;Y/_.>#QZYWPDKA^BT);B,7;^
M6:EH+CMV73W<T'7QS2^=_Q)OX^H613?R6JE%-<![ YOL:P*=Y<3T.A%13M?9
MZK7IAWPS&+PL*$-VJYN,#R?UX**F53\?1$F(O2E>0_6'^A$;-D*$Z5'0B!P\
M.-3@T^.>[UTW;1-TOENAI45L:[JNX_S%:0X,B#2G=HI##C\A&8)2%4YH=0!,
MQ:I'"LY65[3B[!@U^'CDL.<;$HCZAW_;:\?5R"  ]D;C\;$I L@E(G[UPI)V
M%&_VG)=,&!.,:H.$SVQ2Z%VC*V9+$B=,ADPCE)94*7OI*&G!%$@*@G[FK  [
M\;*1I#C4;8_*?BD,E%'(4 D9&JYMO';>WAL\7->E+&Y,^?^! FYO"#65,SU
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MW>X=5"^=G#"77@N^(U$%435+37ID$]+I3_>IVY[_"Q3_RPRBOYY8<)UE__W
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MJ:!&\=WI><Y&@VD[R'Q5!3J11H1&=D*U]U_F(;PH9A(L+'9YG0^[11#S[JT
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MNX/WO^Z_VOWT^E7R9O_=[KN]_=U?DX-/[A=O7[_[]!TF?9NSPV?60;[8.0=
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M)^T'@/>!^4CG+11.5^W5[4MK8L8ON]F"F;S.[5O.V,5 (ML;:+D!V1T9S&K
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M4 A*8*\T9K*<!9*P2/>Z.NZP?(P)?^J7T% 1C;\S# +Z3!*79W90QSXD?]6
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M%[^Z4W<W$5_F"#* -A=6E[J[&N;!.I:QV-<>!K?*%>H_[1;5<6Y$(I$]2V:
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M,=$]^,;3YM)PK86-G_#+[8)?;K-9-8L48>DV/:G&?[_F$[:<=K\ME%3VONK
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M41 D$Y]/D"^.?SX3GB?KZDO':X:U7P&+E32:]??1)W\]Z%3O%/2[GO32A[R
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MQK1@"9RP;/&X.A@\*>7GSNU;\Z;^H9:= &B#9#4KNH+_.?8 AX]<B0O1[N#
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M^"Y0QM/K>\*C:N$4#@V6[A,@^+=@%$NUZ#CB=P8E)QNM%CI%U,G^*<&TS;Z
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M._MF Z</"I&JEL E;/5+,OIE<^6%:YG-7< M:4FJ#I*YN4MPNE= A+"YB[C
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M8"EG=A@48VI@'75=8S%T]J9_?ZWG?ZL]+V?A3+U0*,TV]2Q.O1@R=0Y)/Y+
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MUM*:)7^);$K]$$UQ547@$>]B%PY6,0-_61IYE[6.0GY,O("0_YP7$,0-O8!
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M.[PO9NKE[*.'0>+.E)V/!%E)PD:)!X0A&F5F+#J-L/K%C@]I5J14GG[S8XT
M1@X7D<?P;GPQRF,V/ZA<7):.7N[$393'\(9YRY%',97-3#_+7@4\QHRW?TZ)
M#KZS1A6WI+147;5L]*6[4<#"EG8/*+=*_<Y)! )5&2+0R([JM9YOKDVS]GY2
MBO\Z3Z(J/-("8]@TN<!#C%5>'5@7$5U4Y4<4T9MZ/7W_]I:^*A764D3#M?JR
M1#2;G;U":64-0J>4;-##E%45#TZKE5I8BP\>KTR#W%P<MP9:HK5XBZO<X8QE
M#+Y')H(WO/PRH-CD)!NG*ATTF_F\]%#+_AVLJYB,J;U8A*10F([)N(P"G^/J
MX+J6_UM_.KV3'PN+9J[IO\7A@Y/ *<1_G,!,\;WT?J1:LF;@(6?(B4#:[PQ,
M>JPZ*"L/=W]^]B]MHHV21IPYNSQN/7HL.H@QQUS[(:;W@=[#N>9,&AS@:_/@
M_.U%[>:^_&"+%FSI'?&5>9:X-I8P'DVHK^62@X^K$IMZXL=O%6MW1P%9[%@6
M.UWY5_UQ9=A$$%/" 3_EA^WT(R5<2;HAW)B@<"Q4>)=$09\E)0!W]\?K$OB?
MX0%#Z<BVQ;_7PM-^!4L/*IU&Q[*%;)H=PNP+]TT0$5,"%<DT*A8J\0H$?BR$
M'P@F%@A89'>GQ0H'@DH10/UA_<)II7*S+U1@#!,5F]9/C9\=J:YL"FW3Z+*U
MP8=XK ITO+ED;]8T7HEA";Q$@RBIW1U<-@ZID88D]X<IX$[,J#N5%U_QN__W
M_Y; ?_E^P1^YN[RAGXC?OPGP@$SH@#@YIX*#+71?..F86#"2HK/Z2L^U6M(+
M'I=U:I:JJ)+9]][UC;+$]Q)6U*,;MD T(MM8!>0C!+Y(-2D93&)W3'YXYJ-.
M7=6P$*3=,=N&12R8CF'N[N#\G(_PY;Z2D>'GX<\>4Q@?_),;HG\*S%J=F%@V
MPI[$I6BJ1 ^F5)1F_* K 3\Z(+X&+:,!"VF#8  Q,/-L"3JQO:-  50M&^;V
M_Z16^_N1($NFV<>Z%W:\V)2Z1*@1HB-[VY+)ZFC4NJ#:N'+\5;#P#Y16+I5P
MD9P(K$ZG#N9D5+21U&.'CE/+4K;:;PG:[ZA#SZ:I.*+ H)@06N,T=##,Y-73
M#V.BC3L)PE"LJ=+H)L2PM-5I"8?@.,&W=54"T9!TN8G7(M@SKA[9W8'W-4)3
M;TZ:U?I((I-D?<<15Q[@956 G39V=+OPM,<]>JIAU1N'@=4;,XT('NZO)^OW
M0U'OWHB)N7&);XW1^@'PW&N_K&SI]\_6Q0VOZL#3 $-W"B]<I<VWAD1)-:J\
M0\O+W2H,B9;Q32W#6-Y>6,5^BQ(-??E0-1?33\(=8<R5*^$)?-RC'9 74[7[
M+#'J- T#M\G)?38/KJZN:H_'KP,UP9-[;[XG\\R7^4?H'KF--.OO3[?9Y]/B
M<6TITS[V9=AZ?\PCXUD]/.N*2WGW87@"/!*+'WNGK^VSNGVDE^.HE)ARJ#9K
M8Z!IE31B>JZ<O%,W X%YR#40%GC/-K_UKQ-BB_VW9@K_^S&\9O[9Z@J)9I:6
M-24Q;*U/47+FBTH_Q7H/:=HD$DKLYB\V)B%.]@1OREK\.7@G,!' ) K_3#:S
M(:4@"7>UW<YF4V;C";7KA*7]I91C03">8O#/^($6EEN97=I"O2++9D?2+.<C
MO/#)SN4&K=^7_=O?I>;AG?QE]@T45N+$ Y%<VBW?<Z;P/Y//(=F"OY%O9^8I
M@EN,QA-;4S 7N>IZR#$<*Q8ST[O0K[P.<S/8,AKKQ<&=_/0"JRUWXKC /?GH
M/1<!KGS+AV ^B,DIKTPFQB+RF6WGH=16;4F[,"SXT33[SD&4STS>DEOY5SZG
M7/[-SF$FYX $<);$YT9OX['CLF,!_U+\+A9S27LN,XI8&!V7;0K%5+D\O=_E
MJMS!)1(U 4.6RZ\O$.\2*!N'KDOE\A\5+,53N(5)"O>6-#J:9!MF/^@$SZ=V
M<_JQ<?E;NU4:8HS12=AJ+HAD$>'V^F'-!'4RN9:M77/3BQ=7I@ B=H+)IW'0
M4D;,? _IK[8A*FQ^R?C@@I X&1-TAA>V#D'ZN#Q;\FBH$X:N'!"=U%7;"JZ@
MQG88/J5-WG_7=>GRZ=PH+==79EWG_#-;,SF+@<[+]Z73Q0_C\2V)_DFXW9GI
M^:,M$^)+$Y6W,C^%W D:P&(Q"0OHCTBN62VRWIB4\\F4?M[GL_=_I=O7)00?
M5UZ)M-Z@M:^K%:1P$BW=!!52Q0AIV_7<CXN1,0%+DBFFRL7IO<H_$C7CL+^Y
M5#&WJ39A1JHEJ-G%7$HL+RI\0<K]8%)X<Z[?F(9,+"NX XE/Y=_?M9^NLT^Y
MYI6TG-!E8B6.>ST&%J.N ?KO'./,Y[-,8=BR#5 FE<W/?F-WS?MC;!(S$S"#
MV52Y,-[.>\O3Q'D: ^\*J>P<<$5;WLW/NR1=@E2AF,A&#'(3LI/<A%,3W".?
M,V#VCQ](_OF^KB<9_TWT .B4A*'"4C;73R2OE 9+-_F95+FT;N#U'Y!G25CV
M;"I?F!V,:\NZB*R+Y80KE<_-WBAIRZ)I+$K23A=2A7(B45"R%SBFUKBL4R7-
M=C:;,IL9O$M?*<$YQ51"-_L< 99P!YN&IA&E4L>6+I*-U4]7C@>JJ-5!\[U4
M/OYS;1Z<+>,0PIL?MMVXZ]22)OW7R*IO-BHN_Y@\+\YS0OMM74JBBOEU+8E:
MA8AL)0(DHKB81(14(3G= =SN 0BNH\N4*0QV3B'8I$RM:4X/V2-$8I-5Y\"Z
MTC) _PTDAB[GQ>OUSJ_"@]S-W)T6UR!Y7Y'E3JO#0/X4WP+^)_FFO\E.:\B^
M)'UB_1,3<Y/7XHA/!Y^- WO&U@_[VY;'"_,XEBQ!"*OSL65YMIR>G]-Q<A1&
MW;)TA2R--0D1IJ CU$/.QN,@=R4=$-"YE!NZL3(4LUW_>A!SE<?>K9KDK94(
M!P?^SIW^MF\?4*I'PX$@-BT_*"P4MG[$$IB6P"G"UBU(DG&Q;*ZBN.51$CQ*
M\A A0;.]/3S8SF9#9C,E-09[])"6?/IK=1$.W@6F[DFZ3/RY+^LY?W2=&:C:
M<XP>9X3>9Q.=4'?*@COG#ZAG:3P5E64KRVAE$!=Q:R^7R<<DLU98Y+)U?Y;"
MSEB3C;E4*1M;;=*6;2M+/Q52I73<?%QI(].M=[N=38+>;6ZV]A,^S[:MO%X<
M%GZ]ML]KJW9MAY 6*89G4&EV2K@B4R]K)0_:.-\H,]8(E'/3:@0V#NQR.72;
M6FVSI5L@W0I;NLU%MZFU/(O@C6X]E@VPRMO9S.:Q'$5J%S(>E/A=EU,E38Y^
M=^3+.&MW%W==#IN2WB!8X=MU,W22,W^*IX<(>WTBF0+!>H!-5Y)S-D<8Y^W2
M6RVF\G-<=/W@)F^IW$RBE=<<]\ZW+%V<I;'LQW)I]@/,+?,68%Z"A]'@?,Z1
MPYO%,?X?A8"D:)#._S80)];YA<-:_F\(+G8(L;4B5@=WUGGAN?Q2*;U[^9KX
MESHRIP2).O*F)+%RC^MU(B/*L%>=*=EDN$)S(F#N22!@[NS#5@<]^] TBT_7
MK9_91;F8) YNKCI(M\Z>2TK^NM*H<2!<<VAEB$7H0TY'E-P.WLF0;.KE(IZS
MC+\_[-_M"W6B4.!GRY;L#O8#9O#B'/\](_X7X<-]HW$T:.%KC351I$#O#(-<
M-DR36&U#1^W!AJ!XY"X,N@M4[4#+,XQ=_/9R4':3!Y9>&0)N.?U?9[%[J)T1
MDYE",B\.%\G0Z[X+88%<X!E<C#N@YM*Z]B-B+F?LV&GR&I8RW2" P>@(@RM;
MS(EALIGCAGW&"/D8(^0P:->-94_4U-Y"FR5!!31,\6@ F*MBPOC4 S9'(5[T
MS66LB^)[1M\!:S/OK2BMG2BQ- Q;"P,#WLK55JX67Y>'M_PQY.E#6>UUF=)$
M+.QUF>0:TFT-I[1EY8>9TI:5'V9*6U9^F"EM6?EAIK1E9;).^)Q5<3S#G2T$
MX&"'UOW$O=X;D^ M138Y/-H5_K4ZWDG42:Y<'9RV[M+MF^Y=6FI^^?%5^@8T
MZK3#<J(^<.\E+2%8U*,?A4^$(X]OLO\9)9A#XW+IV'?:%]+/!3XX?B>MMLW^
MS@O39$Q0I\6T6*WB3V(F"S^-#U7IV$W#5.U^Y5VUJE7G=JI[!%^M_SH];E<'
M9X-3Y<]%6NR6M2^"K=JX9BX@ AM,^(HR\FUR?B"0O*-2'E3WNA!]IUR>CT;7
M+Q,.@B=6B"$S3^#%Z72ZG"[$>D,IFRJ5@FK'YMI^R<KXM\U0"DO:\1.-W+*V
M191)K$A:%IK:UHZ,VY'R:NS(:&FE8TZ>#N]KUZ>J?M"5M^8D@CD9+U$=LBJE
M6*U**A>(!KR&:F)K5+9&96M45F94Q#B-"K<,'2G[\+=F/!SU2EO+,*7BU&\#
MQ/0VLECK';TU FLA+?'F\D;O[R5-P^6*[/+E-)+"7YWH+IT@'YW?6XY^-(YN
M=_#GXO>6HQ^-H]L=_+GX_=DXNKQNTLDLYH3=7^17E&"'^BXFVH)WJQ&O(WY8
M45[LR-S]F+>B.V $K-B<MG<.$8=NT\9\LC[094O[6SCZ\UM^C9CJ6L/DU7RD
MG/LP/<9FR:FR& 1/O'05-9J_^CB;='7V9O@.>3E=\NF$*%?EIVH"5:DJ[6KG
MIF.2^!2"65.?B[U?3[\SGD+@\YBFZ(6O;6)B1=RW:=TZ8EA^LKOW_.K$W;Y[
M&=^V16)CD_/]H/8L7,:6OGO_^V%W[P03>[+6)G:LZ&!P<7MTHAW\^7MU7=]:
MVMGJ#&)L9R\&]<3:FML/:&ZSZVMNQY5#Z4:WFM>EVY*17SO;.>=^W)K0]=B1
M$TQH>@4F=)!_*S4?GT].*^+6#(8556PCS W:8.MC\HZ6;?(&9L4X>*U<9Z_3
MJ[9;<VR@3;90,=:++&^/(%=)0,XX)>B$=J>K^Q(-_(^?3&UXQMF_F0\[IDET
M_^8@%5VY,(#?8T8H[@SQR>_KBUJG::CV)L2MLU!J#1+ Y>($%;,USA_)..=G
M-,Y#LNM^CU@)Y7V/1%*YN;THY(L%=YO3*417U?'F?\/6O]+$;W&-78*/OVV#
MSU>7;AS'TS=:+RV_/C\U7XRH5\D^IHU,,G4KIK-;4_DY3.7!&IK*\4U_V6VF
M2;91D<NQQ+[QV+MDDK5;L[<>9N\P?K,W(/J?TENA_?9TG_U$MBNI?*N82A>W
M=NJ3V*GCI=FIP>WA6>/HX*K0U%]796SBS[ 6]XMK:U8VO4+W]O^D5OO[D9=M
ME2G0.<,&D9D6I=![GTQ/>,:T$.GF.,.'MVZ)!;22FW%G5Y_OWF\?E.?WXNL&
MU]^.DVD-4JN%T@3ELK7#'\D.YV:TPT';.I&DZIE]DK\_-$]5W=W<7"]/5,GQ
M)E*7O3NG&/W<_H2>#MM8<FGFK[0R\S>>2GEI7ST]2X_OA4KY\UK!)).GF>TQ
MXR>QA;,>,R9K"\>W>J-^^'I1J;PJSXUU,&[)Y$O3VWSI6MBX:!TGH]NX0>>H
M]Z3\.<ZGF\IG,51)94J+Z6U\]DEL4G$)-FEP=)4YN_A[TW@^*R[?L,2?&\WO
M3[BIM+FYT;%F94Q*SUMM6*, G"(.;UPT9#3.@H:]_XFFME1=0A1E5:>HQ@CS
M1MDEN/MW$G[].(G\8.I#IB,[W71<JCIU><X1 X)8O'4B/X.*.U'8R/TUVN>G
M)_VW^B3;PM?C9_R>1>0]]7VOJ2H*@6_"^C+J>\W4TN6<B$^48%K1^V(,4VPQ
M<D]01DN=QV1+/E-;A^2%8MRG+N;2Q<,_M8KR7HSL=TR2BNSL4I&T/$S_XNJD
M(D%5,;A^.^DW]:-ZX2^9Q-KY',&)LUJ%3QA\/7<:S[\EKHP6]&>F<'^J:W-S
M?=3I68>&?5N*P[59)MNGW;'9S\P?!/PWR9/:V!WQ:[M)/N]A:X2KINAQP["J
MWB#P(;$HP>)VHXXE]:=T]_.T:)!U".#GCM_'"+7,$]=AI9W/KT,<OVV;MZ;%
MN5X@S3=T(B>MA;-^PU"+?PXE[Y8:?9__+'4OSK3 $G;=J/$<]YJ<='-N;7,%
M'W\3!I?G+MW(C8>%YSW#>E)*V=YM<QULW?S)Z@6-7:('J]LD]B>Q>^GUL7OC
M6[W;J;W^K)RWZUTEWN3W\K;;E$A1W"]M;=P:V+A*_#9N<'!Y6*ATM)/#YZAX
M2Q\@*%LXAS9BB"9LCVT4]N&L4>)1V.#O6^OL[<FX/FLVEATYQ9!G# ^5)B0<
M/\ZQ:MCDQ^&NQ'8".^2P*8$>9+-1=:$K:1UV2BMIFM&3='FT*;SS[J7,;J+Z
M"$3R@VD(]*QY%;AI,Y4S,<J?ZT>D3DS8;NA$6A:QK4>'!Q6'!;$W"GH]%/\8
M9VG8GHN@)H;0>CVL_ SD75U"-I?*BY%Q$Z?Q(&!'KA \<([9?GK]L1:;+;:*
ML(3RQYF_%Q>U>KUHG'EM2=EF#S%@B>65UR.EG,WL3SC6B6J[DQ7WT2!\ZT1$
M<2(B5*LLVXD(R&?)Q5S9N"V]WD9MJ+3U)>+-=X^X%(7(=1I;A^*CZY*UV'$C
M#L6LW?Z3<2C&%=G]G=ZH':=E8I96ZB?$E)0/=1?$F?,J6W=AC;?X3/G^>-R%
MP<GC1:[=?U<&^LO6YD^V^3&?'>12Y5+D"\);^_[1-_]:[*X1^SXK>-XL]GT@
M=0_(2??.-,[*2S32"9YR9/,S-]E8L3G>D"+N3W:RN?JS^'4";?[X_-YR]*-Q
M=+N#/Q>_MQS]:!S=[N#/Q>_/QM&55#UE]O-)!/KWABUI;#IMT^BJ%L:/$-D)
M*MNU-O98CAB )33%V7,1="*"8G1J&DDV))P 52K.VFJ[*9GD0+*(<FBT\&(S
M_?3X72:6!0\X@)TM$*?8$=.L7W].M?3#W?U?:9%$9CC=EYS+C)O>JZN,B@S^
M'8$A@?MUW=)U$:;\N53,HB1<LT--=N6@ TR];A.3[KFD*J0.7@=_M)\W=S>_
M55>K47LWP=0MVL@X:'DK;5X\>V/'%:B)J >=GW#[3_ P9BU)7+J',5Y<\%1\
M/^AW[TM_SAM;1V-A1R.!LJFMO_'9%<Y&^1O356#2_L:XCKMM=3)%\?[N0BE&
M=COF/,1=W-M(N,HJ/7-/T*WWL4[*8(+W,3/D93S>QZ!.LL>]5KG]]'NAHJM/
MZ4+$?8-[ZRQ\<OVP4<Y")2%G84!DJ:A?'N:U@3R#Q5^&P8^__^4&YA/X><W_
M; ED#GZ"G]O.:UJ2V5!A!FE/EMOL*_3;@DPTC2_@__N2_D)_AZ%EY_>A8?9L
MHPU#?1?XK\Z*T[C>GJK839Q@^K^PU/##(QACF#@OX*FI]?X7>N;D4I4/EU;U
M\=;3SM_V,WE5#Z>TLS-.T@?5P?.+WNT]U<E-3_L2"P^^2J,]GH(.N]S%C4Q)
MA"G],6YZQ];I[?-K/IXIX8ZK&X:M&S:AKSKAOZ33Z7*Q_$5X;VG_:!*RENA[
M#W=??MPWB>#\PW3O6O_3!C\(8=JP]SQ0!G7.U<VE(.F*P!Q]UIH>G G\JD5T
M;$R/=T2!O/ E8(JA$Z$F6:I%'U(, <@S[:T;0!B3U#50IVX_?M2W1AT4LDU,
M4*\@>GU8MH95[&SEMBF!ET75F_5=L-J@'NNX2[5^2K!!*'1BLP[_)CAJ#1V$
M3!%J?4IM&%JU+1B[2RR[A0AYJNXG_[[@EZJA?S: DD"MFJK#:OVRYM#7HK29
MB\@IM(Y:!Q4M4I%V<R]^M]C30$CX80.HXV.SNP(_H?:I[71TT(]AUXX:JD3-
M%&I$I@RGZ4[NN\F&IDEM"S2H\Y-KR$KI_[J&#JT*VIL\6J,(I1$!%1!3J[GQ
M4(:8WX6P$9?DU-)O]PCZJOAN+<K]D55.W2,T<! __O^^%")?1PI8[&K6]6_M
M!RB%?_]7F_LRP'KP@(^OJ%9;DV!L\*(# LD9)P^?0XQ14S75AB$9/,;(@D9>
MN,#Z@E\V?Y745A5L5<&LJN#$,#E*/'@;%'Z8Z JX)$=$IDEL(2NF! A\16&K
M,3Z%QN N2;[\WZ5M?B><3_B-$2I%ES23296^GE.XFDFLBA!;(0@2@L(G$()I
M"GK"Q#9:^<YXG77E]>TW+/AV&GNRXT&,Q,.2D]M#G4F'OIE(O;2/WTFKS4&Z
M?$>YHGMN(LY?U'E^<OS8:%BY1SF_-@>\<^-$^ D5>(PCNG4;8IPUYB'0$&(F
M52QFHQ[JKN!<9YTW[2>\=[469_:SADHADPR]K?7AS/48H/'V^N-F;\/MA=8M
M1Y<;RWPPC3A' !,_1TX(^+#.75P\+_Q:8V5]WP3)QO-YNV,;9I^"S'^R_3@3
M**O[,8<'=HHC;4[@.X>20X55<8<I^FLF>WO1?ZD5L^N,53<?L=8@5,FD"J4%
M@)B3"TD^^EY<ABR/%F[.>I5^ZEX?K>B,9<L?*JI]7JEUTKV,6P7*YS%-GR]Z
MZW2FY2>[>Z?!IXLSUX\NK5!T=C_HLX:,RU,_*,(DP"=*T0H\HR[4?3N,__&3
M:>3@[.QAQS1!H?@T :GHRH4!_!XS]W$[/S?%GS^S=O[AOEE?"^=G%EJL@6]3
M*D?.P6X]F\WV;&:%Z!V27?=[)."22BP;^?A*Z3;ZNGAR4'-=&CJ%Z,HX7M<F
M;/TK]6F*'\FE^6">RUJD=F[_3VJUOQ]Y;HQ,>VT+=9!306;&B=:Q?3*-ZWDN
MA6@8S:Q%^2VQ@%9R,W:W17D_/NZ?Y+OOZ^&V1";$&O@LN>($\+6MS_*1?);"
MW, &WL9-Q%MYO+8?M?<'8F6]?E]<]4[4NO&Z*,O>GE.<D^Q^\>,X)Y\UWQ*[
M'J& YI],5WK>1BZ:MV'@7?L&@0^)@T$?K\-Q=-@3GYYK!_>WRKH['&.T6 .?
M0RQL\R2?Q.>8'WV9;]Q$'([R6\^ZEO2GGXV\ZW#0]R7E42QAYTUQ)\3]"7MN
MT]R)#^8UQ%*'GPB<' ,1=(KP@\#)HU_26X=:_(^.=!F+=C0&-Y7^Y=&1=%S[
MQ/B7";E$HW"8&3$W;]W^:N$NMSM\,^ L9ZW!F01G&8MZJ8N9/U?E]]N+0Z^5
M--NL(2;&[Y0E#YF9F$,6BJ"97;@SVW(1-!>^X[[-"6V+_-<[C%VC(O\M1S\:
M1[?Q[AK?.]_BJBTTPPE7T*=##,72=SP6'S7;OOW]7B"'9G9*"/RYNI$O)2:.
MC&2R%K>8M]M_8]N*3P="B-96/)ZDV^-+]_CU_?A&+J\?YMFR#BDVKT?YIVYB
MX.]XR]EVU6G!T/*/?]ON1BM5BM6!>:5G_MR<&;^SI=&FMN+TIK9N%UWX:CI!
M?=4>Z=X[YPPY?U4=Z&<[[=SCG/9]D^SN1.P9KNJTVR)\6R:T23-K/#S<2ERR
M!+4N$$EN"O !L%^HJQI\;I&V1.^YF<3NF+KU?7<'QY=D&70Y#.9TU59UMOU1
M\R@&S :[CT?IW>WO)"W "IPVTZS7]FC/ZMT=VK2:+XDMQ.U@'?4U; GNB^)F
M_E8\?]R!D0(!#9)&%"N4-E>P@*MMJ4],&$[A)S6TYD^B9S7T>?!>J4Y2>?=Q
MR;9-M=:QX5>K Q(+PUU=7] _.56#LF2:_3V0R9YD*L!QD =LD.^\C$H_BJC4
ME52-BI%M@-#4X9T@6H9%4()0Q@Q:%> \-R*5BF1+@FKY]A%N0M#',HAI!S=8
MQVS#8#@!7>M/%;4([;U7+&HQS##**%]^C$X$K MYQS;SY,>__\_>GG"B$DWY
M1[B1&F#R[LA;AX#(_2.4B]\%/-_#90E[>XYY5M3N9"?4.YOQ X(4T"2.0((4
MJ"<YTM^=XX>$]7(-0A4)8<#)GG]YSL*^"_?]-GRS8L).D+\+5^#<L<5?&;C,
M3-;_U/^<Q_!/2,%__P<$"*!%&P;8JYE$>MVK$1!=&%/2>E+?FI,,=&G^1O=#
M+_;/$*?.9N=C[&HE;D-U[:6D RT1K0+L&CH"Z N@YO)4&Z@@%7U_JB%U4,;T
M%])5%2HDH/F(98.#CM@J=5"I];HJJUAC7>_8J,5 ^]%Q>.C14S5-J!&A070,
M&E!?&T+'!@T] *5/<20@R,&JPR"-OB_0! 2";=A-T)W$/?!+H2('M>LT@V8,
MX1VA,W3R&(# UV!B,(6 D\+=G2:,42-$I_ >)O:6KA%9ZH!"#[(N30D(0;_.
M24?7 FO3X!>8'_ (T2 RZ>\MV!U@B%Z)UF>?@_6@?Q*_\T=@&R$%E'UTAC?-
MI1ARWB/#4A&(Y-J8K#4[Y,M(Q'G7:<$:^M=U'EKJ#<3V.T2[[)CE>WC'@6;(
MKU^&PH6ROSIFEF&J _&].%#KOYJE>WG1*"/QC3N<C2@=Y*N#V[,S_>6M99\4
MRU]^5)C;$KP;4D*/@/0J[L5-ZA>UVX:)&P(==WK9D][N= C' %^^<H$&CXG+
M[S?ZL&^@W1WVM.M,L>L7PSY5H.L4K#!P^*&TA831"NY9F [UY8V.!5^ROOTS
M&NQOS 9*",UE'*8E(L++K&@N[K+F04KXXG]ZYC*=@'>,.U$AKW"V3ZY<F@<#
MV)=_.[7T[.NO\[.?S5R\T JK(\['>(7'8C$>F.?7IW[^]\O1L9Q.DM/3JG7&
M1AQ^>G9(A?4"3]ET0)0XYX^6'.?KL^8.T$EFE@*O )%)E.=;&9Q1!C/K*X,4
MA&M]16W+VOGGSRP<FS/:N77F\_JIE.4+TD:O:$NQ!63>=673Q[X4Q]@%E?!4
MQUVG]D)D^]XX?F^K[,"^JI[SXJ=!_[@E-RY/>H^B]&7R_IJS*,]!ZT( T21/
MV&],(MP?_JRP"7P%P@B''7X8]-.H64(%S_O G<JDQ>(W <BE&EX& \^"AG(5
M*:%&((H6"!(-$R&9=#8=HB57A4+D QE::GG>R.LS_UUI$=MB6V&X=*5B7=>]
M9&4BA6JX428TZ0B1K!568&VE^V-+]VBR(P8ASY13Z7+D%E&K$_(@*WLXGY6]
M,NS)AK90>WTC#^3.N,[.86BC]N1-//"Y,2R;S0*-;00SVE/MIJ ;PQ\+6'9C
M4Q)M;XINUDW1N+15\(99MCG.EE/Y]-P@:-O+U-LMLI9;) &;7BJD<F)D$(YU
MV"E!UOUH/NONL^,7E[]^=9MF\5>EEDS O();;+[[:Z&6?'M_9=8(8N575^+2
M0\LVROEBJEB8<*ECY;<YMC>ZMCMB%398%//@KI8V:V=LNV!L>R:L;,E;CGXL
MC@;Y])E)/CW%$&&H*;Y<W/$@5SO_([:-YG)\^(2@L@+R;6PJT\^N/L[&"',V
MULF3\*1PV;YTH9#*1^\6N-7/6S%,TH'-IE.Y;'E-I7'KJ&[=FJTBW'(T,4>U
M,,E1A1^<SSA&)2+*F%UB572E(LMF![2KWX<5GQKV_5^Y^9S9/!_604KV ?:P
M]P==&QLKQ8*?P5H5MCMHU?Y$))E=>H55*E\JK*F+L97239;2)"JE(A]SK(']
MRE2)<T-N0F@A^HQ4][15ZI2R]O-A+L&BIUC;T S?8IZ>6]D:H^5N<](GUJ3(
M5ER^O2D7UP*::FMO-D\0$S IN52Y] %3+!,BENT>6O\]M$ZQ^9:C'XVC0=YJ
M>E*VQ?F =8+P>:R_>@\/S[=G9Z^#\H9XK*SA+_-8CP63:-A>B\W ;5_E==)Q
MNEA]I6U^ZMC_1X.UT>Z>+>P$-)#07GP;Z:LE>$V$AAII2C6C2U)"3QIM;[_=
M84N/<X=E>@5N<#GRO;:MPM^*XW*<X?S6%=[NH_7:1^OD.&TY^M$X&F,5PS)6
MP%/QJ.E!=<LP5TG5'>Q@UVEEW6@-?>MEQB^\5ZJV'I*[9>>'8N>,>!_EZD _
MT#OE9_EW^C6_Q?M8>-H/,+*YNX,0'KJM]06B@_]+%.%A_VZ?*E6--%1+DW@;
M;0T[ZC::++8WB61C>W"*:.#!A7C=NS$)P!OV]HED6C ZQ0EA+>'=M,'N#LL;
MB,64@%VVV0 :S :!%&0*X*ND(KZ"'KSI^!:I;A-S-#>![VA)?0%1$["W-N\N
MKNSN>+V&2^G_\B4-]QK6.S@I1&I0+3XM.I9)WCHJK"<(E0)&;<-7G N30\V*
M8>Z\K3&=^NZ.0JPV&%=G>701K+<R&K[Q,5P4"!RJ;:KP)3K2YT4>X8KK!4)%
MM=X/<E]Z#/LH:1@=P^E7;^,&L9N2S3!P./@',@\!2T!@,>)5]0YM=NW(M2M[
M3-Y3X/1TL(4\%W_:)W^X5<9HIVQX_9#XIK !OZ3W<2@0>9R$14:&I:?59%\X
M,WH$_,'4Z$Q1UG'+Z$YO;FQ^SP;B([BS&'V]L^6-CAGX4@'HTY5 @CL68I\0
MBY',I'NL;AHM>CL!/C2I^H%?2D-[8KP=.4*C>&J"OQ[V?VE?.)GPD$^UU/EV
MHD^Q3N:<V(I!-9-#K[N0CN@X!;Z\H"7D,OL"5;\@12Q7DBUE' $YQUZ..J9L
M@14H'8>&0J%CQ'*I0/$,)%"]"NI%F"8^@5]@7 :1 K7 ^@#L[G3P%0U$3I)<
MS &C!XNTFFJ;J[&4 SC@J5Z%U"D2#;Y):*"J1[0:Q"?(IP4.#H=0&VU#U1TE
M+7RM]2EX OF&&DFUD0"@&VW0M^X;C2ZBY" ="-FC]&7M89BX^::.<Q*+W^']
M##?,D3@8EJ(V\7>.TYV2Y.KZ(C4&UN/M$CJ(8=G.*"/BRD6=-J ARKYPX7:B
M8=M TBR#9L7IK'#BS)!(#D840_?Q39,6+_KPA2A=36)U-)9AUX51IL2NQ6?3
MD5N=/^,BKSO@R8"[!)O6ZM0L55$E$_0M>@6@!> AQ$11)NQ"9Q-B,R1^?M(B
M$O5E0$)\2N)KX]NHGMC=F:XHE ZM1:):O:F"'GOK2"9N:]KO$(%0AF623<!L
M..A4H_.E=FAWQV+=1^B6"H"%& %W@.T"%&#.E*_!4PJ9!/:1FC8+&*K655FB
M+BE,"'8-?\&P+J!&MN5'V!K>QN@64>7BP$(XZQ_;:T!(1_DQ1<1GB K'FZ4
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M 7YUZJ!J*,0-[@F+P!#,$3'02#+T#PJ_T<,88?+(AML?>$5N_G+R16N?YJI
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M"ZEB,>^7,G:J-38_%D[H/*T0FC6K6/X(3,4*)>+"S# X!<O"'[$*A\@=F_A
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MA9IG$&4':OY_.JS[G#KLZ /KL/RIR&ZV-5OGCUA^ZJ9>+<__ 5!+ P04
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M5RKKJ<Q<Q,N-?W0\?^8'TOS<^AM02P,$%     @ "6U_5AB..V4>"   8CH
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M\-"9<L\*)"Q@2E$Y-2B@W B60NA\H6$%YT) !/W&Z.&Q(RP0<!GD(RB60!L
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M*_^+T=*S;,@,(LU#G@FI9K&)/@'MCD8\RQA[Q3[U!40_>#WD !(;,3 .05G
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MU->NT5RCHJ*AHZ&AO7XE5-3T#'37Z?_Y_<^?_#/\GU%7W^O7J*Y=_[\6XG<
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MW5,-&SI;]CUJ= C<57K!O]M*?,"I#M9!F.CZ_L/BQ>46T(P&R(G 6T?4LZ%
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MLJ0%,,A%^EO[])OR(+='V7C'HY+PA^.P"X9KNRKAG*,9\5(%23*PK,>7BRG
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M$E-T3\.QDD/[ >8MX60V6_'2@8]#:H;/L(*^^5+PPR*?DF<ZY7NI1<#59"*
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M+$Z/>WD8$';NT<UR@1KU%N]J:))%M\ORH&417^+76K'SPZ/W/?Z"WI@!YX@
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M^&H#I!$!SM*4X1+HF=20RN!%VVVKYS6Y"#795S\%4EBUNF\Q??  $_@\+[/
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M$9.6C(0!-+ /BM-Q\9(VB]U3^<4KKK7F^O$\%>P^,\6XL'4L?Y@BJ2I[ZA[
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M^*FB0E^6 //=6RBSQ3"R@7!^K.H54=GCC2[;NAAPNP,@AL():12>--!VN\&
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M921P;NDZ\$JJI]JT[:^+#U+CU!WM1D/EP\%B(R> BFU_ 94=)FWWT6=UKF*
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M#_+N?V]'NOY>8@=1?KN#&G-0=@(X"\F'44]]]<59FO: EW6/TW-'.>[0LT$
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M#K9^..-F7*>GOF;FU9FP$,OMBT&<I^B.52RO'\EU?Y9$4$KI]Q=C.+)>F4_
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MI$(;8"&42<^%"08CK#:I- TO,>&;H/([X_CV":"!6EYXO$8]?"3RY@* &Q"
M?GL"<$*Q])+TR4>\">V'0A17_ 5LG5>+]=C2+17$E.V+Z/W6E(->9V/;[KH2
M>]EK.;$@9Z'_#4)(RCXA W<!)C[FS\0AZWM=\\'; ]5K#;@K2UB=(?36UJ*9
MQE+@8K9O+#79:NC;N%+7QE;N$\^M!QTBJGH/F] I8'':=0S%O*1\TWWO2\8Q
M[_( PK^1&UXU&I5$,6-1R545-W^)8U TEOFA[MU77;D^71S0F7Y;$]9QZM02
M*Y,4_H6!\G8&X8Y<'@H..O\<P1.'PG4<CNTG ,%2C&*>D=>F4X/A]<C+-PU^
M=M0H0EXI]MIE-*<>+7UU2ENV4$BVO_Y56%R*7PWI;<,>(?F<#%%%O$1>GS9*
M$,A+GC04W[7K\$#4^V:%@7JTSI DF$&MFE6V]F-F@EJU_3KKCF'P85RY5QIZ
MQ<$UL_YPQ5BQG+S7"P\.ZFBV=A @R<Z\;EX_=^M6C,J'>,:G(=:C87#EW/X+
M<,G/Q,W[_)F\ZZ$-:'"'YZ+WE-*ZADEC2L2/QQT>DX:B#P2BBI0S%U%3&>WS
MK#1ASO<_H&PS[@\6N"WO'K[QF]&WV27BW).O%2WC\F7SBCU]4\7%=%)^]QDH
M%XY)C]A4="9:1Q4^_Y99M=5OV7"<Y0^\#).K)(F? +8((]>,9(EZG?UZI;GT
M2WB"FA]PRMNPO#;9,[%8\D./_I^.[S^PC)0.0I@B'IN;N_;J!.#I/CYP^*!Q
MZ._$<NGP2AAHX 1P:C(F16W&,;YY:[]L_XQYZ7R9>?9@F:))5RYYC';9+HB<
MY# BM>OV]>[F86C(1I@G5;RMA!(IJV\VLN69&S K6V](+>R'6>>NP(%QS5/B
M)9_4)U]F(.; 587Y$X:YJQ^F%=.N?7M@V+5@&;JJAHXHCBVVO/$H96B"GMCL
M^EA+9MF6Q>3NPS&KM9[IU9O,P>BV,.^-D)?9<!+?([<BK<M[S,\7N\*/06\&
M]KPICW$\E?8RR%NS$E3+WYOED Q449MX3H-$U;+XQ:W^;W"F($WZ-4@D+SA=
M3SQQ1JNCP6!>T6U>$ACAKV3N  T,=!MKOLSZP/8TZ:6N_T_ ]D5Q8OG=YSGA
M FM3%XH*)SP"IB(JVH4P2)CNGP]Y!_P'_..+JHG@RZ?E]C,EX\<+52Q@U&]D
MJ#1]:5#6&SQ?:+IF"!16%]5&&AUCT&<INR> <PL4?])N1PPAM*ST13IY<VAF
M5>/]=$G7":#@XT[)?AL,R4[<MVMJ+A4T-+37K"ZM]\P_?CB867O?J-!?%OG'
MD2D(U(H5'14T)! Y/_[HNC3RTN92*Y=*DN#;-]PL&R NJM[6L$,C<7^\[:+W
M]A:^=<!QDO5O+S*#>2/$A>1H?>J\]$X "Z@CQ]_JE2CV(./;0_O1I6(G *,T
M\Y'T.8K1-R_7#[226M\:@018&\$X0>?NP./IPDB,<KY-9\7YL8'[X^6X^>D;
MRX! 22*ZMVP$6R)?-/+.4F@_T/2@JA+6*S[4I>YHC[P;^[5@W7>.&03RA,[.
M&\_W0]WK>E>F J-@[ 1C:*9$2X<11XK8J/.74IDM+]&FY\O_I@PV;NIS&),C
MCK.K9)T(+/Q!R-]S/"-*&3&)7P2&;'^J^FXLOHKWK5FW=9 ;S3>1UJRC/?3)
M>=(<.^6:]0X%K:F%A.BYMM\F,\S5%9>H#+>?6E%H;>IB*QBF9S V>_^Y. /&
MC5*191+R!53D@+ LDMSXNRT>B)8.\[,>;S"V=.[K==9+*)N)&7GW+VXC;W0\
MMURADB51([$(SV<<AP ^";HU-^6D='QVJRU_IZ0CX%EBXQW^(4>:-Y$E;MKN
MU$UW6(WMVUMP$WB?9^.?\,X-\A7S7-]'V%ENFOU^%10YN_EM^._S&S9JI83+
M@T+KN\"'4]^?P)1BQV^;4=)LI^V6ER_^<;JM688N;7;EYN7(=&TP$1OQP]F7
MSAUAZU'J<;WK!"EIB_I1S2*EO<#J3*#EZ(N7CVFV1%-<_FJ%S<P,96>3:\.J
M7J4TZL!3&-!9>";T-6_]J7%?9<D)\G%YCY_MC_0/9<HF2[++C"D8F#(8G)$6
M7=960\N<OKFIIT7KDVE[][)@TP/V7J\FAW.Z?[_3#[1!^1150BA0U+HJJGU.
MXE=PR9=/<\TNU4W\BZ( P:_6G<M/[&5D<^^:3%N';@;2?HS-^P>$@:V16=)7
M\^^E5@\/!FH_-$AKM\X2&RG9EL,P$&JSM)NYGS@GPQ4KE^>S"752\GZ>?*TA
MC\9/ ->KNF6#"UYLR:HD>_)_.0%8!*F#AL7B"14T9N>"!&^35$AD2+J^S 5@
MC<W,KZP[P[Y7EAF_0_+]O(O6T07ZT&_307>9>?LVVCA*L5H-AX>'<:3,PQ7;
M$MC?HE"5Q1KZV0;TMGQ*<EB =NB\X^DD?.,')7%3@*T'4S_3=0]:<6S!EZT?
M59JL0STP8K8AH,37+#9'+'BW]D/X+1AH!X'G&*GT/??QSP%[LY-=<D(XD'!D
MW0N6'Y&#R:65($I;B%MS9%:1!-GSS1Y);WMF_*;41!H;R+SC"+S\\*8,D'"3
M!)F2C'&N3AP1RKAU!K/X]NTJ,H2DJ"7F,10^-$8RI,Y'I,EW02A\0YD9CN.'
MJ!]8]G)Z+Q&;Z7T"T/+,->NZ77+YI<+AS1\(OS.FZ%6*?JHT*'O'S/I53JQT
M^/_Y#_VC_<:0X99J9M_@6RUL!]J&>PQUV94I$XM<DMT< 78YF$5SRH9D9E+[
M.>Z_/"&HYJ*:#LUNIW,QWLD#X9!%!UB%ED9 W8:^4'N78VI'T:##,V!'1J0D
M)WF+T2'W:!2*G (_SIN2R0;GL;_5)V<!<0N0?00O&4D(:>,@')P *O5*9)O#
M,I56%B6799AN(9]E5752=@GCL3!;4)Y#6%6TYEWABRX':DJGM[K;SLJA6)R^
MEFB*SF%T2**ZQ-\0Z(B0-7"GU]87?K=.UI@<7\Y<_6=RR>E5PV=7W!E'5;LF
M>!K8LT] GQAS@6O-PX"F]_^4]]]!3;W1_R\:145!C(#T$ND=5)I ("+21$!
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M;UM2+,\39)@ZO<0QB_L<!#L#\]0";Q>Q<O]W4:UH#;1=.D&(L@V%?,JFCKX
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MV29G&(M1>7F!Z&OQRYU2C:@*<F$])Z[.3:YY1A4,G]_#__K<4)R7R_&V6_+
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MY,$<01/W%G.+._Z*EUO5Q/<:RE] %9NX:;YU[BV4T<8*[%SP$.GW.4I+GHN
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MP2JV=SI/_"V$6^5X=)GJY*5O5@Y4K =J:,#=W-P>WW\8)LEZ4B9#]DO!'
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MBYL62TS1IXJ8%H6*B]4H;(+S>^3/E@L695EK(MHH5W1>Z->I+B6M_O!H]<S
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M;\Y2 FE!/2@*^G=V9K!^$;6+I1"1ZO\^EE/F)7GK9W.(7S/SJ5T=_GU:A)D
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M6:RVEV!\49V]:NC'(>WM9]]1]^V0ZN0P7036:LU^"LLE6C84>QHV[CU5G8V
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M7X3K?H_\O(B^4&M,6@?@-^RQ@X,,R@8X=?QMC4^.]J*[#$B!^PCF1T^D>=.
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MTB80YIWYLD36ZW09CV=%E[%(!=$OUR//\/'1G#4<T<>($]B<UV2AK9M'5TW
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M:2OAZ/S_'6#V_S44J;9X8?G^3D'4^$&-QI#%1,#U)+[ (-_J,;N^D*KB\_Q
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M$"4 P-HW,W>&,\ZY_C%: S'3%G2:$;VG@-=GS0W-AC!.V.J\!DO5RWZ$0G#
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MD65"5NLN,6574Q7*[K7KE>-3HYS%'$PV6H6)^;WD>)<^F'N!]<_=O\UQ.D[
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M@RX?5#$_U"$8QQ?@%3,V1#>7VWBG8'G$*0#OII(=NTT]%[P<Y@.1-LR:.<2
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M;4TI2;O&U5'JV*< &IY>ZR85HN_[&LT@&F'PA#UT .%1 +"'/TW]2J+,]63
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MA]BT*S?N'_<_^3(1D*Q-&-F%:*R/K*O&P"3]8:L&](H-^1?3C$2)=VN#,*<
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M^Q\[B.,?F"CJ C;].5G;__R[]9_A_E?07;.CVH>#=OG_-P%02P,$%     @
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M*>YX<&<^@,"#P:,3EQC&"4JE-A";;>'DS4='9[W^PMQ^UY\99O(;7H4(O&F
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M@KN.ED[*8TG1PCI$E.WFF%':<'N;_5Y\C>)5HI"]YOM.-W2JFZ7(XQBY2CV
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M%"^H<6>3VW3/%VRV \.8<-9CV@O+7ECF24]D@ID6?LU5F0B[^90/??D^L<@
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M_M0Y^EA31;!3)#=D!LR[96L7M(SDMI;<D9]H:UKD=Q>2_?3$LY3#^D[GG-+
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M4/C<FR"\3T5$&V^-]>*I5[>_]>[_12V5B)MRBE!H!\QQ9YJ@1ZE*Q)'/B9;
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MI)>?Q@!=ZEBM%JZ*&VOF"\/;GL'K/M\.D/'()4E/:>5-+I7%6/ZLM7#/>V'
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MXGY+PW7M%#66%0<),T#.C4ZB[@P0^LWN5M+A@R:AZIJYZ&K,;!Z6Z[(<!^(
M$%SHIL%!W'E&/[\T>DN17>2(/%EK?^$ZQ\)^>;9NB7S6U_MU#!%:UL8H-0\O
M\ZQ%:&+Y"OAO^]RO?]\'KW]#O46:)UW\?^<@,Q&Y'RCLD,49NK5D"EYIFPBI
M)4XOF:4[E>O+T#6EE![$W7IF4JIR@"/3[5,#K:+Q;%6=$_()/B8Q*,] IK0B
M]0[G"C&W(DM;'G^MO^U%<S.;I]JF+6J%A62@#_CF Q\'VS1D!A *N-5 8;=@
MW6]?ZLN')B[[/U&,:R\KERFMXDH=LU0&!9I_@BL3\EK<[5IQM6Y[J.?H(C7(
M^R4_[LFE*[<G>]Q->J6MIZ<AB>*O,Q6^_-1K],D8/]PM&IN+;O5>6[Q.-+R-
M)3) @QJ/,\B-0(Q<A&^< /UX%&&P<O=!ZM*)XMD$FI_:SZ@4%JV3&>9>.J:W
M57G!$^MX]>H7SL.ZT1ZS0QZ5/J-S;^Y'<52'8E?P1DJS88?/F@N?X'GI#=.S
M '9FI0$D7L%&?];:C\0"DQ&R\=-Q6<WEUY/]6?%Z(DI)O<G[:;^XO-BY R:C
MF)-T(7A/9TSAM!N2/8D,/;) GI!,1T4*&=B*6\2R?YJ<[CC5>K._L.C,W*'W
M3\TE%+YC7J&=Y'9W 6:)T @8PCQ$Q? K^]F)U8XJLC\IL-/Z9&'3\%Q^LN=T
M4KW\+OMG,;WG\77'W%EK!$M@;; *MA@U:^) 9XM0:BFYE^66K]*/;L_#J<=R
MW]PQK.X=RQU[+EOAG!NLCL=.",S2BV>1P(VB#\1-N)YKIG20WEK%B-OJI8 +
M]=-*T@&6!EJ8U'W0':W$6'/?#VXH5HUS\+F1ON8)N=:1RD&$<@',&OK$T=']
MRMD5"8G5D;EQ_P.O/:<<4V^M-[?:Q_M4/@&7>O6;4(/60H)VP^)UU567S7TP
M7-AE-Y]'19X7VE/*[:9>WW>FJ!VYY@IC^75-KT?T8.#H)/T B0%:607'UQL$
M%"PU'DD=-3.X*GM]S"7$-JZ54RUJK0C9/W'#K/:1N]91)<_NA0!W<_)SHD8^
M$7LKR1W6[$GV#/=R>;SX9($B=W]X0$\_VHP;1WB<9Y\JC;I(JI-J*%R(I1?R
M%:9KZ,5H-J)T:H:,OJY64,Y)1.!_7I\QK.LZK.W7P?O9^&G@+#Y+B:?DG0@N
M%%EF('$C>=?YJ_^=PW?&FN\=DG26$&^< 0HIF@A%$K)-/816B8P,_!51B%??
MSP#=KLB I@YPE6IRX.'KEF+=OGXV2>"P$S_/L<30\JB:.'7C671;1@+7PRO,
M2(STA1U?<-:TOJJW>BI^[ZIEX_0OG:@3OGKIBJXWW.K+G!.O%\PL&+5J2PUA
MBJ'?,).8IN,PUW1HE)AP>.JR= K+RR*#;-H^#JXA\V_;>X?QR_"UM<LO<N-.
M1UO/QL?7I0RUGQ4+&Q+:@(C26_:4ZI"GOX?G&V3M/B^M2H)HL$)6-@1UJPQ]
M.\RL,DUFIS)T"T+ZD$1F?6&AV@&L1$R'$#:!JHW3KP_V=/:5V6QU(!]66US'
M)8V,^H0^^!+U:.3!3)U:S45A=8%9?^IQ QQRE6TV >2V!VX#"VC>)TP"-\"N
M88:7>%.M%Y@T)Y'?E@&:N".;XWU3$/$NC84MKK.CWI8"!JH[:SW"G(L _.#=
M2F+5V\MQXJI%D_S\H992QSX>VD5T.WIX><VAB 2R)LFY1>[D(EV*.!KO7@$[
MYGIKW17I^6#&O4[-79BO6^*5G]T[3L>ARIWX5XL?T5 H3&OZ,AB0.M.,87(1
M_@IVR#$ W9;>NIPI'J-=\<,S/#HW*GB_NI'%MOZIUWQP.YWGNYP1B<:)$:P[
M***>9[C&<>(56RX1.+KS"CF7N+3>%NB4^K+*+_'_(.^]@Z)ZFW7104!$!"1G
M!LD9D1S'1!(!$24')><@.8YDR4E!0$ R" .2,T/..6<8$) \ S(,3N#@M_>M
MX_[.J=^N>V_5K5OW_D'56L7TJGZ[G^Y^NM:[^C5;5V$)^S8W/1#09*[MR5]K
M%)-P[_-W=/[.PI^A7Q=)19.;)O)W+&X,_AD-^>Y/% LCQJ/*022T?V9';J>=
MD61+-M1@M )1UU G^(K21HOX*._V!-U'16[V3_UR(>&N*;5;XINN%,DX02NO
M#?3C)U?5"@K3OEC@Y!<E["-]IRAU7:LM?4BZS.HKNRO#)@*>M<RF]/Y6.HD2
MKF/R@<S&Q7#U]J4X.7+RYSBVU$>(1=UZ[1^&SU&9:7<%^,YUG!Y(.J+(5QWO
MX$MKNXR6SZHHH)$6"AU@\8'\.?2FVB4:)X$Z>(&0B@EB:_@@@368/3ZI.!Q6
MDYR]%1H!X/_V[5L)WN/W@!L9+W%OU3J/M!K,H"<*^1U@N/)Z9)#PI#@3^@K
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M(CF4?\OH$_S+R1 G]*";\>FZ'31#IUZ46GIM?^1V!#Y!Z'*&Z=1W?X.+^U>
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M38F7+FOGPV:VWMM:Y7E4B[B9Y59!3K:8R63G?&+S0(.*@%*PU]BW2TN()'+
M7(9F55M%OB5X=ZGAL!1^83SCZ=]2><=@6+&QQ3DAD_>%=_\]VX^2"\:MVJ*V
M7<D6+[5H\F$N[[.IX2ZQ0IYH4DGM<OV%^BPG=X7#"U("TKC]/)4W)$XF_0R.
M[QR^Y\7[.KG*[U\!D,]1OJ6V>Q8BD1RTB$<TM4$F,XA!:C>&:/[F1BO@'E5H
MZ!DQ/7.\@*;(XD7G'-*4K2[F:303B,90R>*;8;]X*>&(:,_WO _=3H\Y7IL,
MX=U35NOU>J4]+KSA6]P+7M3I6J<6'Z<V)Q:'F/7Z>2.=UG()DED&ZU[(/6E5
M/J:X$<'A)3>["D*:P6G3\];W]F#+OD*>1@P>!]O9OM8. Y:9XVX<<K36#S#+
M@RNWZ.5OGY3D9^O6=9RU5"X^Z6!,K*%K)IY)T:K-'EH5J:P0?BF]0U:-J?A!
M:Y74"6X+C86+VO<C[>&Z.4[4ZOD,! +.T=-K6F*;)#EUCTG$DKVTSF)SG+_H
M>2HQ7_N/*Q=S!UX9@5$HLM/UTTLKMFW^.E?.YA!E::3^U2"T:(<38/(]Q]42
MH>^G=1@./W@$_&G*@A8C:?'_X7-2\:1;D)3CL86+&&_I[K,;%71DW?02>^)_
MK.#*2H%-Q1!N*/BQ:*G!,5[>]1?::]ULS>D]E,K6HH>Z[VCTQC-O ;1W6/FO
M>P[<#1^=SF;%NN(]6<=FS[0/)$P#;]JRJ)VMK4_;P2O;Z0G'R--_^<X;?^@0
M9&X6GF&TL]XE^?T*D*<01>*NR,@3K9K#$40B_FZ@<'PTXL#0+_*P9D-#3:(V
MD%8U'T%_!8CZ^,)LY0G+X)8;;S(A87U<#QZT_9W#A&U^MDG'EL3)XDEG-G?K
MA$W;A-,V^,XCEHHO!-7L3^X\AS [?NNT?&JI^]JUXT&(#$3 )=P46 /O"\U7
M*6;?RZ9O##E1#QT),%3'X^8FDI%34U"[J(B(-AXA!S5A4^7Q?/,.#!W;F4-,
MI'KHU/S]K2^HZ%FM/HZP4 5Q8&&"7DZ#/#)$-/9FB_.=*3X95P ]6?Z85<U3
M%N5=IY$RZC11U>2"M1=.P1>]#)R\8Y-?SDSJJ"^W5\CE7!:E8%O[2YY[\-FF
MG&>OC0)6-&I(.*LK?JW7/Y>?IFAE]HTENEFACQO%W9YN9USU452@!I*N#B2W
M?4S34>6PY+<0K9'Q05*_;+FU7&O>$LV[>YW+=E]@4Q2!!Z0"IK8O3>6;O9&Z
MZ+C'.WKQZWZ*,Q;W>'NWXF(JZ#\2R92%7B-+98GGXT_5,Q-0NGB"NY@\9+?;
MK2G*,67W$57*2G'3^'\@*ROA6LTE5!&+ XXB$WS$2U(]Y,S=*7PF1VN"UC]N
MS"F1/M,GX_,P6]3IR&;.9G 4]\]4^_J=T7R0MMBCPJFKFKW&-]T\^K"D_R,!
M(0<^:^2_'HKGCQ;V(7J!\BWR>:E%UHT-S1\4K/?:<Q-WHM)H&1N)ABVHMW6'
M]$B;WY)H<8%?9_QLEOG:#[\R+:?E-4\'OQG=N?16UD_E&1@?NF-;%M[!I"QJ
M0D/MKM[(3%:,%O'!-X"W9@B-1S@63A5.._Z*J!?A[G:PNY>ZIL@$XJB1]/OR
M)45[&,V'44SK-8RH#Y!RP19_TQ1VMJ(:PA_@BG#J]'8R6UONZK=EX!4S#?^7
MOC+7Y3@LFP5^L\:SQ/:WI9=>6E6MV%"U' -%<3(L@I@CO2@)NA'TF69R4DEC
M>>7&OQ\F\&>7H-DF*#R 8]-H%0^CXU2PHF51(M@LTQ8(85E[4"2L;'8;S&%L
M$Z](C2(Q0JEO:=VQU?M-% &&/6B7] N?(:ML>6&C+#?S??5>!_W O@ $E0L7
MZP8RN'@()%#LY>',2$U)L/(G MO/1.?1PQU#V>2%[^A WRN[21H+5. GE =F
M\$2IDS&-=?E=G.\9KO+87[<J6=U+# 3+Z3 CQ?"AEDM&Z:)^66QJ42SNQTAF
MT$I7NM >PU<Y"[U/$I^V)#*_>_!.5D]JTP7%?92:#P<_A5>D;S)E":O?C]2'
MIDX>%\YNQQ-&$-^\E'JRC7?*7M_!'.M14;PY?EA3@E%&G,37H8%46E_7?%*Z
MO7YS9\P55"Y:QCYG57MHTF/^D,[BAJ)SJQYY45!OD&S5G#P++\(D5I>5,5J;
M\P9NK]A%XOA.8OFF!#=[==$:W?""*U.(^,N#D9LY,6!+K3L_I70I-#;)R?;:
M.0.]7\X6-+5/3:E5IKUZL-Q/2Q*QSO2LC.H8)!LK(C'L4XED@)N&( V-<9*3
MOU(*U)TXFSWJ=^@M;3T&-C-45+>5*:N-,N-@C<,VWH8-=FABGPZ?F\-JK?,8
M4$E@M)QK_3R5R6>K4T]1'UH#:H$6^OY4J]OE:F,*CCD++GU:L)GZM#Y)*:G$
M!85:/<JV05M+)WY_P5*9-[1JKT*S>JER,J/KY *_RW)CPW^A5U4>SXBW66@V
M0*=:E0(K3/9%[4*,RL;K-'9)O+B0;@ROALONTULN.*2U88.=?N40[OO117@.
MR\79:$V^N6[^ZHS<O5W%EY>Y,IZTAHDQ7-"] <^^29E1VM):..M9 L<4-$Q:
M9] @P%%+N]JS'GL[9AQJ&6N<K1$'_N^!'NH_Q'T=6VQL:7Z"&<!6HRJ;_3W+
M<8_J?+["CZ;U+S-<FQJCTH6.7,P%/@]L#+J1>/YXZC[&[[N$?J@]"3(WT$.Z
MS\JS<#?6,U:4ECVI%#K.++[%-B6L_=;D>P?S>\F>SOB3] *O+>ER+91779@I
MY<ROSYA'4DG^9/DNQ&E:E"1&OE.K0NR AI'486? ^-J=H".17JU%:+^B:#O*
M(*^SU$61%3Z3ZE?1?*''1RV5-&RIZW&KL^#+AVV^'=)BH<9HC2=(;@3KZDTC
M$>I>EO,Z[/9.OIO0-DR LV'/C70&('EG<KD?Z1I/X&]I<4Z=@7[HE7,':LF+
M8\&\J4-4+AV2E31(-="IVQ0&)@ES--;5![^A?Z?+F['27,GFTD\_N'.>L,"X
M:P(OA6/'8XY!WW^5":!%R'MI/[,W35NT-<7[9MB%[EB_R+S[_O/85E.X*[2F
M\K!E\PIPUR>KHM6DV/XW%Z2B 5OFZB(A$S#ZZ(Z>.O/MDB +ZN0G'#+FR1M@
M;YHR6,Z"1=\:<*+6P5?^K4L@N @5H6!HU )1/K9UUG[]>A6"!%@FWGAV<FET
MA_F4V!_T@?37%2 D*+U5 T8T(Z\I4JMUB^,)3:B= '-#(H,P2925'E-!L@QR
M8%L3J;% F"DCFW!(0Y;83E'5AHK0/7D^PSF[G7S:^W0ILY.K)E_ A5 ^T\$G
MUS&52<WQAH/+8VQ*@$E^T+@B.[R'E;>N"D$ZUM@\%E4BU-O;OW"[FB5EI-/4
M,>$^,"W_O3=%<U-+ HIG]T-% %/)SWE6,<98L65[/\^:-8UW:"'.AF@! K=L
M0TD5.W*$R\"HA()GV@:1-P(?J0U?[X,R!&C, G6-XFR,@L4+EDR?PF=&S=FL
M18ENG;:^Q$_%"U'$ZRP'4H([%4&U$O[D?[;."<?E+?J$:-TUVG.UXV</44Z>
M[.IY$I*#..S8VE9TDWLG9G@%N VU8E'O #()!9C/^YFD2SE>I.K226E07?_+
M^HE]ZCXP@D1>^>&(6(C,.(T9K/(0NF5&8K=.0Z>#T,UR\]Q:)H8<:N1F2SL*
M,QW=<Y:D.&6I[B$;R5D]EW]U5E?[OK@$W"DCKO%$:<J),[NG/=V%?U3 [K;&
MS)2]FVGMT9EKGW1KB*^<4<7-I5+/*P#!@:_\HSRM*P#QI]'L3[EJ/G.Z7LVV
MX1#*38=^6U@B:"A7N.O](_Q!8T*"Z$IO-!FJ:$Y=U6.<MMOAK4,)4Z;MC]8V
MZZD+KB2'DB"7;%?D!;T:<8+3H#QSZ$R (/:3_!/X%:!7RN\] G(>-0/9H:NT
M$C!6F.G#^6YQ.=,D:;])E6Y_6"[??HMY>M<NX*&E'1"NI7_4J@0C?7RA/WW=
M)_1Z;!%&Q"/O#GS0+T!\TPC/:@"*YO@-^"[QK5%@@T]J670>SXC(:Q0[,$:$
M2WRHM\,HRD.KEQ;4S$L;1GE&>/=Q;^15WQ_])!+-Q76NR4RV"A7KYS 8:;F]
M_0:V71F7S/<[*&<OMY\;^\H7+1#74MCYCN%NJ8S]U-05X"V(0N/;_A,#A&4&
M)"(?TI[_#E)J(K+\EL^'PH!:)'5_G@(_\LWPK;UPPX#U-0R!:34V1#A 9"/0
M['EH[V\/W=^?XL+KQG*]<SG3[.M+"5S(LZ=NU%<+,HC&TEAS@FC"P&_;@-VR
M-)"1=M!T,I# Q,YMU9Y.DB%0X7"3XE F;5CW$Y<2NY(K_IT[&U,^D4@JQ&YL
M09N)49^?T@R=(C4KD,-S /TJ9(I^=I?^LB.;.[ GE5VK^98<Q.<,R8*PB;/P
MQ"W"?^FFF Z^:[986:LK^L(H=S>.W-M#LKJ$\D:+S;AQ= "6.<+/I<]L<5H?
M=;EQ=)O\KOV<GVF-C57I\FI=7/Z@"\?:4EO5:?=WIZI(HFPCEAI]1J)#N2O
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MNOY%XTEJ,L@Z8%T\+IZOD&-T-HU4I0^B4B&BJ6%8[.TK"U:FS]V@LXG/!&"
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ME=/0PMS__87_'P?Z(OD'4$L#!!0    (  EM?U:0([Q(FXH  $.9   .
M:6UG,# T7W8Q-2YJ<&?,NP=45$VW-G@0$ $!R9E6B8* DB6UBHB("(@$2:T"
MD@0D-]#0B 3) @H"DB3GV*"D)B-)<I:<DW03FA8Z3/M]WWNO[_WOW)D[_ZP[
M<Z36<G7M755[UP[//J>*.$E< "[<OZMY%R C(P.>DOX!Q!E #3A#1O;[[U\/
M.27Y[^<L!04Y)=59*JK?[1PU+?6Y<S3GJ*AHZ&AH:,^3'BIJ>@:Z\_2___][
MD-_LO[E(?^?/49T[_]]^B,T XSDRBC.OR,DN V<8R<@9R8CM  @ R"C)_O$
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M\O_,9F4&('J26KE 6'9"D.V9HS_IW"KL=.>Q>WH).M>S0VB?IUA;DR?I7+S
ML&S.^A\24-6L>JZ9;.0K;6C%C5K-3]G.0O2#?627-#OO4;R>G CT;X50^@O
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M.7:OU2B-<=@)44;=;^F!+\H3#K$9MQPK9?-UK"E&T6&*'?M[B\L^?F^EJ>@
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MGKO-'F#$XZ)O"O5JQ5A<0HQ?&CS$>C@H2>[,^(X.U_RXY? .%O1.:#7B(F_
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M$Y@DNMY7,/9S[YE1*<?34*>B,?.[#_DL]HW]]-<E9XUUYIK6R^;2Y2V^$!F
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MK<<;A<&6:/(:Z1P-0[]@FQ:U"?A-L 7NPW/'3!Z?W_MQ1.KMBTM.@_M@ZB%
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M1\QP(!VRR9TM)-\EM!)Z0O';L8>K4-F1KIT9_'GES'O[R>IO  #@2U3SZ4/
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MSK4;17DV"/W6U,G4!QBV'.+/=!RX1]G:=6Y<'(?@+MB_;"_UXQQ0D?\K_3*
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M5!Y<+\LJ86W\QS8"TGZP'/TX5C?*=7LUZDH2;PM1T*?3[<;LT]0]AO$N@B*
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M!N>;]:C'EW4.(M^LB70O%#SSE FZH:XK6.W_$87]?U; 3V_^"U!+ P04
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MAQP:^L9JI1\$[_D=<,^5D@%7RJ('9FN)1#BV\!?^5MP^HCZ1Z+.OL<]52DR
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M"L8W) G7)"KI4KP+IP8*7N6Q]0H5*=Z@L[L;O/:BJCC]\$,S10F%U@5*8RZ
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MU^XJ;-]DL-#=!H<0SF"T(R,(TGEF*_5<J:6IJ48M45E&]SLD-)4J3X*CW&1
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MYKOSLT,^><7,DE2Z;\4W7F44?Y/K\?02D7>46^]L8,]G_N?:_E#"B6(9:(7
MR^=KZ>H%+IXE:](S+/*6:181;:)UCU/S=^[RV4<)Y)5/LDY]H"8Q7BCV'88D
M^"NQHP-=:S'7?9U-RX1 *R$*(<';#IR677M,TDC[>$:H]]NIDRI055(7&K+W
M^U> *Y A2O*+I62@32-G)74\/74=60V]=I>>N*5#0L0J3>1-9))ZTI$QU0-3
ME2W[[ZXX0COW%<2KTANN?^Z9H+O<^(/ASL\/<])O/:R>JM!R[A80./AQ5>,H
M^UY=JI4Y_GC;\<:@4LV"LEW'?;[6D;*%I_GI-RM#HD73J SOL2G?-UEPH60W
M>\D8.3+ 2SH&.G2,SYTIQYHYI[Z9,:P:^3ZRV.!MKW%V3MWA680^H_0)QG1@
M5<GTG_Z5@D"28I.;*6HD]*(O$F^[D-@1<')\HO.%)>ED5\%!-K),^8R5>'A*
M7/^34F/SZ-8K'?K^QFTPS(V!DQKOT80[(UOFMG-!8091M**/+W^Z@P6-A^Q&
M#RI*'S0$P(@7WDDH%$C81E@>4.A6<*3>/0HOI52G=Y3T&/R&<)YR+\:,D/SE
MB8?N&&3&M9P]3@W2"3'=@Q7T_BJJ+1&\50;[F8M YY,!1J!)3>^H>>X1PQ#)
M?\MQ%H/,$1YD_!31JDMPAT4@'A -M(8IK!_6\4ZLH6;HE^\E3US9;2<1R_'5
M4!XZE8577O1S3?7HCG$YN%NJ:8>'<(2ZCQ%C#+NF<%(+C^RN9(O8)!EX")^^
MO[_$6K0,I?&571YJI'<5OJ._IO+DVYIO-Y:]')*U9[97\>K\O<,?NJ$IF27X
MRP>H5OG!W4K>JS?6!L$"[Y5Z5#+A81QT"J].S('9;#^;=@L/F.^#+KI'E+[L
M^;BJ4&=IK&7TO:7DXK.4NS^IKCUBO6Q5B9DA,2IBNKL5UASK/V0CYN'LY<>]
MD!Q3S:^5-QZ$#. K07G933@FR0PQH$ZI4-HDSC["'0Q]:+.THVX^6')C1!9_
MCN;X]L/ V==;[S_<PQ?1596\6L :>'8.5[W;":L\*/ B632_-V@U;F^]P:*_
MZI6*BJF$*QX*FN)/@KVWL#Z=B(2*5;/\S"(-T;C4!R[FX2^E@B*FY$,A8LWR
M=_U/Q*_"KT]T*A^G'"EWY\P*$C)@$1J&."DI,_O$_O(;<1]M\WAEW(QBZIQ^
MS"G7JQUA[_Q9J[^!#B1&7EB[MI' R:7(9^XD 7A#5,[$&>-&#''7/Z^%-U$Y
M<:3N0UP[-;.AL8%D9I61F>NU$W FM'LE0II94.(>Y;Z=W%%L\DDH:SH,W'#S
M;6\O1U-JQBV"D-"L<[80QFYS?VII])R60[KBJQP-QQL/[Y_PHQ?Z=.V>[0K?
MP3 E?W/'(.:SWK$TC<@&*>I5U6-8LZQ3Q[U?V_=M5K+D>;X-M^VV4TY91;$A
MG!&14$:V3'9PIMU?4<)3H&_G4B.B/ .=Y[%TP;!HPZE3[H KPR=I+*)(1W#<
M]7U=[8'0*V(]XGN\$QPG[XL@ SHU8^N"0F3@.2>:^%@6([E)R2"TLH.!=@LL
M)W5 'QO/Q3+E&9/JT>V]JP\_6%?3#2^*165'3]$M":FK7GOID>Q+J6LPWBI8
M'()^(U#CO96JIT.I2>F:#>+J_?M9578O;1^_+1*(*BL_<!-E>9JG@/%HS$,1
M&^I7*[_UTB=DP[GU9?("SI,:?+YM.1;#_C@FKB0.1)N:$QFXQD\BRH/&$?Z=
M:Q<3"<)&F;M#J.T11+@?=*,=RPV?(-A@;T-.^"95E[A".B7SG3PHF2</-24^
M?CR_RY;7$[]9YX9X L'RS670*W@69K:[=\[<N#"F]]9ZHI-D?*TXAE+*&3@+
M"+_<\;_0"QI')K!VMLHII&30/Q>A=]14A;OX*,E%'3W@FGOK</!6KOOE<IP]
M=&T&W[NIPN]E"#V:06!_R1#'_N_D&J:C#SW?__$6WAU3G"Z(<A%,XY&2-R(#
MJ:[$)<H*9?X_K)#Z+Q\XZASS7C>N^]@1O_/M 6D3]8DTYOF? #OZ;Z__OB_?
MEJG7+2$7T_LW#6J,'EPD Y=7J$1W.7W^98Y-5%LVQIP>T_1:@/$$3%J%DF&\
M)\'TW?G8VG!A,&2ZK*D[75Q)(,C6KG".BC^$N19QL:/4<%*T_TD(%2\GAC43
M[Q"H"\9C(/>P]^!<U:^\8>%0EBH$^\V:NVJND*AJ3>3/F 5)(=]=J<*GKI\M
MLRJY3GT<6(WLADQ-M,*K$B-=JY#\8/! !Y>< 3%_[NK48/NYX;R4I)0(PZ@K
M2F%A%EWE>%H"_\1VH*2'-^9G.RN)*531E4?\0T=EC/SNB6LQU^M+,Z^P\M")
MU"<[4O^0A 0/H=GVW!/]C>/>8VNJ3U'(/%]BNU\@3R!R8](+5>XF^6-C5VG/
M?>ZUO-=27E BWL!YTP8#[>0:KW3.-1Z5Z7WEM1YTCC\@_O:.^X57&J[,9* A
M]3K5 0_GZ5/8](0)G ;H8HOMT8W6\Y562^R62NXKB4I\:U&0^J#K231C8%[;
MEE#<8MWV-![GB=7H-FUD+P*E.\W@SQK5YN/-7'7&U^\.(ZJRGVLY7"LI2ORJ
M\T1G\O>/^OX3YV<D>&-\E@JB+P4&S*,A(-V^$>:7?(V_3_BO#.69VZBHVS$3
MW"=4-B5G.-^XIW5<Y,495U/2J_:O($4K8IK5'&[7LK))82OM7"(Q.E^M<,U@
M[8(/O[F&.T=I>9H3P/N8@V5J\2/LONZD1A>L$I;X:].\T^K:L)*YTP(9H"\(
MJPH(N,8\J>G^L)9!>558"O5JRL)+P 5)J2!Q3O)\Z U4D-L[]K2N5):BU<WB
M27.S7L\ EJCZN&\69MTGWT<LGF_UFFQ]:A&W1/,[[U_'NAN *>]=DM:5%;"0
M>,GF]O?KY^N1D1M>J2-EVV7ICDG!/;<_ZXPSF^>>Z5*E&:7,\B+P*I8[K@H)
MK#6?'&D^^PT,:^?[6IN:%LS"YS[ST&=&\R2W_'O1U)X?MRR^)R4]-85BM!#,
M*\&\88LRP4P8Y88%>.2PLY'#C>:)T@^;WI;6L7<K#T)7X^)/Z1SK>I3+W ))
M$Z7HGM *U47B;6UVMT9YS$!',&.BT4AI%;@'97>NMR]AV=M V>V>,E.X\/1.
MS&.3>;<KG[,@#I1!GH'JHR21X(%:>;[QO"5M+9,1V76BQ#[I1%6%MOZXH_ D
MYG--R,WL6U>6GK#JTA@W&<<'M\'HW4BT!""L?;]>-%2&81%5]W8&-,*MX7JT
M-S,OY]=]'1!#L-\/L)ZH&/SS2Z.9\%H6,M E((JKGO!V9_%U6>POL,UF.4.X
MZK*PR=6_WG[8^"!RU/BN5##VNYTXGRN^P;C C$B+?(6:ST=71\8A["@LR$$/
M@\*YQN=G^_PVZJU%E @ K=G/-C[)OB_4&Y"88:1Q8&RSI08$Z+9 HZ@7W=M=
M@DP#^1<EJ:+M4V$;\6X]BHJ?:LKYOWI4GF<9/;7#$AB-;6A%5Z9UZ$[;=@3+
MC,.<XK54QB0?HCXBJ_JDN[]8BS.[W6ACK/F>>'H9TM!8:2L\,9)90=]%U,!%
M@ 8^BP&?CYE8NJ3'*8BW5*:.X#6T$WX,CR_UOOC)OP1\7WHB!=!S[NQO$C&[
M&L-DP 7%V+Z@2)&_3LT2V(2(.6CCB#>4B@RXK8[C]HTE*W :ZG&JEY(CHKAF
MES>ZKLA0X2 ;VPON#*#0O$.X3.(Q77?/^5G%.Q%HC72FS*INV8K"XVUW,@Y.
M;0U<_=#?6(D[735$R8]33 N=J,CJ!C+ OI(Z35LJYY^Q65?[J3'>EI%W22E[
MB=]O)N[!DNR:%]4R&:C2W6C/)@W+D: O[HX&JF:Y"'*@%!(22QU]0L?)@&Y*
MCN/[R1^F3QK=>GIZ5*&WOX$"&'-58@:)8V6.!?/UI/E*_:ESYVE&>/.>5THW
M)OQ,]7EB;_NM_$-%#/"C6?P;,;9M^>'2E]U,Y5<UKR;:T1A-K3,+ W'IUY=L
ML-"V=6V5Q.TJ_[BAGSMGFWN)^>ZH2F76=7G8;EO7CFY/OR<<2NHT$E]PCX=7
M*LVG\&VW-?2>$\R_&MY"!@;[@G1TD&GW;0AH_$,[R<$#P@ 1]ZPAN"(.8;!]
M>#ZGV>000$)!\24RP.6;ADL'R[/6#JO#YYXN:'K]&M[,^<C6RU97N]M_("^
M5YT9=$!6!]#ZIK7H'BAN)\+W=K,1JY^,G["+WJYT<42FH3@+OE2^8)LNTA1M
M1.&F8(.XZ?-(92RJ&PE>)RGYWFA!81+7TBK YKGE90%UWC-<N!(WJC1?!TC+
M WRQ9Z/_J<?#N0J)J4SF\CNWMS$*%^_%<?Z8E43=]&?Q@VXBL;!.&#V)@<6]
M35Y!^T-A?7/F@[[":=FOZHJQSVJO&'I?I3-\^#,G::[I<;/1[W=X8/ @B9U
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MGS:Z&GT)[# U/ I[]39V):*RJ*&,W3G>^J:3ER!QL-C%#7KH&1/1>E?BL9]
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M<<RST,5VE:SO=H*:=[%J\49/55X#)<9O!%R6G&LN_]+P=2I#CH7[K*+ @[5
MC<6$9EH6*WW3AVDZ/\_!N$ZRF]GT,AF(AIC#V,K)K[WV: );BBRH 1<!D%QW
MZW XJ0X2ALF<-)0HPJ.%SOX^VINW)MD^<?CBVXR1@Q/CL%BOM^RM)!_Y+\P?
M3^G,G4%HNC87Y5AMU#\=]ZT>/TQ.N6"?2K_(IG,IH_#'<SJ<XNJCBGQ9A\@L
M7B^)TH3HB=*HB0,=05CIW;FVHIC4%Y /+NL[^ \9 MB7V+!(]X(U2</1_8T.
M-NM9JWGZ1Q^,?![6GJ\SBLFLI"8RQ;7W^:%*P.84;9MH%JY=0_H)7=K-2Q%1
MZ_MU.8\V/B-=J@>F0^"&9N%>3'C # B@C2O.&PIA 3LTZPE75_WCUV$97NXB
MFR9;*W@MOX%N./Z"3ACQIM-"H')7_=T:#*%+B!N;D5:PH:*1Y;KKIX1)<9&,
M,KE?WOF]5>#C_HYY:,^B76$R+T'7QUK/OVS,UF]?DO6#?HPRWT:"K1 V*&[_
MA1,RQ:ID-JDRT=#=C?'*13^Q@*;"J#-Z8J6 4\TR)SDPO6)XJU'9$[P?9AS)
M0Q3],D=?E<D]TRN)\^GX!DR>F[QP!G:E1UV> ]NJ;HL(;W2G-![)!FXKI&OS
M*3QOHWIU4N*9DD4.6I$5T??N<?="DGDVVEERU4069J50:)=ZB? \Y)J5=MKC
M02326ELTBI.Q$0!Z,)IAJ*7,6*Z?UVG[M/[FT6%*<F_)7%1N3EQTV&C&R:\U
MI$9 <[)5YA6B/%Z&H$GJTCC[;8@H%8ABB;+C&!'M\-=:<U<UKJ'9]@GVN%=J
MX,Y\E^I4?1P+16G=:;R2NV&01=0<5*207[ZA[ZS0!.[8X<>@E?0?4J(GT+(<
M-V!W$-50LP3>;$]KHG+#]L$=1.1G2FXPGOTJO#BX@-$1S2]V^&#<H8]'^D+\
M=&939C&(.N69H8>NQC%?*\JMM>UVR8"EE+F)>$I[,.\6I.XB<6$WC[4+LFVS
M2<IC93?<!BX2"Y;WS@<6?]IRN$XK0$K:^0;-[SL$55B?3!^ "#*PDX4!O)A.
MR\Y9E_*;/JC>G7.ZNQ^X5NZ/YKIDV7W/E0]Q/J0Y3K2*H=15"9XC:">X$7&H
M:-U*!E2YP;Q^K$\DZ9JD&A'BX01_XINOF4B.-6WVU[*(1@K:<!\EP22QOMJC
M9,!"5H;X<$F5.E\@F'1N6DJN7'Q5VC%J?=E2E!8B^^W'&Y/G5+03P)M_J?UF
MBU'XPMLY1LQA#+!C[A16)QI&6S;-*ILF4](VJ_E(5NG;M+#L>LM;TTQ\G(>4
M 8D/N*BS64= 1-DQ@8%01Z'F2QB8=5XDK7EM^371F;S>M=1&.^:PBYT+E[P4
M.3XZ;/=4EN3IK 4<)X9UC+<72#^13O/8,"T+*AH?WU?/1(=WSTHMC&V_@J Y
M$\;![/.R'W(C'F<L&7E.(E]WL]/T^U?3T@Y.V/X%5H]\%^%;OICI10N\J@]J
M@-<YI0Y[\GKXQL0I_F@?BSRSO<<PE4?I)ML A]# 1W:.<K27.-;J.KON'B(2
MJ\=5OT[F6'G=<^FT&M^SRP'^!?@,F=>/O+_CIMJTK3,KX97PJ9+4/\V]F*":
ME/PSY#H3;,D XM%-,N 5Z.2/,;$G_P%3=^&T1&WLW2S"0SRB+24EU22#>UB!
M7_!N/\_F!]ED@TCQ6T*V2Y>!3EYM+ <AA,8M_=>%%Q5QIF0 !^+!I203@0?K
M6WCE8Z&DOT1"X\_]P#R_V% ?Y$:1V9D70!A),N!;F=1)NF0C/J ,WX!:F411
M^G3@24YV7GHED_Q1=K(X."6>H]>+;M_BK?DW\W=$;R"FM/DB5+([7\FJTXL,
MH.NOGN0A"&Y\:1=E']1Y\=5KRC%QO $#;KS?3@;(CQ -3/?\.^$1J*Z V&NA
M.#L$RA_4H ?2;!@K+8OI"WN* JX)P+-]-*S)@ KSOS0N[6]D - *?@(C [:4
MB[@/A]:2K]K\G!:IB<F)_WIWS#C!\[K:V075J-_OD?[I3-9?NELH)F#1-Y2D
M@3>N&J!;+RA>TU.UYG\=IIOR\QZ#K)BI)'_XTR#3L;'1/)7GGJD5MD)+;<\^
MFGS:_O ?&^P]X[^V4);@'@WNBN^MD\^I^ID-7<V<0A!+5A1:2FFF5V\(*&^I
M$R2@FK@&3'-2-K13T45ZWU9+T=KHJZO\E)HO77'^KRSA](9(WE5/G?.UAEXD
M^E>8LD[S5,6N$NYH1<O]?*YAM,$ Z]P=Y*]ZF[3W*(2,A$>6GMZE<B?JV(_F
M@_OW:-],DEI!3/L[2":2N$[N.FBZ) C94N6N[Y6KDZ^@80"6R=VY8,-#LL4/
M7-_H@P1-VK%1VM$AS@P?FB48U-O6F[_*_5:I#/H,DA?"[FC)\H1ZA_4[KVCJ
M?M0>R_1=(\9V@@3L-IQ7LW  !=WGSQM-O,/;>#FB1^,N=.\,%>^BL-.;0=I@
M"KIJD*Y RQ8/NR*(AB70Q%:S8SFB2);A<"4+LYMOZFNK3S5-NTNC'YQBU=,$
M%$2#5^ _=1DRO4XHBM@>?"9HK#?+""VWU:1JB=GX?FQ7\7G]_EI]4L1;JO-B
M0V]?:'!?>JYA#);[?9!5@4FS'5$9UL02)T,2;5],FV?N+5[=0+-LCKB<I/C!
MQ&OCF>(O222L//+$K^V^I"IKRJ?N SF"IU3;@.60,$5!U;8A5R_#DCG^DP?W
MQ^2RFT<5K^-"612&V?I" 50M ,_KBLN@2J<MR,)\F-TU;$:<9/MWHO6B(,VJ
MIZ7E)2MIDDC=F'@"CTA,]M+3*X*;[0!6\)V)%5HB!]P:6_::#'"G'8<I+]@J
M$<Q'O*?I%0QOPU1)T[6[.A\G_-\B!+H58UFS0O"'+.^V/[%4P)\8Q7 !^4F<
M1H%N*+U&%GBV:XV_1MFG'^=G<^=O$!P,AV"QS*8A9??:FO2;O7^/_-U0GCM_
M\A&RLV-::G;8@<S&(7_6BPR5JAFR&]:Z7K4^=U9/BFN 6I6JI2^0^Y]#"6")
ME+:L.:3 PN8*9O'NG6>&#G3.B8TG6@WO!TJU#R(5$J3'-;?8K\[*=_/?XKI^
M+J3VG2B/#-C:O .!L8H[A_>]@9%[">ZP$QQ2U+4?+?5X-*H88T4PJOIZI2WG
MBW:5MXR7/)=%R%=P/.D=U289@*'06:KU>1:08V^ 8<!=K%)*B9UKS7'HILJ2
MDJ<-KV.M'^^XE+;S^9AH!V,6WE7Z,B:*:U$N]Z%QN(_50S I%((=##TTQ;SF
M-EZO1FZG9R/7ODZM!WFS=4!8DUV&'3VQ<2F][ST$Z7"9>,DS.:A9 YQW)HE5
M4$,5=-8:&FU6/;02=;R\*W-_7+6.3;4R&36G;0D8F)/ZN+5(46T88Z/0<00'
MPF.>V5H]KTW&=9V%6D_,WZG#+3K?^P3A(9);Y=PU<,V3Y\FW6_* >\[4&Y I
MR58FS 3. 2/[$N=KQI*].HX;@'C!!8E?RS_1*&"I!,+5!T_OHYO8:LNF>BF@
MAXDDTF$RTG @1HO Z#MAP KHLZG]]YZ?W*L=C]YHXKWZI:H^,;,LKFQ=7P!-
M!;3C_//B8'I.J&F96_:0IWMB"0K;' VG=<?>HVZ*+0)\.KU)=-CF1*QD&Y\'
MXM,Z5WUU=+%USFS2KXJ=J&5)7K,'JUI0,)$C"XR/IFWEV0>&S3&-$O4*\-66
M"NF:QM^BZ',Q!Z\CS-#0Q:1!M>+77YA:/*[;OPI9!96SO%8@ \(IN*L<HB C
MU>Z_\]I[B]_0@#]0TNJ*X*TQ>_&K5R)G&9J5$XIU!J9S 'X#1,Z #B^H$TX(
MZ_TVIR'MG8'.GM-NA*7\ZSS:@ 5,TU&9]$EM,R_,#!]#N$+D&@D2= $BQZU@
M2MP3!4\?NWRJ#Z.+*<Z\3OWCP3)[+,&KDY+2&,OY2'](*.@)&8#7*2W)J1U5
ML_5/QEU[PQ'ZI2-VL_OSV<M7>F0.R@)/,GV*($)$1DS8MQP[UW-K$\=:Q=78
M'D9G;-Z[3Q=M&^UYR@K:)@J"6^YU77(A[4)L,^M3CJ;[@*"('$8SV5+>_KFE
M%[.N\T>!*^$;8,P]"#_Q',9F L2N08<?,$RY6RD1:&"0RK"EY&(:M*>;=WBA
M;[:B1AUK)T>@AU);GS0$\3JKZ$1D&X)0M.T;/33'=]C82!='^1SKIE49X5D=
MXN!W/J!4TJLY*'1=Z?GTC&V?>N.J??+%\Y'#6J*G+3A::03.N6:&DH0F\4#M
MZ+M#9NJB1N$2JM92%L*A\L\]"U\^=\O(\-%.%GKV6>M6=BJLISJIM#2Q*:.T
M_QAL>%\IP]PLQ[E^S.93HIF+[5:#6?T0OY*9YUKU,^OI3@$NC'#LA:Q[!7RO
M7A;24B#L5$XA:.H!&3"HO4,ZHNBOB"S")?@QW2P9\,? -\Z][LH_3OTY4'KL
M37X$81E$.A^W64 &K(KZ_M=0NHY[I]<OQ>%,R(!]UH;_/;;N NE')BE8&?Y[
M@IP60._/@UK,M,)2E#-]29DO0($GDT='W">I%2=)H!,:#S)@YSUE8Z-^GY[[
M\_W O]CWQ[&VOQI@_#^[?\R@ [Y[BF)JJ7;B7YU] ![.XY.9. Z<?JQT;1JH
M!F_XXQ#@_]5J_^_6VND1M((ZX"P(5PB[LS\B>K\WK6&6]B+#36],)%I:H/,"
MN#$M[%GKTEY/F>&_7ZGD*SZU4G+K0D^7[?B;'U5G?3[WF%TL_5G'* 4YVQ7%
M>NZTJ?'+3]ZG"D#$-T-DP$01Q20W@[^:DHND;"+F;=ZQSSPQH*:O6D/#87&;
M#/AH)I$[QJGSEU!QP/^<$'\<1"S/(P,^Q<R?[ ') %:=?\F'WZ<E_],#-* G
ME"1;2,F@/LD+$G$AB26C#]L.!PMB"83S//:D8?Z:,[""CI>)>[NZ"_N<Y_"L
MA)M$=EX,N%-0JAOY5*TT9=% L(:&!<7M2>P@?"W+ OTG:Z3&8GVB<,^RC O:
M5"^*D0&*/KM.Z=)E+/WKK==ZMM%("O<^S%HD ^(0&&,R(#*S M$NU8T%MTZ7
M,>,CZJTG7;6Q<OOT.3(?%2)^;+QC"ETW6K15;H'C+]6T!<)1=T.?H0>XUN:$
ML&+CA<B8C\F^K)V,*SNOW8MSKOY([WYC/A0DCF'*C%&PK-RR=RS)FWEHX.;G
M3H/I"8E/>B*\UW=_.(AO;=B9"S?@_K0:*YDB<*9K_HDS/=6M]Y@S5U[9L@BF
MF'SYK*;ZIBR@R^PHX(>V 7U,J)WS>*.[FSYH"?V,#T+DH%XH_98W8S,-NX-Y
M'>G.KK\.&0.?E?<,9^R>/&7TR$X/HTPZN[9@Q$Y4:1Z#/2MPL3KS3>BS3%-R
M?&Y.WZ^Q)8::)U] TDI@2>I/W6("48=R[*3O"&:BBXN"2MYKF/*+B@(=^VPK
MZ?>B-.$6[=3;S%K&>&H"%YX=Y_"M-KI-)6"JUT<N76:VU: H5_W44?G%AUD"
M%X1]U VOF?X0U=:_EY;HBNQ>*:FGJ.HH[SU),QG]LRKS.KO#9$#!2C=N#DL&
M=+(]0&6VLG"[7OY^(]H$JQ#YQ9(,:*K:$V7Y5,:-B7L%<MZ92L%%303)08NT
M(7QK?(4\5252M\8T1N2GV:RNT,A^2JH6VS+N.8UH- Q<^6N2_S4S]&.][D8E
MJ9B(]HH[!3DB#YHSQ<+-I=/->4=+9)T;BBS%3F3*^BH2\4P$7:@J+@F3B4.\
M5HQ0Y,D2D75/._0UDYN[_@4D?WGI^65/3\,GQ*?X7K1<.(@[B&]5Q2PQ>]ZE
M67'TU\B.K*S'W,7B#L_*7UGWLI6W%Q,+@)>-YT43\?,$6I<,5>PS;%E(U:Q.
M"Y!-A*:[9"T_6G!MHWR;D\I1<W ELTS_*&W1:"MS$10*K.1N-V*!66-FYJ?G
M&$;G'Z3=PQ"RA]S,1J;[7#BJ,1RTSYRNW_(O )S25KG,:RM@:RX-;"R1:@.S
M'=HV7)2:-G6:%66TT\@5RI25G!T+Z'4J1 2H@G7R'(.B)A2Q<:WC\'-!'- X
M+438<H"AP=T,>K8IY8$? CQ=VD]H3_L!+W,N(#"30/9&GV>_H*(+\ ZI4$]]
M6WQ&@"T;U:I^>04P[TQR;QN\"MSQN 2.S@P',9<\(0Q96#27^/*0 ?XW1 <6
M;4QV?XPZYID]"[':$(?7JPT3F0O?KYL^1-'INZQEVS8?.N#3P9M&!#U;TNC\
MJ4KW%V2 SIB"^P/],?$A19ZRQ=W<Y'6DJ,#P^^,N/L-YT><J?)NDZZ21N;,G
M&8W  M>Y\Q,*^,R[KW*YZ'UXF^I%OVBQ/OS9@9'JV@$MI'-GR%V)$R3:XE/0
MK7[>=NBY_C6%-"55_N4KMYJ@U&+[I0VM0(QA7$C0*6VE.<81B(? N4.5CX])
MO@,VE:T(_=5.Z:(-ML+L(VN$M%GDB^5$"GZ)7VZ'.Q>RYHC5)=0H9)0<_HJ9
M(-UY1!$>4B1Y%Q GPJ'6?9\B457[:!\TA1W3WYAE-_22^?$PY/M%^;WU8E7S
M8=,]\UB*:7Q.H55T,#V,ET4:"OZF^#QK!RZZX<[H/8$C<S-\>P&H<]1?X$$0
M9]!4?5CH(@.$!N947H_W7;P8E^+D_T(IO(SU53URH90S5MNX7_O91^R#V+9V
MWOO08N:"ZAEP1\/:F%_1=$E4VV/QL->>^":^\OL$N>HF8.)\SD#.:ID<AK;+
M8$"0",'&4819>>/-O#A:,1:E H7Q&(CO2BD^^-(ODL.,'S6_KEJ\W6OONG!B
MQS^*"5LXE'[Q^4" Y*[K!D;=RL?>V$[(;7LHI8B]!5E2-1?-R/HS3D'?]Y-:
MV4\MV!'A9M X'%.&<,L,"SH] @MP<7$OGE6P.BE.=;6I=%TX^4C_\I12PLT*
M'C$/1D^5$UX4G=U\NUD$H>;2PVV!#"/%:M'39J\O]G\9=MT(+/.8'_Z6Q&BJ
M4OY1!&>;,5OJ5[;5B>WM!%? -\?01GQ0S78D..( R(+L"5!0B<%6U=34Q"HE
MZ%D[RXA0>;)ZZCWZ#I@(A<$H8B(!NMC"S5<R']8H@XH^$6W18!Q6<T#OU,ST
MI[#K!"T%9GR7_"'(*A8X_$3HC.K$4&85J.4BR&4^A"\O&(Z2'(/)V)=F6;M>
M7</<E*XQ*WV3<).PY/DY)/ 75=@UT50,/7PA;8X+/\$1/(^FM&G%HB<C)8V\
MBXHCTT8^$UN;3GN?*VIW%SL;OQ4'*TU5_5#NZV7S8PXVE"*=E43/VB_ZO(Z'
M>K6'H^RRL.PDSFQEH$L:P6T+X;AW>LK&S^YFRM+4X<L5]:)9Q-,7Y> I<S0M
M[LVQ>U4XCG,"";P7BS:PS;"<$;-^+G%!AT;;UZM;<275G,@>?6NX65TN:J+3
M3A3"U(X.PU8*L4D!1CZ/I[*(;MUL\VNXT4MWZ,XR4.5!FD(PD$2AR$,4J08S
M"'V^:($)JE GXJQ^$7')OO$&#L_<PRYG<5T:H06\<;BY=0,(A+<J:3#AE1=9
MMO@.K;I;$7@39'BH0K2A^9WA[0-#S_74D.)O[YK,TI-%GV1O6>@ZGNY";1S;
M@R\$=8 J!KH& #"S$<7,J,,YOJ9JS$ZP>5MU#5_0-U^X3T$O+OM#J8?:ZBA$
M1%>,S8CS(!# 8=X.KP$2.2LZX.7 +1E0\&<,<QS< <*5@?2VBOV</[U.NI:Z
M^M9]WWGA:\:<B[VHXU1>Q(=K(N8KH&=9D!N>VMJ>_E$ J]^S+?[[.N(GG94*
M0,N]4:E^A9(+$Y(8W,_D6O7_J53?U/4MOZ/^;CJN5M/ZIJ^#]'V9C9F'?A>*
MWCVT%D5,*.XI=\_C)7+BNH%OD'EO%O!)6(8V<Y6F_G2X8G*<>ODT0P/-E+LG
MS=L*R-VLCTY5 '=XJR+32<UF*W-F\0QX%A^B-:[(=-4B=<7$4.M)4S JZWW;
M:D3!F0-54;IFJY>UBY(KE(*3HDD5G*"02!9K:/-BJQ#3X&-,1\T+(?$)V)EF
M"7>K(UE^OL<5I\Z;WA>[I.&T=U?%?"*S@GL3ZT816%<@3--NJ1.10H':.Z;U
MHU5..@T-M74?<I-FOA0N50B-'340'A'=C#B#QN9D,<DA6-I%[G8#6V7+1()Y
MAW]749&=A98P)$/FJF%59(CP=>3 ^7Q!6GW "=])C ]#B37N/C[ *Q"5!CIC
M.^.LE&#XQ<J:WT)A_$KP8]VX*_F;X4FTM#G^MK\_#G-[/)$T,,?LQL*Z(217
MH6*(2"I9_[X66!@3<K@G55C[8ET3H.U6^^E4U"X+,@_W<32(9CV( 7-(*4XR
M@#XN1D/8E7URC>]I:O :CO#P5:EDLN64M6OAA9:S>M)2OCC3DT^;9( K_*6&
M('8V.=,KN[NT;=F /YQ%_./0#ZP!ZZ-V]P0EP)LG ,^K40 P4F<A+Q3D;$35
MB3+B77T1)#RH&)!988.<\; IZCR?$/M:S3W8\WMK^&,I6LV3UQK<>%=TOX$@
MRX,:)6X^\;'ZL@@?.5G)H<^7UR:-*MVG!9P8:Z>5+6^'I^Z#>7Y\,\BJD"^,
MN2EOL1#870+:DH(?[;"<X"[5+4U(^3,D2?:Y&_'6_QY\0Y1HQ/Q$WDX5JGTJ
M.02!J:VJF1:=43)/:2.AE*/34:E+9]BHE\^3MGCMCZ3\?\_O#?1!1RJF#!]H
MYAN4S$ CE_APGSCF9BQB-"R5Z'$T2BT7(EADK ^COAAE-(D2].=) >UD0& 4
MJ+*$#%AI!!U.%O NI?IN<F,0^L,/RREI9X9$]NJ,9#U NQM'A.A]G+$HL/>T
M>/<NX>?=M?#>B_'0G%$RX.% Z'%GTXPYGU)Y3R!S'4TKS*!08FG<1N,+%3>@
M(/[EI#:CH,B5LP=E_^WG!=)P#1F0@:'0_<<OU8:!DP.H7X@(]%B*_IC6/E]7
M>IEHYCE7<:U?H2F3[F"GS,K"Z?027B&;F+WZ!N)8""V1/1,E6!/:]2:5JU[A
M8!"-6=!$-]G43-HC5()U$%O6A]$)UGT#[\T/'7["Q0.,<$D(XF$XB< !=[$F
M P:@\)UO-X0L"X+:$4P^[HYH4J"HN5M1DZ;9F/@CM+KAS=HQ&:V<C=/<5+<:
MA2]]HGH,4KNE?%10#]F\@AG0)<C%9VTPX"0&[03GQ$;G78:H^%YX>7K]6MKI
MIW2+(_?EB4(RX!_+Z/QC:2IT]3S&:"#47,6L(+<ZLN0D=KW]P9#8372,R96J
M40^VW2UJAO36U&=U3VAAFDLQ\1I6JRLGL23@#+2"X+[?=&]=A_+,U]$_*=O)
MOC7_B$#[X=<102DP[==N]5$ PJ_FY]%&\\@!_S/UE1T4&6!+!JC3'G(5_\F4
M&T*:;@0JHG0Y9M/*Q%^V4OKA<&4312MEFDK+>$]7^#FF]?6C>ZY+#[,W&^_J
M]F?*Z.4'M2(8%?6VE]*TQRUWTNS\(K"R^0VQU1RN%J<6W/=.R?ZT_]Z]#2M.
M_7?[6@^<C$,U\LTV?ZG7+L$UV!KHC2W:HV5T\^N&M_JJ$CD)VL,%K")O8Q(R
M4TWCFUV_QY'HQS )<O2"3-XR7H3+J\^A3REH1F]7AMB4"\3AXGX2S$XH'ATU
MSLX]!,^&LQ*3MH!(,S)@;PY(V#0^R8%0O*8XW]P)\ N=V#3"H/<ZV=WD752^
MC<HJQNC8^0J)C ;S]Q)$[+T)-(135?6A%BV[BY ,13T-_Y)'!'K8E9&G6P_#
MM<>YI"XH2#G?Q$KD=MH/V6;>I4D+UHMYOR,I$93(>^-4D_W?E<TG%M':DV -
M;EL7926Y+QL2R-UVBQ%Q8[3[/:X0TX\VX N/O&JYWYXJI7/6Z66-@1; M A\
M1'728.T$J+P*O"4V5D*\70Z'K*MJ3$,>/ST/EQN8^FJ=GBO3;*W<_^/)T>^A
ML_]8JS!(9-1]6K/^A A:C\-& 79?4Y B '8AKLUXU5YSG *C(D/2C2KQ9$#;
M@R((EYEO[O&LVD#ECFP-S;=W->\W=E45X.*V#2>A)-YY5W/?Y\['K1FX'>NF
M#^&1BHI,LM_8.O//G>[B4+E ]^GTRSVZ-PEN8XA_+)[U3^\!NVE&DV!4>FR>
MFY]07#%#M%03VS&7AMCH=TMO:*J,6I(RCPAKA(]P<?>'UZ^I3;+_R\J4MONK
M3G]8Z3@D!U/!_I>52N:^7XZA1(J5S!. R^^4WT?OBDI3BA?XM\7K2@9\RVOO
M4;,Y1@U7&6U=5VS(/%>9.7T<VQ[P[+&TQ!_1FW[Y1:;9JJ:_4.QH0V4>QX '
MNV5;6^1&%T>[&3#QWXDTBO2Y9<8DX:4>G*S,'ZG'D_S<X(Z&Y9WH3O_YOUW3
M*.!WBHQ*EV[]&JH*X3QHKG.[+"0^.EKIWUNT+LSZ+$E>/N;UP]9A]G-BID60
MR3Q47V;4XW'[89]'^>W%+LA=79AF 0=W,I=VUQB.%\=I_=PT2[0WOMF/<WZE
M[.Z?ZB;N'\5$W25."9D/43RM3533G<6&])-/P(Z?-8YS'45J%SR<'@9=_8UU
MF6E]L\N<1PSO2?I5/@0.V/4Z[$Q*6?9ZU_+VBN78KT=H05UJK\);R1/%W ,M
MYA& ?(!N7!];U[RB_\Y_.\JI=< /Q^O9:\! 6$J'[/K]D:IE2AL 8MKU,X9U
M%=P=['HJN5YGLJW'5*Z^"DM[Z\&\(WT5T@\CD@A]+?FE\(>@T)0,@32]1*WQ
MF)BNI(+5!&&L1B$/TE4Y&+=%:52M&9Z\_T"V@YV_QPNTW.0.BB@D39JVE3/A
M2\'-$\7LG'"X3P_^#>#QR>$E=]KRO?D#KW@;NFV^J#?[\*4K$_/.-2>T-/T%
M1.8< NG+I=>__#9]-RY!V_O(;1+T]VE<8H#CQ;L4,2! .N/\6WEV+M_0AH:^
M@D^I\A>YJ2$?*I]VJ<4=V?]RS'Q$. =3&E%L"-06%#6W;G#7T1NSIR":WCL;
MEQ>YPSU1:<$Y]]E,_T T8U'BV#KX[^$)VOC[S4;9ZQ0A;G?>?1G/M:W//:AV
M'JQ=*?^F/#CF9M8\KH1 &J;VJ]L[1=J\%K=4LH:P-PJO$1)-,W67,E4>63^.
MK=]6/+E]L0%13F :V=S#A;K!D^RI>V.:H6/ Y3+]O\^G'N^!26546-SI[!?'
M2N4%]LSA$#H(VWI<E8*37-XIPU9I^\>^B8D@O3=?"J=);7!&GWF&'B>O+#<6
MB(]#B4MY(3[QP:V'8Q[-0[#/R0OG[.Z=_2KR&2BMK8AN2OQG./,^N2HMZL<=
M8@X@B\ Y!:HV*U)W)LMFXP.A*J&40B9M&8_Y#BF1B:I3P3@&ZKP. B/A+,-C
MD\XXF;3#-[E&&5_=R8"%#"!]"4R1ZRV%]D@+4[!,+0)F6L1%0;(NTJQR6OJO
M\:5M^<1E%6)L'[#'KO=/H?UG/[A'F[2>^76EW=#Q>!F]J#.&M&Y(]]B^WRPZ
M.JB0VG%+YL9+60#5("#JLHA:FZC:4 ZI'<ZDX+9AG18(-+<LWJZT_AX-C7O@
M6;Z*Y7E*?V8AF)6>.9OURK*QR'+3@[]O +R9)/IY3.I*^W,7EL\;86VV7(?M
M/T,ZK;[:._C!Y+;9X4C?,+?X6H/,*]R'SKW 'BN^LDUQ3)$-_A5W% 0F[4'4
M/%/EA::#Y([N".G*>4B'OBG]D$(7-GN#]0)K%@EK^KL+_"T.NU1]337RZJG<
MF=1$Q2;E3B,ULS;.,UC+\!M%*$=6Z9P7E%B8L;CH6"OVF[;IN?Q!V[),*925
M9\-LXM[,*K*]V^],G?L%,-MZ9)UB"INK,&<M#2_/J?]",W23T]_YFWWU1RD9
M8#\0CA.Z-'R@2Z$H=MUE:\?(.LK.?MGN-@J0<IITNF3J3C*+XQ>#I(_-+Q=/
MP_&2D#9K"(/$&\K&*NQ3B!OZ,]:LU,:B&^9#$^=7/]]HDS[G 6M#-,A2Z.QX
M5:#VS*P+&8 ()VG FT$K:6/S_\SE7LJ>/P:&(9-K-+*4XHNJ9OL_%[DF7,9R
M91=Z*!H\<O.?UFJY5T9'=8_I&S!5A!\V%HFF*+")UC(AZ+W5U(%0B*+ZY>XO
M'2+U$P<7;S&)\$K3R7CJ.H]-7O5) S7)/S2O_CL:QVG\[LOHE\W!'$[Q7IFX
MOODP!.9FNE$[\!S,]ND\*_'F9ZBR^4B9@H78\$'#FJ(4@>%#1Q]-E][ET!<O
MQ<QD:]LX[FL%V( P6H@PE>;/XCM1:@^P;IT3-=QD -*7";ZH.AKE%B=LO7VE
M:[UV]Z4MPO?-HJ_B >)OVI%=#FR#T\QF0F^M\OZT^_VZ5@.I]A&;^JK2K29B
MVK>C16PBB=X<([F V#(D@-:"!##N_9F/BNST' *X<;@L2>2#N\9^CC\'KKNO
M@7Y:7W^V6^> ;F[ FQ(D\.QM*G,QZ&@FY0=Q5B.0JIC[<RZ*O4=9UC$4T\>O
MJ'4I,0^5CCI(<=%%:-,/! ?-@:H@P20!$A)(*SJZLP+$A SX%6RPG&ZX(_.E
MKOK*K3-SEI$V;ZE:A _+"DD,T#U=?#RF6WO<VV#5ATGY?C4WUVY7T/$5]9M+
MK(,AWX6CYA5S(HY+^:I,-M$'<'2BU;'E,8_#P863QTV7W&WUG!'MG#5E:!O\
M9\R$#KX;LV>!J8D0KJT;\MDPKVB*8J@K$4N0Y'E8WM9S'NC],'!CV6@*3*++
MP1CA[N(UR_! G9#.^M)7I3'Z$PX[$64BJ<@?)&N7O"KSF@1ITBY2OB)^)?_'
MT7M)C2:"&6F$&UZQ+\0VHB#'#&^S7F01<@-.(B62)]JZ> 4TQ89[I3NMG[@(
M/+W+D: +\+*"ESMM<4(()K"SPXT.S"D:X8HS-4HIJ=[#D79=ZW-^PJDR"X 6
M-?>PEN_""^:O_7\](_ 3U85DW+T(4B:D87</""LOJ.: *=,]M7N3#92RLCGI
M'C;$-2]CO7*60E]D62:Y4>[5,>X/4V7+9=P5MD3U*?2EZE8O)&>&/TU<!I?>
MF7#?X+KX+Z!TR7EBU>:[>[1OYX/:$(Q54@'YN4,'80:359..U!VIJ=NV+DE5
M JR>='MG?Y,5,D":PM^7$>X(9'DOB1Z%N=KB:^9OF-2?5HBON(F1?N!:7X2<
M<JX^]))!3,N6VNC.V1@7B*>)IWE8/$D]9FXVI/"3'_C$^YC#S:RL8C#+ 3!*
M@V,4YI U!9UH?R'$\_M;0AO&@T*/(;?-/K$OGS:5.H^*#_[Z\/<O/<B K2R"
M"IX6]X;RD!(\'(4K0)<\L*[!MR]LF8/#?K0;5]7&M:969[K]_D^@M)!QPG7#
MQN' #'M9+I/GA7I]0>]O9YCHUSDB ;T"B0=E7?-XD9.2S%<4?1]'X])\^B1%
MS1JC7F7-PHGH4+<VPYPFI;O[>M3$"YYA"-B8$H]GF>I:^Z)CZJ*MJZH-<KCP
MC]\>_,M%W4D&N!E-9=KAITKQW)U"3%CUE%"8"V:;A-Z[4X<8B3EYU^/E,;[7
M*7US*/9>,-VCX*Q2MYR3))#3!F0*LD ;KL;@EF]8Q,3,S0XVY(G9D4PV3[74
M?Q,Z*Q9[:VGAX9-%Q57O>S3*U>=<S9:E(AYGG']^_S9C'D;1B'3N1)3TRM^7
M1"V)-T\*&LNLW*[!F'<*T6'R7JO)N*$'>/'' 6,C6Q!%N4V"[J.*&F7V'K$&
M@;@4UWR&7N5[I[W)@/*![FDC9!P.AJF)*RYV&D9AQ3.1?/U.S+@$*87GVA:>
MTT^T>5OZK[Y*!6P@4"S#H%7N//B"/#P4B E? ^XSC" PO*"VROQ/C/-XS?VX
MX]-K\WC&3)0.4>18Y^34_@[QC!&FY-(%:N4_VVI,!M %4:3'C295,H JD2BE
M'P7HH^0!2)<,^&273@:\[/D]JP:8#1^4NTL&M#PA \X.EX(7=6+E@OB(TN,'
M6RH#=YH;A[?>K''E%.1^<'JIO9SZJ]4BR[3WZCGH XJM%.GP6O4_/ U/:,W$
MF) ![$3#0848U78PLW>@?1>RJZEX3:F )9)J$%*R7RN:BMZ=V[]UYUM-:GRI
MZ*^>GE/-*2?OF]4F22/S%61 J%I@GI71(S=T-$TC5X72F@PX"=HC(%A:7+?S
MYO 3<]'_M<=?7EZ%_X]"CJ2$O/)_A_RH!I=X@EC$7R?HK($9*]/ =$K?GN6U
M%]K-XM,Z"KY8Z0B,O'\<?,K^12KJ1]U9P#U SU$^]2K+O]W$L@\4 UMU(4%B
M,+]!!1<86[+0:6QI4S'4K;T>,Z;66Y36I' ]*;=ZMSN%(^SBK7.;0<9OKX)-
M[YV!_/DI67\.BED2!U7:OP3FPK\$A3-'"^!(D7]_B0SHSU%Q,;[!B_AS9.+P
MFI44'US^\,$(:Q[Q&1,>>B!C]<LAP%UVW+K.3'QF,_[SB[.J'ZE?@5F=@1C+
M@(83KMG2(.!:7Q&TP6!$$4QK:0%-5OT&D]LQZ[\@9W-;H_?2U:):*DP==?P-
MH#O\/UCCA]B,)NC;!0T%\6/5_,=#N<.(Q@MQYVSP$*NOP7M;R6O/Z'38M&0[
MY/BS(]HOT?70/+.K^G_:_\\]L#+Y_RF"S!2;.?_+9FA[T 1)&((D VSP5AI"
MLQW5=EQU6*Y$N$;!68W&P5Z!FZ)OGFCQJVZQB%+O)I@PN_5.D,Y&H^7H7<#L
ME60 -TRA>H3H@B&1 5K#6_M;RF#K#1GM'3//Y$'%@7=?E&^U].Q^9%R<H=Z
M__OLNGH2CW )H' <?@.L3W+3)TU4)B>> 9S2CNR+:=J9=F\<C;UNINLP&1H_
MK*66+QS,Y'_P_R$O_L_C^IBHA94A T*(K 7K5F;A?FA;_?Y3.*1M]K=.Q?UT
MKLN[\E^6,BQC 3TK.0"+_P8;L[\OY",6*TK[*G(U@U-IL.++0?3X!W='@R[,
MKK^(.=.$[AS>W[I8G*HELHUDRT:DO-J-U>4LP<Z3SIJ7$(7&JDY78#C#$'EX
M8+N_>23LF1^D#)#ZU'R7PZ3\9(A;ZU9C6FS+CS/7%:@.E/^M-Z8;JI6(RBAH
MFO<#X7C^4=:WKOK_)^"C)KJX0V0/1SEM"2Z*31QL2>"F'U@_<MUUJ7%WEM#J
M'_[1R&7SEEG%I_^T?U[;SNMF(?S5A2W5FYCE#Y \%Z1M/;(EORXP)//#P,^.
MCPEZ2Q\G=+1\3+L?7[H?<S;1X\J4\I?K:RCGMJPBNAS)ANIB[ !R ^<TUJP.
M;^,NP5MW*&7P8//:9Y]L\"EN_8ILJGR.Z:'YVG?.6USH.HO(J]-:3TD]H-]O
M;29:8B1;%TT2K>NKDI=W"<;0VQ*X]64_68FWPI+.<J*/GGL">!773,PO#G+\
MRQ>6_MT%[=XR)\BZ 04:C1<R.? /.C<6$#SXLV[C(SN.PQ/WJY/Y>^'GH4NO
MZYU^M=[G#S-N[?-!5(!: E5QC_$LJ#BJ-7-EY?$@O@JNMO4%*IF19#FQ8EI
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M4OHB-$^G:<T13@#;E2,S@=)XMNOL,&T^\:@YRSQ=6?M.27?^P.5_U0,75PM
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M4??Q>E.5 ,X$0ZNQO\,/ZOE@SU/FOCZ)M_O"A;.LS&@SQVMW_#P:S&T QZ+
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M;-_(>)SDAMV:<#0RH-78)(41-SG*RZ=0C&(Z]8"&#4==1Y-8 2W7 )J$X60
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M7E.TK9YXLHDFG:F:#GA4K#_6^]".\@%G5=N=%=MW:3W)22I/*G#]*T.\5-+
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MA5_J66HETPD)O:D%7SZO/LG4VDHVX92IO7V[_[T[1^#HR4P,7<",?#<\#T:
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M$4USO#$*8,T.CB;0@56LCTD-S[O(CCY6_>DEG@@TL<&;M$FP7FQ9RRS"D-5
M2+3)Y"9=[--*-5O N3^CGF9ZRX79[8D6#6;G,P5:V(5:JA<57D%,SE6.S"*
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MKJRIHKUG7(TUNUC=X1ET/G-U@3DRT=0T*;5&)WGN[O_X71DQ$T62  9[YL]
M>/25 S#2]C]G8'O0Q\Z$#R(7A']+/I=&/MB^_<J-P)EVQAH7>""$.@=DA>XY
M[+VB0TJ'M2AM^>J9"W$9>:]5R)=>77NKK-Z;Y21T(9;MLM"JYCT6Q=='DEY0
M+LV6017FV[5C<"W.@PJK/TIN,[7.3D/C3G?0L\FV@?_=C^ZPMFL"N+XDJG$#
M#F@FP 7-C;PM1JE[><F1;7ZJ\SREL#Z#CZWWQYD<KQEI,;<G2UK+[^ZQ1O$
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M>L4N?#WY8V4'AYS:'9+((_\Q3E%Y=;P"^6_7_L.S?\^Q\/\MS_XOQ_YOO^9
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M$8B"./S0(D>] $C1!8Y ;.MESJ[GT6Z-Z>XW,5I5*U*K;[>[>4$XIE'.288
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MZ,/(6C11$:_$M3DDUMXF5JDU5ICE0A^^>^72EX",OX) N-3:@ \V0V@Q/4G
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MF>+1_'&O C5ZOFLL_]GX2I4^8=G)_=@"7KOUCX<Q'OAEWYFB^L?B X..PL,
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M4MG@[9K[=&6214S@D,6=Z2>-V?H3RMWU%3V^QQ2SD)V?C7=X;\2P&ODK$6N
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MJ):(CELU?[=_;R/PCY,ZL;%HP99[JM$V/7QLK]5G5&%Q<MKM=FD_C;X] ^'
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M>P>7S(3]#>2>^XO[ME^6,?)+SK5' )<#\ 0(R>(,PHT/N-YRP^LGV2K$C"Z
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M=<1 ?=R/S5]204HF.UH2?:> AD1":(.&&6&"H"IEJ=\&-Z?@$2%XM@1Y39U
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MKX0O/[>D&C_'E%+90_1(^;\6] >$U%\/YV_*WFBVOKL]XW5\$X2A?_2MB;]
M[A.DNY4 );\;5X8SX]6N[UU'F+_N:3*$AZVTJ >L?_@SP+*G,'X[3DJ;E31
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MZP5Y6](&H&2:<(LBO!LEP$DO5MVF1HVVWM< ;O]=,LH)0>8:O?H[0E/Z ?0
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M(-T!?@=;L-?:#!TD9#[>%L&UI ;1+^I];^,%_VK?2/C@>?%AHF_>F 4[P S
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M)/U432"X-#0:5YHL5T/58& 5@E7/SV"'G]'LJONUQV[%\NKTVPP(F$NYN\D
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M<U71UUJV]<U0X,2J+(C&!#[6\435GZRGKJ&I-V3CDB*EYR'RHX6-Q!5WJH:
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MJ!&>4L V1@V)"'TY= K@H?W,?88*\2]U'&)%6'-0LA^!^13:K[O/W@?>9F1
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M1N"7QRH.N 'Z&\D7?QQ7J,/L(C'Y.T,G-IE1O<7^X+^'J-7B0X5_OT&5K#Y
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M]R+_8VWIW;MI/O1NB;87E(^K0/.<V!\HEP"8QZ_A32BO8,<$\'C$,=>PXQ1
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M>E6>QZ;&Z7.2QW"I"7\/6'Z1/SX>K]K[?,/AMG:/&!"2>6.D90H@E-O#74U
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M,#(R,3(S,2YX<V102P$"% ,4    "  );7]6AE9C, @3  #GM@  %0
M        @ $=%   97EE<RTR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @
M"6U_5K=.*T#<,    \H" !4              ( !6"<  &5Y97,M,C R,C$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    (  EM?U9D=HBVNF8  .*[!0 5
M      "  6=8  !E>65S+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  )
M;7]6\)XBB@1$  !)) 0 %0              @ %4OP  97EE<RTR,#(R,3(S
M,5]P<F4N>&UL4$L! A0#%     @ "6U_5F%J_O+/M ( T[,3  \
M     ( !BP,! &<P.#,T,3E?,3!K+FAT;5!+ 0(4 Q0    (  EM?U:[<TPU
MO (  , *   2              "  8>X P!G,#@S-#$Y7V5X,C,M,2YH=&U0
M2P$"% ,4    "  );7]6&(X[91X(  !B.@  $@              @ %SNP,
M9S X,S0Q.5]E>#,Q+3$N:'1M4$L! A0#%     @ "6U_5KPSDVA)"   [SP
M !(              ( !P<,# &<P.#,T,3E?97@S,2TR+FAT;5!+ 0(4 Q0
M   (  EM?U;WIU(Q2@4  '4B   2              "  3K, P!G,#@S-#$Y
M7V5X,S(M,2YH=&U02P$"% ,4    "  );7]6B'?PNX"]  !HQ0  #@
M        @ &TT0, :6UG,# Q7W8Q-2YJ<&=02P$"% ,4    "  );7]6 UV'
M\V;)  "JW@  #@              @ %@CP0 :6UG,# R7W8Q-2YJ<&=02P$"
M% ,4    "  );7]6G9]B^-7+  #)Y0  #@              @ 'R6 4 :6UG
M,# S7W8Q-2YJ<&=02P$"% ,4    "  );7]6D".\2)N*  !#F0  #@
M        @ 'S) 8 :6UG,# T7W8Q-2YJ<&=02P$"% ,4    "  );7]6[SLC
MCSVX  #ES0  #@              @ &ZKP8 :6UG,# U7W8Q-2YJ<&=02P$"
M% ,4    "  );7]6[#J=*3FU   1P0  #@              @ $C: < :6UG
A,# V7W8Q-2YJ<&=02P4&     !  $ #P P  B!T(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
